# doc_id = PMC6930932
Pilonidal	0	9	O
sinus	10	15	O
disease	16	23	O
:	23	24	O
Preliminary	25	36	O
case	37	41	O
-	41	42	O
control	42	49	O
study	50	55	O
on	56	58	O
heat	59	63	O
-	63	64	O
related	64	71	O
wound	72	77	O
dehiscence	78	88	O

Abstract	90	98	O
Background	99	109	O
Pilonidal	110	119	O
disease	120	127	O
is	128	130	O
a	131	132	O
morbid	133	139	O
condition	140	149	O
of	150	152	O
the	153	156	O
young	157	162	O
population	163	173	O
,	173	174	O
that	175	179	O
could	180	185	O
impair	186	192	O
quality	193	200	O
of	201	203	O
life	204	208	O
with	209	213	O
a	214	215	O
high	216	220	O
cost	221	225	O
for	226	229	O
the	230	233	O
health	234	240	O
care	241	245	O
system	246	252	O
.	252	253	O

No	254	256	O
consensus	257	266	O
exists	267	273	O
on	274	276	O
optimal	277	284	O
surgical	285	293	O
treatment	294	303	O
,	303	304	O
even	305	309	O
if	310	312	O
several	313	320	O
techniques	321	331	O
have	332	336	O
been	337	341	O
proposed	342	350	O
.	350	351	O

In	352	354	O
this	355	359	O
preliminary	360	371	O
case	372	376	O
-	376	377	O
control	377	384	O
study	385	390	O
we	391	393	O
compared	394	402	O
excision	403	411	O
by	412	414	O
knife	415	420	O
and	421	424	O
diathermy	425	434	O
to	435	437	O
investigate	438	449	O
if	450	452	O
wound	453	458	O
dehiscence	459	469	O
could	470	475	O
be	476	478	O
related	479	486	O
to	487	489	O
heat	490	494	O
spreading	495	504	O
during	505	511	O
excision	512	520	O
of	521	523	O
the	524	527	O
sinus	528	533	O
.	533	534	O

Materials	535	544	O
and	545	548	O
method	549	555	O
Between	556	563	O
January	564	571	O
2017	572	576	O
and	577	580	O
February	581	589	O
2018	590	594	O
,	594	595	O
29	596	598	O
patients	599	607	O
underwent	608	617	O
to	618	620	O
sinus	621	626	O
excision	627	635	O
.	635	636	O
16	636	638	O
patients	639	647	O
underwent	648	657	O
sinus	658	663	O
excision	664	672	O
by	673	675	O
diathermy	676	685	O
(	686	687	O
named	687	692	O
“	693	694	O
Hot	694	697	O
”	697	698	O
group	699	704	O
,	704	705	O
case	706	710	O
-	710	711	O
group	711	716	O
)	716	717	O
while	718	723	O
13	724	726	O
patients	727	735	O
underwent	736	745	O
excision	746	754	O
by	755	757	O
the	758	761	O
knife	762	767	O
as	768	770	O
the	771	774	O
control	775	782	O
group	783	788	O
(	789	790	O
named	790	795	O
“	796	797	O
Cold	797	801	O
”	801	802	O
group	803	808	O
)	808	809	O
.	809	810	O

The	811	814	O
temperature	815	826	O
data	827	831	O
were	832	836	O
recorded	837	845	O
for	846	849	O
both	850	854	O
groups	855	861	O
.	861	862	O

Were	863	867	O
considered	868	878	O
primary	879	886	O
and	887	890	O
secondary	891	900	O
outcomes	901	909	O
.	909	910	O

Results	911	918	O
the	919	922	O
cold	923	927	O
group	928	933	O
has	934	937	O
worse	938	943	O
outcomes	944	952	O
in	953	955	O
operative	956	965	O
time	966	970	O
and	971	974	O
blood	975	980	O
loss	981	985	O
,	985	986	O
but	987	990	O
better	991	997	O
results	998	1005	O
in	1006	1008	O
post	1009	1013	O
-	1013	1014	O
operative	1014	1023	O
pain	1024	1028	O
at	1029	1031	O
first	1032	1037	O
day	1038	1041	O
and	1042	1045	O
first	1046	1051	O
control	1052	1059	O
,	1059	1060	O
number	1061	1067	O
of	1068	1070	O
weekly	1071	1077	O
and	1078	1081	O
total	1082	1087	O
dressings	1088	1097	O
until	1098	1103	O
healing	1104	1111	O
,	1111	1112	O
time	1113	1117	O
for	1118	1121	O
full	1122	1126	O
wound	1127	1132	O
recovery	1133	1141	O
,	1141	1142	O
days	1143	1147	O
to	1148	1150	O
return	1151	1157	O
to	1158	1160	O
work	1161	1165	O
,	1165	1166	O
patient	1167	1174	O
feeling	1175	1182	O
feedback	1183	1191	O
and	1192	1195	O
scar	1196	1200	O
aspect	1201	1207	O
.	1207	1208	O

Wounds	1209	1215	O
healed	1216	1222	O
within	1223	1229	O
8	1230	1231	O
–	1231	1232	O
12	1232	1234	O
days	1235	1239	O
were	1240	1244	O
84	1245	1247	O
.	1247	1248	O
6	1248	1249	O
%	1249	1250	O
in	1251	1253	O
the	1254	1257	O
Cold	1258	1262	O
group	1263	1268	O
and	1269	1272	O
18	1273	1275	O
.	1275	1276	O
8	1276	1277	O
%	1277	1278	O
in	1279	1281	O
the	1282	1285	O
Hot	1286	1289	O
one	1290	1293	O
.	1293	1294	O

I	1295	1296	O
°	1296	1297	O
Dindo	1298	1303	O
-	1303	1304	O
Clavien	1304	1311	O
complications	1312	1325	O
were	1326	1330	O
respectively	1331	1343	O
15	1344	1346	O
.	1346	1347	O
4	1347	1348	O
%	1348	1349	O
and	1350	1353	O
100	1354	1357	O
.	1357	1358	O
0	1358	1359	O
%	1359	1360	O
for	1361	1364	O
the	1365	1368	O
Cold	1369	1373	O
and	1374	1377	O
Hot	1378	1381	O
group	1382	1387	O
.	1387	1388	O

No	1389	1391	O
differences	1392	1403	O
were	1404	1408	O
recorded	1409	1417	O
for	1418	1421	O
II	1422	1424	O
°	1424	1425	O
Dindo	1426	1431	O
-	1431	1432	O
Clavien	1432	1439	O
complications	1440	1453	O
and	1454	1457	O
in	1458	1460	O
days	1461	1465	O
of	1466	1468	O
hospitalization	1469	1484	O
.	1484	1485	O

Conclusion	1486	1496	O
cold	1497	1501	O
excision	1502	1510	O
of	1511	1513	O
the	1514	1517	O
sinus	1518	1523	O
pilonidalis	1524	1535	O
has	1536	1539	O
better	1540	1546	O
results	1547	1554	O
both	1555	1559	O
in	1560	1562	O
terms	1563	1568	O
of	1569	1571	O
precarious	1572	1582	O
healing	1583	1590	O
and	1591	1594	O
quality	1595	1602	O
of	1603	1605	O
life	1606	1610	O
,	1610	1611	O
probably	1612	1620	O
because	1621	1628	O
the	1629	1632	O
tissues	1633	1640	O
are	1641	1644	O
not	1645	1648	O
subjected	1649	1658	O
to	1659	1661	O
diathermocoagulation	1662	1682	O
damage	1683	1689	O
and	1690	1693	O
therefore	1694	1703	O
the	1704	1707	O
healing	1708	1715	O
occurs	1716	1722	O
more	1723	1727	O
quickly	1728	1735	O
.	1735	1736	O

(	1737	1738	O
United	1738	1744	O
States	1745	1751	O
National	1752	1760	O
Institutes	1761	1771	O
of	1772	1774	O
Health	1775	1781	O
,	1781	1782	O
www	1783	1786	O
.	1786	1787	O
clinicaltrial	1787	1800	O
.	1800	1801	O
gov	1801	1804	O
,	1804	1805	O
number	1806	1812	O
NCT	1813	1816	O
03764657	1817	1825	O
,	1825	1826	O
www	1827	1830	O
.	1830	1831	O
researchregistry	1831	1847	O
.	1847	1848	O
com	1848	1851	O
UIN	1852	1855	O
5003	1856	1860	O
)	1860	1861	O
.	1861	1862	O

Author	1863	1869	O
-	1869	1870	O
highlights	1870	1880	O
Highlights	1881	1891	O
•	1892	1893	O
Pilonidal	1893	1902	O
sinus	1903	1908	O
disease	1909	1916	O
.	1916	1917	O
•	1917	1918	O
Cold	1918	1922	O
and	1923	1926	O
Hot	1927	1930	O
surgical	1931	1939	O
procedures	1940	1950	O
.	1950	1951	O
•	1951	1952	O
Wounds	1952	1958	O
healed	1959	1965	O
within	1966	1972	O
8	1973	1974	O
–	1974	1975	O
12	1975	1977	O
days	1978	1982	O
were	1983	1987	O
84	1988	1990	O
.	1990	1991	O
6	1991	1992	O
%	1992	1993	O
in	1994	1996	O
the	1997	2000	O
Cold	2001	2005	O
group	2006	2011	O
and	2012	2015	O
18	2016	2018	O
.	2018	2019	O
8	2019	2020	O
%	2020	2021	O
in	2022	2024	O
the	2025	2028	O
Hot	2029	2032	O
one	2033	2036	O
.	2036	2037	O

I	2038	2039	O
°	2039	2040	O
Dindo	2041	2046	O
-	2046	2047	O
Clavien	2047	2054	O
complications	2055	2068	O
were	2069	2073	O
15	2074	2076	O
.	2076	2077	O
4	2077	2078	O
%	2078	2079	O
for	2080	2083	O
the	2084	2087	O
Cold	2088	2092	O
and	2093	2096	O
100	2097	2100	O
.	2100	2101	O
0	2101	2102	O
%	2102	2103	O
for	2104	2107	O
the	2108	2111	O
Hot	2112	2115	O
group	2116	2121	O
.	2121	2122	O

Pilonidal	2123	2132	O
sinus	2133	2138	O
disease	2139	2146	O
.	2146	2147	O

Cold	2148	2152	O
and	2153	2156	O
Hot	2157	2160	O
surgical	2161	2169	O
procedures	2170	2180	O
.	2180	2181	O

Wounds	2182	2188	O
healed	2189	2195	O
within	2196	2202	O
8	2203	2204	O
–	2204	2205	O
12	2205	2207	O
days	2208	2212	O
were	2213	2217	O
84	2218	2220	O
.	2220	2221	O
6	2221	2222	O
%	2222	2223	O
in	2224	2226	O
the	2227	2230	O
Cold	2231	2235	O
group	2236	2241	O
and	2242	2245	O
18	2246	2248	O
.	2248	2249	O
8	2249	2250	O
%	2250	2251	O
in	2252	2254	O
the	2255	2258	O
Hot	2259	2262	O
one	2263	2266	O
.	2266	2267	O

I	2268	2269	O
°	2269	2270	O
Dindo	2271	2276	O
-	2276	2277	O
Clavien	2277	2284	O
complications	2285	2298	O
were	2299	2303	O
15	2304	2306	O
.	2306	2307	O
4	2307	2308	O
%	2308	2309	O
for	2310	2313	O
the	2314	2317	O
Cold	2318	2322	O
and	2323	2326	O
100	2327	2330	O
.	2330	2331	O
0	2331	2332	O
%	2332	2333	O
for	2334	2337	O
the	2338	2341	O
Hot	2342	2345	O
group	2346	2351	O
.	2351	2352	O

1	2354	2355	O
Introduction	2356	2368	O
Pilonidal	2369	2378	O
disease	2379	2386	O
is	2387	2389	O
a	2390	2391	O
“	2392	2393	O
minor	2393	2398	O
”	2398	2399	O
but	2400	2403	O
,	2403	2404	O
often	2405	2410	O
potentially	2411	2422	O
invaliding	2423	2433	O
morbid	2434	2440	O
condition	2441	2450	O
that	2451	2455	O
affects	2456	2463	O
a	2464	2465	O
wide	2466	2470	O
slice	2471	2476	O
of	2477	2479	O
young	2480	2485	O
people	2486	2492	O
,	2492	2493	O
lives	2494	2499	O
of	2500	2502	O
whom	2503	2507	O
could	2508	2513	O
be	2514	2516	O
severely	2517	2525	O
impaired	2526	2534	O
in	2535	2537	O
quality	2538	2545	O
.	2545	2546	O

Incidence	2547	2556	O
reaches	2557	2564	O
0	2565	2566	O
,	2566	2567	O
7	2567	2568	O
%	2568	2569	O
in	2570	2572	O
male	2573	2577	O
patients	2578	2586	O
in	2587	2589	O
a	2590	2591	O
range	2592	2597	O
of	2598	2600	O
age	2601	2604	O
15	2605	2607	O
–	2607	2608	O
45	2608	2610	O
years	2611	2616	O
,	2616	2617	O
being	2618	2623	O
exceptional	2624	2635	O
in	2636	2638	O
younger	2639	2646	O
or	2647	2649	O
older	2650	2655	O
ones	2656	2660	O
[	2661	2662	O
[	2662	2663	O
1	2663	2664	O
]	2664	2665	O
,	2665	2666	O
[	2667	2668	O
2	2668	2669	O
]	2669	2670	O
,	2670	2671	O
[	2672	2673	O
3	2673	2674	O
]	2674	2675	O
]	2675	2676	O
.	2676	2677	O

Considering	2678	2689	O
that	2690	2694	O
in	2695	2697	O
98	2698	2700	O
.	2700	2701	O
9	2701	2702	O
%	2702	2703	O
the	2704	2707	O
age	2708	2711	O
of	2712	2714	O
affected	2715	2723	O
patients	2724	2732	O
range	2733	2738	O
from	2739	2743	O
<	2744	2745	O
15	2745	2747	O
to	2748	2750	O
>	2751	2752	O
50	2752	2754	O
,	2754	2755	O
being	2756	2761	O
this	2762	2766	O
a	2767	2768	O
“	2769	2770	O
productive	2770	2780	O
age	2781	2784	O
”	2784	2785	O
,	2785	2786	O
and	2787	2790	O
that	2791	2795	O
,	2795	2796	O
if	2797	2799	O
not	2800	2803	O
well	2804	2808	O
treated	2809	2816	O
,	2816	2817	O
this	2818	2822	O
disease	2823	2830	O
could	2831	2836	O
become	2837	2843	O
a	2844	2845	O
“	2846	2847	O
never	2847	2852	O
-	2852	2853	O
ending	2853	2859	O
story	2860	2865	O
”	2865	2866	O
,	2866	2867	O
clearly	2868	2875	O
that	2876	2880	O
it	2881	2883	O
could	2884	2889	O
have	2890	2894	O
a	2895	2896	O
heavyweight	2897	2908	O
on	2909	2911	O
social	2912	2918	O
and	2919	2922	O
economic	2923	2931	O
aspects	2932	2939	O
.	2939	2940	O

A	2941	2942	O
delay	2943	2948	O
in	2949	2951	O
healing	2952	2959	O
turns	2960	2965	O
in	2966	2968	O
longer	2969	2975	O
hospitalization	2976	2991	O
,	2991	2992	O
high	2993	2997	O
use	2998	3001	O
of	3002	3004	O
painkiller	3005	3015	O
drugs	3016	3021	O
,	3021	3022	O
in	3023	3025	O
several	3026	3033	O
wound	3034	3039	O
controls	3040	3048	O
and	3049	3052	O
lack	3053	3057	O
of	3058	3060	O
days	3061	3065	O
of	3066	3068	O
work	3069	3073	O
.	3073	3074	O

The	3075	3078	O
impact	3079	3085	O
on	3086	3088	O
the	3089	3092	O
health	3093	3099	O
care	3100	3104	O
system	3105	3111	O
and	3112	3115	O
economic	3116	3124	O
community	3125	3134	O
could	3135	3140	O
be	3141	3143	O
very	3144	3148	O
high	3149	3153	O
.	3153	3154	O

For	3155	3158	O
this	3159	3163	O
reason	3164	3170	O
,	3170	3171	O
a	3172	3173	O
recent	3174	3180	O
renewed	3181	3188	O
interest	3189	3197	O
in	3198	3200	O
the	3201	3204	O
comprehension	3205	3218	O
of	3219	3221	O
arising	3222	3229	O
mechanisms	3230	3240	O
and	3241	3244	O
in	3245	3247	O
finding	3248	3255	O
the	3256	3259	O
ideal	3260	3265	O
method	3266	3272	O
of	3273	3275	O
treatment	3276	3285	O
,	3285	3286	O
lead	3287	3291	O
to	3292	3294	O
the	3295	3298	O
development	3299	3310	O
of	3311	3313	O
a	3314	3315	O
bit	3316	3319	O
of	3320	3322	O
technique	3323	3332	O
and	3333	3336	O
different	3337	3346	O
approaches	3347	3357	O
,	3357	3358	O
from	3359	3363	O
plastic	3364	3371	O
reconstruction	3372	3386	O
to	3387	3389	O
the	3390	3393	O
mininvasive	3394	3405	O
way	3406	3409	O
.	3409	3410	O

We	3411	3413	O
hypothesized	3414	3426	O
this	3427	3431	O
preliminary	3432	3443	O
case	3444	3448	O
-	3448	3449	O
control	3449	3456	O
study	3457	3462	O
comparing	3463	3472	O
excision	3473	3481	O
by	3482	3484	O
knife	3485	3490	O
and	3491	3494	O
diathermy	3495	3504	O
to	3505	3507	O
deepen	3508	3514	O
if	3515	3517	O
the	3518	3521	O
thermal	3522	3529	O
effect	3530	3536	O
of	3537	3539	O
diathermy	3540	3549	O
,	3549	3550	O
may	3551	3554	O
impair	3555	3561	O
wound	3562	3567	O
healing	3568	3575	O
and	3576	3579	O
if	3580	3582	O
wound	3583	3588	O
dehiscence	3589	3599	O
could	3600	3605	O
be	3606	3608	O
related	3609	3616	O
to	3617	3619	O
heat	3620	3624	O
spreading	3625	3634	O
during	3635	3641	O
excision	3642	3650	O
of	3651	3653	O
the	3654	3657	O
sinus	3658	3663	O
.	3663	3664	O

In	3665	3667	O
literature	3668	3678	O
,	3678	3679	O
the	3680	3683	O
reports	3684	3691	O
are	3692	3695	O
few	3696	3699	O
and	3700	3703	O
clinical	3704	3712	O
studies	3713	3720	O
on	3721	3723	O
a	3724	3725	O
comparison	3726	3736	O
between	3737	3744	O
diathermy	3745	3754	O
and	3755	3758	O
classical	3759	3768	O
blade	3769	3774	O
sinus	3775	3780	O
excision	3781	3789	O
are	3790	3793	O
rare	3794	3798	O
.	3798	3799	O

2	3801	3802	O
Materials	3803	3812	O
and	3813	3816	O
Method	3817	3823	O
Between	3824	3831	O
January	3832	3839	O
2017	3840	3844	O
and	3845	3848	O
February	3849	3857	O
2018	3858	3862	O
,	3862	3863	O
in	3864	3866	O
our	3867	3870	O
General	3871	3878	O
Surgery	3879	3886	O
Unit	3887	3891	O
,	3891	3892	O
were	3893	3897	O
performed	3898	3907	O
29	3908	3910	O
pilonidal	3911	3920	O
sinus	3921	3926	O
excision	3927	3935	O
using	3936	3941	O
knife	3942	3947	O
or	3948	3950	O
diathermy	3951	3960	O
,	3960	3961	O
and	3962	3965	O
primary	3966	3973	O
midline	3974	3981	O
closure	3982	3989	O
,	3989	3990	O
on	3991	3993	O
selected	3994	4002	O
patients	4003	4011	O
,	4011	4012	O
to	4013	4015	O
exclude	4016	4023	O
other	4024	4029	O
risks	4030	4035	O
factors	4036	4043	O
influence	4044	4053	O
that	4054	4058	O
could	4059	4064	O
impair	4065	4071	O
the	4072	4075	O
study	4076	4081	O
.	4081	4082	O

We	4083	4085	O
considered	4086	4096	O
16	4097	4099	O
sinus	4100	4105	O
excision	4106	4114	O
by	4115	4117	O
diathermy	4118	4127	O
as	4128	4130	O
a	4131	4132	O
case	4133	4137	O
group	4138	4143	O
(	4144	4145	O
named	4145	4150	O
“	4151	4152	O
Hot	4152	4155	O
”	4155	4156	O
group	4157	4162	O
)	4162	4163	O
and	4164	4167	O
the	4168	4171	O
last	4172	4176	O
13	4177	4179	O
procedures	4180	4190	O
performed	4191	4200	O
by	4201	4203	O
knife	4204	4209	O
as	4210	4212	O
control	4213	4220	O
group	4221	4226	O
(	4227	4228	O
named	4228	4233	O
“	4234	4235	O
Cold	4235	4239	O
”	4239	4240	O
group	4241	4246	O
)	4246	4247	O
.	4247	4248	O

No	4249	4251	O
Approval	4252	4260	O
of	4261	4263	O
the	4264	4267	O
Ethics	4268	4274	O
committee	4275	4284	O
was	4285	4288	O
required	4289	4297	O
;	4297	4298	O
all	4299	4302	O
patients	4303	4311	O
signed	4312	4318	O
informed	4319	4327	O
consent	4328	4335	O
to	4336	4338	O
the	4339	4342	O
surgical	4343	4351	O
procedure	4352	4361	O
.	4361	4362	O

The	4363	4366	O
work	4367	4371	O
has	4372	4375	O
been	4376	4380	O
reported	4381	4389	O
in	4390	4392	O
line	4393	4397	O
with	4398	4402	O
the	4403	4406	O
STROCSS	4407	4414	O
criteria	4415	4423	O
[	4424	4425	O
17	4425	4427	O
]	4427	4428	O
.	4428	4429	O

2	4430	4431	O
.	4431	4432	O
1	4432	4433	O
Patients	4434	4442	O
selection	4443	4452	O
All	4453	4456	O
patients	4457	4465	O
were	4466	4470	O
enrolled	4471	4479	O
by	4480	4482	O
outpatient	4483	4493	O
surgical	4494	4502	O
control	4503	4510	O
for	4511	4514	O
signs	4515	4520	O
and	4521	4524	O
symptoms	4525	4533	O
of	4534	4536	O
chronic	4537	4544	O
sinus	4545	4550	O
referred	4551	4559	O
to	4560	4562	O
us	4563	4565	O
by	4566	4568	O
a	4569	4570	O
family	4571	4577	O
doctor	4578	4584	O
;	4584	4585	O
median	4586	4592	O
age	4593	4596	O
was	4597	4600	O
19	4601	4603	O
.	4603	4604	O
2	4604	4605	O
±	4606	4607	O
4	4608	4609	O
.	4609	4610	O
3	4610	4611	O
years	4612	4617	O
,	4617	4618	O
ranging	4619	4626	O
from	4627	4631	O
14	4632	4634	O
to	4635	4637	O
52	4638	4640	O
years	4641	4646	O
old	4647	4650	O
;	4650	4651	O
6	4652	4653	O
patients	4654	4662	O
were	4663	4667	O
females	4668	4675	O
and	4676	4679	O
23	4680	4682	O
males	4683	4688	O
and	4689	4692	O
them	4693	4697	O
were	4698	4702	O
request	4703	4710	O
to	4711	4713	O
give	4714	4718	O
informed	4719	4727	O
consensus	4728	4737	O
to	4738	4740	O
underwent	4741	4750	O
to	4751	4753	O
pilonidal	4754	4763	O
sinus	4764	4769	O
excision	4770	4778	O
;	4778	4779	O
16	4780	4782	O
patients	4783	4791	O
of	4792	4794	O
whom	4795	4799	O
12	4800	4802	O
males	4803	4808	O
and	4809	4812	O
4	4813	4814	O
females	4815	4822	O
,	4822	4823	O
were	4824	4828	O
treated	4829	4836	O
by	4837	4839	O
electrosurgery	4840	4854	O
as	4855	4857	O
case	4858	4862	O
group	4863	4868	O
(	4869	4870	O
“	4870	4871	O
hot	4871	4874	O
”	4874	4875	O
)	4875	4876	O
,	4876	4877	O
while	4878	4883	O
in	4884	4886	O
the	4887	4890	O
control	4891	4898	O
group	4899	4904	O
(	4905	4906	O
“	4906	4907	O
cold	4907	4911	O
”	4911	4912	O
)	4912	4913	O
,	4913	4914	O
13	4915	4917	O
patients	4918	4926	O
11	4927	4929	O
were	4930	4934	O
male	4935	4939	O
and	4940	4943	O
2	4944	4945	O
were	4946	4950	O
females	4951	4958	O
.	4958	4959	O

Median	4960	4966	O
time	4967	4971	O
elapsed	4972	4979	O
from	4980	4984	O
first	4985	4990	O
symptoms	4991	4999	O
and	5000	5003	O
surgery	5004	5011	O
was	5012	5015	O
about	5016	5021	O
1	5022	5023	O
.	5023	5024	O
2	5024	5025	O
±	5026	5027	O
2	5028	5029	O
.	5029	5030	O
3	5030	5031	O
months	5032	5038	O
.	5038	5039	O

Only	5040	5044	O
two	5045	5048	O
patients	5049	5057	O
had	5058	5061	O
ASA	5062	5065	O
score	5066	5071	O
III	5072	5075	O
,	5075	5076	O
no	5077	5079	O
one	5080	5083	O
of	5084	5086	O
IV	5087	5089	O
ASA	5090	5093	O
score	5094	5099	O
was	5100	5103	O
enrolled	5104	5112	O
and	5113	5116	O
mean	5117	5121	O
pre	5122	5125	O
-	5125	5126	O
operative	5126	5135	O
pain	5136	5140	O
,	5140	5141	O
valued	5142	5148	O
by	5149	5151	O
VAS	5152	5155	O
was	5156	5159	O
2	5160	5161	O
.	5161	5162	O
5	5162	5163	O
(	5164	5165	O
±	5165	5166	O
1	5166	5167	O
.	5167	5168	O
5	5168	5169	O
)	5169	5170	O
.	5170	5171	O

Inclusion	5172	5181	O
criteria	5182	5190	O
were	5191	5195	O
:	5195	5196	O
male	5197	5201	O
and	5202	5205	O
female	5206	5212	O
patients	5213	5221	O
between	5222	5229	O
14	5230	5232	O
and	5233	5236	O
65	5237	5239	O
years	5240	5245	O
old	5246	5249	O
,	5249	5250	O
primary	5251	5258	O
,	5258	5259	O
non	5260	5263	O
recurrent	5264	5273	O
pilonidal	5274	5283	O
disease	5284	5291	O
,	5291	5292	O
midline	5293	5300	O
and	5301	5304	O
intergluteal	5305	5317	O
location	5318	5326	O
,	5326	5327	O
spinal	5328	5334	O
anesthesia	5335	5345	O
,	5345	5346	O
dimension	5347	5356	O
no	5357	5359	O
more	5360	5364	O
than	5365	5369	O
5	5370	5371	O
cm	5372	5374	O
in	5375	5377	O
length	5378	5384	O
,	5384	5385	O
primary	5386	5393	O
closure	5394	5401	O
performed	5402	5411	O
;	5411	5412	O
Exclusion	5413	5422	O
criteria	5423	5431	O
were	5432	5436	O
the	5437	5440	O
following	5441	5450	O
:	5450	5451	O
age	5452	5455	O
<	5456	5457	O
14	5457	5459	O
and	5460	5463	O
>	5464	5465	O
65	5465	5467	O
years	5468	5473	O
old	5474	5477	O
,	5477	5478	O
secondary	5479	5488	O
fistulous	5489	5498	O
tracts	5499	5505	O
or	5506	5508	O
lateral	5509	5516	O
developing	5517	5527	O
/	5527	5528	O
cutaneous	5528	5537	O
opening	5538	5545	O
;	5545	5546	O
dimension	5547	5556	O
over	5557	5561	O
5	5562	5563	O
cm	5564	5566	O
in	5567	5569	O
length	5570	5576	O
,	5576	5577	O
local	5578	5583	O
anesthesia	5584	5594	O
employ	5595	5601	O
;	5601	5602	O
smoker	5603	5609	O
and	5610	5613	O
obese	5614	5619	O
patients	5620	5628	O
(	5629	5630	O
BMI	5630	5633	O
>	5633	5634	O
25	5635	5637	O
kg	5638	5640	O
/	5640	5641	O
m2	5641	5643	O
)	5643	5644	O
,	5644	5645	O
diabetic	5646	5654	O
and	5655	5658	O
coagulopathies	5659	5673	O
affected	5674	5682	O
ones	5683	5687	O
;	5687	5688	O
flogged	5689	5696	O
or	5697	5699	O
acute	5700	5705	O
or	5706	5708	O
infected	5709	5717	O
or	5718	5720	O
abscessed	5721	5730	O
forms	5731	5736	O
,	5736	5737	O
ASA	5738	5741	O
score	5742	5747	O
>	5748	5749	O
IV	5750	5752	O
,	5752	5753	O
normal	5754	5760	O
range	5761	5766	O
WBC	5767	5770	O
and	5771	5774	O
Hb	5775	5777	O
preoperative	5778	5790	O
values	5791	5797	O
.	5797	5798	O

Characteristics	5799	5814	O
and	5815	5818	O
selection	5819	5828	O
criteria	5829	5837	O
are	5838	5841	O
resumed	5842	5849	O
in	5850	5852	O
Table	5853	5858	O
1	5859	5860	O
.	5860	5861	O
Table	5861	5866	O
1Patient	5867	5875	O
'	5875	5876	O
s	5876	5877	O
characteristics	5878	5893	O
.	5893	5894	O
Table	5894	5899	O
1CriteriaInclusionExclusionSexM	5900	5931	O
/	5931	5932	O
FAge	5932	5936	O
(	5937	5938	O
year	5938	5942	O
)	5942	5943	O
14	5943	5945	O
–	5945	5946	O
65	5946	5948	O
<	5948	5949	O
14	5949	5951	O
>	5952	5953	O
65ASA	5953	5958	O
scoreI	5959	5965	O
-	5965	5966	O
II	5966	5968	O
-	5968	5969	O
IIIIVBMI	5969	5977	O
<	5977	5978	O
25	5978	5980	O
kg	5981	5983	O
/	5983	5984	O
m2	5984	5986	O
>	5986	5987	O
25	5987	5989	O
kg	5990	5992	O
/	5992	5993	O
m2DiseasePrimaryNot	5993	6012	O
acuteRecurrenceAcute	6013	6033	O
/	6033	6034	O
abscessLocalizationMidlineLateral	6034	6067	O
/	6067	6068	O
perianalDimension	6068	6085	O
<	6085	6086	O
5	6086	6087	O
cm	6088	6090	O
<	6090	6091	O
5	6091	6092	O
cmAnesthesiaSpinalLocalCo	6093	6118	O
morbidities	6119	6130	O
and	6131	6134	O
HabitsNoneDiabetes	6135	6153	O
/	6153	6154	O
coagulopathies	6154	6168	O
/	6168	6169	O
other	6169	6174	O
/	6174	6175	O
smokersBlood	6175	6187	O
assessmentNormal	6188	6204	O
>	6204	6205	O
WBC	6206	6209	O
<	6209	6210	O
Hb	6211	6213	O
Table	6214	6219	O
1	6220	6221	O
Patient	6222	6229	O
'	6229	6230	O
s	6230	6231	O
characteristics	6232	6247	O
.	6247	6248	O

In	6249	6251	O
Fig	6252	6255	O
.	6255	6256	O

1	6257	6258	O
,	6258	6259	O
Fig	6260	6263	O
.	6263	6264	O

2	6265	6266	O
we	6267	6269	O
report	6270	6276	O
respectively	6277	6289	O
infected	6290	6298	O
sinus	6299	6304	O
and	6305	6308	O
delayed	6309	6316	O
closure	6317	6324	O
.	6324	6325	O
Fig	6325	6328	O
.	6328	6329	O

1Infected	6330	6339	O
sinus	6340	6345	O
.	6345	6346	O
Fig	6346	6349	O
.	6349	6350	O

1Fig	6351	6355	O
.	6355	6356	O

2Delayed	6357	6365	O
closure	6366	6373	O
.	6373	6374	O
Fig	6374	6377	O
.	6377	6378	O

2	6379	6380	O
Fig	6381	6384	O
.	6384	6385	O

1	6386	6387	O
Infected	6388	6396	O
sinus	6397	6402	O
.	6402	6403	O

Fig	6404	6407	O
.	6407	6408	O

2	6409	6410	O
Delayed	6411	6418	O
closure	6419	6426	O
.	6426	6427	O

2	6428	6429	O
.	6429	6430	O
2	6430	6431	O
Surgical	6432	6440	O
technique	6441	6450	O
In	6451	6453	O
“	6454	6455	O
hot	6455	6458	O
”	6458	6459	O
group	6460	6465	O
16	6466	6468	O
patients	6469	6477	O
were	6478	6482	O
treated	6483	6490	O
by	6491	6493	O
diathermy	6494	6503	O
while	6504	6509	O
in	6510	6512	O
“	6513	6514	O
Cold	6514	6518	O
”	6518	6519	O
group	6520	6525	O
13	6526	6528	O
patients	6529	6537	O
were	6538	6542	O
treated	6543	6550	O
by	6551	6553	O
scalpel	6554	6561	O
.	6561	6562	O

A	6563	6564	O
Short	6565	6570	O
Term	6571	6575	O
antibiotic	6576	6586	O
prophylaxis	6587	6598	O
using	6599	6604	O
Cefazoline	6605	6615	O
2	6616	6617	O
gr	6618	6620	O
in	6621	6623	O
100	6624	6627	O
cc	6628	6630	O
of	6631	6633	O
saline	6634	6640	O
solution	6641	6649	O
was	6650	6653	O
routinely	6654	6663	O
administered	6664	6676	O
and	6677	6680	O
subarachnoid	6681	6693	O
anesthesia	6694	6704	O
employed	6705	6713	O
after	6714	6719	O
bland	6720	6725	O
sedation	6726	6734	O
with	6735	6739	O
Midazolam	6740	6749	O
2	6750	6751	O
–	6751	6752	O
3	6752	6753	O
ml	6754	6756	O
i	6757	6758	O
.	6758	6759	O
v	6759	6760	O
.	6760	6761	O
Patients	6762	6770	O
were	6771	6775	O
placed	6776	6782	O
in	6783	6785	O
prone	6786	6791	O
position	6792	6800	O
on	6801	6803	O
operating	6804	6813	O
table	6814	6819	O
with	6820	6824	O
the	6825	6828	O
gluteal	6829	6836	O
line	6837	6841	O
opened	6842	6848	O
wide	6849	6853	O
by	6854	6856	O
adhesive	6857	6865	O
patches	6866	6873	O
;	6873	6874	O
after	6875	6880	O
skin	6881	6885	O
disinfection	6886	6898	O
,	6898	6899	O
dimension	6900	6909	O
and	6910	6913	O
extension	6914	6923	O
of	6924	6926	O
cystic	6927	6933	O
disease	6934	6941	O
was	6942	6945	O
studied	6946	6953	O
by	6954	6956	O
injection	6957	6966	O
of	6967	6969	O
hydrogen	6970	6978	O
peroxide	6979	6987	O
through	6988	6995	O
superficial	6996	7007	O
skin	7008	7012	O
orifice	7013	7020	O
.	7020	7021	O

The	7022	7025	O
same	7026	7030	O
procedure	7031	7040	O
was	7041	7044	O
performed	7045	7054	O
:	7054	7055	O
an	7056	7058	O
elliptical	7059	7069	O
incision	7070	7078	O
on	7079	7081	O
midline	7082	7089	O
around	7090	7096	O
the	7097	7100	O
sinus	7101	7106	O
was	7107	7110	O
made	7111	7115	O
and	7116	7119	O
the	7120	7123	O
sinus	7124	7129	O
was	7130	7133	O
excided	7134	7141	O
laterally	7142	7151	O
and	7152	7155	O
in	7156	7158	O
depth	7159	7164	O
on	7165	7167	O
healthy	7168	7175	O
tissue	7176	7182	O
,	7182	7183	O
down	7184	7188	O
till	7189	7193	O
the	7194	7197	O
pre	7198	7201	O
-	7201	7202	O
sacral	7202	7208	O
fascia	7209	7215	O
:	7215	7216	O
this	7217	7221	O
common	7222	7228	O
approach	7229	7237	O
was	7238	7241	O
made	7242	7246	O
both	7247	7251	O
using	7252	7257	O
scalpel	7258	7265	O
and	7266	7269	O
electrosurgery	7270	7284	O
in	7285	7287	O
the	7288	7291	O
two	7292	7295	O
groups	7296	7302	O
.	7302	7303	O

Monopolar	7304	7313	O
knife	7314	7319	O
,	7319	7320	O
used	7321	7325	O
in	7326	7328	O
hot	7329	7332	O
group	7333	7338	O
,	7338	7339	O
(	7340	7341	O
ForceTriad	7341	7351	O
™	7351	7352	O
energy	7353	7359	O
platform	7360	7368	O
,	7368	7369	O
Valleylab	7370	7379	O
™	7379	7380	O
Covidien	7381	7389	O
,	7389	7390	O
Medtronics	7391	7401	O
)	7401	7402	O
,	7402	7403	O
was	7404	7407	O
setted	7408	7414	O
for	7415	7418	O
common	7419	7425	O
standard	7426	7434	O
open	7435	7439	O
surgery	7440	7447	O
with	7448	7452	O
forced	7453	7459	O
and	7460	7463	O
spray	7464	7469	O
assessment	7470	7480	O
35	7481	7483	O
/	7483	7484	O
40	7484	7486	O
W	7487	7488	O
respectively	7489	7501	O
.	7501	7502	O

During	7503	7509	O
dissection	7510	7520	O
and	7521	7524	O
excision	7525	7533	O
,	7533	7534	O
in	7535	7537	O
each	7538	7542	O
group	7543	7548	O
were	7549	7553	O
measured	7554	7562	O
and	7563	7566	O
recorded	7567	7575	O
the	7576	7579	O
temperatures	7580	7592	O
developing	7593	7603	O
,	7603	7604	O
both	7605	7609	O
on	7610	7612	O
the	7613	7616	O
section	7617	7624	O
surface	7625	7632	O
using	7633	7638	O
an	7639	7641	O
infrared	7642	7650	O
thermometer	7651	7662	O
and	7663	7666	O
thermal	7667	7674	O
imaging	7675	7682	O
camera	7683	7689	O
,	7689	7690	O
and	7691	7694	O
deeper	7695	7701	O
until	7702	7707	O
1	7708	7709	O
cm	7710	7712	O
from	7713	7717	O
the	7718	7721	O
section	7722	7729	O
frontline	7730	7739	O
using	7740	7745	O
a	7746	7747	O
“	7748	7749	O
immersion	7749	7758	O
thermometer	7759	7770	O
”	7770	7771	O
sealed	7772	7778	O
by	7779	7781	O
a	7782	7783	O
steri	7784	7789	O
-	7789	7790	O
drape	7790	7795	O
to	7796	7798	O
guarantee	7799	7808	O
the	7809	7812	O
sterility	7813	7822	O
on	7823	7825	O
surgical	7826	7834	O
field	7835	7840	O
(	7841	7842	O
Fig	7842	7845	O
.	7845	7846	O

3	7847	7848	O
)	7848	7849	O
.	7849	7850	O
Fig	7850	7853	O
.	7853	7854	O

3Thermal	7855	7863	O
camera	7864	7870	O
data	7871	7875	O
.	7875	7876	O
Fig	7876	7879	O
.	7879	7880	O

3	7881	7882	O
Fig	7883	7886	O
.	7886	7887	O

3	7888	7889	O
Thermal	7890	7897	O
camera	7898	7904	O
data	7905	7909	O
.	7909	7910	O

We	7911	7913	O
documented	7914	7924	O
,	7924	7925	O
in	7926	7928	O
“	7929	7930	O
off	7930	7933	O
-	7933	7934	O
field	7934	7939	O
testes	7940	7946	O
”	7946	7947	O
,	7947	7948	O
that	7949	7953	O
the	7954	7957	O
isolation	7958	7967	O
of	7968	7970	O
the	7971	7974	O
thermometer	7975	7986	O
by	7987	7989	O
a	7990	7991	O
sterile	7992	7999	O
adhesive	8000	8008	O
film	8009	8013	O
,	8013	8014	O
does	8015	8019	O
not	8020	8023	O
impair	8024	8030	O
and	8031	8034	O
does	8035	8039	O
not	8040	8043	O
alter	8044	8049	O
temperature	8050	8061	O
values	8062	8068	O
recorded	8069	8077	O
,	8077	8078	O
because	8079	8086	O
the	8087	8090	O
difference	8091	8101	O
between	8102	8109	O
recording	8110	8119	O
with	8120	8124	O
and	8125	8128	O
without	8129	8136	O
sterile	8137	8144	O
film	8145	8149	O
was	8150	8153	O
minimal	8154	8161	O
,	8161	8162	O
causing	8163	8170	O
only	8171	8175	O
loss	8176	8180	O
of	8181	8183	O
0	8184	8185	O
,	8185	8186	O
2	8186	8187	O
-	8187	8188	O
0	8188	8189	O
,	8189	8190	O
5	8190	8191	O
°	8192	8193	O
C	8193	8194	O
:	8194	8195	O
this	8196	8200	O
could	8201	8206	O
not	8207	8210	O
be	8211	8213	O
relevant	8214	8222	O
.	8222	8223	O

Accurate	8224	8232	O
hemostasis	8233	8243	O
control	8244	8251	O
was	8252	8255	O
obtained	8256	8264	O
using	8265	8270	O
monopolar	8271	8280	O
coagulation	8281	8292	O
in	8293	8295	O
“	8296	8297	O
hot	8297	8300	O
”	8300	8301	O
group	8302	8307	O
one	8308	8311	O
and	8312	8315	O
single	8316	8322	O
stitches	8323	8331	O
in	8332	8334	O
“	8335	8336	O
cold	8336	8340	O
”	8340	8341	O
one	8342	8345	O
;	8345	8346	O
the	8347	8350	O
cavity	8351	8357	O
was	8358	8361	O
washed	8362	8368	O
and	8369	8372	O
irrigated	8373	8382	O
by	8383	8385	O
saline	8386	8392	O
solution	8393	8401	O
and	8402	8405	O
a	8406	8407	O
primary	8408	8415	O
closure	8416	8423	O
was	8424	8427	O
performed	8428	8437	O
using	8438	8443	O
resorbable	8444	8454	O
separated	8455	8464	O
0	8465	8466	O
/	8466	8467	O
0	8467	8468	O
stitches	8469	8477	O
.	8477	8478	O

A	8479	8480	O
moderate	8481	8489	O
compression	8490	8501	O
by	8502	8504	O
medical	8505	8512	O
dress	8513	8518	O
completed	8519	8528	O
the	8529	8532	O
procedure	8533	8542	O
.	8542	8543	O

No	8544	8546	O
drains	8547	8553	O
were	8554	8558	O
used	8559	8563	O
.	8563	8564	O

Patients	8565	8573	O
were	8574	8578	O
discharged	8579	8589	O
the	8590	8593	O
day	8594	8597	O
after	8598	8603	O
in	8604	8606	O
the	8607	8610	O
morning	8611	8618	O
or	8619	8621	O
the	8622	8625	O
afternoon	8626	8635	O
and	8636	8639	O
the	8640	8643	O
dress	8644	8649	O
controlled	8650	8660	O
before	8661	8667	O
discharge	8668	8677	O
.	8677	8678	O

Follow	8679	8685	O
-	8685	8686	O
up	8686	8688	O
was	8689	8692	O
planned	8693	8700	O
for	8701	8704	O
interval	8705	8713	O
control	8714	8721	O
until	8722	8727	O
complete	8728	8736	O
healing	8737	8744	O
,	8744	8745	O
and	8746	8749	O
patient	8750	8757	O
were	8758	8762	O
seen	8763	8767	O
after	8768	8773	O
4	8774	8775	O
,	8775	8776	O
8	8777	8778	O
,	8778	8779	O
12	8780	8782	O
days	8783	8787	O
and	8788	8791	O
then	8792	8796	O
based	8797	8802	O
on	8803	8805	O
wound	8806	8811	O
evolution	8812	8821	O
.	8821	8822	O

A	8823	8824	O
telephone	8825	8834	O
number	8835	8841	O
was	8842	8845	O
given	8846	8851	O
for	8852	8855	O
any	8856	8859	O
problems	8860	8868	O
.	8868	8869	O

2	8870	8871	O
.	8871	8872	O
3	8872	8873	O
Evaluation	8874	8884	O
of	8885	8887	O
surgical	8888	8896	O
outcomes	8897	8905	O
We	8906	8908	O
established	8909	8920	O
as	8921	8923	O
primary	8924	8931	O
outcomes	8932	8940	O
,	8940	8941	O
the	8942	8945	O
number	8946	8952	O
of	8953	8955	O
wound	8956	8961	O
completely	8962	8972	O
healed	8973	8979	O
after	8980	8985	O
8	8986	8987	O
–	8987	8988	O
12	8988	8990	O
days	8991	8995	O
,	8995	8996	O
the	8997	9000	O
total	9001	9006	O
time	9007	9011	O
,	9011	9012	O
in	9013	9015	O
days	9016	9020	O
,	9020	9021	O
needed	9022	9028	O
to	9029	9031	O
complete	9032	9040	O
wound	9041	9046	O
healing	9047	9054	O
by	9055	9057	O
first	9058	9063	O
-	9063	9064	O
intention	9064	9073	O
midline	9074	9081	O
closure	9082	9089	O
,	9089	9090	O
without	9091	9098	O
delaying	9099	9107	O
from	9108	9112	O
the	9113	9116	O
“	9117	9118	O
standard	9118	9126	O
”	9126	9127	O
way	9128	9131	O
,	9131	9132	O
the	9133	9136	O
number	9137	9143	O
of	9144	9146	O
dressing	9147	9155	O
in	9156	9158	O
week	9159	9163	O
and	9164	9167	O
total	9168	9173	O
ones	9174	9178	O
until	9179	9184	O
complete	9185	9193	O
healing	9194	9201	O
during	9202	9208	O
outpatient	9209	9219	O
management	9220	9230	O
and	9231	9234	O
time	9235	9239	O
needed	9240	9246	O
for	9247	9250	O
hospitalization	9251	9266	O
and	9267	9270	O
to	9271	9273	O
return	9274	9280	O
to	9281	9283	O
work	9284	9288	O
.	9288	9289	O

Secondary	9290	9299	O
outcomes	9300	9308	O
were	9309	9313	O
valued	9314	9320	O
too	9321	9324	O
,	9324	9325	O
to	9326	9328	O
assess	9329	9335	O
:	9335	9336	O
number	9337	9343	O
and	9344	9347	O
types	9348	9353	O
of	9354	9356	O
complications	9357	9370	O
(	9371	9372	O
Dindo	9372	9377	O
-	9377	9378	O
Clavien	9378	9385	O
)	9385	9386	O
,	9386	9387	O
post	9388	9392	O
-	9392	9393	O
operative	9393	9402	O
pain	9403	9407	O
in	9408	9410	O
first	9411	9416	O
postoperative	9417	9430	O
day	9431	9434	O
and	9435	9438	O
at	9439	9441	O
first	9442	9447	O
control	9448	9455	O
by	9456	9458	O
VAS	9459	9462	O
,	9462	9463	O
operative	9464	9473	O
time	9474	9478	O
for	9479	9482	O
complete	9483	9491	O
excision	9492	9500	O
of	9501	9503	O
the	9504	9507	O
sinus	9508	9513	O
,	9513	9514	O
blood	9515	9520	O
loss	9521	9525	O
,	9525	9526	O
patient	9527	9534	O
'	9534	9535	O
s	9535	9536	O
feeling	9537	9544	O
feedback	9545	9553	O
,	9553	9554	O
scar	9555	9559	O
aspect	9560	9566	O
at	9567	9569	O
the	9570	9573	O
end	9574	9577	O
of	9578	9580	O
complete	9581	9589	O
healing	9590	9597	O
.	9597	9598	O

2	9599	9600	O
.	9600	9601	O
4	9601	9602	O
Statistical	9603	9614	O
evaluation	9615	9625	O
Test	9626	9630	O
F	9631	9632	O
for	9633	9636	O
variances	9637	9646	O
and	9647	9650	O
Fisher	9651	9657	O
exact	9658	9663	O
test	9664	9668	O
were	9669	9673	O
used	9674	9678	O
between	9679	9686	O
two	9687	9690	O
groups	9691	9697	O
.	9697	9698	O

3	9700	9701	O
Results	9702	9709	O
Statistical	9710	9721	O
evaluation	9722	9732	O
are	9733	9736	O
reported	9737	9745	O
in	9746	9748	O
Table	9749	9754	O
2	9755	9756	O
and	9757	9760	O
Table	9761	9766	O
3	9767	9768	O
.	9768	9769	O

The	9770	9773	O
comparison	9774	9784	O
between	9785	9792	O
the	9793	9796	O
case	9797	9801	O
group	9802	9807	O
“	9808	9809	O
hot	9809	9812	O
”	9812	9813	O
and	9814	9817	O
case	9818	9822	O
control	9823	9830	O
group	9831	9836	O
“	9837	9838	O
cold	9838	9842	O
”	9842	9843	O
in	9844	9846	O
terms	9847	9852	O
of	9853	9855	O
outcomes	9856	9864	O
,	9864	9865	O
shows	9866	9871	O
that	9872	9876	O
the	9877	9880	O
“	9881	9882	O
cold	9882	9886	O
”	9886	9887	O
has	9888	9891	O
a	9892	9893	O
significantly	9894	9907	O
higher	9908	9914	O
median	9915	9921	O
value	9922	9927	O
compared	9928	9936	O
to	9937	9939	O
the	9940	9943	O
“	9944	9945	O
hot	9945	9948	O
”	9948	9949	O
one	9950	9953	O
referring	9954	9963	O
to	9964	9966	O
the	9967	9970	O
operative	9971	9980	O
time	9981	9985	O
and	9986	9989	O
blood	9990	9995	O
loss	9996	10000	O
.	10000	10001	O

On	10002	10004	O
the	10005	10008	O
other	10009	10014	O
hand	10015	10019	O
,	10019	10020	O
were	10021	10025	O
observed	10026	10034	O
significantly	10035	10048	O
better	10049	10055	O
mean	10056	10060	O
values	10061	10067	O
for	10068	10071	O
the	10072	10075	O
“	10076	10077	O
cold	10077	10081	O
”	10081	10082	O
technique	10083	10092	O
in	10093	10095	O
several	10096	10103	O
outcomes	10104	10112	O
variables	10113	10122	O
:	10122	10123	O
pain	10124	10128	O
after	10129	10134	O
intervention	10135	10147	O
at	10148	10150	O
first	10151	10156	O
day	10157	10160	O
,	10160	10161	O
pain	10162	10166	O
after	10167	10172	O
intervention	10173	10185	O
at	10186	10188	O
first	10189	10194	O
control	10195	10202	O
,	10202	10203	O
number	10204	10210	O
of	10211	10213	O
dressings	10214	10223	O
in	10224	10226	O
week	10227	10231	O
,	10231	10232	O
number	10233	10239	O
of	10240	10242	O
total	10243	10248	O
dressings	10249	10258	O
until	10259	10264	O
recovery	10265	10273	O
,	10273	10274	O
time	10275	10279	O
for	10280	10283	O
a	10284	10285	O
full	10286	10290	O
recovery	10291	10299	O
(	10300	10301	O
days	10301	10305	O
)	10305	10306	O
,	10306	10307	O
days	10308	10312	O
for	10313	10316	O
coming	10317	10323	O
at	10324	10326	O
work	10327	10331	O
,	10331	10332	O
patient	10333	10340	O
feeling	10341	10348	O
feedback	10349	10357	O
and	10358	10361	O
scar	10362	10366	O
aspect	10367	10373	O
vas	10374	10377	O
,	10377	10378	O
as	10379	10381	O
showed	10382	10388	O
by	10389	10391	O
P	10392	10393	O
value	10394	10399	O
.	10399	10400	O

Also	10401	10405	O
the	10406	10409	O
comparison	10410	10420	O
on	10421	10423	O
the	10424	10427	O
proportion	10428	10438	O
of	10439	10441	O
recovered	10442	10451	O
wounds	10452	10458	O
after	10459	10464	O
8	10465	10466	O
–	10466	10467	O
12	10467	10469	O
days	10470	10474	O
and	10475	10478	O
Dindo	10479	10484	O
-	10484	10485	O
Clavien	10485	10492	O
complications	10493	10506	O
-	10506	10507	O
grade	10507	10512	O
I	10513	10514	O
,	10514	10515	O
shows	10516	10521	O
that	10522	10526	O
the	10527	10530	O
“	10531	10532	O
cold	10532	10536	O
”	10536	10537	O
technique	10538	10547	O
is	10548	10550	O
safer	10551	10556	O
than	10557	10561	O
“	10562	10563	O
hot	10563	10566	O
”	10566	10567	O
,	10567	10568	O
in	10569	10571	O
fact	10572	10576	O
the	10577	10580	O
percentage	10581	10591	O
of	10592	10594	O
wounds	10595	10601	O
healed	10602	10608	O
within	10609	10615	O
8	10616	10617	O
–	10617	10618	O
12	10618	10620	O
days	10621	10625	O
is	10626	10628	O
about	10629	10634	O
to	10635	10637	O
84	10638	10640	O
.	10640	10641	O
6	10641	10642	O
%	10642	10643	O
in	10644	10646	O
the	10647	10650	O
“	10651	10652	O
cold	10652	10656	O
”	10656	10657	O
group	10658	10663	O
compared	10664	10672	O
to	10673	10675	O
18	10676	10678	O
.	10678	10679	O
8	10679	10680	O
%	10680	10681	O
of	10682	10684	O
the	10685	10688	O
“	10689	10690	O
hot	10690	10693	O
”	10693	10694	O
group	10695	10700	O
.	10700	10701	O

I	10702	10703	O
degree	10704	10710	O
Dindo	10711	10716	O
-	10716	10717	O
Clavien	10717	10724	O
complications	10725	10738	O
recorded	10739	10747	O
about	10748	10753	O
to	10754	10756	O
15	10757	10759	O
.	10759	10760	O
4	10760	10761	O
%	10761	10762	O
for	10763	10766	O
the	10767	10770	O
“	10771	10772	O
cold	10772	10776	O
”	10776	10777	O
technique	10778	10787	O
and	10788	10791	O
100	10792	10795	O
.	10795	10796	O
0	10796	10797	O
%	10797	10798	O
for	10799	10802	O
the	10803	10806	O
“	10807	10808	O
hot	10808	10811	O
”	10811	10812	O
one	10813	10816	O
.	10816	10817	O

No	10818	10820	O
significant	10821	10832	O
differences	10833	10844	O
were	10845	10849	O
recorded	10850	10858	O
for	10859	10862	O
II	10863	10865	O
degree	10866	10872	O
Dindo	10873	10878	O
-	10878	10879	O
Clavien	10879	10886	O
complications	10887	10900	O
.	10900	10901	O
Table	10901	10906	O
2Selection	10907	10917	O
criteria	10918	10926	O
.	10926	10927	O
Table	10927	10932	O
2Cold	10933	10938	O
(	10939	10940	O
n	10940	10941	O
=	10942	10943	O
13	10944	10946	O
)	10946	10947	O
Hot	10947	10950	O
(	10951	10952	O
n	10952	10953	O
=	10954	10955	O
16	10956	10958	O
)	10958	10959	O
p	10959	10960	O
-	10960	10961	O
valueTime	10961	10970	O
for	10971	10974	O
intervention	10975	10987	O
(	10988	10989	O
minutes	10989	10996	O
)	10996	10997	O
25	10997	10999	O
.	10999	11000	O
7	11000	11001	O
(	11002	11003	O
36	11003	11005	O
.	11005	11006	O
4	11006	11007	O
)	11007	11008	O
13	11008	11010	O
.	11010	11011	O
4	11011	11012	O
(	11013	11014	O
6	11014	11015	O
.	11015	11016	O
3	11016	11017	O
)	11017	11018	O
<	11018	11019	O
0	11019	11020	O
.	11020	11021	O
0001Blood	11021	11030	O
loss	11031	11035	O
(	11036	11037	O
ml	11037	11039	O
)	11039	11040	O
12	11040	11042	O
.	11042	11043	O
7	11043	11044	O
(	11045	11046	O
6	11046	11047	O
.	11047	11048	O
7	11048	11049	O
)	11049	11050	O
5	11050	11051	O
.	11051	11052	O
9	11052	11053	O
(	11054	11055	O
3	11055	11056	O
.	11056	11057	O
1	11057	11058	O
)	11058	11059	O
<	11059	11060	O
0	11060	11061	O
.	11061	11062	O
0001Pain	11062	11070	O
after	11071	11076	O
intervention	11077	11089	O
(	11090	11091	O
first	11091	11096	O
day	11097	11100	O
)	11100	11101	O
3	11101	11102	O
.	11102	11103	O
3	11103	11104	O
(	11105	11106	O
0	11106	11107	O
.	11107	11108	O
7	11108	11109	O
)	11109	11110	O
5	11110	11111	O
.	11111	11112	O
1	11112	11113	O
(	11114	11115	O
0	11115	11116	O
.	11116	11117	O
7	11117	11118	O
)	11118	11119	O
<	11119	11120	O
0	11120	11121	O
.	11121	11122	O
0001Pain	11122	11130	O
after	11131	11136	O
intervention	11137	11149	O
(	11150	11151	O
at	11151	11153	O
first	11154	11159	O
control	11160	11167	O
)	11167	11168	O
3	11168	11169	O
.	11169	11170	O
3	11170	11171	O
(	11172	11173	O
1	11173	11174	O
.	11174	11175	O
4	11175	11176	O
)	11176	11177	O
4	11177	11178	O
.	11178	11179	O
5	11179	11180	O
(	11181	11182	O
1	11182	11183	O
.	11183	11184	O
0	11184	11185	O
)	11185	11186	O
<	11186	11187	O
0	11187	11188	O
.	11188	11189	O
01Number	11189	11197	O
of	11198	11200	O
dressings	11201	11210	O
-	11211	11212	O
week1	11213	11218	O
.	11218	11219	O
5	11219	11220	O
(	11221	11222	O
0	11222	11223	O
.	11223	11224	O
4	11224	11225	O
)	11225	11226	O
3	11226	11227	O
.	11227	11228	O
2	11228	11229	O
(	11230	11231	O
0	11231	11232	O
.	11232	11233	O
8	11233	11234	O
)	11234	11235	O
<	11235	11236	O
0	11236	11237	O
.	11237	11238	O
0001Number	11238	11248	O
of	11249	11251	O
total	11252	11257	O
dressings	11258	11267	O
-	11268	11269	O
until	11270	11275	O
recovery2	11276	11285	O
.	11285	11286	O
7	11286	11287	O
(	11288	11289	O
2	11289	11290	O
.	11290	11291	O
7	11291	11292	O
)	11292	11293	O
7	11293	11294	O
.	11294	11295	O
8	11295	11296	O
(	11297	11298	O
16	11298	11300	O
.	11300	11301	O
6	11301	11302	O
)	11302	11303	O
<	11303	11304	O
0	11304	11305	O
.	11305	11306	O
0001Time	11306	11314	O
for	11315	11318	O
a	11319	11320	O
complete	11321	11329	O
recovery	11330	11338	O
(	11339	11340	O
days	11340	11344	O
)	11344	11345	O
11	11345	11347	O
.	11347	11348	O
0	11348	11349	O
(	11350	11351	O
50	11351	11353	O
.	11353	11354	O
3	11354	11355	O
)	11355	11356	O
28	11356	11358	O
.	11358	11359	O
3	11359	11360	O
(	11361	11362	O
228	11362	11365	O
.	11365	11366	O
2	11366	11367	O
)	11367	11368	O
<	11368	11369	O
0	11369	11370	O
.	11370	11371	O
001Days	11371	11378	O
of	11379	11381	O
hospitalization1	11382	11398	O
.	11398	11399	O
1	11399	11400	O
(	11401	11402	O
0	11402	11403	O
.	11403	11404	O
1	11404	11405	O
)	11405	11406	O
1	11406	11407	O
.	11407	11408	O
3	11408	11409	O
(	11410	11411	O
0	11411	11412	O
.	11412	11413	O
1	11413	11414	O
)	11414	11415	O
0	11415	11416	O
.	11416	11417	O
09Days	11417	11423	O
for	11424	11427	O
coming	11428	11434	O
at	11435	11437	O
work11	11438	11444	O
.	11444	11445	O
7	11445	11446	O
(	11447	11448	O
34	11448	11450	O
.	11450	11451	O
1	11451	11452	O
)	11452	11453	O
28	11453	11455	O
.	11455	11456	O
8	11456	11457	O
(	11458	11459	O
142	11459	11462	O
.	11462	11463	O
6	11463	11464	O
)	11464	11465	O
<	11465	11466	O
0	11466	11467	O
.	11467	11468	O
0001Patient	11468	11479	O
feeling	11480	11487	O
feedback7	11488	11497	O
.	11497	11498	O
9	11498	11499	O
(	11500	11501	O
0	11501	11502	O
.	11502	11503	O
6	11503	11504	O
)	11504	11505	O
5	11505	11506	O
.	11506	11507	O
3	11507	11508	O
(	11509	11510	O
2	11510	11511	O
.	11511	11512	O
5	11512	11513	O
)	11513	11514	O
<	11514	11515	O
0	11515	11516	O
.	11516	11517	O
0001Scar	11517	11525	O
aspect	11526	11532	O
VAS8	11533	11537	O
.	11537	11538	O
1	11538	11539	O
(	11540	11541	O
0	11541	11542	O
.	11542	11543	O
3	11543	11544	O
)	11544	11545	O
5	11545	11546	O
.	11546	11547	O
4	11547	11548	O
(	11549	11550	O
1	11550	11551	O
.	11551	11552	O
3	11552	11553	O
)	11553	11554	O
<	11554	11555	O
0	11555	11556	O
.	11556	11557	O
0001Table	11557	11566	O
3Temperature	11567	11579	O
data	11580	11584	O
.	11584	11585	O
Table	11585	11590	O
3Cold	11591	11596	O
(	11597	11598	O
n	11598	11599	O
=	11600	11601	O
13	11602	11604	O
)	11604	11605	O
Hot	11605	11608	O
(	11609	11610	O
n	11610	11611	O
=	11612	11613	O
16	11614	11616	O
)	11616	11617	O
p	11617	11618	O
-	11618	11619	O
valueRecovered	11619	11633	O
wounds	11634	11640	O
after	11641	11646	O
8	11647	11648	O
–	11648	11649	O
12	11649	11651	O
days84	11652	11658	O
.	11658	11659	O
6	11659	11660	O
%	11660	11661	O
18	11661	11663	O
.	11663	11664	O
8	11664	11665	O
%	11665	11666	O
<	11666	11667	O
0	11667	11668	O
.	11668	11669	O
001Dindo	11669	11677	O
Clavien	11678	11685	O
complications	11686	11699	O
-	11699	11700	O
grade	11700	11705	O
I15	11706	11709	O
.	11709	11710	O
4	11710	11711	O
%	11711	11712	O
100	11712	11715	O
.	11715	11716	O
0	11716	11717	O
%	11717	11718	O
<	11718	11719	O
0	11719	11720	O
.	11720	11721	O
0001Dindo	11721	11730	O
Clavien	11731	11738	O
complications	11739	11752	O
-	11752	11753	O
grade	11753	11758	O
II0	11759	11762	O
.	11762	11763	O
0	11763	11764	O
%	11764	11765	O
6	11765	11766	O
.	11766	11767	O
3	11767	11768	O
%	11768	11769	O
0	11769	11770	O
.	11770	11771	O
36	11771	11773	O
Table	11774	11779	O
2	11780	11781	O
Selection	11782	11791	O
criteria	11792	11800	O
.	11800	11801	O

Table	11802	11807	O
3	11808	11809	O
Temperature	11810	11821	O
data	11822	11826	O
.	11826	11827	O

In	11828	11830	O
the	11831	11834	O
group	11835	11840	O
treated	11841	11848	O
by	11849	11851	O
classic	11852	11859	O
scalpel	11860	11867	O
,	11867	11868	O
the	11869	11872	O
number	11873	11879	O
of	11880	11882	O
complete	11883	11891	O
healing	11892	11899	O
in	11900	11902	O
8	11903	11904	O
–	11904	11905	O
12	11905	11907	O
days	11908	11912	O
was	11913	11916	O
very	11917	11921	O
high	11922	11926	O
and	11927	11930	O
11	11931	11933	O
patients	11934	11942	O
,	11942	11943	O
corresponding	11944	11957	O
to	11958	11960	O
the	11961	11964	O
84	11965	11967	O
.	11967	11968	O
6	11968	11969	O
%	11969	11970	O
,	11970	11971	O
had	11972	11975	O
a	11976	11977	O
complete	11978	11986	O
resolution	11987	11997	O
;	11997	11998	O
only	11999	12003	O
two	12004	12007	O
patients	12008	12016	O
(	12017	12018	O
15	12018	12020	O
.	12020	12021	O
4	12021	12022	O
%	12022	12023	O
)	12023	12024	O
had	12025	12028	O
delayed	12029	12036	O
healing	12037	12044	O
.	12044	12045	O

Mean	12046	12050	O
time	12051	12055	O
to	12056	12058	O
complete	12059	12067	O
healing	12068	12075	O
,	12075	12076	O
measured	12077	12085	O
in	12086	12088	O
days	12089	12093	O
,	12093	12094	O
was	12095	12098	O
shorter	12099	12106	O
for	12107	12110	O
“	12111	12112	O
cold	12112	12116	O
”	12116	12117	O
group	12118	12123	O
about	12124	12129	O
8	12130	12131	O
.	12131	12132	O
5	12132	12133	O
with	12134	12138	O
a	12139	12140	O
range	12141	12146	O
between	12147	12154	O
6	12155	12156	O
and	12157	12160	O
11	12161	12163	O
days	12164	12168	O
,	12168	12169	O
while	12170	12175	O
longer	12176	12182	O
healing	12183	12190	O
time	12191	12195	O
in	12196	12198	O
the	12199	12202	O
“	12203	12204	O
hot	12204	12207	O
”	12207	12208	O
group	12209	12214	O
with	12215	12219	O
a	12220	12221	O
median	12222	12228	O
of	12229	12231	O
28	12232	12234	O
.	12234	12235	O
25	12235	12237	O
in	12238	12240	O
a	12241	12242	O
range	12243	12248	O
of	12249	12251	O
10	12252	12254	O
–	12254	12255	O
62	12255	12257	O
days	12258	12262	O
.	12262	12263	O

This	12264	12268	O
was	12269	12272	O
related	12273	12280	O
to	12281	12283	O
the	12284	12287	O
number	12288	12294	O
of	12295	12297	O
dressings	12298	12307	O
in	12308	12310	O
week	12311	12315	O
,	12315	12316	O
about	12317	12322	O
2	12323	12324	O
±	12325	12326	O
1	12327	12328	O
in	12329	12331	O
the	12332	12335	O
“	12336	12337	O
cold	12337	12341	O
”	12341	12342	O
group	12343	12348	O
and	12349	12352	O
3	12353	12354	O
±	12355	12356	O
2	12357	12358	O
in	12359	12361	O
the	12362	12365	O
“	12366	12367	O
hot	12367	12370	O
”	12370	12371	O
one	12372	12375	O
and	12376	12379	O
also	12380	12384	O
the	12385	12388	O
number	12389	12395	O
of	12396	12398	O
total	12399	12404	O
dressing	12405	12413	O
until	12414	12419	O
healing	12420	12427	O
,	12427	12428	O
very	12429	12433	O
high	12434	12438	O
in	12439	12441	O
some	12442	12446	O
cases	12447	12452	O
,	12452	12453	O
such	12454	12458	O
as	12459	12461	O
15	12462	12464	O
changes	12465	12472	O
.	12472	12473	O

Some	12474	12478	O
differences	12479	12490	O
were	12491	12495	O
notice	12496	12502	O
about	12503	12508	O
quality	12509	12516	O
of	12517	12519	O
life	12520	12524	O
and	12525	12528	O
return	12529	12535	O
to	12536	12538	O
work	12539	12543	O
and	12544	12547	O
daily	12548	12553	O
activities	12554	12564	O
:	12564	12565	O
median	12566	12572	O
time	12573	12577	O
to	12578	12580	O
return	12581	12587	O
to	12588	12590	O
normal	12591	12597	O
activity	12598	12606	O
was	12607	12610	O
25	12611	12613	O
.	12613	12614	O
8	12614	12615	O
days	12616	12620	O
until	12621	12626	O
45	12627	12629	O
days	12630	12634	O
for	12635	12638	O
“	12639	12640	O
hot	12640	12643	O
”	12643	12644	O
group	12645	12650	O
.	12650	12651	O

Time	12652	12656	O
of	12657	12659	O
hospitalization	12660	12675	O
was	12676	12679	O
similar	12680	12687	O
.	12687	12688	O

A	12689	12690	O
better	12691	12697	O
outcomes	12698	12706	O
feedback	12707	12715	O
was	12716	12719	O
recorded	12720	12728	O
also	12729	12733	O
for	12734	12737	O
the	12738	12741	O
“	12742	12743	O
cold	12743	12747	O
”	12747	12748	O
ones	12749	12753	O
,	12753	12754	O
with	12755	12759	O
low	12760	12763	O
incidence	12764	12773	O
of	12774	12776	O
postoperative	12777	12790	O
pain	12791	12795	O
and	12796	12799	O
postoperative	12800	12813	O
complications	12814	12827	O
,	12827	12828	O
reaching	12829	12837	O
100	12838	12841	O
.	12841	12842	O
0	12842	12843	O
%	12843	12844	O
in	12845	12847	O
“	12848	12849	O
hot	12849	12852	O
”	12852	12853	O
group	12854	12859	O
for	12860	12863	O
Dindo	12864	12869	O
-	12869	12870	O
Clavien	12870	12877	O
Grade	12878	12883	O
I	12884	12885	O
.	12885	12886	O

Blood	12887	12892	O
loss	12893	12897	O
were	12898	12902	O
little	12903	12909	O
higher	12910	12916	O
in	12917	12919	O
the	12920	12923	O
scalpel	12924	12931	O
group	12932	12937	O
,	12937	12938	O
but	12939	12942	O
satisfaction	12943	12955	O
of	12956	12958	O
the	12959	12962	O
patients	12963	12971	O
and	12972	12975	O
cosmetics	12976	12985	O
results	12986	12993	O
were	12994	12998	O
quite	12999	13004	O
high	13005	13009	O
in	13010	13012	O
the	13013	13016	O
cold	13017	13021	O
group	13022	13027	O
too	13028	13031	O
.	13031	13032	O

In	13033	13035	O
this	13036	13040	O
study	13041	13046	O
blood	13047	13052	O
loss	13053	13057	O
was	13058	13061	O
a	13062	13063	O
secondary	13064	13073	O
outcome	13074	13081	O
that	13082	13086	O
we	13087	13089	O
measured	13090	13098	O
using	13099	13104	O
a	13105	13106	O
common	13107	13113	O
suction	13114	13121	O
system	13122	13128	O
connected	13129	13138	O
to	13139	13141	O
a	13142	13143	O
receptacle	13144	13154	O
,	13154	13155	O
with	13156	13160	O
volume	13161	13167	O
marks	13168	13173	O
,	13173	13174	O
to	13175	13177	O
maintain	13178	13186	O
cleaned	13187	13194	O
the	13195	13198	O
operative	13199	13208	O
field	13209	13214	O
.	13214	13215	O

Blood	13216	13221	O
was	13222	13225	O
collected	13226	13235	O
,	13235	13236	O
measured	13237	13245	O
and	13246	13249	O
compared	13250	13258	O
between	13259	13266	O
the	13267	13270	O
two	13271	13274	O
groups	13275	13281	O
.	13281	13282	O

More	13283	13287	O
post	13288	13292	O
-	13292	13293	O
operative	13293	13302	O
pain	13303	13307	O
was	13308	13311	O
recorded	13312	13320	O
at	13321	13323	O
the	13324	13327	O
first	13328	13333	O
control	13334	13341	O
and	13342	13345	O
worse	13346	13351	O
scar	13352	13356	O
aspect	13357	13363	O
at	13364	13366	O
the	13367	13370	O
end	13371	13374	O
of	13375	13377	O
complete	13378	13386	O
healing	13387	13394	O
and	13395	13398	O
also	13399	13403	O
worse	13404	13409	O
feeling	13410	13417	O
feedback	13418	13426	O
was	13427	13430	O
recorded	13431	13439	O
among	13440	13445	O
the	13446	13449	O
patients	13450	13458	O
treated	13459	13466	O
by	13467	13469	O
electro	13470	13477	O
-	13477	13478	O
surgery	13478	13485	O
on	13486	13488	O
VAS	13489	13492	O
evaluation	13493	13503	O
.	13503	13504	O

The	13505	13508	O
average	13509	13516	O
number	13517	13523	O
of	13524	13526	O
days	13527	13531	O
of	13532	13534	O
hospitalization	13535	13550	O
is	13551	13553	O
not	13554	13557	O
significantly	13558	13571	O
different	13572	13581	O
between	13582	13589	O
the	13590	13593	O
two	13594	13597	O
groups	13598	13604	O
.	13604	13605	O

4	13607	13608	O
Discussion	13609	13619	O
Several	13620	13627	O
medical	13628	13635	O
and	13636	13639	O
surgical	13640	13648	O
options	13649	13656	O
have	13657	13661	O
been	13662	13666	O
proposed	13667	13675	O
to	13676	13678	O
manage	13679	13685	O
at	13686	13688	O
its	13689	13692	O
best	13693	13697	O
the	13698	13701	O
disease	13702	13709	O
and	13710	13713	O
to	13714	13716	O
reduce	13717	13723	O
recurrence	13724	13734	O
rates	13735	13740	O
and	13741	13744	O
,	13744	13745	O
so	13746	13748	O
,	13748	13749	O
different	13750	13759	O
techniques	13760	13770	O
were	13771	13775	O
introduced	13776	13786	O
with	13787	13791	O
the	13792	13795	O
purpose	13796	13803	O
to	13804	13806	O
improve	13807	13814	O
wound	13815	13820	O
healing	13821	13828	O
and	13829	13832	O
reduce	13833	13839	O
morbidity	13840	13849	O
related	13850	13857	O
.	13857	13858	O

The	13859	13862	O
“	13863	13864	O
ideal	13864	13869	O
surgery	13870	13877	O
”	13877	13878	O
should	13879	13885	O
be	13886	13888	O
simple	13889	13895	O
and	13896	13899	O
short	13900	13905	O
in	13906	13908	O
time	13909	13913	O
,	13913	13914	O
with	13915	13919	O
rapid	13920	13925	O
recovery	13926	13934	O
and	13935	13938	O
short	13939	13944	O
hospitalization	13945	13960	O
,	13960	13961	O
faster	13962	13968	O
return	13969	13975	O
to	13976	13978	O
normal	13979	13985	O
activity	13986	13994	O
,	13994	13995	O
with	13996	14000	O
low	14001	14004	O
recurrence	14005	14015	O
rates	14016	14021	O
,	14021	14022	O
and	14023	14026	O
in	14027	14029	O
end	14030	14033	O
,	14033	14034	O
good	14035	14039	O
cosmetic	14040	14048	O
results	14049	14056	O
.	14056	14057	O

Small	14058	14063	O
incision	14064	14072	O
or	14073	14075	O
limited	14076	14083	O
excision	14084	14092	O
,	14092	14093	O
rather	14094	14100	O
than	14101	14105	O
large	14106	14111	O
removal	14112	14119	O
with	14120	14124	O
delayed	14125	14132	O
closure	14133	14140	O
or	14141	14143	O
flaps	14144	14149	O
creation	14150	14158	O
are	14159	14162	O
some	14163	14167	O
of	14168	14170	O
the	14171	14174	O
very	14175	14179	O
wide	14180	14184	O
approaches	14185	14195	O
to	14196	14198	O
the	14199	14202	O
disease	14203	14210	O
,	14210	14211	O
but	14212	14215	O
until	14216	14221	O
now	14222	14225	O
which	14226	14231	O
should	14232	14238	O
be	14239	14241	O
the	14242	14245	O
gold	14246	14250	O
standard	14251	14259	O
surgery	14260	14267	O
is	14268	14270	O
still	14271	14276	O
a	14277	14278	O
debate	14279	14285	O
[	14286	14287	O
[	14287	14288	O
4	14288	14289	O
]	14289	14290	O
,	14290	14291	O
[	14292	14293	O
5	14293	14294	O
]	14294	14295	O
,	14295	14296	O
[	14297	14298	O
6	14298	14299	O
]	14299	14300	O
,	14300	14301	O
[	14302	14303	O
7	14303	14304	O
]	14304	14305	O
]	14305	14306	O
.	14306	14307	O

Different	14308	14317	O
energy	14318	14324	O
sources	14325	14332	O
have	14333	14337	O
been	14338	14342	O
employed	14343	14351	O
to	14352	14354	O
improve	14355	14362	O
outcomes	14363	14371	O
,	14371	14372	O
but	14373	14376	O
no	14377	14379	O
consensus	14380	14389	O
does	14390	14394	O
exist	14395	14400	O
on	14401	14403	O
real	14404	14408	O
advantages	14409	14419	O
[	14420	14421	O
8	14421	14422	O
,	14422	14423	O
9	14423	14424	O
]	14424	14425	O
and	14426	14429	O
minimally	14430	14439	O
invasive	14440	14448	O
approach	14449	14457	O
seems	14458	14463	O
to	14464	14466	O
be	14467	14469	O
the	14470	14473	O
current	14474	14481	O
trend	14482	14487	O
[	14488	14489	O
[	14489	14490	O
10	14490	14492	O
]	14492	14493	O
,	14493	14494	O
[	14495	14496	O
11	14496	14498	O
]	14498	14499	O
,	14499	14500	O
[	14501	14502	O
12	14502	14504	O
]	14504	14505	O
]	14505	14506	O
.	14506	14507	O

However	14508	14515	O
no	14516	14518	O
one	14519	14522	O
of	14523	14525	O
these	14526	14531	O
techniques	14532	14542	O
seems	14543	14548	O
to	14549	14551	O
be	14552	14554	O
without	14555	14562	O
postoperative	14563	14576	O
complications	14577	14590	O
as	14591	14593	O
pain	14594	14598	O
,	14598	14599	O
recurrence	14600	14610	O
rates	14611	14616	O
,	14616	14617	O
wound	14618	14623	O
infection	14624	14633	O
and	14634	14637	O
delayed	14638	14645	O
healing	14646	14653	O
.	14653	14654	O

One	14655	14658	O
of	14659	14661	O
the	14662	14665	O
worst	14666	14671	O
aspect	14672	14678	O
in	14679	14681	O
pilonidalis	14682	14693	O
disease	14694	14701	O
management	14702	14712	O
regards	14713	14720	O
exactly	14721	14728	O
wound	14729	14734	O
evolution	14735	14744	O
in	14745	14747	O
post	14748	14752	O
operative	14753	14762	O
time	14763	14767	O
,	14767	14768	O
because	14769	14776	O
a	14777	14778	O
primary	14779	14786	O
closure	14787	14794	O
with	14795	14799	O
a	14800	14801	O
proper	14802	14808	O
healing	14809	14816	O
between	14817	14824	O
7	14825	14826	O
and	14827	14830	O
10	14831	14833	O
days	14834	14838	O
is	14839	14841	O
the	14842	14845	O
desirable	14846	14855	O
and	14856	14859	O
normal	14860	14866	O
course	14867	14873	O
,	14873	14874	O
but	14875	14878	O
a	14879	14880	O
problem	14881	14888	O
in	14889	14891	O
wound	14892	14897	O
healing	14898	14905	O
should	14906	14912	O
because	14913	14920	O
of	14921	14923	O
weighty	14924	14931	O
morbidity	14932	14941	O
,	14941	14942	O
annoying	14943	14951	O
and	14952	14955	O
limiting	14956	14964	O
consequences	14965	14977	O
on	14978	14980	O
activities	14981	14991	O
of	14992	14994	O
daily	14995	15000	O
living	15001	15007	O
,	15007	15008	O
forcing	15009	15016	O
the	15017	15020	O
patients	15021	15029	O
to	15030	15032	O
several	15033	15040	O
outpatient	15041	15051	O
access	15052	15058	O
and	15059	15062	O
medication	15063	15073	O
until	15074	15079	O
30	15080	15082	O
–	15082	15083	O
40	15083	15085	O
days	15086	15090	O
;	15090	15091	O
this	15092	15096	O
clearly	15097	15104	O
could	15105	15110	O
became	15111	15117	O
a	15118	15119	O
stressing	15120	15129	O
situation	15130	15139	O
[	15140	15141	O
13	15141	15143	O
,	15143	15144	O
14	15144	15146	O
]	15146	15147	O
.	15147	15148	O

Secondary	15149	15158	O
intention	15159	15168	O
pilonidalis	15169	15180	O
wound	15181	15186	O
healing	15187	15194	O
,	15194	15195	O
may	15196	15199	O
requires	15200	15208	O
a	15209	15210	O
very	15211	15215	O
long	15216	15220	O
laps	15221	15225	O
of	15226	15228	O
time	15229	15233	O
,	15233	15234	O
from	15235	15239	O
2	15240	15241	O
to	15242	15244	O
6	15245	15246	O
months	15247	15253	O
or	15254	15256	O
even	15257	15261	O
up	15262	15264	O
to	15265	15267	O
1	15268	15269	O
–	15269	15270	O
2	15270	15271	O
years	15272	15277	O
,	15277	15278	O
to	15279	15281	O
return	15282	15288	O
to	15289	15291	O
normality	15292	15301	O
and	15302	15305	O
this	15306	15310	O
traduces	15311	15319	O
in	15320	15322	O
several	15323	15330	O
and	15331	15334	O
repeated	15335	15343	O
medical	15344	15351	O
dressing	15352	15360	O
with	15361	15365	O
patients	15366	15374	O
and	15375	15378	O
hospital	15379	15387	O
burdensomeness	15388	15402	O
[	15403	15404	O
15	15404	15406	O
,	15406	15407	O
16	15407	15409	O
]	15409	15410	O
.	15410	15411	O

Moving	15412	15418	O
by	15419	15421	O
the	15422	15425	O
observation	15426	15437	O
that	15438	15442	O
a	15443	15444	O
cut	15445	15448	O
,	15448	15449	O
an	15450	15452	O
incision	15453	15461	O
or	15462	15464	O
injury	15465	15471	O
heals	15472	15477	O
better	15478	15484	O
and	15485	15488	O
faster	15489	15495	O
if	15496	15498	O
the	15499	15502	O
tissues	15503	15510	O
are	15511	15514	O
healthy	15515	15522	O
,	15522	15523	O
well	15524	15528	O
vascularized	15529	15541	O
and	15542	15545	O
not	15546	15549	O
so	15550	15552	O
much	15553	15557	O
damaged	15558	15565	O
by	15566	15568	O
chemical	15569	15577	O
or	15578	15580	O
physical	15581	15589	O
agents	15590	15596	O
,	15596	15597	O
we	15598	15600	O
hypothesized	15601	15613	O
that	15614	15618	O
,	15618	15619	O
in	15620	15622	O
addition	15623	15631	O
to	15632	15634	O
classical	15635	15644	O
risk	15645	15649	O
factors	15650	15657	O
for	15658	15661	O
recurrence	15662	15672	O
and	15673	15676	O
wound	15677	15682	O
healing	15683	15690	O
failure	15691	15698	O
,	15698	15699	O
an	15700	15702	O
independent	15703	15714	O
technical	15715	15724	O
cause	15725	15730	O
may	15731	15734	O
worsen	15735	15741	O
the	15742	15745	O
clinical	15746	15754	O
course	15755	15761	O
and	15762	15765	O
outcomes	15766	15774	O
delaying	15775	15783	O
healing	15784	15791	O
.	15791	15792	O

This	15793	15797	O
is	15798	15800	O
especially	15801	15811	O
true	15812	15816	O
in	15817	15819	O
burn	15820	15824	O
injuries	15825	15833	O
,	15833	15834	O
were	15835	15839	O
tissue	15840	15846	O
are	15847	15850	O
severely	15851	15859	O
and	15860	15863	O
variably	15864	15872	O
mortified	15873	15882	O
by	15883	15885	O
the	15886	15889	O
heat	15890	15894	O
and	15895	15898	O
the	15899	15902	O
biological	15903	15913	O
recovery	15914	15922	O
is	15923	15925	O
very	15926	15930	O
slow	15931	15935	O
impaired	15936	15944	O
by	15945	15947	O
fluid	15948	15953	O
secretions	15954	15964	O
,	15964	15965	O
exudations	15966	15976	O
,	15976	15977	O
edema	15978	15983	O
,	15983	15984	O
necrotizing	15985	15996	O
areas	15997	16002	O
development	16003	16014	O
or	16015	16017	O
fibrin	16018	16024	O
deposition	16025	16035	O
.	16035	16036	O

We	16037	16039	O
notice	16040	16046	O
in	16047	16049	O
our	16050	16053	O
daily	16054	16059	O
experience	16060	16070	O
in	16071	16073	O
outpatient	16074	16084	O
management	16085	16095	O
,	16095	16096	O
that	16097	16101	O
,	16101	16102	O
often	16103	16108	O
,	16108	16109	O
different	16110	16119	O
course	16120	16126	O
was	16127	16130	O
evident	16131	16138	O
between	16139	16146	O
patients	16147	16155	O
treated	16156	16163	O
by	16164	16166	O
classical	16167	16176	O
diathermy	16177	16186	O
or	16187	16189	O
knife	16190	16195	O
:	16195	16196	O
while	16197	16202	O
a	16203	16204	O
greater	16205	16212	O
incidence	16213	16222	O
of	16223	16225	O
wound	16226	16231	O
complications	16232	16245	O
,	16245	16246	O
specially	16247	16256	O
infection	16257	16266	O
but	16267	16270	O
,	16270	16271	O
above	16272	16277	O
all	16278	16281	O
dehiscence	16282	16292	O
,	16292	16293	O
and	16294	16297	O
delayed	16298	16305	O
healing	16306	16313	O
was	16314	16317	O
noticed	16318	16325	O
in	16326	16328	O
the	16329	16332	O
first	16333	16338	O
ones	16339	16343	O
,	16343	16344	O
on	16345	16347	O
the	16348	16351	O
contrary	16352	16360	O
,	16360	16361	O
a	16362	16363	O
rapid	16364	16369	O
recovery	16370	16378	O
,	16378	16379	O
often	16380	16385	O
,	16385	16386	O
distinguished	16387	16400	O
the	16401	16404	O
second	16405	16411	O
ones	16412	16416	O
.	16416	16417	O

Aim	16418	16421	O
of	16422	16424	O
this	16425	16429	O
study	16430	16435	O
was	16436	16439	O
to	16440	16442	O
evaluate	16443	16451	O
if	16452	16454	O
energy	16455	16461	O
employed	16462	16470	O
in	16471	16473	O
surgical	16474	16482	O
technique	16483	16492	O
,	16492	16493	O
can	16494	16497	O
improve	16498	16505	O
or	16506	16508	O
worse	16509	16514	O
outcomes	16515	16523	O
.	16523	16524	O

No	16525	16527	O
evaluation	16528	16538	O
was	16539	16542	O
made	16543	16547	O
on	16548	16550	O
recurrence	16551	16561	O
rates	16562	16567	O
and	16568	16571	O
problem	16572	16579	O
related	16580	16587	O
,	16587	16588	O
because	16589	16596	O
we	16597	16599	O
want	16600	16604	O
to	16605	16607	O
deepen	16608	16614	O
what	16615	16619	O
can	16620	16623	O
influence	16624	16633	O
patients	16634	16642	O
’	16642	16643	O
quality	16644	16651	O
of	16652	16654	O
life	16655	16659	O
.	16659	16660	O

Surely	16661	16667	O
,	16667	16668	O
a	16669	16670	O
great	16671	16676	O
number	16677	16683	O
of	16684	16686	O
outpatient	16687	16697	O
access	16698	16704	O
,	16704	16705	O
several	16706	16713	O
dressing	16714	16722	O
changes	16723	16730	O
,	16730	16731	O
moist	16732	16737	O
sensation	16738	16747	O
and	16748	16751	O
embarrassing	16752	16764	O
feeling	16765	16772	O
related	16773	16780	O
,	16780	16781	O
but	16782	16785	O
also	16786	16790	O
delayed	16791	16798	O
return	16799	16805	O
to	16806	16808	O
normal	16809	16815	O
activity	16816	16824	O
,	16824	16825	O
are	16826	16829	O
very	16830	16834	O
bad	16835	16838	O
aspects	16839	16846	O
of	16847	16849	O
this	16850	16854	O
disease	16855	16862	O
.	16862	16863	O

The	16864	16867	O
purpose	16868	16875	O
of	16876	16878	O
the	16879	16882	O
healing	16883	16890	O
process	16891	16898	O
is	16899	16901	O
to	16902	16904	O
replace	16905	16912	O
the	16913	16916	O
tissue	16917	16923	O
that	16924	16928	O
has	16929	16932	O
been	16933	16937	O
damaged	16938	16945	O
,	16945	16946	O
with	16947	16951	O
living	16952	16958	O
tissue	16959	16965	O
,	16965	16966	O
and	16967	16970	O
to	16971	16973	O
restore	16974	16981	O
the	16982	16985	O
continuity	16986	16996	O
of	16997	16999	O
the	17000	17003	O
skin	17004	17008	O
.	17008	17009	O

Open	17010	17014	O
wounds	17015	17021	O
,	17021	17022	O
heal	17023	17027	O
through	17028	17035	O
a	17036	17037	O
long	17038	17042	O
and	17043	17046	O
complex	17047	17054	O
process	17055	17062	O
by	17063	17065	O
formation	17066	17075	O
of	17076	17078	O
granulation	17079	17090	O
tissue	17091	17097	O
and	17098	17101	O
re	17102	17104	O
-	17104	17105	O
epithelialization	17105	17122	O
,	17122	17123	O
that	17124	17128	O
requires	17129	17137	O
several	17138	17145	O
days	17146	17150	O
,	17150	17151	O
maintaining	17152	17163	O
of	17164	17166	O
good	17167	17171	O
local	17172	17177	O
condition	17178	17187	O
of	17188	17190	O
cleaning	17191	17199	O
and	17200	17203	O
vascularization	17204	17219	O
.	17219	17220	O

If	17221	17223	O
the	17224	17227	O
healing	17228	17235	O
process	17236	17243	O
of	17244	17246	O
a	17247	17248	O
closed	17249	17255	O
wound	17256	17261	O
is	17262	17264	O
“	17265	17266	O
regular	17266	17273	O
”	17273	17274	O
,	17274	17275	O
generally	17276	17285	O
it	17286	17288	O
is	17289	17291	O
completed	17292	17301	O
in	17302	17304	O
8	17305	17306	O
–	17306	17307	O
10	17307	17309	O
days	17310	17314	O
without	17315	17322	O
complications	17323	17336	O
and	17337	17340	O
integrity	17341	17350	O
of	17351	17353	O
tissues	17354	17361	O
,	17361	17362	O
from	17363	17367	O
down	17368	17372	O
to	17373	17375	O
up	17376	17378	O
,	17378	17379	O
is	17380	17382	O
replaced	17383	17391	O
.	17391	17392	O

A	17393	17394	O
Such	17395	17399	O
“	17400	17401	O
regular	17401	17408	O
”	17408	17409	O
and	17410	17413	O
fast	17414	17418	O
healing	17419	17426	O
process	17427	17434	O
is	17435	17437	O
the	17438	17441	O
aim	17442	17445	O
of	17446	17448	O
the	17449	17452	O
surgeon	17453	17460	O
and	17461	17464	O
the	17465	17468	O
hope	17469	17473	O
of	17474	17476	O
the	17477	17480	O
patient	17481	17488	O
,	17488	17489	O
but	17490	17493	O
sometimes	17494	17503	O
it	17504	17506	O
is	17507	17509	O
slow	17510	17514	O
and	17515	17518	O
difficult	17519	17528	O
with	17529	17533	O
important	17534	17543	O
delaying	17544	17552	O
tissue	17553	17559	O
sealing	17560	17567	O
due	17568	17571	O
to	17572	17574	O
the	17575	17578	O
creation	17579	17587	O
of	17588	17590	O
unfavorable	17591	17602	O
conditions	17603	17613	O
.	17613	17614	O

Generally	17615	17624	O
a	17625	17626	O
smaller	17627	17634	O
tissue	17635	17641	O
damage	17642	17648	O
and	17649	17652	O
loss	17653	17657	O
,	17657	17658	O
is	17659	17661	O
correlated	17662	17672	O
to	17673	17675	O
a	17676	17677	O
faster	17678	17684	O
and	17685	17688	O
more	17689	17693	O
physiologic	17694	17705	O
healing	17706	17713	O
process	17714	17721	O
;	17721	17722	O
big	17723	17726	O
tissues	17727	17734	O
destruction	17735	17746	O
,	17746	17747	O
damaging	17748	17756	O
and	17757	17760	O
mortification	17761	17774	O
can	17775	17778	O
lead	17779	17783	O
to	17784	17786	O
necrosis	17787	17795	O
,	17795	17796	O
even	17797	17801	O
if	17802	17804	O
partial	17805	17812	O
or	17813	17815	O
isolated	17816	17824	O
,	17824	17825	O
edema	17826	17831	O
,	17831	17832	O
excessive	17833	17842	O
exudation	17843	17852	O
production	17853	17863	O
,	17863	17864	O
chronic	17865	17872	O
inflammatory	17873	17885	O
state	17886	17891	O
,	17891	17892	O
overpressure	17893	17905	O
and	17906	17909	O
tension	17910	17917	O
in	17918	17920	O
the	17921	17924	O
wound	17925	17930	O
with	17931	17935	O
delayed	17936	17943	O
new	17944	17947	O
tissue	17948	17954	O
ingrowths	17955	17964	O
and	17965	17968	O
lack	17969	17973	O
of	17974	17976	O
sealing	17977	17984	O
with	17985	17989	O
dehiscence	17990	18000	O
of	18001	18003	O
sutured	18004	18011	O
skin	18012	18016	O
and	18017	18020	O
subcutaneous	18021	18033	O
tissues	18034	18041	O
.	18041	18042	O

Example	18043	18050	O
of	18051	18053	O
non	18054	18057	O
or	18058	18060	O
delaying	18061	18069	O
healing	18070	18077	O
wounds	18078	18084	O
,	18084	18085	O
where	18086	18091	O
necrosis	18092	18100	O
,	18100	18101	O
exudates	18102	18110	O
,	18110	18111	O
seroma	18112	18118	O
formation	18119	18128	O
,	18128	18129	O
and	18130	18133	O
difficult	18134	18143	O
growth	18144	18150	O
are	18151	18154	O
evident	18155	18162	O
,	18162	18163	O
could	18164	18169	O
be	18170	18172	O
venous	18173	18179	O
legs	18180	18184	O
ulcers	18185	18191	O
,	18191	18192	O
pressure	18193	18201	O
ulcers	18202	18208	O
,	18208	18209	O
skin	18210	18214	O
and	18215	18218	O
soft	18219	18223	O
tissues	18224	18231	O
burns	18232	18237	O
,	18237	18238	O
infected	18239	18247	O
wounds	18248	18254	O
,	18254	18255	O
sutured	18256	18263	O
“	18264	18265	O
no	18265	18267	O
-	18267	18268	O
tension	18268	18275	O
-	18275	18276	O
free	18276	18280	O
”	18280	18281	O
wounds	18282	18288	O
,	18288	18289	O
excessively	18290	18301	O
exuding	18302	18309	O
injury	18310	18316	O
;	18316	18317	O
on	18318	18320	O
the	18321	18324	O
contrary	18325	18333	O
,	18333	18334	O
cutting	18335	18342	O
wound	18343	18348	O
that	18349	18353	O
are	18354	18357	O
not	18358	18361	O
burned	18362	18368	O
or	18369	18371	O
without	18372	18379	O
wide	18380	18384	O
tissue	18385	18391	O
lack	18392	18396	O
or	18397	18399	O
destruction	18400	18411	O
,	18411	18412	O
sutured	18413	18420	O
with	18421	18425	O
no	18426	18428	O
tension	18429	18436	O
among	18437	18442	O
the	18443	18446	O
margins	18447	18454	O
seems	18455	18460	O
to	18461	18463	O
heal	18464	18468	O
faster	18469	18475	O
and	18476	18479	O
better	18480	18486	O
especially	18487	18497	O
if	18498	18500	O
blood	18501	18506	O
or	18507	18509	O
serous	18510	18516	O
secretion	18517	18526	O
are	18527	18530	O
periodically	18531	18543	O
drained	18544	18551	O
.	18551	18552	O

The	18553	18556	O
entity	18557	18563	O
of	18564	18566	O
tissue	18567	18573	O
damage	18574	18580	O
and	18581	18584	O
the	18585	18588	O
nature	18589	18595	O
of	18596	18598	O
the	18599	18602	O
energy	18603	18609	O
and	18610	18613	O
the	18614	18617	O
time	18618	18622	O
of	18623	18625	O
its	18626	18629	O
application	18630	18641	O
on	18642	18644	O
tissues	18645	18652	O
could	18653	18658	O
impair	18659	18665	O
the	18666	18669	O
regeneration	18670	18682	O
events	18683	18689	O
and	18690	18693	O
growth	18694	18700	O
process	18701	18708	O
;	18708	18709	O
in	18710	18712	O
particular	18713	18723	O
thermal	18724	18731	O
energy	18732	18738	O
,	18738	18739	O
as	18740	18742	O
diathermy	18743	18752	O
,	18752	18753	O
used	18754	18758	O
to	18759	18761	O
incision	18762	18770	O
and	18771	18774	O
tissue	18775	18781	O
dissection	18782	18792	O
seems	18793	18798	O
to	18799	18801	O
be	18802	18804	O
associated	18805	18815	O
with	18816	18820	O
more	18821	18825	O
cellular	18826	18834	O
damage	18835	18841	O
and	18842	18845	O
soft	18846	18850	O
tissue	18851	18857	O
devastation	18858	18869	O
.	18869	18870	O

Have	18871	18875	O
been	18876	18880	O
shown	18881	18886	O
faster	18887	18893	O
operating	18894	18903	O
times	18904	18909	O
,	18909	18910	O
reduced	18911	18918	O
blood	18919	18924	O
loss	18925	18929	O
and	18930	18933	O
early	18934	18939	O
post	18940	18944	O
-	18944	18945	O
operative	18945	18954	O
pain	18955	18959	O
and	18960	18963	O
lower	18964	18969	O
analgesia	18970	18979	O
using	18980	18985	O
diathermy	18986	18995	O
for	18996	18999	O
skin	19000	19004	O
incision	19005	19013	O
if	19014	19016	O
compared	19017	19025	O
with	19026	19030	O
cold	19031	19035	O
blade	19036	19041	O
[	19042	19043	O
18	19043	19045	O
,	19045	19046	O
19	19046	19048	O
]	19048	19049	O
,	19049	19050	O
but	19051	19054	O
this	19055	19059	O
is	19060	19062	O
a	19063	19064	O
“	19065	19066	O
speedy	19066	19072	O
procedure	19073	19082	O
”	19082	19083	O
for	19084	19087	O
a	19088	19089	O
linear	19090	19096	O
and	19097	19100	O
regular	19101	19108	O
cutting	19109	19116	O
with	19117	19121	O
short	19122	19127	O
and	19128	19131	O
“	19132	19133	O
constant	19133	19141	O
moving	19142	19148	O
”	19148	19149	O
energy	19150	19156	O
application	19157	19168	O
and	19169	19172	O
quickly	19173	19180	O
heat	19181	19185	O
dispersion	19186	19196	O
and	19197	19200	O
rapid	19201	19206	O
return	19207	19213	O
of	19214	19216	O
cut	19217	19220	O
tissues	19221	19228	O
to	19229	19231	O
normal	19232	19238	O
body	19239	19243	O
temperature	19244	19255	O
.	19255	19256	O

In	19257	19259	O
this	19260	19264	O
use	19265	19268	O
the	19269	19272	O
damage	19273	19279	O
and	19280	19283	O
the	19284	19287	O
heat	19288	19292	O
burn	19293	19297	O
is	19298	19300	O
limited	19301	19308	O
to	19309	19311	O
the	19312	19315	O
section	19316	19323	O
line	19324	19328	O
and	19329	19332	O
short	19333	19338	O
in	19339	19341	O
time	19342	19346	O
,	19346	19347	O
with	19348	19352	O
no	19353	19355	O
involvement	19356	19367	O
and	19368	19371	O
spreading	19372	19381	O
to	19382	19384	O
the	19385	19388	O
close	19389	19394	O
tissues	19395	19402	O
.	19402	19403	O

The	19404	19407	O
results	19408	19415	O
could	19416	19421	O
be	19422	19424	O
different	19425	19434	O
when	19435	19439	O
diathermy	19440	19449	O
is	19450	19452	O
used	19453	19457	O
to	19458	19460	O
cut	19461	19464	O
skin	19465	19469	O
,	19469	19470	O
dissect	19471	19478	O
underlying	19479	19489	O
soft	19490	19494	O
tissue	19495	19501	O
and	19502	19505	O
fat	19506	19509	O
and	19510	19513	O
to	19514	19516	O
control	19517	19524	O
bleeding	19525	19533	O
,	19533	19534	O
because	19535	19542	O
this	19543	19547	O
use	19548	19551	O
implies	19552	19559	O
not	19560	19563	O
only	19564	19568	O
a	19569	19570	O
longer	19571	19577	O
the	19578	19581	O
time	19582	19586	O
of	19587	19589	O
contact	19590	19597	O
and	19598	19601	O
of	19602	19604	O
energy	19605	19611	O
application	19612	19623	O
and	19624	19627	O
higher	19628	19634	O
energy	19635	19641	O
concentration	19642	19655	O
in	19656	19658	O
a	19659	19660	O
restricted	19661	19671	O
area	19672	19676	O
for	19677	19680	O
a	19681	19682	O
longer	19683	19689	O
time	19690	19694	O
compared	19695	19703	O
to	19704	19706	O
a	19707	19708	O
linear	19709	19715	O
incision	19716	19724	O
,	19724	19725	O
but	19726	19729	O
also	19730	19734	O
a	19735	19736	O
greater	19737	19744	O
heat	19745	19749	O
development	19750	19761	O
in	19762	19764	O
small	19765	19770	O
areas	19771	19776	O
and	19777	19780	O
a	19781	19782	O
wide	19783	19787	O
spreading	19788	19797	O
in	19798	19800	O
near	19801	19805	O
healthy	19806	19813	O
tissue	19814	19820	O
.	19820	19821	O

The	19822	19825	O
full	19826	19830	O
thickness	19831	19840	O
heat	19841	19845	O
dissection	19846	19856	O
,	19856	19857	O
produced	19858	19866	O
by	19867	19869	O
diathermy	19870	19879	O
excision	19880	19888	O
with	19889	19893	O
cautery	19894	19901	O
,	19901	19902	O
translate	19903	19912	O
in	19913	19915	O
a	19916	19917	O
bigger	19918	19924	O
harm	19925	19929	O
from	19930	19934	O
heat	19935	19939	O
,	19939	19940	O
like	19941	19945	O
in	19946	19948	O
second	19949	19955	O
-	19955	19956	O
third	19956	19961	O
degrees	19962	19969	O
burns	19970	19975	O
producing	19976	19985	O
edema	19986	19991	O
,	19991	19992	O
serous	19993	19999	O
secretion	20000	20009	O
,	20009	20010	O
necrotic	20011	20019	O
areas	20020	20025	O
covered	20026	20033	O
with	20034	20038	O
fibrin	20039	20045	O
film	20046	20050	O
,	20050	20051	O
excess	20052	20058	O
of	20059	20061	O
exudates	20062	20070	O
with	20071	20075	O
high	20076	20080	O
concentration	20081	20094	O
of	20095	20097	O
proteases	20098	20107	O
and	20108	20111	O
reduced	20112	20119	O
level	20120	20125	O
of	20126	20128	O
grown	20129	20134	O
factors	20135	20142	O
,	20142	20143	O
inhibiting	20144	20154	O
cell	20155	20159	O
migration	20160	20169	O
and	20170	20173	O
tissue	20174	20180	O
regeneration	20181	20193	O
,	20193	20194	O
high	20195	20199	O
intra	20200	20205	O
-	20205	20206	O
wound	20206	20211	O
pressure	20212	20220	O
and	20221	20224	O
tension	20225	20232	O
on	20233	20235	O
suture	20236	20242	O
stitches	20243	20251	O
,	20251	20252	O
leading	20253	20260	O
to	20261	20263	O
maceration	20264	20274	O
of	20275	20277	O
the	20278	20281	O
surrounding	20282	20293	O
skin	20294	20298	O
and	20299	20302	O
,	20302	20303	O
in	20304	20306	O
end	20307	20310	O
,	20310	20311	O
as	20312	20314	O
demonstrating	20315	20328	O
by	20329	20331	O
several	20332	20339	O
studies	20340	20347	O
showing	20348	20355	O
that	20356	20360	O
high	20361	20365	O
levels	20366	20372	O
of	20373	20375	O
neutrophil	20376	20386	S-CL:0000775
-	20386	20387	O
derived	20387	20394	O
proteases	20395	20404	O
are	20405	20408	O
associated	20409	20419	O
with	20420	20424	O
chronic	20425	20432	O
,	20432	20433	O
non	20434	20437	O
-	20437	20438	O
healing	20438	20445	O
wounds	20446	20452	O
,	20452	20453	O
to	20454	20456	O
an	20457	20459	O
high	20460	20464	O
probability	20465	20476	O
of	20477	20479	O
wound	20480	20485	O
failure	20486	20493	O
[	20494	20495	O
20	20495	20497	O
]	20497	20498	O
.	20498	20499	O

There	20500	20505	O
are	20506	20509	O
few	20510	20513	O
literature	20514	20524	O
reports	20525	20532	O
regarding	20533	20542	O
comparison	20543	20553	O
between	20554	20561	O
different	20562	20571	O
energy	20572	20578	O
source	20579	20585	O
used	20586	20590	O
to	20591	20593	O
perform	20594	20601	O
pilonidal	20602	20611	O
sinus	20612	20617	O
excision	20618	20626	O
.	20626	20627	O

Main	20628	20632	O
data	20633	20637	O
are	20638	20641	O
related	20642	20649	O
only	20650	20654	O
to	20655	20657	O
evaluation	20658	20668	O
of	20669	20671	O
skin	20672	20676	O
incision	20677	20685	O
in	20686	20688	O
animal	20689	20695	O
and	20696	20699	O
abdominal	20700	20709	O
laparotomy	20710	20720	O
in	20721	20723	O
human	20724	20729	O
.	20729	20730	O

No	20731	20733	O
scientific	20734	20744	O
works	20745	20750	O
can	20751	20754	O
be	20755	20757	O
find	20758	20762	O
in	20763	20765	O
literature	20766	20776	O
on	20777	20779	O
comparison	20780	20790	O
between	20791	20798	O
electronic	20799	20809	O
and	20810	20813	O
cold	20814	20818	O
scalpel	20819	20826	O
for	20827	20830	O
the	20831	20834	O
excision	20835	20843	O
of	20844	20846	O
pilonidal	20847	20856	O
disease	20857	20864	O
.	20864	20865	O

First	20866	20871	O
report	20872	20878	O
regarding	20879	20888	O
the	20889	20892	O
use	20893	20896	O
of	20897	20899	O
monopolar	20900	20909	O
electrosurgery	20910	20924	O
for	20925	20928	O
hemostasis	20929	20939	O
in	20940	20942	O
human	20943	20948	O
surgery	20949	20956	O
has	20957	20960	O
been	20961	20965	O
well	20966	20970	O
described	20971	20980	O
since	20981	20986	O
1926	20987	20991	O
[	20992	20993	O
21	20993	20995	O
]	20995	20996	O
.	20996	20997	O

Several	20998	21005	O
experimental	21006	21018	O
studies	21019	21026	O
on	21027	21029	O
animals	21030	21037	O
,	21037	21038	O
demonstrated	21039	21051	O
that	21052	21056	O
incisions	21057	21066	O
made	21067	21071	O
by	21072	21074	O
monopolar	21075	21084	O
electrosurgery	21085	21099	O
can	21100	21103	O
lead	21104	21108	O
to	21109	21111	O
a	21112	21113	O
reduction	21114	21123	O
of	21124	21126	O
tensile	21127	21134	O
strength	21135	21143	O
,	21143	21144	O
delayed	21145	21152	O
healing	21153	21160	O
,	21160	21161	O
increased	21162	21171	O
infection	21172	21181	O
and	21182	21185	O
seroma	21186	21192	O
rate	21193	21197	O
and	21198	21201	O
a	21202	21203	O
greater	21204	21211	O
areas	21212	21217	O
of	21218	21220	O
necrosis	21221	21229	O
if	21230	21232	O
compared	21233	21241	O
to	21242	21244	O
scalpel	21245	21252	O
incision	21253	21261	O
[	21262	21263	O
[	21263	21264	O
22	21264	21266	O
]	21266	21267	O
,	21267	21268	O
[	21269	21270	O
23	21270	21272	O
]	21272	21273	O
,	21273	21274	O
[	21275	21276	O
24	21276	21278	O
]	21278	21279	O
,	21279	21280	O
[	21281	21282	O
25	21282	21284	O
]	21284	21285	O
]	21285	21286	O
.	21286	21287	O

Recently	21288	21296	O
,	21296	21297	O
some	21298	21302	O
clinical	21303	21311	O
trials	21312	21318	O
on	21319	21321	O
human	21322	21327	O
tissue	21328	21334	O
have	21335	21339	O
rebutted	21340	21348	O
these	21349	21354	O
conclusions	21355	21366	O
,	21366	21367	O
suggesting	21368	21378	O
that	21379	21383	O
a	21384	21385	O
judicious	21386	21395	O
use	21396	21399	O
of	21400	21402	O
monopolar	21403	21412	O
electrosurgery	21413	21427	O
,	21427	21428	O
can	21429	21432	O
reduced	21433	21440	O
blood	21441	21446	O
loss	21447	21451	O
and	21452	21455	O
surgical	21456	21464	O
time	21465	21469	O
,	21469	21470	O
without	21471	21478	O
influencing	21479	21490	O
inflammation	21491	21503	O
or	21504	21506	O
complications	21507	21520	O
associated	21521	21531	O
with	21532	21536	O
skin	21537	21541	O
incisions	21542	21551	O
[	21552	21553	O
26	21553	21555	O
,	21555	21556	O
27	21556	21558	O
]	21558	21559	O
.	21559	21560	O

This	21561	21565	O
discrepancy	21566	21577	O
may	21578	21581	O
be	21582	21584	O
explained	21585	21594	O
by	21595	21597	O
more	21598	21602	O
aggressive	21603	21613	O
use	21614	21617	O
of	21618	21620	O
coagulation	21621	21632	O
or	21633	21635	O
blended	21636	21643	O
waveforms	21644	21653	O
with	21654	21658	O
higher	21659	21665	O
power	21666	21671	O
settings	21672	21680	O
,	21680	21681	O
leading	21682	21689	O
to	21690	21692	O
excessive	21693	21702	O
collateral	21703	21713	O
tissue	21714	21720	O
damage	21721	21727	O
,	21727	21728	O
as	21729	21731	O
described	21732	21741	O
in	21742	21744	O
older	21745	21750	O
research	21751	21759	O
[	21760	21761	O
28	21761	21763	O
]	21763	21764	O
.	21764	21765	O

Charoenkwan	21766	21777	O
et	21778	21780	O
Al	21781	21783	O
.	21783	21784	O

in	21785	21787	O
a	21788	21789	O
recent	21790	21796	O
Cochrane	21797	21805	O
Database	21806	21814	O
Systematic	21815	21825	O
Review	21826	21832	O
,	21832	21833	O
analysing	21834	21843	O
1901	21844	21848	O
participants	21849	21861	O
in	21862	21864	O
nine	21865	21869	O
randomised	21870	21880	O
controlled	21881	21891	O
trials	21892	21898	O
,	21898	21899	O
found	21900	21905	O
no	21906	21908	O
statistically	21909	21922	O
significant	21923	21934	O
difference	21935	21945	O
in	21946	21948	O
overall	21949	21956	O
wound	21957	21962	O
complication	21963	21975	O
rates	21976	21981	O
,	21981	21982	O
nor	21983	21986	O
in	21987	21989	O
rates	21990	21995	O
of	21996	21998	O
wound	21999	22004	O
dehiscence	22005	22015	O
.	22015	22016	O

An	22017	22019	O
update	22020	22026	O
of	22027	22029	O
this	22030	22034	O
research	22035	22043	O
including	22044	22053	O
seven	22054	22059	O
additional	22060	22070	O
RCTs	22071	22075	O
for	22076	22079	O
a	22080	22081	O
total	22082	22087	O
of	22088	22090	O
16	22091	22093	O
studies	22094	22101	O
on	22102	22104	O
2769	22105	22109	O
participants	22110	22122	O
demonstrated	22123	22135	O
no	22136	22138	O
clear	22139	22144	O
difference	22145	22155	O
in	22156	22158	O
wound	22159	22164	O
infections	22165	22175	O
between	22176	22183	O
electrosurgery	22184	22198	O
and	22199	22202	O
scalpel	22203	22210	O
(	22211	22212	O
7	22212	22213	O
.	22213	22214	O
7	22214	22215	O
%	22215	22216	O
for	22217	22220	O
electrosurgery	22221	22235	O
versus	22236	22242	O
7	22243	22244	O
.	22244	22245	O
4	22245	22246	O
%	22246	22247	O
for	22248	22251	O
scalpel	22252	22259	O
)	22259	22260	O
,	22260	22261	O
no	22262	22264	O
difference	22265	22275	O
in	22276	22278	O
time	22279	22283	O
incision	22284	22292	O
and	22293	22296	O
blood	22297	22302	O
loss	22303	22307	O
;	22307	22308	O
it	22309	22311	O
seems	22312	22317	O
unclear	22318	22325	O
if	22326	22328	O
electrosurgery	22329	22343	O
decreases	22344	22353	O
wound	22354	22359	O
dehiscence	22360	22370	O
compared	22371	22379	O
to	22380	22382	O
scalpel	22383	22390	O
(	22391	22392	O
2	22392	22393	O
.	22393	22394	O
7	22394	22395	O
%	22395	22396	O
for	22397	22400	O
electrosurgery	22401	22415	O
versus	22416	22422	O
2	22423	22424	O
.	22424	22425	O
4	22425	22426	O
%	22426	22427	O
for	22428	22431	O
scalpel	22432	22439	O
)	22439	22440	O
.	22440	22441	O

The	22442	22445	O
Authors	22446	22453	O
concluded	22454	22463	O
that	22464	22468	O
both	22469	22473	O
these	22474	22479	O
comparisons	22480	22491	O
are	22492	22495	O
weak	22496	22500	O
and	22501	22504	O
certainty	22505	22514	O
of	22515	22517	O
evidence	22518	22526	O
was	22527	22530	O
moderate	22531	22539	O
to	22540	22542	O
very	22543	22547	O
low	22548	22551	O
due	22552	22555	O
to	22556	22558	O
risk	22559	22563	O
of	22564	22566	O
bias	22567	22571	O
and	22572	22575	O
imprecise	22576	22585	O
results	22586	22593	O
[	22594	22595	O
29	22595	22597	O
,	22597	22598	O
30	22598	22600	O
]	22600	22601	O
.	22601	22602	O

New	22603	22606	O
“	22607	22608	O
mini	22608	22612	O
invasive	22613	22621	O
”	22621	22622	O
treatments	22623	22633	O
were	22634	22638	O
proposed	22639	22647	O
with	22648	22652	O
the	22653	22656	O
aim	22657	22660	O
to	22661	22663	O
local	22664	22669	O
destruction	22670	22681	O
of	22682	22684	O
tissue	22685	22691	O
so	22692	22694	O
-	22694	22695	O
called	22695	22701	O
pit	22702	22705	O
picking	22706	22713	O
as	22714	22716	O
laser	22717	22722	O
treatment	22723	22732	O
,	22732	22733	O
fistuloscopy	22734	22746	O
and	22747	22750	O
phenol	22751	22757	O
injection	22758	22767	O
;	22767	22768	O
but	22769	22772	O
final	22773	22778	O
evaluation	22779	22789	O
of	22790	22792	O
the	22793	22796	O
results	22797	22804	O
is	22805	22807	O
still	22808	22813	O
pending	22814	22821	O
[	22822	22823	O
[	22823	22824	O
31	22824	22826	O
]	22826	22827	O
,	22827	22828	O
[	22829	22830	O
32	22830	22832	O
]	22832	22833	O
,	22833	22834	O
[	22835	22836	O
33	22836	22838	O
]	22838	22839	O
]	22839	22840	O
.	22840	22841	O

Petersen	22842	22850	O
in	22851	22853	O
a	22854	22855	O
recent	22856	22862	O
work	22863	22867	O
,	22867	22868	O
analysing	22869	22878	O
the	22879	22882	O
best	22883	22887	O
treatment	22888	22897	O
options	22898	22905	O
,	22905	22906	O
states	22907	22913	O
that	22914	22918	O
maybe	22919	22924	O
tailored	22925	22933	O
approach	22934	22942	O
and	22943	22946	O
patient	22947	22954	O
-	22954	22955	O
oriented	22955	22963	O
planned	22964	22971	O
therapy	22972	22979	O
,	22979	22980	O
can	22981	22984	O
offer	22985	22990	O
better	22991	22997	O
outcomes	22998	23006	O
.	23006	23007	O

5	23009	23010	O
Conclusions	23011	23022	O
Data	23023	23027	O
emerging	23028	23036	O
from	23037	23041	O
this	23042	23046	O
preliminary	23047	23058	O
study	23059	23064	O
,	23064	23065	O
seems	23066	23071	O
to	23072	23074	O
suggest	23075	23082	O
that	23083	23087	O
excision	23088	23096	O
by	23097	23099	O
classic	23100	23107	O
blade	23108	23113	O
is	23114	23116	O
safer	23117	23122	O
and	23123	23126	O
superior	23127	23135	O
than	23136	23140	O
using	23141	23146	O
diathermy	23147	23156	O
and	23157	23160	O
seems	23161	23166	O
to	23167	23169	O
have	23170	23174	O
a	23175	23176	O
better	23177	23183	O
impact	23184	23190	O
on	23191	23193	O
patient	23194	23201	O
'	23201	23202	O
s	23202	23203	O
postoperative	23204	23217	O
quality	23218	23225	O
of	23226	23228	O
life	23229	23233	O
than	23234	23238	O
the	23239	23242	O
excision	23243	23251	O
using	23252	23257	O
electro	23258	23265	O
-	23265	23266	O
surgery	23266	23273	O
,	23273	23274	O
improving	23275	23284	O
and	23285	23288	O
speeding	23289	23297	O
up	23298	23300	O
surgical	23301	23309	O
recovery	23310	23318	O
.	23318	23319	O

Maybe	23320	23325	O
the	23326	23329	O
choice	23330	23336	O
should	23337	23343	O
be	23344	23346	O
evaluated	23347	23356	O
on	23357	23359	O
the	23360	23363	O
basis	23364	23369	O
of	23370	23372	O
sinus	23373	23378	O
characteristics	23379	23394	O
,	23394	23395	O
patients	23396	23404	O
characteristics	23405	23420	O
,	23420	23421	O
risks	23422	23427	O
factors	23428	23435	O
,	23435	23436	O
personal	23437	23445	O
and	23446	23449	O
work	23450	23454	O
habits	23455	23461	O
,	23461	23462	O
anatomical	23463	23473	O
conditions	23474	23484	O
,	23484	23485	O
family	23486	23492	O
history	23493	23500	O
,	23500	23501	O
patients	23502	23510	O
compliance	23511	23521	O
and	23522	23525	O
collaboration	23526	23539	O
;	23539	23540	O
however	23541	23548	O
seem	23549	23553	O
from	23554	23558	O
these	23559	23564	O
preliminary	23565	23576	O
results	23577	23584	O
that	23585	23589	O
“	23590	23591	O
less	23591	23595	O
damage	23596	23602	O
”	23602	23603	O
are	23604	23607	O
related	23608	23615	O
with	23616	23620	O
“	23621	23622	O
best	23622	23626	O
healing	23627	23634	O
”	23634	23635	O
supporting	23636	23646	O
“	23647	23648	O
non	23648	23651	O
-	23651	23652	O
energy	23652	23658	O
,	23658	23659	O
non	23660	23663	O
-	23663	23664	O
hot	23664	23667	O
”	23667	23668	O
excision	23669	23677	O
of	23678	23680	O
the	23681	23684	O
sinus	23685	23690	O
.	23690	23691	O

Because	23692	23699	O
this	23700	23704	O
condition	23705	23714	O
is	23715	23717	O
generally	23718	23727	O
a	23728	23729	O
benign	23730	23736	O
disease	23737	23744	O
,	23744	23745	O
often	23746	23751	O
small	23752	23757	O
,	23757	23758	O
in	23759	23761	O
a	23762	23763	O
unfavorable	23764	23775	O
place	23776	23781	O
and	23782	23785	O
that	23786	23790	O
could	23791	23796	O
became	23797	23803	O
very	23804	23808	O
uncomfortable	23809	23822	O
for	23823	23826	O
the	23827	23830	O
patient	23831	23838	O
,	23838	23839	O
it	23840	23842	O
is	23843	23845	O
worth	23846	23851	O
trying	23852	23858	O
for	23859	23862	O
better	23863	23869	O
and	23870	23873	O
less	23874	23878	O
.	23878	23879	O

This	23880	23884	O
is	23885	23887	O
a	23888	23889	O
preliminary	23890	23901	O
study	23902	23907	O
with	23908	23912	O
the	23913	23916	O
limits	23917	23923	O
of	23924	23926	O
a	23927	23928	O
small	23929	23934	O
sample	23935	23941	O
and	23942	23945	O
short	23946	23951	O
follow	23952	23958	O
-	23958	23959	O
up	23959	23961	O
,	23961	23962	O
but	23963	23966	O
will	23967	23971	O
be	23972	23974	O
extended	23975	23983	O
to	23984	23986	O
other	23987	23992	O
hospitals	23993	24002	O
to	24003	24005	O
carry	24006	24011	O
out	24012	24015	O
a	24016	24017	O
multicenter	24018	24029	O
randomized	24030	24040	O
controlled	24041	24051	O
trial	24052	24057	O
involving	24058	24067	O
a	24068	24069	O
large	24070	24075	O
number	24076	24082	O
of	24083	24085	O
patients	24086	24094	O
and	24095	24098	O
will	24099	24103	O
be	24104	24106	O
completed	24107	24116	O
with	24117	24121	O
anatomopathological	24122	24141	O
analysis	24142	24150	O
of	24151	24153	O
the	24154	24157	O
percentage	24158	24168	O
of	24169	24171	O
necrosis	24172	24180	O
areas	24181	24186	O
and	24187	24190	O
with	24191	24195	O
the	24196	24199	O
analysis	24200	24208	O
of	24209	24211	O
costs	24212	24217	O
for	24218	24221	O
the	24222	24225	O
health	24226	24232	O
care	24233	24237	O
system	24238	24244	O
.	24244	24245	O

Ethical	24247	24254	O
approval	24255	24263	O
No	24264	24266	O
Approval	24267	24275	O
of	24276	24278	O
the	24279	24282	O
Ethics	24283	24289	O
committee	24290	24299	O
was	24300	24303	O
required	24304	24312	O
;	24312	24313	O
all	24314	24317	O
patients	24318	24326	O
signed	24327	24333	O
informed	24334	24342	O
consent	24343	24350	O
to	24351	24353	O
the	24354	24357	O
surgical	24358	24366	O
procedure	24367	24376	O
.	24376	24377	O

Unique	24379	24385	O
identifying	24386	24397	O
number	24398	24404	O
(	24405	24406	O
UIN	24406	24409	O
)	24409	24410	O
NCT	24411	24414	O
03764657	24415	24423	O
.	24423	24424	O

https	24425	24430	O
:	24430	24431	O
/	24431	24432	O
/	24432	24433	O
clinicaltrials	24433	24447	O
.	24447	24448	O
gov	24448	24451	O
/	24451	24452	O
ct2	24452	24455	O
/	24455	24456	O

Sources	24458	24465	O
of	24466	24468	O
funding	24469	24476	O
None	24477	24481	O
.	24481	24482	O

Author	24484	24490	O
contribution	24491	24503	O
Frazzetta	24504	24513	O
,	24513	24514	O
Giuseppe	24515	24523	O
:	24523	24524	O
study	24525	24530	O
design	24531	24537	O
,	24537	24538	O
data	24539	24543	O
collections	24544	24555	O
,	24555	24556	O
data	24557	24561	O
analysis	24562	24570	O
,	24570	24571	O
writing	24572	24579	O
.	24579	24580	O

Di	24581	24583	O
Giovanni	24584	24592	O
,	24592	24593	O
Silvia	24594	24600	O
:	24600	24601	O
data	24602	24606	O
collections	24607	24618	O
and	24619	24622	O
writing	24623	24630	O
.	24630	24631	O

Rosi	24632	24636	O
,	24636	24637	O
Patrizia	24638	24646	O
:	24646	24647	O
data	24648	24652	O
analysis	24653	24661	O
.	24661	24662	O

Pertile	24663	24670	O
,	24670	24671	O
Riccardo	24672	24680	O
:	24680	24681	O
data	24682	24686	O
collections	24687	24698	O
and	24699	24702	O
data	24703	24707	O
analysis	24708	24716	O
.	24716	24717	O

Di	24718	24720	O
Sipio	24721	24726	O
Antonio	24727	24734	O
:	24734	24735	O
data	24736	24740	O
collections	24741	24752	O
.	24752	24753	O

Rizzo	24754	24759	O
,	24759	24760	O
Salvatore	24761	24770	O
Aldo	24771	24775	O
:	24775	24776	O
writing	24777	24784	O
.	24784	24785	O

Inviati	24786	24793	O
,	24793	24794	O
Angela	24795	24801	O
:	24801	24802	O
study	24803	24808	O
design	24809	24815	O
,	24815	24816	O
data	24817	24821	O
collections	24822	24833	O
.	24833	24834	O

Mascagni	24835	24843	O
,	24843	24844	O
Pietro	24845	24851	O
:	24851	24852	O
Supervision	24853	24864	O
,	24864	24865	O
validation	24866	24876	O
;	24876	24877	O
Mascagni	24878	24886	O
,	24886	24887	O
Domenico	24888	24896	O
:	24896	24897	O
data	24898	24902	O
analysis	24903	24911	O
.	24911	24912	O

Turri	24913	24918	O
,	24918	24919	O
Luciano	24920	24927	O
:	24927	24928	O
study	24929	24934	O
design	24935	24941	O
,	24941	24942	O
data	24943	24947	O
collections	24948	24959	O
.	24959	24960	O

Conflicts	24962	24971	O
of	24972	24974	O
interest	24975	24983	O
None	24984	24988	O
.	24988	24989	O

Trial	24991	24996	O
registry	24997	25005	O
number	25006	25012	O
None	25013	25017	O
.	25017	25018	O

Guarantor	25020	25029	O
The	25030	25033	O
Guarantors	25034	25044	O
are	25045	25048	O
Frazzetta	25049	25058	O
Giuseppe	25059	25067	O
,	25067	25068	O
Di	25069	25071	O
Giovanni	25072	25080	O
Silvia	25081	25087	O
,	25087	25088	O
Inviati	25089	25096	O
Angela	25097	25103	O
.	25103	25104	O

Provenance	25106	25116	O
and	25117	25120	O
peer	25121	25125	O
review	25126	25132	O
Not	25133	25136	O
commissioned	25137	25149	O
,	25149	25150	O
externally	25151	25161	O
peer	25162	25166	O
reviewed	25167	25175	O
.	25175	25176	O

# doc_id = PMC6930139
Emerging	0	8	O
trends	9	15	O
in	16	18	O
modeling	19	27	O
human	28	33	O
liver	34	39	O
disease	40	47	O
in	48	50	O
vitro	51	56	O

Abstract	58	66	O
The	67	70	O
liver	71	76	O
executes	77	85	O
500	86	89	O
+	89	90	O
functions	91	100	O
,	100	101	O
such	102	106	O
as	107	109	O
protein	110	117	O
synthesis	118	127	O
,	127	128	O
xenobiotic	129	139	O
metabolism	140	150	O
,	150	151	O
bile	152	156	O
production	157	167	O
,	167	168	O
and	169	172	O
metabolism	173	183	O
of	184	186	O
carbohydrates	187	200	O
/	200	201	O
fats	201	205	O
/	205	206	O
proteins	206	214	O
.	214	215	O

Such	216	220	O
functions	221	230	O
can	231	234	O
be	235	237	O
severely	238	246	O
degraded	247	255	O
by	256	258	O
drug	259	263	O
-	263	264	O
induced	264	271	O
liver	272	277	O
injury	278	284	O
,	284	285	O
nonalcoholic	286	298	O
fatty	299	304	O
liver	305	310	O
disease	311	318	O
,	318	319	O
hepatitis	320	329	O
B	330	331	O
and	332	335	O
viral	336	341	O
infections	342	352	O
,	352	353	O
and	354	357	O
hepatocellular	358	372	O
carcinoma	373	382	O
.	382	383	O

These	384	389	O
liver	390	395	O
diseases	396	404	O
,	404	405	O
which	406	411	O
represent	412	421	O
a	422	423	O
significant	424	435	O
global	436	442	O
health	443	449	O
burden	450	456	O
,	456	457	O
are	458	461	O
the	462	465	O
subject	466	473	O
of	474	476	O
novel	477	482	O
drug	483	487	O
discovery	488	497	O
by	498	500	O
the	501	504	O
pharmaceutical	505	519	O
industry	520	528	O
via	529	532	O
the	533	536	O
use	537	540	O
of	541	543	O
in	544	546	O
vitro	547	552	O
models	553	559	O
of	560	562	O
the	563	566	O
human	567	572	O
liver	573	578	O
,	578	579	O
given	580	585	O
significant	586	597	O
species	598	605	O
-	605	606	O
specific	606	614	O
differences	615	626	O
in	627	629	O
disease	630	637	O
profiles	638	646	O
and	647	650	O
drug	651	655	O
outcomes	656	664	O
.	664	665	O

Isolated	666	674	O
primary	675	682	O
human	683	688	O
hepatocytes	689	700	S-CL:0000182
(	701	702	O
PHHs	702	706	O
)	706	707	O
are	708	711	O
a	712	713	O
physiologically	714	729	O
relevant	730	738	O
cell	739	743	O
source	744	750	O
to	751	753	O
construct	754	763	O
such	764	768	O
models	769	775	O
;	775	776	O
however	777	784	O
,	784	785	O
these	786	791	O
cells	792	797	O
display	798	805	O
a	806	807	O
rapid	808	813	O
decline	814	821	O
in	822	824	O
the	825	828	O
phenotypic	829	839	O
function	840	848	O
within	849	855	O
conventional	856	868	O
2	869	870	O
-	870	871	O
dimensional	871	882	O
monocultures	883	895	O
.	895	896	O

To	897	899	O
address	900	907	O
such	908	912	O
a	913	914	O
limitation	915	925	O
,	925	926	O
several	927	934	O
engineered	935	945	O
platforms	946	955	O
have	956	960	O
been	961	965	O
developed	966	975	O
such	976	980	O
as	981	983	O
high	984	988	O
-	988	989	O
throughput	989	999	O
cellular	1000	1008	O
microarrays	1009	1020	O
,	1020	1021	O
micropatterned	1022	1036	O
cocultures	1037	1047	O
,	1047	1048	O
self	1049	1053	O
-	1053	1054	O
assembled	1054	1063	O
spheroids	1064	1073	O
,	1073	1074	O
bioprinted	1075	1085	O
tissues	1086	1093	O
,	1093	1094	O
and	1095	1098	O
perfusion	1099	1108	O
devices	1109	1116	O
;	1116	1117	O
many	1118	1122	O
of	1123	1125	O
these	1126	1131	O
platforms	1132	1141	O
are	1142	1145	O
being	1146	1151	O
used	1152	1156	O
to	1157	1159	O
coculture	1160	1169	O
PHHs	1170	1174	O
with	1175	1179	O
liver	1180	1185	O
nonparenchymal	1186	1200	O
cells	1201	1206	O
to	1207	1209	O
model	1210	1215	O
complex	1216	1223	O
cell	1224	1228	O
cross	1229	1234	O
talk	1235	1239	O
in	1240	1242	O
liver	1243	1248	O
pathophysiology	1249	1264	O
.	1264	1265	O

In	1266	1268	O
this	1269	1273	O
perspective	1274	1285	O
,	1285	1286	O
we	1287	1289	O
focus	1290	1295	O
on	1296	1298	O
the	1299	1302	O
utility	1303	1310	O
of	1311	1313	O
representative	1314	1328	O
platforms	1329	1338	O
for	1339	1342	O
mimicking	1343	1352	O
key	1353	1356	O
features	1357	1365	O
of	1366	1368	O
liver	1369	1374	O
dysfunction	1375	1386	O
in	1387	1389	O
the	1390	1393	O
context	1394	1401	O
of	1402	1404	O
chronic	1405	1412	O
liver	1413	1418	O
diseases	1419	1427	O
and	1428	1431	O
liver	1432	1437	O
cancer	1438	1444	O
.	1444	1445	O

We	1446	1448	O
further	1449	1456	O
discuss	1457	1464	O
pending	1465	1472	O
issues	1473	1479	O
that	1480	1484	O
will	1485	1489	O
need	1490	1494	O
to	1495	1497	O
be	1498	1500	O
addressed	1501	1510	O
in	1511	1513	O
this	1514	1518	O
field	1519	1524	O
moving	1525	1531	O
forward	1532	1539	O
.	1539	1540	O

Collectively	1541	1553	O
,	1553	1554	O
these	1555	1560	O
in	1561	1563	O
vitro	1564	1569	O
liver	1570	1575	O
disease	1576	1583	O
models	1584	1590	O
are	1591	1594	O
being	1595	1600	O
increasingly	1601	1613	O
applied	1614	1621	O
toward	1622	1628	O
the	1629	1632	O
development	1633	1644	O
of	1645	1647	O
new	1648	1651	O
therapeutics	1652	1664	O
that	1665	1669	O
display	1670	1677	O
an	1678	1680	O
optimal	1681	1688	O
balance	1689	1696	O
of	1697	1699	O
safety	1700	1706	O
and	1707	1710	O
efficacy	1711	1719	O
,	1719	1720	O
with	1721	1725	O
a	1726	1727	O
focus	1728	1733	O
on	1734	1736	O
expediting	1737	1747	O
development	1748	1759	O
,	1759	1760	O
reducing	1761	1769	O
high	1770	1774	O
costs	1775	1780	O
,	1780	1781	O
and	1782	1785	O
preventing	1786	1796	O
harm	1797	1801	O
to	1802	1804	O
patients	1805	1813	O
.	1813	1814	O

NOMENCLATURE	1816	1828	O
cholangiocellular	1829	1846	O
carcinoma	1847	1856	O
cytochrome	1857	1867	O
P450	1868	1872	O
drug	1873	1877	O
-	1877	1878	O
induced	1878	1885	O
liver	1886	1891	O
injury	1892	1898	O
extracellular	1899	1912	O
matrix	1913	1919	O
Food	1920	1924	O
and	1925	1928	O
Drug	1929	1933	O
Administration	1934	1948	O
free	1949	1953	O
fatty	1954	1959	O
acids	1960	1965	O
hepatitis	1966	1975	O
B	1976	1977	O
virus	1978	1983	O
hepatocellular	1984	1998	O
carcinoma	1999	2008	O
hepatitis	2009	2018	O
C	2019	2020	O
virus	2021	2026	O
hepatic	2027	2034	S-CL:0000632
stellate	2035	2043	B-CL:0000632;CL:0000122
cells	2044	2049	E-CL:0000632;CL:0000122
human	2050	2055	O
umbilical	2056	2065	O
vein	2066	2070	S-CL:0002543
endothelial	2071	2082	B-CL:0002543;CL:0000115
cells	2083	2088	E-CL:0002543;CL:0000115
induced	2089	2096	O
pluripotent	2097	2108	S-CL:0002248
stem	2109	2113	B-CL:0002248;CL:0000034
cell	2114	2118	E-CL:0002248;CL:0000034
-	2118	2119	O
derived	2119	2126	O
human	2127	2132	O
hepatocytelike	2133	2147	O
cells	2148	2153	O
induced	2154	2161	O
pluripotent	2162	2173	S-CL:0002248
stem	2174	2178	B-CL:0002248;CL:0000034
cells	2179	2184	E-CL:0002248;CL:0000034
janus	2185	2190	O
kinase	2191	2197	O
Kupffer	2198	2205	B-CL:0000091
cells	2206	2211	E-CL:0000091
liver	2212	2217	O
sinusoidal	2218	2228	O
endothelial	2229	2240	B-CL:0000115
cells	2241	2246	E-CL:0000115
multiplicity	2247	2259	O
of	2260	2262	O
infection	2263	2272	O
micropatterned	2273	2287	O
cocultures	2288	2298	O
micropatterned	2299	2313	O
tr	2314	2316	O
-	2316	2317	O
cultures	2317	2325	O
nonalcoholic	2326	2338	O
fatty	2339	2344	O
liver	2345	2350	O
disease	2351	2358	O
nonparenchymal	2359	2373	O
cells	2374	2379	O
polydimethylsiloxane	2380	2400	O
-	2400	2401	O
siloxane	2401	2409	O
patient	2410	2417	O
-	2417	2418	O
derived	2418	2425	O
xenograft	2426	2435	O
polyethylene	2436	2448	O
glycol	2449	2455	O
primary	2456	2463	O
human	2464	2469	O
hepatocytes	2470	2481	S-CL:0000182

INTRODUCTION	2483	2495	O
The	2496	2499	O
liver	2500	2505	O
is	2506	2508	O
the	2509	2512	O
largest	2513	2520	O
internal	2521	2529	O
organ	2530	2535	O
in	2536	2538	O
the	2539	2542	O
body	2543	2547	O
and	2548	2551	O
executes	2552	2560	O
well	2561	2565	O
over	2566	2570	O
500	2571	2574	O
functions	2575	2584	O
,	2584	2585	O
including	2586	2595	O
(	2596	2597	O
a	2597	2598	O
)	2598	2599	O
the	2600	2603	O
metabolism	2604	2614	O
of	2615	2617	O
carbohydrates	2618	2631	O
,	2631	2632	O
fats	2633	2637	O
,	2637	2638	O
and	2639	2642	O
proteins	2643	2651	O
;	2651	2652	O
(	2653	2654	O
b	2654	2655	O
)	2655	2656	O
production	2657	2667	O
of	2668	2670	O
serum	2671	2676	O
proteins	2677	2685	O
such	2686	2690	O
as	2691	2693	O
albumin	2694	2701	O
,	2701	2702	O
transferrin	2703	2714	O
,	2714	2715	O
and	2716	2719	O
clotting	2720	2728	O
factors	2729	2736	O
;	2736	2737	O
(	2738	2739	O
c	2739	2740	O
)	2740	2741	O
biotransformation	2742	2759	O
of	2760	2762	O
lipophilic	2763	2773	O
pharmaceutical	2774	2788	O
and	2789	2792	O
industrial	2793	2803	O
compounds	2804	2813	O
into	2814	2818	O
water	2819	2824	O
-	2824	2825	O
soluble	2825	2832	O
metabolites	2833	2844	O
that	2845	2849	O
can	2850	2853	O
be	2854	2856	O
excreted	2857	2865	O
from	2866	2870	O
the	2871	2874	O
body	2875	2879	O
;	2879	2880	O
and	2881	2884	O
(	2885	2886	O
d	2886	2887	O
)	2887	2888	O
production	2889	2899	O
of	2900	2902	O
bile	2903	2907	O
that	2908	2912	O
aids	2913	2917	O
in	2918	2920	O
the	2921	2924	O
digestion	2925	2934	O
of	2935	2937	O
fats	2938	2942	O
and	2943	2946	O
fat	2947	2950	O
-	2950	2951	O
soluble	2951	2958	O
vitamins	2959	2967	O
in	2968	2970	O
the	2971	2974	O
intestine	2975	2984	O
.	2984	2985	O

These	2986	2991	O
critical	2992	3000	O
functions	3001	3010	O
can	3011	3014	O
be	3015	3017	O
compromised	3018	3029	O
by	3030	3032	O
drug	3033	3037	O
-	3037	3038	O
induced	3038	3045	O
liver	3046	3051	O
injury	3052	3058	O
(	3059	3060	O
DILI	3060	3064	O
)	3064	3065	O
as	3066	3068	O
well	3069	3073	O
as	3074	3076	O
several	3077	3084	O
liver	3085	3090	O
diseases	3091	3099	O
such	3100	3104	O
as	3105	3107	O
nonalcoholic	3108	3120	O
fatty	3121	3126	O
liver	3127	3132	O
disease	3133	3140	O
(	3141	3142	O
NAFLD	3142	3147	O
)	3147	3148	O
,	3148	3149	O
infection	3150	3159	O
with	3160	3164	O
hepatitis	3165	3174	O
B	3175	3176	O
and	3177	3180	O
C	3181	3182	O
viruses	3183	3190	O
(	3191	3192	O
HBV	3192	3195	O
and	3196	3199	O
HCV	3200	3203	O
,	3203	3204	O
respectively	3205	3217	O
)	3217	3218	O
,	3218	3219	O
and	3220	3223	O
hepatocellular	3224	3238	O
carcinoma	3239	3248	O
(	3249	3250	O
HCC	3250	3253	O
)	3253	3254	O
.	3254	3255	O

Many	3256	3260	O
of	3261	3263	O
these	3264	3269	O
diseases	3270	3278	O
represent	3279	3288	O
significant	3289	3300	O
global	3301	3307	O
health	3308	3314	O
burdens	3315	3322	O
.	3322	3323	O

For	3324	3327	O
instance	3328	3336	O
,	3336	3337	O
DILI	3338	3342	O
is	3343	3345	O
a	3346	3347	O
leading	3348	3355	O
cause	3356	3361	O
of	3362	3364	O
preclinical	3365	3376	O
and	3377	3380	O
clinical	3381	3389	O
drug	3390	3394	O
failures	3395	3403	O
,	3403	3404	O
black	3405	3410	O
-	3410	3411	O
box	3411	3414	O
warnings	3415	3423	O
and	3424	3427	O
withdrawals	3428	3439	O
of	3440	3442	O
marketed	3443	3451	O
drugs	3452	3457	O
,	3457	3458	O
and	3459	3462	O
acute	3463	3468	O
liver	3469	3474	O
failures	3475	3483	O
;	3483	3484	O
overall	3485	3492	O
,	3492	3493	O
DILI	3494	3498	O
has	3499	3502	O
been	3503	3507	O
linked	3508	3514	O
to	3515	3517	O
∼	3518	3519	O
1000	3519	3523	O
marketed	3524	3532	O
drugs1	3533	3539	O
,	3539	3540	O
2	3540	3541	O
NAFLD	3542	3547	O
affects	3548	3555	O
almost	3556	3562	O
a	3563	3564	O
third	3565	3570	O
of	3571	3573	O
the	3574	3577	O
US	3578	3580	O
population	3581	3591	O
,	3591	3592	O
and	3593	3596	O
individuals	3597	3608	O
with	3609	3613	O
either	3614	3620	O
type	3621	3625	O
2	3626	3627	O
diabetes	3628	3636	O
mellitus	3637	3645	O
or	3646	3648	O
obesity	3649	3656	O
are	3657	3660	O
disproportionately	3661	3679	O
affected	3680	3688	O
;	3688	3689	O
3	3689	3690	O
the	3691	3694	O
number	3695	3701	O
of	3702	3704	O
cases	3705	3710	O
with	3711	3715	O
NAFLD	3716	3721	O
is	3722	3724	O
expected	3725	3733	O
to	3734	3736	O
rise	3737	3741	O
from	3742	3746	O
83	3747	3749	O
.	3749	3750	O
1	3750	3751	O
million	3752	3759	O
people	3760	3766	O
in	3767	3769	O
2015	3770	3774	O
to	3775	3777	O
100	3778	3781	O
.	3781	3782	O
9	3782	3783	O
million	3784	3791	O
in	3792	3794	O
2030	3795	3799	O
.	3799	3800	O
4	3800	3801	O
Finally	3802	3809	O
,	3809	3810	O
HBV	3811	3814	O
and	3815	3818	O
HCV	3819	3822	O
infect	3823	3829	O
the	3830	3833	O
livers	3834	3840	O
of	3841	3843	O
more	3844	3848	O
than	3849	3853	O
350	3854	3857	O
million	3858	3865	O
people	3866	3872	O
globally	3873	3881	O
.	3881	3882	O
5	3882	3883	O
A	3884	3885	O
common	3886	3892	O
feature	3893	3900	O
of	3901	3903	O
the	3904	3907	O
liver	3908	3913	O
diseases	3914	3922	O
discussed	3923	3932	O
above	3933	3938	O
is	3939	3941	O
that	3942	3946	O
they	3947	3951	O
increase	3952	3960	O
patient	3961	3968	O
risk	3969	3973	O
to	3974	3976	O
the	3977	3980	O
development	3981	3992	O
of	3993	3995	O
liver	3996	4001	O
fibrosis	4002	4010	O
,	4010	4011	O
cirrhosis	4012	4021	O
,	4021	4022	O
and	4023	4026	O
ultimately	4027	4037	O
HCC	4038	4041	O
,	4041	4042	O
which	4043	4048	O
are	4049	4052	O
the	4053	4056	O
most	4057	4061	O
common	4062	4068	O
primary	4069	4076	O
liver	4077	4082	O
malignancy	4083	4093	O
and	4094	4097	O
the	4098	4101	O
second	4102	4108	O
leading	4109	4116	O
cause	4117	4122	O
of	4123	4125	O
cancer	4126	4132	O
-	4132	4133	O
related	4133	4140	O
deaths	4141	4147	O
worldwide	4148	4157	O
.	4157	4158	O
6	4158	4159	O
Once	4160	4164	O
patients	4165	4173	O
develop	4174	4181	O
decompensated	4182	4195	O
cirrhosis	4196	4205	O
and	4206	4209	O
/	4209	4210	O
or	4210	4212	O
HCC	4213	4216	O
,	4216	4217	O
orthotopic	4218	4228	O
liver	4229	4234	O
transplantation	4235	4250	O
is	4251	4253	O
the	4254	4257	O
only	4258	4262	O
option	4263	4269	O
to	4270	4272	O
significantly	4273	4286	O
extend	4287	4293	O
their	4294	4299	O
lives	4300	4305	O
;	4305	4306	O
however	4307	4314	O
,	4314	4315	O
there	4316	4321	O
is	4322	4324	O
a	4325	4326	O
severe	4327	4333	O
shortage	4334	4342	O
of	4343	4345	O
donor	4346	4351	O
organs	4352	4358	O
and	4359	4362	O
the	4363	4366	O
list	4367	4371	O
of	4372	4374	O
patients	4375	4383	O
waiting	4384	4391	O
for	4392	4395	O
a	4396	4397	O
liver	4398	4403	O
transplant	4404	4414	O
continues	4415	4424	O
to	4425	4427	O
grow	4428	4432	O
.	4432	4433	O

Halting	4434	4441	O
disease	4442	4449	O
progression	4450	4461	O
prior	4462	4467	O
to	4468	4470	O
the	4471	4474	O
initiation	4475	4485	O
of	4486	4488	O
cirrhosis	4489	4498	O
and	4499	4502	O
HCC	4503	4506	O
is	4507	4509	O
the	4510	4513	O
critical	4514	4522	O
goal	4523	4527	O
for	4528	4531	O
pharmaceutical	4532	4546	O
development	4547	4558	O
.	4558	4559	O

While	4560	4565	O
the	4566	4569	O
latest	4570	4576	O
drugs	4577	4582	O
for	4583	4586	O
HCV	4587	4590	O
are	4591	4594	O
highly	4595	4601	O
effective	4602	4611	O
(	4612	4613	O
>	4613	4614	O
90	4614	4616	O
%	4616	4617	O
cure	4618	4622	O
rates	4623	4628	O
)	4628	4629	O
,	4629	4630	O
there	4631	4636	O
is	4637	4639	O
no	4640	4642	O
vaccine	4643	4650	O
available	4651	4660	O
;	4660	4661	O
additionally	4662	4674	O
,	4674	4675	O
the	4676	4679	O
current	4680	4687	O
drug	4688	4692	O
therapies	4693	4702	O
are	4703	4706	O
very	4707	4711	O
expensive	4712	4721	O
(	4722	4723	O
∼	4723	4724	O
$	4724	4725	O
1K	4725	4727	O
per	4728	4731	O
pill	4732	4736	O
and	4737	4740	O
∼	4741	4742	O
$	4742	4743	O
84K	4743	4746	O
for	4747	4750	O
a	4751	4752	O
12	4753	4755	O
-	4755	4756	O
week	4756	4760	O
treatment	4761	4770	O
regimen7	4771	4779	O
)	4779	4780	O
to	4781	4783	O
be	4784	4786	O
disseminated	4787	4799	O
globally	4800	4808	O
outside	4809	4816	O
of	4817	4819	O
the	4820	4823	O
industrialized	4824	4838	O
nations	4839	4846	O
.	4846	4847	O

For	4848	4851	O
HBV	4852	4855	O
,	4855	4856	O
current	4857	4864	O
drugs	4865	4870	O
are	4871	4874	O
not	4875	4878	O
curative	4879	4887	O
and	4888	4891	O
lifetime	4892	4900	O
drug	4901	4905	O
therapy	4906	4913	O
is	4914	4916	O
required	4917	4925	O
.	4925	4926	O

Finally	4927	4934	O
,	4934	4935	O
there	4936	4941	O
are	4942	4945	O
currently	4946	4955	O
no	4956	4958	O
drugs	4959	4964	O
approved	4965	4973	O
by	4974	4976	O
the	4977	4980	O
US	4981	4983	O
Food	4984	4988	O
and	4989	4992	O
Drug	4993	4997	O
Administration	4998	5012	O
(	5013	5014	O
FDA	5014	5017	O
)	5017	5018	O
for	5019	5022	O
NAFLD	5023	5028	O
,	5028	5029	O
while	5030	5035	O
surgical	5036	5044	O
resection	5045	5054	O
or	5055	5057	O
liver	5058	5063	O
transplantation	5064	5079	O
is	5080	5082	O
the	5083	5086	O
best	5087	5091	O
option	5092	5098	O
for	5099	5102	O
long	5103	5107	O
-	5107	5108	O
term	5108	5112	O
survival	5113	5121	O
in	5122	5124	O
HCC	5125	5128	O
patients	5129	5137	O
as	5138	5140	O
drug	5141	5145	O
therapies	5146	5155	O
have	5156	5160	O
not	5161	5164	O
shown	5165	5170	O
to	5171	5173	O
provide	5174	5181	O
the	5182	5185	O
survival	5186	5194	O
advantage	5195	5204	O
beyond	5205	5211	O
a	5212	5213	O
few	5214	5217	O
weeks	5218	5223	O
.	5223	5224	O

Therefore	5225	5234	O
,	5234	5235	O
there	5236	5241	O
is	5242	5244	O
active	5245	5251	O
interest	5252	5260	O
in	5261	5263	O
the	5264	5267	O
pharmaceutical	5268	5282	O
industry	5283	5291	O
to	5292	5294	O
develop	5295	5302	O
novel	5303	5308	O
drug	5309	5313	O
therapies	5314	5323	O
for	5324	5327	O
the	5328	5331	O
above	5332	5337	O
-	5337	5338	O
discussed	5338	5347	O
liver	5348	5353	O
diseases	5354	5362	O
.	5362	5363	O

The	5364	5367	O
FDA	5368	5371	O
requires	5372	5380	O
preclinical	5381	5392	O
drug	5393	5397	O
testing	5398	5405	O
in	5406	5408	O
one	5409	5412	O
rodent	5413	5419	O
and	5420	5423	O
one	5424	5427	O
nonrodent	5428	5437	O
animal	5438	5444	O
species	5445	5452	O
to	5453	5455	O
mitigate	5456	5464	O
the	5465	5468	O
risk	5469	5473	O
of	5474	5476	O
adverse	5477	5484	O
effects	5485	5492	O
in	5493	5495	O
humans	5496	5502	O
.	5502	5503	O

However	5504	5511	O
,	5511	5512	O
it	5513	5515	O
is	5516	5518	O
now	5519	5522	O
clear	5523	5528	O
via	5529	5532	O
several	5533	5540	O
high	5541	5545	O
-	5545	5546	O
profile	5546	5553	O
clinical	5554	5562	O
drug	5563	5567	O
failures	5568	5576	O
that	5577	5581	O
animal	5582	5588	O
models	5589	5595	O
do	5596	5598	O
not	5599	5602	O
completely	5603	5613	O
suffice	5614	5621	O
to	5622	5624	O
mitigate	5625	5633	O
the	5634	5637	O
risk	5638	5642	O
of	5643	5645	O
DILI	5646	5650	O
,	5650	5651	O
likely	5652	5658	O
due	5659	5662	O
to	5663	5665	O
significant	5666	5677	O
differences	5678	5689	O
across	5690	5696	O
species	5697	5704	O
in	5705	5707	O
drug	5708	5712	O
metabolism	5713	5723	O
pathways	5724	5732	O
.	5732	5733	O
8	5733	5734	O
Additionally	5735	5747	O
,	5747	5748	O
testing	5749	5756	O
drugs	5757	5762	O
in	5763	5765	O
isogenic	5766	5774	O
strains	5775	5782	O
of	5783	5785	O
rodents	5786	5793	O
does	5794	5798	O
not	5799	5802	O
adequately	5803	5813	O
capture	5814	5821	O
the	5822	5825	O
risk	5826	5830	O
factors	5831	5838	O
in	5839	5841	O
humans	5842	5848	O
such	5849	5853	O
as	5854	5856	O
pre	5857	5860	O
-	5860	5861	O
existing	5861	5869	O
disease	5870	5877	O
,	5877	5878	O
age	5879	5882	O
,	5882	5883	O
gender	5884	5890	O
,	5890	5891	O
nutritional	5892	5903	O
status	5904	5910	O
,	5910	5911	O
comedication	5912	5924	O
,	5924	5925	O
and	5926	5929	O
genetic	5930	5937	O
predisposition	5938	5952	O
.	5952	5953	O

Therefore	5954	5963	O
,	5963	5964	O
animal	5965	5971	O
models	5972	5978	O
are	5979	5982	O
less	5983	5987	O
than	5988	5992	O
50	5993	5995	O
%	5995	5996	O
predictive	5997	6007	O
of	6008	6010	O
human	6011	6016	O
DILI	6017	6021	O
.	6021	6022	O
1	6022	6023	O
,	6023	6024	O
9	6024	6025	O
Rodent	6026	6032	O
models	6033	6039	O
also	6040	6044	O
do	6045	6047	O
not	6048	6051	O
suffice	6052	6059	O
for	6060	6063	O
mimicking	6064	6073	O
key	6074	6077	O
features	6078	6086	O
and	6087	6090	O
progression	6091	6102	O
of	6103	6105	O
liver	6106	6111	O
diseases	6112	6120	O
.	6120	6121	O

For	6122	6125	O
instance	6126	6134	O
,	6134	6135	O
HBV	6136	6139	O
and	6140	6143	O
HCV	6144	6147	O
do	6148	6150	O
not	6151	6154	O
infect	6155	6161	O
rodents	6162	6169	O
unless	6170	6176	O
the	6177	6180	O
livers	6181	6187	O
are	6188	6191	O
“	6192	6193	O
humanized	6193	6202	O
”	6202	6203	O
with	6204	6208	O
transplantation	6209	6224	O
of	6225	6227	O
human	6228	6233	O
liver	6234	6239	O
cells	6240	6245	O
under	6246	6251	O
an	6252	6254	O
injury	6255	6261	O
background	6262	6272	O
;	6272	6273	O
10	6273	6275	O
however	6276	6283	O
,	6283	6284	O
humanized	6285	6294	O
rodent	6295	6301	O
models	6302	6308	O
are	6309	6312	O
very	6313	6317	O
expensive	6318	6327	O
and	6328	6331	O
labor	6332	6337	O
-	6337	6338	O
intensive	6338	6347	O
to	6348	6350	O
create	6351	6357	O
and	6358	6361	O
present	6362	6369	O
the	6370	6373	O
challenge	6374	6383	O
of	6384	6386	O
a	6387	6388	O
humanized	6389	6398	O
liver	6399	6404	O
interacting	6405	6416	O
with	6417	6421	O
other	6422	6427	O
rodent	6428	6434	O
organs	6435	6441	O
.	6441	6442	O

Similarly	6443	6452	O
,	6452	6453	O
testing	6454	6461	O
HBV	6462	6465	O
drugs	6466	6471	O
on	6472	6474	O
the	6475	6478	O
chimpanzee	6479	6489	O
is	6490	6492	O
prohibitively	6493	6506	O
expensive	6507	6516	O
,	6516	6517	O
severely	6518	6526	O
restricted	6527	6537	O
in	6538	6540	O
the	6541	6544	O
US	6545	6547	O
and	6548	6551	O
Europe	6552	6558	O
,	6558	6559	O
and	6560	6563	O
does	6564	6568	O
not	6569	6572	O
fully	6573	6578	O
mimic	6579	6584	O
human	6585	6590	O
HBV	6591	6594	O
pathogenesis	6595	6607	O
.	6607	6608	O

NAFLD	6609	6614	O
-	6614	6615	O
like	6615	6619	O
phenotypes	6620	6630	O
can	6631	6634	O
be	6635	6637	O
created	6638	6645	O
in	6646	6648	O
rodent	6649	6655	O
models	6656	6662	O
via	6663	6666	O
a	6667	6668	O
combination	6669	6680	O
of	6681	6683	O
genetic	6684	6691	O
,	6691	6692	O
chemical	6693	6701	O
,	6701	6702	O
or	6703	6705	O
nutritional	6706	6717	O
conditions	6718	6728	O
;	6728	6729	O
however	6730	6737	O
,	6737	6738	O
none	6739	6743	O
of	6744	6746	O
these	6747	6752	O
approaches	6753	6763	O
entirely	6764	6772	O
mimics	6773	6779	O
the	6780	6783	O
human	6784	6789	O
condition	6790	6799	O
.	6799	6800	O
11	6800	6802	O
The	6803	6806	O
mouse	6807	6812	O
model	6813	6818	O
of	6819	6821	O
NAFLD	6822	6827	O
that	6828	6832	O
most	6833	6837	O
closely	6838	6845	O
recapitulates	6846	6859	O
human	6860	6865	O
NAFLD	6866	6871	O
is	6872	6874	O
the	6875	6878	O
“	6879	6880	O
Diet	6880	6884	O
-	6884	6885	O
induced	6885	6892	O
Animal	6893	6899	O
Model	6900	6905	O
of	6906	6908	O
Nonalcoholic	6909	6921	O
Fatty	6922	6927	O
Liver	6928	6933	O
Disease	6934	6941	O
”	6941	6942	O
(	6943	6944	O
DIAMOND	6944	6951	O
)	6951	6952	O
in	6953	6955	O
which	6956	6961	O
mice	6962	6966	O
of	6967	6969	O
a	6970	6971	O
specific	6972	6980	O
genetic	6981	6988	O
strain	6989	6995	O
which	6996	7001	O
are	7002	7005	O
fed	7006	7009	O
a	7010	7011	O
high	7012	7016	O
fat	7017	7020	O
and	7021	7024	O
fructose	7025	7033	O
diet	7034	7038	O
develop	7039	7046	O
progressive	7047	7058	O
stages	7059	7065	O
of	7066	7068	O
NAFLD	7069	7074	O
and	7075	7078	O
end	7079	7082	O
with	7083	7087	O
HCC	7088	7091	O
.	7091	7092	O
11	7092	7094	O
,	7094	7095	O
12	7095	7097	O
However	7098	7105	O
,	7105	7106	O
ultimately	7107	7117	O
,	7117	7118	O
this	7119	7123	O
model	7124	7129	O
is	7130	7132	O
limited	7133	7140	O
to	7141	7143	O
the	7144	7147	O
specific	7148	7156	O
genetic	7157	7164	O
strain	7165	7171	O
of	7172	7174	O
mouse	7175	7180	O
,	7180	7181	O
takes	7182	7187	O
months	7188	7194	O
to	7195	7197	O
recapitulate	7198	7210	O
phenotypic	7211	7221	O
features	7222	7230	O
,	7230	7231	O
and	7232	7235	O
is	7236	7238	O
too	7239	7242	O
slow	7243	7247	O
and	7248	7251	O
expensive	7252	7261	O
for	7262	7265	O
high	7266	7270	O
-	7270	7271	O
throughput	7271	7281	O
drug	7282	7286	O
discovery	7287	7296	O
.	7296	7297	O

Owing	7298	7303	O
to	7304	7306	O
the	7307	7310	O
aforementioned	7311	7325	O
major	7326	7331	O
limitations	7332	7343	O
with	7344	7348	O
animal	7349	7355	O
models	7356	7362	O
,	7362	7363	O
there	7364	7369	O
has	7370	7373	O
been	7374	7378	O
considerable	7379	7391	O
interest	7392	7400	O
in	7401	7403	O
the	7404	7407	O
regulatory	7408	7418	O
and	7419	7422	O
pharmaceutical	7423	7437	O
communities	7438	7449	O
to	7450	7452	O
adopt	7453	7458	O
in	7459	7461	O
vitro	7462	7467	O
models	7468	7474	O
of	7475	7477	O
the	7478	7481	O
human	7482	7487	O
liver	7488	7493	O
,	7493	7494	O
which	7495	7500	O
can	7501	7504	O
be	7505	7507	O
employed	7508	7516	O
across	7517	7523	O
all	7524	7527	O
stages	7528	7534	O
of	7535	7537	O
drug	7538	7542	O
development	7543	7554	O
for	7555	7558	O
investigating	7559	7572	O
drug	7573	7577	O
metabolism	7578	7588	O
and	7589	7592	O
toxicity	7593	7601	O
,	7601	7602	O
and	7603	7606	O
to	7607	7609	O
develop	7610	7617	O
novel	7618	7623	O
drug	7624	7628	O
therapies	7629	7638	O
against	7639	7646	O
liver	7647	7652	O
diseases	7653	7661	O
.	7661	7662	O

The	7663	7666	O
ultimate	7667	7675	O
goal	7676	7680	O
of	7681	7683	O
utilizing	7684	7693	O
in	7694	7696	O
vitro	7697	7702	O
tissue	7703	7709	O
models	7710	7716	O
is	7717	7719	O
to	7720	7722	O
reduce	7723	7729	O
the	7730	7733	O
astronomical	7734	7746	O
cost	7747	7751	O
and	7752	7755	O
time	7756	7760	O
required	7761	7769	O
for	7770	7773	O
successful	7774	7784	O
drug	7785	7789	O
development	7790	7801	O
(	7802	7803	O
∼	7803	7804	O
$	7804	7805	O
3	7805	7806	O
–	7806	7807	O
5B	7807	7809	O
and	7810	7813	O
12	7814	7816	O
–	7816	7817	O
15	7817	7819	O
years	7820	7825	O
to	7826	7828	O
bring	7829	7834	O
1	7835	7836	O
drug	7837	7841	O
to	7842	7844	O
the	7845	7848	O
market13	7849	7857	O
,	7857	7858	O
14	7858	7860	O
)	7860	7861	O
as	7862	7864	O
well	7865	7869	O
as	7870	7872	O
prevent	7873	7880	O
harm	7881	7885	O
to	7886	7888	O
patients	7889	7897	O
.	7897	7898	O

In	7899	7901	O
the	7902	7905	O
native	7906	7912	O
liver	7913	7918	O
,	7918	7919	O
primary	7920	7927	O
human	7928	7933	O
hepatocytes	7934	7945	S-CL:0000182
(	7946	7947	O
PHHs	7947	7951	O
)	7951	7952	O
represent	7953	7962	O
nearly	7963	7969	O
80	7970	7972	O
%	7972	7973	O
of	7974	7976	O
liver	7977	7982	O
volume	7983	7989	O
(	7990	7991	O
60	7991	7993	O
%	7993	7994	O
of	7995	7997	O
the	7998	8001	O
total	8002	8007	O
cell	8008	8012	O
population	8013	8023	O
)	8023	8024	O
and	8025	8028	O
execute	8029	8036	O
a	8037	8038	O
majority	8039	8047	O
of	8048	8050	O
liver	8051	8056	O
functions	8057	8066	O
.	8066	8067	O

These	8068	8073	O
cells	8074	8079	O
are	8080	8083	O
also	8084	8088	O
surrounded	8089	8099	O
by	8100	8102	O
resident	8103	8111	O
liver	8112	8117	O
nonparenchymal	8118	8132	O
cells	8133	8138	O
(	8139	8140	O
NPCs	8140	8144	O
)	8144	8145	O
that	8146	8150	O
represent	8151	8160	O
∼	8161	8162	O
6	8162	8163	O
.	8163	8164	O
5	8164	8165	O
%	8165	8166	O
of	8167	8169	O
liver	8170	8175	O
volume	8176	8182	O
and	8183	8186	O
40	8187	8189	O
%	8189	8190	O
of	8191	8193	O
the	8194	8197	O
total	8198	8203	O
population	8204	8214	O
of	8215	8217	O
cells	8218	8223	O
.	8223	8224	O
15	8224	8226	O
Liver	8227	8232	O
NPCs	8233	8237	O
include	8238	8245	O
liver	8246	8251	O
sinusoidal	8252	8262	O
endothelial	8263	8274	B-CL:0000115
cells	8275	8280	E-CL:0000115
(	8281	8282	O
LSECs	8282	8287	O
)	8287	8288	O
,	8288	8289	O
hepatic	8290	8297	S-CL:0000632
stellate	8298	8306	B-CL:0000632;CL:0000122
cells	8307	8312	E-CL:0000632;CL:0000122
(	8313	8314	O
HSCs	8314	8318	S-CL:0000037
)	8318	8319	O
,	8319	8320	O
and	8321	8324	O
Kupffer	8325	8332	B-CL:0000091
cells	8333	8338	E-CL:0000091
/	8338	8339	O
macrophages	8339	8350	S-CL:0000235
(	8351	8352	O
KCs	8352	8355	O
)	8355	8356	O
,	8356	8357	O
which	8358	8363	O
modulate	8364	8372	O
hepatic	8373	8380	O
functions	8381	8390	O
in	8391	8393	O
physiology	8394	8404	O
and	8405	8408	O
disease	8409	8416	O
via	8417	8420	O
paracrine	8421	8430	O
and	8431	8434	O
juxtacrine	8435	8445	O
interactions	8446	8458	O
.	8458	8459	O

Additionally	8460	8472	O
,	8472	8473	O
the	8474	8477	O
cholangiocytes	8478	8492	S-CL:1000488
form	8493	8497	O
the	8498	8501	O
lining	8502	8508	O
of	8509	8511	O
the	8512	8515	O
bile	8516	8520	O
ducts	8521	8526	O
in	8527	8529	O
the	8530	8533	O
liver	8534	8539	O
,	8539	8540	O
which	8541	8546	O
constitutes	8547	8558	O
a	8559	8560	O
separate	8561	8569	O
flow	8570	8574	O
system	8575	8581	O
from	8582	8586	O
the	8587	8590	O
blood	8591	8596	O
flow	8597	8601	O
through	8602	8609	O
the	8610	8613	O
liver	8614	8619	O
sinusoids	8620	8629	O
.	8629	8630	O

All	8631	8634	O
these	8635	8640	O
cell	8641	8645	O
types	8646	8651	O
can	8652	8655	O
now	8656	8659	O
be	8660	8662	O
isolated	8663	8671	O
via	8672	8675	O
established	8676	8687	O
protocols	8688	8697	O
from	8698	8702	O
human	8703	8708	O
livers	8709	8715	O
that	8716	8720	O
are	8721	8724	O
rejected	8725	8733	O
for	8734	8737	O
transplantation	8738	8753	O
into	8754	8758	O
patients	8759	8767	O
;	8767	8768	O
16	8768	8770	O
furthermore	8771	8782	O
,	8782	8783	O
cryopreserved	8784	8797	O
human	8798	8803	O
liver	8804	8809	O
cells	8810	8815	O
are	8816	8819	O
now	8820	8823	O
available	8824	8833	O
commercially	8834	8846	O
from	8847	8851	O
several	8852	8859	O
companies	8860	8869	O
(	8870	8871	O
e	8871	8872	O
.	8872	8873	O
g	8873	8874	O
.	8874	8875	O
,	8875	8876	O
Lonza	8877	8882	O
,	8882	8883	O
Bio	8884	8887	O
-	8887	8888	O
IVT	8888	8891	O
,	8891	8892	O
and	8893	8896	O
Thermo	8897	8903	O
-	8903	8904	O
Fisher	8904	8910	O
)	8910	8911	O
.	8911	8912	O

It	8913	8915	O
is	8916	8918	O
preferable	8919	8929	O
to	8930	8932	O
use	8933	8936	O
primary	8937	8944	O
human	8945	8950	O
liver	8951	8956	O
cells	8957	8962	O
instead	8963	8970	O
of	8971	8973	O
cancerous	8974	8983	O
cell	8984	8988	O
lines	8989	8994	O
since	8995	9000	O
the	9001	9004	O
latter	9005	9011	O
are	9012	9015	O
known	9016	9021	O
to	9022	9024	O
display	9025	9032	O
abnormal	9033	9041	O
proliferation	9042	9055	O
and	9056	9059	O
very	9060	9064	O
low	9065	9068	O
liver	9069	9074	O
-	9074	9075	O
specific	9075	9083	O
functions	9084	9093	O
(	9094	9095	O
e	9095	9096	O
.	9096	9097	O
g	9097	9098	O
.	9098	9099	O
,	9099	9100	O
drug	9101	9105	O
metabolism	9106	9116	O
enzymes	9117	9124	O
)	9124	9125	O
.	9125	9126	O
17	9126	9128	O
However	9129	9136	O
,	9136	9137	O
culture	9138	9145	O
of	9146	9148	O
PHHs	9149	9153	O
and	9154	9157	O
other	9158	9163	O
liver	9164	9169	O
cell	9170	9174	O
types	9175	9180	O
in	9181	9183	O
conventional	9184	9196	O
2D	9197	9199	O
monolayers	9200	9210	O
leads	9211	9216	O
to	9217	9219	O
a	9220	9221	O
decline	9222	9229	O
in	9230	9232	O
phenotypic	9233	9243	O
functions	9244	9253	O
within	9254	9260	O
hours	9261	9266	O
.	9266	9267	O
16	9267	9269	O
The	9270	9273	O
loss	9274	9278	O
of	9279	9281	O
functions	9282	9291	O
can	9292	9295	O
be	9296	9298	O
slowed	9299	9305	O
down	9306	9310	O
but	9311	9314	O
not	9315	9318	O
prevented	9319	9328	O
beyond	9329	9335	O
a	9336	9337	O
few	9338	9341	O
days	9342	9346	O
by	9347	9349	O
extracellular	9350	9363	O
matrix	9364	9370	O
(	9371	9372	O
ECM	9372	9375	O
)	9375	9376	O
manipulations	9377	9390	O
such	9391	9395	O
as	9396	9398	O
overlaying	9399	9409	O
a	9410	9411	O
PHH	9412	9415	O
monolayer	9416	9425	O
with	9426	9430	O
a	9431	9432	O
protein	9433	9440	O
gel	9441	9444	O
made	9445	9449	O
of	9450	9452	O
either	9453	9459	O
collagen	9460	9468	O
or	9469	9471	O
Matrigel	9472	9480	O
™	9480	9481	O
.	9481	9482	O
18	9482	9484	O
More	9485	9489	O
recently	9490	9498	O
,	9498	9499	O
the	9500	9503	O
inclusion	9504	9513	O
of	9514	9516	O
5	9517	9518	O
chemicals	9519	9528	O
that	9529	9533	O
modulate	9534	9542	O
key	9543	9546	O
hepatic	9547	9554	O
pathways	9555	9563	O
in	9564	9566	O
the	9567	9570	O
culture	9571	9578	O
medium	9579	9585	O
was	9586	9589	O
shown	9590	9595	O
to	9596	9598	O
prolong	9599	9606	O
some	9607	9611	O
hepatic	9612	9619	O
functions	9620	9629	O
for	9630	9633	O
30	9634	9636	O
days	9637	9641	O
and	9642	9645	O
enable	9646	9652	O
HBV	9653	9656	O
infection	9657	9666	O
of	9667	9669	O
primary	9670	9677	O
human	9678	9683	O
hepatocytes	9684	9695	S-CL:0000182
in	9696	9698	O
vitro	9699	9704	O
.	9704	9705	O
19	9705	9707	O
However	9708	9715	O
,	9715	9716	O
how	9717	9720	O
the	9721	9724	O
inclusion	9725	9734	O
of	9735	9737	O
these	9738	9743	O
synthetic	9744	9753	O
chemicals	9754	9763	O
affects	9764	9771	O
the	9772	9775	O
physiology	9776	9786	O
of	9787	9789	O
the	9790	9793	O
cell	9794	9798	O
in	9799	9801	O
unexpected	9802	9812	O
ways	9813	9817	O
remains	9818	9825	O
to	9826	9828	O
be	9829	9831	O
determined	9832	9842	O
.	9842	9843	O

Furthermore	9844	9855	O
,	9855	9856	O
inclusion	9857	9866	O
of	9867	9869	O
chemicals	9870	9879	O
in	9880	9882	O
the	9883	9886	O
culture	9887	9894	O
medium	9895	9901	O
during	9902	9908	O
compound	9909	9917	O
screening	9918	9927	O
is	9928	9930	O
typically	9931	9940	O
problematic	9941	9952	O
for	9953	9956	O
drug	9957	9961	O
development	9962	9973	O
efforts	9974	9981	O
in	9982	9984	O
our	9985	9988	O
experience	9989	9999	O
.	9999	10000	O

In	10001	10003	O
contrast	10004	10012	O
to	10013	10015	O
rapidly	10016	10023	O
declining	10024	10033	O
conventional	10034	10046	O
PHH	10047	10050	O
monocultures	10051	10063	O
,	10063	10064	O
several	10065	10072	O
bioengineered	10073	10086	O
culture	10087	10094	O
strategies	10095	10105	O
have	10106	10110	O
been	10111	10115	O
developed	10116	10125	O
to	10126	10128	O
enable	10129	10135	O
precise	10136	10143	O
control	10144	10151	O
of	10152	10154	O
culture	10155	10162	O
conditions	10163	10173	O
,	10173	10174	O
which	10175	10180	O
has	10181	10184	O
led	10185	10188	O
to	10189	10191	O
relative	10192	10200	O
phenotypic	10201	10211	O
stability	10212	10221	O
of	10222	10224	O
human	10225	10230	O
liver	10231	10236	O
cells	10237	10242	O
for	10243	10246	O
several	10247	10254	O
weeks	10255	10260	O
in	10261	10263	O
vitro	10264	10269	O
.	10269	10270	O

In	10271	10273	O
this	10274	10278	O
perspective	10279	10290	O
,	10290	10291	O
we	10292	10294	O
discuss	10295	10302	O
design	10303	10309	O
features	10310	10318	O
and	10319	10322	O
validation	10323	10333	O
of	10334	10336	O
key	10337	10340	O
bioengineered	10341	10354	O
human	10355	10360	O
liver	10361	10366	O
platforms	10367	10376	O
that	10377	10381	O
have	10382	10386	O
been	10387	10391	O
utilized	10392	10400	O
for	10401	10404	O
modeling	10405	10413	O
liver	10414	10419	O
disease	10420	10427	O
with	10428	10432	O
special	10433	10440	O
focus	10441	10446	O
on	10447	10449	O
HBV	10450	10453	O
/	10453	10454	O
HCV	10454	10457	O
,	10457	10458	O
NAFLD	10459	10464	O
,	10464	10465	O
and	10466	10469	O
liver	10470	10475	O
cancer	10476	10482	O
since	10483	10488	O
these	10489	10494	O
represent	10495	10504	O
the	10505	10508	O
majority	10509	10517	O
of	10518	10520	O
global	10521	10527	O
burden	10528	10534	O
of	10535	10537	O
liver	10538	10543	O
disease	10544	10551	O
over	10552	10556	O
the	10557	10560	O
next	10561	10565	O
few	10566	10569	O
decades	10570	10577	O
.	10577	10578	O

We	10579	10581	O
also	10582	10586	O
highlight	10587	10596	O
pending	10597	10604	O
issues	10605	10611	O
and	10612	10615	O
emerging	10616	10624	O
trends	10625	10631	O
in	10632	10634	O
this	10635	10639	O
field	10640	10645	O
.	10645	10646	O

While	10647	10652	O
the	10653	10656	O
evaluation	10657	10667	O
of	10668	10670	O
drug	10671	10675	O
metabolism	10676	10686	O
and	10687	10690	O
toxicity	10691	10699	O
represents	10700	10710	O
a	10711	10712	O
major	10713	10718	O
application	10719	10730	O
of	10731	10733	O
human	10734	10739	O
liver	10740	10745	O
models	10746	10752	O
and	10753	10756	O
the	10757	10760	O
first	10761	10766	O
point	10767	10772	O
of	10773	10775	O
entry	10776	10781	O
for	10782	10785	O
such	10786	10790	O
models	10791	10797	O
into	10798	10802	O
the	10803	10806	O
marketplace	10807	10818	O
,	10818	10819	O
we	10820	10822	O
refer	10823	10828	O
the	10829	10832	O
readers	10833	10840	O
to	10841	10843	O
other	10844	10849	O
articles	10850	10858	O
that	10859	10863	O
comprehensively	10864	10879	O
discuss	10880	10887	O
validation	10888	10898	O
datasets	10899	10907	O
in	10908	10910	O
this	10911	10915	O
area	10916	10920	O
;	10920	10921	O
20	10921	10923	O
,	10923	10924	O
21	10924	10926	O
nonetheless	10927	10938	O
,	10938	10939	O
most	10940	10944	O
of	10945	10947	O
the	10948	10951	O
platforms	10952	10961	O
we	10962	10964	O
discuss	10965	10972	O
in	10973	10975	O
this	10976	10980	O
review	10981	10987	O
have	10988	10992	O
been	10993	10997	O
utilized	10998	11006	O
for	11007	11010	O
drug	11011	11015	O
metabolism	11016	11026	O
and	11027	11030	O
toxicity	11031	11039	O
studies	11040	11047	O
.	11047	11048	O

HEPATITIS	11050	11059	O
B	11060	11061	O
AND	11062	11065	O
C	11066	11067	O
VIRUSES	11068	11075	O
HCV	11076	11079	O
and	11080	11083	O
HBV	11084	11087	O
chronically	11088	11099	O
infect	11100	11106	O
the	11107	11110	O
livers	11111	11117	O
of	11118	11120	O
130	11121	11124	O
–	11124	11125	O
170	11125	11128	O
million	11129	11136	O
and	11137	11140	O
400	11141	11144	O
million	11145	11152	O
people	11153	11159	O
worldwide	11160	11169	O
,	11169	11170	O
respectively	11171	11183	O
.	11183	11184	O

HCV	11185	11188	O
/	11188	11189	O
HBV	11189	11192	O
only	11193	11197	O
infects	11198	11205	O
hepatocytes	11206	11217	S-CL:0000182
of	11218	11220	O
humans	11221	11227	O
,	11227	11228	O
chimpanzees	11229	11240	O
,	11240	11241	O
tree	11242	11246	O
shrews	11247	11253	O
(	11254	11255	O
tupaia	11255	11261	O
belangeri	11262	11271	O
,	11271	11272	O
HCV	11273	11276	O
)	11276	11277	O
,	11277	11278	O
and	11279	11282	O
woodchuck	11283	11292	O
(	11293	11294	O
HBV	11294	11297	O
)	11297	11298	O
.	11298	11299	O

Although	11300	11308	O
the	11309	11312	O
cost	11313	11317	O
of	11318	11320	O
direct	11321	11327	O
acting	11328	11334	O
antiviral	11335	11344	O
drug	11345	11349	O
therapies	11350	11359	O
for	11360	11363	O
HCV	11364	11367	O
is	11368	11370	O
decreasing	11371	11381	O
,	11381	11382	O
the	11383	11386	O
global	11387	11393	O
dissemination	11394	11407	O
of	11408	11410	O
these	11411	11416	O
therapies	11417	11426	O
remains	11427	11434	O
challenging	11435	11446	O
,	11446	11447	O
and	11448	11451	O
further	11452	11459	O
,	11459	11460	O
prophylactic	11461	11473	O
treatments	11474	11484	O
for	11485	11488	O
HCV	11489	11492	O
are	11493	11496	O
not	11497	11500	O
available	11501	11510	O
.	11510	11511	O

While	11512	11517	O
HBV	11518	11521	O
can	11522	11525	O
be	11526	11528	O
suppressed	11529	11539	O
using	11540	11545	O
nucleoside	11546	11556	O
/	11556	11557	O
nucleotide	11557	11567	O
inhibitors	11568	11578	O
,	11578	11579	O
these	11580	11585	O
therapies	11586	11595	O
are	11596	11599	O
not	11600	11603	O
curative	11604	11612	O
due	11613	11616	O
to	11617	11619	O
the	11620	11623	O
stable	11624	11630	O
nature	11631	11637	O
of	11638	11640	O
HBV	11641	11644	O
episomal	11645	11653	O
DNA	11654	11657	O
,	11657	11658	O
which	11659	11664	O
necessitates	11665	11677	O
lifetime	11678	11686	O
drug	11687	11691	O
therapy	11692	11699	O
.	11699	11700	O

Thus	11701	11705	O
,	11705	11706	O
since	11707	11712	O
testing	11713	11720	O
HCV	11721	11724	O
/	11724	11725	O
HBV	11725	11728	O
drugs	11729	11734	O
on	11735	11737	O
chimpanzees	11738	11749	O
is	11750	11752	O
cost	11753	11757	O
prohibitive	11758	11769	O
and	11770	11773	O
restricted	11774	11784	O
in	11785	11787	O
the	11788	11791	O
US	11792	11794	O
/	11794	11795	O
Europe	11795	11801	O
and	11802	11805	O
tree	11806	11810	O
shrew	11811	11816	O
is	11817	11819	O
not	11820	11823	O
a	11824	11825	O
standard	11826	11834	O
preclinical	11835	11846	O
drug	11847	11851	O
screening	11852	11861	O
animal	11862	11868	O
,	11868	11869	O
there	11870	11875	O
is	11876	11878	O
a	11879	11880	O
need	11881	11885	O
for	11886	11889	O
robust	11890	11896	O
human	11897	11902	O
-	11902	11903	O
relevant	11903	11911	O
model	11912	11917	O
systems	11918	11925	O
for	11926	11929	O
developing	11930	11940	O
novel	11941	11946	O
therapeutics	11947	11959	O
that	11960	11964	O
are	11965	11968	O
curative	11969	11977	O
via	11978	11981	O
the	11982	11985	O
disruption	11986	11996	O
of	11997	11999	O
either	12000	12006	O
the	12007	12010	O
virus	12011	12016	O
lifecycle	12017	12026	O
and	12027	12030	O
/	12030	12031	O
or	12031	12033	O
its	12034	12037	O
interaction	12038	12049	O
with	12050	12054	O
the	12055	12058	O
host	12059	12063	O
.	12063	12064	O

While	12065	12070	O
transformed	12071	12082	O
hepatic	12083	12090	O
cell	12091	12095	O
lines	12096	12101	O
are	12102	12105	O
capable	12106	12113	O
of	12114	12116	O
supporting	12117	12127	O
the	12128	12131	O
entire	12132	12138	O
lifecycle	12139	12148	O
of	12149	12151	O
HCV	12152	12155	O
/	12155	12156	O
HBV	12156	12159	O
,	12159	12160	O
they	12161	12165	O
have	12166	12170	O
uncontrolled	12171	12183	O
proliferation	12184	12197	O
and	12198	12201	O
altered	12202	12209	O
host	12210	12214	O
responses	12215	12224	O
to	12225	12227	O
infection	12228	12237	O
.	12237	12238	O
22	12238	12240	O
,	12240	12241	O
23	12241	12243	O
Additionally	12244	12256	O
,	12256	12257	O
cell	12258	12262	O
lines	12263	12268	O
display	12269	12276	O
severely	12277	12285	O
low	12286	12289	O
drug	12290	12294	O
metabolism	12295	12305	O
capacity	12306	12314	O
,	12314	12315	O
24	12315	12317	O
which	12318	12323	O
can	12324	12327	O
confound	12328	12336	O
the	12337	12340	O
results	12341	12348	O
of	12349	12351	O
a	12352	12353	O
de	12354	12356	O
novo	12357	12361	O
drug	12362	12366	O
screen	12367	12373	O
.	12373	12374	O

On	12375	12377	O
the	12378	12381	O
other	12382	12387	O
hand	12388	12392	O
,	12392	12393	O
conventional	12394	12406	O
2D	12407	12409	O
PHH	12410	12413	O
monocultures	12414	12426	O
can	12427	12430	O
be	12431	12433	O
infected	12434	12442	O
with	12443	12447	O
both	12448	12452	O
viruses	12453	12460	O
and	12461	12464	O
are	12465	12468	O
a	12469	12470	O
more	12471	12475	O
physiological	12476	12489	O
representation	12490	12504	O
of	12505	12507	O
infection	12508	12517	O
than	12518	12522	O
transformed	12523	12534	O
cell	12535	12539	O
lines	12540	12545	O
;	12545	12546	O
25	12546	12548	O
,	12548	12549	O
26	12549	12551	O
however	12552	12559	O
,	12559	12560	O
maintaining	12561	12572	O
chronic	12573	12580	O
(	12581	12582	O
weeks	12582	12587	O
)	12587	12588	O
infection	12589	12598	O
in	12599	12601	O
such	12602	12606	O
monocultures	12607	12619	O
across	12620	12626	O
multiple	12627	12635	O
donors	12636	12642	O
is	12643	12645	O
very	12646	12650	O
challenging	12651	12662	O
and	12663	12666	O
there	12667	12672	O
is	12673	12675	O
a	12676	12677	O
rapid	12678	12683	O
decline	12684	12691	O
in	12692	12694	O
drug	12695	12699	O
metabolism	12700	12710	O
enzyme	12711	12717	O
(	12718	12719	O
e	12719	12720	O
.	12720	12721	O
g	12721	12722	O
.	12722	12723	O
,	12723	12724	O
cytochrome	12725	12735	O
P450	12736	12740	O
or	12741	12743	O
CYP	12744	12747	O
)	12747	12748	O
activities27	12749	12761	O
that	12762	12766	O
do	12767	12769	O
not	12770	12773	O
fully	12774	12779	O
mimic	12780	12785	O
drug	12786	12790	O
metabolism	12791	12801	O
in	12802	12804	O
the	12805	12808	O
liver	12809	12814	O
.	12814	12815	O

Unlike	12816	12822	O
randomly	12823	12831	O
distributing	12832	12844	O
cells	12845	12850	O
on	12851	12853	O
a	12854	12855	O
substrate	12856	12865	O
,	12865	12866	O
which	12867	12872	O
do	12873	12875	O
not	12876	12879	O
allow	12880	12885	O
for	12886	12889	O
the	12890	12893	O
precise	12894	12901	O
control	12902	12909	O
over	12910	12914	O
cell	12915	12919	O
-	12919	12920	O
cell	12920	12924	O
interactions	12925	12937	O
that	12938	12942	O
affect	12943	12949	O
cell	12950	12954	O
phenotype	12955	12964	O
,	12964	12965	O
photolithographic	12966	12983	O
and	12984	12987	O
soft	12988	12992	O
-	12992	12993	O
lithographic	12993	13005	O
techniques	13006	13016	O
have	13017	13021	O
been	13022	13026	O
used	13027	13031	O
to	13032	13034	O
fabricate	13035	13044	O
micropatterned	13045	13059	O
cocultures	13060	13070	O
(	13071	13072	O
MPCCs	13072	13077	O
)	13077	13078	O
of	13079	13081	O
PHHs	13082	13086	O
organized	13087	13096	O
onto	13097	13101	O
circular	13102	13110	O
collagen	13111	13119	O
-	13119	13120	O
coated	13120	13126	O
domains	13127	13134	O
of	13135	13137	O
empirically	13138	13149	O
optimized	13150	13159	O
dimensions	13160	13170	O
and	13171	13174	O
surrounded	13175	13185	O
by	13186	13188	O
3T3	13189	13192	O
-	13192	13193	O
J2	13193	13195	O
murine	13196	13202	O
embryonic	13203	13212	O
fibroblasts	13213	13224	S-CL:0000057
.	13224	13225	O
27	13225	13227	O
Precisely	13228	13237	O
tuning	13238	13244	O
the	13245	13248	O
homotypic	13249	13258	O
and	13259	13262	O
heterotypic	13263	13274	O
cell	13275	13279	O
-	13279	13280	O
cell	13280	13284	O
interactions	13285	13297	O
in	13298	13300	O
MPCCs	13301	13306	O
allows	13307	13313	O
for	13314	13317	O
relative	13318	13326	O
stability	13327	13336	O
of	13337	13339	O
hepatic	13340	13347	O
functions	13348	13357	O
for	13358	13361	O
up	13362	13364	O
to	13365	13367	O
6	13368	13369	O
weeks	13370	13375	O
in	13376	13378	O
vitro	13379	13384	O
in	13385	13387	O
industry	13388	13396	O
-	13396	13397	O
standard	13397	13405	O
multiwell	13406	13415	O
plates	13416	13422	O
without	13423	13430	O
the	13431	13434	O
need	13435	13439	O
for	13440	13443	O
any	13444	13447	O
fluid	13448	13453	O
perfusion	13454	13463	O
.	13463	13464	O
28	13464	13466	O
–	13466	13467	O
30	13467	13469	O
Interestingly	13470	13483	O
,	13483	13484	O
the	13485	13488	O
3T3	13489	13492	O
-	13492	13493	O
J2	13493	13495	O
fibroblasts	13496	13507	S-CL:0000057
induce	13508	13514	O
higher	13515	13521	O
functions	13522	13531	O
in	13532	13534	O
hepatocytes	13535	13546	S-CL:0000182
than	13547	13551	O
other	13552	13557	O
3T3	13558	13561	O
subclones	13562	13571	O
,	13571	13572	O
31	13572	13574	O
LSEC	13575	13579	O
,	13579	13580	O
32	13580	13582	O
KCs	13583	13586	O
,	13586	13587	O
33	13587	13589	O
and	13590	13593	O
HSCs	13594	13598	S-CL:0000037
,	13598	13599	O
34	13599	13601	O
likely	13602	13608	O
due	13609	13612	O
to	13613	13615	O
the	13616	13619	O
expression	13620	13630	O
of	13631	13633	O
liverlike	13634	13643	O
molecules	13644	13653	O
such	13654	13658	O
as	13659	13661	O
T	13662	13663	O
-	13663	13664	O
cadherin35	13664	13674	O
and	13675	13678	O
decorin31	13679	13688	O
by	13689	13691	O
the	13692	13695	O
3T3	13696	13699	O
-	13699	13700	O
J2	13700	13702	O
fibroblasts	13703	13714	S-CL:0000057
;	13714	13715	O
nonetheless	13716	13727	O
,	13727	13728	O
the	13729	13732	O
above	13733	13738	O
-	13738	13739	O
mentioned	13739	13748	O
liver	13749	13754	O
-	13754	13755	O
derived	13755	13762	O
NPCs	13763	13767	O
,	13767	13768	O
when	13769	13773	O
cultured	13774	13782	O
with	13783	13787	O
the	13788	13791	O
fibroblasts	13792	13803	S-CL:0000057
,	13803	13804	O
are	13805	13808	O
still	13809	13814	O
able	13815	13819	O
to	13820	13822	O
interact	13823	13831	O
with	13832	13836	O
stabilized	13837	13847	O
PHHs	13848	13852	O
for	13853	13856	O
modeling	13857	13865	O
specific	13866	13874	O
disease	13875	13882	O
scenarios	13883	13892	O
as	13893	13895	O
we	13896	13898	O
discuss	13899	13906	O
in	13907	13909	O
subsequent	13910	13920	O
paragraphs	13921	13931	O
.	13931	13932	O

In	13933	13935	O
addition	13936	13944	O
to	13945	13947	O
primary	13948	13955	O
cells	13956	13961	O
,	13961	13962	O
the	13963	13966	O
MPCC	13967	13971	O
platform	13972	13980	O
can	13981	13984	O
further	13985	13992	O
mature	13993	13999	O
adultlike	14000	14009	O
functions	14010	14019	O
in	14020	14022	O
induced	14023	14030	O
pluripotent	14031	14042	S-CL:0002248
stem	14043	14047	B-CL:0002248;CL:0000034
cell	14048	14052	E-CL:0002248;CL:0000034
-	14052	14053	O
derived	14053	14060	O
human	14061	14066	O
hepatocytelike	14067	14081	O
cells	14082	14087	O
(	14088	14089	O
iHeps	14089	14094	O
)	14094	14095	O
,	14095	14096	O
36	14096	14098	O
which	14099	14104	O
afford	14105	14111	O
the	14112	14115	O
opportunity	14116	14127	O
to	14128	14130	O
sustainably	14131	14142	O
evaluate	14143	14151	O
disease	14152	14159	O
and	14160	14163	O
drug	14164	14168	O
responses	14169	14178	O
across	14179	14185	O
diverse	14186	14193	O
genetic	14194	14201	O
backgrounds	14202	14213	O
.	14213	14214	O

MPCCs	14215	14220	O
containing	14221	14231	O
PHHs	14232	14236	O
can	14237	14240	O
be	14241	14243	O
infected	14244	14252	O
with	14253	14257	O
both	14258	14262	O
HCV37	14263	14268	O
and	14269	14272	O
HBV38	14273	14278	O
and	14279	14282	O
are	14283	14286	O
able	14287	14291	O
to	14292	14294	O
replicate	14295	14304	O
infectious	14305	14315	O
virions	14316	14323	O
for	14324	14327	O
∼	14328	14329	O
3	14329	14330	O
weeks	14331	14336	O
[	14337	14338	O
Fig	14338	14341	O
.	14341	14342	O

1	14343	14344	O
(	14344	14345	O
a	14345	14346	O
)	14346	14347	O
]	14347	14348	O
.	14348	14349	O

However	14350	14357	O
,	14357	14358	O
for	14359	14362	O
HBV	14363	14366	O
,	14366	14367	O
the	14368	14371	O
use	14372	14375	O
of	14376	14378	O
broad	14379	14384	O
-	14384	14385	O
spectrum	14385	14393	O
Janus	14394	14399	O
Kinase	14400	14406	O
(	14407	14408	O
JAK	14408	14411	O
)	14411	14412	O
inhibitors	14413	14423	O
is	14424	14426	O
necessary	14427	14436	O
to	14437	14439	O
attenuate	14440	14449	O
the	14450	14453	O
innate	14454	14460	O
immune	14461	14467	O
response	14468	14476	O
and	14477	14480	O
allow	14481	14486	O
hepatocytes	14487	14498	S-CL:0000182
to	14499	14501	O
sufficiently	14502	14514	O
replicate	14515	14524	O
the	14525	14528	O
virus	14529	14534	O
.	14534	14535	O

In	14536	14538	O
contrast	14539	14547	O
,	14547	14548	O
randomly	14549	14557	O
distributed	14558	14569	O
cocultures	14570	14580	O
of	14581	14583	O
the	14584	14587	O
same	14588	14592	O
two	14593	14596	O
cell	14597	14601	O
types	14602	14607	O
(	14608	14609	O
PHHs	14609	14613	O
and	14614	14617	O
3T3	14618	14621	O
-	14621	14622	O
J2	14622	14624	O
fibroblasts	14625	14636	S-CL:0000057
)	14636	14637	O
were	14638	14642	O
not	14643	14646	O
able	14647	14651	O
to	14652	14654	O
chronically	14655	14666	O
support	14667	14674	O
HCV	14675	14678	O
or	14679	14681	O
HBV	14682	14685	O
replication	14686	14697	O
in	14698	14700	O
the	14701	14704	O
aforementioned	14705	14719	O
studies	14720	14727	O
,	14727	14728	O
potentially	14729	14740	O
due	14741	14744	O
to	14745	14747	O
an	14748	14750	O
incomplete	14751	14761	O
polarization	14762	14774	O
and	14775	14778	O
lower	14779	14784	O
functionality	14785	14798	O
of	14799	14801	O
the	14802	14805	O
hepatocytes	14806	14817	S-CL:0000182
than	14818	14822	O
in	14823	14825	O
MPCCs	14826	14831	O
.	14831	14832	O

However	14833	14840	O
,	14840	14841	O
another	14842	14849	O
group	14850	14855	O
has	14856	14859	O
recently	14860	14868	O
shown	14869	14874	O
that	14875	14879	O
randomly	14880	14888	O
distributed	14889	14900	O
PHH	14901	14904	O
/	14904	14905	O
3T3	14905	14908	O
-	14908	14909	O
J2	14909	14911	O
cocultures	14912	14922	O
created	14923	14930	O
from	14931	14935	O
several	14936	14943	O
PHH	14944	14947	O
donors	14948	14954	O
are	14955	14958	O
able	14959	14963	O
to	14964	14966	O
support	14967	14974	O
HBV	14975	14978	O
infection	14979	14988	O
for	14989	14992	O
up	14993	14995	O
30	14996	14998	O
days	14999	15003	O
without	15004	15011	O
the	15012	15015	O
use	15016	15019	O
of	15020	15022	O
the	15023	15026	O
JAK	15027	15030	O
inhibitor	15031	15040	O
as	15041	15043	O
long	15044	15048	O
as	15049	15051	O
the	15052	15055	O
virus	15056	15061	O
was	15062	15065	O
purified	15066	15074	O
in	15075	15077	O
a	15078	15079	O
specific	15080	15088	O
way	15089	15092	O
and	15093	15096	O
a	15097	15098	O
proprietary	15099	15110	O
commercially	15111	15123	O
available	15124	15133	O
culture	15134	15141	O
medium	15142	15148	O
was	15149	15152	O
utilized	15153	15161	O
;	15161	15162	O
39	15162	15164	O
it	15165	15167	O
remains	15168	15175	O
unclear	15176	15183	O
in	15184	15186	O
a	15187	15188	O
direct	15189	15195	O
comparison	15196	15206	O
using	15207	15212	O
these	15213	15218	O
specialized	15219	15230	O
reagents	15231	15239	O
whether	15240	15247	O
MPCCs	15248	15253	O
can	15254	15257	O
continue	15258	15266	O
to	15267	15269	O
outperform	15270	15280	O
the	15281	15284	O
randomly	15285	15293	O
distributed	15294	15305	O
cocultures	15306	15316	O
.	15316	15317	O

Regardless	15318	15328	O
,	15328	15329	O
across	15330	15336	O
all	15337	15340	O
the	15341	15344	O
above	15345	15350	O
studies	15351	15358	O
,	15358	15359	O
stabilized	15360	15370	O
PHHs	15371	15375	O
cocultured	15376	15386	O
with	15387	15391	O
3T3	15392	15395	O
-	15395	15396	O
J2	15396	15398	O
fibroblasts	15399	15410	S-CL:0000057
were	15411	15415	O
shown	15416	15421	O
to	15422	15424	O
be	15425	15427	O
a	15428	15429	O
robust	15430	15436	O
model	15437	15442	O
for	15443	15446	O
evaluating	15447	15457	O
the	15458	15461	O
interplay	15462	15471	O
between	15472	15479	O
drug	15480	15484	O
metabolism	15485	15495	O
,	15495	15496	O
toxicity	15497	15505	O
,	15505	15506	O
and	15507	15510	O
efficacy	15511	15519	O
since	15520	15525	O
all	15526	15529	O
three	15530	15535	O
aspects	15536	15543	O
are	15544	15547	O
critical	15548	15556	O
for	15557	15560	O
drug	15561	15565	O
effectiveness	15566	15579	O
in	15580	15582	O
the	15583	15586	O
clinic	15587	15593	O
.	15593	15594	O

FIG	15595	15598	O
.	15598	15599	O

1	15600	15601	O
.	15601	15602	O

In	15603	15605	O
vitro	15606	15611	O
human	15612	15617	O
liver	15618	15623	O
models	15624	15630	O
of	15631	15633	O
HBV	15634	15637	O
and	15638	15641	O
NAFLD	15642	15647	O
.	15647	15648	O

(	15649	15650	O
a	15650	15651	O
)	15651	15652	O
Infection	15653	15662	O
of	15663	15665	O
MPCCs	15666	15671	O
with	15672	15676	O
HBV	15677	15680	O
.	15680	15681	O
38	15681	15683	O
Left	15684	15688	O
to	15689	15691	O
right	15692	15697	O
:	15697	15698	O
Phase	15699	15704	O
contrast	15705	15713	O
image	15714	15719	O
of	15720	15722	O
a	15723	15724	O
PHH	15725	15728	O
island	15729	15735	O
surrounded	15736	15746	O
by	15747	15749	O
3T3	15750	15753	O
-	15753	15754	O
J2	15754	15756	O
fibroblasts	15757	15768	S-CL:0000057
.	15768	15769	O

Schematic	15770	15779	O
of	15780	15782	O
HBV	15783	15786	O
infection	15787	15796	O
and	15797	15800	O
lifecycle	15801	15810	O
inside	15811	15817	O
a	15818	15819	O
hepatocyte	15820	15830	S-CL:0000182
.	15830	15831	O

Viral	15832	15837	O
antigens	15838	15846	O
and	15847	15850	O
cccDNA	15851	15857	O
are	15858	15861	O
detectable	15862	15872	O
in	15873	15875	O
MPCCs	15876	15881	O
at	15882	15884	O
higher	15885	15891	O
levels	15892	15898	O
when	15899	15903	O
the	15904	15907	O
cultures	15908	15916	O
are	15917	15920	O
incubated	15921	15930	O
with	15931	15935	O
a	15936	15937	O
small	15938	15943	O
molecule	15944	15952	O
inhibitor	15953	15962	O
of	15963	15965	O
JAK	15966	15969	O
.	15969	15970	O

Reprinted	15971	15980	O
with	15981	15985	O
permission	15986	15996	O
from	15997	16001	O
Shlomai	16002	16009	O
et	16010	16012	O
al	16013	16015	O
.	16015	16016	O
,	16016	16017	O
Proc	16018	16022	O
.	16022	16023	O

Natl	16024	16028	O
.	16028	16029	O

Acad	16030	16034	O
.	16034	16035	O

Sci	16036	16039	O
.	16039	16040	O

111	16041	16044	O
(	16044	16045	O
33	16045	16047	O
)	16047	16048	O
,	16048	16049	O
12193	16050	16055	O
(	16056	16057	O
2014	16057	16061	O
)	16061	16062	O
.	16062	16063	O

Copyright	16064	16073	O
2014	16074	16078	O
National	16079	16087	O
Academy	16088	16095	O
of	16096	16098	O
Sciences	16099	16107	O
.	16107	16108	O

(	16109	16110	O
b	16110	16111	O
)	16111	16112	O
HBV	16113	16116	O
infection	16117	16126	O
in	16127	16129	O
the	16130	16133	O
LiverChip	16134	16143	O
.	16143	16144	O
40	16144	16146	O
Left	16147	16151	O
:	16151	16152	O
Bioreactor	16153	16163	O
cross	16164	16169	O
section	16170	16177	O
schematic	16178	16187	O
showing	16188	16195	O
the	16196	16199	O
fluid	16200	16205	O
flow	16206	16210	O
direction	16211	16220	O
and	16221	16224	O
polycarbonate	16225	16238	O
filter	16239	16245	O
on	16246	16248	O
which	16249	16254	O
cells	16255	16260	O
attach	16261	16267	O
in	16268	16270	O
spheroidal	16271	16281	O
structures	16282	16292	O
.	16292	16293	O

Middle	16294	16300	O
:	16300	16301	O
HBV	16302	16305	O
antigens	16306	16314	O
(	16315	16316	O
HBV	16316	16319	O
“	16320	16321	O
e	16321	16322	O
”	16322	16323	O
antigen	16324	16331	O
or	16332	16334	O
HBeAg	16335	16340	O
in	16341	16343	O
green	16344	16349	O
;	16349	16350	O
HBV	16351	16354	O
“	16355	16356	O
core	16356	16360	O
”	16360	16361	O
antigen	16362	16369	O
or	16370	16372	O
HBcAg	16373	16378	O
in	16379	16381	O
red	16382	16385	O
;	16385	16386	O
nuclei	16387	16393	O
are	16394	16397	O
in	16398	16400	O
blue	16401	16405	O
)	16405	16406	O
were	16407	16411	O
present	16412	16419	O
in	16420	16422	O
the	16423	16426	O
self	16427	16431	O
-	16431	16432	O
assembled	16432	16441	O
spheroids	16442	16451	O
within	16452	16458	O
the	16459	16462	O
chip	16463	16467	O
following	16468	16477	O
infection	16478	16487	O
with	16488	16492	O
HBV	16493	16496	O
.	16496	16497	O

Scale	16498	16503	O
bars	16504	16508	O
:	16508	16509	O
white	16510	16515	O
(	16516	16517	O
200	16517	16520	O
μm	16521	16523	O
)	16523	16524	O
,	16524	16525	O
gray	16526	16530	O
(	16531	16532	O
100	16532	16535	O
μm	16536	16538	O
)	16538	16539	O
.	16539	16540	O

Right	16541	16546	O
:	16546	16547	O
HBeAg	16548	16553	O
and	16554	16557	O
HBV	16558	16561	O
DNA	16562	16565	O
secretion	16566	16575	O
in	16576	16578	O
supernatants	16579	16591	O
of	16592	16594	O
HBV	16595	16598	O
-	16598	16599	O
infected	16599	16607	O
cultures	16608	16616	O
in	16617	16619	O
the	16620	16623	O
LiverChip	16624	16633	O
±	16634	16635	O
treatment	16636	16645	O
with	16646	16650	O
HBV	16651	16654	O
drug	16655	16659	O
,	16659	16660	O
tenofovir	16661	16670	O
alafenamide	16671	16682	O
(	16683	16684	O
TAF	16684	16687	O
,	16687	16688	O
1	16689	16690	O
μM	16691	16693	O
,	16693	16694	O
10	16695	16697	O
day	16698	16701	O
treatment	16702	16711	O
)	16711	16712	O
.	16712	16713	O

Reprinted	16714	16723	O
with	16724	16728	O
permission	16729	16739	O
from	16740	16744	O
Ortega	16745	16751	O
-	16751	16752	O
Prieto	16752	16758	O
et	16759	16761	O
al	16762	16764	O
.	16764	16765	O
,	16765	16766	O
Nat	16767	16770	O
.	16770	16771	O

Commun	16772	16778	O
.	16778	16779	O

9	16780	16781	O
(	16781	16782	O
1	16782	16783	O
)	16783	16784	O
,	16784	16785	O
682	16786	16789	O
(	16790	16791	O
2018	16791	16795	O
)	16795	16796	O
;	16796	16797	O
Copyright	16798	16807	O
2018	16808	16812	O
Author	16813	16819	O
(	16819	16820	O
s	16820	16821	O
)	16821	16822	O
,	16822	16823	O
licensed	16824	16832	O
under	16833	16838	O
a	16839	16840	O
Creative	16841	16849	O
Commons	16850	16857	O
Attribution	16858	16869	O
(	16870	16871	O
CC	16871	16873	O
BY	16874	16876	O
)	16876	16877	O
license	16878	16885	O
.	16885	16886	O

(	16887	16888	O
c	16888	16889	O
)	16889	16890	O
PHHs	16891	16895	O
in	16896	16898	O
MPCCs	16899	16904	O
treated	16905	16912	O
with	16913	16917	O
a	16918	16919	O
hyperglycemic	16920	16933	O
culture	16934	16941	O
medium	16942	16948	O
for	16949	16952	O
18	16953	16955	O
days	16956	16960	O
become	16961	16967	O
steatotic	16968	16977	O
(	16978	16979	O
green	16979	16984	O
:	16984	16985	O
Nile	16986	16990	O
red	16991	16994	O
,	16994	16995	O
stains	16996	17002	O
neutral	17003	17010	O
lipids	17011	17017	O
)	17017	17018	O
.	17018	17019	O
52	17019	17021	O
Scale	17022	17027	O
bars	17028	17032	O
are	17033	17036	O
400	17037	17040	O
μm	17041	17043	O
.	17043	17044	O

Reprinted	17045	17054	O
with	17055	17059	O
permission	17060	17070	O
from	17071	17075	O
Davidson	17076	17084	O
et	17085	17087	O
al	17088	17090	O
.	17090	17091	O
,	17091	17092	O
Sci	17093	17096	O
.	17096	17097	O

Rep	17098	17101	O
.	17101	17102	O

6	17103	17104	O
,	17104	17105	O
28178	17106	17111	O
(	17112	17113	O
2016	17113	17117	O
)	17117	17118	O
.	17118	17119	O

Copyright	17120	17129	O
2016	17130	17134	O
Authors	17135	17142	O
,	17142	17143	O
licensed	17144	17152	O
under	17153	17158	O
a	17159	17160	O
Creative	17161	17169	O
Commons	17170	17177	O
Attribution	17178	17189	O
(	17190	17191	O
CC	17191	17193	O
BY	17194	17196	O
)	17196	17197	O
license	17198	17205	O
.	17205	17206	O

(	17207	17208	O
d	17208	17209	O
)	17209	17210	O
Self	17211	17215	O
-	17215	17216	O
assembled	17216	17225	O
PHH	17226	17229	O
spheroids	17230	17239	O
created	17240	17247	O
using	17248	17253	O
ultralow	17254	17262	O
attachment	17263	17273	O
plates	17274	17280	O
can	17281	17284	O
be	17285	17287	O
made	17288	17292	O
steatotic	17293	17302	O
(	17303	17304	O
green	17304	17309	O
:	17309	17310	O
Nile	17311	17315	O
red	17316	17319	O
stain	17320	17325	O
for	17326	17329	O
neutral	17330	17337	O
lipids	17338	17344	O
;	17344	17345	O
blue	17346	17350	O
:	17350	17351	O
nuclei	17352	17358	O
stained	17359	17366	O
with	17367	17371	O
Hoechst	17372	17379	O
33342	17380	17385	O
)	17385	17386	O
by	17387	17389	O
incubating	17390	17400	O
over	17401	17405	O
time	17406	17410	O
with	17411	17415	O
varying	17416	17423	O
concentrations	17424	17438	O
of	17439	17441	O
insulin	17442	17449	O
and	17450	17453	O
free	17454	17458	O
fatty	17459	17464	O
acids	17465	17470	O
(	17471	17472	O
FFA	17472	17475	O
)	17475	17476	O
.	17476	17477	O
54	17477	17479	O
with	17480	17484	O
permission	17485	17495	O
Kozyra	17496	17502	O
et	17503	17505	O
al	17506	17508	O
.	17508	17509	O
,	17509	17510	O
Sci	17511	17514	O
.	17514	17515	O

Rep	17516	17519	O
.	17519	17520	O

8	17521	17522	O
(	17522	17523	O
1	17523	17524	O
)	17524	17525	O
,	17525	17526	O
14297	17527	17532	O
(	17533	17534	O
2018	17534	17538	O
)	17538	17539	O
.	17539	17540	O

Copyright	17541	17550	O
2018	17551	17555	O
Author	17556	17562	O
(	17562	17563	O
s	17563	17564	O
)	17564	17565	O
,	17565	17566	O
licensed	17567	17575	O
under	17576	17581	O
a	17582	17583	O
Creative	17584	17592	O
Commons	17593	17600	O
Attribution	17601	17612	O
(	17613	17614	O
CC	17614	17616	O
BY	17617	17619	O
)	17619	17620	O
license	17621	17628	O
.	17628	17629	O

(	17630	17631	O
e	17631	17632	O
)	17632	17633	O
MPTCs	17634	17639	O
containing	17640	17650	O
PHHs	17651	17655	O
,	17655	17656	O
3T3	17657	17660	O
-	17660	17661	O
J2	17661	17663	O
fibroblasts	17664	17675	S-CL:0000057
,	17675	17676	O
and	17677	17680	O
activated	17681	17690	O
(	17691	17692	O
fibrogenic	17692	17702	O
)	17702	17703	O
HSCs	17704	17708	S-CL:0000037
.	17708	17709	O
34	17709	17711	O
Left	17712	17716	O
to	17717	17719	O
right	17720	17725	O
:	17725	17726	O
Fluorescence	17727	17739	O
images	17740	17746	O
showing	17747	17754	O
albumin	17755	17762	O
(	17763	17764	O
ALB	17764	17767	O
)	17767	17768	O
positive	17769	17777	O
PHHs	17778	17782	O
,	17782	17783	O
alpha	17784	17789	O
smooth	17790	17796	O
muscle	17797	17803	O
actin	17804	17809	O
(	17810	17811	O
alpha	17811	17816	O
-	17816	17817	O
SMA	17817	17820	O
)	17820	17821	O
positive	17822	17830	O
activated	17831	17840	O
HSCs	17841	17845	S-CL:0000037
,	17845	17846	O
and	17847	17850	O
collagen	17851	17859	O
(	17860	17861	O
COL	17861	17864	O
-	17864	17865	O
1	17865	17866	O
)	17866	17867	O
deposition	17868	17878	O
by	17879	17881	O
the	17882	17885	O
HSCs	17886	17890	S-CL:0000037
as	17891	17893	O
in	17894	17896	O
liver	17897	17902	O
fibrosis	17903	17911	O
.	17911	17912	O

CYP3A4	17913	17919	O
enzyme	17920	17926	O
activity	17927	17935	O
in	17936	17938	O
PHHs	17939	17943	O
is	17944	17946	O
downregulated	17947	17960	O
with	17961	17965	O
the	17966	17969	O
addition	17970	17978	O
of	17979	17981	O
increasing	17982	17992	O
numbers	17993	18000	O
of	18001	18003	O
HSCs	18004	18008	S-CL:0000037
in	18009	18011	O
the	18012	18015	O
MPTC	18016	18020	O
model	18021	18026	O
.	18026	18027	O

Higher	18028	18034	O
levels	18035	18041	O
of	18042	18044	O
inflammatory	18045	18057	O
cytokine	18058	18066	O
,	18066	18067	O
interleukin	18068	18079	O
-	18079	18080	O
6	18080	18081	O
(	18082	18083	O
IL	18083	18085	O
-	18085	18086	O
6	18086	18087	O
)	18087	18088	O
,	18088	18089	O
are	18090	18093	O
secreted	18094	18102	O
from	18103	18107	O
MPTCs	18108	18113	O
with	18114	18118	O
increasing	18119	18129	O
numbers	18130	18137	O
of	18138	18140	O
fibrogenic	18141	18151	O
HSCs	18152	18156	S-CL:0000037
.	18156	18157	O

Reprinted	18158	18167	O
with	18168	18172	O
permission	18173	18183	O
from	18184	18188	O
Davidson	18189	18197	O
et	18198	18200	O
al	18201	18203	O
.	18203	18204	O
,	18204	18205	O
Integr	18206	18212	O
.	18212	18213	O

Biol	18214	18218	O
.	18218	18219	O

9	18220	18221	O
(	18221	18222	O
8	18222	18223	O
)	18223	18224	O
,	18224	18225	O
662	18226	18229	O
.	18229	18230	O

Copyright	18231	18240	O
2017	18241	18245	O
Oxford	18246	18252	O
University	18253	18263	O
Press	18264	18269	O
.	18269	18270	O

The	18271	18274	O
PHH	18275	18278	O
/	18278	18279	O
3T3	18279	18282	O
-	18282	18283	O
J2	18283	18285	O
cocultures	18286	18296	O
,	18296	18297	O
in	18298	18300	O
either	18301	18307	O
MPCC	18308	18312	O
or	18313	18315	O
randomly	18316	18324	O
distributed	18325	18336	O
formats	18337	18344	O
,	18344	18345	O
require	18346	18353	O
the	18354	18357	O
use	18358	18361	O
of	18362	18364	O
polyethylene	18365	18377	O
glycol	18378	18384	O
(	18385	18386	O
PEG	18386	18389	O
)	18389	18390	O
at	18391	18393	O
high	18394	18398	O
multiplicity	18399	18411	O
of	18412	18414	O
infection	18415	18424	O
(	18425	18426	O
MOI	18426	18429	O
)	18429	18430	O
to	18431	18433	O
effectively	18434	18445	O
infect	18446	18452	O
the	18453	18456	O
PHHs	18457	18461	O
with	18462	18466	O
HBV	18467	18470	O
;	18470	18471	O
such	18472	18476	O
a	18477	18478	O
protocol	18479	18487	O
does	18488	18492	O
not	18493	18496	O
mimic	18497	18502	O
the	18503	18506	O
natural	18507	18514	O
infection	18515	18524	O
of	18525	18527	O
PHHs	18528	18532	O
with	18533	18537	O
HBV	18538	18541	O
in	18542	18544	O
vivo	18545	18549	O
via	18550	18553	O
cell	18554	18558	O
receptors	18559	18568	O
such	18569	18573	O
as	18574	18576	O
sodium	18577	18583	O
taurocholate	18584	18596	O
cotransporting	18597	18611	O
peptide	18612	18619	O
(	18620	18621	O
NTCP	18621	18625	O
)	18625	18626	O
.	18626	18627	O

Furthermore	18628	18639	O
,	18639	18640	O
the	18641	18644	O
use	18645	18648	O
of	18649	18651	O
PHHs	18652	18656	O
alone	18657	18662	O
in	18663	18665	O
culture	18666	18673	O
platforms	18674	18683	O
does	18684	18688	O
not	18689	18692	O
allow	18693	18698	O
modeling	18699	18707	O
of	18708	18710	O
infected	18711	18719	O
PHH	18720	18723	O
cross	18724	18729	O
talk	18730	18734	O
with	18735	18739	O
NPCs	18740	18744	O
in	18745	18747	O
the	18748	18751	O
liver	18752	18757	O
involved	18758	18766	O
in	18767	18769	O
inflammation	18770	18782	O
and	18783	18786	O
fibrosis	18787	18795	O
.	18795	18796	O

To	18797	18799	O
mitigate	18800	18808	O
such	18809	18813	O
limitations	18814	18825	O
,	18825	18826	O
the	18827	18830	O
“	18831	18832	O
LiverChip	18832	18841	O
”	18841	18842	O
containing	18843	18853	O
PHH	18854	18857	O
/	18857	18858	O
KC	18858	18860	O
aggregates	18861	18871	O
adhered	18872	18879	O
to	18880	18882	O
collagen	18883	18891	O
-	18891	18892	O
coated	18892	18898	O
and	18899	18902	O
perfused	18903	18911	O
polycarbonate	18912	18925	O
microchannels	18926	18939	O
was	18940	18943	O
shown	18944	18949	O
to	18950	18952	O
support	18953	18960	O
infection	18961	18970	O
and	18971	18974	O
replication	18975	18986	O
of	18987	18989	O
HBV	18990	18993	O
from	18994	18998	O
both	18999	19003	O
cell	19004	19008	O
culture	19009	19016	O
-	19016	19017	O
derived	19017	19024	O
and	19025	19028	O
patient	19029	19036	O
-	19036	19037	O
derived	19037	19044	O
HBV	19045	19048	O
sources	19049	19056	O
for	19057	19060	O
up	19061	19063	O
to	19064	19066	O
40	19067	19069	O
days	19070	19074	O
across	19075	19081	O
multiple	19082	19090	O
donors	19091	19097	O
without	19098	19105	O
the	19106	19109	O
use	19110	19113	O
of	19114	19116	O
PEG	19117	19120	O
and	19121	19124	O
at	19125	19127	O
MOIs	19128	19132	O
that	19133	19137	O
were	19138	19142	O
10	19143	19145	O
K	19146	19147	O
-	19147	19148	O
fold	19148	19152	O
lower	19153	19158	O
than	19159	19163	O
other	19164	19169	O
tested	19170	19176	O
models	19177	19183	O
(	19184	19185	O
spheroids	19185	19194	O
and	19195	19198	O
randomly	19199	19207	O
distributed	19208	19219	O
PHH	19220	19223	O
/	19223	19224	O
3T3	19224	19227	O
-	19227	19228	O
J2	19228	19230	O
cocultures	19231	19241	O
)	19241	19242	O
;	19242	19243	O
furthermore	19244	19255	O
,	19255	19256	O
HBV	19257	19260	O
-	19260	19261	O
infected	19261	19269	O
PHH	19270	19273	O
/	19273	19274	O
KC	19274	19276	O
aggregates	19277	19287	O
in	19288	19290	O
the	19291	19294	O
LiverChip	19295	19304	O
were	19305	19309	O
useful	19310	19316	O
to	19317	19319	O
evaluate	19320	19328	O
the	19329	19332	O
effects	19333	19340	O
of	19341	19343	O
direct	19344	19350	O
acting	19351	19357	O
antiviral	19358	19367	O
drugs	19368	19373	O
on	19374	19376	O
secretion	19377	19386	O
of	19387	19389	O
HBV	19390	19393	O
DNA	19394	19397	O
and	19398	19401	O
antigens	19402	19410	O
in	19411	19413	O
a	19414	19415	O
nondestructive	19416	19430	O
manner	19431	19437	O
[	19438	19439	O
Fig	19439	19442	O
.	19442	19443	O

1	19444	19445	O
(	19445	19446	O
b	19446	19447	O
)	19447	19448	O
]	19448	19449	O
.	19449	19450	O
40	19450	19452	O
The	19453	19456	O
ability	19457	19464	O
of	19465	19467	O
LiverChip	19468	19477	O
to	19478	19480	O
sustain	19481	19488	O
clinically	19489	19499	O
relevant	19500	19508	O
HBV	19509	19512	O
infection	19513	19522	O
is	19523	19525	O
likely	19526	19532	O
due	19533	19536	O
to	19537	19539	O
a	19540	19541	O
combination	19542	19553	O
of	19554	19556	O
3D	19557	19559	O
spheroidal	19560	19570	O
architecture	19571	19583	O
and	19584	19587	O
fluid	19588	19593	O
perfusion	19594	19603	O
(	19604	19605	O
can	19605	19608	O
form	19609	19613	O
gradients	19614	19623	O
of	19624	19626	O
oxygen	19627	19633	O
,	19633	19634	O
nutrients	19635	19644	O
,	19644	19645	O
and	19646	19649	O
hormones	19650	19658	O
as	19659	19661	O
in	19662	19664	O
the	19665	19668	O
liver	19669	19674	O
sinusoid	19675	19683	O
)	19683	19684	O
since	19685	19690	O
neither	19691	19698	O
2D	19699	19701	O
PHH	19702	19705	O
cultures	19706	19714	O
nor	19715	19718	O
static	19719	19725	O
PHH	19726	19729	O
spheroids	19730	19739	O
reached	19740	19747	O
the	19748	19751	O
same	19752	19756	O
levels	19757	19763	O
of	19764	19766	O
liver	19767	19772	O
function	19773	19781	O
or	19782	19784	O
infection	19785	19794	O
as	19795	19797	O
the	19798	19801	O
LiverChip	19802	19811	O
.	19811	19812	O

In	19813	19815	O
particular	19816	19826	O
,	19826	19827	O
the	19828	19831	O
inclusion	19832	19841	O
of	19842	19844	O
KCs	19845	19848	O
in	19849	19851	O
this	19852	19856	O
chip	19857	19861	O
allowed	19862	19869	O
investigation	19870	19883	O
of	19884	19886	O
how	19887	19890	O
HBV	19891	19894	O
could	19895	19900	O
potentially	19901	19912	O
evade	19913	19918	O
the	19919	19922	O
immune	19923	19929	O
response	19930	19938	O
in	19939	19941	O
the	19942	19945	O
liver	19946	19951	O
and	19952	19955	O
establish	19956	19965	O
chronic	19966	19973	O
infection	19974	19983	O
.	19983	19984	O

However	19985	19992	O
,	19992	19993	O
similar	19994	20001	O
to	20002	20004	O
other	20005	20010	O
advanced	20011	20019	O
liver	20020	20025	O
models	20026	20032	O
,	20032	20033	O
the	20034	20037	O
virus	20038	20043	O
did	20044	20047	O
not	20048	20051	O
spread	20052	20058	O
from	20059	20063	O
infected	20064	20072	O
cells	20073	20078	O
to	20079	20081	O
neighboring	20082	20093	O
uninfected	20094	20104	O
cells	20105	20110	O
at	20111	20113	O
the	20114	20117	O
low	20118	20121	O
MOIs	20122	20126	O
,	20126	20127	O
which	20128	20133	O
suggests	20134	20142	O
that	20143	20147	O
additional	20148	20158	O
host	20159	20163	O
factors	20164	20171	O
or	20172	20174	O
cell	20175	20179	O
populations	20180	20191	O
may	20192	20195	O
be	20196	20198	O
involved	20199	20207	O
in	20208	20210	O
HBV	20211	20214	O
spread	20215	20221	O
as	20222	20224	O
in	20225	20227	O
vivo	20228	20232	O
(	20233	20234	O
>	20234	20235	O
80	20235	20237	O
%	20237	20238	O
of	20239	20241	O
the	20242	20245	O
human	20246	20251	O
liver	20252	20257	O
becomes	20258	20265	O
infected	20266	20274	O
)	20274	20275	O
.	20275	20276	O

While	20277	20282	O
PHHs	20283	20287	O
can	20288	20291	O
now	20292	20295	O
be	20296	20298	O
successfully	20299	20311	O
infected	20312	20320	O
with	20321	20325	O
HCV	20326	20329	O
and	20330	20333	O
HBV	20334	20337	O
in	20338	20340	O
different	20341	20350	O
engineered	20351	20361	O
platforms	20362	20371	O
as	20372	20374	O
discussed	20375	20384	O
above	20385	20390	O
,	20390	20391	O
these	20392	20397	O
cells	20398	20403	O
do	20404	20406	O
not	20407	20410	O
allow	20411	20416	O
modeling	20417	20425	O
of	20426	20428	O
genotype	20429	20437	O
-	20437	20438	O
phenotype	20438	20447	O
relationships	20448	20461	O
across	20462	20468	O
many	20469	20473	O
donor	20474	20479	O
backgrounds	20480	20491	O
due	20492	20495	O
to	20496	20498	O
a	20499	20500	O
restricted	20501	20511	O
supply	20512	20518	O
of	20519	20521	O
donor	20522	20527	O
organs	20528	20534	O
rejected	20535	20543	O
for	20544	20547	O
transplantation	20548	20563	O
into	20564	20568	O
patients	20569	20577	O
.	20577	20578	O

To	20579	20581	O
mitigate	20582	20590	O
this	20591	20595	O
limitation	20596	20606	O
,	20606	20607	O
iHep	20608	20612	O
monocultures	20613	20625	O
have	20626	20630	O
been	20631	20635	O
shown	20636	20641	O
to	20642	20644	O
be	20645	20647	O
successfully	20648	20660	O
infected	20661	20669	O
with	20670	20674	O
HCV41	20675	20680	O
and	20681	20684	O
HBV38	20685	20690	O
,	20690	20691	O
42	20691	20693	O
which	20694	20699	O
enables	20700	20707	O
the	20708	20711	O
investigation	20712	20725	O
of	20726	20728	O
the	20729	20732	O
effects	20733	20740	O
of	20741	20743	O
donor	20744	20749	O
genotype	20750	20758	O
and	20759	20762	O
host	20763	20767	O
genes	20768	20773	O
on	20774	20776	O
infection	20777	20786	O
efficiency	20787	20797	O
,	20797	20798	O
propagation	20799	20810	O
,	20810	20811	O
and	20812	20815	O
resistance	20816	20826	O
to	20827	20829	O
drug	20830	20834	O
therapies	20835	20844	O
.	20844	20845	O

However	20846	20853	O
,	20853	20854	O
2D	20855	20857	O
iHep	20858	20862	O
monocultures	20863	20875	O
are	20876	20879	O
also	20880	20884	O
known	20885	20890	O
to	20891	20893	O
lose	20894	20898	O
drug	20899	20903	O
metabolism	20904	20914	O
capacity	20915	20923	O
over	20924	20928	O
time	20929	20933	O
,	20933	20934	O
36	20934	20936	O
which	20937	20942	O
limits	20943	20949	O
their	20950	20955	O
use	20956	20959	O
for	20960	20963	O
evaluating	20964	20974	O
the	20975	20978	O
critical	20979	20987	O
interplay	20988	20997	O
between	20998	21005	O
the	21006	21009	O
metabolism	21010	21020	O
,	21020	21021	O
toxicity	21022	21030	O
,	21030	21031	O
and	21032	21035	O
efficacy	21036	21044	O
(	21045	21046	O
i	21046	21047	O
.	21047	21048	O
e	21048	21049	O
.	21049	21050	O
,	21050	21051	O
inhibition	21052	21062	O
of	21063	21065	O
viral	21066	21071	O
load	21072	21076	O
)	21076	21077	O
of	21078	21080	O
novel	21081	21086	O
drug	21087	21091	O
therapies	21092	21101	O
and	21102	21105	O
their	21106	21111	O
combinations	21112	21124	O
.	21124	21125	O

We	21126	21128	O
have	21129	21133	O
recently	21134	21142	O
shown	21143	21148	O
that	21149	21153	O
the	21154	21157	O
MPCCs	21158	21163	O
created	21164	21171	O
using	21172	21177	O
iHeps	21178	21183	O
(	21184	21185	O
instead	21185	21192	O
of	21193	21195	O
PHHs	21196	21200	O
)	21200	21201	O
show	21202	21206	O
higher	21207	21213	O
drug	21214	21218	O
metabolism	21219	21229	O
capacity	21230	21238	O
than	21239	21243	O
iHep	21244	21248	O
monocultures	21249	21261	O
that	21262	21266	O
can	21267	21270	O
be	21271	21273	O
chronically	21274	21285	O
infected	21286	21294	O
with	21295	21299	O
both	21300	21304	O
HCV	21305	21308	O
and	21309	21312	O
HBV	21313	21316	O
for	21317	21320	O
∼	21321	21322	O
3	21322	21323	O
weeks	21324	21329	O
in	21330	21332	O
vitro	21333	21338	O
and	21339	21342	O
can	21343	21346	O
serve	21347	21352	O
as	21353	21355	O
a	21356	21357	O
robust	21358	21364	O
platform	21365	21373	O
for	21374	21377	O
drug	21378	21382	O
screening	21383	21392	O
(	21393	21394	O
manuscript	21394	21404	O
in	21405	21407	O
preparation	21408	21419	O
)	21419	21420	O
.	21420	21421	O

We	21422	21424	O
anticipate	21425	21435	O
that	21436	21440	O
further	21441	21448	O
progress	21449	21457	O
with	21458	21462	O
utilization	21463	21474	O
of	21475	21477	O
iHeps	21478	21483	O
in	21484	21486	O
engineered	21487	21497	O
platforms	21498	21507	O
for	21508	21511	O
HCV	21512	21515	O
/	21515	21516	O
HBV	21516	21519	O
infection	21520	21529	O
will	21530	21534	O
enable	21535	21541	O
patient	21542	21549	O
-	21549	21550	O
specific	21550	21558	O
drug	21559	21563	O
testing	21564	21571	O
for	21572	21575	O
these	21576	21581	O
diseases	21582	21590	O
.	21590	21591	O

However	21592	21599	O
,	21599	21600	O
two	21601	21604	O
key	21605	21608	O
issues	21609	21615	O
with	21616	21620	O
induced	21621	21628	O
pluripotent	21629	21640	S-CL:0002248
stem	21641	21645	B-CL:0002248;CL:0000034
cells	21646	21651	E-CL:0002248;CL:0000034
(	21652	21653	O
iPSCs	21653	21658	O
)	21658	21659	O
technology	21660	21670	O
will	21671	21675	O
need	21676	21680	O
to	21681	21683	O
be	21684	21686	O
addressed	21687	21696	O
including	21697	21706	O
continuous	21707	21717	O
optimization	21718	21730	O
of	21731	21733	O
culture	21734	21741	O
protocols	21742	21751	O
to	21752	21754	O
further	21755	21762	O
mature	21763	21769	O
iHeps	21770	21775	O
toward	21776	21782	O
the	21783	21786	O
adult	21787	21792	O
PHH	21793	21796	O
phenotype	21797	21806	O
and	21807	21810	O
differentiation	21811	21826	O
of	21827	21829	O
iPSCs	21830	21835	O
into	21836	21840	O
liver	21841	21846	O
NPCs	21847	21851	O
to	21852	21854	O
adequately	21855	21865	O
model	21866	21871	O
interaction	21872	21883	O
of	21884	21886	O
multiple	21887	21895	O
liver	21896	21901	O
cell	21902	21906	O
types	21907	21912	O
with	21913	21917	O
the	21918	21921	O
same	21922	21926	O
donor	21927	21932	O
background	21933	21943	O
.	21943	21944	O
43	21944	21946	O
,	21946	21947	O
44	21947	21949	O
Some	21950	21954	O
useful	21955	21961	O
observations	21962	21974	O
from	21975	21979	O
the	21980	21983	O
aforementioned	21984	21998	O
liver	21999	22004	O
model	22005	22010	O
examples	22011	22019	O
are	22020	22023	O
that	22024	22028	O
neither	22029	22036	O
biomimicry	22037	22047	O
of	22048	22050	O
liver	22051	22056	O
architecture	22057	22069	O
nor	22070	22073	O
liver	22074	22079	O
-	22079	22080	O
derived	22080	22087	O
NPC	22088	22091	O
types	22092	22097	O
from	22098	22102	O
even	22103	22107	O
the	22108	22111	O
same	22112	22116	O
species	22117	22124	O
are	22125	22128	O
necessary	22129	22138	O
for	22139	22142	O
enabling	22143	22151	O
high	22152	22156	O
levels	22157	22163	O
of	22164	22166	O
PHH	22167	22170	O
(	22171	22172	O
or	22172	22174	O
iHep	22175	22179	O
)	22179	22180	O
functions	22181	22190	O
and	22191	22194	O
infection	22195	22204	O
with	22205	22209	O
HCV	22210	22213	O
/	22213	22214	O
HBV	22214	22217	O
in	22218	22220	O
vitro	22221	22226	O
.	22226	22227	O

Such	22228	22232	O
observations	22233	22245	O
suggest	22246	22253	O
that	22254	22258	O
liverlike	22259	22268	O
microenvironmental	22269	22287	O
signals	22288	22295	O
(	22296	22297	O
soluble	22297	22304	O
and	22305	22308	O
insoluble	22309	22318	O
)	22318	22319	O
are	22320	22323	O
the	22324	22327	O
most	22328	22332	O
important	22333	22342	O
for	22343	22346	O
stabilizing	22347	22358	O
the	22359	22362	O
hepatic	22363	22370	O
phenotype	22371	22380	O
.	22380	22381	O

In	22382	22384	O
particular	22385	22395	O
,	22395	22396	O
neither	22397	22404	O
MPCCs	22405	22410	O
nor	22411	22414	O
the	22415	22418	O
LiverChip	22419	22428	O
mimic	22429	22434	O
the	22435	22438	O
architecture	22439	22451	O
of	22452	22454	O
the	22455	22458	O
liver	22459	22464	O
;	22464	22465	O
yet	22466	22469	O
,	22469	22470	O
both	22471	22475	O
platforms	22476	22485	O
are	22486	22489	O
able	22490	22494	O
to	22495	22497	O
keep	22498	22502	O
hepatocytes	22503	22514	S-CL:0000182
highly	22515	22521	O
functional	22522	22532	O
for	22533	22536	O
several	22537	22544	O
weeks	22545	22550	O
in	22551	22553	O
vitro	22554	22559	O
.	22559	22560	O

Furthermore	22561	22572	O
,	22572	22573	O
MPCCs	22574	22579	O
use	22580	22583	O
3T3	22584	22587	O
-	22587	22588	O
J2	22588	22590	O
fibroblasts	22591	22602	S-CL:0000057
,	22602	22603	O
which	22604	22609	O
likely	22610	22616	O
mimic	22617	22622	O
a	22623	22624	O
developmental	22625	22638	O
program	22639	22646	O
that	22647	22651	O
crosses	22652	22659	O
the	22660	22663	O
species	22664	22671	O
barrier	22672	22679	O
to	22680	22682	O
provide	22683	22690	O
differentiation	22691	22706	O
signals	22707	22714	O
to	22715	22717	O
the	22718	22721	O
neighboring	22722	22733	O
hepatocytes	22734	22745	S-CL:0000182
.	22745	22746	O

The	22747	22750	O
ability	22751	22758	O
to	22759	22761	O
use	22762	22765	O
different	22766	22775	O
engineered	22776	22786	O
culture	22787	22794	O
formats	22795	22802	O
for	22803	22806	O
long	22807	22811	O
-	22811	22812	O
term	22812	22816	O
PHH	22817	22820	O
/	22820	22821	O
NPC	22821	22824	O
cocultures	22825	22835	O
provides	22836	22844	O
the	22845	22848	O
end	22849	22852	O
-	22852	22853	O
user	22853	22857	O
a	22858	22859	O
high	22860	22864	O
level	22865	22870	O
of	22871	22873	O
flexibility	22874	22885	O
to	22886	22888	O
vary	22889	22893	O
the	22894	22897	O
throughput	22898	22908	O
and	22909	22912	O
cellular	22913	22921	O
complexity	22922	22932	O
in	22933	22935	O
vitro	22936	22941	O
to	22942	22944	O
test	22945	22949	O
the	22950	22953	O
hypotheses	22954	22964	O
being	22965	22970	O
posed	22971	22976	O
.	22976	22977	O

Nonalcoholic	22978	22990	O
fatty	22991	22996	O
liver	22997	23002	O
disease	23003	23010	O
NAFLD	23011	23016	O
is	23017	23019	O
on	23020	23022	O
an	23023	23025	O
epidemic	23026	23034	O
rise	23035	23039	O
(	23040	23041	O
∼	23041	23042	O
1	23042	23043	O
in	23044	23046	O
4	23047	23048	O
individuals	23049	23060	O
in	23061	23063	O
the	23064	23067	O
US	23068	23070	O
)	23070	23071	O
,	23071	23072	O
is	23073	23075	O
a	23076	23077	O
major	23078	23083	O
risk	23084	23088	O
factor	23089	23095	O
for	23096	23099	O
type	23100	23104	O
2	23105	23106	O
diabetes	23107	23115	O
mellitus	23116	23124	O
,	23124	23125	O
45	23125	23127	O
and	23128	23131	O
can	23132	23135	O
progress	23136	23144	O
to	23145	23147	O
inflammation	23148	23160	O
,	23160	23161	O
fibrosis	23162	23170	O
,	23170	23171	O
and	23172	23175	O
liver	23176	23181	O
cancer	23182	23188	O
,	23188	23189	O
which	23190	23195	O
is	23196	23198	O
a	23199	23200	O
virtually	23201	23210	O
untreatable	23211	23222	O
disease	23223	23230	O
.	23230	23231	O
46	23231	23233	O
Animal	23234	23240	O
models	23241	23247	O
of	23248	23250	O
NAFLD	23251	23256	O
suffer	23257	23263	O
from	23264	23268	O
significant	23269	23280	O
differences	23281	23292	O
in	23293	23295	O
NAFLD47	23296	23303	O
and	23304	23307	O
drug	23308	23312	O
metabolism48	23313	23325	O
pathways	23326	23334	O
as	23335	23337	O
compared	23338	23346	O
to	23347	23349	O
humans	23350	23356	O
;	23356	23357	O
thus	23358	23362	O
,	23362	23363	O
human	23364	23369	O
liver	23370	23375	O
models	23376	23382	O
are	23383	23386	O
essential	23387	23396	O
for	23397	23400	O
preclinical	23401	23412	O
drug	23413	23417	O
development	23418	23429	O
.	23429	23430	O

Conventional	23431	23443	O
2D	23444	23446	O
PHH	23447	23450	O
monocultures	23451	23463	O
have	23464	23468	O
been	23469	23473	O
shown	23474	23479	O
to	23480	23482	O
become	23483	23489	O
steatotic	23490	23499	O
(	23500	23501	O
fatty	23501	23506	O
)	23506	23507	O
upon	23508	23512	O
treatment	23513	23522	O
with	23523	23527	O
mixtures	23528	23536	O
of	23537	23539	O
saturated	23540	23549	O
and	23550	23553	O
unsaturated	23554	23565	O
fatty	23566	23571	O
acids	23572	23577	O
toward	23578	23584	O
mimicking	23585	23594	O
the	23595	23598	O
early	23599	23604	O
stages	23605	23611	O
of	23612	23614	O
NAFLD	23615	23620	O
.	23620	23621	O
49	23621	23623	O
However	23624	23631	O
,	23631	23632	O
since	23633	23638	O
these	23639	23644	O
cultures	23645	23653	O
display	23654	23661	O
a	23662	23663	O
rapid	23664	23669	O
decline	23670	23677	O
in	23678	23680	O
the	23681	23684	O
activities	23685	23695	O
of	23696	23698	O
drug	23699	23703	O
metabolism	23704	23714	O
enzymes	23715	23722	O
,	23722	23723	O
their	23724	23729	O
use	23730	23733	O
for	23734	23737	O
screening	23738	23747	O
novel	23748	23753	O
drug	23754	23758	O
therapies	23759	23768	O
to	23769	23771	O
alleviate	23772	23781	O
hepatic	23782	23789	O
steatosis	23790	23799	O
is	23800	23802	O
challenging	23803	23814	O
.	23814	23815	O

Furthermore	23816	23827	O
,	23827	23828	O
conventional	23829	23841	O
2D	23842	23844	O
PHH	23845	23848	O
monocultures	23849	23861	O
with	23862	23866	O
or	23867	23869	O
without	23870	23877	O
a	23878	23879	O
Matrigel	23880	23888	O
™	23888	23889	O
overlay	23890	23897	O
(	23898	23899	O
a	23899	23900	O
.	23900	23901	O
k	23901	23902	O
.	23902	23903	O
a	23903	23904	O
.	23904	23905	O
sandwich	23906	23914	O
cultures	23915	23923	O
)	23923	23924	O
spontaneously	23925	23938	O
lose	23939	23943	O
sensitivity	23944	23955	O
to	23956	23958	O
pancreatic	23959	23969	O
hormones	23970	23978	O
,	23978	23979	O
insulin	23980	23987	O
,	23987	23988	O
and	23989	23992	O
glucagon	23993	24001	O
,	24001	24002	O
50	24002	24004	O
which	24005	24010	O
precludes	24011	24020	O
their	24021	24026	O
use	24027	24030	O
to	24031	24033	O
determine	24034	24043	O
how	24044	24047	O
overnutritional	24048	24063	O
stimuli	24064	24071	O
and	24072	24075	O
ensuing	24076	24083	O
steatosis	24084	24093	O
cause	24094	24099	O
insulin	24100	24107	O
resistance	24108	24118	O
in	24119	24121	O
PHHs	24122	24126	O
.	24126	24127	O

Notably	24128	24135	O
,	24135	24136	O
hepatocytic	24137	24148	S-CL:0000182
insulin	24149	24156	O
resistance	24157	24167	O
,	24167	24168	O
which	24169	24174	O
is	24175	24177	O
characterized	24178	24191	O
by	24192	24194	O
the	24195	24198	O
inability	24199	24208	O
of	24209	24211	O
hepatocytes	24212	24223	S-CL:0000182
to	24224	24226	O
regulate	24227	24235	O
glucose	24236	24243	O
metabolism	24244	24254	O
in	24255	24257	O
response	24258	24266	O
to	24267	24269	O
insulin	24270	24277	O
(	24278	24279	O
i	24279	24280	O
.	24280	24281	O
e	24281	24282	O
.	24282	24283	O
,	24283	24284	O
glucose	24285	24292	O
uptake	24293	24299	O
and	24300	24303	O
downregulation	24304	24318	O
of	24319	24321	O
gluconeogenesis	24322	24337	O
in	24338	24340	O
the	24341	24344	O
presence	24345	24353	O
of	24354	24356	O
insulin	24357	24364	O
are	24365	24368	O
impaired	24369	24377	O
)	24377	24378	O
,	24378	24379	O
is	24380	24382	O
a	24383	24384	O
major	24385	24390	O
outcome	24391	24398	O
of	24399	24401	O
the	24402	24405	O
NAFLD	24406	24411	O
disease	24412	24419	O
spectrum	24420	24428	O
.	24428	24429	O
51	24429	24431	O
In	24432	24434	O
contrast	24435	24443	O
to	24444	24446	O
the	24447	24450	O
above	24451	24456	O
-	24456	24457	O
mentioned	24457	24466	O
limitations	24467	24478	O
with	24479	24483	O
conventional	24484	24496	O
PHH	24497	24500	O
monocultures	24501	24513	O
,	24513	24514	O
MPCCs	24515	24520	O
were	24521	24525	O
shown	24526	24531	O
to	24532	24534	O
retain	24535	24541	O
in	24542	24544	O
vivo	24545	24549	O
-	24549	24550	O
like	24550	24554	O
responsiveness	24555	24569	O
to	24570	24572	O
insulin	24573	24580	O
and	24581	24584	O
glucagon	24585	24593	O
for	24594	24597	O
3	24598	24599	O
+	24599	24600	O
weeks	24601	24606	O
as	24607	24609	O
assessed	24610	24618	O
via	24619	24622	O
the	24623	24626	O
dynamics	24627	24635	O
of	24636	24638	O
glycogen	24639	24647	O
storage	24648	24655	O
and	24656	24659	O
gluconeogenesis	24660	24675	O
.	24675	24676	O
50	24676	24678	O
In	24679	24681	O
a	24682	24683	O
follow	24684	24690	O
-	24690	24691	O
up	24691	24693	O
study	24694	24699	O
,	24699	24700	O
MPCCs	24701	24706	O
exposed	24707	24714	O
to	24715	24717	O
a	24718	24719	O
hyperglycemic	24720	24733	O
culture	24734	24741	O
medium	24742	24748	O
for	24749	24752	O
3	24753	24754	O
weeks	24755	24760	O
developed	24761	24770	O
steatosis	24771	24780	O
and	24781	24784	O
became	24785	24791	O
resistant	24792	24801	O
to	24802	24804	O
insulin	24805	24812	O
-	24812	24813	O
mediated	24813	24821	O
suppression	24822	24833	O
of	24834	24836	O
gluconeogenesis	24837	24852	O
concomitantly	24853	24866	O
,	24866	24867	O
while	24868	24873	O
other	24874	24879	O
measured	24880	24888	O
liver	24889	24894	O
functions	24895	24904	O
(	24905	24906	O
i	24906	24907	O
.	24907	24908	O
e	24908	24909	O
.	24909	24910	O
,	24910	24911	O
CYP	24912	24915	O
activities	24916	24926	O
,	24926	24927	O
albumin	24928	24935	O
secretion	24936	24945	O
,	24945	24946	O
and	24947	24950	O
urea	24951	24955	O
synthesis	24956	24965	O
)	24965	24966	O
were	24967	24971	O
not	24972	24975	O
affected	24976	24984	O
[	24985	24986	O
Fig	24986	24989	O
.	24989	24990	O

1	24991	24992	O
(	24992	24993	O
c	24993	24994	O
)	24994	24995	O
]	24995	24996	O
.	24996	24997	O
52	24997	24999	O
Further	25000	25007	O
treating	25008	25016	O
the	25017	25020	O
steatotic	25021	25030	O
MPCCs	25031	25036	O
with	25037	25041	O
the	25042	25045	O
antidiabetic	25046	25058	O
drug	25059	25063	O
,	25063	25064	O
metformin	25065	25074	O
,	25074	25075	O
significantly	25076	25089	O
reduced	25090	25097	O
gluconeogenesis	25098	25113	O
.	25113	25114	O

Interestingly	25115	25128	O
,	25128	25129	O
MPCCs	25130	25135	O
treated	25136	25143	O
with	25144	25148	O
a	25149	25150	O
hypoglycemic	25151	25163	O
culture	25164	25171	O
medium	25172	25178	O
increased	25179	25188	O
CYP	25189	25192	O
activity	25193	25201	O
,	25201	25202	O
which	25203	25208	O
can	25209	25212	O
have	25213	25217	O
implications	25218	25230	O
for	25231	25234	O
patients	25235	25243	O
with	25244	25248	O
type	25249	25253	O
2	25254	25255	O
diabetes	25256	25264	O
mellitus	25265	25273	O
,	25273	25274	O
who	25275	25278	O
experience	25279	25289	O
hypoglycemia	25290	25302	O
due	25303	25306	O
to	25307	25309	O
side	25310	25314	O
effects	25315	25322	O
of	25323	25325	O
specific	25326	25334	O
drug	25335	25339	O
therapies	25340	25349	O
.	25349	25350	O

Similar	25351	25358	O
to	25359	25361	O
the	25362	25365	O
above	25366	25371	O
MPCC	25372	25376	O
platform	25377	25385	O
,	25385	25386	O
the	25387	25390	O
LiverChip	25391	25400	O
containing	25401	25411	O
perfused	25412	25420	O
PHHs	25421	25425	O
was	25426	25429	O
incubated	25430	25439	O
for	25440	25443	O
14	25444	25446	O
days	25447	25451	O
with	25452	25456	O
excess	25457	25463	O
nutrition	25464	25473	O
,	25473	25474	O
specifically	25475	25487	O
palmitic	25488	25496	O
and	25497	25500	O
oleic	25501	25506	O
free	25507	25511	O
fatty	25512	25517	O
acids	25518	25523	O
(	25524	25525	O
FFA	25525	25528	O
)	25528	25529	O
.	25529	25530	O
53	25530	25532	O
While	25533	25538	O
the	25539	25542	O
FFAs	25543	25547	O
were	25548	25552	O
not	25553	25556	O
toxic	25557	25562	O
to	25563	25565	O
PHHs	25566	25570	O
,	25570	25571	O
several	25572	25579	O
genes	25580	25585	O
associated	25586	25596	O
with	25597	25601	O
NAFLD	25602	25607	O
were	25608	25612	O
increased	25613	25622	O
,	25622	25623	O
whereas	25624	25631	O
CYP	25632	25635	O
activities	25636	25646	O
were	25647	25651	O
reduced	25652	25659	O
.	25659	25660	O

Metformin	25661	25670	O
therapy	25671	25678	O
reduced	25679	25686	O
the	25687	25690	O
steatosis	25691	25700	O
in	25701	25703	O
PHHs	25704	25708	O
relative	25709	25717	O
to	25718	25720	O
vehicle	25721	25728	O
-	25728	25729	O
treated	25729	25736	O
control	25737	25744	O
cultures	25745	25753	O
.	25753	25754	O

Even	25755	25759	O
static	25760	25766	O
PHH	25767	25770	O
spheroids	25771	25780	O
generated	25781	25790	O
via	25791	25794	O
ultralow	25795	25803	O
attachment	25804	25814	O
plates	25815	25821	O
have	25822	25826	O
been	25827	25831	O
shown	25832	25837	O
to	25838	25840	O
mimic	25841	25846	O
the	25847	25850	O
early	25851	25856	O
stages	25857	25863	O
of	25864	25866	O
NAFLD	25867	25872	O
[	25873	25874	O
Fig	25874	25877	O
.	25877	25878	O

1	25879	25880	O
(	25880	25881	O
d	25881	25882	O
)	25882	25883	O
]	25883	25884	O
.	25884	25885	O
54	25885	25887	O
Specifically	25888	25900	O
,	25900	25901	O
PHH	25902	25905	O
spheroids	25906	25915	O
incubated	25916	25925	O
with	25926	25930	O
pathophysiological	25931	25949	O
concentrations	25950	25964	O
of	25965	25967	O
FFAs	25968	25972	O
,	25972	25973	O
glucose	25974	25981	O
,	25981	25982	O
fructose	25983	25991	O
,	25991	25992	O
and	25993	25996	O
high	25997	26001	O
levels	26002	26008	O
of	26009	26011	O
insulin	26012	26019	O
became	26020	26026	O
steatotic	26027	26036	O
and	26037	26040	O
concomitantly	26041	26054	O
displayed	26055	26064	O
enhanced	26065	26073	O
expression	26074	26084	O
of	26085	26087	O
genes	26088	26093	O
associated	26094	26104	O
with	26105	26109	O
denovo	26110	26116	O
lipogenesis	26117	26128	O
and	26129	26132	O
insulin	26133	26140	O
resistance	26141	26151	O
.	26151	26152	O

These	26153	26158	O
symptoms	26159	26167	O
could	26168	26173	O
be	26174	26176	O
alleviated	26177	26187	O
by	26188	26190	O
either	26191	26197	O
removing	26198	26206	O
the	26207	26210	O
pathophysiological	26211	26229	O
stimuli	26230	26237	O
or	26238	26240	O
treatment	26241	26250	O
with	26251	26255	O
antisteatotic	26256	26269	O
compounds	26270	26279	O
.	26279	26280	O

While	26281	26286	O
phenotypically	26287	26301	O
stabilized	26302	26312	O
PHHs	26313	26317	O
can	26318	26321	O
be	26322	26324	O
used	26325	26329	O
to	26330	26332	O
investigate	26333	26344	O
steatosis	26345	26354	O
and	26355	26358	O
insulin	26359	26366	O
resistance	26367	26377	O
as	26378	26380	O
discussed	26381	26390	O
above	26391	26396	O
,	26396	26397	O
the	26398	26401	O
later	26402	26407	O
stages	26408	26414	O
of	26415	26417	O
NAFLD	26418	26423	O
,	26423	26424	O
called	26425	26431	O
nonalcoholic	26432	26444	O
steatohepatitis	26445	26460	O
(	26461	26462	O
NASH	26462	26466	O
)	26466	26467	O
,	26467	26468	O
cause	26469	26474	O
inflammation	26475	26487	O
and	26488	26491	O
fibrosis	26492	26500	O
in	26501	26503	O
the	26504	26507	O
liver	26508	26513	O
,	26513	26514	O
which	26515	26520	O
are	26521	26524	O
mediated	26525	26533	O
by	26534	26536	O
liver	26537	26542	O
NPCs	26543	26547	O
.	26547	26548	O

For	26549	26552	O
instance	26553	26561	O
,	26561	26562	O
with	26563	26567	O
progressing	26568	26579	O
disease	26580	26587	O
,	26587	26588	O
HSCs	26589	26593	S-CL:0000037
become	26594	26600	O
activated	26601	26610	O
into	26611	26615	O
myofibroblasts	26616	26630	O
that	26631	26635	O
secrete	26636	26643	O
proinflammatory	26644	26659	O
cytokines	26660	26669	O
and	26670	26673	O
deposit	26674	26681	O
excessive	26682	26691	O
collagen	26692	26700	O
,	26700	26701	O
which	26702	26707	O
is	26708	26710	O
a	26711	26712	O
hallmark	26713	26721	O
of	26722	26724	O
fibrosis	26725	26733	O
.	26733	26734	O
46	26734	26736	O
Reversing	26737	26746	O
such	26747	26751	O
fibrosis	26752	26760	O
using	26761	26766	O
pharmaceuticals	26767	26782	O
can	26783	26786	O
potentially	26787	26798	O
halt	26799	26803	O
the	26804	26807	O
progression	26808	26819	O
of	26820	26822	O
NASH	26823	26827	O
into	26828	26832	O
cirrhosis	26833	26842	O
and	26843	26846	O
HCC	26847	26850	O
.	26850	26851	O

To	26852	26854	O
model	26855	26860	O
the	26861	26864	O
interactions	26865	26877	O
between	26878	26885	O
HSCs	26886	26890	S-CL:0000037
and	26891	26894	O
stabilized	26895	26905	O
PHHs	26906	26910	O
,	26910	26911	O
a	26912	26913	O
micropatterned	26914	26928	O
triculture	26929	26939	O
(	26940	26941	O
MPTC	26941	26945	O
)	26945	26946	O
platform	26947	26955	O
was	26956	26959	O
developed	26960	26969	O
in	26970	26972	O
which	26973	26978	O
(	26979	26980	O
a	26980	26981	O
)	26981	26982	O
micropatterned	26983	26997	O
PHHs	26998	27002	O
were	27003	27007	O
functionally	27008	27020	O
stabilized	27021	27031	O
using	27032	27037	O
the	27038	27041	O
3T3	27042	27045	O
-	27045	27046	O
J2	27046	27048	O
fibroblasts	27049	27060	S-CL:0000057
(	27061	27062	O
as	27062	27064	O
in	27065	27067	O
MPCCs	27068	27073	O
described	27074	27083	O
above	27084	27089	O
)	27089	27090	O
and	27091	27094	O
(	27095	27096	O
b	27096	27097	O
)	27097	27098	O
the	27099	27102	O
PHH	27103	27106	O
phenotype	27107	27116	O
was	27117	27120	O
modulated	27121	27130	O
by	27131	27133	O
culturing	27134	27143	O
activated	27144	27153	O
(	27154	27155	O
fibrogenic	27155	27165	O
)	27165	27166	O
HSCs	27167	27171	S-CL:0000037
within	27172	27178	O
the	27179	27182	O
fibroblast	27183	27193	S-CL:0000057
monolayer	27194	27203	O
at	27204	27206	O
physiologically	27207	27222	O
relevant	27223	27231	O
ratios	27232	27238	O
with	27239	27243	O
PHHs	27244	27248	O
;	27248	27249	O
such	27250	27254	O
a	27255	27256	O
triculture	27257	27267	O
configuration	27268	27281	O
was	27282	27285	O
used	27286	27290	O
since	27291	27296	O
the	27297	27300	O
HSCs	27301	27305	S-CL:0000037
were	27306	27310	O
not	27311	27314	O
able	27315	27319	O
to	27320	27322	O
stabilize	27323	27332	O
the	27333	27336	O
PHH	27337	27340	O
phenotype	27341	27350	O
to	27351	27353	O
the	27354	27357	O
same	27358	27362	O
magnitude	27363	27372	O
and	27373	27376	O
longevity	27377	27386	O
as	27387	27389	O
the	27390	27393	O
fibroblasts	27394	27405	S-CL:0000057
.	27405	27406	O
34	27406	27408	O
While	27409	27414	O
albumin	27415	27422	O
and	27423	27426	O
urea	27427	27431	O
secretions	27432	27442	O
were	27443	27447	O
relatively	27448	27458	O
similar	27459	27466	O
in	27467	27469	O
MPTCs	27470	27475	O
and	27476	27479	O
MPCCs	27480	27485	O
(	27486	27487	O
suggesting	27487	27497	O
well	27498	27502	O
-	27502	27503	O
differentiated	27503	27517	O
PHHs	27518	27522	O
)	27522	27523	O
,	27523	27524	O
over	27525	27529	O
the	27530	27533	O
course	27534	27540	O
of	27541	27543	O
2	27544	27545	O
weeks	27546	27551	O
,	27551	27552	O
increasing	27553	27563	O
HSC	27564	27567	S-CL:0000037
numbers	27568	27575	O
within	27576	27582	O
MPTCs	27583	27588	O
downregulated	27589	27602	O
hepatic	27603	27610	O
CYP	27611	27614	O
and	27615	27618	O
drug	27619	27623	O
transporter	27624	27635	O
activities	27636	27646	O
,	27646	27647	O
caused	27648	27654	O
hepatic	27655	27662	O
steatosis	27663	27672	O
independent	27673	27684	O
of	27685	27687	O
overnutritional	27688	27703	O
stimuli	27704	27711	O
,	27711	27712	O
and	27713	27716	O
enhanced	27717	27725	O
the	27726	27729	O
secretion	27730	27739	O
of	27740	27742	O
proinflammatory	27743	27758	O
cytokines	27759	27768	O
,	27768	27769	O
which	27770	27775	O
are	27776	27779	O
effects	27780	27787	O
also	27788	27792	O
observed	27793	27801	O
clinically	27802	27812	O
in	27813	27815	O
patients	27816	27824	O
suffering	27825	27834	O
from	27835	27839	O
early	27840	27845	O
stages	27846	27852	O
of	27853	27855	O
NASH	27856	27860	O
/	27860	27861	O
fibrosis	27861	27869	O
[	27870	27871	O
Fig	27871	27874	O
.	27874	27875	O

1	27876	27877	O
(	27877	27878	O
e	27878	27879	O
)	27879	27880	O
]	27880	27881	O
.	27881	27882	O
55	27882	27884	O
,	27884	27885	O
56	27885	27887	O
Importantly	27888	27899	O
,	27899	27900	O
inhibition	27901	27911	O
of	27912	27914	O
nicotinamide	27915	27927	O
adenine	27928	27935	O
dinucleotide	27936	27948	O
phosphate	27949	27958	O
oxidase	27959	27966	O
(	27967	27968	O
NADPH	27968	27973	O
oxidase	27974	27981	O
)	27981	27982	O
and	27983	27986	O
/	27986	27987	O
or	27987	27989	O
activation	27990	28000	O
of	28001	28003	O
farnesoid	28004	28013	O
X	28014	28015	O
receptor	28016	28024	O
(	28025	28026	O
FXR	28026	28029	O
)	28029	28030	O
using	28031	28036	O
clinically	28037	28047	O
relevant	28048	28056	O
drugs	28057	28062	O
,	28062	28063	O
GKT137831	28064	28073	O
and	28074	28077	O
obeticholic	28078	28089	O
acid	28090	28094	O
(	28095	28096	O
OCA	28096	28099	O
)	28099	28100	O
,	28100	28101	O
respectively	28102	28114	O
,	28114	28115	O
alleviated	28116	28126	O
hepatic	28127	28134	O
dysfunctions	28135	28147	O
in	28148	28150	O
MPTCs	28151	28156	O
at	28157	28159	O
nontoxic	28160	28168	O
concentrations	28169	28183	O
,	28183	28184	O
thereby	28185	28192	O
suggesting	28193	28203	O
MPTC	28204	28208	O
utility	28209	28216	O
for	28217	28220	O
screening	28221	28230	O
the	28231	28234	O
efficacy	28235	28243	O
and	28244	28247	O
toxicity	28248	28256	O
of	28257	28259	O
anti	28260	28264	O
-	28264	28265	O
NASH	28265	28269	O
/	28269	28270	O
fibrosis	28270	28278	O
drugs	28279	28284	O
.	28284	28285	O

In	28286	28288	O
another	28289	28296	O
example	28297	28304	O
of	28305	28307	O
an	28308	28310	O
engineered	28311	28321	O
NASH	28322	28326	O
human	28327	28332	O
liver	28333	28338	O
model	28339	28344	O
by	28345	28347	O
HemoShear	28348	28357	O
Therapeutics	28358	28370	O
,	28370	28371	O
Inc	28372	28375	O
.	28375	28376	O
,	28376	28377	O
PHHs	28378	28382	O
were	28383	28387	O
cultured	28388	28396	O
in	28397	28399	O
a	28400	28401	O
collagen	28402	28410	O
gel	28411	28414	O
on	28415	28417	O
one	28418	28421	O
surface	28422	28429	O
of	28430	28432	O
a	28433	28434	O
polycarbonate	28435	28448	O
membrane	28449	28457	O
,	28457	28458	O
while	28459	28464	O
a	28465	28466	O
mixture	28467	28474	O
of	28475	28477	O
HSCs	28478	28482	S-CL:0000037
and	28483	28486	O
macrophages	28487	28498	S-CL:0000235
was	28499	28502	O
cultured	28503	28511	O
on	28512	28514	O
the	28515	28518	O
other	28519	28524	O
surface	28525	28532	O
of	28533	28535	O
the	28536	28539	O
membrane	28540	28548	O
.	28548	28549	O
57	28549	28551	O
The	28552	28555	O
NPC	28556	28559	O
compartment	28560	28571	O
was	28572	28575	O
subsequently	28576	28588	O
subjected	28589	28598	O
to	28599	28601	O
hemodynamic	28602	28613	O
flow	28614	28618	O
using	28619	28624	O
a	28625	28626	O
cone	28627	28631	O
-	28631	28632	O
and	28632	28635	O
-	28635	28636	O
plate	28636	28641	O
viscometer	28642	28652	O
,	28652	28653	O
while	28654	28659	O
the	28660	28663	O
hepatic	28664	28671	O
compartment	28672	28683	O
was	28684	28687	O
subjected	28688	28697	O
to	28698	28700	O
continuous	28701	28711	O
perfusion	28712	28721	O
to	28722	28724	O
recapitulate	28725	28737	O
interstitial	28738	28750	O
-	28750	28751	O
like	28751	28755	O
flow	28756	28760	O
patterns	28761	28769	O
.	28769	28770	O

When	28771	28775	O
this	28776	28780	O
platform	28781	28789	O
was	28790	28793	O
exposed	28794	28801	O
for	28802	28805	O
10	28806	28808	O
days	28809	28813	O
to	28814	28816	O
a	28817	28818	O
lipotoxic	28819	28828	O
milieu	28829	28835	O
(	28836	28837	O
high	28837	28841	O
insulin	28842	28849	O
and	28850	28853	O
glucose	28854	28861	O
and	28862	28865	O
FFAs	28866	28870	O
)	28870	28871	O
,	28871	28872	O
PHHs	28873	28877	O
accumulated	28878	28889	O
lipids	28890	28896	O
,	28896	28897	O
increased	28898	28907	O
glucose	28908	28915	O
output	28916	28922	O
,	28922	28923	O
and	28924	28927	O
displayed	28928	28937	O
reduced	28938	28945	O
insulin	28946	28953	O
sensitivity	28954	28965	O
.	28965	28966	O
57	28966	28968	O
Furthermore	28969	28980	O
,	28980	28981	O
inflammatory	28982	28994	O
markers	28995	29002	O
were	29003	29007	O
secreted	29008	29016	O
at	29017	29019	O
higher	29020	29026	O
levels	29027	29033	O
,	29033	29034	O
and	29035	29038	O
HSCs	29039	29043	S-CL:0000037
displayed	29044	29053	O
increased	29054	29063	O
activation	29064	29074	O
as	29075	29077	O
assessed	29078	29086	O
via	29087	29090	O
the	29091	29094	O
staining	29095	29103	O
of	29104	29106	O
alpha	29107	29112	O
-	29112	29113	O
smooth	29113	29119	O
muscle	29120	29126	O
actin	29127	29132	O
.	29132	29133	O

Importantly	29134	29145	O
,	29145	29146	O
transcriptomic	29147	29161	O
and	29162	29165	O
lipidomic	29166	29175	O
data	29176	29180	O
obtained	29181	29189	O
in	29190	29192	O
vitro	29193	29198	O
correlated	29199	29209	O
to	29210	29212	O
some	29213	29217	O
extent	29218	29224	O
with	29225	29229	O
those	29230	29235	O
obtained	29236	29244	O
from	29245	29249	O
human	29250	29255	O
liver	29256	29261	O
NASH	29262	29266	O
biopsies	29267	29275	O
.	29275	29276	O

Treating	29277	29285	O
the	29286	29289	O
in	29290	29292	O
vitro	29293	29298	O
diseased	29299	29307	O
cocultures	29308	29318	O
with	29319	29323	O
OCA	29324	29327	O
led	29328	29331	O
to	29332	29334	O
improvements	29335	29347	O
in	29348	29350	O
the	29351	29354	O
lipidomic	29355	29364	O
signature	29365	29374	O
and	29375	29378	O
a	29379	29380	O
reduction	29381	29390	O
in	29391	29393	O
inflammatory	29394	29406	O
and	29407	29410	O
fibrotic	29411	29419	O
secreted	29420	29428	O
factors	29429	29436	O
.	29436	29437	O

Finally	29438	29445	O
,	29445	29446	O
a	29447	29448	O
bioprinted	29449	29459	O
human	29460	29465	O
liver	29466	29471	O
spheroid	29472	29480	O
(	29481	29482	O
centimeter	29482	29492	O
scale	29493	29498	O
)	29498	29499	O
that	29500	29504	O
contains	29505	29513	O
a	29514	29515	O
compartment	29516	29527	O
of	29528	29530	O
PHHs	29531	29535	O
next	29536	29540	O
to	29541	29543	O
a	29544	29545	O
NPC	29546	29549	O
compartment	29550	29561	O
containing	29562	29572	O
HSCs	29573	29577	S-CL:0000037
and	29578	29581	O
endothelial	29582	29593	B-CL:0000115
cells	29594	29599	E-CL:0000115
housed	29600	29606	O
in	29607	29609	O
a	29610	29611	O
24	29612	29614	O
-	29614	29615	O
well	29615	29619	O
transwell	29620	29629	O
format58	29630	29638	O
can	29639	29642	O
also	29643	29647	O
be	29648	29650	O
induced	29651	29658	O
toward	29659	29665	O
a	29666	29667	O
steatotic	29668	29677	O
state	29678	29683	O
when	29684	29688	O
treated	29689	29696	O
with	29697	29701	O
excess	29702	29708	O
FFAs	29709	29713	O
;	29713	29714	O
furthermore	29715	29726	O
,	29726	29727	O
HSCs	29728	29732	S-CL:0000037
expressed	29733	29742	O
higher	29743	29749	O
alpha	29750	29755	O
-	29755	29756	O
smooth	29756	29762	O
muscle	29763	29769	O
actin	29770	29775	O
staining	29776	29784	O
,	29784	29785	O
a	29786	29787	O
marker	29788	29794	O
of	29795	29797	O
fibrosis	29798	29806	O
,	29806	29807	O
in	29808	29810	O
such	29811	29815	O
bioprinted	29816	29826	O
livers	29827	29833	O
.	29833	29834	O
59	29834	29836	O
It	29837	29839	O
is	29840	29842	O
now	29843	29846	O
clear	29847	29852	O
through	29853	29860	O
the	29861	29864	O
aforementioned	29865	29879	O
pioneering	29880	29890	O
studies	29891	29898	O
that	29899	29903	O
engineered	29904	29914	O
human	29915	29920	O
liver	29921	29926	O
models	29927	29933	O
can	29934	29937	O
be	29938	29940	O
coaxed	29941	29947	O
into	29948	29952	O
a	29953	29954	O
steatotic	29955	29964	O
phenotype	29965	29974	O
via	29975	29978	O
treatment	29979	29988	O
with	29989	29993	O
overnutrition	29994	30007	O
stimuli	30008	30015	O
(	30016	30017	O
e	30017	30018	O
.	30018	30019	O
g	30019	30020	O
.	30020	30021	O
,	30021	30022	O
glucose	30023	30030	O
,	30030	30031	O
fructose	30032	30040	O
,	30040	30041	O
FFAs	30042	30046	O
,	30046	30047	O
and	30048	30051	O
high	30052	30056	O
insulin	30057	30064	O
levels	30065	30071	O
)	30071	30072	O
for	30073	30076	O
a	30077	30078	O
few	30079	30082	O
weeks	30083	30088	O
.	30088	30089	O

Inclusion	30090	30099	O
of	30100	30102	O
activated	30103	30112	O
HSCs	30113	30117	S-CL:0000037
into	30118	30122	O
PHH	30123	30126	O
-	30126	30127	O
based	30127	30132	O
models	30133	30139	O
has	30140	30143	O
shown	30144	30149	O
that	30150	30154	O
these	30155	30160	O
cells	30161	30166	O
secrete	30167	30174	O
inflammatory	30175	30187	O
cytokines	30188	30197	O
,	30197	30198	O
secrete	30199	30206	O
collagen	30207	30215	O
,	30215	30216	O
and	30217	30220	O
express	30221	30228	O
markers	30229	30236	O
reminiscent	30237	30248	O
of	30249	30251	O
the	30252	30255	O
early	30256	30261	O
stages	30262	30268	O
of	30269	30271	O
fibrosis	30272	30280	O
in	30281	30283	O
NAFLD	30284	30289	O
.	30289	30290	O

However	30291	30298	O
,	30298	30299	O
the	30300	30303	O
ability	30304	30311	O
to	30312	30314	O
transdifferentiate	30315	30333	O
quiescent	30334	30343	O
HSCs	30344	30348	S-CL:0000037
(	30349	30350	O
vitamin	30350	30357	O
A	30358	30359	O
storing	30360	30367	O
cells	30368	30373	O
in	30374	30376	O
the	30377	30380	O
liver	30381	30386	O
)	30386	30387	O
to	30388	30390	O
an	30391	30393	O
activated	30394	30403	O
phenotype	30404	30413	O
via	30414	30417	O
incubation	30418	30428	O
with	30429	30433	O
excess	30434	30440	O
nutritional	30441	30452	O
stimuli	30453	30460	O
has	30461	30464	O
not	30465	30468	O
been	30469	30473	O
achieved	30474	30482	O
in	30483	30485	O
human	30486	30491	O
systems	30492	30499	O
since	30500	30505	O
commercially	30506	30518	O
available	30519	30528	O
HSCs	30529	30533	S-CL:0000037
have	30534	30538	O
already	30539	30546	O
become	30547	30553	O
myofibroblasts	30554	30568	O
due	30569	30572	O
to	30573	30575	O
their	30576	30581	O
expansion	30582	30591	O
onto	30592	30596	O
stiff	30597	30602	O
tissue	30603	30609	O
culture	30610	30617	O
plastic	30618	30625	O
.	30625	30626	O

Isolating	30627	30636	O
fresh	30637	30642	O
quiescent	30643	30652	O
HSCs	30653	30657	S-CL:0000037
for	30658	30661	O
every	30662	30667	O
experiment	30668	30678	O
is	30679	30681	O
unpractical	30682	30693	O
for	30694	30697	O
routine	30698	30705	O
drug	30706	30710	O
screening	30711	30720	O
;	30720	30721	O
thus	30722	30726	O
,	30726	30727	O
the	30728	30731	O
ability	30732	30739	O
to	30740	30742	O
design	30743	30749	O
substrates	30750	30760	O
that	30761	30765	O
can	30766	30769	O
revert	30770	30776	O
activated	30777	30786	O
HSCs	30787	30791	S-CL:0000037
to	30792	30794	O
a	30795	30796	O
more	30797	30801	O
quiescent	30802	30811	O
phenotype	30812	30821	O
is	30822	30824	O
desirable	30825	30834	O
.	30834	30835	O

High	30836	30840	O
-	30840	30841	O
throughput	30841	30851	O
ECM	30852	30855	O
microarrays	30856	30867	O
provide	30868	30875	O
an	30876	30878	O
opportunity	30879	30890	O
to	30891	30893	O
determine	30894	30903	O
the	30904	30907	O
optimal	30908	30915	O
ECM	30916	30919	O
(	30920	30921	O
protein	30921	30928	O
composition	30929	30940	O
and	30941	30944	O
substrate	30945	30954	O
stiffness	30955	30964	O
)	30964	30965	O
and	30966	30969	O
soluble	30970	30977	O
factor	30978	30984	O
microenvironment	30985	31001	O
that	31002	31006	O
can	31007	31010	O
induce	31011	31017	O
quiescent	31018	31027	O
states	31028	31034	O
in	31035	31037	O
human	31038	31043	O
liver	31044	31049	O
NPCs	31050	31054	O
as	31055	31057	O
well	31058	31062	O
as	31063	31065	O
enable	31066	31072	O
optimal	31073	31080	O
functions	31081	31090	O
in	31091	31093	O
PHHs	31094	31098	O
.	31098	31099	O

In	31100	31102	O
such	31103	31107	O
microarrays	31108	31119	O
,	31119	31120	O
cells	31121	31126	O
are	31127	31130	O
seeded	31131	31137	O
onto	31138	31142	O
printed	31143	31150	O
spots	31151	31156	O
of	31157	31159	O
biomolecules	31160	31172	O
that	31173	31177	O
include	31178	31185	O
adhesive	31186	31194	O
components	31195	31205	O
to	31206	31208	O
promote	31209	31216	O
localized	31217	31226	O
cell	31227	31231	O
adhesion	31232	31240	O
as	31241	31243	O
well	31244	31248	O
as	31249	31251	O
combinations	31252	31264	O
of	31265	31267	O
other	31268	31273	O
factors	31274	31281	O
to	31282	31284	O
stimulate	31285	31294	O
or	31295	31297	O
measure	31298	31305	O
cellular	31306	31314	O
processes	31315	31324	O
.	31324	31325	O
60	31325	31327	O
–	31327	31328	O
64	31328	31330	O
Furthermore	31331	31342	O
,	31342	31343	O
it	31344	31346	O
is	31347	31349	O
currently	31350	31359	O
not	31360	31363	O
possible	31364	31372	O
to	31373	31375	O
mimic	31376	31381	O
the	31382	31385	O
more	31386	31390	O
severe	31391	31397	O
stages	31398	31404	O
of	31405	31407	O
NAFLD	31408	31413	O
in	31414	31416	O
vitro	31417	31422	O
,	31422	31423	O
namely	31424	31430	O
,	31430	31431	O
cirrhosis	31432	31441	O
and	31442	31445	O
HCC	31446	31449	O
.	31449	31450	O

Nonetheless	31451	31462	O
,	31462	31463	O
we	31464	31466	O
anticipate	31467	31477	O
that	31478	31482	O
even	31483	31487	O
human	31488	31493	O
liver	31494	31499	O
models	31500	31506	O
of	31507	31509	O
the	31510	31513	O
early	31514	31519	O
stages	31520	31526	O
of	31527	31529	O
NAFLD	31530	31535	O
,	31535	31536	O
which	31537	31542	O
have	31543	31547	O
been	31548	31552	O
already	31553	31560	O
developed	31561	31570	O
,	31570	31571	O
will	31572	31576	O
prove	31577	31582	O
to	31583	31585	O
be	31586	31588	O
highly	31589	31595	O
useful	31596	31602	O
to	31603	31605	O
develop	31606	31613	O
drug	31614	31618	O
therapies	31619	31628	O
that	31629	31633	O
target	31634	31640	O
different	31641	31650	O
molecular	31651	31660	O
aspects	31661	31668	O
of	31669	31671	O
this	31672	31676	O
disease	31677	31684	O
;	31684	31685	O
certainly	31686	31695	O
,	31695	31696	O
Takeda	31697	31703	O
pharmaceuticals	31704	31719	O
is	31720	31722	O
leading	31723	31730	O
the	31731	31734	O
way	31735	31738	O
via	31739	31742	O
their	31743	31748	O
substantial	31749	31760	O
partnership	31761	31772	O
with	31773	31777	O
HemoShear	31778	31787	O
Therapeutics	31788	31800	O
to	31801	31803	O
discover	31804	31812	O
novel	31813	31818	O
drugs	31819	31824	O
for	31825	31828	O
NAFLD	31829	31834	O
using	31835	31840	O
their	31841	31846	O
perfused	31847	31855	O
human	31856	31861	O
liver	31862	31867	O
platform	31868	31876	O
.	31876	31877	O

Finally	31878	31885	O
,	31885	31886	O
additional	31887	31897	O
efforts	31898	31905	O
are	31906	31909	O
also	31910	31914	O
needed	31915	31921	O
to	31922	31924	O
better	31925	31931	O
understand	31932	31942	O
the	31943	31946	O
processes	31947	31956	O
that	31957	31961	O
mediate	31962	31969	O
the	31970	31973	O
progression	31974	31985	O
from	31986	31990	O
NAFLD	31991	31996	O
to	31997	31999	O
HCC	32000	32003	O
.	32003	32004	O

In	32005	32007	O
particular	32008	32018	O
,	32018	32019	O
NAFLD	32020	32025	O
-	32025	32026	O
associated	32026	32036	O
HCC	32037	32040	O
in	32041	32043	O
the	32044	32047	O
absence	32048	32055	O
of	32056	32058	O
cirrhosis	32059	32068	O
has	32069	32072	O
been	32073	32077	O
identified	32078	32088	O
in	32089	32091	O
some	32092	32096	O
cases	32097	32102	O
,	32102	32103	O
65	32103	32105	O
,	32105	32106	O
66	32106	32108	O
suggesting	32109	32119	O
that	32120	32124	O
a	32125	32126	O
linear	32127	32133	O
progression	32134	32145	O
through	32146	32153	O
worsening	32154	32163	O
stages	32164	32170	O
of	32171	32173	O
cirrhosis	32174	32183	O
may	32184	32187	O
not	32188	32191	O
be	32192	32194	O
a	32195	32196	O
requirement	32197	32208	O
for	32209	32212	O
HCC	32213	32216	O
.	32216	32217	O

The	32218	32221	O
application	32222	32233	O
of	32234	32236	O
engineered	32237	32247	O
in	32248	32250	O
vitro	32251	32256	O
culture	32257	32264	O
models	32265	32271	O
could	32272	32277	O
enable	32278	32284	O
the	32285	32288	O
types	32289	32294	O
of	32295	32297	O
systematic	32298	32308	O
studies	32309	32316	O
required	32317	32325	O
to	32326	32328	O
evaluate	32329	32337	O
the	32338	32341	O
connections	32342	32353	O
between	32354	32361	O
the	32362	32365	O
genetic	32366	32373	O
and	32374	32377	O
microenvironmental	32378	32396	O
changes	32397	32404	O
occurring	32405	32414	O
during	32415	32421	O
NAFLD	32422	32427	O
and	32428	32431	O
HCC	32432	32435	O
tumorigenesis	32436	32449	O
.	32449	32450	O

A	32451	32452	O
key	32453	32456	O
advantage	32457	32466	O
of	32467	32469	O
a	32470	32471	O
3D	32472	32474	O
liver	32475	32480	O
model	32481	32486	O
for	32487	32490	O
NAFLD	32491	32496	O
/	32496	32497	O
NASH	32497	32501	O
studies	32502	32509	O
is	32510	32512	O
the	32513	32516	O
ability	32517	32524	O
to	32525	32527	O
determine	32528	32537	O
reorganization	32538	32552	O
of	32553	32555	O
cells	32556	32561	O
and	32562	32565	O
ECM	32566	32569	O
with	32570	32574	O
fibrosis	32575	32583	O
progression	32584	32595	O
.	32595	32596	O

However	32597	32604	O
,	32604	32605	O
while	32606	32611	O
self	32612	32616	O
-	32616	32617	O
assembled	32617	32626	O
spheroids	32627	32636	O
enable	32637	32643	O
3D	32644	32646	B-CL:0000502
cell	32647	32651	E-CL:0000502
-	32651	32652	O
cell	32652	32656	O
and	32657	32660	O
cell	32661	32665	O
-	32665	32666	O
ECM	32666	32669	O
interactions	32670	32682	O
,	32682	32683	O
it	32684	32686	O
is	32687	32689	O
difficult	32690	32699	O
to	32700	32702	O
form	32703	32707	O
structurally	32708	32720	O
stable	32721	32727	O
spheroids	32728	32737	O
with	32738	32742	O
>	32743	32744	O
50	32744	32746	O
%	32746	32747	O
of	32748	32750	O
PHH	32751	32754	O
donors	32755	32761	O
/	32761	32762	O
lots	32762	32766	O
,	32766	32767	O
67	32767	32769	O
potentially	32770	32781	O
due	32782	32785	O
to	32786	32788	O
variable	32789	32797	O
ECM	32798	32801	O
secretion	32802	32811	O
rates	32812	32817	O
across	32818	32824	O
PHH	32825	32828	O
donor	32829	32834	O
cells	32835	32840	O
.	32840	32841	O

Encapsulating	32842	32855	O
cells	32856	32861	O
or	32862	32864	O
spheroids	32865	32874	O
in	32875	32877	O
hydrogels	32878	32887	O
can	32888	32891	O
mitigate	32892	32900	O
the	32901	32904	O
above	32905	32910	O
-	32910	32911	O
mentioned	32911	32920	O
limitation	32921	32931	O
,	32931	32932	O
but	32933	32936	O
the	32937	32940	O
choice	32941	32947	O
of	32948	32950	O
the	32951	32954	O
hydrogel	32955	32963	O
type	32964	32968	O
is	32969	32971	O
important	32972	32981	O
.	32981	32982	O

While	32983	32988	O
bioinert	32989	32997	O
alginate68	32998	33008	O
and	33009	33012	O
poly	33013	33017	O
(	33017	33018	O
ethylene	33018	33026	O
glycol	33027	33033	O
)	33033	33034	O
(	33035	33036	O
PEG	33036	33039	O
)	33039	33040	O
69	33040	33042	O
have	33043	33047	O
been	33048	33052	O
used	33053	33057	O
to	33058	33060	O
encapsulate	33061	33072	O
hepatocytes	33073	33084	S-CL:0000182
,	33084	33085	O
neither	33086	33093	O
material	33094	33102	O
type	33103	33107	O
allows	33108	33114	O
the	33115	33118	O
cells	33119	33124	O
to	33125	33127	O
remodel	33128	33135	O
the	33136	33139	O
ECM	33140	33143	O
as	33144	33146	O
in	33147	33149	O
fibrosis	33150	33158	O
progression	33159	33170	O
.	33170	33171	O

Thus	33172	33176	O
,	33176	33177	O
natural	33178	33185	O
ECM	33186	33189	O
containing	33190	33200	O
collagens	33201	33210	O
is	33211	33213	O
preferable	33214	33224	O
for	33225	33228	O
modeling	33229	33237	O
liver	33238	33243	O
fibrosis	33244	33252	O
.	33252	33253	O

While	33254	33259	O
3D	33260	33262	O
bioprinting	33263	33274	O
can	33275	33278	O
be	33279	33281	O
used	33282	33286	O
to	33287	33289	O
embed	33290	33295	O
cells	33296	33301	O
in	33302	33304	O
ECM	33305	33308	O
hydrogel	33309	33317	O
“	33318	33319	O
inks	33319	33323	O
”	33323	33324	O
and	33325	33328	O
create	33329	33335	O
on	33336	33338	O
-	33338	33339	O
demand	33339	33345	O
architectures	33346	33359	O
,	33359	33360	O
this	33361	33365	O
is	33366	33368	O
an	33369	33371	O
expensive	33372	33381	O
and	33382	33385	O
low	33386	33389	O
-	33389	33390	O
throughput	33390	33400	O
process	33401	33408	O
requiring	33409	33418	O
an	33419	33421	O
unsustainably	33422	33435	O
large	33436	33441	O
number	33442	33448	O
of	33449	33451	O
expensive	33452	33461	O
and	33462	33465	O
limited	33466	33473	O
PHHs	33474	33478	O
for	33479	33482	O
applications	33483	33495	O
in	33496	33498	O
drug	33499	33503	O
development	33504	33515	O
.	33515	33516	O
58	33516	33518	O
Furthermore	33519	33530	O
,	33530	33531	O
large	33532	33537	O
(	33538	33539	O
>	33539	33540	O
500	33540	33543	O
μm	33544	33546	O
)	33546	33547	O
hydrogels	33548	33557	O
pose	33558	33562	O
significant	33563	33574	O
diffusion	33575	33584	O
limitations	33585	33596	O
for	33597	33600	O
oxygen	33601	33607	O
and	33608	33611	O
nutrients	33612	33621	O
to	33622	33624	O
cells	33625	33630	O
in	33631	33633	O
the	33634	33637	O
construct	33638	33647	O
'	33647	33648	O
s	33648	33649	O
core	33650	33654	O
;	33654	33655	O
70	33655	33657	O
this	33658	33662	O
limitation	33663	33673	O
can	33674	33677	O
be	33678	33680	O
mitigated	33681	33690	O
by	33691	33693	O
miniaturizing	33694	33707	O
the	33708	33711	O
hydrogel	33712	33720	O
scaffolds	33721	33730	O
to	33731	33733	O
∼	33734	33735	O
100	33735	33738	O
–	33738	33739	O
300	33739	33742	O
μm	33743	33745	O
.	33745	33746	O

Such	33747	33751	O
miniaturized	33752	33764	O
cell	33765	33769	O
-	33769	33770	O
laden	33770	33775	O
hydrogels	33776	33785	O
can	33786	33789	O
be	33790	33792	O
created	33793	33800	O
using	33801	33806	O
microfluidic	33807	33819	O
droplet	33820	33827	O
generators	33828	33838	O
,	33838	33839	O
which	33840	33845	O
typically	33846	33855	O
use	33856	33859	O
fluorocarbon	33860	33872	O
oil	33873	33876	O
with	33877	33881	O
surfactant	33882	33892	O
to	33893	33895	O
create	33896	33902	O
aqueous	33903	33910	O
emulsions	33911	33920	O
containing	33921	33931	O
unpolymerized	33932	33945	O
ECM	33946	33949	O
mixed	33950	33955	O
with	33956	33960	O
cells	33961	33966	O
.	33966	33967	O
71	33967	33969	O
,	33969	33970	O
72	33970	33972	O
We	33973	33975	O
have	33976	33980	O
recently	33981	33989	O
utilized	33990	33998	O
high	33999	34003	O
-	34003	34004	O
throughput	34004	34014	O
droplet	34015	34022	O
microfluidics	34023	34036	O
to	34037	34039	O
fabricate	34040	34049	O
collagen	34050	34058	O
-	34058	34059	O
based	34059	34064	O
3D	34065	34067	O
human	34068	34073	O
liver	34074	34079	O
microtissues	34080	34092	O
containing	34093	34103	O
PHHs	34104	34108	O
and	34109	34112	O
3T3	34113	34116	O
-	34116	34117	O
J2	34117	34119	O
fibroblasts	34120	34131	S-CL:0000057
that	34132	34136	O
displayed	34137	34146	O
6	34147	34148	O
+	34148	34149	O
weeks	34150	34155	O
of	34156	34158	O
functions	34159	34168	O
,	34168	34169	O
which	34170	34175	O
were	34176	34180	O
up	34181	34183	O
to	34184	34186	O
10	34187	34189	O
-	34189	34190	O
fold	34190	34194	O
higher	34195	34201	O
in	34202	34204	O
levels	34205	34211	O
than	34212	34216	O
conventional	34217	34229	O
self	34230	34234	O
-	34234	34235	O
assembled	34235	34244	O
spheroids	34245	34254	O
and	34255	34258	O
bulk	34259	34263	O
collagen	34264	34272	O
hydrogels	34273	34282	O
with	34283	34287	O
encapsulated	34288	34300	O
cells	34301	34306	O
.	34306	34307	O
176	34307	34310	O
We	34311	34313	O
anticipate	34314	34324	O
that	34325	34329	O
such	34330	34334	O
a	34335	34336	O
platform	34337	34345	O
will	34346	34350	O
be	34351	34353	O
useful	34354	34360	O
to	34361	34363	O
study	34364	34369	O
reorganization	34370	34384	O
of	34385	34387	O
cell	34388	34392	O
-	34392	34393	O
cell	34393	34397	O
and	34398	34401	O
cell	34402	34406	O
-	34406	34407	O
ECM	34407	34410	O
interactions	34411	34423	O
in	34424	34426	O
fibrosis	34427	34435	O
induced	34436	34443	O
by	34444	34446	O
not	34447	34450	O
only	34451	34455	O
NAFLD	34456	34461	O
but	34462	34465	O
also	34466	34470	O
HCV	34471	34474	O
and	34475	34478	O
HBV	34479	34482	O
infections	34483	34493	O
.	34493	34494	O

Gradients	34495	34504	O
of	34505	34507	O
oxygen	34508	34514	O
and	34515	34518	O
hormones	34519	34527	O
play	34528	34532	O
important	34533	34542	O
roles	34543	34548	O
in	34549	34551	O
the	34552	34555	O
induction	34556	34565	O
of	34566	34568	O
differential	34569	34581	O
functions	34582	34591	O
in	34592	34594	O
hepatocytes	34595	34606	S-CL:0000182
along	34607	34612	O
the	34613	34616	O
length	34617	34623	O
of	34624	34626	O
the	34627	34630	O
sinusoid	34631	34639	O
,	34639	34640	O
a	34641	34642	O
phenomenon	34643	34653	O
termed	34654	34660	O
“	34661	34662	O
zonation	34662	34670	O
”	34670	34671	O
;	34671	34672	O
73	34672	34674	O
,	34674	34675	O
74	34675	34677	O
as	34678	34680	O
many	34681	34685	O
as	34686	34688	O
50	34689	34691	O
%	34691	34692	O
of	34693	34695	O
liver	34696	34701	O
genes	34702	34707	O
are	34708	34711	O
found	34712	34717	O
to	34718	34720	O
be	34721	34723	O
zonated	34724	34731	O
.	34731	34732	O
75	34732	34734	O
In	34735	34737	O
addition	34738	34746	O
to	34747	34749	O
its	34750	34753	O
key	34754	34757	O
role	34758	34762	O
in	34763	34765	O
normal	34766	34772	O
liver	34773	34778	O
physiology	34779	34789	O
,	34789	34790	O
steatosis	34791	34800	O
resulting	34801	34810	O
from	34811	34815	O
NAFLD	34816	34821	O
is	34822	34824	O
typically	34825	34834	O
localized	34835	34844	O
in	34845	34847	O
the	34848	34851	O
perivenous	34852	34862	O
zone	34863	34867	O
with	34868	34872	O
low	34873	34876	O
O2	34877	34879	O
levels	34880	34886	O
,	34886	34887	O
76	34887	34889	O
,	34889	34890	O
77	34890	34892	O
and	34893	34896	O
is	34897	34899	O
more	34900	34904	O
often	34905	34910	O
associated	34911	34921	O
with	34922	34926	O
hepatocyte	34927	34937	S-CL:0000182
injury	34938	34944	O
and	34945	34948	O
advanced	34949	34957	O
fibrosis	34958	34966	O
in	34967	34969	O
human	34970	34975	O
NAFLD	34976	34981	O
liver	34982	34987	O
biopsies	34988	34996	O
.	34996	34997	O
78	34997	34999	O
While	35000	35005	O
aspects	35006	35013	O
of	35014	35016	O
liver	35017	35022	O
zonation	35023	35031	O
,	35031	35032	O
especially	35033	35043	O
those	35044	35049	O
related	35050	35057	O
to	35058	35060	O
drug	35061	35065	O
-	35065	35066	O
induced	35066	35073	O
cell	35074	35078	O
responses	35079	35088	O
(	35089	35090	O
e	35090	35091	O
.	35091	35092	O
g	35092	35093	O
.	35093	35094	O
,	35094	35095	O
toxicity	35096	35104	O
and	35105	35108	O
induction	35109	35118	O
of	35119	35121	O
CYP	35122	35125	O
enzymes	35126	35133	O
)	35133	35134	O
,	35134	35135	O
have	35136	35140	O
been	35141	35145	O
modeled	35146	35153	O
in	35154	35156	O
vitro	35157	35162	O
in	35163	35165	O
several	35166	35173	O
studies	35174	35181	O
,	35181	35182	O
79	35182	35184	O
–	35184	35185	O
83	35185	35187	O
application	35188	35199	O
to	35200	35202	O
modeling	35203	35211	O
NAFLD	35212	35217	O
is	35218	35220	O
lacking	35221	35228	O
and	35229	35232	O
thus	35233	35237	O
presents	35238	35246	O
an	35247	35249	O
opportunity	35250	35261	O
for	35262	35265	O
further	35266	35273	O
research	35274	35282	O
in	35283	35285	O
this	35286	35290	O
space	35291	35296	O
.	35296	35297	O

Liver	35298	35303	O
cancer	35304	35310	O
Current	35311	35318	O
strategies	35319	35329	O
and	35330	35333	O
limitations	35334	35345	O
Chronic	35346	35353	O
liver	35354	35359	O
diseases	35360	35368	O
such	35369	35373	O
as	35374	35376	O
NAFLD	35377	35382	O
or	35383	35385	O
chronic	35386	35393	O
hepatitis	35394	35403	O
infection	35404	35413	O
are	35414	35417	O
associated	35418	35428	O
with	35429	35433	O
an	35434	35436	O
increased	35437	35446	O
risk	35447	35451	O
for	35452	35455	O
the	35456	35459	O
primary	35460	35467	O
liver	35468	35473	O
cancer	35474	35480	O
termed	35481	35487	O
hepatocellular	35488	35502	O
carcinoma	35503	35512	O
(	35513	35514	O
HCC	35514	35517	O
)	35517	35518	O
.	35518	35519	O
84	35519	35521	O
–	35521	35522	O
87	35522	35524	O
HCC	35525	35528	O
accounts	35529	35537	O
for	35538	35541	O
approximately	35542	35555	O
70	35556	35558	O
%	35558	35559	O
–	35559	35560	O
80	35560	35562	O
%	35562	35563	O
of	35564	35566	O
all	35567	35570	O
liver	35571	35576	O
cancers	35577	35584	O
and	35585	35588	O
is	35589	35591	O
the	35592	35595	O
second	35596	35602	O
leading	35603	35610	O
cause	35611	35616	O
of	35617	35619	O
cancer	35620	35626	O
-	35626	35627	O
related	35627	35634	O
death	35635	35640	O
globally	35641	35649	O
.	35649	35650	O
88	35650	35652	O
,	35652	35653	O
89	35653	35655	O
Additional	35656	35666	O
types	35667	35672	O
of	35673	35675	O
liver	35676	35681	O
cancers	35682	35689	O
include	35690	35697	O
cholangiocellular	35698	35715	O
carcinoma	35716	35725	O
(	35726	35727	O
CCC	35727	35730	O
)	35730	35731	O
,	35731	35732	O
90	35732	35734	O
a	35735	35736	O
malignancy	35737	35747	O
of	35748	35750	O
the	35751	35754	O
liver	35755	35760	O
bile	35761	35765	O
ducts	35766	35771	O
,	35771	35772	O
and	35773	35776	O
hepatoblastoma	35777	35791	O
,	35791	35792	O
91	35792	35794	O
which	35795	35800	O
is	35801	35803	O
the	35804	35807	O
most	35808	35812	O
common	35813	35819	O
pediatric	35820	35829	O
malignant	35830	35839	O
tumor	35840	35845	O
of	35846	35848	O
the	35849	35852	O
liver	35853	35858	O
.	35858	35859	O

For	35860	35863	O
HCC	35864	35867	O
,	35867	35868	O
depending	35869	35878	O
on	35879	35881	O
the	35882	35885	O
stage	35886	35891	O
at	35892	35894	O
presentation	35895	35907	O
,	35907	35908	O
treatments	35909	35919	O
range	35920	35925	O
from	35926	35930	O
resection	35931	35940	O
and	35941	35944	O
ablation	35945	35953	O
for	35954	35957	O
the	35958	35961	O
early	35962	35967	O
stage	35968	35973	O
,	35973	35974	O
transarterial	35975	35988	O
chemoembolization	35989	36006	O
for	36007	36010	O
the	36011	36014	O
intermediate	36015	36027	O
stage	36028	36033	O
,	36033	36034	O
and	36035	36038	O
kinase	36039	36045	O
inhibitors	36046	36056	O
and	36057	36060	O
supportive	36061	36071	O
care	36072	36076	O
for	36077	36080	O
advanced	36081	36089	O
stage	36090	36095	O
disease	36096	36103	O
.	36103	36104	O
92	36104	36106	O
Numerous	36107	36115	O
ongoing	36116	36123	O
research	36124	36132	O
studies	36133	36140	O
are	36141	36144	O
focused	36145	36152	O
on	36153	36155	O
the	36156	36159	O
development	36160	36171	O
and	36172	36175	O
application	36176	36187	O
of	36188	36190	O
new	36191	36194	O
therapeutic	36195	36206	O
strategies	36207	36217	O
including	36218	36227	O
checkpoint	36228	36238	O
inhibitors	36239	36249	O
and	36250	36253	O
procedures	36254	36264	O
,	36264	36265	O
such	36266	36270	O
as	36271	36273	O
selective	36274	36283	O
internal	36284	36292	O
radiotherapy	36293	36305	O
,	36305	36306	O
which	36307	36312	O
could	36313	36318	O
be	36319	36321	O
used	36322	36326	O
throughout	36327	36337	O
the	36338	36341	O
distinct	36342	36350	O
disease	36351	36358	O
stages	36359	36365	O
.	36365	36366	O
93	36366	36368	O
–	36368	36369	O
95	36369	36371	O
For	36372	36375	O
pediatric	36376	36385	O
hepatoblastoma	36386	36400	O
,	36400	36401	O
although	36402	36410	O
early	36411	36416	O
stage	36417	36422	O
tumors	36423	36429	O
can	36430	36433	O
often	36434	36439	O
be	36440	36442	O
cured	36443	36448	O
by	36449	36451	O
surgery	36452	36459	O
alone	36460	36465	O
without	36466	36473	O
chemotherapy	36474	36486	O
,	36486	36487	O
all	36488	36491	O
other	36492	36497	O
stages	36498	36504	O
usually	36505	36512	O
require	36513	36520	O
aggressive	36521	36531	O
cisplatin	36532	36541	O
/	36541	36542	O
doxorubicin	36542	36553	O
-	36553	36554	O
based	36554	36559	O
chemotherapy	36560	36572	O
together	36573	36581	O
with	36582	36586	O
surgical	36587	36595	O
resection	36596	36605	O
and	36606	36609	O
in	36610	36612	O
some	36613	36617	O
cases	36618	36623	O
liver	36624	36629	O
transplantation	36630	36645	O
.	36645	36646	O
96	36646	36648	O
A	36649	36650	O
number	36651	36657	O
of	36658	36660	O
challenges	36661	36671	O
exist	36672	36677	O
for	36678	36681	O
the	36682	36685	O
development	36686	36697	O
of	36698	36700	O
new	36701	36704	O
and	36705	36708	O
more	36709	36713	O
effective	36714	36723	O
treatments	36724	36734	O
for	36735	36738	O
liver	36739	36744	O
cancers	36745	36752	O
.	36752	36753	O

Typically	36754	36763	O
,	36763	36764	O
liver	36765	36770	O
cancer	36771	36777	O
surveillance	36778	36790	O
and	36791	36794	O
diagnosis	36795	36804	O
is	36805	36807	O
achieved	36808	36816	O
through	36817	36824	O
a	36825	36826	O
combination	36827	36838	O
of	36839	36841	O
abdominal	36842	36851	O
ultrasonographic	36852	36868	O
imaging	36869	36876	O
,	36876	36877	O
biopsy	36878	36884	O
analysis	36885	36893	O
,	36893	36894	O
and	36895	36898	O
serum	36899	36904	O
biomarker	36905	36914	O
assessment	36915	36925	O
.	36925	36926	O
97	36926	36928	O
The	36929	36932	O
sensitivity	36933	36944	O
of	36945	36947	O
imaging	36948	36955	O
and	36956	36959	O
biomarker	36960	36969	O
-	36969	36970	O
based	36970	36975	O
methods	36976	36983	O
is	36984	36986	O
often	36987	36992	O
a	36993	36994	O
limitation	36995	37005	O
.	37005	37006	O
98	37006	37008	O
Also	37009	37013	O
,	37013	37014	O
heterogeneity	37015	37028	O
within	37029	37035	O
a	37036	37037	O
liver	37038	37043	O
tumor	37044	37049	O
can	37050	37053	O
enhance	37054	37061	O
the	37062	37065	O
possibility	37066	37077	O
that	37078	37082	O
biopsy	37083	37089	O
samples	37090	37097	O
do	37098	37100	O
not	37101	37104	O
accurately	37105	37115	O
represent	37116	37125	O
the	37126	37129	O
collective	37130	37140	O
characteristics	37141	37156	O
of	37157	37159	O
the	37160	37163	O
tumor	37164	37169	O
.	37169	37170	O
99	37170	37172	O
Further	37173	37180	O
,	37180	37181	O
although	37182	37190	O
several	37191	37198	O
common	37199	37205	O
driver	37206	37212	O
mutations	37213	37222	O
have	37223	37227	O
been	37228	37232	O
identified	37233	37243	O
in	37244	37246	O
liver	37247	37252	O
cancers	37253	37260	O
,	37260	37261	O
there	37262	37267	O
is	37268	37270	O
an	37271	37273	O
increasing	37274	37284	O
appreciation	37285	37297	O
for	37298	37301	O
the	37302	37305	O
significant	37306	37317	O
interpatient	37318	37330	O
variability	37331	37342	O
often	37343	37348	O
observed	37349	37357	O
.	37357	37358	O

For	37359	37362	O
example	37363	37370	O
,	37370	37371	O
in	37372	37374	O
hepatoblastoma	37375	37389	O
,	37389	37390	O
despite	37391	37398	O
the	37399	37402	O
commonalities	37403	37416	O
in	37417	37419	O
beta	37420	37424	O
-	37424	37425	O
catenin	37425	37432	O
mutational	37433	37443	O
status	37444	37450	O
observed	37451	37459	O
across	37460	37466	O
a	37467	37468	O
majority	37469	37477	O
of	37478	37480	O
hepatoblastoma	37481	37495	O
patients	37496	37504	O
,	37504	37505	O
the	37506	37509	O
presentation	37510	37522	O
of	37523	37525	O
hepatoblastoma	37526	37540	O
is	37541	37543	O
highly	37544	37550	O
diverse	37551	37558	O
,	37558	37559	O
with	37560	37564	O
the	37565	37568	O
tumors	37569	37575	O
typically	37576	37585	O
classified	37586	37596	O
based	37597	37602	O
on	37603	37605	O
morphological	37606	37619	O
patterns	37620	37628	O
.	37628	37629	O
100	37629	37632	O
Interpatient	37633	37645	O
variability	37646	37657	O
can	37658	37661	O
also	37662	37666	O
greatly	37667	37674	O
influence	37675	37684	O
the	37685	37688	O
overall	37689	37696	O
response	37697	37705	O
to	37706	37708	O
specific	37709	37717	O
therapies	37718	37727	O
.	37727	37728	O

For	37729	37732	O
instance	37733	37741	O
,	37741	37742	O
variations	37743	37753	O
in	37754	37756	O
the	37757	37760	O
response	37761	37769	O
rate	37770	37774	O
of	37775	37777	O
HCC	37778	37781	O
patients	37782	37790	O
to	37791	37793	O
the	37794	37797	O
kinase	37798	37804	O
inhibitor	37805	37814	O
sorafenib	37815	37824	O
have	37825	37829	O
been	37830	37834	O
observed	37835	37843	O
,	37843	37844	O
which	37845	37850	O
has	37851	37854	O
led	37855	37858	O
to	37859	37861	O
a	37862	37863	O
number	37864	37870	O
of	37871	37873	O
studies	37874	37881	O
aimed	37882	37887	O
at	37888	37890	O
identifying	37891	37902	O
the	37903	37906	O
factors	37907	37914	O
underlying	37915	37925	O
these	37926	37931	O
variations	37932	37942	O
and	37943	37946	O
toward	37947	37953	O
the	37954	37957	O
establishment	37958	37971	O
of	37972	37974	O
molecular	37975	37984	O
predictors	37985	37995	O
of	37996	37998	O
treatment	37999	38008	O
response	38009	38017	O
.	38017	38018	O
101	38018	38021	O
–	38021	38022	O
103	38022	38025	O
One	38026	38029	O
major	38030	38035	O
limitation	38036	38046	O
that	38047	38051	O
greatly	38052	38059	O
influences	38060	38070	O
not	38071	38074	O
only	38075	38079	O
the	38080	38083	O
development	38084	38095	O
of	38096	38098	O
new	38099	38102	O
drug	38103	38107	O
treatments	38108	38118	O
but	38119	38122	O
also	38123	38127	O
the	38128	38131	O
overall	38132	38139	O
understanding	38140	38153	O
of	38154	38156	O
liver	38157	38162	O
cancer	38163	38169	O
progression	38170	38181	O
and	38182	38185	O
heterogeneity	38186	38199	O
is	38200	38202	O
the	38203	38206	O
lack	38207	38211	O
of	38212	38214	O
appropriate	38215	38226	O
in	38227	38229	O
vitro	38230	38235	O
cell	38236	38240	O
culture	38241	38248	O
models	38249	38255	O
.	38255	38256	O

To	38257	38259	O
better	38260	38266	O
recapitulate	38267	38279	O
patient	38280	38287	O
genetics	38288	38296	O
and	38297	38300	O
interpatient	38301	38313	O
variations	38314	38324	O
,	38324	38325	O
numerous	38326	38334	O
efforts	38335	38342	O
have	38343	38347	O
focused	38348	38355	O
on	38356	38358	O
the	38359	38362	O
generation	38363	38373	O
of	38374	38376	O
culture	38377	38384	O
models	38385	38391	O
that	38392	38396	O
utilize	38397	38404	O
cells	38405	38410	O
directly	38411	38419	O
from	38420	38424	O
tumor	38425	38430	O
biopsies	38431	38439	O
or	38440	38442	O
patient	38443	38450	O
-	38450	38451	O
derived	38451	38458	O
xenograft	38459	38468	O
(	38469	38470	O
PDX	38470	38473	O
)	38473	38474	O
systems	38475	38482	O
,	38482	38483	O
as	38484	38486	O
opposed	38487	38494	O
to	38495	38497	O
cultures	38498	38506	O
using	38507	38512	O
strictly	38513	38521	O
HCC	38522	38525	O
cell	38526	38530	O
lines	38531	38536	O
.	38536	38537	O

However	38538	38545	O
,	38545	38546	O
independent	38547	38558	O
of	38559	38561	O
the	38562	38565	O
cell	38566	38570	O
source	38571	38577	O
,	38577	38578	O
conventional	38579	38591	O
culture	38592	38599	O
configurations	38600	38614	O
often	38615	38620	O
do	38621	38623	O
not	38624	38627	O
accurately	38628	38638	O
mimic	38639	38644	O
the	38645	38648	O
microenvironmental	38649	38667	O
signals	38668	38675	O
present	38676	38683	O
within	38684	38690	O
liver	38691	38696	O
tumors	38697	38703	O
.	38703	38704	O

Accordingly	38705	38716	O
,	38716	38717	O
many	38718	38722	O
of	38723	38725	O
the	38726	38729	O
engineered	38730	38740	O
culture	38741	38748	O
approaches	38749	38759	O
introduced	38760	38770	O
earlier	38771	38778	O
in	38779	38781	O
this	38782	38786	O
perspective	38787	38798	O
have	38799	38803	O
been	38804	38808	O
applied	38809	38816	O
toward	38817	38823	O
studies	38824	38831	O
aimed	38832	38837	O
at	38838	38840	O
investigating	38841	38854	O
liver	38855	38860	O
cancer	38861	38867	O
processes	38868	38877	O
and	38878	38881	O
for	38882	38885	O
evaluating	38886	38896	O
therapeutic	38897	38908	O
responsiveness	38909	38923	O
as	38924	38926	O
part	38927	38931	O
of	38932	38934	O
the	38935	38938	O
preclinical	38939	38950	O
development	38951	38962	O
phase	38963	38968	O
.	38968	38969	O

In	38970	38972	O
the	38973	38976	O
next	38977	38981	O
sections	38982	38990	O
,	38990	38991	O
we	38992	38994	O
will	38995	38999	O
highlight	39000	39009	O
a	39010	39011	O
number	39012	39018	O
of	39019	39021	O
these	39022	39027	O
efforts	39028	39035	O
with	39036	39040	O
a	39041	39042	O
focus	39043	39048	O
on	39049	39051	O
recent	39052	39058	O
advances	39059	39067	O
in	39068	39070	O
the	39071	39074	O
areas	39075	39080	O
of	39081	39083	O
three	39084	39089	O
-	39089	39090	O
dimensional	39090	39101	O
(	39102	39103	O
3D	39103	39105	O
)	39105	39106	O
liver	39107	39112	O
cancer	39113	39119	O
microenvironments	39120	39137	O
,	39137	39138	O
microfluidic	39139	39151	O
devices	39152	39159	O
,	39159	39160	O
and	39161	39164	O
patient	39165	39172	O
-	39172	39173	O
specific	39173	39181	O
organoid	39182	39190	O
systems	39191	39198	O
.	39198	39199	O

3D	39200	39202	O
liver	39203	39208	O
cancer	39209	39215	O
microenvironments	39216	39233	O
For	39234	39237	O
a	39238	39239	O
wide	39240	39244	O
range	39245	39250	O
of	39251	39253	O
tumor	39254	39259	O
cell	39260	39264	O
types	39265	39270	O
,	39270	39271	O
3D	39272	39274	B-CL:0000502
cell	39275	39279	E-CL:0000502
cultures	39280	39288	O
have	39289	39293	O
been	39294	39298	O
suggested	39299	39308	O
to	39309	39311	O
better	39312	39318	O
represent	39319	39328	O
in	39329	39331	O
vivo	39332	39336	O
microenvironments	39337	39354	O
,	39354	39355	O
including	39356	39365	O
more	39366	39370	O
in	39371	39373	O
vivo	39374	39378	O
-	39378	39379	O
like	39379	39383	O
gene	39384	39388	O
expression	39389	39399	O
profiles	39400	39408	O
and	39409	39412	O
drug	39413	39417	O
responses	39418	39427	O
.	39427	39428	O
104	39428	39431	O
–	39431	39432	O
107	39432	39435	O
One	39436	39439	O
common	39440	39446	O
approach	39447	39455	O
for	39456	39459	O
evaluating	39460	39470	O
tumor	39471	39476	O
cells	39477	39482	O
in	39483	39485	O
a	39486	39487	O
3D	39488	39490	O
context	39491	39498	O
is	39499	39501	O
the	39502	39505	O
establishment	39506	39519	O
of	39520	39522	O
3D	39523	39525	O
aggregates	39526	39536	O
,	39536	39537	O
often	39538	39543	O
referred	39544	39552	O
to	39553	39555	O
as	39556	39558	O
multicellular	39559	39572	O
spheroids	39573	39582	O
.	39582	39583	O

Enhanced	39584	39592	O
drug	39593	39597	O
resistance	39598	39608	O
within	39609	39615	O
3D	39616	39618	O
spheroids	39619	39628	O
,	39628	39629	O
compared	39630	39638	O
to	39639	39641	O
standard	39642	39650	O
2D	39651	39653	O
cultures	39654	39662	O
,	39662	39663	O
has	39664	39667	O
been	39668	39672	O
observed	39673	39681	O
for	39682	39685	O
numerous	39686	39694	O
cancer	39695	39701	O
cell	39702	39706	O
lines	39707	39712	O
and	39713	39716	O
treatment	39717	39726	O
protocols	39727	39736	O
.	39736	39737	O
108	39737	39740	O
,	39740	39741	O
109	39741	39744	O
In	39745	39747	O
particular	39748	39758	O
,	39758	39759	O
spheroidal	39760	39770	O
tumor	39771	39776	O
cell	39777	39781	O
cultures	39782	39790	O
have	39791	39795	O
been	39796	39800	O
demonstrated	39801	39813	O
to	39814	39816	O
exhibit	39817	39824	O
a	39825	39826	O
number	39827	39833	O
of	39834	39836	O
signaling	39837	39846	O
pathway	39847	39854	O
alterations	39855	39866	O
such	39867	39871	O
as	39872	39874	O
changes	39875	39882	O
in	39883	39885	O
epidermal	39886	39895	O
growth	39896	39902	O
factor	39903	39909	O
family	39910	39916	O
,	39916	39917	O
mitogen	39918	39925	O
-	39925	39926	O
activated	39926	39935	O
protein	39936	39943	O
kinase	39944	39950	O
,	39950	39951	O
and	39952	39955	O
protein	39956	39963	O
kinase	39964	39970	O
B	39971	39972	O
(	39973	39974	O
AKT	39974	39977	O
)	39977	39978	O
-	39978	39979	O
mammalian	39979	39988	O
target	39989	39995	O
of	39996	39998	O
rapamycin	39999	40008	O
(	40009	40010	O
mTOR	40010	40014	O
)	40014	40015	O
signaling	40016	40025	O
that	40026	40030	O
can	40031	40034	O
broadly	40035	40042	O
influence	40043	40052	O
tumor	40053	40058	O
cell	40059	40063	O
phenotype	40064	40073	O
and	40074	40077	O
drug	40078	40082	O
sensitivities	40083	40096	O
.	40096	40097	O
110	40097	40100	O
–	40100	40101	O
112	40101	40104	O
For	40105	40108	O
liver	40109	40114	O
tumor	40115	40120	O
cell	40121	40125	O
spheroids	40126	40135	O
,	40135	40136	O
the	40137	40140	O
“	40141	40142	O
age	40142	40145	O
”	40145	40146	O
/	40146	40147	O
culture	40147	40154	O
time	40155	40159	O
of	40160	40162	O
the	40163	40166	O
spheroidal	40167	40177	O
culture	40178	40185	O
,	40185	40186	O
ranging	40187	40194	O
from	40195	40199	O
1	40200	40201	O
to	40202	40204	O
18	40205	40207	O
days	40208	40212	O
,	40212	40213	O
was	40214	40217	O
demonstrated	40218	40230	O
to	40231	40233	O
influence	40234	40243	O
drug	40244	40248	O
diffusivity	40249	40260	O
and	40261	40264	O
toxicity	40265	40273	O
,	40273	40274	O
with	40275	40279	O
increased	40280	40289	O
drug	40290	40294	O
resistance	40295	40305	O
at	40306	40308	O
the	40309	40312	O
later	40313	40318	O
stages	40319	40325	O
of	40326	40328	O
culture	40329	40336	O
.	40336	40337	O
113	40337	40340	O
Further	40341	40348	O
,	40348	40349	O
proteomic	40350	40359	O
analysis	40360	40368	O
of	40369	40371	O
liver	40372	40377	O
tumor	40378	40383	O
spheroids	40384	40393	O
cultured	40394	40402	O
in	40403	40405	O
a	40406	40407	O
rotating	40408	40416	O
wall	40417	40421	O
vessel	40422	40428	O
bioreactor	40429	40439	O
highlights	40440	40450	O
the	40451	40454	O
dynamic	40455	40462	O
changes	40463	40470	O
in	40471	40473	O
protein	40474	40481	O
expression	40482	40492	O
patterns	40493	40501	O
that	40502	40506	O
occur	40507	40512	O
over	40513	40517	O
two	40518	40521	O
weeks	40522	40527	O
of	40528	40530	O
culture	40531	40538	O
.	40538	40539	O
114	40539	40542	O
Collectively	40543	40555	O
,	40555	40556	O
such	40557	40561	O
results	40562	40569	O
suggest	40570	40577	O
that	40578	40582	O
microenvironmental	40583	40601	O
signals	40602	40609	O
including	40610	40619	O
cell	40620	40624	O
-	40624	40625	O
cell	40625	40629	O
and	40630	40633	O
cell	40634	40638	O
-	40638	40639	O
ECM	40639	40642	O
interactions	40643	40655	O
,	40655	40656	O
as	40657	40659	O
well	40660	40664	O
as	40665	40667	O
microenvironmental	40668	40686	O
pH	40687	40689	O
or	40690	40692	O
hypoxia	40693	40700	O
,	40700	40701	O
likely	40702	40708	O
evolve	40709	40715	O
during	40716	40722	O
the	40723	40726	O
culture	40727	40734	O
period	40735	40741	O
.	40741	40742	O

As	40743	40745	O
a	40746	40747	O
means	40748	40753	O
to	40754	40756	O
generate	40757	40765	O
spheroidal	40766	40776	O
tumor	40777	40782	O
cell	40783	40787	O
cultures	40788	40796	O
with	40797	40801	O
well	40802	40806	O
-	40806	40807	O
defined	40807	40814	O
cell	40815	40819	O
numbers	40820	40827	O
and	40828	40831	O
drug	40832	40836	O
diffusion	40837	40846	O
characteristics	40847	40862	O
,	40862	40863	O
several	40864	40871	O
approaches	40872	40882	O
including	40883	40892	O
hanging	40893	40900	O
drop	40901	40905	O
cultures	40906	40914	O
and	40915	40918	O
microfabricated	40919	40934	O
microwells	40935	40945	O
have	40946	40950	O
been	40951	40955	O
employed	40956	40964	O
.	40964	40965	O

For	40966	40969	O
example	40970	40977	O
,	40977	40978	O
3D	40979	40981	O
spheroids	40982	40991	O
of	40992	40994	O
the	40995	40998	O
HCC	40999	41002	O
cell	41003	41007	O
line	41008	41012	O
Huh7	41013	41017	O
were	41018	41022	O
formed	41023	41029	O
using	41030	41035	O
a	41036	41037	O
hanging	41038	41045	O
drop	41046	41050	O
method	41051	41057	O
combined	41058	41066	O
with	41067	41071	O
rotary	41072	41078	O
culture	41079	41086	O
,	41086	41087	O
and	41088	41091	O
it	41092	41094	O
was	41095	41098	O
demonstrated	41099	41111	O
that	41112	41116	O
large	41117	41122	O
spheroids	41123	41132	O
(	41133	41134	O
diameter	41134	41142	O
∼	41143	41144	O
3	41145	41146	O
mm	41147	41149	O
)	41149	41150	O
exhibited	41151	41160	O
apoptosis	41161	41170	O
and	41171	41174	O
increased	41175	41184	O
expression	41185	41195	O
of	41196	41198	O
hypoxia	41199	41206	O
-	41206	41207	O
inducible	41207	41216	O
factor	41217	41223	O
-	41223	41224	O
1	41224	41225	O
-	41225	41226	O
alpha	41226	41231	O
(	41232	41233	O
HIF	41233	41236	O
-	41236	41237	O
1alpha	41237	41243	O
)	41243	41244	O
in	41245	41247	O
the	41248	41251	O
center	41252	41258	O
of	41259	41261	O
the	41262	41265	O
spheroid	41266	41274	O
and	41275	41278	O
an	41279	41281	O
overall	41282	41289	O
increase	41290	41298	O
in	41299	41301	O
phosphorylated	41302	41316	O
extracellular	41317	41330	O
-	41330	41331	O
signal	41331	41337	O
-	41337	41338	O
regulated	41338	41347	O
kinase	41348	41354	O
(	41355	41356	O
ERK	41356	41359	O
)	41359	41360	O
compared	41361	41369	O
to	41370	41372	O
smaller	41373	41380	O
spheroids	41381	41390	O
.	41390	41391	O
115	41391	41394	O
Microwell	41395	41404	O
substrates	41405	41415	O
for	41416	41419	O
generating	41420	41430	O
defined	41431	41438	O
multicellular	41439	41452	O
tumor	41453	41458	O
spheroids	41459	41468	O
have	41469	41473	O
been	41474	41478	O
produced	41479	41487	O
using	41488	41493	O
a	41494	41495	O
variety	41496	41503	O
of	41504	41506	O
strategies	41507	41517	O
including	41518	41527	O
the	41528	41531	O
molding	41532	41539	O
of	41540	41542	O
agarose	41543	41550	O
hydrogel	41551	41559	O
scaffolds	41560	41569	O
,	41569	41570	O
116	41570	41573	O
the	41574	41577	O
molding	41578	41585	O
of	41586	41588	O
collagen	41589	41597	O
coated	41598	41604	O
PDMS	41605	41609	O
arrays	41610	41616	O
compatible	41617	41627	O
with	41628	41632	O
molecular	41633	41642	O
imaging	41643	41650	O
techniques	41651	41661	O
,	41661	41662	O
117	41662	41665	O
and	41666	41669	O
the	41670	41673	O
fabrication	41674	41685	O
of	41686	41688	O
networked	41689	41698	O
concave	41699	41706	O
PDMS	41707	41711	O
microwell	41712	41721	O
structures	41722	41732	O
.	41732	41733	O
118	41733	41736	O
Each	41737	41741	O
of	41742	41744	O
these	41745	41750	O
approaches	41751	41761	O
was	41762	41765	O
utilized	41766	41774	O
for	41775	41778	O
examining	41779	41788	O
drug	41789	41793	O
cytotoxicity	41794	41806	O
,	41806	41807	O
with	41808	41812	O
the	41813	41816	O
goal	41817	41821	O
of	41822	41824	O
integrating	41825	41836	O
3D	41837	41839	O
spheroid	41840	41848	O
culture	41849	41856	O
with	41857	41861	O
drug	41862	41866	O
screening	41867	41876	O
.	41876	41877	O

Microwells	41878	41888	O
have	41889	41893	O
also	41894	41898	O
been	41899	41903	O
combined	41904	41912	O
with	41913	41917	O
micropillar	41918	41929	O
structures	41930	41940	O
toward	41941	41947	O
the	41948	41951	O
development	41952	41963	O
of	41964	41966	O
a	41967	41968	O
modular	41969	41976	O
2	41977	41978	O
-	41978	41979	O
chip	41979	41983	O
platform	41984	41992	O
for	41993	41996	O
testing	41997	42004	O
cancer	42005	42011	O
therapeutics	42012	42024	O
.	42024	42025	O
119	42025	42028	O
,	42028	42029	O
120	42029	42032	O
In	42033	42035	O
this	42036	42040	O
strategy	42041	42049	O
,	42049	42050	O
tumor	42051	42056	O
cell	42057	42061	O
aggregates	42062	42072	O
are	42073	42076	O
encapsulated	42077	42089	O
within	42090	42096	O
30	42097	42099	O
nl	42100	42102	O
alginate	42103	42111	O
hydrogels	42112	42121	O
on	42122	42124	O
top	42125	42128	O
of	42129	42131	O
an	42132	42134	O
array	42135	42140	O
of	42141	42143	O
micropillar	42144	42155	O
structures	42156	42166	O
using	42167	42172	O
a	42173	42174	O
spotting	42175	42183	O
process	42184	42191	O
.	42191	42192	O

The	42193	42196	O
inversion	42197	42206	O
of	42207	42209	O
the	42210	42213	O
micropillar	42214	42225	O
chip	42226	42230	O
,	42230	42231	O
and	42232	42235	O
insertion	42236	42245	O
of	42246	42248	O
the	42249	42252	O
micropillar	42253	42264	O
-	42264	42265	O
resident	42265	42273	O
cells	42274	42279	O
into	42280	42284	O
the	42285	42288	O
adjacent	42289	42297	O
microwell	42298	42307	O
substrate	42308	42317	O
chip	42318	42322	O
containing	42323	42333	O
panels	42334	42340	O
of	42341	42343	O
drug	42344	42348	O
solutions	42349	42358	O
,	42358	42359	O
can	42360	42363	O
then	42364	42368	O
facilitate	42369	42379	O
high	42380	42384	O
-	42384	42385	O
throughput	42385	42395	O
drug	42396	42400	O
efficacy	42401	42409	O
testing	42410	42417	O
.	42417	42418	O

The	42419	42422	O
introduction	42423	42435	O
of	42436	42438	O
additional	42439	42449	O
cell	42450	42454	O
types	42455	42460	O
for	42461	42464	O
the	42465	42468	O
generation	42469	42479	O
of	42480	42482	O
coculture	42483	42492	O
spheroids	42493	42502	O
has	42503	42506	O
also	42507	42511	O
been	42512	42516	O
explored	42517	42525	O
.	42525	42526	O

For	42527	42530	O
instance	42531	42539	O
,	42539	42540	O
the	42541	42544	O
incorporation	42545	42558	O
of	42559	42561	O
human	42562	42567	O
umbilical	42568	42577	O
vein	42578	42582	S-CL:0002543
endothelial	42583	42594	B-CL:0002543;CL:0000115
cells	42595	42600	E-CL:0002543;CL:0000115
(	42601	42602	O
HUVECs	42602	42608	O
)	42608	42609	O
into	42610	42614	O
large	42615	42620	O
Huh7	42621	42625	O
spheroids	42626	42635	O
was	42636	42639	O
shown	42640	42645	O
to	42646	42648	O
promote	42649	42656	O
Huh7	42657	42661	O
proliferation	42662	42675	O
and	42676	42679	O
an	42680	42682	O
increased	42683	42692	O
expression	42693	42703	O
of	42704	42706	O
cancer	42707	42713	O
stem	42714	42718	B-CL:0000034
cell	42719	42723	E-CL:0000034
markers	42724	42731	O
.	42731	42732	O
115	42732	42735	O
The	42736	42739	O
introduction	42740	42752	O
of	42753	42755	O
a	42756	42757	O
human	42758	42763	O
hepatic	42764	42771	S-CL:0000632
stellate	42772	42780	B-CL:0000632;CL:0000122
cell	42781	42785	E-CL:0000632;CL:0000122
line	42786	42790	O
(	42791	42792	O
LX2	42792	42795	O
)	42795	42796	O
into	42797	42801	O
spheroidal	42802	42812	O
cultures	42813	42821	O
generated	42822	42831	O
using	42832	42837	O
both	42838	42842	O
liver	42843	42848	O
tumor	42849	42854	O
cell	42855	42859	O
lines	42860	42865	O
and	42866	42869	O
primary	42870	42877	O
HCC	42878	42881	O
cells	42882	42887	O
identified	42888	42898	O
an	42899	42901	O
effect	42902	42908	O
of	42909	42911	O
stellate	42912	42920	B-CL:0000122
cells	42921	42926	E-CL:0000122
on	42927	42929	O
increasing	42930	42940	O
spheroid	42941	42949	O
compactness	42950	42961	O
and	42962	42965	O
decreasing	42966	42976	O
drug	42977	42981	O
sensitivity	42982	42993	O
.	42993	42994	O
121	42994	42997	O
Recently	42998	43006	O
,	43006	43007	O
HCC	43008	43011	O
cell	43012	43016	O
lines	43017	43022	O
specifically	43023	43035	O
derived	43036	43043	O
from	43044	43048	O
HBV	43049	43052	O
-	43052	43053	O
infected	43053	43061	O
patients	43062	43070	O
were	43071	43075	O
utilized	43076	43084	O
for	43085	43088	O
drug	43089	43093	O
response	43094	43102	O
experiments	43103	43114	O
incorporating	43115	43128	O
coculture	43129	43138	O
spheroids	43139	43148	O
containing	43149	43159	O
HUVECS	43160	43166	O
,	43166	43167	O
stellate	43168	43176	B-CL:0000122
cells	43177	43182	E-CL:0000122
,	43182	43183	O
or	43184	43186	O
human	43187	43192	O
fibroblasts	43193	43204	S-CL:0000057
.	43204	43205	O
122	43205	43208	O
In	43209	43211	O
addition	43212	43220	O
,	43220	43221	O
stellate	43222	43230	B-CL:0000122
cell	43231	43235	E-CL:0000122
conditioning	43236	43248	O
media	43249	43254	O
have	43255	43259	O
been	43260	43264	O
shown	43265	43270	O
to	43271	43273	O
promote	43274	43281	O
proliferation	43282	43295	O
of	43296	43298	O
human	43299	43304	O
HCC	43305	43308	O
cells	43309	43314	O
within	43315	43321	O
spheroidal	43322	43332	O
cultures	43333	43341	O
.	43341	43342	O
123	43342	43345	O
Stellate	43346	43354	B-CL:0000122
cell	43355	43359	E-CL:0000122
production	43360	43370	O
of	43371	43373	O
factors	43374	43381	O
such	43382	43386	O
as	43387	43389	O
ECM	43390	43393	O
protein	43394	43401	O
collagen	43402	43410	O
type	43411	43415	O
I	43416	43417	O
,	43417	43418	O
121	43418	43421	O
and	43422	43425	O
cytokine	43426	43434	O
IL	43435	43437	O
-	43437	43438	O
6	43438	43439	O
,	43439	43440	O
124	43440	43443	O
has	43444	43447	O
been	43448	43452	O
determined	43453	43463	O
to	43464	43466	O
be	43467	43469	O
relevant	43470	43478	O
as	43479	43481	O
part	43482	43486	O
of	43487	43489	O
the	43490	43493	O
stellate	43494	43502	B-CL:0000122
cell	43503	43507	E-CL:0000122
-	43507	43508	O
mediated	43508	43516	O
alterations	43517	43528	O
in	43529	43531	O
liver	43532	43537	O
tumor	43538	43543	O
cell	43544	43548	O
responses	43549	43558	O
.	43558	43559	O

Overall	43560	43567	O
,	43567	43568	O
since	43569	43574	O
stellate	43575	43583	B-CL:0000122
cell	43584	43588	E-CL:0000122
activation	43589	43599	O
and	43600	43603	O
proliferation	43604	43617	O
are	43618	43621	O
correlated	43622	43632	O
with	43633	43637	O
the	43638	43641	O
presence	43642	43650	O
and	43651	43654	O
progression	43655	43666	O
of	43667	43669	O
chronic	43670	43677	O
liver	43678	43683	O
diseases	43684	43692	O
,	43692	43693	O
which	43694	43699	O
in	43700	43702	O
turn	43703	43707	O
are	43708	43711	O
associated	43712	43722	O
with	43723	43727	O
an	43728	43730	O
increased	43731	43740	O
liver	43741	43746	O
cancer	43747	43753	O
risk	43754	43758	O
,	43758	43759	O
the	43760	43763	O
continuous	43764	43774	O
investigation	43775	43788	O
of	43789	43791	O
stellate	43792	43800	B-CL:0000122
cell	43801	43805	E-CL:0000122
-	43805	43806	O
tumor	43806	43811	O
cell	43812	43816	O
intercellular	43817	43830	O
interactions	43831	43843	O
is	43844	43846	O
highly	43847	43853	O
warranted	43854	43863	O
.	43863	43864	O

The	43865	43868	O
encapsulation	43869	43882	O
of	43883	43885	O
liver	43886	43891	O
tumor	43892	43897	O
cells	43898	43903	O
(	43904	43905	O
as	43905	43907	O
either	43908	43914	O
multicellular	43915	43928	O
spheroids	43929	43938	O
or	43939	43941	O
dispersed	43942	43951	O
cell	43952	43956	O
suspensions	43957	43968	O
)	43968	43969	O
within	43970	43976	O
biomaterial	43977	43988	O
scaffolds	43989	43998	O
has	43999	44002	O
also	44003	44007	O
been	44008	44012	O
broadly	44013	44020	O
used	44021	44025	O
for	44026	44029	O
the	44030	44033	O
study	44034	44039	O
of	44040	44042	O
tumor	44043	44048	O
cell	44049	44053	O
behavior	44054	44062	O
in	44063	44065	O
3D	44066	44068	O
.	44068	44069	O

For	44070	44073	O
instance	44074	44082	O
,	44082	44083	O
coculture	44084	44093	O
spheroids	44094	44103	O
containing	44104	44114	O
the	44115	44118	O
human	44119	44124	O
liver	44125	44130	O
tumor	44131	44136	O
cell	44137	44141	O
line	44142	44146	O
HepG2	44147	44152	O
together	44153	44161	O
with	44162	44166	O
murine	44167	44173	O
fibroblasts	44174	44185	S-CL:0000057
were	44186	44190	O
encapsulated	44191	44203	O
within	44204	44210	O
collagen	44211	44219	O
gels	44220	44224	O
,	44224	44225	O
and	44226	44229	O
the	44230	44233	O
presence	44234	44242	O
of	44243	44245	O
both	44246	44250	O
the	44251	44254	O
fibroblasts	44255	44266	S-CL:0000057
and	44267	44270	O
the	44271	44274	O
collagen	44275	44283	O
gel	44284	44287	O
contributed	44288	44299	O
to	44300	44302	O
increased	44303	44312	O
resistance	44313	44323	O
to	44324	44326	O
doxorubicin	44327	44338	O
treatment	44339	44348	O
.	44348	44349	O
125	44349	44352	O
In	44353	44355	O
another	44356	44363	O
work	44364	44368	O
,	44368	44369	O
HepG2	44370	44375	O
and	44376	44379	O
Hep3B	44380	44385	B-CL:0000236
cell	44386	44390	E-CL:0000236
lines	44391	44396	O
were	44397	44401	O
examined	44402	44410	O
following	44411	44420	O
seeding	44421	44428	O
within	44429	44435	O
the	44436	44439	O
commercial	44440	44450	O
AlgiMatrix	44451	44461	O
™	44461	44462	O
culture	44463	44470	O
system	44471	44477	O
(	44478	44479	O
Thermo	44479	44485	O
-	44485	44486	O
Fisher	44486	44492	O
)	44492	44493	O
,	44493	44494	O
which	44495	44500	O
is	44501	44503	O
a	44504	44505	O
porous	44506	44512	O
alginate	44513	44521	O
scaffold	44522	44530	O
.	44530	44531	O
126	44531	44534	O
Within	44535	44541	O
the	44542	44545	O
AlgiMatrix	44546	44556	O
™	44556	44557	O
scaffold	44558	44566	B-CL:0000426
,	44566	44567	I-CL:0000426
cells	44568	44573	E-CL:0000426
increased	44574	44583	O
expression	44584	44594	O
of	44595	44597	O
the	44598	44601	O
cancer	44602	44608	O
stem	44609	44613	B-CL:0000034
cell	44614	44618	E-CL:0000034
marker	44619	44625	O
EpCAM	44626	44631	O
,	44631	44632	O
exhibited	44633	44642	O
morphogenetic	44643	44656	O
patterns	44657	44665	O
consistent	44666	44676	O
with	44677	44681	O
acinar	44682	44688	O
formation	44689	44698	O
,	44698	44699	O
and	44700	44703	O
were	44704	44708	O
more	44709	44713	O
resistant	44714	44723	O
to	44724	44726	O
chemotherapeutic	44727	44743	O
agents	44744	44750	O
compared	44751	44759	O
to	44760	44762	O
cells	44763	44768	O
in	44769	44771	O
standard	44772	44780	O
2D	44781	44783	O
culture	44784	44791	O
.	44791	44792	O

In	44793	44795	O
addition	44796	44804	O
,	44804	44805	O
building	44806	44814	O
on	44815	44817	O
the	44818	44821	O
studies	44822	44829	O
using	44830	44835	O
liver	44836	44841	O
tumor	44842	44847	O
cell	44848	44852	O
lines	44853	44858	O
,	44858	44859	O
recent	44860	44866	O
efforts	44867	44874	O
have	44875	44879	O
begun	44880	44885	O
to	44886	44888	O
evaluate	44889	44897	O
the	44898	44901	O
possibility	44902	44913	O
of	44914	44916	O
incorporating	44917	44930	O
PDX	44931	44934	O
-	44934	44935	O
derived	44935	44942	O
cells	44943	44948	O
within	44949	44955	O
biomaterial	44956	44967	O
-	44967	44968	O
based	44968	44973	O
in	44974	44976	O
vitro	44977	44982	O
3D	44983	44985	O
culture	44986	44993	O
models	44994	45000	O
.	45000	45001	O

For	45002	45005	O
example	45006	45013	O
,	45013	45014	O
14	45015	45017	O
distinct	45018	45026	O
PDX	45027	45030	O
lines	45031	45036	O
were	45037	45041	O
derived	45042	45049	O
from	45050	45054	O
HCC	45055	45058	O
patients	45059	45067	O
and	45068	45071	O
cultured	45072	45080	O
within	45081	45087	O
a	45088	45089	O
3D	45090	45092	O
macroporous	45093	45104	O
cellulosic	45105	45115	O
sponge	45116	45122	O
scaffold	45123	45131	O
[	45132	45133	O
Fig	45133	45136	O
.	45136	45137	O

2	45138	45139	O
(	45139	45140	O
a	45140	45141	O
)	45141	45142	O
]	45142	45143	O
.	45143	45144	O
127	45144	45147	O
Whole	45148	45153	O
exome	45154	45159	O
and	45160	45163	O
RNA	45164	45167	O
sequencing	45168	45178	O
were	45179	45183	O
performed	45184	45193	O
following	45194	45203	O
in	45204	45206	O
vitro	45207	45212	O
scaffold	45213	45221	O
culture	45222	45229	O
,	45229	45230	O
and	45231	45234	O
an	45235	45237	O
overall	45238	45245	O
positive	45246	45254	O
correlation	45255	45266	O
was	45267	45270	O
observed	45271	45279	O
with	45280	45284	O
the	45285	45288	O
in	45289	45291	O
vivo	45292	45296	O
PDX	45297	45300	O
models	45301	45307	O
.	45307	45308	O

Further	45309	45316	O
,	45316	45317	O
the	45318	45321	O
scaffold	45322	45330	O
cultures	45331	45339	O
were	45340	45344	O
compatible	45345	45355	O
with	45356	45360	O
cytotoxicity	45361	45373	O
analysis	45374	45382	O
,	45382	45383	O
suggesting	45384	45394	O
that	45395	45399	O
this	45400	45404	O
in	45405	45407	O
vitro	45408	45413	O
culture	45414	45421	O
approach	45422	45430	O
could	45431	45436	O
be	45437	45439	O
utilized	45440	45448	O
for	45449	45452	O
preclinical	45453	45464	O
drug	45465	45469	O
testing	45470	45477	O
.	45477	45478	O

FIG	45479	45482	O
.	45482	45483	O

2	45484	45485	O
.	45485	45486	O

Engineered	45487	45497	O
culture	45498	45505	O
systems	45506	45513	O
and	45514	45517	O
devices	45518	45525	O
for	45526	45529	O
liver	45530	45535	O
cancer	45536	45542	O
.	45542	45543	O

(	45544	45545	O
a	45545	45546	O
)	45546	45547	O
Three	45548	45553	O
-	45553	45554	O
dimensional	45554	45565	O
scaffold	45566	45574	O
culture	45575	45582	O
model	45583	45588	O
for	45589	45592	O
hepatocellular	45593	45607	O
carcinoma	45608	45617	O
(	45618	45619	O
HCC	45619	45622	O
)	45622	45623	O
incorporating	45624	45637	O
patient	45638	45645	O
-	45645	45646	O
derived	45646	45653	O
xenograft	45654	45663	O
cells	45664	45669	O
,	45669	45670	O
figure	45671	45677	O
adapted	45678	45685	O
from	45686	45690	O
Ref	45691	45694	O
.	45694	45695	O

127	45696	45699	O
.	45699	45700	O

Left	45701	45705	O
:	45705	45706	O
Schematic	45707	45716	O
of	45717	45719	O
the	45720	45723	O
process	45724	45731	O
for	45732	45735	O
fabricating	45736	45747	O
a	45748	45749	O
macroporous	45750	45761	O
hydrogel	45762	45770	O
sponge	45771	45777	O
from	45778	45782	O
hydroxypropyl	45783	45796	O
cellulose	45797	45806	O
(	45807	45808	O
HPC	45808	45811	O
)	45811	45812	O
using	45813	45818	O
photocrosslinking	45819	45836	O
following	45837	45846	O
the	45847	45850	O
introduction	45851	45863	O
of	45864	45866	O
methacrylate	45867	45879	O
(	45880	45881	O
MA	45881	45883	O
)	45883	45884	O
groups	45885	45891	O
.	45891	45892	O

Right	45893	45898	O
:	45898	45899	O
Brightfield	45900	45911	O
(	45912	45913	O
top	45913	45916	O
)	45916	45917	O
and	45918	45921	O
phalloidin	45922	45932	O
-	45932	45933	O
based	45933	45938	O
actin	45939	45944	O
staining	45945	45953	O
(	45954	45955	O
bottom	45955	45961	O
)	45961	45962	O
of	45963	45965	O
HCC	45966	45969	O
cells	45970	45975	O
cultured	45976	45984	O
in	45985	45987	O
a	45988	45989	O
representative	45990	46004	O
MA	46005	46007	O
-	46007	46008	O
HPC	46008	46011	O
scaffold	46012	46020	O
(	46021	46022	O
scale	46022	46027	O
bars	46028	46032	O
=	46033	46034	O
100	46035	46038	O
μm	46039	46041	O
)	46041	46042	O
.	46042	46043	O

Reprinted	46044	46053	O
with	46054	46058	O
permission	46059	46069	O
from	46070	46074	O
Fong	46075	46079	O
et	46080	46082	O
al	46083	46085	O
.	46085	46086	O
,	46086	46087	O
Biomaterials	46088	46100	O
159	46101	46104	O
,	46104	46105	O
229	46106	46109	O
(	46110	46111	O
2018	46111	46115	O
)	46115	46116	O
.	46116	46117	O

Copyright	46118	46127	O
2018	46128	46132	O
Elsevier	46133	46141	O
.	46141	46142	O

(	46143	46144	O
b	46144	46145	O
)	46145	46146	O
Chip	46147	46151	O
-	46151	46152	O
based	46152	46157	O
approach	46158	46166	O
for	46167	46170	O
the	46171	46174	O
detection	46175	46184	O
and	46185	46188	O
analysis	46189	46197	O
of	46198	46200	O
circulating	46201	46212	O
epithelial	46213	46223	B-CL:0000066
cells	46224	46229	E-CL:0000066
(	46230	46231	O
CECs	46231	46235	O
)	46235	46236	O
in	46237	46239	O
patients	46240	46248	O
with	46249	46253	O
liver	46254	46259	O
cancer	46260	46266	O
,	46266	46267	O
figure	46268	46274	O
adapted	46275	46282	O
from	46283	46287	O
Ref	46288	46291	O
.	46291	46292	O

158	46293	46296	O
.	46296	46297	O

Top	46298	46301	O
:	46301	46302	O
Schematic	46303	46312	O
of	46313	46315	O
the	46316	46319	O
microfluidic	46320	46332	O
device	46333	46339	O
(	46340	46341	O
iChip	46341	46346	O
)	46346	46347	O
process	46348	46355	O
,	46355	46356	O
which	46357	46362	O
separates	46363	46372	O
CECs	46373	46377	O
from	46378	46382	O
hematopoietic	46383	46396	B-CL:0000988
cells	46397	46402	E-CL:0000988
for	46403	46406	O
subsequent	46407	46417	O
staining	46418	46426	O
or	46427	46429	O
sequencing	46430	46440	O
analysis	46441	46449	O
.	46449	46450	O

Bottom	46451	46457	O
left	46458	46462	O
:	46462	46463	O
CECs	46464	46468	O
collected	46469	46478	O
using	46479	46484	O
the	46485	46488	O
iChip	46489	46494	O
process	46495	46502	O
were	46503	46507	O
stained	46508	46515	O
with	46516	46520	O
DAPI	46521	46525	O
(	46526	46527	O
blue	46527	46531	O
)	46531	46532	O
,	46532	46533	O
anti	46534	46538	O
-	46538	46539	O
CD45	46539	46543	O
(	46544	46545	O
green	46545	46550	O
)	46550	46551	O
to	46552	46554	O
detect	46555	46561	O
hematopoietic	46562	46575	B-CL:0000988
cells	46576	46581	E-CL:0000988
,	46581	46582	O
as	46583	46585	O
well	46586	46590	O
as	46591	46593	O
anti	46594	46598	O
-	46598	46599	O
glypican	46599	46607	O
-	46607	46608	O
3	46608	46609	O
(	46610	46611	O
GPC3	46611	46615	O
,	46615	46616	O
yellow	46617	46623	O
)	46623	46624	O
and	46625	46628	O
antiwide	46629	46637	O
spectrum	46638	46646	O
cytokeratin	46647	46658	O
(	46659	46660	O
CK	46660	46662	O
-	46662	46663	O
WS	46663	46665	O
,	46665	46666	O
red	46667	46670	O
)	46670	46671	O
,	46671	46672	O
which	46673	46678	O
are	46679	46682	O
both	46683	46687	O
epithelial	46688	46698	O
markers	46699	46706	O
.	46706	46707	O

iChip	46708	46713	O
-	46713	46714	O
enriched	46714	46722	O
samples	46723	46730	O
from	46731	46735	O
two	46736	46739	O
chronic	46740	46747	O
liver	46748	46753	O
disease	46754	46761	O
without	46762	46769	O
HCC	46770	46773	O
(	46774	46775	O
CLD	46775	46778	O
)	46778	46779	O
patients	46780	46788	O
and	46789	46792	O
two	46793	46796	O
HCC	46797	46800	O
patients	46801	46809	O
are	46810	46813	O
shown	46814	46819	O
.	46819	46820	O

A	46821	46822	O
control	46823	46830	O
white	46831	46836	S-CL:0000738
blood	46837	46842	B-CL:0000738;CL:0000081
cell	46843	46847	E-CL:0000738;CL:0000081
(	46848	46849	O
WBC	46849	46852	O
)	46852	46853	O
is	46854	46856	O
also	46857	46861	O
shown	46862	46867	O
as	46868	46870	O
a	46871	46872	O
comparison	46873	46883	O
.	46883	46884	O

Bottom	46885	46891	O
middle	46892	46898	O
:	46898	46899	O
Quantification	46900	46914	O
of	46915	46917	O
CECs	46918	46922	O
using	46923	46928	O
immunofluorescence	46929	46947	O
of	46948	46950	O
the	46951	46954	O
iChip	46955	46960	O
-	46960	46961	O
processed	46961	46970	O
sample	46971	46977	O
,	46977	46978	O
from	46979	46983	O
healthy	46984	46991	O
donors	46992	46998	O
(	46999	47000	O
HDs	47000	47003	O
)	47003	47004	O
,	47004	47005	O
chronic	47006	47013	O
liver	47014	47019	O
disease	47020	47027	O
patients	47028	47036	O
without	47037	47044	O
HCC	47045	47048	O
(	47049	47050	O
CLD	47050	47053	O
)	47053	47054	O
,	47054	47055	O
HCC	47056	47059	O
patients	47060	47068	O
(	47069	47070	O
HCC	47070	47073	O
)	47073	47074	O
,	47074	47075	O
and	47076	47079	O
treated	47080	47087	O
HCC	47088	47091	O
patients	47092	47100	O
with	47101	47105	O
no	47106	47108	O
evidence	47109	47117	O
of	47118	47120	O
malignant	47121	47130	O
disease	47131	47138	O
(	47139	47140	O
NED	47140	47143	O
)	47143	47144	O
.	47144	47145	O

Bottom	47146	47152	O
right	47153	47158	O
:	47158	47159	O
HCC	47160	47163	O
score	47164	47169	O
derived	47170	47177	O
from	47178	47182	O
gene	47183	47187	O
signature	47188	47197	O
analysis	47198	47206	O
of	47207	47209	O
cells	47210	47215	O
post	47216	47220	O
-	47220	47221	O
iChip	47221	47226	O
separation	47227	47237	O
from	47238	47242	O
CLD	47243	47246	O
,	47246	47247	O
early	47248	47253	O
HCC	47254	47257	O
,	47257	47258	O
and	47259	47262	O
late	47263	47267	O
HCC	47268	47271	O
patients	47272	47280	O
.	47280	47281	O

Reprinted	47282	47291	O
with	47292	47296	O
permission	47297	47307	O
from	47308	47312	O
Bhan	47313	47317	O
et	47318	47320	O
al	47321	47323	O
.	47323	47324	O
,	47324	47325	O
Gastroenterology	47326	47342	O
155	47343	47346	O
(	47346	47347	O
6	47347	47348	O
)	47348	47349	O
,	47349	47350	O
2016	47351	47355	O
(	47356	47357	O
2018	47357	47361	O
)	47361	47362	O
.	47362	47363	O

Copyright	47364	47373	O
2018	47374	47378	O
Elsevier	47379	47387	O
.	47387	47388	O

(	47389	47390	O
c	47390	47391	O
)	47391	47392	O
Organoid	47393	47401	O
cultures	47402	47410	O
derived	47411	47418	O
from	47419	47423	O
human	47424	47429	O
liver	47430	47435	O
cancer	47436	47442	O
patients	47443	47451	O
;	47451	47452	O
figure	47453	47459	O
adapted	47460	47467	O
from	47468	47472	O
Ref	47473	47476	O
.	47476	47477	O

169	47478	47481	O
.	47481	47482	O

Organoid	47483	47491	O
cultures	47492	47500	O
were	47501	47505	O
established	47506	47517	O
from	47518	47522	O
needle	47523	47529	O
biopsies	47530	47538	O
from	47539	47543	O
liver	47544	47549	O
cancer	47550	47556	O
patients	47557	47565	O
.	47565	47566	O

Left	47567	47571	O
:	47571	47572	O
Representative	47573	47587	O
biopsy	47588	47594	O
pieces	47595	47601	O
of	47602	47604	O
tumor	47605	47610	O
tissue	47611	47617	O
and	47618	47621	O
paired	47622	47628	O
nontumor	47629	47637	O
liver	47638	47643	O
tissue	47644	47650	O
used	47651	47655	O
for	47656	47659	O
organoid	47660	47668	O
generation	47669	47679	O
shown	47680	47685	O
on	47686	47688	O
the	47689	47692	O
right	47693	47698	O
.	47698	47699	O

Right	47700	47705	O
:	47705	47706	O
Brightfield	47707	47718	O
images	47719	47725	O
of	47726	47728	O
tumor	47729	47734	O
and	47735	47738	O
paired	47739	47745	O
nontumor	47746	47754	O
liver	47755	47760	O
tissue	47761	47767	O
organoids	47768	47777	O
from	47778	47782	O
three	47783	47788	O
different	47789	47798	O
patients	47799	47807	O
,	47807	47808	O
including	47809	47818	O
two	47819	47822	O
HCC	47823	47826	O
patients	47827	47835	O
and	47836	47839	O
one	47840	47843	O
cholangiocellular	47844	47861	O
carcinoma	47862	47871	O
(	47872	47873	O
CCC	47873	47876	O
)	47876	47877	O
patient	47878	47885	O
(	47886	47887	O
scale	47887	47892	O
bar	47893	47896	O
=	47897	47898	O
500	47899	47902	O
μm	47903	47905	O
)	47905	47906	O
.	47906	47907	O

Reprinted	47908	47917	O
with	47918	47922	O
permission	47923	47933	O
from	47934	47938	O
Nuciforo	47939	47947	O
et	47948	47950	O
al	47951	47953	O
.	47953	47954	O
,	47954	47955	O
Cell	47956	47960	O
Rep	47961	47964	O
.	47964	47965	O

24	47966	47968	O
(	47968	47969	O
5	47969	47970	O
)	47970	47971	O
,	47971	47972	O
1363	47973	47977	O
(	47978	47979	O
2018	47979	47983	O
)	47983	47984	O
.	47984	47985	O

Copyright	47986	47995	O
2018	47996	48000	O
Elsevier	48001	48009	O
.	48009	48010	O

Toward	48011	48017	O
the	48018	48021	O
further	48022	48029	O
advancement	48030	48041	O
of	48042	48044	O
3D	48045	48047	O
scaffold	48048	48056	O
systems	48057	48064	O
,	48064	48065	O
the	48066	48069	O
assessment	48070	48080	O
of	48081	48083	O
the	48084	48087	O
effects	48088	48095	O
of	48096	48098	O
scaffold	48099	48107	O
biochemical	48108	48119	O
and	48120	48123	O
biomechanical	48124	48137	O
properties	48138	48148	O
on	48149	48151	O
liver	48152	48157	O
tumor	48158	48163	O
cell	48164	48168	O
behavior	48169	48177	O
is	48178	48180	O
another	48181	48188	O
point	48189	48194	O
of	48195	48197	O
emphasis	48198	48206	O
.	48206	48207	O

In	48208	48210	O
particular	48211	48221	O
,	48221	48222	O
analogous	48223	48232	O
to	48233	48235	O
studies	48236	48243	O
examining	48244	48253	O
the	48254	48257	O
effects	48258	48265	O
of	48266	48268	O
fibrotic	48269	48277	O
liver	48278	48283	O
microenvironments	48284	48301	O
on	48302	48304	O
hepatocyte	48305	48315	S-CL:0000182
functions	48316	48325	O
,	48325	48326	O
it	48327	48329	O
is	48330	48332	O
hypothesized	48333	48345	O
that	48346	48350	O
modular	48351	48358	O
hydrogel	48359	48367	O
systems	48368	48375	O
that	48376	48380	O
exhibit	48381	48388	O
defined	48389	48396	O
material	48397	48405	O
characteristics	48406	48421	O
could	48422	48427	O
similarly	48428	48437	O
provide	48438	48445	O
insights	48446	48454	O
into	48455	48459	O
microenvironmental	48460	48478	O
regulation	48479	48489	O
of	48490	48492	O
liver	48493	48498	O
tumor	48499	48504	O
cell	48505	48509	O
processes	48510	48519	O
.	48519	48520	O

In	48521	48523	O
studies	48524	48531	O
using	48532	48537	O
the	48538	48541	O
encapsulation	48542	48555	O
of	48556	48558	O
the	48559	48562	O
HepG2	48563	48568	O
cell	48569	48573	O
line	48574	48578	O
in	48579	48581	O
hybrid	48582	48588	O
PEG	48589	48592	O
-	48592	48593	O
collagen	48593	48601	O
hydrogels	48602	48611	O
,	48611	48612	O
it	48613	48615	O
was	48616	48619	O
demonstrated	48620	48632	O
that	48633	48637	O
cells	48638	48643	O
cultured	48644	48652	O
in	48653	48655	O
softer	48656	48662	O
hydrogels	48663	48672	O
formed	48673	48679	O
spheroids	48680	48689	O
with	48690	48694	O
a	48695	48696	O
malignant	48697	48706	O
phenotype	48707	48716	O
,	48716	48717	O
while	48718	48723	O
cells	48724	48729	O
in	48730	48732	O
stiffer	48733	48740	O
hydrogels	48741	48750	O
formed	48751	48757	O
more	48758	48762	O
compact	48763	48770	O
structures	48771	48781	O
with	48782	48786	O
suppressed	48787	48797	O
malignancy	48798	48808	O
.	48808	48809	O
128	48809	48812	O
Although	48813	48821	O
these	48822	48827	O
hybrid	48828	48834	O
hydrogels	48835	48844	O
were	48845	48849	O
selected	48850	48858	O
such	48859	48863	O
that	48864	48868	O
they	48869	48873	O
exhibited	48874	48883	O
a	48884	48885	O
fairly	48886	48892	O
uniform	48893	48900	O
mesh	48901	48905	O
size	48906	48910	O
across	48911	48917	O
the	48918	48921	O
distinct	48922	48930	O
stiffnesses	48931	48942	O
,	48942	48943	O
continuous	48944	48954	O
endeavors	48955	48964	O
in	48965	48967	O
the	48968	48971	O
field	48972	48977	O
aim	48978	48981	O
to	48982	48984	O
further	48985	48992	O
decouple	48993	49001	O
the	49002	49005	O
effects	49006	49013	O
of	49014	49016	O
tissue	49017	49023	O
stiffness	49024	49033	O
,	49033	49034	O
porosity	49035	49043	O
,	49043	49044	O
and	49045	49048	O
biomaterial	49049	49060	O
/	49060	49061	O
ECM	49061	49064	O
composition	49065	49076	O
on	49077	49079	O
cell	49080	49084	O
responses	49085	49094	O
.	49094	49095	O

For	49096	49099	O
example	49100	49107	O
,	49107	49108	O
complementary	49109	49122	O
efforts	49123	49130	O
using	49131	49136	O
2D	49137	49139	O
polyacrylamide	49140	49154	O
substrates	49155	49165	O
with	49166	49170	O
defined	49171	49178	O
elastic	49179	49186	O
moduli	49187	49193	O
have	49194	49198	O
demonstrated	49199	49211	O
that	49212	49216	O
increased	49217	49226	O
stiffness	49227	49236	O
can	49237	49240	O
upregulate	49241	49251	O
the	49252	49255	O
expression	49256	49266	O
of	49267	49269	O
osteopontin	49270	49281	O
,	49281	49282	O
129	49282	49285	O
and	49286	49289	O
cancer	49290	49296	O
stem	49297	49301	B-CL:0000034
cell	49302	49306	E-CL:0000034
markers	49307	49314	O
,	49314	49315	O
130	49315	49318	O
in	49319	49321	O
HCC	49322	49325	O
cell	49326	49330	O
lines	49331	49336	O
.	49336	49337	O

Huh7	49338	49342	O
.	49342	49343	O
5	49343	49344	O
cells	49345	49350	O
encapsulated	49351	49363	O
within	49364	49370	O
PEG	49371	49374	O
-	49374	49375	O
diacrylate	49375	49385	O
hydrogels	49386	49395	O
exhibited	49396	49405	O
increased	49406	49415	O
proliferation	49416	49429	O
,	49429	49430	O
as	49431	49433	O
well	49434	49438	O
as	49439	49441	O
increased	49442	49451	O
hepatocellular	49452	49466	O
functions	49467	49476	O
such	49477	49481	O
as	49482	49484	O
albumin	49485	49492	O
secretion	49493	49502	O
and	49503	49506	O
CYP450	49507	49513	O
expression	49514	49524	O
,	49524	49525	O
in	49526	49528	O
hydrogels	49529	49538	O
with	49539	49543	O
relatively	49544	49554	O
low	49555	49558	O
elastic	49559	49566	O
modulus	49567	49574	O
(	49575	49576	O
∼	49576	49577	O
0	49577	49578	O
.	49578	49579	O
1	49579	49580	O
kPa	49581	49584	O
)	49584	49585	O
,	49585	49586	O
and	49587	49590	O
the	49591	49594	O
modification	49595	49607	O
of	49608	49610	O
the	49611	49614	O
hydrogels	49615	49624	O
with	49625	49629	O
fibrinogen	49630	49640	O
further	49641	49648	O
modulated	49649	49658	O
encapsulated	49659	49671	O
spheroid	49672	49680	O
growth	49681	49687	O
.	49687	49688	O
131	49688	49691	O
In	49692	49694	O
the	49695	49698	O
3D	49699	49701	O
PEG	49702	49705	O
-	49705	49706	O
collagen	49706	49714	O
hydrogel	49715	49723	O
system	49724	49730	O
,	49730	49731	O
scaffold	49732	49740	O
softening	49741	49750	O
through	49751	49758	O
the	49759	49762	O
treatment	49763	49772	O
with	49773	49777	O
exogenous	49778	49787	O
matrix	49788	49794	O
metalloproteinase	49795	49812	O
(	49813	49814	O
MMP	49814	49817	O
)	49817	49818	O
-	49818	49819	O
1	49819	49820	O
was	49821	49824	O
shown	49825	49830	O
to	49831	49833	O
enhance	49834	49841	O
HepG2	49842	49847	O
proliferation	49848	49861	O
,	49861	49862	O
decrease	49863	49871	O
the	49872	49875	O
expression	49876	49886	O
of	49887	49889	O
E	49890	49891	O
-	49891	49892	O
cadherin	49892	49900	O
,	49900	49901	O
and	49902	49905	O
increase	49906	49914	O
the	49915	49918	O
sensitivity	49919	49930	O
to	49931	49933	O
radiation	49934	49943	O
exposure	49944	49952	O
.	49952	49953	O
132	49953	49956	O
In	49957	49959	O
addition	49960	49968	O
to	49969	49971	O
synthetic	49972	49981	O
hydrogels	49982	49991	O
,	49991	49992	O
recent	49993	49999	O
studies	50000	50007	O
have	50008	50012	O
examined	50013	50021	O
the	50022	50025	O
efficacy	50026	50034	O
of	50035	50037	O
decellularized	50038	50052	O
rodent	50053	50059	O
,	50059	50060	O
133	50060	50063	O
,	50063	50064	O
134	50064	50067	O
porcine	50068	50075	O
,	50075	50076	O
135	50076	50079	O
,	50079	50080	O
136	50080	50083	O
and	50084	50087	O
human137	50088	50096	O
liver	50097	50102	O
tissues	50103	50110	O
as	50111	50113	O
the	50114	50117	O
basis	50118	50123	O
for	50124	50127	O
3D	50128	50130	O
culture	50131	50138	O
approaches	50139	50149	O
aimed	50150	50155	O
at	50156	50158	O
better	50159	50165	O
representing	50166	50178	O
the	50179	50182	O
complement	50183	50193	O
of	50194	50196	O
ECM	50197	50200	O
factors	50201	50208	O
present	50209	50216	O
in	50217	50219	O
vivo	50220	50224	O
.	50224	50225	O

In	50226	50228	O
order	50229	50234	O
to	50235	50237	O
directly	50238	50246	O
evaluate	50247	50255	O
the	50256	50259	O
ECM	50260	50263	O
composition	50264	50275	O
and	50276	50279	O
the	50280	50283	O
presence	50284	50292	O
of	50293	50295	O
other	50296	50301	O
key	50302	50305	O
signals	50306	50313	O
within	50314	50320	O
typical	50321	50328	O
liver	50329	50334	O
tumor	50335	50340	O
microenvironments	50341	50358	O
,	50358	50359	O
a	50360	50361	O
broad	50362	50367	O
range	50368	50373	O
of	50374	50376	O
studies	50377	50384	O
have	50385	50389	O
employed	50390	50398	O
a	50399	50400	O
combination	50401	50412	O
of	50413	50415	O
animal	50416	50422	O
models	50423	50429	O
together	50430	50438	O
with	50439	50443	O
the	50444	50447	O
direct	50448	50454	O
assessment	50455	50465	O
of	50466	50468	O
patient	50469	50476	O
samples	50477	50484	O
.	50484	50485	O
138	50485	50488	O
For	50489	50492	O
future	50493	50499	O
efforts	50500	50507	O
,	50507	50508	O
the	50509	50512	O
integration	50513	50524	O
of	50525	50527	O
proteomics	50528	50538	O
-	50538	50539	O
based	50539	50544	O
analysis	50545	50553	O
of	50554	50556	O
patient	50557	50564	O
tissues	50565	50572	O
,	50572	50573	O
139	50573	50576	O
including	50577	50586	O
comparisons	50587	50598	O
to	50599	50601	O
associated	50602	50612	O
chronic	50613	50620	O
liver	50621	50626	O
diseases	50627	50635	O
such	50636	50640	O
as	50641	50643	O
fibrosis	50644	50652	O
,	50652	50653	O
140	50653	50656	O
could	50657	50662	O
help	50663	50667	O
to	50668	50670	O
identify	50671	50679	O
additional	50680	50690	O
microenvironmental	50691	50709	O
cues	50710	50714	O
for	50715	50718	O
integration	50719	50730	O
into	50731	50735	O
biomaterial	50736	50747	O
scaffold	50748	50756	O
culture	50757	50764	O
models	50765	50771	O
.	50771	50772	O

Microfluidic	50773	50785	O
chip	50786	50790	O
-	50790	50791	O
based	50791	50796	O
analysis	50797	50805	O
of	50806	50808	O
cancer	50809	50815	O
progression	50816	50827	O
Microfabricated	50828	50843	O
devices	50844	50851	O
,	50851	50852	O
such	50853	50857	O
as	50858	50860	O
microfluidic	50861	50873	O
chips	50874	50879	O
,	50879	50880	O
have	50881	50885	O
been	50886	50890	O
applied	50891	50898	O
toward	50899	50905	O
the	50906	50909	O
study	50910	50915	O
of	50916	50918	O
a	50919	50920	O
wide	50921	50925	O
range	50926	50931	O
of	50932	50934	O
cancer	50935	50941	O
types	50942	50947	O
including	50948	50957	O
liver	50958	50963	O
cancer	50964	50970	O
.	50970	50971	O

Overall	50972	50979	O
,	50979	50980	O
the	50981	50984	O
modularity	50985	50995	O
of	50996	50998	O
microfluidic	50999	51011	O
device	51012	51018	O
design	51019	51025	O
has	51026	51029	O
enabled	51030	51037	O
the	51038	51041	O
investigation	51042	51055	O
of	51056	51058	O
numerous	51059	51067	O
aspects	51068	51075	O
of	51076	51078	O
cancer	51079	51085	O
progression	51086	51097	O
including	51098	51107	O
vascularization	51108	51123	O
,	51123	51124	O
metastasis	51125	51135	O
,	51135	51136	O
immune	51137	51143	O
interactions	51144	51156	O
,	51156	51157	O
and	51158	51161	O
tissue	51162	51168	O
mechanics	51169	51178	O
.	51178	51179	O
141	51179	51182	O
–	51182	51183	O
144	51183	51186	O
For	51187	51190	O
instance	51191	51199	O
,	51199	51200	O
a	51201	51202	O
microfluidic	51203	51215	O
platform	51216	51224	O
was	51225	51228	O
developed	51229	51238	O
and	51239	51242	O
applied	51243	51250	O
toward	51251	51257	O
the	51258	51261	O
evaluation	51262	51272	O
of	51273	51275	O
liver	51276	51281	O
cancer	51282	51288	O
cell	51289	51293	O
line	51294	51298	O
migration	51299	51308	O
in	51309	51311	O
response	51312	51320	O
to	51321	51323	O
physical	51324	51332	O
cues	51333	51337	O
such	51338	51342	O
as	51343	51345	O
confinement	51346	51357	O
.	51357	51358	O
145	51358	51361	O
A	51362	51363	O
microfluidic	51364	51376	O
approach	51377	51385	O
has	51386	51389	O
also	51390	51394	O
been	51395	51399	O
employed	51400	51408	O
for	51409	51412	O
single	51413	51419	O
cell	51420	51424	O
capture	51425	51432	O
and	51433	51436	O
subsequent	51437	51447	O
growth	51448	51454	O
of	51455	51457	O
multicellular	51458	51471	O
spheroids	51472	51481	O
,	51481	51482	O
146	51482	51485	O
and	51486	51489	O
the	51490	51493	O
integration	51494	51505	O
of	51506	51508	O
liver	51509	51514	O
tumor	51515	51520	O
cell	51521	51525	O
/	51525	51526	O
stellate	51526	51534	B-CL:0000122
cell	51535	51539	E-CL:0000122
coculture	51540	51549	O
spheroids	51550	51559	O
with	51560	51564	O
drug	51565	51569	O
treatment	51570	51579	O
experiments	51580	51591	O
.	51591	51592	O
147	51592	51595	O
Multiorgan	51596	51606	O
on	51607	51609	O
chip	51610	51614	O
systems	51615	51622	O
incorporating	51623	51636	O
liver	51637	51642	O
cell	51643	51647	O
types	51648	51653	O
have	51654	51658	O
also	51659	51663	O
been	51664	51668	O
explored	51669	51677	O
.	51677	51678	O
148	51678	51681	O
,	51681	51682	O
149	51682	51685	O
For	51686	51689	O
example	51690	51697	O
,	51697	51698	O
a	51699	51700	O
microfluidic	51701	51713	O
system	51714	51720	O
containing	51721	51731	O
both	51732	51736	O
HepG2	51737	51742	O
cells	51743	51748	O
and	51749	51752	O
a	51753	51754	O
human	51755	51760	O
colon	51761	51766	O
cancer	51767	51773	O
cell	51774	51778	O
line	51779	51783	O
was	51784	51787	O
established	51788	51799	O
for	51800	51803	O
the	51804	51807	O
measurement	51808	51819	O
of	51820	51822	O
colon	51823	51828	O
cell	51829	51833	O
migration	51834	51843	O
toward	51844	51850	O
the	51851	51854	O
distinct	51855	51863	O
liver	51864	51869	O
culture	51870	51877	O
chamber	51878	51885	O
,	51885	51886	O
as	51887	51889	O
a	51890	51891	O
model	51892	51897	O
of	51898	51900	O
colon	51901	51906	O
tumor	51907	51912	O
cell	51913	51917	O
metastasis	51918	51928	O
.	51928	51929	O
150	51929	51932	O
Broadly	51933	51940	O
,	51940	51941	O
such	51942	51946	O
multiorgan	51947	51957	O
platforms	51958	51967	O
could	51968	51973	O
enable	51974	51980	O
unique	51981	51987	O
investigations	51988	52002	O
into	52003	52007	O
the	52008	52011	O
pharmacokinetics	52012	52028	O
of	52029	52031	O
liver	52032	52037	O
cancer	52038	52044	O
therapies	52045	52054	O
and	52055	52058	O
the	52059	52062	O
overall	52063	52070	O
effects	52071	52078	O
of	52079	52081	O
metabolite	52082	52092	O
and	52093	52096	O
drug	52097	52101	O
transport	52102	52111	O
on	52112	52114	O
tumor	52115	52120	O
responses	52121	52130	O
.	52130	52131	O

In	52132	52134	O
addition	52135	52143	O
,	52143	52144	O
a	52145	52146	O
recent	52147	52153	O
series	52154	52160	O
of	52161	52163	O
investigations	52164	52178	O
have	52179	52183	O
highlighted	52184	52195	O
the	52196	52199	O
capability	52200	52210	O
of	52211	52213	O
microfluidic	52214	52226	O
-	52226	52227	O
based	52227	52232	O
coculture	52233	52242	O
models	52243	52249	O
for	52250	52253	O
analyzing	52254	52263	O
interactions	52264	52276	O
between	52277	52284	O
liver	52285	52290	O
tumor	52291	52296	O
cells	52297	52302	O
and	52303	52306	O
hematopoietic	52307	52320	B-CL:0000988
cells	52321	52326	E-CL:0000988
,	52326	52327	O
which	52328	52333	O
underlie	52334	52342	O
the	52343	52346	O
potential	52347	52356	O
effectiveness	52357	52370	O
of	52371	52373	O
immunotherapies	52374	52389	O
.	52389	52390	O

In	52391	52393	O
particular	52394	52404	O
,	52404	52405	O
in	52406	52408	O
one	52409	52412	O
approach	52413	52421	O
,	52421	52422	O
HepG2	52423	52428	O
spheroids	52429	52438	O
expressing	52439	52449	O
a	52450	52451	O
component	52452	52461	O
of	52462	52464	O
the	52465	52468	O
HBV	52469	52472	O
genotype	52473	52481	O
D	52482	52483	O
envelope	52484	52492	O
protein	52493	52500	O
were	52501	52505	O
encapsulated	52506	52518	O
within	52519	52525	O
a	52526	52527	O
collagen	52528	52536	O
gel	52537	52540	O
located	52541	52548	O
in	52549	52551	O
the	52552	52555	O
central	52556	52563	O
channel	52564	52571	O
of	52572	52574	O
the	52575	52578	O
device	52579	52585	O
.	52585	52586	O
151	52586	52589	O
HBV	52590	52593	O
-	52593	52594	O
specific	52594	52602	O
T	52603	52604	B-CL:0000084
cells	52605	52610	E-CL:0000084
were	52611	52615	O
introduced	52616	52626	O
into	52627	52631	O
the	52632	52635	O
outer	52636	52641	O
channels	52642	52650	O
with	52651	52655	O
or	52656	52658	O
without	52659	52666	O
monocytes	52667	52676	S-CL:0000576
,	52676	52677	O
and	52678	52681	O
following	52682	52691	O
coculture	52692	52701	O
,	52701	52702	O
it	52703	52705	O
was	52706	52709	O
determined	52710	52720	O
that	52721	52725	O
the	52726	52729	O
monocytes	52730	52739	S-CL:0000576
reduced	52740	52747	O
T	52748	52749	B-CL:0000084
cell	52750	52754	E-CL:0000084
-	52754	52755	O
mediated	52755	52763	O
cytotoxicity	52764	52776	O
,	52776	52777	O
which	52778	52783	O
is	52784	52786	O
consistent	52787	52797	O
with	52798	52802	O
the	52803	52806	O
suggested	52807	52816	O
physiologic	52817	52828	O
function	52829	52837	O
of	52838	52840	O
monocytes	52841	52850	S-CL:0000576
within	52851	52857	O
tumor	52858	52863	O
microenvironments	52864	52881	O
.	52881	52882	O
152	52882	52885	O
Notably	52886	52893	O
,	52893	52894	O
this	52895	52899	O
immunosuppressive	52900	52917	O
effect	52918	52924	O
was	52925	52928	O
specific	52929	52937	O
to	52938	52940	O
the	52941	52944	O
3D	52945	52947	O
microfluidic	52948	52960	O
coculture	52961	52970	O
,	52970	52971	O
as	52972	52974	O
it	52975	52977	O
was	52978	52981	O
not	52982	52985	O
observed	52986	52994	O
in	52995	52997	O
parallel	52998	53006	O
experiments	53007	53018	O
using	53019	53024	O
standard	53025	53033	O
2D	53034	53036	O
cocultures	53037	53047	O
.	53047	53048	O

Further	53049	53056	O
,	53056	53057	O
using	53058	53063	O
a	53064	53065	O
similar	53066	53073	O
device	53074	53080	O
design	53081	53087	O
that	53088	53092	O
incorporated	53093	53105	O
either	53106	53112	O
dispersed	53113	53122	O
or	53123	53125	O
aggregated	53126	53136	O
HepG2	53137	53142	O
cells	53143	53148	O
within	53149	53155	O
collagen	53156	53164	O
gels	53165	53169	O
,	53169	53170	O
together	53171	53179	O
with	53180	53184	O
engineered	53185	53195	O
T	53196	53197	B-CL:0000084
cells	53198	53203	E-CL:0000084
in	53204	53206	O
adjacent	53207	53215	O
channels	53216	53224	O
,	53224	53225	O
the	53226	53229	O
co	53230	53232	O
-	53232	53233	O
operative	53233	53242	O
effects	53243	53250	O
of	53251	53253	O
cytokines	53254	53263	O
and	53264	53267	O
oxygen	53268	53274	O
tension	53275	53282	O
on	53283	53285	O
tumor	53286	53291	O
cell	53292	53296	O
killing	53297	53304	O
were	53305	53309	O
examined	53310	53318	O
.	53318	53319	O
153	53319	53322	O
These	53323	53328	O
studies	53329	53336	O
demonstrated	53337	53349	O
that	53350	53354	O
the	53355	53358	O
presence	53359	53367	O
of	53368	53370	O
inflammatory	53371	53383	O
cytokines	53384	53393	O
,	53393	53394	O
IFN	53395	53398	O
-	53398	53399	O
gamma	53399	53404	O
and	53405	53408	O
TNF	53409	53412	O
-	53412	53413	O
alpha	53413	53418	O
,	53418	53419	O
enhanced	53420	53428	O
the	53429	53432	O
capability	53433	53443	O
of	53444	53446	O
T	53447	53448	B-CL:0000084
cells	53449	53454	E-CL:0000084
to	53455	53457	O
lyse	53458	53462	O
tumor	53463	53468	O
cell	53469	53473	O
multicellular	53474	53487	O
aggregates	53488	53498	O
,	53498	53499	O
and	53500	53503	O
for	53504	53507	O
the	53508	53511	O
dispersed	53512	53521	O
tumor	53522	53527	O
cells	53528	53533	O
,	53533	53534	O
T	53535	53536	B-CL:0000084
cell	53537	53541	E-CL:0000084
-	53541	53542	O
mediated	53542	53550	O
killing	53551	53558	O
was	53559	53562	O
decreased	53563	53572	O
in	53573	53575	O
2	53576	53577	O
%	53577	53578	O
O2	53579	53581	O
compared	53582	53590	O
to	53591	53593	O
the	53594	53597	O
20	53598	53600	O
%	53600	53601	O
O2	53602	53604	O
condition	53605	53614	O
.	53614	53615	O

Microfluidic	53616	53628	O
devices	53629	53636	O
have	53637	53641	O
also	53642	53646	O
been	53647	53651	O
utilized	53652	53660	O
in	53661	53663	O
the	53664	53667	O
setting	53668	53675	O
of	53676	53678	O
cancer	53679	53685	O
diagnostics	53686	53697	O
,	53697	53698	O
including	53699	53708	O
most	53709	53713	O
notably	53714	53721	O
an	53722	53724	O
approach	53725	53733	O
for	53734	53737	O
detecting	53738	53747	O
and	53748	53751	O
enriching	53752	53761	O
circulating	53762	53773	O
tumor	53774	53779	O
cells	53780	53785	O
as	53786	53788	O
part	53789	53793	O
of	53794	53796	O
the	53797	53800	O
assessment	53801	53811	O
of	53812	53814	O
liquid	53815	53821	O
biopsies	53822	53830	O
.	53830	53831	O
154	53831	53834	O
Circulating	53835	53846	O
tumor	53847	53852	O
cells	53853	53858	O
have	53859	53863	O
been	53864	53868	O
identified	53869	53879	O
in	53880	53882	O
patients	53883	53891	O
with	53892	53896	O
HCC	53897	53900	O
,	53900	53901	O
155	53901	53904	O
,	53904	53905	O
156	53905	53908	O
and	53909	53912	O
recent	53913	53919	O
efforts	53920	53927	O
have	53928	53932	O
aimed	53933	53938	O
to	53939	53941	O
pair	53942	53946	O
circulating	53947	53958	O
tumor	53959	53964	O
cell	53965	53969	O
enrichment	53970	53980	O
with	53981	53985	O
a	53986	53987	O
variety	53988	53995	O
of	53996	53998	O
downstream	53999	54009	O
analysis	54010	54018	O
strategies	54019	54029	O
.	54029	54030	O

For	54031	54034	O
example	54035	54042	O
,	54042	54043	O
HCC	54044	54047	O
patient	54048	54055	O
blood	54056	54061	O
samples	54062	54069	O
were	54070	54074	O
enriched	54075	54083	O
for	54084	54087	O
circulating	54088	54099	O
tumor	54100	54105	O
cells	54106	54111	O
using	54112	54117	O
a	54118	54119	O
microfluidic	54120	54132	O
chip	54133	54137	O
based	54138	54143	O
on	54144	54146	O
the	54147	54150	O
capture	54151	54158	O
and	54159	54162	O
positive	54163	54171	O
selection	54172	54181	O
of	54182	54184	O
cells	54185	54190	O
expressing	54191	54201	O
asialoglycoprotein	54202	54220	O
receptor	54221	54229	O
(	54230	54231	O
ASGPR	54231	54236	O
)	54236	54237	O
,	54237	54238	O
which	54239	54244	O
is	54245	54247	O
selectively	54248	54259	O
expressed	54260	54269	O
by	54270	54272	O
hepatic	54273	54280	O
cell	54281	54285	O
types	54286	54291	O
.	54291	54292	O
157	54292	54295	O
These	54296	54301	O
enriched	54302	54310	O
cells	54311	54316	O
were	54317	54321	O
then	54322	54326	O
utilized	54327	54335	O
to	54336	54338	O
establish	54339	54348	O
3D	54349	54351	O
spheroid	54352	54360	O
cultures	54361	54369	O
and	54370	54373	O
were	54374	54378	O
tested	54379	54385	O
for	54386	54389	O
sensitivity	54390	54401	O
to	54402	54404	O
chemotherapeutic	54405	54421	O
drugs	54422	54427	O
.	54427	54428	O

In	54429	54431	O
another	54432	54439	O
set	54440	54443	O
of	54444	54446	O
studies	54447	54454	O
,	54454	54455	O
a	54456	54457	O
microfluidic	54458	54470	O
device	54471	54477	O
termed	54478	54484	O
the	54485	54488	O
iChip	54489	54494	O
was	54495	54498	O
applied	54499	54506	O
toward	54507	54513	O
the	54514	54517	O
enrichment	54518	54528	O
of	54529	54531	O
circulating	54532	54543	O
HCC	54544	54547	O
cells158	54548	54556	O
,	54556	54557	O
159	54557	54560	O
[	54561	54562	O
Fig	54562	54565	O
.	54565	54566	O

2	54567	54568	O
(	54568	54569	O
b	54569	54570	O
)	54570	54571	O
]	54571	54572	O
.	54572	54573	O

In	54574	54576	O
this	54577	54581	O
platform	54582	54590	O
,	54590	54591	O
patient	54592	54599	O
blood	54600	54605	O
first	54606	54611	O
undergoes	54612	54621	O
a	54622	54623	O
size	54624	54628	O
-	54628	54629	O
based	54629	54634	O
separation	54635	54645	O
that	54646	54650	O
removes	54651	54658	O
red	54659	54662	S-CL:0000232
blood	54663	54668	B-CL:0000232;CL:0000081
cells	54669	54674	E-CL:0000232;CL:0000081
,	54674	54675	O
platelets	54676	54685	S-CL:0000233
,	54685	54686	O
and	54687	54690	O
plasma	54691	54697	O
,	54697	54698	O
followed	54699	54707	O
by	54708	54710	O
magnetic	54711	54719	O
depletion	54720	54729	O
of	54730	54732	O
white	54733	54738	S-CL:0000738
blood	54739	54744	B-CL:0000738;CL:0000081
cells	54745	54750	E-CL:0000738;CL:0000081
using	54751	54756	O
magnetic	54757	54765	O
beads	54766	54771	O
conjugated	54772	54782	O
with	54783	54787	O
antibodies	54788	54798	O
to	54799	54801	O
hematopoietic	54802	54815	O
markers	54816	54823	O
(	54824	54825	O
CD45	54825	54829	O
and	54830	54833	O
CD66b	54834	54839	O
)	54839	54840	O
.	54840	54841	O
160	54841	54844	O
Cells	54845	54850	O
enriched	54851	54859	O
from	54860	54864	O
HCC	54865	54868	O
patients	54869	54877	O
using	54878	54883	O
this	54884	54888	O
device	54889	54895	O
were	54896	54900	O
demonstrated	54901	54913	O
to	54914	54916	O
be	54917	54919	O
compatible	54920	54930	O
with	54931	54935	O
RNA	54936	54939	O
-	54939	54940	O
based	54940	54945	O
digital	54946	54953	O
polymerase	54954	54964	O
chain	54965	54970	O
reaction	54971	54979	O
(	54980	54981	O
PCR	54981	54984	O
)	54984	54985	O
measurements	54986	54998	O
for	54999	55002	O
the	55003	55006	O
quantitative	55007	55019	O
analysis	55020	55028	O
of	55029	55031	O
gene	55032	55036	O
expression	55037	55047	O
.	55047	55048	O
159	55048	55051	O
In	55052	55054	O
addition	55055	55063	O
,	55063	55064	O
the	55065	55068	O
iChip	55069	55074	O
platform	55075	55083	O
was	55084	55087	O
also	55088	55092	O
recently	55093	55101	O
applied	55102	55109	O
toward	55110	55116	O
the	55117	55120	O
parallel	55121	55129	O
evaluation	55130	55140	O
of	55141	55143	O
both	55144	55148	O
circulating	55149	55160	O
tumor	55161	55166	O
cells	55167	55172	O
from	55173	55177	O
HCC	55178	55181	O
patients	55182	55190	O
and	55191	55194	O
circulating	55195	55206	O
epithelial	55207	55217	B-CL:0000066
cells	55218	55223	E-CL:0000066
from	55224	55228	O
chronic	55229	55236	O
liver	55237	55242	O
disease	55243	55250	O
patients	55251	55259	O
without	55260	55267	O
HCC	55268	55271	O
.	55271	55272	O
158	55272	55275	O
Accordingly	55276	55287	O
,	55287	55288	O
this	55289	55293	O
type	55294	55298	O
of	55299	55301	O
approach	55302	55310	O
for	55311	55314	O
analyzing	55315	55324	O
liquid	55325	55331	O
biopsies	55332	55340	O
could	55341	55346	O
have	55347	55351	O
great	55352	55357	O
utility	55358	55365	O
toward	55366	55372	O
the	55373	55376	O
tracking	55377	55385	O
of	55386	55388	O
chronic	55389	55396	O
liver	55397	55402	O
disease	55403	55410	O
(	55411	55412	O
e	55412	55413	O
.	55413	55414	O
g	55414	55415	O
.	55415	55416	O
,	55416	55417	O
fibrosis	55418	55426	O
)	55426	55427	O
severity	55428	55436	O
and	55437	55440	O
for	55441	55444	O
liver	55445	55450	O
cancer	55451	55457	O
surveillance	55458	55470	O
.	55470	55471	O

Patient	55472	55479	O
-	55479	55480	O
specific	55480	55488	O
tumor	55489	55494	O
organoids	55495	55504	O
Building	55505	55513	O
on	55514	55516	O
the	55517	55520	O
knowledge	55521	55530	O
gained	55531	55537	O
from	55538	55542	O
healthy	55543	55550	O
adult	55551	55556	O
stem	55557	55561	B-CL:0000034
cell	55562	55566	E-CL:0000034
organoids	55567	55576	O
,	55576	55577	O
numerous	55578	55586	O
recent	55587	55593	O
efforts	55594	55601	O
have	55602	55606	O
focused	55607	55614	O
on	55615	55617	O
organoids	55618	55627	O
as	55628	55630	O
potential	55631	55640	O
model	55641	55646	O
systems	55647	55654	O
for	55655	55658	O
cancer	55659	55665	O
research	55666	55674	O
.	55674	55675	O
161	55675	55678	O
Long	55679	55683	O
-	55683	55684	O
term	55684	55688	O
organoid	55689	55697	O
cultures	55698	55706	O
have	55707	55711	O
been	55712	55716	O
initiated	55717	55726	O
directly	55727	55735	O
from	55736	55740	O
patient	55741	55748	O
-	55748	55749	O
derived	55749	55756	O
tumor	55757	55762	O
tissues	55763	55770	O
.	55770	55771	O

For	55772	55775	O
instance	55776	55784	O
,	55784	55785	O
primary	55786	55793	O
and	55794	55797	O
metastatic	55798	55808	O
breast	55809	55815	O
cancer	55816	55822	O
organoid	55823	55831	O
culture	55832	55839	O
lines	55840	55845	O
have	55846	55850	O
been	55851	55855	O
demonstrated	55856	55868	O
to	55869	55871	O
exhibit	55872	55879	O
strong	55880	55886	O
correlations	55887	55899	O
with	55900	55904	O
the	55905	55908	O
original	55909	55917	O
tumors	55918	55924	O
with	55925	55929	O
regard	55930	55936	O
to	55937	55939	O
numerous	55940	55948	O
criteria	55949	55957	O
including	55958	55967	O
DNA	55968	55971	O
copy	55972	55976	O
number	55977	55983	O
variations	55984	55994	O
,	55994	55995	O
hormone	55996	56003	O
receptor	56004	56012	O
status	56013	56019	O
,	56019	56020	O
and	56021	56024	O
HER2	56025	56029	O
status	56030	56036	O
.	56036	56037	O
162	56037	56040	O
Patient	56041	56048	O
-	56048	56049	O
derived	56049	56056	O
organoids	56057	56066	O
from	56067	56071	O
gastroesophageal	56072	56088	O
and	56089	56092	O
colorectal	56093	56103	O
cancer	56104	56110	O
patients	56111	56119	O
were	56120	56124	O
demonstrated	56125	56137	O
to	56138	56140	O
enable	56141	56147	O
molecular	56148	56157	O
profiling	56158	56167	O
toward	56168	56174	O
the	56175	56178	O
prediction	56179	56189	O
of	56190	56192	O
responses	56193	56202	O
to	56203	56205	O
anticancer	56206	56216	O
therapeutics	56217	56229	O
,	56229	56230	O
which	56231	56236	O
matched	56237	56244	O
well	56245	56249	O
with	56250	56254	O
patient	56255	56262	O
responses	56263	56272	O
in	56273	56275	O
clinical	56276	56284	O
trials	56285	56291	O
.	56291	56292	O
163	56292	56295	O
Further	56296	56303	O
,	56303	56304	O
in	56305	56307	O
recent	56308	56314	O
studies	56315	56322	O
investigating	56323	56336	O
colon	56337	56342	O
cancer	56343	56349	O
,	56349	56350	O
organoid	56351	56359	O
cultures	56360	56368	O
originated	56369	56379	O
with	56380	56384	O
healthy	56385	56392	O
stem	56393	56397	B-CL:0000034
cells	56398	56403	E-CL:0000034
,	56403	56404	O
and	56405	56408	O
gene	56409	56413	O
editing	56414	56421	O
strategies	56422	56432	O
were	56433	56437	O
utilized	56438	56446	O
to	56447	56449	O
investigate	56450	56461	O
genetic	56462	56469	O
perturbations	56470	56483	O
underlying	56484	56494	O
colorectal	56495	56505	O
tumorigenesis	56506	56519	O
.	56519	56520	O
164	56520	56523	O
,	56523	56524	O
165	56524	56527	O
Long	56528	56532	O
-	56532	56533	O
term	56533	56537	O
organoid	56538	56546	O
cultures	56547	56555	O
have	56556	56560	O
also	56561	56565	O
been	56566	56570	O
established	56571	56582	O
directly	56583	56591	O
from	56592	56596	O
patient	56597	56604	O
-	56604	56605	O
derived	56605	56612	O
tumor	56613	56618	O
tissue	56619	56625	O
in	56626	56628	O
the	56629	56632	O
context	56633	56640	O
of	56641	56643	O
liver	56644	56649	O
cancers	56650	56657	O
.	56657	56658	O

For	56659	56662	O
example	56663	56670	O
,	56670	56671	O
primary	56672	56679	O
liver	56680	56685	O
cancer	56686	56692	O
organoids	56693	56702	O
were	56703	56707	O
generated	56708	56717	O
from	56718	56722	O
HCC	56723	56726	O
,	56726	56727	O
CCC	56728	56731	O
,	56731	56732	O
and	56733	56736	O
combined	56737	56745	O
HCC	56746	56749	O
/	56749	56750	O
CCC	56750	56753	O
tumors	56754	56760	O
.	56760	56761	O
166	56761	56764	O
Similar	56765	56772	O
to	56773	56775	O
other	56776	56781	O
stem	56782	56786	B-CL:0000034
cell	56787	56791	E-CL:0000034
-	56791	56792	O
based	56792	56797	O
organoid	56798	56806	O
culture	56807	56814	O
approaches	56815	56825	O
,	56825	56826	O
these	56827	56832	O
tissue	56833	56839	O
samples	56840	56847	O
were	56848	56852	O
suspended	56853	56862	O
within	56863	56869	O
a	56870	56871	O
basement	56872	56880	O
membranelike	56881	56893	O
hydrogel	56894	56902	O
and	56903	56906	O
the	56907	56910	O
culture	56911	56918	O
medium	56919	56925	O
consisted	56926	56935	O
of	56936	56938	O
an	56939	56941	O
optimized	56942	56951	O
cocktail	56952	56960	O
of	56961	56963	O
growth	56964	56970	O
factors	56971	56978	O
and	56979	56982	O
small	56983	56988	O
molecules	56989	56998	O
.	56998	56999	O

These	57000	57005	O
patient	57006	57013	O
-	57013	57014	O
derived	57014	57021	O
liver	57022	57027	O
cancer	57028	57034	O
organoids	57035	57044	O
maintained	57045	57055	O
histological	57056	57068	O
features	57069	57077	O
and	57078	57081	O
gene	57082	57086	O
expression	57087	57097	O
characteristics	57098	57113	O
of	57114	57116	O
the	57117	57120	O
original	57121	57129	O
tumors	57130	57136	O
and	57137	57140	O
also	57141	57145	O
supported	57146	57155	O
drug	57156	57160	O
screening	57161	57170	O
,	57170	57171	O
which	57172	57177	O
led	57178	57181	O
to	57182	57184	O
the	57185	57188	O
identification	57189	57203	O
of	57204	57206	O
an	57207	57209	O
ERK	57210	57213	O
inhibitor	57214	57223	O
as	57224	57226	O
a	57227	57228	O
promising	57229	57238	O
therapeutic	57239	57250	O
candidate	57251	57260	O
based	57261	57266	O
on	57267	57269	O
growth	57270	57276	O
inhibitory	57277	57287	O
effects	57288	57295	O
observed	57296	57304	O
on	57305	57307	O
some	57308	57312	O
of	57313	57315	O
the	57316	57319	O
patient	57320	57327	O
organoid	57328	57336	O
lines	57337	57342	O
.	57342	57343	O

For	57344	57347	O
the	57348	57351	O
analysis	57352	57360	O
of	57361	57363	O
CCC	57364	57367	O
,	57367	57368	O
defined	57369	57376	O
genetic	57377	57384	O
modifications	57385	57398	O
in	57399	57401	O
normal	57402	57408	O
human	57409	57414	O
cholangiocyte	57415	57428	S-CL:1000488
organoids	57429	57438	O
revealed	57439	57447	O
the	57448	57451	O
important	57452	57461	O
role	57462	57466	O
of	57467	57469	O
the	57470	57473	O
deubiquitinating	57474	57490	O
enzyme	57491	57497	O
BAP1	57498	57502	S-CL:0000613
in	57503	57505	O
the	57506	57509	O
CCC	57510	57513	O
malignant	57514	57523	O
phenotype	57524	57533	O
.	57533	57534	O
167	57534	57537	O
In	57538	57540	O
another	57541	57548	O
work	57549	57553	O
,	57553	57554	O
the	57555	57558	O
generation	57559	57569	O
of	57570	57572	O
multiple	57573	57581	O
organoid	57582	57590	O
lines	57591	57596	O
,	57596	57597	O
taken	57598	57603	O
from	57604	57608	O
distinct	57609	57617	O
regions	57618	57625	O
of	57626	57628	O
the	57629	57632	O
same	57633	57637	O
liver	57638	57643	O
tumors	57644	57650	O
,	57650	57651	O
provided	57652	57660	O
unique	57661	57667	O
insights	57668	57676	O
into	57677	57681	O
intratumor	57682	57692	O
heterogeneity	57693	57706	O
and	57707	57710	O
how	57711	57714	O
such	57715	57719	O
heterogeneity	57720	57733	O
can	57734	57737	O
influence	57738	57747	O
drug	57748	57752	O
efficacy	57753	57761	O
.	57761	57762	O
168	57762	57765	O
Recent	57766	57772	O
efforts	57773	57780	O
have	57781	57785	O
also	57786	57790	O
demonstrated	57791	57803	O
the	57804	57807	O
capability	57808	57818	O
to	57819	57821	O
generate	57822	57830	O
tumor	57831	57836	O
organoids	57837	57846	O
from	57847	57851	O
needle	57852	57858	O
biopsies	57859	57867	O
taken	57868	57873	O
from	57874	57878	O
HCC	57879	57882	O
and	57883	57886	O
CCC	57887	57890	O
tumors	57891	57897	O
,	57897	57898	O
as	57899	57901	O
well	57902	57906	O
as	57907	57909	O
from	57910	57914	O
comparison	57915	57925	O
nontumor	57926	57934	O
liver	57935	57940	O
biopsy	57941	57947	O
samples	57948	57955	O
from	57956	57960	O
the	57961	57964	O
same	57965	57969	O
patients	57970	57978	O
[	57979	57980	O
Fig	57980	57983	O
.	57983	57984	O

2	57985	57986	O
(	57986	57987	O
c	57987	57988	O
)	57988	57989	O
]	57989	57990	O
.	57990	57991	O
169	57991	57994	O
In	57995	57997	O
these	57998	58003	O
studies	58004	58011	O
,	58011	58012	O
organoids	58013	58022	O
derived	58023	58030	O
from	58031	58035	O
tumor	58036	58041	O
biopsies	58042	58050	O
formed	58051	58057	O
compact	58058	58065	O
spheroids	58066	58075	O
,	58075	58076	O
while	58077	58082	O
the	58083	58086	O
nontumor	58087	58095	O
samples	58096	58103	O
grew	58104	58108	O
as	58109	58111	O
larger	58112	58118	O
cystic	58119	58125	O
structures	58126	58136	O
,	58136	58137	O
and	58138	58141	O
collectively	58142	58154	O
,	58154	58155	O
the	58156	58159	O
tumor	58160	58165	O
organoids	58166	58175	O
maintained	58176	58186	O
the	58187	58190	O
genetic	58191	58198	O
alterations	58199	58210	O
identified	58211	58221	O
within	58222	58228	O
the	58229	58232	O
source	58233	58239	O
tumors	58240	58246	O
.	58246	58247	O

In	58248	58250	O
addition	58251	58259	O
,	58259	58260	O
the	58261	58264	O
organoid	58265	58273	O
cultures	58274	58282	O
were	58283	58287	O
compatible	58288	58298	O
with	58299	58303	O
the	58304	58307	O
assessment	58308	58318	O
of	58319	58321	O
drug	58322	58326	O
responses	58327	58336	O
,	58336	58337	O
with	58338	58342	O
the	58343	58346	O
HCC	58347	58350	O
-	58350	58351	O
derived	58351	58358	O
organoids	58359	58368	O
exhibiting	58369	58379	O
variable	58380	58388	O
sensitives	58389	58399	O
to	58400	58402	O
the	58403	58406	O
drug	58407	58411	O
sorafenib	58412	58421	O
.	58421	58422	O

Moving	58423	58429	O
forward	58430	58437	O
,	58437	58438	O
continuous	58439	58449	O
efforts	58450	58457	O
will	58458	58462	O
likely	58463	58469	O
focus	58470	58475	O
on	58476	58478	O
ways	58479	58483	O
to	58484	58486	O
further	58487	58494	O
integrate	58495	58504	O
organoid	58505	58513	O
culture	58514	58521	O
models	58522	58528	O
with	58529	58533	O
high	58534	58538	O
-	58538	58539	O
throughput	58539	58549	O
drug	58550	58554	O
screening	58555	58564	O
.	58564	58565	O

For	58566	58569	O
instance	58570	58578	O
,	58578	58579	O
recent	58580	58586	O
studies	58587	58594	O
examining	58595	58604	O
colorectal	58605	58615	O
cancer	58616	58622	O
have	58623	58627	O
implemented	58628	58639	O
various	58640	58647	O
automation	58648	58658	O
tools	58659	58664	O
for	58665	58668	O
pairing	58669	58676	O
the	58677	58680	O
culture	58681	58688	O
of	58689	58691	O
patient	58692	58699	O
-	58699	58700	O
derived	58700	58707	O
spheroidal	58708	58718	O
aggregates	58719	58729	O
with	58730	58734	O
the	58735	58738	O
evaluation	58739	58749	O
of	58750	58752	O
>	58753	58754	O
2400	58754	58758	O
drugs	58759	58764	O
.	58764	58765	O
170	58765	58768	O
Modification	58769	58781	O
of	58782	58784	O
the	58785	58788	O
culture	58789	58796	O
configurations	58797	58811	O
may	58812	58815	O
also	58816	58820	O
enable	58821	58827	O
increased	58828	58837	O
throughput	58838	58848	O
.	58848	58849	O

For	58850	58853	O
example	58854	58861	O
,	58861	58862	O
the	58863	58866	O
establishment	58867	58880	O
of	58881	58883	O
tumor	58884	58889	O
organoids	58890	58899	O
as	58900	58902	O
rings	58903	58908	O
around	58909	58915	O
the	58916	58919	O
exterior	58920	58928	O
of	58929	58931	O
the	58932	58935	O
culture	58936	58943	O
wells	58944	58949	O
can	58950	58953	O
help	58954	58958	O
to	58959	58961	O
facilitate	58962	58972	O
the	58973	58976	O
types	58977	58982	O
of	58983	58985	O
automated	58986	58995	O
sample	58996	59002	O
handling	59003	59011	O
required	59012	59020	O
for	59021	59024	O
large	59025	59030	O
-	59030	59031	O
scale	59031	59036	O
screens	59037	59044	O
.	59044	59045	O
171	59045	59048	O
In	59049	59051	O
addition	59052	59060	O
,	59060	59061	O
despite	59062	59069	O
the	59070	59073	O
extensive	59074	59083	O
insights	59084	59092	O
into	59093	59097	O
tumor	59098	59103	O
genetics	59104	59112	O
that	59113	59117	O
have	59118	59122	O
been	59123	59127	O
provided	59128	59136	O
by	59137	59139	O
organoid	59140	59148	O
systems	59149	59156	O
,	59156	59157	O
much	59158	59162	O
less	59163	59167	O
is	59168	59170	O
known	59171	59176	O
about	59177	59182	O
how	59183	59186	O
extracellular	59187	59200	O
signals	59201	59208	O
modulate	59209	59217	O
organoid	59218	59226	O
processes	59227	59236	O
.	59236	59237	O

For	59238	59241	O
instance	59242	59250	O
,	59250	59251	O
murine	59252	59258	O
CCC	59259	59262	O
organoids	59263	59272	O
that	59273	59277	O
show	59278	59282	O
a	59283	59284	O
reproducible	59285	59297	O
ductlike	59298	59306	O
phenotype	59307	59316	O
in	59317	59319	O
vitro	59320	59325	O
have	59326	59330	O
been	59331	59335	O
demonstrated	59336	59348	O
to	59349	59351	O
exhibit	59352	59359	O
broader	59360	59367	O
differentiation	59368	59383	O
plasticity	59384	59394	O
following	59395	59404	O
subsequent	59405	59415	O
transplantation	59416	59431	O
into	59432	59436	O
recipient	59437	59446	O
mice	59447	59451	O
,	59451	59452	O
172	59452	59455	O
which	59456	59461	O
underscores	59462	59473	O
the	59474	59477	O
involvement	59478	59489	O
of	59490	59492	O
tumor	59493	59498	O
cell	59499	59503	O
-	59503	59504	O
extrinsic	59504	59513	O
factors	59514	59521	O
.	59521	59522	O

Notably	59523	59530	O
,	59530	59531	O
by	59532	59534	O
interfacing	59535	59546	O
with	59547	59551	O
strategies	59552	59562	O
for	59563	59566	O
engineering	59567	59578	O
3D	59579	59581	O
cultures	59582	59590	O
discussed	59591	59600	O
earlier	59601	59608	O
in	59609	59611	O
this	59612	59616	O
review	59617	59623	O
,	59623	59624	O
tumor	59625	59630	O
organoid	59631	59639	O
cultures	59640	59648	O
could	59649	59654	O
ultimately	59655	59665	O
be	59666	59668	O
utilized	59669	59677	O
as	59678	59680	O
a	59681	59682	O
tool	59683	59687	O
to	59688	59690	O
investigate	59691	59702	O
the	59703	59706	O
regulatory	59707	59717	O
roles	59718	59723	O
of	59724	59726	O
factors	59727	59734	O
within	59735	59741	O
the	59742	59745	O
tumor	59746	59751	O
microenvironment	59752	59768	O
.	59768	59769	O

Such	59770	59774	O
efforts	59775	59782	O
have	59783	59787	O
recently	59788	59796	O
been	59797	59801	O
pursued	59802	59809	O
for	59810	59813	O
epithelial	59814	59824	O
stem	59825	59829	B-CL:0000034
cell	59830	59834	E-CL:0000034
organoids	59835	59844	O
,	59844	59845	O
in	59846	59848	O
which	59849	59854	O
defined	59855	59862	O
hydrogel	59863	59871	O
materials	59872	59881	O
have	59882	59886	O
provided	59887	59895	O
important	59896	59905	O
clues	59906	59911	O
into	59912	59916	O
how	59917	59920	O
the	59921	59924	O
ECM	59925	59928	O
composition	59929	59940	O
,	59940	59941	O
mechanical	59942	59952	O
stiffness	59953	59962	O
,	59962	59963	O
and	59964	59967	O
material	59968	59976	O
degradation	59977	59988	O
influence	59989	59998	O
organoid	59999	60007	O
growth	60008	60014	O
and	60015	60018	O
morphogenesis	60019	60032	O
.	60032	60033	O
173	60033	60036	O
–	60036	60037	O
175	60037	60040	O

CONCLUSION	60042	60052	O
Engineered	60053	60063	O
human	60064	60069	O
liver	60070	60075	O
platforms	60076	60085	O
with	60086	60090	O
varying	60091	60098	O
throughputs	60099	60110	O
and	60111	60114	O
technological	60115	60128	O
complexities	60129	60141	O
are	60142	60145	O
now	60146	60149	O
available	60150	60159	O
to	60160	60162	O
investigate	60163	60174	O
liver	60175	60180	O
disease	60181	60188	O
and	60189	60192	O
drug	60193	60197	O
outcomes	60198	60206	O
at	60207	60209	O
different	60210	60219	O
stages	60220	60226	O
of	60227	60229	O
preclinical	60230	60241	O
drug	60242	60246	O
development	60247	60258	O
.	60258	60259	O

The	60260	60263	O
use	60264	60267	O
of	60268	60270	O
these	60271	60276	O
platforms	60277	60286	O
will	60287	60291	O
continue	60292	60300	O
to	60301	60303	O
increase	60304	60312	O
with	60313	60317	O
continuous	60318	60328	O
participation	60329	60342	O
from	60343	60347	O
the	60348	60351	O
pharmaceutical	60352	60366	O
industry	60367	60375	O
and	60376	60379	O
regulatory	60380	60390	O
agencies	60391	60399	O
in	60400	60402	O
validating	60403	60413	O
and	60414	60417	O
adopting	60418	60426	O
commercially	60427	60439	O
available	60440	60449	O
platforms	60450	60459	O
.	60459	60460	O

Furthermore	60461	60472	O
,	60472	60473	O
these	60474	60479	O
platforms	60480	60489	O
can	60490	60493	O
be	60494	60496	O
used	60497	60501	O
for	60502	60505	O
elucidating	60506	60517	O
structure	60518	60527	O
-	60527	60528	O
function	60528	60536	O
relationships	60537	60550	O
in	60551	60553	O
liver	60554	60559	O
physiology	60560	60570	O
and	60571	60574	O
disease	60575	60582	O
.	60582	60583	O

Overall	60584	60591	O
,	60591	60592	O
we	60593	60595	O
anticipate	60596	60606	O
that	60607	60611	O
the	60612	60615	O
increased	60616	60625	O
use	60626	60629	O
of	60630	60632	O
these	60633	60638	O
optimized	60639	60648	O
in	60649	60651	O
vitro	60652	60657	O
platforms	60658	60667	O
should	60668	60674	O
reduce	60675	60681	O
the	60682	60685	O
overall	60686	60693	O
cost	60694	60698	O
of	60699	60701	O
drug	60702	60706	O
development	60707	60718	O
,	60718	60719	O
reduce	60720	60726	O
the	60727	60730	O
reliance	60731	60739	O
on	60740	60742	O
in	60743	60745	O
vivo	60746	60750	O
animal	60751	60757	O
studies	60758	60765	O
,	60765	60766	O
and	60767	60770	O
accelerate	60771	60781	O
the	60782	60785	O
market	60786	60792	O
availability	60793	60805	O
of	60806	60808	O
novel	60809	60814	O
drugs	60815	60820	O
.	60820	60821	O

The	60822	60825	O
beneficiaries	60826	60839	O
of	60840	60842	O
such	60843	60847	O
advances	60848	60856	O
will	60857	60861	O
be	60862	60864	O
patients	60865	60873	O
who	60874	60877	O
will	60878	60882	O
have	60883	60887	O
faster	60888	60894	O
and	60895	60898	O
more	60899	60903	O
cost	60904	60908	O
-	60908	60909	O
effective	60909	60918	O
access	60919	60925	O
to	60926	60928	O
highly	60929	60935	O
efficacious	60936	60947	O
and	60948	60951	O
safe	60952	60956	O
drug	60957	60961	O
therapies	60962	60971	O
.	60971	60972	O

# doc_id = PMC6930685
The	0	3	O
somatic	4	11	O
mutation	12	20	O
landscape	21	30	O
of	31	33	O
the	34	37	O
human	38	43	O
body	44	48	O

Abstract	50	58	O
Background	59	69	O
Somatic	70	77	O
mutations	78	87	O
in	88	90	O
healthy	91	98	O
tissues	99	106	O
contribute	107	117	O
to	118	120	O
aging	121	126	O
,	126	127	O
neurodegeneration	128	145	O
,	145	146	O
and	147	150	O
cancer	151	157	O
initiation	158	168	O
,	168	169	O
yet	170	173	O
they	174	178	O
remain	179	185	O
largely	186	193	O
uncharacterized	194	209	O
.	209	210	O

Results	211	218	O
To	219	221	O
gain	222	226	O
a	227	228	O
better	229	235	O
understanding	236	249	O
of	250	252	O
the	253	256	O
genome	257	263	O
-	263	264	O
wide	264	268	O
distribution	269	281	O
and	282	285	O
functional	286	296	O
impact	297	303	O
of	304	306	O
somatic	307	314	O
mutations	315	324	O
,	324	325	O
we	326	328	O
leverage	329	337	O
the	338	341	O
genomic	342	349	O
information	350	361	O
contained	362	371	O
in	372	374	O
the	375	378	O
transcriptome	379	392	O
to	393	395	O
uniformly	396	405	O
call	406	410	O
somatic	411	418	O
mutations	419	428	O
from	429	433	O
over	434	438	O
7500	439	443	O
tissue	444	450	O
samples	451	458	O
,	458	459	O
representing	460	472	O
36	473	475	O
distinct	476	484	O
tissues	485	492	O
.	492	493	O

This	494	498	O
catalog	499	506	O
,	506	507	O
containing	508	518	O
over	519	523	O
280	524	527	O
,	527	528	O
000	528	531	O
mutations	532	541	O
,	541	542	O
reveals	543	550	O
a	551	552	O
wide	553	557	O
diversity	558	567	O
of	568	570	O
tissue	571	577	O
-	577	578	O
specific	578	586	O
mutation	587	595	O
profiles	596	604	O
associated	605	615	O
with	616	620	O
gene	621	625	O
expression	626	636	O
levels	637	643	O
and	644	647	O
chromatin	648	657	O
states	658	664	O
.	664	665	O

For	666	669	O
example	670	677	O
,	677	678	O
lung	679	683	O
samples	684	691	O
with	692	696	O
low	697	700	O
expression	701	711	O
of	712	714	O
the	715	718	O
mismatch	719	727	O
-	727	728	O
repair	728	734	O
gene	735	739	O
MLH1	740	744	O
show	745	749	O
a	750	751	O
mutation	752	760	O
signature	761	770	O
of	771	773	O
deficient	774	783	O
mismatch	784	792	O
repair	793	799	O
.	799	800	O

In	801	803	O
addition	804	812	O
,	812	813	O
we	814	816	O
find	817	821	O
pervasive	822	831	O
negative	832	840	O
selection	841	850	O
acting	851	857	O
on	858	860	O
missense	861	869	O
and	870	873	O
nonsense	874	882	O
mutations	883	892	O
,	892	893	O
except	894	900	O
for	901	904	O
mutations	905	914	O
previously	915	925	O
observed	926	934	O
in	935	937	O
cancer	938	944	O
samples	945	952	O
,	952	953	O
which	954	959	O
are	960	963	O
under	964	969	O
positive	970	978	O
selection	979	988	O
and	989	992	O
are	993	996	O
highly	997	1003	O
enriched	1004	1012	O
in	1013	1015	O
many	1016	1020	O
healthy	1021	1028	O
tissues	1029	1036	O
.	1036	1037	O

Conclusions	1038	1049	O
These	1050	1055	O
findings	1056	1064	O
reveal	1065	1071	O
fundamental	1072	1083	O
patterns	1084	1092	O
of	1093	1095	O
tissue	1096	1102	O
-	1102	1103	O
specific	1103	1111	O
somatic	1112	1119	O
evolution	1120	1129	O
and	1130	1133	O
shed	1134	1138	O
light	1139	1144	O
on	1145	1147	O
aging	1148	1153	O
and	1154	1157	O
the	1158	1161	O
earliest	1162	1170	O
stages	1171	1177	O
of	1178	1180	O
tumorigenesis	1181	1194	O
.	1194	1195	O

Background	1197	1207	O
In	1208	1210	O
humans	1211	1217	O
,	1217	1218	O
somatic	1219	1226	O
mutations	1227	1236	O
play	1237	1241	O
a	1242	1243	O
key	1244	1247	O
role	1248	1252	O
in	1253	1255	O
senescence	1256	1266	O
and	1267	1270	O
tumorigenesis	1271	1284	O
[	1285	1286	O
1	1286	1287	O
]	1287	1288	O
.	1288	1289	O

Pioneering	1290	1300	O
work	1301	1305	O
on	1306	1308	O
somatic	1309	1316	O
evolution	1317	1326	O
in	1327	1329	O
cancer	1330	1336	O
has	1337	1340	O
led	1341	1344	O
to	1345	1347	O
the	1348	1351	O
characterization	1352	1368	O
of	1369	1371	O
cancer	1372	1378	O
driver	1379	1385	O
genes	1386	1391	O
[	1392	1393	O
2	1393	1394	O
]	1394	1395	O
and	1396	1399	O
mutation	1400	1408	O
signatures	1409	1419	O
[	1420	1421	O
3	1421	1422	O
]	1422	1423	O
;	1423	1424	O
the	1425	1428	O
interplay	1429	1438	O
between	1439	1446	O
chromatin	1447	1456	O
,	1456	1457	O
nuclear	1458	1465	O
architecture	1466	1478	O
,	1478	1479	O
carcinogens	1480	1491	O
,	1491	1492	O
and	1493	1496	O
the	1497	1500	O
mutational	1501	1511	O
landscape	1512	1521	O
[	1522	1523	O
4	1523	1524	O
–	1524	1525	O
7	1525	1526	O
]	1526	1527	O
;	1527	1528	O
the	1529	1532	O
evolutionary	1533	1545	O
forces	1546	1552	O
acting	1553	1559	O
on	1560	1562	O
somatic	1563	1570	O
mutations	1571	1580	O
[	1581	1582	O
8	1582	1583	O
–	1583	1584	O
11	1584	1586	O
]	1586	1587	O
;	1587	1588	O
and	1589	1592	O
clinical	1593	1601	O
implications	1602	1614	O
of	1615	1617	O
somatic	1618	1625	O
mutations	1626	1635	O
[	1636	1637	O
12	1637	1639	O
]	1639	1640	O
.	1640	1641	O

Somatic	1642	1649	O
mutations	1650	1659	O
have	1660	1664	O
been	1665	1669	O
far	1670	1673	O
less	1674	1678	O
studied	1679	1686	O
in	1687	1689	O
healthy	1690	1697	O
human	1698	1703	O
tissues	1704	1711	O
than	1712	1716	O
in	1717	1719	O
cancer	1720	1726	O
.	1726	1727	O

Early	1728	1733	O
studies	1734	1741	O
focused	1742	1749	O
on	1750	1752	O
blood	1753	1758	O
[	1759	1760	O
13	1760	1762	O
,	1762	1763	O
14	1764	1766	O
]	1766	1767	O
as	1768	1770	O
it	1771	1773	O
is	1774	1776	O
readily	1777	1784	O
accessible	1785	1795	O
and	1796	1799	O
because	1800	1807	O
of	1808	1810	O
the	1811	1814	O
known	1815	1820	O
effects	1821	1828	O
of	1829	1831	O
immune	1832	1838	O
-	1838	1839	O
driven	1839	1845	O
somatic	1846	1853	O
mutation	1854	1862	O
.	1862	1863	O

Recently	1864	1872	O
,	1872	1873	O
somatic	1874	1881	O
mutations	1882	1891	O
have	1892	1896	O
been	1897	1901	O
characterized	1902	1915	O
in	1916	1918	O
tissues	1919	1926	O
like	1927	1931	O
the	1932	1935	O
skin	1936	1940	O
[	1941	1942	O
15	1942	1944	O
]	1944	1945	O
,	1945	1946	O
brain	1947	1952	O
[	1953	1954	O
16	1954	1956	O
,	1956	1957	O
17	1958	1960	O
]	1960	1961	O
,	1961	1962	O
esophagus	1963	1972	O
[	1973	1974	O
18	1974	1976	O
,	1976	1977	O
19	1978	1980	O
]	1980	1981	O
,	1981	1982	O
and	1983	1986	O
colon	1987	1992	O
[	1993	1994	O
20	1994	1996	O
]	1996	1997	O
.	1997	1998	O

These	1999	2004	O
studies	2005	2012	O
confirmed	2013	2022	O
that	2023	2027	O
cells	2028	2033	O
harboring	2034	2043	O
certain	2044	2051	O
mutations	2052	2061	O
expand	2062	2068	O
clonally	2069	2077	O
,	2077	2078	O
and	2079	2082	O
the	2083	2086	O
number	2087	2093	O
of	2094	2096	O
clonal	2097	2103	O
populations	2104	2115	O
—	2115	2116	O
as	2116	2118	O
well	2119	2123	O
as	2124	2126	O
the	2127	2130	O
total	2131	2136	O
number	2137	2143	O
of	2144	2146	O
somatic	2147	2154	O
mutations	2155	2164	O
—	2164	2165	O
increases	2165	2174	O
with	2175	2179	O
age	2180	2183	O
.	2183	2184	O

Additionally	2185	2197	O
,	2197	2198	O
recurrent	2199	2208	O
positively	2209	2219	O
selected	2220	2228	O
mutations	2229	2238	O
in	2239	2241	O
specific	2242	2250	O
genes	2251	2256	O
(	2257	2258	O
e	2258	2259	O
.	2259	2260	O
g	2260	2261	O
.	2261	2262	O
,	2262	2263	O
NOTCH1	2264	2270	O
)	2270	2271	O
were	2272	2276	O
observed	2277	2285	O
.	2285	2286	O

However	2287	2294	O
,	2294	2295	O
a	2296	2297	O
more	2298	2302	O
comprehensive	2303	2316	O
understanding	2317	2330	O
of	2331	2333	O
somatic	2334	2341	O
mutations	2342	2351	O
across	2352	2358	O
the	2359	2362	O
human	2363	2368	O
body	2369	2373	O
has	2374	2377	O
been	2378	2382	O
limited	2383	2390	O
by	2391	2393	O
the	2394	2397	O
small	2398	2403	O
number	2404	2410	O
of	2411	2413	O
tissues	2414	2421	O
studied	2422	2429	O
to	2430	2432	O
date	2433	2437	O
.	2437	2438	O

Most	2439	2443	O
studies	2444	2451	O
on	2452	2454	O
somatic	2455	2462	O
evolution	2463	2472	O
in	2473	2475	O
healthy	2476	2483	O
tissues	2484	2491	O
have	2492	2496	O
sequenced	2497	2506	O
DNA	2507	2510	O
from	2511	2515	O
biopsies	2516	2524	O
to	2525	2527	O
high	2528	2532	O
coverage	2533	2541	O
.	2541	2542	O

However	2543	2550	O
,	2550	2551	O
the	2552	2555	O
transcriptome	2556	2569	O
also	2570	2574	O
carries	2575	2582	O
all	2583	2586	O
the	2587	2590	O
genomic	2591	2598	O
information	2599	2610	O
of	2611	2613	O
a	2614	2615	O
cell	2616	2620	O
’	2620	2621	O
s	2621	2622	O
transcribed	2623	2634	O
genome	2635	2641	O
,	2641	2642	O
in	2643	2645	O
addition	2646	2654	O
to	2655	2657	O
RNA	2658	2661	O
-	2661	2662	O
specific	2662	2670	O
mutations	2671	2680	O
or	2681	2683	O
edits	2684	2689	O
.	2689	2690	O

RNA	2691	2694	O
-	2694	2695	O
seq	2695	2698	O
has	2699	2702	O
been	2703	2707	O
used	2708	2712	O
to	2713	2715	O
identify	2716	2724	O
germline	2725	2733	O
DNA	2734	2737	O
variants	2738	2746	O
[	2747	2748	O
21	2748	2750	O
]	2750	2751	O
,	2751	2752	O
and	2753	2756	O
recently	2757	2765	O
,	2765	2766	O
single	2767	2773	O
-	2773	2774	O
cell	2774	2778	O
(	2779	2780	O
sc	2780	2782	O
)	2782	2783	O
RNA	2784	2787	O
-	2787	2788	O
seq	2788	2791	O
was	2792	2795	O
used	2796	2800	O
to	2801	2803	O
call	2804	2808	O
DNA	2809	2812	O
somatic	2813	2820	O
mutations	2821	2830	O
in	2831	2833	O
the	2834	2837	O
pancreas	2838	2846	O
of	2847	2849	O
several	2850	2857	O
people	2858	2864	O
[	2865	2866	O
22	2866	2868	O
]	2868	2869	O
.	2869	2870	O

To	2871	2873	O
systematically	2874	2888	O
identify	2889	2897	O
somatic	2898	2905	O
mutations	2906	2915	O
in	2916	2918	O
the	2919	2922	O
human	2923	2928	O
body	2929	2933	O
and	2934	2937	O
to	2938	2940	O
investigate	2941	2952	O
their	2953	2958	O
distribution	2959	2971	O
and	2972	2975	O
functional	2976	2986	O
impact	2987	2993	O
,	2993	2994	O
we	2995	2997	O
developed	2998	3007	O
a	3008	3009	O
method	3010	3016	O
that	3017	3021	O
leverages	3022	3031	O
the	3032	3035	O
genomic	3036	3043	O
information	3044	3055	O
carried	3056	3063	O
by	3064	3066	O
RNA	3067	3070	O
to	3071	3073	O
identify	3074	3082	O
DNA	3083	3086	O
somatic	3087	3094	O
mutations	3095	3104	O
while	3105	3110	O
avoiding	3111	3119	O
most	3120	3124	O
sources	3125	3132	O
of	3133	3135	O
false	3136	3141	O
positives	3142	3151	O
.	3151	3152	O

We	3153	3155	O
applied	3156	3163	O
it	3164	3166	O
to	3167	3169	O
infer	3170	3175	O
somatic	3176	3183	O
mutations	3184	3193	O
across	3194	3200	O
36	3201	3203	O
non	3204	3207	O
-	3207	3208	O
cancerous	3208	3217	O
tissues	3218	3225	O
,	3225	3226	O
allowing	3227	3235	O
us	3236	3238	O
to	3239	3241	O
explore	3242	3249	O
the	3250	3253	O
landscape	3254	3263	O
of	3264	3266	O
somatic	3267	3274	O
mutations	3275	3284	O
throughout	3285	3295	O
the	3296	3299	O
human	3300	3305	O
body	3306	3310	O
.	3310	3311	O

Results	3313	3320	O
Somatic	3321	3328	O
mutation	3329	3337	O
calling	3338	3345	O
across	3346	3352	O
36	3353	3355	O
non	3356	3359	O
-	3359	3360	O
disease	3360	3367	O
tissues	3368	3375	O
from	3376	3380	O
547	3381	3384	O
people	3385	3391	O
Our	3392	3395	O
method	3396	3402	O
considers	3403	3412	O
genomic	3413	3420	O
positions	3421	3430	O
where	3431	3436	O
we	3437	3439	O
observed	3440	3448	O
two	3449	3452	O
alleles	3453	3460	O
in	3461	3463	O
the	3464	3467	O
RNA	3468	3471	O
-	3471	3472	O
seq	3472	3475	O
reads	3476	3481	O
and	3482	3485	O
assesses	3486	3494	O
whether	3495	3502	O
they	3503	3507	O
are	3508	3511	O
likely	3512	3518	O
to	3519	3521	O
be	3522	3524	O
bona	3525	3529	O
fide	3530	3534	O
DNA	3535	3538	O
somatic	3539	3546	O
mutations	3547	3556	O
(	3557	3558	O
Fig	3558	3561	O
.	3561	3562	O

1a	3563	3565	O
)	3565	3566	O
.	3566	3567	O

We	3568	3570	O
optimized	3571	3580	O
the	3581	3584	O
minimum	3585	3592	O
levels	3593	3599	O
of	3600	3602	O
RNA	3603	3606	O
-	3606	3607	O
seq	3607	3610	O
read	3611	3615	O
depth	3616	3621	O
,	3621	3622	O
sequence	3623	3631	O
quality	3632	3639	O
,	3639	3640	O
and	3641	3644	O
number	3645	3651	O
of	3652	3654	O
reads	3655	3660	O
supporting	3661	3671	O
the	3672	3675	O
variant	3676	3683	O
allele	3684	3690	O
to	3691	3693	O
limit	3694	3699	O
the	3700	3703	O
impact	3704	3710	O
of	3711	3713	O
sequencing	3714	3724	O
errors	3725	3731	O
(	3732	3733	O
Additional	3733	3743	O
file	3744	3748	O
1	3749	3750	O
:	3750	3751	O
Figure	3752	3758	O
S1a	3759	3762	O
;	3762	3763	O
see	3764	3767	O
the	3768	3771	O
“	3772	3773	O
Methods	3773	3780	O
”	3780	3781	O
section	3782	3789	O
)	3789	3790	O
.	3790	3791	O

We	3792	3794	O
then	3795	3799	O
applied	3800	3807	O
extensive	3808	3817	O
filters	3818	3825	O
to	3826	3828	O
eliminate	3829	3838	O
false	3839	3844	O
positives	3845	3854	O
from	3855	3859	O
biological	3860	3870	O
and	3871	3874	O
technical	3875	3884	O
sources	3885	3892	O
,	3892	3893	O
including	3894	3903	O
RNA	3904	3907	O
editing	3908	3915	O
,	3915	3916	O
sequencing	3917	3927	O
errors	3928	3934	O
,	3934	3935	O
and	3936	3939	O
mapping	3940	3947	O
errors	3948	3954	O
(	3955	3956	O
see	3956	3959	O
the	3960	3963	O
“	3964	3965	O
Methods	3965	3972	O
”	3972	3973	O
section	3974	3981	O
;	3981	3982	O
Fig	3983	3986	O
.	3986	3987	O

1b	3988	3990	O
,	3990	3991	O
c	3992	3993	O
;	3993	3994	O
Additional	3995	4005	O
file	4006	4010	O
1	4011	4012	O
:	4012	4013	O
Figure	4014	4020	O
S2a	4021	4024	O
;	4024	4025	O
Additional	4026	4036	O
file	4037	4041	O
2	4042	4043	O
:	4043	4044	O
Supplementary	4045	4058	O
Tables	4059	4065	O
legends	4066	4073	O
and	4074	4077	O
Additional	4078	4088	O
file	4089	4093	O
3	4094	4095	O
:	4095	4096	O
Table	4097	4102	O
S1	4103	4105	O
)	4105	4106	O
.	4106	4107	O

Fig	4108	4111	O
.	4111	4112	O

1A	4113	4115	O
method	4116	4122	O
to	4123	4125	O
identify	4126	4134	O
DNA	4135	4138	O
somatic	4139	4146	O
mutations	4147	4156	O
from	4157	4161	O
RNA	4162	4165	O
-	4165	4166	O
seq	4166	4169	O
.	4169	4170	O

a	4171	4172	O
A	4173	4174	O
general	4175	4182	O
overview	4183	4191	O
of	4192	4194	O
the	4195	4198	O
method	4199	4205	O
.	4205	4206	O

RNA	4207	4210	O
-	4210	4211	O
seq	4211	4214	O
reads	4215	4220	O
were	4221	4225	O
downloaded	4226	4236	O
from	4237	4241	O
GTEx	4242	4246	O
v7	4247	4249	O
(	4250	4251	O
left	4251	4255	O
)	4255	4256	O
and	4257	4260	O
processed	4261	4270	O
to	4271	4273	O
identify	4274	4282	O
positions	4283	4292	O
with	4293	4297	O
two	4298	4301	O
different	4302	4311	O
base	4312	4316	O
calls	4317	4322	O
at	4323	4325	O
a	4326	4327	O
high	4328	4332	O
confidence	4333	4343	O
.	4343	4344	O

Then	4345	4349	O
,	4349	4350	O
sources	4351	4358	O
of	4359	4361	O
biological	4362	4372	O
and	4373	4376	O
technical	4377	4386	O
artifacts	4387	4396	O
were	4397	4401	O
removed	4402	4409	O
(	4410	4411	O
right	4411	4416	O
,	4416	4417	O
see	4418	4421	O
the	4422	4425	O
“	4426	4427	O
Methods	4427	4434	O
”	4434	4435	O
section	4436	4443	O
)	4443	4444	O
.	4444	4445	O

b	4446	4447	O
Schematic	4448	4457	O
illustrating	4458	4470	O
potential	4471	4480	O
sources	4481	4488	O
of	4489	4491	O
sequence	4492	4500	O
variation	4501	4510	O
.	4510	4511	O

c	4512	4513	O
Average	4514	4521	O
percentage	4522	4532	O
of	4533	4535	O
variants	4536	4544	O
detected	4545	4553	O
in	4554	4556	O
blood	4557	4562	O
RNA	4563	4566	O
-	4566	4567	O
seq	4567	4570	O
that	4571	4575	O
are	4576	4579	O
retained	4580	4588	O
after	4589	4594	O
each	4595	4599	O
step	4600	4604	O
of	4605	4607	O
filtering	4608	4617	O
(	4618	4619	O
see	4619	4622	O
the	4623	4626	O
“	4627	4628	O
Methods	4628	4635	O
”	4635	4636	O
section	4637	4644	O
)	4644	4645	O
.	4645	4646	O

d	4647	4648	O
Validation	4649	4659	O
of	4660	4662	O
the	4663	4666	O
method	4667	4673	O
.	4673	4674	O

For	4675	4678	O
105	4679	4682	O
individuals	4683	4694	O
,	4694	4695	O
we	4696	4698	O
compared	4699	4707	O
variant	4708	4715	O
calls	4716	4721	O
from	4722	4726	O
exome	4727	4732	O
DNA	4733	4736	O
-	4736	4737	O
seq	4737	4740	O
data	4741	4745	O
with	4746	4750	O
those	4751	4756	O
from	4757	4761	O
RNA	4762	4765	O
-	4765	4766	O
seq	4766	4769	O
of	4770	4772	O
the	4773	4776	O
same	4777	4781	O
samples	4782	4789	O
.	4789	4790	O

Median	4791	4797	O
FDR	4798	4801	O
values	4802	4808	O
per	4809	4812	O
mutation	4813	4821	O
type	4822	4826	O
are	4827	4830	O
shown	4831	4836	O
,	4836	4837	O
and	4838	4841	O
they	4842	4846	O
represent	4847	4856	O
the	4857	4860	O
fraction	4861	4869	O
of	4870	4872	O
mutations	4873	4882	O
called	4883	4889	O
in	4890	4892	O
RNA	4893	4896	O
-	4896	4897	O
seq	4897	4900	O
for	4901	4904	O
which	4905	4910	O
there	4911	4916	O
are	4917	4920	O
no	4921	4923	O
exome	4924	4929	O
reads	4930	4935	O
supporting	4936	4946	O
the	4947	4950	O
same	4951	4955	O
variant	4956	4963	O
(	4964	4965	O
see	4965	4968	O
the	4969	4972	O
“	4973	4974	O
Methods	4974	4981	O
”	4981	4982	O
section	4983	4990	O
and	4991	4994	O
Additional	4995	5005	O
file	5006	5010	O
1	5011	5012	O
:	5012	5013	O
Figure	5014	5020	O
S1c	5021	5024	O
)	5024	5025	O
.	5025	5026	O

Error	5027	5032	O
bars	5033	5037	O
represent	5038	5047	O
the	5048	5051	O
95	5052	5054	O
%	5054	5055	O
confidence	5056	5066	O
interval	5067	5075	O
after	5076	5081	O
bootstrapping	5082	5095	O
10	5096	5098	O
,	5098	5099	O
000	5099	5102	O
times	5103	5108	O
Fig	5109	5112	O
.	5112	5113	O

1	5114	5115	O
A	5116	5117	O
method	5118	5124	O
to	5125	5127	O
identify	5128	5136	O
DNA	5137	5140	O
somatic	5141	5148	O
mutations	5149	5158	O
from	5159	5163	O
RNA	5164	5167	O
-	5167	5168	O
seq	5168	5171	O
.	5171	5172	O

a	5173	5174	O
A	5175	5176	O
general	5177	5184	O
overview	5185	5193	O
of	5194	5196	O
the	5197	5200	O
method	5201	5207	O
.	5207	5208	O

RNA	5209	5212	O
-	5212	5213	O
seq	5213	5216	O
reads	5217	5222	O
were	5223	5227	O
downloaded	5228	5238	O
from	5239	5243	O
GTEx	5244	5248	O
v7	5249	5251	O
(	5252	5253	O
left	5253	5257	O
)	5257	5258	O
and	5259	5262	O
processed	5263	5272	O
to	5273	5275	O
identify	5276	5284	O
positions	5285	5294	O
with	5295	5299	O
two	5300	5303	O
different	5304	5313	O
base	5314	5318	O
calls	5319	5324	O
at	5325	5327	O
a	5328	5329	O
high	5330	5334	O
confidence	5335	5345	O
.	5345	5346	O

Then	5347	5351	O
,	5351	5352	O
sources	5353	5360	O
of	5361	5363	O
biological	5364	5374	O
and	5375	5378	O
technical	5379	5388	O
artifacts	5389	5398	O
were	5399	5403	O
removed	5404	5411	O
(	5412	5413	O
right	5413	5418	O
,	5418	5419	O
see	5420	5423	O
the	5424	5427	O
“	5428	5429	O
Methods	5429	5436	O
”	5436	5437	O
section	5438	5445	O
)	5445	5446	O
.	5446	5447	O

b	5448	5449	O
Schematic	5450	5459	O
illustrating	5460	5472	O
potential	5473	5482	O
sources	5483	5490	O
of	5491	5493	O
sequence	5494	5502	O
variation	5503	5512	O
.	5512	5513	O

c	5514	5515	O
Average	5516	5523	O
percentage	5524	5534	O
of	5535	5537	O
variants	5538	5546	O
detected	5547	5555	O
in	5556	5558	O
blood	5559	5564	O
RNA	5565	5568	O
-	5568	5569	O
seq	5569	5572	O
that	5573	5577	O
are	5578	5581	O
retained	5582	5590	O
after	5591	5596	O
each	5597	5601	O
step	5602	5606	O
of	5607	5609	O
filtering	5610	5619	O
(	5620	5621	O
see	5621	5624	O
the	5625	5628	O
“	5629	5630	O
Methods	5630	5637	O
”	5637	5638	O
section	5639	5646	O
)	5646	5647	O
.	5647	5648	O

d	5649	5650	O
Validation	5651	5661	O
of	5662	5664	O
the	5665	5668	O
method	5669	5675	O
.	5675	5676	O

For	5677	5680	O
105	5681	5684	O
individuals	5685	5696	O
,	5696	5697	O
we	5698	5700	O
compared	5701	5709	O
variant	5710	5717	O
calls	5718	5723	O
from	5724	5728	O
exome	5729	5734	O
DNA	5735	5738	O
-	5738	5739	O
seq	5739	5742	O
data	5743	5747	O
with	5748	5752	O
those	5753	5758	O
from	5759	5763	O
RNA	5764	5767	O
-	5767	5768	O
seq	5768	5771	O
of	5772	5774	O
the	5775	5778	O
same	5779	5783	O
samples	5784	5791	O
.	5791	5792	O

Median	5793	5799	O
FDR	5800	5803	O
values	5804	5810	O
per	5811	5814	O
mutation	5815	5823	O
type	5824	5828	O
are	5829	5832	O
shown	5833	5838	O
,	5838	5839	O
and	5840	5843	O
they	5844	5848	O
represent	5849	5858	O
the	5859	5862	O
fraction	5863	5871	O
of	5872	5874	O
mutations	5875	5884	O
called	5885	5891	O
in	5892	5894	O
RNA	5895	5898	O
-	5898	5899	O
seq	5899	5902	O
for	5903	5906	O
which	5907	5912	O
there	5913	5918	O
are	5919	5922	O
no	5923	5925	O
exome	5926	5931	O
reads	5932	5937	O
supporting	5938	5948	O
the	5949	5952	O
same	5953	5957	O
variant	5958	5965	O
(	5966	5967	O
see	5967	5970	O
the	5971	5974	O
“	5975	5976	O
Methods	5976	5983	O
”	5983	5984	O
section	5985	5992	O
and	5993	5996	O
Additional	5997	6007	O
file	6008	6012	O
1	6013	6014	O
:	6014	6015	O
Figure	6016	6022	O
S1c	6023	6026	O
)	6026	6027	O
.	6027	6028	O

Error	6029	6034	O
bars	6035	6039	O
represent	6040	6049	O
the	6050	6053	O
95	6054	6056	O
%	6056	6057	O
confidence	6058	6068	O
interval	6069	6077	O
after	6078	6083	O
bootstrapping	6084	6097	O
10	6098	6100	O
,	6100	6101	O
000	6101	6104	O
times	6105	6110	O
To	6111	6113	O
validate	6114	6122	O
the	6123	6126	O
method	6127	6133	O
,	6133	6134	O
we	6135	6137	O
compared	6138	6146	O
somatic	6147	6154	O
mutation	6155	6163	O
calls	6164	6169	O
from	6170	6174	O
105	6175	6178	O
blood	6179	6184	O
RNA	6185	6188	O
-	6188	6189	O
seq	6189	6192	O
samples	6193	6200	O
to	6201	6203	O
exome	6204	6209	O
DNA	6210	6213	O
sequencing	6214	6224	O
performed	6225	6234	O
on	6235	6237	O
the	6238	6241	O
same	6242	6246	O
samples	6247	6254	O
(	6255	6256	O
GTEx	6256	6260	O
Consortium	6261	6271	O
,	6271	6272	O
2017	6273	6277	O
)	6277	6278	O
(	6279	6280	O
Fig	6280	6283	O
.	6283	6284	O

1d	6285	6287	O
)	6287	6288	O
.	6288	6289	O

We	6290	6292	O
observed	6293	6301	O
a	6302	6303	O
false	6304	6309	O
-	6309	6310	O
discovery	6310	6319	O
rate	6320	6324	O
(	6325	6326	O
FDR	6326	6329	O
)	6329	6330	O
of	6331	6333	O
29	6334	6336	O
%	6336	6337	O
which	6338	6343	O
represents	6344	6354	O
the	6355	6358	O
percentage	6359	6369	O
of	6370	6372	O
somatic	6373	6380	O
mutations	6381	6390	O
called	6391	6397	O
from	6398	6402	O
RNA	6403	6406	O
-	6406	6407	O
seq	6407	6410	O
not	6411	6414	O
having	6415	6421	O
evidence	6422	6430	O
in	6431	6433	O
the	6434	6437	O
corresponding	6438	6451	O
DNA	6452	6455	O
exome	6456	6461	O
-	6461	6462	O
seq	6462	6465	O
sample	6466	6472	O
(	6473	6474	O
Fig	6474	6477	O
.	6477	6478	O

1d	6479	6481	O
,	6481	6482	O
Additional	6483	6493	O
file	6494	6498	O
1	6499	6500	O
:	6500	6501	O
Figure	6502	6508	O
S1c	6509	6512	O
;	6512	6513	O
see	6514	6517	O
the	6518	6521	O
“	6522	6523	O
Methods	6523	6530	O
”	6530	6531	O
section	6532	6539	O
)	6539	6540	O
.	6540	6541	O

Mutations	6542	6551	O
with	6552	6556	O
a	6557	6558	O
higher	6559	6565	O
variant	6566	6573	O
allele	6574	6580	O
frequency	6581	6590	O
(	6591	6592	O
VAF	6592	6595	O
)	6595	6596	O
had	6597	6600	O
an	6601	6603	O
overall	6604	6611	O
lower	6612	6617	O
FDR	6618	6621	O
(	6622	6623	O
Additional	6623	6633	O
file	6634	6638	O
1	6639	6640	O
:	6640	6641	O
Figure	6642	6648	O
S1d	6649	6652	O
)	6652	6653	O
;	6653	6654	O
accounting	6655	6665	O
for	6666	6669	O
this	6670	6674	O
trend	6675	6680	O
yielded	6681	6688	O
an	6689	6691	O
estimated	6692	6701	O
34	6702	6704	O
%	6704	6705	O
FDR	6706	6709	O
for	6710	6713	O
our	6714	6717	O
complete	6718	6726	O
set	6727	6730	O
of	6731	6733	O
mutation	6734	6742	O
calls	6743	6748	O
(	6749	6750	O
see	6750	6753	O
the	6754	6757	O
“	6758	6759	O
Methods	6759	6766	O
”	6766	6767	O
section	6768	6775	O
)	6775	6776	O
.	6776	6777	O

This	6778	6782	O
is	6783	6785	O
comparable	6786	6796	O
to	6797	6799	O
the	6800	6803	O
40	6804	6806	O
%	6806	6807	O
FDR	6808	6811	O
in	6812	6814	O
a	6815	6816	O
previous	6817	6825	O
study	6826	6831	O
that	6832	6836	O
inferred	6837	6845	O
mutations	6846	6855	O
from	6856	6860	O
scRNA	6861	6866	O
-	6866	6867	O
seq	6867	6870	O
in	6871	6873	O
the	6874	6877	O
pancreas	6878	6886	O
[	6887	6888	O
22	6888	6890	O
]	6890	6891	O
.	6891	6892	O

After	6893	6898	O
applying	6899	6907	O
the	6908	6911	O
pipeline	6912	6920	O
and	6921	6924	O
filters	6925	6932	O
to	6933	6935	O
RNA	6936	6939	O
-	6939	6940	O
seq	6940	6943	O
data	6944	6948	O
from	6949	6953	O
the	6954	6957	O
GTEx	6958	6962	O
project	6963	6970	O
,	6970	6971	O
we	6972	6974	O
retained	6975	6983	O
a	6984	6985	O
total	6986	6991	O
of	6992	6994	O
7584	6995	6999	O
samples	7000	7007	O
from	7008	7012	O
36	7013	7015	O
different	7016	7025	O
tissues	7026	7033	O
and	7034	7037	O
547	7038	7041	O
different	7042	7051	O
individuals	7052	7063	O
with	7064	7068	O
no	7069	7071	O
detectable	7072	7082	O
cancer	7083	7089	O
(	7090	7091	O
Additional	7091	7101	O
file	7102	7106	O
4	7107	7108	O
:	7108	7109	O
Table	7110	7115	O
S2	7116	7118	O
)	7118	7119	O
.	7119	7120	O

This	7121	7125	O
resulted	7126	7134	O
in	7135	7137	O
a	7138	7139	O
total	7140	7145	O
of	7146	7148	O
280	7149	7152	O
,	7152	7153	O
843	7153	7156	O
unique	7157	7163	O
mutations	7164	7173	O
(	7174	7175	O
Additional	7175	7185	O
file	7186	7190	O
5	7191	7192	O
:	7192	7193	O
Table	7194	7199	O
S3	7200	7202	O
)	7202	7203	O
,	7203	7204	O
most	7205	7209	O
of	7210	7212	O
which	7213	7218	O
were	7219	7223	O
rare	7224	7228	O
across	7229	7235	O
samples	7236	7243	O
(	7244	7245	O
median	7245	7251	O
frequency	7252	7261	O
=	7262	7263	O
0	7264	7265	O
.	7265	7266	O
026	7266	7269	O
%	7269	7270	O
of	7271	7273	O
samples	7274	7281	O
;	7281	7282	O
Additional	7283	7293	O
file	7294	7298	O
1	7299	7300	O
:	7300	7301	O
Figure	7302	7308	O
S2b	7309	7312	O
)	7312	7313	O
and	7314	7317	O
across	7318	7324	O
individuals	7325	7336	O
(	7337	7338	O
median	7338	7344	O
frequency	7345	7354	O
=	7355	7356	O
0	7357	7358	O
.	7358	7359	O
37	7359	7361	O
%	7361	7362	O
of	7363	7365	O
individuals	7366	7377	O
;	7377	7378	O
Additional	7379	7389	O
file	7390	7394	O
1	7395	7396	O
:	7396	7397	O
Figure	7398	7404	O
S2c	7405	7408	O
)	7408	7409	O
.	7409	7410	O

We	7411	7413	O
found	7414	7419	O
no	7420	7422	O
enrichment	7423	7433	O
of	7434	7436	O
mutations	7437	7446	O
with	7447	7451	O
VAF	7452	7455	O
close	7456	7461	O
to	7462	7464	O
0	7465	7466	O
.	7466	7467	O
5	7467	7468	O
(	7469	7470	O
Additional	7470	7480	O
file	7481	7485	O
1	7486	7487	O
:	7487	7488	O
Figure	7489	7495	O
S1e	7496	7499	O
)	7499	7500	O
,	7500	7501	O
suggesting	7502	7512	O
that	7513	7517	O
there	7518	7523	O
is	7524	7526	O
little	7527	7533	O
contamination	7534	7547	O
of	7548	7550	O
heterozygous	7551	7563	O
germline	7564	7572	O
variants	7573	7581	O
.	7581	7582	O

We	7583	7585	O
first	7586	7591	O
investigated	7592	7604	O
the	7605	7608	O
factors	7609	7616	O
influencing	7617	7628	O
mutation	7629	7637	O
counts	7638	7644	O
per	7645	7648	O
sample	7649	7655	O
and	7656	7659	O
tissue	7660	7666	O
(	7667	7668	O
see	7668	7671	O
the	7672	7675	O
“	7676	7677	O
Methods	7677	7684	O
”	7684	7685	O
section	7686	7693	O
)	7693	7694	O
.	7694	7695	O

The	7696	7699	O
main	7700	7704	O
contributor	7705	7716	O
was	7717	7720	O
sequencing	7721	7731	O
depth	7732	7737	O
and	7738	7741	O
to	7742	7744	O
a	7745	7746	O
lesser	7747	7753	O
extent	7754	7760	O
other	7761	7766	O
biological	7767	7777	O
and	7778	7781	O
technical	7782	7791	O
factors	7792	7799	O
(	7800	7801	O
Additional	7801	7811	O
file	7812	7816	O
1	7817	7818	O
:	7818	7819	O
Figure	7820	7826	O
S2d	7827	7830	O
,	7830	7831	O
Additional	7832	7842	O
file	7843	7847	O
6	7848	7849	O
:	7849	7850	O
Table	7851	7856	O
S4	7857	7859	O
)	7859	7860	O
.	7860	7861	O

Tissues	7862	7869	O
that	7870	7874	O
have	7875	7879	O
more	7880	7884	O
mutations	7885	7894	O
than	7895	7899	O
expected	7900	7908	O
from	7909	7913	O
sequencing	7914	7924	O
depth	7925	7930	O
include	7931	7938	O
those	7939	7944	O
most	7945	7949	O
often	7950	7955	O
exposed	7956	7963	O
to	7964	7966	O
environmental	7967	7980	O
mutagens	7981	7989	O
or	7990	7992	O
with	7993	7997	O
a	7998	7999	O
high	8000	8004	O
cellular	8005	8013	O
turnover	8014	8022	O
like	8023	8027	O
the	8028	8031	O
skin	8032	8036	O
,	8036	8037	O
lung	8038	8042	O
,	8042	8043	O
blood	8044	8049	O
,	8049	8050	O
esophagus	8051	8060	O
mucosa	8061	8067	O
,	8067	8068	O
spleen	8069	8075	O
,	8075	8076	O
liver	8077	8082	O
,	8082	8083	O
and	8084	8087	O
small	8088	8093	O
intestine	8094	8103	O
(	8104	8105	O
Fig	8105	8108	O
.	8108	8109	O

2a	8110	8112	O
)	8112	8113	O
.	8113	8114	O

On	8115	8117	O
the	8118	8121	O
other	8122	8127	O
end	8128	8131	O
of	8132	8134	O
the	8135	8138	O
spectrum	8139	8147	O
are	8148	8151	O
those	8152	8157	O
with	8158	8162	O
low	8163	8166	O
environmental	8167	8180	O
exposure	8181	8189	O
or	8190	8192	O
low	8193	8196	O
cellular	8197	8205	O
turnover	8206	8214	O
such	8215	8219	O
as	8220	8222	O
the	8223	8226	O
brain	8227	8232	O
,	8232	8233	O
adrenal	8234	8241	O
gland	8242	8247	O
,	8247	8248	O
prostate	8249	8257	O
,	8257	8258	O
and	8259	8262	O
several	8263	8270	O
types	8271	8276	O
of	8277	8279	O
muscle	8280	8286	O
—	8286	8287	O
heart	8287	8292	O
,	8292	8293	O
esophagus	8294	8303	O
muscularis	8304	8314	O
,	8314	8315	O
and	8316	8319	O
skeletal	8320	8328	O
muscle	8329	8335	O
(	8336	8337	O
Fig	8337	8340	O
.	8340	8341	O

2a	8342	8344	O
)	8344	8345	O
.	8345	8346	O

Fig	8347	8350	O
.	8350	8351	O

2Cross	8352	8358	O
-	8358	8359	O
tissue	8359	8365	O
analysis	8366	8374	O
of	8375	8377	O
somatic	8378	8385	O
mutations	8386	8395	O
.	8395	8396	O

a	8397	8398	O
The	8399	8402	O
total	8403	8408	O
number	8409	8415	O
of	8416	8418	O
mutations	8419	8428	O
observed	8429	8437	O
in	8438	8440	O
a	8441	8442	O
tissue	8443	8449	O
depends	8450	8457	O
on	8458	8460	O
the	8461	8464	O
sequencing	8465	8475	O
depth	8476	8481	O
of	8482	8484	O
that	8485	8489	O
tissue	8490	8496	O
.	8496	8497	O

Sequencing	8498	8508	O
depth	8509	8514	O
is	8515	8517	O
defined	8518	8525	O
as	8526	8528	O
the	8529	8532	O
cumulative	8533	8543	O
amount	8544	8550	O
of	8551	8553	O
uniquely	8554	8562	O
mapped	8563	8569	O
reads	8570	8575	O
across	8576	8582	O
all	8583	8586	O
samples	8587	8594	O
of	8595	8597	O
a	8598	8599	O
tissue	8600	8606	O
.	8606	8607	O

A	8608	8609	O
linear	8610	8616	O
regression	8617	8627	O
line	8628	8632	O
is	8633	8635	O
shown	8636	8641	O
in	8642	8644	O
blue	8645	8649	O
;	8649	8650	O
tissues	8651	8658	O
above	8659	8664	O
it	8665	8667	O
exhibit	8668	8675	O
more	8676	8680	O
mutations	8681	8690	O
than	8691	8695	O
expected	8696	8704	O
by	8705	8707	O
sequencing	8708	8718	O
depth	8719	8724	O
,	8724	8725	O
while	8726	8731	O
tissues	8732	8739	O
below	8740	8745	O
it	8746	8748	O
show	8749	8753	O
fewer	8754	8759	O
mutations	8760	8769	O
than	8770	8774	O
expected	8775	8783	O
.	8783	8784	O

Rho	8785	8788	O
is	8789	8791	O
the	8792	8795	O
Spearman	8796	8804	O
coefficient	8805	8816	O
.	8816	8817	O

b	8818	8819	O
Examples	8820	8828	O
of	8829	8831	O
significant	8832	8843	O
mutation	8844	8852	O
associations	8853	8865	O
with	8866	8870	O
age	8871	8874	O
and	8875	8878	O
biological	8879	8889	O
sex	8890	8893	O
(	8894	8895	O
see	8895	8898	O
Additional	8899	8909	O
file	8910	8914	O
1	8915	8916	O
:	8916	8917	O
Fig	8918	8921	O
.	8921	8922	O

S4	8923	8925	O
and	8926	8929	O
Additional	8930	8940	O
file	8941	8945	O
6	8946	8947	O
:	8947	8948	O
Table	8949	8954	O
S4	8955	8957	O
for	8958	8961	O
all	8962	8965	O
tissue	8966	8972	O
data	8973	8977	O
)	8977	8978	O
.	8978	8979	O

Age	8980	8983	O
ranges	8984	8990	O
represent	8991	9000	O
the	9001	9004	O
youngest	9005	9013	O
and	9014	9017	O
oldest	9018	9024	O
quartiles	9025	9034	O
for	9035	9038	O
each	9039	9043	O
tissue	9044	9050	O
.	9050	9051	O

To	9052	9054	O
control	9055	9062	O
for	9063	9066	O
sequencing	9067	9077	O
depth	9078	9083	O
and	9084	9087	O
other	9088	9093	O
technical	9094	9103	O
artifacts	9104	9113	O
,	9113	9114	O
mutation	9115	9123	O
values	9124	9130	O
were	9131	9135	O
obtained	9136	9144	O
as	9145	9147	O
the	9148	9151	O
residuals	9152	9161	O
from	9162	9166	O
a	9167	9168	O
linear	9169	9175	O
regression	9176	9186	O
(	9187	9188	O
see	9188	9191	O
the	9192	9195	O
“	9196	9197	O
Methods	9197	9204	O
”	9204	9205	O
section	9206	9213	O
)	9213	9214	O
.	9214	9215	O

p	9216	9217	O
values	9218	9224	O
are	9225	9228	O
from	9229	9233	O
a	9234	9235	O
two	9236	9239	O
-	9239	9240	O
sided	9240	9245	O
Mann	9246	9250	O
-	9250	9251	O
Whitney	9251	9258	O
test	9259	9263	O
.	9263	9264	O

c	9265	9266	O
Caucasian	9267	9276	O
sun	9277	9280	O
-	9280	9281	O
exposed	9281	9288	O
skin	9289	9293	O
shows	9294	9299	O
a	9300	9301	O
higher	9302	9308	O
percentage	9309	9319	O
of	9320	9322	O
C	9323	9324	O
>	9324	9325	O
T	9325	9326	O
mutations	9327	9336	O
compared	9337	9345	O
to	9346	9348	O
the	9349	9352	O
sun	9353	9356	O
-	9356	9357	O
protected	9357	9366	O
skin	9367	9371	O
,	9371	9372	O
while	9373	9378	O
no	9379	9381	O
such	9382	9386	O
difference	9387	9397	O
was	9398	9401	O
seen	9402	9406	O
for	9407	9410	O
African	9411	9418	O
-	9418	9419	O
American	9419	9427	O
skin	9428	9432	O
.	9432	9433	O

p	9434	9435	O
values	9436	9442	O
are	9443	9446	O
from	9447	9451	O
two	9452	9455	O
-	9455	9456	O
sided	9456	9461	O
Mann	9462	9466	O
-	9466	9467	O
Whitney	9467	9474	O
tests	9475	9480	O
.	9480	9481	O

d	9482	9483	O
Median	9484	9490	O
variant	9491	9498	O
allele	9499	9505	O
frequency	9506	9515	O
(	9516	9517	O
VAF	9517	9520	O
)	9520	9521	O
for	9522	9525	O
each	9526	9530	O
mutation	9531	9539	O
type	9540	9544	O
based	9545	9550	O
on	9551	9553	O
their	9554	9559	O
impact	9560	9566	O
to	9567	9569	O
the	9570	9573	O
amino	9574	9579	O
acid	9580	9584	O
sequence	9585	9593	O
;	9593	9594	O
error	9595	9600	O
bars	9601	9605	O
represent	9606	9615	O
the	9616	9619	O
95	9620	9622	O
%	9622	9623	O
confidence	9624	9634	O
interval	9635	9643	O
after	9644	9649	O
bootstrapping	9650	9663	O
1000	9664	9668	O
times	9669	9674	O
;	9674	9675	O
p	9676	9677	O
values	9678	9684	O
are	9685	9688	O
from	9689	9693	O
two	9694	9697	O
-	9697	9698	O
sided	9698	9703	O
Mann	9704	9708	O
-	9708	9709	O
Whitney	9709	9716	O
tests	9717	9722	O
.	9722	9723	O

e	9724	9725	O
tSNE	9726	9730	O
plot	9731	9735	O
constructed	9736	9747	O
from	9748	9752	O
a	9753	9754	O
normalized	9755	9765	O
pentanucleotide	9766	9781	O
mutation	9782	9790	O
profile	9791	9798	O
(	9799	9800	O
the	9800	9803	O
mutated	9804	9811	O
base	9812	9816	O
plus	9817	9821	O
two	9822	9825	O
nucleotides	9826	9837	O
in	9838	9840	O
each	9841	9845	O
direction	9846	9855	O
;	9855	9856	O
see	9857	9860	O
the	9861	9864	O
“	9865	9866	O
Methods	9866	9873	O
”	9873	9874	O
section	9875	9882	O
for	9883	9886	O
normalization	9887	9900	O
details	9901	9908	O
)	9908	9909	O
and	9910	9913	O
all	9914	9917	O
samples	9918	9925	O
in	9926	9928	O
this	9929	9933	O
study	9934	9939	O
.	9939	9940	O

f	9941	9942	O
Average	9943	9950	O
silhouette	9951	9961	O
scores	9962	9968	O
representing	9969	9981	O
the	9982	9985	O
coherence	9986	9995	O
of	9996	9998	O
selected	9999	10007	O
groups	10008	10014	O
of	10015	10017	O
samples	10018	10025	O
from	10026	10030	O
the	10031	10034	O
tSNE	10035	10039	O
space	10040	10045	O
in	10046	10048	O
panel	10049	10054	O
e	10055	10056	O
;	10056	10057	O
a	10058	10059	O
score	10060	10065	O
of	10066	10068	O
1	10069	10070	O
represents	10071	10081	O
maximal	10082	10089	O
clustering	10090	10100	O
,	10100	10101	O
whereas	10102	10109	O
0	10110	10111	O
represents	10112	10122	O
no	10123	10125	O
clustering	10126	10136	O
(	10137	10138	O
see	10138	10141	O
the	10142	10145	O
“	10146	10147	O
Methods	10147	10154	O
”	10154	10155	O
section	10156	10163	O
)	10163	10164	O
.	10164	10165	O

Grouping	10166	10174	O
was	10175	10178	O
performed	10179	10188	O
by	10189	10191	O
tissue	10192	10198	O
-	10198	10199	O
of	10199	10201	O
-	10201	10202	O
origin	10202	10208	O
,	10208	10209	O
or	10210	10212	O
multiple	10213	10221	O
tissues	10222	10229	O
combined	10230	10238	O
(	10239	10240	O
red	10240	10243	O
labels	10244	10250	O
)	10250	10251	O
.	10251	10252	O

“	10253	10254	O
Grouped	10254	10261	O
by	10262	10264	O
people	10265	10271	O
”	10271	10272	O
(	10273	10274	O
green	10274	10279	O
label	10280	10285	O
)	10285	10286	O
is	10287	10289	O
an	10290	10292	O
average	10293	10300	O
silhouette	10301	10311	O
score	10312	10317	O
after	10318	10323	O
grouping	10324	10332	O
samples	10333	10340	O
by	10341	10343	O
their	10344	10349	O
person	10350	10356	O
-	10356	10357	O
of	10357	10359	O
-	10359	10360	O
origin	10360	10366	O
from	10367	10371	O
20	10372	10374	O
randomly	10375	10383	O
selected	10384	10392	O
people	10393	10399	O
.	10399	10400	O

The	10401	10404	O
blue	10405	10409	O
dashed	10410	10416	O
line	10417	10421	O
represents	10422	10432	O
the	10433	10436	O
average	10437	10444	O
random	10445	10451	O
score	10452	10457	O
expectation	10458	10469	O
after	10470	10475	O
permuting	10476	10485	O
tissue	10486	10492	O
labels	10493	10499	O
(	10500	10501	O
see	10501	10504	O
the	10505	10508	O
“	10509	10510	O
Methods	10510	10517	O
”	10517	10518	O
section	10519	10526	O
)	10526	10527	O
,	10527	10528	O
and	10529	10532	O
the	10533	10536	O
blue	10537	10541	O
stripes	10542	10549	O
are	10550	10553	O
±	10554	10555	O
two	10556	10559	O
standard	10560	10568	O
deviations	10569	10579	O
.	10579	10580	O

Error	10581	10586	O
bars	10587	10591	O
in	10592	10594	O
points	10595	10601	O
represent	10602	10611	O
the	10612	10615	O
95	10616	10618	O
%	10618	10619	O
confidence	10620	10630	O
interval	10631	10639	O
based	10640	10645	O
on	10646	10648	O
bootstrapping	10649	10662	O
10	10663	10665	O
,	10665	10666	O
000	10666	10669	O
times	10670	10675	O
.	10675	10676	O

g	10677	10678	O
Mutation	10679	10687	O
load	10688	10692	O
is	10693	10695	O
positively	10696	10706	O
associated	10707	10717	O
with	10718	10722	O
H3K9me3	10723	10730	O
and	10731	10734	O
/	10734	10735	O
or	10735	10737	O
negatively	10738	10748	O
associated	10749	10759	O
with	10760	10764	O
H3K36me3	10765	10773	O
across	10774	10780	O
most	10781	10785	O
tissues	10786	10793	O
analyzed	10794	10802	O
.	10802	10803	O

p	10804	10805	O
values	10806	10812	O
were	10813	10817	O
obtained	10818	10826	O
from	10827	10831	O
a	10832	10833	O
linear	10834	10840	O
regression	10841	10851	O
using	10852	10857	O
all	10858	10861	O
histone	10862	10869	O
modifications	10870	10883	O
as	10884	10886	O
explanatory	10887	10898	O
variables	10899	10908	O
(	10909	10910	O
see	10910	10913	O
the	10914	10917	O
“	10918	10919	O
Methods	10919	10926	O
”	10926	10927	O
section	10928	10935	O
)	10935	10936	O
.	10936	10937	O

Gray	10938	10942	O
range	10943	10948	O
denotes	10949	10956	O
non	10957	10960	O
-	10960	10961	O
significant	10961	10972	O
p	10973	10974	O
values	10975	10981	O
after	10982	10987	O
Bonferroni	10988	10998	O
correction	10999	11009	O
Fig	11010	11013	O
.	11013	11014	O

2	11015	11016	O
Cross	11017	11022	O
-	11022	11023	O
tissue	11023	11029	O
analysis	11030	11038	O
of	11039	11041	O
somatic	11042	11049	O
mutations	11050	11059	O
.	11059	11060	O

a	11061	11062	O
The	11063	11066	O
total	11067	11072	O
number	11073	11079	O
of	11080	11082	O
mutations	11083	11092	O
observed	11093	11101	O
in	11102	11104	O
a	11105	11106	O
tissue	11107	11113	O
depends	11114	11121	O
on	11122	11124	O
the	11125	11128	O
sequencing	11129	11139	O
depth	11140	11145	O
of	11146	11148	O
that	11149	11153	O
tissue	11154	11160	O
.	11160	11161	O

Sequencing	11162	11172	O
depth	11173	11178	O
is	11179	11181	O
defined	11182	11189	O
as	11190	11192	O
the	11193	11196	O
cumulative	11197	11207	O
amount	11208	11214	O
of	11215	11217	O
uniquely	11218	11226	O
mapped	11227	11233	O
reads	11234	11239	O
across	11240	11246	O
all	11247	11250	O
samples	11251	11258	O
of	11259	11261	O
a	11262	11263	O
tissue	11264	11270	O
.	11270	11271	O

A	11272	11273	O
linear	11274	11280	O
regression	11281	11291	O
line	11292	11296	O
is	11297	11299	O
shown	11300	11305	O
in	11306	11308	O
blue	11309	11313	O
;	11313	11314	O
tissues	11315	11322	O
above	11323	11328	O
it	11329	11331	O
exhibit	11332	11339	O
more	11340	11344	O
mutations	11345	11354	O
than	11355	11359	O
expected	11360	11368	O
by	11369	11371	O
sequencing	11372	11382	O
depth	11383	11388	O
,	11388	11389	O
while	11390	11395	O
tissues	11396	11403	O
below	11404	11409	O
it	11410	11412	O
show	11413	11417	O
fewer	11418	11423	O
mutations	11424	11433	O
than	11434	11438	O
expected	11439	11447	O
.	11447	11448	O

Rho	11449	11452	O
is	11453	11455	O
the	11456	11459	O
Spearman	11460	11468	O
coefficient	11469	11480	O
.	11480	11481	O

b	11482	11483	O
Examples	11484	11492	O
of	11493	11495	O
significant	11496	11507	O
mutation	11508	11516	O
associations	11517	11529	O
with	11530	11534	O
age	11535	11538	O
and	11539	11542	O
biological	11543	11553	O
sex	11554	11557	O
(	11558	11559	O
see	11559	11562	O
Additional	11563	11573	O
file	11574	11578	O
1	11579	11580	O
:	11580	11581	O
Fig	11582	11585	O
.	11585	11586	O

S4	11587	11589	O
and	11590	11593	O
Additional	11594	11604	O
file	11605	11609	O
6	11610	11611	O
:	11611	11612	O
Table	11613	11618	O
S4	11619	11621	O
for	11622	11625	O
all	11626	11629	O
tissue	11630	11636	O
data	11637	11641	O
)	11641	11642	O
.	11642	11643	O

Age	11644	11647	O
ranges	11648	11654	O
represent	11655	11664	O
the	11665	11668	O
youngest	11669	11677	O
and	11678	11681	O
oldest	11682	11688	O
quartiles	11689	11698	O
for	11699	11702	O
each	11703	11707	O
tissue	11708	11714	O
.	11714	11715	O

To	11716	11718	O
control	11719	11726	O
for	11727	11730	O
sequencing	11731	11741	O
depth	11742	11747	O
and	11748	11751	O
other	11752	11757	O
technical	11758	11767	O
artifacts	11768	11777	O
,	11777	11778	O
mutation	11779	11787	O
values	11788	11794	O
were	11795	11799	O
obtained	11800	11808	O
as	11809	11811	O
the	11812	11815	O
residuals	11816	11825	O
from	11826	11830	O
a	11831	11832	O
linear	11833	11839	O
regression	11840	11850	O
(	11851	11852	O
see	11852	11855	O
the	11856	11859	O
“	11860	11861	O
Methods	11861	11868	O
”	11868	11869	O
section	11870	11877	O
)	11877	11878	O
.	11878	11879	O

p	11880	11881	O
values	11882	11888	O
are	11889	11892	O
from	11893	11897	O
a	11898	11899	O
two	11900	11903	O
-	11903	11904	O
sided	11904	11909	O
Mann	11910	11914	O
-	11914	11915	O
Whitney	11915	11922	O
test	11923	11927	O
.	11927	11928	O

c	11929	11930	O
Caucasian	11931	11940	O
sun	11941	11944	O
-	11944	11945	O
exposed	11945	11952	O
skin	11953	11957	O
shows	11958	11963	O
a	11964	11965	O
higher	11966	11972	O
percentage	11973	11983	O
of	11984	11986	O
C	11987	11988	O
>	11988	11989	O
T	11989	11990	O
mutations	11991	12000	O
compared	12001	12009	O
to	12010	12012	O
the	12013	12016	O
sun	12017	12020	O
-	12020	12021	O
protected	12021	12030	O
skin	12031	12035	O
,	12035	12036	O
while	12037	12042	O
no	12043	12045	O
such	12046	12050	O
difference	12051	12061	O
was	12062	12065	O
seen	12066	12070	O
for	12071	12074	O
African	12075	12082	O
-	12082	12083	O
American	12083	12091	O
skin	12092	12096	O
.	12096	12097	O

p	12098	12099	O
values	12100	12106	O
are	12107	12110	O
from	12111	12115	O
two	12116	12119	O
-	12119	12120	O
sided	12120	12125	O
Mann	12126	12130	O
-	12130	12131	O
Whitney	12131	12138	O
tests	12139	12144	O
.	12144	12145	O

d	12146	12147	O
Median	12148	12154	O
variant	12155	12162	O
allele	12163	12169	O
frequency	12170	12179	O
(	12180	12181	O
VAF	12181	12184	O
)	12184	12185	O
for	12186	12189	O
each	12190	12194	O
mutation	12195	12203	O
type	12204	12208	O
based	12209	12214	O
on	12215	12217	O
their	12218	12223	O
impact	12224	12230	O
to	12231	12233	O
the	12234	12237	O
amino	12238	12243	O
acid	12244	12248	O
sequence	12249	12257	O
;	12257	12258	O
error	12259	12264	O
bars	12265	12269	O
represent	12270	12279	O
the	12280	12283	O
95	12284	12286	O
%	12286	12287	O
confidence	12288	12298	O
interval	12299	12307	O
after	12308	12313	O
bootstrapping	12314	12327	O
1000	12328	12332	O
times	12333	12338	O
;	12338	12339	O
p	12340	12341	O
values	12342	12348	O
are	12349	12352	O
from	12353	12357	O
two	12358	12361	O
-	12361	12362	O
sided	12362	12367	O
Mann	12368	12372	O
-	12372	12373	O
Whitney	12373	12380	O
tests	12381	12386	O
.	12386	12387	O

e	12388	12389	O
tSNE	12390	12394	O
plot	12395	12399	O
constructed	12400	12411	O
from	12412	12416	O
a	12417	12418	O
normalized	12419	12429	O
pentanucleotide	12430	12445	O
mutation	12446	12454	O
profile	12455	12462	O
(	12463	12464	O
the	12464	12467	O
mutated	12468	12475	O
base	12476	12480	O
plus	12481	12485	O
two	12486	12489	O
nucleotides	12490	12501	O
in	12502	12504	O
each	12505	12509	O
direction	12510	12519	O
;	12519	12520	O
see	12521	12524	O
the	12525	12528	O
“	12529	12530	O
Methods	12530	12537	O
”	12537	12538	O
section	12539	12546	O
for	12547	12550	O
normalization	12551	12564	O
details	12565	12572	O
)	12572	12573	O
and	12574	12577	O
all	12578	12581	O
samples	12582	12589	O
in	12590	12592	O
this	12593	12597	O
study	12598	12603	O
.	12603	12604	O

f	12605	12606	O
Average	12607	12614	O
silhouette	12615	12625	O
scores	12626	12632	O
representing	12633	12645	O
the	12646	12649	O
coherence	12650	12659	O
of	12660	12662	O
selected	12663	12671	O
groups	12672	12678	O
of	12679	12681	O
samples	12682	12689	O
from	12690	12694	O
the	12695	12698	O
tSNE	12699	12703	O
space	12704	12709	O
in	12710	12712	O
panel	12713	12718	O
e	12719	12720	O
;	12720	12721	O
a	12722	12723	O
score	12724	12729	O
of	12730	12732	O
1	12733	12734	O
represents	12735	12745	O
maximal	12746	12753	O
clustering	12754	12764	O
,	12764	12765	O
whereas	12766	12773	O
0	12774	12775	O
represents	12776	12786	O
no	12787	12789	O
clustering	12790	12800	O
(	12801	12802	O
see	12802	12805	O
the	12806	12809	O
“	12810	12811	O
Methods	12811	12818	O
”	12818	12819	O
section	12820	12827	O
)	12827	12828	O
.	12828	12829	O

Grouping	12830	12838	O
was	12839	12842	O
performed	12843	12852	O
by	12853	12855	O
tissue	12856	12862	O
-	12862	12863	O
of	12863	12865	O
-	12865	12866	O
origin	12866	12872	O
,	12872	12873	O
or	12874	12876	O
multiple	12877	12885	O
tissues	12886	12893	O
combined	12894	12902	O
(	12903	12904	O
red	12904	12907	O
labels	12908	12914	O
)	12914	12915	O
.	12915	12916	O

“	12917	12918	O
Grouped	12918	12925	O
by	12926	12928	O
people	12929	12935	O
”	12935	12936	O
(	12937	12938	O
green	12938	12943	O
label	12944	12949	O
)	12949	12950	O
is	12951	12953	O
an	12954	12956	O
average	12957	12964	O
silhouette	12965	12975	O
score	12976	12981	O
after	12982	12987	O
grouping	12988	12996	O
samples	12997	13004	O
by	13005	13007	O
their	13008	13013	O
person	13014	13020	O
-	13020	13021	O
of	13021	13023	O
-	13023	13024	O
origin	13024	13030	O
from	13031	13035	O
20	13036	13038	O
randomly	13039	13047	O
selected	13048	13056	O
people	13057	13063	O
.	13063	13064	O

The	13065	13068	O
blue	13069	13073	O
dashed	13074	13080	O
line	13081	13085	O
represents	13086	13096	O
the	13097	13100	O
average	13101	13108	O
random	13109	13115	O
score	13116	13121	O
expectation	13122	13133	O
after	13134	13139	O
permuting	13140	13149	O
tissue	13150	13156	O
labels	13157	13163	O
(	13164	13165	O
see	13165	13168	O
the	13169	13172	O
“	13173	13174	O
Methods	13174	13181	O
”	13181	13182	O
section	13183	13190	O
)	13190	13191	O
,	13191	13192	O
and	13193	13196	O
the	13197	13200	O
blue	13201	13205	O
stripes	13206	13213	O
are	13214	13217	O
±	13218	13219	O
two	13220	13223	O
standard	13224	13232	O
deviations	13233	13243	O
.	13243	13244	O

Error	13245	13250	O
bars	13251	13255	O
in	13256	13258	O
points	13259	13265	O
represent	13266	13275	O
the	13276	13279	O
95	13280	13282	O
%	13282	13283	O
confidence	13284	13294	O
interval	13295	13303	O
based	13304	13309	O
on	13310	13312	O
bootstrapping	13313	13326	O
10	13327	13329	O
,	13329	13330	O
000	13330	13333	O
times	13334	13339	O
.	13339	13340	O

g	13341	13342	O
Mutation	13343	13351	O
load	13352	13356	O
is	13357	13359	O
positively	13360	13370	O
associated	13371	13381	O
with	13382	13386	O
H3K9me3	13387	13394	O
and	13395	13398	O
/	13398	13399	O
or	13399	13401	O
negatively	13402	13412	O
associated	13413	13423	O
with	13424	13428	O
H3K36me3	13429	13437	O
across	13438	13444	O
most	13445	13449	O
tissues	13450	13457	O
analyzed	13458	13466	O
.	13466	13467	O

p	13468	13469	O
values	13470	13476	O
were	13477	13481	O
obtained	13482	13490	O
from	13491	13495	O
a	13496	13497	O
linear	13498	13504	O
regression	13505	13515	O
using	13516	13521	O
all	13522	13525	O
histone	13526	13533	O
modifications	13534	13547	O
as	13548	13550	O
explanatory	13551	13562	O
variables	13563	13572	O
(	13573	13574	O
see	13574	13577	O
the	13578	13581	O
“	13582	13583	O
Methods	13583	13590	O
”	13590	13591	O
section	13592	13599	O
)	13599	13600	O
.	13600	13601	O

Gray	13602	13606	O
range	13607	13612	O
denotes	13613	13620	O
non	13621	13624	O
-	13624	13625	O
significant	13625	13636	O
p	13637	13638	O
values	13639	13645	O
after	13646	13651	O
Bonferroni	13652	13662	O
correction	13663	13673	O
We	13674	13676	O
observed	13677	13685	O
similar	13686	13693	O
trends	13694	13700	O
across	13701	13707	O
all	13708	13711	O
six	13712	13715	O
possible	13716	13724	O
point	13725	13730	O
mutation	13731	13739	O
types	13740	13745	O
(	13746	13747	O
complementary	13747	13760	O
mutations	13761	13770	O
—	13770	13771	O
such	13771	13775	O
as	13776	13778	O
C	13779	13780	O
>	13780	13781	O
T	13781	13782	O
and	13783	13786	O
G	13787	13788	O
>	13788	13789	O
A	13789	13790	O
—	13790	13791	O
were	13791	13795	O
collapsed	13796	13805	O
because	13806	13813	O
when	13814	13818	O
one	13819	13822	O
is	13823	13825	O
detected	13826	13834	O
the	13835	13838	O
other	13839	13844	O
is	13845	13847	O
always	13848	13854	O
present	13855	13862	O
on	13863	13865	O
the	13866	13869	O
other	13870	13875	O
DNA	13876	13879	O
strand	13880	13886	O
)	13886	13887	O
(	13888	13889	O
Additional	13889	13899	O
file	13900	13904	O
1	13905	13906	O
:	13906	13907	O
Figure	13908	13914	O
S3a	13915	13918	O
)	13918	13919	O
.	13919	13920	O

C	13921	13922	O
>	13922	13923	O
T	13923	13924	O
and	13925	13928	O
T	13929	13930	O
>	13930	13931	O
C	13931	13932	O
mutations	13933	13942	O
were	13943	13947	O
the	13948	13951	O
most	13952	13956	O
abundant	13957	13965	O
types	13966	13971	O
,	13971	13972	O
followed	13973	13981	O
by	13982	13984	O
C	13985	13986	O
>	13986	13987	O
A	13987	13988	O
(	13989	13990	O
Additional	13990	14000	O
file	14001	14005	O
1	14006	14007	O
:	14007	14008	O
Figure	14009	14015	O
S3b	14016	14019	O
;	14019	14020	O
Additional	14021	14031	O
file	14032	14036	O
7	14037	14038	O
:	14038	14039	O
Table	14040	14045	O
S5	14046	14048	O
)	14048	14049	O
.	14049	14050	O

Mutation	14051	14059	O
load	14060	14064	O
is	14065	14067	O
affected	14068	14076	O
by	14077	14079	O
age	14080	14083	O
,	14083	14084	O
sex	14085	14088	O
,	14088	14089	O
ethnicity	14090	14099	O
,	14099	14100	O
and	14101	14104	O
natural	14105	14112	O
selection	14113	14122	O
After	14123	14128	O
controlling	14129	14140	O
for	14141	14144	O
all	14145	14148	O
known	14149	14154	O
technical	14155	14164	O
factors	14165	14172	O
(	14173	14174	O
see	14174	14177	O
the	14178	14181	O
“	14182	14183	O
Methods	14183	14190	O
”	14190	14191	O
section	14192	14199	O
)	14199	14200	O
,	14200	14201	O
we	14202	14204	O
observed	14205	14213	O
that	14214	14218	O
age	14219	14222	O
was	14223	14226	O
positively	14227	14237	O
correlated	14238	14248	O
with	14249	14253	O
mutation	14254	14262	O
load	14263	14267	O
across	14268	14274	O
most	14275	14279	O
tissues	14280	14287	O
(	14288	14289	O
Additional	14289	14299	O
file	14300	14304	O
1	14305	14306	O
:	14306	14307	O
Figure	14308	14314	O
S4a	14315	14318	O
;	14318	14319	O
29	14320	14322	O
/	14322	14323	O
36	14323	14325	O
tissues	14326	14333	O
with	14334	14338	O
Spearman	14339	14347	O
ρ	14348	14349	O
>	14350	14351	O
0	14352	14353	O
,	14353	14354	O
binomial	14355	14363	O
p	14364	14365	O
=	14366	14367	O
1	14368	14369	O
.	14369	14370	O
6	14370	14371	O
×	14372	14373	O
10	14374	14376	O
−	14376	14377	O
4	14377	14378	O
)	14378	14379	O
.	14379	14380	O

Blood	14381	14386	O
showed	14387	14393	O
the	14394	14397	O
most	14398	14402	O
significant	14403	14414	O
age	14415	14418	O
association	14419	14430	O
for	14431	14434	O
all	14435	14438	O
mutation	14439	14447	O
types	14448	14453	O
combined	14454	14462	O
(	14463	14464	O
Fig	14464	14467	O
.	14467	14468	O

2b	14469	14471	O
;	14471	14472	O
1st	14473	14476	O
–	14476	14477	O
4th	14477	14480	O
-	14480	14481	O
quartile	14481	14489	O
Wilcoxon	14490	14498	O
p	14499	14500	O
=	14501	14502	O
0	14503	14504	O
.	14504	14505	O
013	14505	14508	O
;	14508	14509	O
Spearman	14510	14518	O
ρ	14519	14520	O
=	14521	14522	O
0	14523	14524	O
.	14524	14525	O
21	14525	14527	O
,	14527	14528	O
Benjamini	14529	14538	O
-	14538	14539	O
Hochberg	14539	14547	O
[	14548	14549	O
BH	14549	14551	O
]	14551	14552	O
FDR	14553	14556	O
<	14557	14558	O
0	14559	14560	O
.	14560	14561	O
0001	14561	14565	O
)	14565	14566	O
,	14566	14567	O
whereas	14568	14575	O
the	14576	14579	O
sun	14580	14583	O
-	14583	14584	O
exposed	14584	14591	O
skin	14592	14596	O
was	14597	14600	O
the	14601	14604	O
most	14605	14609	O
significant	14610	14621	O
for	14622	14625	O
C	14626	14627	O
>	14627	14628	O
T	14628	14629	O
mutations	14630	14639	O
,	14639	14640	O
the	14641	14644	O
most	14645	14649	O
common	14650	14656	O
mutation	14657	14665	O
associated	14666	14676	O
with	14677	14681	O
UV	14682	14684	O
radiation	14685	14694	O
(	14695	14696	O
1st	14696	14699	O
–	14699	14700	O
4th	14700	14703	O
-	14703	14704	O
quartile	14704	14712	O
Wilcoxon	14713	14721	O
p	14722	14723	O
=	14724	14725	O
0	14726	14727	O
.	14727	14728	O
00041	14728	14733	O
;	14733	14734	O
Spearman	14735	14743	O
ρ	14744	14745	O
=	14746	14747	O
0	14748	14749	O
.	14749	14750	O
17	14750	14752	O
BH	14753	14755	O
-	14755	14756	O
FDR	14756	14759	O
=	14760	14761	O
0	14762	14763	O
.	14763	14764	O
02	14764	14766	O
)	14766	14767	O
.	14767	14768	O

We	14769	14771	O
observed	14772	14780	O
other	14781	14786	O
strong	14787	14793	O
age	14794	14797	O
associations	14798	14810	O
in	14811	14813	O
several	14814	14821	O
brain	14822	14827	O
regions	14828	14835	O
,	14835	14836	O
and	14837	14840	O
in	14841	14843	O
particular	14844	14854	O
the	14855	14858	O
basal	14859	14864	O
ganglia	14865	14872	O
(	14873	14874	O
Additional	14874	14884	O
file	14885	14889	O
1	14890	14891	O
:	14891	14892	O
Figure	14893	14899	O
S4a	14900	14903	O
)	14903	14904	O
,	14904	14905	O
supporting	14906	14916	O
the	14917	14920	O
hypothesis	14921	14931	O
that	14932	14936	O
somatic	14937	14944	O
mutation	14945	14953	O
load	14954	14958	O
could	14959	14964	O
contribute	14965	14975	O
to	14976	14978	O
the	14979	14982	O
increasing	14983	14993	O
risk	14994	14998	O
of	14999	15001	O
neurodegenerative	15002	15019	O
diseases	15020	15028	O
with	15029	15033	O
age	15034	15037	O
[	15038	15039	O
23	15039	15041	O
]	15041	15042	O
.	15042	15043	O

In	15044	15046	O
addition	15047	15055	O
to	15056	15058	O
age	15059	15062	O
,	15062	15063	O
other	15064	15069	O
biological	15070	15080	O
factors	15081	15088	O
also	15089	15093	O
contributed	15094	15105	O
to	15106	15108	O
somatic	15109	15116	O
mutations	15117	15126	O
.	15126	15127	O

For	15128	15131	O
example	15132	15139	O
,	15139	15140	O
women	15141	15146	O
show	15147	15151	O
a	15152	15153	O
much	15154	15158	O
greater	15159	15166	O
mutation	15167	15175	O
load	15176	15180	O
in	15181	15183	O
breast	15184	15190	O
than	15191	15195	O
men	15196	15199	O
(	15200	15201	O
Fig	15201	15204	O
.	15204	15205	O

2b	15206	15208	O
;	15208	15209	O
Wilcoxon	15210	15218	O
p	15219	15220	O
=	15221	15222	O
1	15223	15224	O
.	15224	15225	O
7	15225	15226	O
×	15227	15228	O
10	15229	15231	O
−	15231	15232	O
8	15232	15233	O
)	15233	15234	O
.	15234	15235	O

We	15236	15238	O
also	15239	15243	O
observed	15244	15252	O
female	15253	15259	O
-	15259	15260	O
biased	15260	15266	O
mutations	15267	15276	O
(	15277	15278	O
BH	15278	15280	O
-	15280	15281	O
FDR	15281	15284	O
<	15285	15286	O
0	15287	15288	O
.	15288	15289	O
1	15289	15290	O
)	15290	15291	O
in	15292	15294	O
the	15295	15298	O
subcutaneous	15299	15311	O
adipose	15312	15319	O
,	15319	15320	O
visceral	15321	15329	O
adipose	15330	15337	O
,	15337	15338	O
liver	15339	15344	O
,	15344	15345	O
and	15346	15349	O
adrenal	15350	15357	O
gland	15358	15363	O
;	15363	15364	O
in	15365	15367	O
contrast	15368	15376	O
,	15376	15377	O
we	15378	15380	O
found	15381	15386	O
no	15387	15389	O
significant	15390	15401	O
male	15402	15406	O
-	15406	15407	O
biased	15407	15413	O
mutations	15414	15423	O
after	15424	15429	O
multiple	15430	15438	O
hypothesis	15439	15449	O
correction	15450	15460	O
(	15461	15462	O
Additional	15462	15472	O
file	15473	15477	O
1	15478	15479	O
:	15479	15480	O
Figure	15481	15487	O
S4c	15488	15491	O
;	15491	15492	O
Additional	15493	15503	O
file	15504	15508	O
8	15509	15510	O
:	15510	15511	O
Table	15512	15517	O
S6	15518	15520	O
)	15520	15521	O
.	15521	15522	O

Ethnicity	15523	15532	O
can	15533	15536	O
also	15537	15541	O
affect	15542	15548	O
mutation	15549	15557	O
rates	15558	15563	O
:	15563	15564	O
we	15565	15567	O
found	15568	15573	O
a	15574	15575	O
significant	15576	15587	O
increase	15588	15596	O
of	15597	15599	O
C	15600	15601	O
>	15601	15602	O
T	15602	15603	O
mutations	15604	15613	O
in	15614	15616	O
Caucasian	15617	15626	O
sun	15627	15630	O
-	15630	15631	O
exposed	15631	15638	O
skin	15639	15643	O
compared	15644	15652	O
to	15653	15655	O
non	15656	15659	O
-	15659	15660	O
exposed	15660	15667	O
skin	15668	15672	O
,	15672	15673	O
but	15674	15677	O
no	15678	15680	O
corresponding	15681	15694	O
difference	15695	15705	O
in	15706	15708	O
African	15709	15716	O
-	15716	15717	O
Americans	15717	15726	O
(	15727	15728	O
Fig	15728	15731	O
.	15731	15732	O

2c	15733	15735	O
,	15735	15736	O
Additional	15737	15747	O
file	15748	15752	O
1	15753	15754	O
:	15754	15755	O
Figure	15756	15762	O
S4b	15763	15766	O
)	15766	15767	O
,	15767	15768	O
likely	15769	15775	O
due	15776	15779	O
to	15780	15782	O
protection	15783	15793	O
against	15794	15801	O
UV	15802	15804	O
radiation	15805	15814	O
provided	15815	15823	O
by	15824	15826	O
higher	15827	15833	O
melanin	15834	15841	O
content	15842	15849	O
.	15849	15850	O

Finally	15851	15858	O
,	15858	15859	O
we	15860	15862	O
observed	15863	15871	O
that	15872	15876	O
the	15877	15880	O
number	15881	15887	O
of	15888	15890	O
stem	15891	15895	B-CL:0000034
cell	15896	15900	E-CL:0000034
divisions	15901	15910	O
[	15911	15912	O
24	15912	15914	O
]	15914	15915	O
in	15916	15918	O
a	15919	15920	O
tissue	15921	15927	O
was	15928	15931	O
weakly	15932	15938	O
correlated	15939	15949	O
with	15950	15954	O
mutation	15955	15963	O
load	15964	15968	O
(	15969	15970	O
Additional	15970	15980	O
file	15981	15985	O
9	15986	15987	O
:	15987	15988	O
Note	15989	15993	O
S1	15994	15996	O
,	15996	15997	O
Additional	15998	16008	O
file	16009	16013	O
1	16014	16015	O
:	16015	16016	O
Figure	16017	16023	O
S5	16024	16026	O
)	16026	16027	O
.	16027	16028	O

To	16029	16031	O
investigate	16032	16043	O
the	16044	16047	O
role	16048	16052	O
of	16053	16055	O
natural	16056	16063	O
selection	16064	16073	O
on	16074	16076	O
somatic	16077	16084	O
mutations	16085	16094	O
,	16094	16095	O
we	16096	16098	O
examined	16099	16107	O
the	16108	16111	O
variant	16112	16119	O
allele	16120	16126	O
frequency	16127	16136	O
(	16137	16138	O
VAF	16138	16141	O
)	16141	16142	O
within	16143	16149	O
every	16150	16155	O
sample	16156	16162	O
where	16163	16168	O
a	16169	16170	O
given	16171	16176	O
mutation	16177	16185	O
was	16186	16189	O
observed	16190	16198	O
.	16198	16199	O

We	16200	16202	O
expected	16203	16211	O
that	16212	16216	O
most	16217	16221	O
mutations	16222	16231	O
we	16232	16234	O
observed	16235	16243	O
were	16244	16248	O
present	16249	16256	O
in	16257	16259	O
clonal	16260	16266	O
expansions	16267	16277	O
of	16278	16280	O
cells	16281	16286	O
,	16286	16287	O
since	16288	16293	O
mutations	16294	16303	O
only	16304	16308	O
present	16309	16316	O
in	16317	16319	O
a	16320	16321	O
single	16322	16328	O
cell	16329	16333	O
would	16334	16339	O
be	16340	16342	O
too	16343	16346	O
rare	16347	16351	O
for	16352	16355	O
our	16356	16359	O
method	16360	16366	O
to	16367	16369	O
detect	16370	16376	O
;	16376	16377	O
therefore	16378	16387	O
,	16387	16388	O
VAFs	16389	16393	O
reflect	16394	16401	O
the	16402	16405	O
extent	16406	16412	O
of	16413	16415	O
this	16416	16420	O
expansion	16421	16430	O
,	16430	16431	O
which	16432	16437	O
can	16438	16441	O
be	16442	16444	O
affected	16445	16453	O
by	16454	16456	O
natural	16457	16464	O
selection	16465	16474	O
on	16475	16477	O
cellular	16478	16486	O
proliferation	16487	16500	O
rate	16501	16505	O
as	16506	16508	O
well	16509	16513	O
as	16514	16516	O
other	16517	16522	O
factors	16523	16530	O
such	16531	16535	O
as	16536	16538	O
how	16539	16542	O
long	16543	16547	O
the	16548	16551	O
clone	16552	16557	O
has	16558	16561	O
been	16562	16566	O
proliferating	16567	16580	O
.	16580	16581	O

In	16582	16584	O
general	16585	16592	O
,	16592	16593	O
we	16594	16596	O
expect	16597	16603	O
synonymous	16604	16614	O
mutations	16615	16624	O
that	16625	16629	O
do	16630	16632	O
not	16633	16636	O
change	16637	16643	O
the	16644	16647	O
amino	16648	16653	O
acid	16654	16658	O
sequence	16659	16667	O
to	16668	16670	O
have	16671	16675	O
the	16676	16679	O
weakest	16680	16687	O
effects	16688	16695	O
on	16696	16698	O
cellular	16699	16707	O
fitness	16708	16715	O
,	16715	16716	O
missense	16717	16725	O
variants	16726	16734	O
that	16735	16739	O
change	16740	16746	O
an	16747	16749	O
amino	16750	16755	O
acid	16756	16760	O
to	16761	16763	O
have	16764	16768	O
intermediate	16769	16781	O
effects	16782	16789	O
,	16789	16790	O
and	16791	16794	O
nonsense	16795	16803	O
mutations	16804	16813	O
that	16814	16818	O
introduce	16819	16828	O
a	16829	16830	O
premature	16831	16840	O
termination	16841	16852	O
codon	16853	16858	O
to	16859	16861	O
have	16862	16866	O
the	16867	16870	O
strongest	16871	16880	O
effects	16881	16888	O
.	16888	16889	O

These	16890	16895	O
mutations	16896	16905	O
could	16906	16911	O
then	16912	16916	O
show	16917	16921	O
differing	16922	16931	O
VAFs	16932	16936	O
according	16937	16946	O
to	16947	16949	O
how	16950	16953	O
likely	16954	16960	O
they	16961	16965	O
are	16966	16969	O
to	16970	16972	O
affect	16973	16979	O
(	16980	16981	O
and	16981	16984	O
most	16985	16989	O
likely	16990	16996	O
reduce	16997	17003	O
)	17003	17004	O
cellular	17005	17013	O
fitness	17014	17021	O
,	17021	17022	O
with	17023	17027	O
stronger	17028	17036	O
deleterious	17037	17048	O
effects	17049	17056	O
leading	17057	17064	O
to	17065	17067	O
lower	17068	17073	O
VAF	17074	17077	O
.	17077	17078	O

Indeed	17079	17085	O
,	17085	17086	O
this	17087	17091	O
was	17092	17095	O
the	17096	17099	O
pattern	17100	17107	O
we	17108	17110	O
observed	17111	17119	O
,	17119	17120	O
with	17121	17125	O
synonymous	17126	17136	O
variants	17137	17145	O
having	17146	17152	O
significantly	17153	17166	O
higher	17167	17173	O
VAF	17174	17177	O
than	17178	17182	O
both	17183	17187	O
missense	17188	17196	O
and	17197	17200	O
nonsense	17201	17209	O
variants	17210	17218	O
(	17219	17220	O
Fig	17220	17223	O
.	17223	17224	O

2d	17225	17227	O
)	17227	17228	O
.	17228	17229	O

Since	17230	17235	O
our	17236	17239	O
mutations	17240	17249	O
are	17250	17253	O
called	17254	17260	O
from	17261	17265	O
the	17266	17269	O
transcriptome	17270	17283	O
,	17283	17284	O
these	17285	17290	O
results	17291	17298	O
could	17299	17304	O
be	17305	17307	O
influenced	17308	17318	O
by	17319	17321	O
nonsense	17322	17330	O
-	17330	17331	O
mediated	17331	17339	O
decay	17340	17345	O
(	17346	17347	O
NMD	17347	17350	O
)	17350	17351	O
,	17351	17352	O
which	17353	17358	O
degrades	17359	17367	O
transcripts	17368	17379	O
containing	17380	17390	O
premature	17391	17400	O
termination	17401	17412	O
codons	17413	17419	O
.	17419	17420	O

While	17421	17426	O
we	17427	17429	O
did	17430	17433	O
observe	17434	17441	O
evidence	17442	17450	O
of	17451	17453	O
NMD	17454	17457	O
(	17458	17459	O
Additional	17459	17469	O
file	17470	17474	O
1	17475	17476	O
:	17476	17477	O
Figure	17478	17484	O
S4d	17485	17488	O
)	17488	17489	O
,	17489	17490	O
we	17491	17493	O
found	17494	17499	O
that	17500	17504	O
nonsense	17505	17513	O
mutations	17514	17523	O
in	17524	17526	O
the	17527	17530	O
last	17531	17535	O
exon	17536	17540	O
of	17541	17543	O
genes	17544	17549	O
—	17549	17550	O
which	17550	17555	O
are	17556	17559	O
not	17560	17563	O
subjected	17564	17573	O
to	17574	17576	O
NMD	17577	17580	O
[	17581	17582	O
25	17582	17584	O
]	17584	17585	O
—	17585	17586	O
still	17586	17591	O
have	17592	17596	O
significantly	17597	17610	O
lower	17611	17616	O
VAF	17617	17620	O
compared	17621	17629	O
to	17630	17632	O
synonymous	17633	17643	O
and	17644	17647	O
missense	17648	17656	O
mutations	17657	17666	O
(	17667	17668	O
Wilcoxon	17668	17676	O
p	17677	17678	O
=	17679	17680	O
1	17681	17682	O
.	17682	17683	O
9	17683	17684	O
×	17685	17686	O
10	17687	17689	O
−	17689	17690	O
213	17690	17693	O
and	17694	17697	O
p	17698	17699	O
=	17700	17701	O
5	17702	17703	O
.	17703	17704	O
6	17704	17705	O
×	17706	17707	O
10	17708	17710	O
−	17710	17711	O
150	17711	17714	O
,	17714	17715	O
respectively	17716	17728	O
;	17728	17729	O
Additional	17730	17740	O
file	17741	17745	O
1	17746	17747	O
:	17747	17748	O
Figure	17749	17755	O
S4d	17756	17759	O
)	17759	17760	O
,	17760	17761	O
confirming	17762	17772	O
the	17773	17776	O
existence	17777	17786	O
of	17787	17789	O
negative	17790	17798	O
selection	17799	17808	O
against	17809	17816	O
nonsense	17817	17825	O
mutations	17826	17835	O
.	17835	17836	O

Therefore	17837	17846	O
,	17846	17847	O
in	17848	17850	O
contrast	17851	17859	O
to	17860	17862	O
what	17863	17867	O
has	17868	17871	O
been	17872	17876	O
observed	17877	17885	O
in	17886	17888	O
cancer	17889	17895	O
[	17896	17897	O
9	17897	17898	O
]	17898	17899	O
,	17899	17900	O
we	17901	17903	O
found	17904	17909	O
evidence	17910	17918	O
of	17919	17921	O
negative	17922	17930	O
selection	17931	17940	O
acting	17941	17947	O
against	17948	17955	O
both	17956	17960	O
missense	17961	17969	O
and	17970	17973	O
nonsense	17974	17982	O
mutations	17983	17992	O
.	17992	17993	O

Somatic	17994	18001	O
mutation	18002	18010	O
profiles	18011	18019	O
are	18020	18023	O
tissue	18024	18030	O
-	18030	18031	O
specific	18031	18039	O
and	18040	18043	O
associated	18044	18054	O
with	18055	18059	O
chromatin	18060	18069	O
state	18070	18075	O
To	18076	18078	O
visualize	18079	18088	O
the	18089	18092	O
tissue	18093	18099	O
specificity	18100	18111	O
of	18112	18114	O
somatic	18115	18122	O
mutational	18123	18133	O
patterns	18134	18142	O
,	18142	18143	O
we	18144	18146	O
applied	18147	18154	O
t	18155	18156	O
-	18156	18157	O
SNE	18157	18160	O
[	18161	18162	O
26	18162	18164	O
]	18164	18165	O
to	18166	18168	O
the	18169	18172	O
full	18173	18177	O
set	18178	18181	O
of	18182	18184	O
mutations	18185	18194	O
called	18195	18201	O
in	18202	18204	O
each	18205	18209	O
of	18210	18212	O
the	18213	18216	O
7584	18217	18221	O
tissue	18222	18228	O
samples	18229	18236	O
(	18237	18238	O
including	18238	18247	O
the	18248	18251	O
2	18252	18253	O
-	18253	18254	O
bp	18254	18256	O
flanking	18257	18265	O
each	18266	18270	O
mutation	18271	18279	O
;	18279	18280	O
see	18281	18284	O
the	18285	18288	O
“	18289	18290	O
Methods	18290	18297	O
”	18297	18298	O
section	18299	18306	O
;	18306	18307	O
Fig	18308	18311	O
.	18311	18312	O

2e	18313	18315	O
)	18315	18316	O
.	18316	18317	O

We	18318	18320	O
then	18321	18325	O
used	18326	18330	O
a	18331	18332	O
silhouette	18333	18343	O
score	18344	18349	O
(	18350	18351	O
SS	18351	18353	O
)	18353	18354	O
to	18355	18357	O
quantify	18358	18366	O
clustering	18367	18377	O
of	18378	18380	O
samples	18381	18388	O
in	18389	18391	O
this	18392	18396	O
two	18397	18400	O
-	18400	18401	O
dimensional	18401	18412	O
space	18413	18418	O
(	18419	18420	O
see	18420	18423	O
the	18424	18427	O
“	18428	18429	O
Methods	18429	18436	O
”	18436	18437	O
section	18438	18445	O
)	18445	18446	O
,	18446	18447	O
where	18448	18453	O
a	18454	18455	O
value	18456	18461	O
SS	18462	18464	O
=	18465	18466	O
1	18467	18468	O
indicates	18469	18478	O
samples	18479	18486	O
that	18487	18491	O
are	18492	18495	O
maximally	18496	18505	O
clustered	18506	18515	O
within	18516	18522	O
a	18523	18524	O
group	18525	18530	O
and	18531	18534	O
a	18535	18536	O
value	18537	18542	O
SS	18543	18545	O
=	18546	18547	O
0	18548	18549	O
means	18550	18555	O
that	18556	18560	O
samples	18561	18568	O
are	18569	18572	O
equidistant	18573	18584	O
to	18585	18587	O
samples	18588	18595	O
within	18596	18602	O
vs	18603	18605	O
outside	18606	18613	O
a	18614	18615	O
group	18616	18621	O
.	18621	18622	O

Grouping	18623	18631	O
samples	18632	18639	O
by	18640	18642	O
their	18643	18648	O
donor	18649	18654	O
-	18654	18655	O
of	18655	18657	O
-	18657	18658	O
origin	18658	18664	O
results	18665	18672	O
in	18673	18675	O
a	18676	18677	O
mean	18678	18682	O
SS	18683	18685	O
=	18686	18687	O
0	18688	18689	O
,	18689	18690	O
no	18691	18693	O
different	18694	18703	O
than	18704	18708	O
expected	18709	18717	O
by	18718	18720	O
chance	18721	18727	O
(	18728	18729	O
Fig	18729	18732	O
.	18732	18733	O

2f	18734	18736	O
)	18736	18737	O
.	18737	18738	O

However	18739	18746	O
,	18746	18747	O
grouping	18748	18756	O
samples	18757	18764	O
by	18765	18767	O
tissue	18768	18774	O
resulted	18775	18783	O
in	18784	18786	O
values	18787	18793	O
0	18794	18795	O
.	18795	18796	O
7	18796	18797	O
>	18798	18799	O
SS	18800	18802	O
>	18803	18804	O
0	18805	18806	O
.	18806	18807	O
1	18807	18808	O
,	18808	18809	O
suggesting	18810	18820	O
tissue	18821	18827	O
-	18827	18828	O
specific	18828	18836	O
mutation	18837	18845	O
patterns	18846	18854	O
.	18854	18855	O

The	18856	18859	O
spleen	18860	18866	O
,	18866	18867	O
blood	18868	18873	O
,	18873	18874	O
skin	18875	18879	O
,	18879	18880	O
liver	18881	18886	O
,	18886	18887	O
and	18888	18891	O
esophagus	18892	18901	O
mucosa	18902	18908	O
exhibited	18909	18918	O
the	18919	18922	O
most	18923	18927	O
coherent	18928	18936	O
profiles	18937	18945	O
(	18946	18947	O
Fig	18947	18950	O
.	18950	18951	O

2f	18952	18954	O
,	18954	18955	O
Additional	18956	18966	O
file	18967	18971	O
1	18972	18973	O
:	18973	18974	O
Figure	18975	18981	O
S6a	18982	18985	O
,	18985	18986	O
d	18987	18988	O
)	18988	18989	O
;	18989	18990	O
conversely	18991	19001	O
,	19001	19002	O
the	19003	19006	O
artery	19007	19013	O
,	19013	19014	O
lung	19015	19019	O
,	19019	19020	O
stomach	19021	19028	O
,	19028	19029	O
and	19030	19033	O
thyroid	19034	19041	O
had	19042	19045	O
the	19046	19049	O
least	19050	19055	O
consistent	19056	19066	O
profiles	19067	19075	O
(	19076	19077	O
Fig	19077	19080	O
.	19080	19081	O

2f	19082	19084	O
,	19084	19085	O
Additional	19086	19096	O
file	19097	19101	O
1	19102	19103	O
:	19103	19104	O
Figure	19105	19111	O
S6e	19112	19115	O
,	19115	19116	O
f	19117	19118	O
)	19118	19119	O
.	19119	19120	O

Interestingly	19121	19134	O
,	19134	19135	O
some	19136	19140	O
tissues	19141	19148	O
cluster	19149	19156	O
together	19157	19165	O
as	19166	19168	O
shown	19169	19174	O
by	19175	19177	O
SSs	19178	19181	O
obtained	19182	19190	O
by	19191	19193	O
grouping	19194	19202	O
samples	19203	19210	O
from	19211	19215	O
more	19216	19220	O
than	19221	19225	O
one	19226	19229	O
tissue	19230	19236	O
,	19236	19237	O
suggesting	19238	19248	O
shared	19249	19255	O
mutagenic	19256	19265	O
or	19266	19268	O
repair	19269	19275	O
processes	19276	19285	O
(	19286	19287	O
Fig	19287	19290	O
.	19290	19291	O

2f	19292	19294	O
;	19294	19295	O
Additional	19296	19306	O
file	19307	19311	O
1	19312	19313	O
:	19313	19314	O
Figure	19315	19321	O
S6b	19322	19325	O
,	19325	19326	O
c	19327	19328	O
;	19328	19329	O
e	19330	19331	O
.	19331	19332	O
g	19332	19333	O
.	19333	19334	O
,	19334	19335	O
skeletal	19336	19344	O
muscle	19345	19351	O
and	19352	19355	O
heart	19356	19361	O
,	19361	19362	O
SS	19363	19365	O
=	19366	19367	O
0	19368	19369	O
.	19369	19370	O
38	19370	19372	O
;	19372	19373	O
seven	19374	19379	O
brain	19380	19385	O
regions	19386	19393	O
,	19393	19394	O
SS	19395	19397	O
=	19398	19399	O
0	19400	19401	O
.	19401	19402	O
53	19402	19404	O
;	19404	19405	O
colon	19406	19411	O
and	19412	19415	O
small	19416	19421	O
intestine	19422	19431	O
,	19431	19432	O
SS	19433	19435	O
=	19436	19437	O
0	19438	19439	O
.	19439	19440	O
31	19440	19442	O
)	19442	19443	O
.	19443	19444	O

These	19445	19450	O
results	19451	19458	O
suggest	19459	19466	O
that	19467	19471	O
the	19472	19475	O
somatic	19476	19483	O
mutation	19484	19492	O
landscape	19493	19502	O
of	19503	19505	O
the	19506	19509	O
transcribed	19510	19521	O
genome	19522	19528	O
is	19529	19531	O
largely	19532	19539	O
defined	19540	19547	O
by	19548	19550	O
tissue	19551	19557	O
-	19557	19558	O
of	19558	19560	O
-	19560	19561	O
origin	19561	19567	O
.	19567	19568	O

To	19569	19571	O
explore	19572	19579	O
the	19580	19583	O
source	19584	19590	O
of	19591	19593	O
this	19594	19598	O
tissue	19599	19605	O
specificity	19606	19617	O
,	19617	19618	O
we	19619	19621	O
hypothesized	19622	19634	O
that	19635	19639	O
chromatin	19640	19649	O
may	19650	19653	O
play	19654	19658	O
an	19659	19661	O
important	19662	19671	O
role	19672	19676	O
,	19676	19677	O
as	19678	19680	O
it	19681	19683	O
does	19684	19688	O
in	19689	19691	O
cancer	19692	19698	O
[	19699	19700	O
4	19700	19701	O
,	19701	19702	O
5	19703	19704	O
]	19704	19705	O
.	19705	19706	O

We	19707	19709	O
assessed	19710	19718	O
the	19719	19722	O
association	19723	19734	O
between	19735	19742	O
tissue	19743	19749	O
-	19749	19750	O
specific	19750	19758	O
mutation	19759	19767	O
rates	19768	19773	O
and	19774	19777	O
five	19778	19782	O
histone	19783	19790	O
modifications	19791	19804	O
measured	19805	19813	O
across	19814	19820	O
many	19821	19825	O
human	19826	19831	O
tissues	19832	19839	O
by	19840	19842	O
the	19843	19846	O
Roadmap	19847	19854	O
Epigenomics	19855	19866	O
Project	19867	19874	O
[	19875	19876	O
27	19876	19878	O
]	19878	19879	O
(	19880	19881	O
Additional	19881	19891	O
file	19892	19896	O
10	19897	19899	O
:	19899	19900	O
Table	19901	19906	O
S7	19907	19909	O
;	19909	19910	O
see	19911	19914	O
the	19915	19918	O
“	19919	19920	O
Methods	19920	19927	O
”	19927	19928	O
section	19929	19936	O
)	19936	19937	O
.	19937	19938	O

Across	19939	19945	O
most	19946	19950	O
tissues	19951	19958	O
(	19959	19960	O
except	19960	19966	O
the	19967	19970	O
brain	19971	19976	O
)	19976	19977	O
,	19977	19978	O
there	19979	19984	O
is	19985	19987	O
a	19988	19989	O
strong	19990	19996	O
positive	19997	20005	O
association	20006	20017	O
between	20018	20025	O
mutation	20026	20034	O
rate	20035	20039	O
and	20040	20043	O
a	20044	20045	O
marker	20046	20052	O
for	20053	20056	O
heterochromatin	20057	20072	O
(	20073	20074	O
H3K9me3	20074	20081	O
)	20081	20082	O
;	20082	20083	O
conversely	20084	20094	O
,	20094	20095	O
we	20096	20098	O
found	20099	20104	O
strong	20105	20111	O
negative	20112	20120	O
associations	20121	20133	O
with	20134	20138	O
actively	20139	20147	O
transcribed	20148	20159	O
regions	20160	20167	O
(	20168	20169	O
H3K36me3	20169	20177	O
;	20177	20178	O
Fig	20179	20182	O
.	20182	20183	O

2g	20184	20186	O
;	20186	20187	O
Additional	20188	20198	O
file	20199	20203	O
1	20204	20205	O
:	20205	20206	O
Figure	20207	20213	O
S4e	20214	20217	O
)	20217	20218	O
.	20218	20219	O

These	20220	20225	O
results	20226	20233	O
suggest	20234	20241	O
that	20242	20246	O
chromatin	20247	20256	O
associations	20257	20269	O
with	20270	20274	O
mutation	20275	20283	O
rates	20284	20289	O
in	20290	20292	O
the	20293	20296	O
human	20297	20302	O
body	20303	20307	O
are	20308	20311	O
nearly	20312	20318	O
ubiquitous	20319	20329	O
and	20330	20333	O
arise	20334	20339	O
prior	20340	20345	O
to	20346	20348	O
cancer	20349	20355	O
development	20356	20367	O
.	20367	20368	O

Mutational	20369	20379	O
strand	20380	20386	O
asymmetries	20387	20398	O
are	20399	20402	O
widespread	20403	20413	O
and	20414	20417	O
vary	20418	20422	O
across	20423	20429	O
individuals	20430	20441	O
Cancer	20442	20448	O
mutations	20449	20458	O
often	20459	20464	O
occur	20465	20470	O
preferentially	20471	20485	O
on	20486	20488	O
one	20489	20492	O
DNA	20493	20496	O
strand	20497	20503	O
,	20503	20504	O
either	20505	20511	O
in	20512	20514	O
reference	20515	20524	O
to	20525	20527	O
transcription	20528	20541	O
or	20542	20544	O
to	20545	20547	O
DNA	20548	20551	O
replication	20552	20563	O
(	20564	20565	O
leading	20565	20572	O
vs	20573	20575	O
lagging	20576	20583	O
strand	20584	20590	O
)	20590	20591	O
[	20592	20593	O
28	20593	20595	O
]	20595	20596	O
.	20596	20597	O

Since	20598	20603	O
our	20604	20607	O
mutations	20608	20617	O
are	20618	20621	O
derived	20622	20629	O
from	20630	20634	O
transcribed	20635	20646	O
exons	20647	20652	O
,	20652	20653	O
we	20654	20656	O
focused	20657	20664	O
on	20665	20667	O
transcriptional	20668	20683	O
mutational	20684	20694	O
strand	20695	20701	O
asymmetries	20702	20713	O
.	20713	20714	O

We	20715	20717	O
observed	20718	20726	O
the	20727	20730	O
strongest	20731	20740	O
asymmetry	20741	20750	O
for	20751	20754	O
C	20755	20756	O
>	20756	20757	O
A	20757	20758	O
mutations	20759	20768	O
,	20768	20769	O
which	20770	20775	O
preferentially	20776	20790	O
occur	20791	20796	O
on	20797	20799	O
the	20800	20803	O
transcribed	20804	20815	O
strand	20816	20822	O
in	20823	20825	O
most	20826	20830	O
tissues	20831	20838	O
except	20839	20845	O
for	20846	20849	O
the	20850	20853	O
brain	20854	20859	O
(	20860	20861	O
Fig	20861	20864	O
.	20864	20865	O

3a	20866	20868	O
,	20868	20869	O
b	20870	20871	O
;	20871	20872	O
mean	20873	20877	O
[	20878	20879	O
transcribed	20879	20890	O
/	20890	20891	O
non	20891	20894	O
-	20894	20895	O
transcribed	20895	20906	O
]	20906	20907	O
ratio	20908	20913	O
=	20914	20915	O
1	20916	20917	O
.	20917	20918	O
6	20918	20919	O
in	20920	20922	O
the	20923	20926	O
non	20927	20930	O
-	20930	20931	O
brain	20931	20936	O
,	20936	20937	O
0	20938	20939	O
.	20939	20940	O
98	20940	20942	O
in	20943	20945	O
the	20946	20949	O
brain	20950	20955	O
)	20955	20956	O
.	20956	20957	O

C	20958	20959	O
>	20959	20960	O
A	20960	20961	O
mutation	20962	20970	O
load	20971	20975	O
on	20976	20978	O
the	20979	20982	O
transcribed	20983	20994	O
strand	20995	21001	O
also	21002	21006	O
showed	21007	21013	O
the	21014	21017	O
greatest	21018	21026	O
variation	21027	21036	O
between	21037	21044	O
individuals	21045	21056	O
(	21057	21058	O
Fig	21058	21061	O
.	21061	21062	O

3a	21063	21065	O
,	21065	21066	O
b	21067	21068	O
)	21068	21069	O
.	21069	21070	O

C	21071	21072	O
>	21072	21073	O
A	21073	21074	O
asymmetries	21075	21086	O
were	21087	21091	O
often	21092	21097	O
correlated	21098	21108	O
between	21109	21116	O
different	21117	21126	O
tissues	21127	21134	O
of	21135	21137	O
the	21138	21141	O
same	21142	21146	O
person	21147	21153	O
(	21154	21155	O
Fig	21155	21158	O
.	21158	21159	O

3c	21160	21162	O
,	21162	21163	O
Additional	21164	21174	O
file	21175	21179	O
1	21180	21181	O
:	21181	21182	O
Figure	21183	21189	O
S7a	21190	21193	O
)	21193	21194	O
,	21194	21195	O
suggesting	21196	21206	O
a	21207	21208	O
common	21209	21215	O
factor	21216	21222	O
can	21223	21226	O
induce	21227	21233	O
C	21234	21235	O
>	21235	21236	O
A	21236	21237	O
mutations	21238	21247	O
specifically	21248	21260	O
on	21261	21263	O
the	21264	21267	O
transcribed	21268	21279	O
strand	21280	21286	O
(	21287	21288	O
or	21288	21290	O
equivalently	21291	21303	O
,	21303	21304	O
G	21305	21306	O
>	21306	21307	O
T	21307	21308	O
mutations	21309	21318	O
on	21319	21321	O
the	21322	21325	O
non	21326	21329	O
-	21329	21330	O
transcribed	21330	21341	O
strand	21342	21348	O
)	21348	21349	O
across	21350	21356	O
many	21357	21361	O
of	21362	21364	O
an	21365	21367	O
individual	21368	21378	O
’	21378	21379	O
s	21379	21380	O
tissues	21381	21388	O
.	21388	21389	O

This	21390	21394	O
factor	21395	21401	O
is	21402	21404	O
of	21405	21407	O
unknown	21408	21415	O
origin	21416	21422	O
;	21422	21423	O
it	21424	21426	O
could	21427	21432	O
be	21433	21435	O
intrinsic	21436	21445	O
(	21446	21447	O
e	21447	21448	O
.	21448	21449	O
g	21449	21450	O
.	21450	21451	O
,	21451	21452	O
genetic	21453	21460	O
)	21460	21461	O
,	21461	21462	O
extrinsic	21463	21472	O
(	21473	21474	O
e	21474	21475	O
.	21475	21476	O
g	21476	21477	O
.	21477	21478	O
,	21478	21479	O
exposure	21480	21488	O
to	21489	21491	O
a	21492	21493	O
mutagen	21494	21501	O
)	21501	21502	O
,	21502	21503	O
or	21504	21506	O
a	21507	21508	O
combination	21509	21520	O
of	21521	21523	O
the	21524	21527	O
two	21528	21531	O
.	21531	21532	O

Interestingly	21533	21546	O
,	21546	21547	O
this	21548	21552	O
same	21553	21557	O
C	21558	21559	O
>	21559	21560	O
A	21560	21561	O
asymmetry	21562	21571	O
has	21572	21575	O
been	21576	21580	O
observed	21581	21589	O
in	21590	21592	O
lung	21593	21597	O
and	21598	21601	O
ovarian	21602	21609	O
cancer	21610	21616	O
[	21617	21618	O
28	21618	21620	O
]	21620	21621	O
and	21622	21625	O
in	21626	21628	O
cell	21629	21633	O
lines	21634	21639	O
exposed	21640	21647	O
to	21648	21650	O
different	21651	21660	O
environmental	21661	21674	O
agents	21675	21681	O
[	21682	21683	O
29	21683	21685	O
]	21685	21686	O
;	21686	21687	O
our	21688	21691	O
results	21692	21699	O
suggest	21700	21707	O
it	21708	21710	O
is	21711	21713	O
far	21714	21717	O
more	21718	21722	O
widespread	21723	21733	O
,	21733	21734	O
occurring	21735	21744	O
in	21745	21747	O
most	21748	21752	O
tissues	21753	21760	O
except	21761	21767	O
for	21768	21771	O
the	21772	21775	O
brain	21776	21781	O
.	21781	21782	O

Fig	21783	21786	O
.	21786	21787	O

3Somatic	21788	21796	O
mutational	21797	21807	O
strand	21808	21814	O
asymmetries	21815	21826	O
.	21826	21827	O

a	21828	21829	O
Mutation	21830	21838	O
average	21839	21846	O
and	21847	21850	O
S	21851	21852	O
.	21852	21853	O
D	21853	21854	O
.	21854	21855	O
for	21856	21859	O
each	21860	21864	O
strand	21865	21871	O
with	21872	21876	O
respect	21877	21884	O
to	21885	21887	O
transcription	21888	21901	O
(	21902	21903	O
left	21903	21907	O
and	21908	21911	O
middle	21912	21918	O
panels	21919	21925	O
)	21925	21926	O
and	21927	21930	O
the	21931	21934	O
ratio	21935	21940	O
of	21941	21943	O
mean	21944	21948	O
mutations	21949	21958	O
on	21959	21961	O
the	21962	21965	O
transcribed	21966	21977	O
over	21978	21982	O
the	21983	21986	O
non	21987	21990	O
-	21990	21991	O
transcribed	21991	22002	O
strand	22003	22009	O
(	22010	22011	O
right	22011	22016	O
panel	22017	22022	O
)	22022	22023	O
.	22023	22024	O

b	22025	22026	O
Distribution	22027	22039	O
of	22040	22042	O
z	22043	22044	O
-	22044	22045	O
scores	22045	22051	O
for	22052	22055	O
mutation	22056	22064	O
averages	22065	22073	O
and	22074	22077	O
standard	22078	22086	O
deviations	22087	22097	O
on	22098	22100	O
each	22101	22105	O
strand	22106	22112	O
(	22113	22114	O
from	22114	22118	O
panel	22119	22124	O
a	22125	22126	O
)	22126	22127	O
across	22128	22134	O
all	22135	22138	O
samples	22139	22146	O
.	22146	22147	O

c	22148	22149	O
Example	22150	22157	O
of	22158	22160	O
intra	22161	22166	O
-	22166	22167	O
individual	22167	22177	O
correlation	22178	22189	O
of	22190	22192	O
C	22193	22194	O
>	22194	22195	O
A	22195	22196	O
strand	22197	22203	O
asymmetry	22204	22213	O
in	22214	22216	O
two	22217	22220	O
tissues	22221	22228	O
;	22228	22229	O
each	22230	22234	O
point	22235	22240	O
represents	22241	22251	O
an	22252	22254	O
individual	22255	22265	O
for	22266	22269	O
which	22270	22275	O
we	22276	22278	O
generated	22279	22288	O
mutation	22289	22297	O
maps	22298	22302	O
in	22303	22305	O
the	22306	22309	O
two	22310	22313	O
tissues	22314	22321	O
(	22322	22323	O
see	22323	22326	O
Additional	22327	22337	O
file	22338	22342	O
1	22343	22344	O
:	22344	22345	O
Figure	22346	22352	O
S7a	22353	22356	O
for	22357	22360	O
all	22361	22364	O
tissue	22365	22371	O
pairwise	22372	22380	O
comparisons	22381	22392	O
)	22392	22393	O
.	22393	22394	O

d	22395	22396	O
Correlation	22397	22408	O
of	22409	22411	O
mutational	22412	22422	O
strand	22423	22429	O
biases	22430	22436	O
between	22437	22444	O
calls	22445	22450	O
from	22451	22455	O
RNA	22456	22459	O
-	22459	22460	O
seq	22460	22463	O
and	22464	22467	O
matched	22468	22475	O
DNA	22476	22479	O
-	22479	22480	O
seq	22480	22483	O
;	22483	22484	O
each	22485	22489	O
point	22490	22495	O
represents	22496	22506	O
the	22507	22510	O
mutation	22511	22519	O
strand	22520	22526	O
bias	22527	22531	O
observed	22532	22540	O
in	22541	22543	O
one	22544	22547	O
gene	22548	22552	O
across	22553	22559	O
all	22560	22563	O
105	22564	22567	O
blood	22568	22573	O
samples	22574	22581	O
.	22581	22582	O

Blue	22583	22587	O
lines	22588	22593	O
in	22594	22596	O
all	22597	22600	O
scatter	22601	22608	O
plots	22609	22614	O
are	22615	22618	O
based	22619	22624	O
on	22625	22627	O
a	22628	22629	O
linear	22630	22636	O
regression	22637	22647	O
;	22647	22648	O
rho	22649	22652	O
values	22653	22659	O
are	22660	22663	O
the	22664	22667	O
Spearman	22668	22676	O
correlation	22677	22688	O
coefficients	22689	22701	O
Fig	22702	22705	O
.	22705	22706	O

3	22707	22708	O
Somatic	22709	22716	O
mutational	22717	22727	O
strand	22728	22734	O
asymmetries	22735	22746	O
.	22746	22747	O

a	22748	22749	O
Mutation	22750	22758	O
average	22759	22766	O
and	22767	22770	O
S	22771	22772	O
.	22772	22773	O
D	22773	22774	O
.	22774	22775	O
for	22776	22779	O
each	22780	22784	O
strand	22785	22791	O
with	22792	22796	O
respect	22797	22804	O
to	22805	22807	O
transcription	22808	22821	O
(	22822	22823	O
left	22823	22827	O
and	22828	22831	O
middle	22832	22838	O
panels	22839	22845	O
)	22845	22846	O
and	22847	22850	O
the	22851	22854	O
ratio	22855	22860	O
of	22861	22863	O
mean	22864	22868	O
mutations	22869	22878	O
on	22879	22881	O
the	22882	22885	O
transcribed	22886	22897	O
over	22898	22902	O
the	22903	22906	O
non	22907	22910	O
-	22910	22911	O
transcribed	22911	22922	O
strand	22923	22929	O
(	22930	22931	O
right	22931	22936	O
panel	22937	22942	O
)	22942	22943	O
.	22943	22944	O

b	22945	22946	O
Distribution	22947	22959	O
of	22960	22962	O
z	22963	22964	O
-	22964	22965	O
scores	22965	22971	O
for	22972	22975	O
mutation	22976	22984	O
averages	22985	22993	O
and	22994	22997	O
standard	22998	23006	O
deviations	23007	23017	O
on	23018	23020	O
each	23021	23025	O
strand	23026	23032	O
(	23033	23034	O
from	23034	23038	O
panel	23039	23044	O
a	23045	23046	O
)	23046	23047	O
across	23048	23054	O
all	23055	23058	O
samples	23059	23066	O
.	23066	23067	O

c	23068	23069	O
Example	23070	23077	O
of	23078	23080	O
intra	23081	23086	O
-	23086	23087	O
individual	23087	23097	O
correlation	23098	23109	O
of	23110	23112	O
C	23113	23114	O
>	23114	23115	O
A	23115	23116	O
strand	23117	23123	O
asymmetry	23124	23133	O
in	23134	23136	O
two	23137	23140	O
tissues	23141	23148	O
;	23148	23149	O
each	23150	23154	O
point	23155	23160	O
represents	23161	23171	O
an	23172	23174	O
individual	23175	23185	O
for	23186	23189	O
which	23190	23195	O
we	23196	23198	O
generated	23199	23208	O
mutation	23209	23217	O
maps	23218	23222	O
in	23223	23225	O
the	23226	23229	O
two	23230	23233	O
tissues	23234	23241	O
(	23242	23243	O
see	23243	23246	O
Additional	23247	23257	O
file	23258	23262	O
1	23263	23264	O
:	23264	23265	O
Figure	23266	23272	O
S7a	23273	23276	O
for	23277	23280	O
all	23281	23284	O
tissue	23285	23291	O
pairwise	23292	23300	O
comparisons	23301	23312	O
)	23312	23313	O
.	23313	23314	O

d	23315	23316	O
Correlation	23317	23328	O
of	23329	23331	O
mutational	23332	23342	O
strand	23343	23349	O
biases	23350	23356	O
between	23357	23364	O
calls	23365	23370	O
from	23371	23375	O
RNA	23376	23379	O
-	23379	23380	O
seq	23380	23383	O
and	23384	23387	O
matched	23388	23395	O
DNA	23396	23399	O
-	23399	23400	O
seq	23400	23403	O
;	23403	23404	O
each	23405	23409	O
point	23410	23415	O
represents	23416	23426	O
the	23427	23430	O
mutation	23431	23439	O
strand	23440	23446	O
bias	23447	23451	O
observed	23452	23460	O
in	23461	23463	O
one	23464	23467	O
gene	23468	23472	O
across	23473	23479	O
all	23480	23483	O
105	23484	23487	O
blood	23488	23493	O
samples	23494	23501	O
.	23501	23502	O

Blue	23503	23507	O
lines	23508	23513	O
in	23514	23516	O
all	23517	23520	O
scatter	23521	23528	O
plots	23529	23534	O
are	23535	23538	O
based	23539	23544	O
on	23545	23547	O
a	23548	23549	O
linear	23550	23556	O
regression	23557	23567	O
;	23567	23568	O
rho	23569	23572	O
values	23573	23579	O
are	23580	23583	O
the	23584	23587	O
Spearman	23588	23596	O
correlation	23597	23608	O
coefficients	23609	23621	O
Strand	23622	23628	O
asymmetries	23629	23640	O
could	23641	23646	O
potentially	23647	23658	O
arise	23659	23664	O
from	23665	23669	O
RNA	23670	23673	O
-	23673	23674	O
specific	23674	23682	O
edits	23683	23688	O
or	23689	23691	O
transcriptional	23692	23707	O
errors	23708	23714	O
.	23714	23715	O

To	23716	23718	O
test	23719	23723	O
if	23724	23726	O
these	23727	23732	O
are	23733	23736	O
bona	23737	23741	O
fide	23742	23746	O
DNA	23747	23750	O
mutations	23751	23760	O
,	23760	23761	O
we	23762	23764	O
examined	23765	23773	O
exome	23774	23779	O
data	23780	23784	O
from	23785	23789	O
matching	23790	23798	O
blood	23799	23804	O
samples	23805	23812	O
and	23813	23816	O
observed	23817	23825	O
general	23826	23833	O
agreement	23834	23843	O
between	23844	23851	O
the	23852	23855	O
level	23856	23861	O
of	23862	23864	O
asymmetry	23865	23874	O
per	23875	23878	O
gene	23879	23883	O
as	23884	23886	O
measured	23887	23895	O
by	23896	23898	O
DNA	23899	23902	O
vs	23903	23905	O
RNA	23906	23909	O
-	23909	23910	O
seq	23910	23913	O
(	23914	23915	O
Fig	23915	23918	O
.	23918	23919	O

3d	23920	23922	O
)	23922	23923	O
.	23923	23924	O

In	23925	23927	O
addition	23928	23936	O
,	23936	23937	O
we	23938	23940	O
found	23941	23946	O
blood	23947	23952	O
samples	23953	23960	O
to	23961	23963	O
have	23964	23968	O
the	23969	23972	O
highest	23973	23980	O
levels	23981	23987	O
for	23988	23991	O
C	23992	23993	O
>	23993	23994	O
T	23994	23995	O
and	23996	23999	O
T	24000	24001	O
>	24001	24002	O
C	24002	24003	O
asymmetries	24004	24015	O
.	24015	24016	O

However	24017	24024	O
,	24024	24025	O
the	24026	24029	O
directionality	24030	24044	O
of	24045	24047	O
these	24048	24053	O
asymmetries	24054	24065	O
suggests	24066	24074	O
that	24075	24079	O
samples	24080	24087	O
with	24088	24092	O
high	24093	24097	O
biases	24098	24104	O
may	24105	24108	O
be	24109	24111	O
driven	24112	24118	O
by	24119	24121	O
the	24122	24125	O
two	24126	24129	O
major	24130	24135	O
types	24136	24141	O
of	24142	24144	O
RNA	24145	24148	O
editing	24149	24156	O
:	24156	24157	O
A	24158	24159	O
>	24159	24160	O
I	24160	24161	O
(	24162	24163	O
represented	24163	24174	O
in	24175	24177	O
our	24178	24181	O
data	24182	24186	O
by	24187	24189	O
T	24190	24191	O
>	24191	24192	O
C	24192	24193	O
on	24194	24196	O
the	24197	24200	O
transcribed	24201	24212	O
strand	24213	24219	O
)	24219	24220	O
and	24221	24224	O
C	24225	24226	O
>	24226	24227	O
U	24227	24228	O
(	24229	24230	O
represented	24230	24241	O
in	24242	24244	O
our	24245	24248	O
data	24249	24253	O
by	24254	24256	O
C	24257	24258	O
>	24258	24259	O
T	24259	24260	O
on	24261	24263	O
the	24264	24267	O
non	24268	24271	O
-	24271	24272	O
transcribed	24272	24283	O
strand	24284	24290	O
)	24290	24291	O
(	24292	24293	O
Fig	24293	24296	O
.	24296	24297	O

3a	24298	24300	O
,	24300	24301	O
right	24302	24307	O
panel	24308	24313	O
)	24313	24314	O
.	24314	24315	O

Interestingly	24316	24329	O
,	24329	24330	O
estimating	24331	24341	O
cell	24342	24346	O
type	24347	24351	O
abundances	24352	24362	O
in	24363	24365	O
each	24366	24370	O
blood	24371	24376	O
sample	24377	24383	O
(	24384	24385	O
see	24385	24388	O
the	24389	24392	O
“	24393	24394	O
Methods	24394	24401	O
”	24401	24402	O
section	24403	24410	O
)	24410	24411	O
revealed	24412	24420	O
that	24421	24425	O
the	24426	24429	O
abundances	24430	24440	O
of	24441	24443	O
two	24444	24447	O
cell	24448	24452	O
types	24453	24458	O
,	24458	24459	O
resting	24460	24467	O
NK	24468	24470	B-CL:0000623
cells	24471	24476	E-CL:0000623
and	24477	24480	O
CD8	24481	24484	O
+	24484	24485	O
T	24486	24487	B-CL:0000084
cells	24488	24493	E-CL:0000084
,	24493	24494	O
showed	24495	24501	O
the	24502	24505	O
strongest	24506	24515	O
associations	24516	24528	O
with	24529	24533	O
the	24534	24537	O
extent	24538	24544	O
of	24545	24547	O
both	24548	24552	O
of	24553	24555	O
these	24556	24561	O
asymmetries	24562	24573	O
(	24574	24575	O
Additional	24575	24585	O
file	24586	24590	O
1	24591	24592	O
:	24592	24593	O
Figure	24594	24600	O
S7b	24601	24604	O
,	24604	24605	O
c	24605	24606	O
)	24606	24607	O
.	24607	24608	O

Consistent	24609	24619	O
with	24620	24624	O
this	24625	24629	O
result	24630	24636	O
,	24636	24637	O
these	24638	24643	O
same	24644	24648	O
two	24649	24652	O
cell	24653	24657	O
types	24658	24663	O
have	24664	24668	O
been	24669	24673	O
shown	24674	24679	O
to	24680	24682	O
have	24683	24687	O
increased	24688	24697	O
levels	24698	24704	O
of	24705	24707	O
both	24708	24712	O
types	24713	24718	O
of	24719	24721	O
editing	24722	24729	O
in	24730	24732	O
stress	24733	24739	O
conditions	24740	24750	O
[	24751	24752	O
30	24752	24754	O
]	24754	24755	O
.	24755	24756	O

This	24757	24761	O
suggests	24762	24770	O
that	24771	24775	O
some	24776	24780	O
RNA	24781	24784	O
editing	24785	24792	O
sites	24793	24798	O
may	24799	24802	O
be	24803	24805	O
present	24806	24813	O
in	24814	24816	O
our	24817	24820	O
catalog	24821	24828	O
of	24829	24831	O
somatic	24832	24839	O
mutations	24840	24849	O
,	24849	24850	O
though	24851	24857	O
we	24858	24860	O
did	24861	24864	O
not	24865	24868	O
observe	24869	24876	O
an	24877	24879	O
increased	24880	24889	O
FDR	24890	24893	O
for	24894	24897	O
these	24898	24903	O
two	24904	24907	O
mutation	24908	24916	O
types	24917	24922	O
in	24923	24925	O
the	24926	24929	O
blood	24930	24935	O
(	24936	24937	O
Fig	24937	24940	O
.	24940	24941	O

1d	24942	24944	O
)	24944	24945	O
,	24945	24946	O
suggesting	24947	24957	O
that	24958	24962	O
RNA	24963	24966	O
editing	24967	24974	O
has	24975	24978	O
not	24979	24982	O
substantially	24983	24996	O
inflated	24997	25005	O
our	25006	25009	O
FDRs	25010	25014	O
.	25014	25015	O

Gene	25016	25020	O
expression	25021	25031	O
implicates	25032	25042	O
pathways	25043	25051	O
associated	25052	25062	O
with	25063	25067	O
somatic	25068	25075	O
mutation	25076	25084	O
load	25085	25089	O
To	25090	25092	O
explore	25093	25100	O
cellular	25101	25109	O
factors	25110	25117	O
accompanying	25118	25130	O
an	25131	25133	O
increase	25134	25142	O
in	25143	25145	O
somatic	25146	25153	O
mutation	25154	25162	O
load	25163	25167	O
across	25168	25174	O
non	25175	25178	O
-	25178	25179	O
disease	25179	25186	O
tissues	25187	25194	O
,	25194	25195	O
we	25196	25198	O
performed	25199	25208	O
an	25209	25211	O
unbiased	25212	25220	O
tissue	25221	25227	O
-	25227	25228	O
level	25228	25233	O
search	25234	25240	O
for	25241	25244	O
genes	25245	25250	O
whose	25251	25256	O
expression	25257	25267	O
was	25268	25271	O
associated	25272	25282	O
—	25282	25283	O
either	25283	25289	O
positively	25290	25300	O
or	25301	25303	O
negatively	25304	25314	O
—	25314	25315	O
with	25315	25319	O
exome	25320	25325	O
-	25325	25326	O
wide	25326	25330	O
mutational	25331	25341	O
load	25342	25346	O
(	25347	25348	O
see	25348	25351	O
the	25352	25355	O
“	25356	25357	O
Methods	25357	25364	O
”	25364	25365	O
section	25366	25373	O
)	25373	25374	O
.	25374	25375	O

These	25376	25381	O
enrichments	25382	25393	O
may	25394	25397	O
reflect	25398	25405	O
a	25406	25407	O
mixture	25408	25415	O
of	25416	25418	O
causal	25419	25425	O
scenarios	25426	25435	O
:	25435	25436	O
gene	25437	25441	O
expression	25442	25452	O
impacting	25453	25462	O
mutations	25463	25472	O
or	25473	25475	O
vice	25476	25480	O
versa	25481	25486	O
,	25486	25487	O
or	25488	25490	O
both	25491	25495	O
driven	25496	25502	O
by	25503	25505	O
a	25506	25507	O
third	25508	25513	O
variable	25514	25522	O
.	25522	25523	O

Here	25524	25528	O
we	25529	25531	O
focused	25532	25539	O
on	25540	25542	O
the	25543	25546	O
most	25547	25551	O
abundant	25552	25560	O
C	25561	25562	O
>	25562	25563	O
T	25563	25564	O
mutations	25565	25574	O
(	25575	25576	O
Fig	25576	25579	O
.	25579	25580	O

4	25581	25582	O
;	25582	25583	O
Additional	25584	25594	O
file	25595	25599	O
1	25600	25601	O
:	25601	25602	O
Figure	25603	25609	O
S8	25610	25612	O
)	25612	25613	O
;	25613	25614	O
other	25615	25620	O
mutation	25621	25629	O
types	25630	25635	O
are	25636	25639	O
described	25640	25649	O
in	25650	25652	O
the	25653	25656	O
supplement	25657	25667	O
(	25668	25669	O
Additional	25669	25679	O
file	25680	25684	O
1	25685	25686	O
:	25686	25687	O
Figures	25688	25695	O
S9	25696	25698	O
,	25698	25699	O
S10	25700	25703	O
)	25703	25704	O
.	25704	25705	O

Fig	25706	25709	O
.	25709	25710	O

4Mutation	25711	25720	O
load	25721	25725	O
is	25726	25728	O
associated	25729	25739	O
with	25740	25744	O
the	25745	25748	O
expression	25749	25759	O
of	25760	25762	O
genes	25763	25768	O
and	25769	25772	O
pathways	25773	25781	O
.	25781	25782	O

a	25783	25784	O
Histogram	25785	25794	O
of	25795	25797	O
the	25798	25801	O
number	25802	25808	O
of	25809	25811	O
tissues	25812	25819	O
for	25820	25823	O
which	25824	25829	O
each	25830	25834	O
gene	25835	25839	O
was	25840	25843	O
significantly	25844	25857	O
associated	25858	25868	O
with	25869	25873	O
mutation	25874	25882	O
load	25883	25887	O
(	25888	25889	O
Bonferroni	25889	25899	O
-	25899	25900	O
corrected	25900	25909	O
p	25910	25911	O
<	25912	25913	O
0	25914	25915	O
.	25915	25916	O
05	25916	25918	O
)	25918	25919	O
.	25919	25920	O

Associations	25921	25933	O
were	25934	25938	O
estimated	25939	25948	O
for	25949	25952	O
each	25953	25957	O
tissue	25958	25964	O
using	25965	25970	O
linear	25971	25977	O
models	25978	25984	O
controlling	25985	25996	O
for	25997	26000	O
population	26001	26011	O
structure	26012	26021	O
and	26022	26025	O
biological	26026	26036	O
and	26037	26040	O
technical	26041	26050	O
cofactors	26051	26060	O
(	26061	26062	O
see	26062	26065	O
the	26066	26069	O
“	26070	26071	O
Methods	26071	26078	O
”	26078	26079	O
section	26080	26087	O
)	26087	26088	O
.	26088	26089	O

b	26090	26091	O
Genes	26092	26097	O
whose	26098	26103	O
expression	26104	26114	O
was	26115	26118	O
negatively	26119	26129	O
(	26130	26131	O
top	26131	26134	O
)	26134	26135	O
or	26136	26138	O
positively	26139	26149	O
(	26150	26151	O
bottom	26151	26157	O
)	26157	26158	O
associated	26159	26169	O
with	26170	26174	O
C	26175	26176	O
>	26176	26177	O
T	26177	26178	O
mutation	26179	26187	O
load	26188	26192	O
in	26193	26195	O
multiple	26196	26204	O
tissues	26205	26212	O
are	26213	26216	O
enriched	26217	26225	O
in	26226	26228	O
these	26229	26234	O
representative	26235	26249	O
GO	26250	26252	O
categories	26253	26263	O
(	26264	26265	O
see	26265	26268	O
the	26269	26272	O
“	26273	26274	O
Methods	26274	26281	O
”	26281	26282	O
section	26283	26290	O
and	26291	26294	O
Additional	26295	26305	O
file	26306	26310	O
11	26311	26313	O
:	26313	26314	O
Table	26315	26320	O
S8	26321	26323	O
,	26323	26324	O
Additional	26325	26335	O
file	26336	26340	O
12	26341	26343	O
:	26343	26344	O
Tables	26345	26351	O
S9	26352	26354	O
)	26354	26355	O
.	26355	26356	O

c	26357	26358	O
Individual	26359	26369	O
gene	26370	26374	O
-	26374	26375	O
tissue	26375	26381	O
associations	26382	26394	O
between	26395	26402	O
C	26403	26404	O
>	26404	26405	O
T	26405	26406	O
mutations	26407	26416	O
and	26417	26420	O
expression	26421	26431	O
of	26432	26434	O
genes	26435	26440	O
involved	26441	26449	O
in	26450	26452	O
DNA	26453	26456	O
repair	26457	26463	O
or	26464	26466	O
DNA	26467	26470	O
mutagenesis	26471	26482	O
(	26483	26484	O
right	26484	26489	O
panel	26490	26495	O
)	26495	26496	O
.	26496	26497	O

Blue	26498	26502	O
asterisks	26503	26512	O
denote	26513	26519	O
significant	26520	26531	O
associations	26532	26544	O
using	26545	26550	O
a	26551	26552	O
permutation	26553	26564	O
-	26564	26565	O
based	26565	26570	O
FDR	26571	26574	O
strategy	26575	26583	O
(	26584	26585	O
see	26585	26588	O
the	26589	26592	O
“	26593	26594	O
Methods	26594	26601	O
”	26601	26602	O
section	26603	26610	O
;	26610	26611	O
*	26612	26613	O
FDR	26613	26616	O
<	26617	26618	O
0	26619	26620	O
.	26620	26621	O
2	26621	26622	O
,	26622	26623	O
*	26624	26625	O
*	26625	26626	O
FDR	26626	26629	O
<	26630	26631	O
0	26632	26633	O
.	26633	26634	O
1	26634	26635	O
,	26635	26636	O
*	26637	26638	O
*	26638	26639	O
*	26639	26640	O
FDR	26640	26643	O
<	26644	26645	O
0	26646	26647	O
.	26647	26648	O
05	26648	26650	O
)	26650	26651	O
.	26651	26652	O

Shown	26653	26658	O
on	26659	26661	O
the	26662	26665	O
left	26666	26670	O
panel	26671	26676	O
are	26677	26680	O
genes	26681	26686	O
whose	26687	26692	O
expression	26693	26703	O
was	26704	26707	O
associated	26708	26718	O
with	26719	26723	O
mutation	26724	26732	O
load	26733	26737	O
across	26738	26744	O
all	26745	26748	O
tissues	26749	26756	O
more	26757	26761	O
than	26762	26766	O
expected	26767	26775	O
by	26776	26778	O
chance	26779	26785	O
at	26786	26788	O
the	26789	26792	O
indicated	26793	26802	O
FDR	26803	26806	O
(	26807	26808	O
see	26808	26811	O
the	26812	26815	O
“	26816	26817	O
Methods	26817	26824	O
”	26824	26825	O
section	26826	26833	O
)	26833	26834	O
.	26834	26835	O

d	26836	26837	O
COSMIC	26838	26844	O
cancer	26845	26851	O
signature	26852	26861	O
6	26862	26863	O
(	26864	26865	O
linked	26865	26871	O
to	26872	26874	O
MMR	26875	26878	O
deficiency	26879	26889	O
;	26889	26890	O
left	26891	26895	O
)	26895	26896	O
is	26897	26899	O
significantly	26900	26913	O
similar	26914	26921	O
to	26922	26924	O
profiles	26925	26933	O
from	26934	26938	O
lung	26939	26943	O
samples	26944	26951	O
expressing	26952	26962	O
low	26963	26966	O
levels	26967	26973	O
of	26974	26976	O
MLH1	26977	26981	O
(	26982	26983	O
right	26983	26988	O
)	26988	26989	O
.	26989	26990	O

The	26991	26994	O
plot	26995	26999	O
in	27000	27002	O
the	27003	27006	O
left	27007	27011	O
panel	27012	27017	O
represents	27018	27028	O
the	27029	27032	O
frequency	27033	27042	O
of	27043	27045	O
C	27046	27047	O
>	27047	27048	O
T	27048	27049	O
mutations	27050	27059	O
at	27060	27062	O
the	27063	27066	O
indicated	27067	27076	O
tri	27077	27080	O
-	27080	27081	O
nucleotide	27081	27091	O
context	27092	27099	O
for	27100	27103	O
signature	27104	27113	O
6	27114	27115	O
.	27115	27116	O

The	27117	27120	O
plot	27121	27125	O
in	27126	27128	O
the	27129	27132	O
right	27133	27138	O
panel	27139	27144	O
is	27145	27147	O
the	27148	27151	O
log	27152	27155	O
ratio	27156	27161	O
of	27162	27164	O
C	27165	27166	O
>	27166	27167	O
T	27167	27168	O
mutation	27169	27177	O
rates	27178	27183	O
comparing	27184	27193	O
the	27194	27197	O
20	27198	27200	O
%	27200	27201	O
of	27202	27204	O
lung	27205	27209	O
samples	27210	27217	O
with	27218	27222	O
the	27223	27226	O
lowest	27227	27233	O
MLH1	27234	27238	O
expression	27239	27249	O
vs	27250	27252	O
the	27253	27256	O
20	27257	27259	O
%	27259	27260	O
with	27261	27265	O
the	27266	27269	O
highest	27270	27277	O
MLH1	27278	27282	O
expression	27283	27293	O
.	27293	27294	O

Cosine	27295	27301	O
similarity	27302	27312	O
is	27313	27315	O
indicated	27316	27325	O
for	27326	27329	O
C	27330	27331	O
>	27331	27332	O
T	27332	27333	O
mutation	27334	27342	O
across	27343	27349	O
contexts	27350	27358	O
,	27358	27359	O
and	27360	27363	O
the	27364	27367	O
p	27368	27369	O
value	27370	27375	O
represents	27376	27386	O
the	27387	27390	O
frequency	27391	27400	O
of	27401	27403	O
cosine	27404	27410	O
similarity	27411	27421	O
values	27422	27428	O
that	27429	27433	O
were	27434	27438	O
greater	27439	27446	O
than	27447	27451	O
the	27452	27455	O
original	27456	27464	O
from	27465	27469	O
permuted	27470	27478	O
values	27479	27485	O
—	27485	27486	O
permutations	27486	27498	O
were	27499	27503	O
done	27504	27508	O
by	27509	27511	O
randomly	27512	27520	O
selecting	27521	27530	O
2	27531	27532	O
groups	27533	27539	O
of	27540	27542	O
20	27543	27545	O
%	27545	27546	O
of	27547	27549	O
samples	27550	27557	O
and	27558	27561	O
calculating	27562	27573	O
the	27574	27577	O
fold	27578	27582	O
-	27582	27583	O
change	27583	27589	O
mutation	27590	27598	O
frequencies	27599	27610	O
between	27611	27618	O
them	27619	27623	O
.	27623	27624	O

e	27625	27626	O
Group	27627	27632	O
-	27632	27633	O
level	27633	27638	O
gene	27639	27643	O
expression	27644	27654	O
associations	27655	27667	O
of	27668	27670	O
the	27671	27674	O
shown	27675	27680	O
pathways	27681	27689	O
and	27690	27693	O
C	27694	27695	O
>	27695	27696	O
T	27696	27697	O
mutations	27698	27707	O
across	27708	27714	O
tissues	27715	27722	O
(	27723	27724	O
see	27724	27727	O
the	27728	27731	O
“	27732	27733	O
Methods	27733	27740	O
”	27740	27741	O
section	27742	27749	O
)	27749	27750	O
.	27750	27751	O

Heatmap	27752	27759	O
columns	27760	27767	O
in	27768	27770	O
c	27771	27772	O
and	27773	27776	O
e	27777	27778	O
are	27779	27782	O
ordered	27783	27790	O
based	27791	27796	O
on	27797	27799	O
a	27800	27801	O
hierarchical	27802	27814	O
clustering	27815	27825	O
Fig	27826	27829	O
.	27829	27830	O

4	27831	27832	O
Mutation	27833	27841	O
load	27842	27846	O
is	27847	27849	O
associated	27850	27860	O
with	27861	27865	O
the	27866	27869	O
expression	27870	27880	O
of	27881	27883	O
genes	27884	27889	O
and	27890	27893	O
pathways	27894	27902	O
.	27902	27903	O

a	27904	27905	O
Histogram	27906	27915	O
of	27916	27918	O
the	27919	27922	O
number	27923	27929	O
of	27930	27932	O
tissues	27933	27940	O
for	27941	27944	O
which	27945	27950	O
each	27951	27955	O
gene	27956	27960	O
was	27961	27964	O
significantly	27965	27978	O
associated	27979	27989	O
with	27990	27994	O
mutation	27995	28003	O
load	28004	28008	O
(	28009	28010	O
Bonferroni	28010	28020	O
-	28020	28021	O
corrected	28021	28030	O
p	28031	28032	O
<	28033	28034	O
0	28035	28036	O
.	28036	28037	O
05	28037	28039	O
)	28039	28040	O
.	28040	28041	O

Associations	28042	28054	O
were	28055	28059	O
estimated	28060	28069	O
for	28070	28073	O
each	28074	28078	O
tissue	28079	28085	O
using	28086	28091	O
linear	28092	28098	O
models	28099	28105	O
controlling	28106	28117	O
for	28118	28121	O
population	28122	28132	O
structure	28133	28142	O
and	28143	28146	O
biological	28147	28157	O
and	28158	28161	O
technical	28162	28171	O
cofactors	28172	28181	O
(	28182	28183	O
see	28183	28186	O
the	28187	28190	O
“	28191	28192	O
Methods	28192	28199	O
”	28199	28200	O
section	28201	28208	O
)	28208	28209	O
.	28209	28210	O

b	28211	28212	O
Genes	28213	28218	O
whose	28219	28224	O
expression	28225	28235	O
was	28236	28239	O
negatively	28240	28250	O
(	28251	28252	O
top	28252	28255	O
)	28255	28256	O
or	28257	28259	O
positively	28260	28270	O
(	28271	28272	O
bottom	28272	28278	O
)	28278	28279	O
associated	28280	28290	O
with	28291	28295	O
C	28296	28297	O
>	28297	28298	O
T	28298	28299	O
mutation	28300	28308	O
load	28309	28313	O
in	28314	28316	O
multiple	28317	28325	O
tissues	28326	28333	O
are	28334	28337	O
enriched	28338	28346	O
in	28347	28349	O
these	28350	28355	O
representative	28356	28370	O
GO	28371	28373	O
categories	28374	28384	O
(	28385	28386	O
see	28386	28389	O
the	28390	28393	O
“	28394	28395	O
Methods	28395	28402	O
”	28402	28403	O
section	28404	28411	O
and	28412	28415	O
Additional	28416	28426	O
file	28427	28431	O
11	28432	28434	O
:	28434	28435	O
Table	28436	28441	O
S8	28442	28444	O
,	28444	28445	O
Additional	28446	28456	O
file	28457	28461	O
12	28462	28464	O
:	28464	28465	O
Tables	28466	28472	O
S9	28473	28475	O
)	28475	28476	O
.	28476	28477	O

c	28478	28479	O
Individual	28480	28490	O
gene	28491	28495	O
-	28495	28496	O
tissue	28496	28502	O
associations	28503	28515	O
between	28516	28523	O
C	28524	28525	O
>	28525	28526	O
T	28526	28527	O
mutations	28528	28537	O
and	28538	28541	O
expression	28542	28552	O
of	28553	28555	O
genes	28556	28561	O
involved	28562	28570	O
in	28571	28573	O
DNA	28574	28577	O
repair	28578	28584	O
or	28585	28587	O
DNA	28588	28591	O
mutagenesis	28592	28603	O
(	28604	28605	O
right	28605	28610	O
panel	28611	28616	O
)	28616	28617	O
.	28617	28618	O

Blue	28619	28623	O
asterisks	28624	28633	O
denote	28634	28640	O
significant	28641	28652	O
associations	28653	28665	O
using	28666	28671	O
a	28672	28673	O
permutation	28674	28685	O
-	28685	28686	O
based	28686	28691	O
FDR	28692	28695	O
strategy	28696	28704	O
(	28705	28706	O
see	28706	28709	O
the	28710	28713	O
“	28714	28715	O
Methods	28715	28722	O
”	28722	28723	O
section	28724	28731	O
;	28731	28732	O
*	28733	28734	O
FDR	28734	28737	O
<	28738	28739	O
0	28740	28741	O
.	28741	28742	O
2	28742	28743	O
,	28743	28744	O
*	28745	28746	O
*	28746	28747	O
FDR	28747	28750	O
<	28751	28752	O
0	28753	28754	O
.	28754	28755	O
1	28755	28756	O
,	28756	28757	O
*	28758	28759	O
*	28759	28760	O
*	28760	28761	O
FDR	28761	28764	O
<	28765	28766	O
0	28767	28768	O
.	28768	28769	O
05	28769	28771	O
)	28771	28772	O
.	28772	28773	O

Shown	28774	28779	O
on	28780	28782	O
the	28783	28786	O
left	28787	28791	O
panel	28792	28797	O
are	28798	28801	O
genes	28802	28807	O
whose	28808	28813	O
expression	28814	28824	O
was	28825	28828	O
associated	28829	28839	O
with	28840	28844	O
mutation	28845	28853	O
load	28854	28858	O
across	28859	28865	O
all	28866	28869	O
tissues	28870	28877	O
more	28878	28882	O
than	28883	28887	O
expected	28888	28896	O
by	28897	28899	O
chance	28900	28906	O
at	28907	28909	O
the	28910	28913	O
indicated	28914	28923	O
FDR	28924	28927	O
(	28928	28929	O
see	28929	28932	O
the	28933	28936	O
“	28937	28938	O
Methods	28938	28945	O
”	28945	28946	O
section	28947	28954	O
)	28954	28955	O
.	28955	28956	O

d	28957	28958	O
COSMIC	28959	28965	O
cancer	28966	28972	O
signature	28973	28982	O
6	28983	28984	O
(	28985	28986	O
linked	28986	28992	O
to	28993	28995	O
MMR	28996	28999	O
deficiency	29000	29010	O
;	29010	29011	O
left	29012	29016	O
)	29016	29017	O
is	29018	29020	O
significantly	29021	29034	O
similar	29035	29042	O
to	29043	29045	O
profiles	29046	29054	O
from	29055	29059	O
lung	29060	29064	O
samples	29065	29072	O
expressing	29073	29083	O
low	29084	29087	O
levels	29088	29094	O
of	29095	29097	O
MLH1	29098	29102	O
(	29103	29104	O
right	29104	29109	O
)	29109	29110	O
.	29110	29111	O

The	29112	29115	O
plot	29116	29120	O
in	29121	29123	O
the	29124	29127	O
left	29128	29132	O
panel	29133	29138	O
represents	29139	29149	O
the	29150	29153	O
frequency	29154	29163	O
of	29164	29166	O
C	29167	29168	O
>	29168	29169	O
T	29169	29170	O
mutations	29171	29180	O
at	29181	29183	O
the	29184	29187	O
indicated	29188	29197	O
tri	29198	29201	O
-	29201	29202	O
nucleotide	29202	29212	O
context	29213	29220	O
for	29221	29224	O
signature	29225	29234	O
6	29235	29236	O
.	29236	29237	O

The	29238	29241	O
plot	29242	29246	O
in	29247	29249	O
the	29250	29253	O
right	29254	29259	O
panel	29260	29265	O
is	29266	29268	O
the	29269	29272	O
log	29273	29276	O
ratio	29277	29282	O
of	29283	29285	O
C	29286	29287	O
>	29287	29288	O
T	29288	29289	O
mutation	29290	29298	O
rates	29299	29304	O
comparing	29305	29314	O
the	29315	29318	O
20	29319	29321	O
%	29321	29322	O
of	29323	29325	O
lung	29326	29330	O
samples	29331	29338	O
with	29339	29343	O
the	29344	29347	O
lowest	29348	29354	O
MLH1	29355	29359	O
expression	29360	29370	O
vs	29371	29373	O
the	29374	29377	O
20	29378	29380	O
%	29380	29381	O
with	29382	29386	O
the	29387	29390	O
highest	29391	29398	O
MLH1	29399	29403	O
expression	29404	29414	O
.	29414	29415	O

Cosine	29416	29422	O
similarity	29423	29433	O
is	29434	29436	O
indicated	29437	29446	O
for	29447	29450	O
C	29451	29452	O
>	29452	29453	O
T	29453	29454	O
mutation	29455	29463	O
across	29464	29470	O
contexts	29471	29479	O
,	29479	29480	O
and	29481	29484	O
the	29485	29488	O
p	29489	29490	O
value	29491	29496	O
represents	29497	29507	O
the	29508	29511	O
frequency	29512	29521	O
of	29522	29524	O
cosine	29525	29531	O
similarity	29532	29542	O
values	29543	29549	O
that	29550	29554	O
were	29555	29559	O
greater	29560	29567	O
than	29568	29572	O
the	29573	29576	O
original	29577	29585	O
from	29586	29590	O
permuted	29591	29599	O
values	29600	29606	O
—	29606	29607	O
permutations	29607	29619	O
were	29620	29624	O
done	29625	29629	O
by	29630	29632	O
randomly	29633	29641	O
selecting	29642	29651	O
2	29652	29653	O
groups	29654	29660	O
of	29661	29663	O
20	29664	29666	O
%	29666	29667	O
of	29668	29670	O
samples	29671	29678	O
and	29679	29682	O
calculating	29683	29694	O
the	29695	29698	O
fold	29699	29703	O
-	29703	29704	O
change	29704	29710	O
mutation	29711	29719	O
frequencies	29720	29731	O
between	29732	29739	O
them	29740	29744	O
.	29744	29745	O

e	29746	29747	O
Group	29748	29753	O
-	29753	29754	O
level	29754	29759	O
gene	29760	29764	O
expression	29765	29775	O
associations	29776	29788	O
of	29789	29791	O
the	29792	29795	O
shown	29796	29801	O
pathways	29802	29810	O
and	29811	29814	O
C	29815	29816	O
>	29816	29817	O
T	29817	29818	O
mutations	29819	29828	O
across	29829	29835	O
tissues	29836	29843	O
(	29844	29845	O
see	29845	29848	O
the	29849	29852	O
“	29853	29854	O
Methods	29854	29861	O
”	29861	29862	O
section	29863	29870	O
)	29870	29871	O
.	29871	29872	O

Heatmap	29873	29880	O
columns	29881	29888	O
in	29889	29891	O
c	29892	29893	O
and	29894	29897	O
e	29898	29899	O
are	29900	29903	O
ordered	29904	29911	O
based	29912	29917	O
on	29918	29920	O
a	29921	29922	O
hierarchical	29923	29935	O
clustering	29936	29946	O
While	29947	29952	O
most	29953	29957	O
genes	29958	29963	O
were	29964	29968	O
tested	29969	29975	O
in	29976	29978	O
the	29979	29982	O
majority	29983	29991	O
of	29992	29994	O
tissues	29995	30002	O
(	30003	30004	O
Additional	30004	30014	O
file	30015	30019	O
1	30020	30021	O
:	30021	30022	O
Figure	30023	30029	O
S8a	30030	30033	O
)	30033	30034	O
,	30034	30035	O
the	30036	30039	O
most	30040	30044	O
significant	30045	30056	O
associations	30057	30069	O
were	30070	30074	O
specific	30075	30083	O
to	30084	30086	O
only	30087	30091	O
1	30092	30093	O
–	30093	30094	O
3	30094	30095	O
tissues	30096	30103	O
(	30104	30105	O
Bonferroni	30105	30115	O
-	30115	30116	O
corrected	30116	30125	O
p	30126	30127	O
<	30128	30129	O
0	30130	30131	O
.	30131	30132	O
05	30132	30134	O
;	30134	30135	O
Fig	30136	30139	O
.	30139	30140	O

4a	30141	30143	O
,	30143	30144	O
Additional	30145	30155	O
file	30156	30160	O
1	30161	30162	O
:	30162	30163	O
Figure	30164	30170	O
S8b	30171	30174	O
)	30174	30175	O
.	30175	30176	O

Among	30177	30182	O
genes	30183	30188	O
positively	30189	30199	O
associated	30200	30210	O
with	30211	30215	O
mutation	30216	30224	O
load	30225	30229	O
in	30230	30232	O
multiple	30233	30241	O
tissues	30242	30249	O
(	30250	30251	O
see	30251	30254	O
the	30255	30258	O
“	30259	30260	O
Methods	30260	30267	O
”	30267	30268	O
section	30269	30276	O
)	30276	30277	O
,	30277	30278	O
we	30279	30281	O
observed	30282	30290	O
enrichments	30291	30302	O
for	30303	30306	O
GO	30307	30309	O
categories	30310	30320	O
that	30321	30325	O
included	30326	30334	O
nucleotide	30335	30345	O
excision	30346	30354	O
repair	30355	30361	O
,	30361	30362	O
cellular	30363	30371	O
transport	30372	30381	B-CL:0000627
,	30381	30382	I-CL:0000627
cell	30383	30387	E-CL:0000627
adhesion	30388	30396	O
,	30396	30397	O
and	30398	30401	O
macroautophagy	30402	30416	O
and	30417	30420	O
categories	30421	30431	O
including	30432	30441	O
immune	30442	30448	O
response	30449	30457	O
,	30457	30458	O
keratinization	30459	30473	O
,	30473	30474	O
and	30475	30478	O
cell	30479	30483	O
polarity	30484	30492	O
for	30493	30496	O
negative	30497	30505	O
expression	30506	30516	O
-	30516	30517	O
mutation	30517	30525	O
associations	30526	30538	O
(	30539	30540	O
Fig	30540	30543	O
.	30543	30544	O

4b	30545	30547	O
;	30547	30548	O
Additional	30549	30559	O
file	30560	30564	O
11	30565	30567	O
:	30567	30568	O
Tables	30569	30575	O
S8	30576	30578	O
,	30578	30579	O
Additional	30580	30590	O
file	30591	30595	O
12	30596	30598	O
:	30598	30599	O
Table	30600	30605	O
S9	30606	30608	O
)	30608	30609	O
.	30609	30610	O

Consistent	30611	30621	O
with	30622	30626	O
these	30627	30632	O
results	30633	30640	O
,	30640	30641	O
several	30642	30649	O
of	30650	30652	O
these	30653	30658	O
same	30659	30663	O
processes	30664	30673	O
(	30674	30675	O
e	30675	30676	O
.	30676	30677	O
g	30677	30678	O
.	30678	30679	O
,	30679	30680	O
cellular	30681	30689	O
transport	30690	30699	O
,	30699	30700	O
autophagy	30701	30710	O
,	30710	30711	O
and	30712	30715	O
cell	30716	30720	O
adhesion	30721	30729	O
)	30729	30730	O
are	30731	30734	O
known	30735	30740	O
to	30741	30743	O
be	30744	30746	O
associated	30747	30757	O
with	30758	30762	O
mutation	30763	30771	O
load	30772	30776	O
in	30777	30779	O
cancer	30780	30786	O
or	30787	30789	O
normal	30790	30796	O
cells	30797	30802	O
[	30803	30804	O
31	30804	30806	O
–	30806	30807	O
33	30807	30809	O
]	30809	30810	O
.	30810	30811	O

To	30812	30814	O
further	30815	30822	O
explore	30823	30830	O
the	30831	30834	O
contribution	30835	30847	O
of	30848	30850	O
different	30851	30860	O
DNA	30861	30864	O
repair	30865	30871	O
pathways	30872	30880	O
to	30881	30883	O
mutagenesis	30884	30895	O
,	30895	30896	O
we	30897	30899	O
focused	30900	30907	O
on	30908	30910	O
the	30911	30914	O
associations	30915	30927	O
between	30928	30935	O
the	30936	30939	O
expression	30940	30950	O
of	30951	30953	O
repair	30954	30960	O
pathway	30961	30968	O
members	30969	30976	O
with	30977	30981	O
mutation	30982	30990	O
load	30991	30995	O
.	30995	30996	O

Specifically	30997	31009	O
,	31009	31010	O
we	31011	31013	O
analyzed	31014	31022	O
genes	31023	31028	O
involved	31029	31037	O
in	31038	31040	O
double	31041	31047	O
-	31047	31048	O
strand	31048	31054	O
break	31055	31060	O
(	31061	31062	O
DSB	31062	31065	O
)	31065	31066	O
repair	31067	31073	O
,	31073	31074	O
mismatch	31075	31083	O
repair	31084	31090	O
(	31091	31092	O
MMR	31092	31095	O
)	31095	31096	O
,	31096	31097	O
nucleotide	31098	31108	O
excision	31109	31117	O
repair	31118	31124	O
(	31125	31126	O
NER	31126	31129	O
)	31129	31130	O
,	31130	31131	O
base	31132	31136	O
excision	31137	31145	O
repair	31146	31152	O
(	31153	31154	O
BER	31154	31157	O
)	31157	31158	O
,	31158	31159	O
the	31160	31163	O
DNA	31164	31167	O
deaminases	31168	31178	O
APOBEC3A	31179	31187	O
/	31187	31188	O
B	31188	31189	O
,	31189	31190	O
and	31191	31194	O
the	31195	31198	O
translesion	31199	31210	O
polymerase	31211	31221	O
POLH	31222	31226	O
.	31226	31227	O

We	31228	31230	O
found	31231	31236	O
14	31237	31239	O
associations	31240	31252	O
at	31253	31255	O
a	31256	31257	O
<	31258	31259	O
20	31260	31262	O
%	31262	31263	O
FDR	31264	31267	O
,	31267	31268	O
8	31269	31270	O
at	31271	31273	O
<	31274	31275	O
10	31276	31278	O
%	31278	31279	O
FDR	31280	31283	O
,	31283	31284	O
and	31285	31288	O
2	31289	31290	O
at	31291	31293	O
<	31294	31295	O
5	31296	31297	O
%	31297	31298	O
FDR	31299	31302	O
(	31303	31304	O
Fig	31304	31307	O
.	31307	31308	O

4c	31309	31311	O
blue	31312	31316	O
asterisks	31317	31326	O
;	31326	31327	O
Additional	31328	31338	O
file	31339	31343	O
1	31344	31345	O
:	31345	31346	O
Figure	31347	31353	O
S8c	31354	31357	O
-	31357	31358	O
g	31358	31359	O
)	31359	31360	O
which	31361	31366	O
are	31367	31370	O
further	31371	31378	O
described	31379	31388	O
in	31389	31391	O
Additional	31392	31402	O
file	31403	31407	O
9	31408	31409	O
:	31409	31410	O
Note	31411	31415	O
S2	31416	31418	O
.	31418	31419	O

We	31420	31422	O
then	31423	31427	O
tested	31428	31434	O
genes	31435	31440	O
in	31441	31443	O
these	31444	31449	O
pathways	31450	31458	O
for	31459	31462	O
consistent	31463	31473	O
associations	31474	31486	O
with	31487	31491	O
mutation	31492	31500	O
load	31501	31505	O
across	31506	31512	O
tissues	31513	31520	O
(	31521	31522	O
see	31522	31525	O
the	31526	31529	O
“	31530	31531	O
Methods	31531	31538	O
”	31538	31539	O
section	31540	31547	O
;	31547	31548	O
Fig	31549	31552	O
.	31552	31553	O

4c	31554	31556	O
,	31556	31557	O
left	31558	31562	O
panel	31563	31568	O
;	31568	31569	O
Additional	31570	31580	O
file	31581	31585	O
1	31586	31587	O
:	31587	31588	O
Figure	31589	31595	O
S10a	31596	31600	O
-	31600	31601	O
e	31601	31602	O
)	31602	31603	O
.	31603	31604	O

We	31605	31607	O
observed	31608	31616	O
significant	31617	31628	O
hits	31629	31633	O
from	31634	31638	O
NER	31639	31642	O
(	31643	31644	O
XPA	31644	31647	O
,	31647	31648	O
FDR	31649	31652	O
=	31653	31654	O
0	31655	31656	O
.	31656	31657	O
01	31657	31659	O
;	31659	31660	O
XPC	31661	31664	O
,	31664	31665	O
FDR	31666	31669	O
=	31670	31671	O
0	31672	31673	O
.	31673	31674	O
07	31674	31676	O
;	31676	31677	O
DDB1	31678	31682	O
,	31682	31683	O
FDR	31684	31687	O
=	31688	31689	O
0	31690	31691	O
.	31691	31692	O
07	31692	31694	O
)	31694	31695	O
,	31695	31696	O
MMR	31697	31700	O
(	31701	31702	O
MLH1	31702	31706	O
,	31706	31707	O
FDR	31708	31711	O
=	31712	31713	O
0	31714	31715	O
.	31715	31716	O
05	31716	31718	O
;	31718	31719	O
MSH6	31720	31724	O
,	31724	31725	O
FDR	31726	31729	O
=	31730	31731	O
0	31732	31733	O
.	31733	31734	O
16	31734	31736	O
;	31736	31737	O
PMS2	31738	31742	O
FDR	31743	31746	O
=	31747	31748	O
0	31749	31750	O
.	31750	31751	O
17	31751	31753	O
)	31753	31754	O
,	31754	31755	O
and	31756	31759	O
BER	31760	31763	O
(	31764	31765	O
NEIL2	31765	31770	O
,	31770	31771	O
FDR	31772	31775	O
=	31776	31777	O
0	31778	31779	O
.	31779	31780	O
15	31780	31782	O
)	31782	31783	O
.	31783	31784	O

The	31785	31788	O
associations	31789	31801	O
were	31802	31806	O
generally	31807	31816	O
in	31817	31819	O
the	31820	31823	O
expected	31824	31832	O
direction	31833	31842	O
,	31842	31843	O
based	31844	31849	O
on	31850	31852	O
what	31853	31857	O
is	31858	31860	O
known	31861	31866	O
about	31867	31872	O
each	31873	31877	O
gene	31878	31882	O
(	31883	31884	O
see	31884	31887	O
Additional	31888	31898	O
file	31899	31903	O
9	31904	31905	O
:	31905	31906	O
Note	31907	31911	O
S3	31912	31914	O
)	31914	31915	O
;	31915	31916	O
for	31917	31920	O
example	31921	31928	O
,	31928	31929	O
all	31930	31933	O
associations	31934	31946	O
of	31947	31949	O
MLH1	31950	31954	O
were	31955	31959	O
negative	31960	31968	O
,	31968	31969	O
indicating	31970	31980	O
lower	31981	31986	O
expression	31987	31997	O
associated	31998	32008	O
with	32009	32013	O
higher	32014	32020	O
mutation	32021	32029	O
load	32030	32034	O
(	32035	32036	O
Fig	32036	32039	O
.	32039	32040	O

4c	32041	32043	O
,	32043	32044	O
Additional	32045	32055	O
file	32056	32060	O
1	32061	32062	O
:	32062	32063	O
Figure	32064	32070	O
S8e	32071	32074	O
)	32074	32075	O
.	32075	32076	O

If	32077	32079	O
this	32080	32084	O
association	32085	32096	O
reflects	32097	32105	O
a	32106	32107	O
causal	32108	32114	O
relationship	32115	32127	O
,	32127	32128	O
we	32129	32131	O
hypothesized	32132	32144	O
that	32145	32149	O
tissue	32150	32156	O
samples	32157	32164	O
with	32165	32169	O
low	32170	32173	O
expression	32174	32184	O
of	32185	32187	O
MLH1	32188	32192	O
might	32193	32198	O
show	32199	32203	O
a	32204	32205	O
mutation	32206	32214	O
profile	32215	32222	O
suggestive	32223	32233	O
of	32234	32236	O
deficient	32237	32246	O
mismatch	32247	32255	O
repair	32256	32262	O
.	32262	32263	O

Supporting	32264	32274	O
this	32275	32279	O
hypothesis	32280	32290	O
,	32290	32291	O
we	32292	32294	O
observed	32295	32303	O
that	32304	32308	O
in	32309	32311	O
the	32312	32315	O
lung	32316	32320	O
—	32320	32321	O
the	32321	32324	O
tissue	32325	32331	O
with	32332	32336	O
the	32337	32340	O
strongest	32341	32350	O
association	32351	32362	O
between	32363	32370	O
MLH1	32371	32375	O
expression	32376	32386	O
and	32387	32390	O
C	32391	32392	O
>	32392	32393	O
T	32393	32394	O
mutation	32395	32403	O
load	32404	32408	O
—	32408	32409	O
samples	32409	32416	O
with	32417	32421	O
low	32422	32425	O
expression	32426	32436	O
of	32437	32439	O
MLH1	32440	32444	O
had	32445	32448	O
a	32449	32450	O
significant	32451	32462	O
resemblance	32463	32474	O
to	32475	32477	O
a	32478	32479	O
cancer	32480	32486	O
mutation	32487	32495	O
signature	32496	32505	O
that	32506	32510	O
has	32511	32514	O
been	32515	32519	O
attributed	32520	32530	O
to	32531	32533	O
deficient	32534	32543	O
MMR	32544	32547	O
(	32548	32549	O
Fig	32549	32552	O
.	32552	32553	O

4d	32554	32556	O
;	32556	32557	O
similarity	32558	32568	O
to	32569	32571	O
COSMIC	32572	32578	O
signature	32579	32588	O
6	32589	32590	O
:	32590	32591	O
cosine	32592	32598	O
similarity	32599	32609	O
=	32610	32611	O
0	32612	32613	O
.	32613	32614	O
76	32614	32616	O
,	32616	32617	O
p	32618	32619	O
=	32620	32621	O
0	32622	32623	O
.	32623	32624	O
001	32624	32627	O
for	32628	32631	O
C	32632	32633	O
>	32633	32634	O
T	32634	32635	O
mutations	32636	32645	O
,	32645	32646	O
and	32647	32650	O
cosine	32651	32657	O
similarity	32658	32668	O
=	32669	32670	O
0	32671	32672	O
.	32672	32673	O
28	32673	32675	O
,	32675	32676	O
p	32677	32678	O
=	32679	32680	O
0	32681	32682	O
.	32682	32683	O
02	32683	32685	O
across	32686	32692	O
all	32693	32696	O
mutation	32697	32705	O
types	32706	32711	O
)	32711	32712	O
.	32712	32713	O

MLH1	32714	32718	O
silencing	32719	32728	O
contributes	32729	32740	O
to	32741	32743	O
cancer	32744	32750	O
development	32751	32762	O
and	32763	32766	O
mutagenesis	32767	32778	O
[	32779	32780	O
34	32780	32782	O
]	32782	32783	O
,	32783	32784	O
and	32785	32788	O
our	32789	32792	O
results	32793	32800	O
suggest	32801	32808	O
that	32809	32813	O
natural	32814	32821	O
variation	32822	32831	O
of	32832	32834	O
MLH1	32835	32839	O
expression	32840	32850	O
may	32851	32854	O
affect	32855	32861	O
mutagenesis	32862	32873	O
in	32874	32876	O
pre	32877	32880	O
-	32880	32881	O
cancerous	32881	32890	O
tissues	32891	32898	O
as	32899	32901	O
well	32902	32906	O
.	32906	32907	O

To	32908	32910	O
further	32911	32918	O
explore	32919	32926	O
factors	32927	32934	O
that	32935	32939	O
may	32940	32943	O
contribute	32944	32954	O
to	32955	32957	O
mutation	32958	32966	O
load	32967	32971	O
,	32971	32972	O
we	32973	32975	O
analyzed	32976	32984	O
the	32985	32988	O
expression	32989	32999	O
of	33000	33002	O
entire	33003	33009	O
pathways	33010	33018	O
or	33019	33021	O
functionally	33022	33034	O
related	33035	33042	O
gene	33043	33047	O
sets	33048	33052	O
in	33053	33055	O
each	33056	33060	O
tissue	33061	33067	O
(	33068	33069	O
see	33069	33072	O
the	33073	33076	O
“	33077	33078	O
Methods	33078	33085	O
”	33085	33086	O
section	33087	33094	O
)	33094	33095	O
.	33095	33096	O

MMR	33097	33100	O
,	33100	33101	O
BER	33102	33105	O
,	33105	33106	O
and	33107	33110	O
NER	33111	33114	O
are	33115	33118	O
all	33119	33122	O
strongly	33123	33131	O
associated	33132	33142	O
with	33143	33147	O
mutation	33148	33156	O
load	33157	33161	O
in	33162	33164	O
multiple	33165	33173	O
tissues	33174	33181	O
,	33181	33182	O
but	33183	33186	O
with	33187	33191	O
very	33192	33196	O
little	33197	33203	O
overlap	33204	33211	O
among	33212	33217	O
them	33218	33222	O
(	33223	33224	O
Fig	33224	33227	O
.	33227	33228	O

4e	33229	33231	O
;	33231	33232	O
Additional	33233	33243	O
file	33244	33248	O
1	33249	33250	O
:	33250	33251	O
Figure	33252	33258	O
S10f	33259	33263	O
-	33263	33264	O
j	33264	33265	O
)	33265	33266	O
.	33266	33267	O

As	33268	33270	O
a	33271	33272	O
result	33273	33279	O
,	33279	33280	O
these	33281	33286	O
associations	33287	33299	O
are	33300	33303	O
primarily	33304	33313	O
dominated	33314	33323	O
by	33324	33326	O
just	33327	33331	O
one	33332	33335	O
or	33336	33338	O
two	33339	33342	O
pathways	33343	33351	O
per	33352	33355	O
tissue	33356	33362	O
.	33362	33363	O

In	33364	33366	O
summary	33367	33374	O
,	33374	33375	O
most	33376	33380	O
transcriptional	33381	33396	O
signatures	33397	33407	O
associated	33408	33418	O
with	33419	33423	O
mutation	33424	33432	O
load	33433	33437	O
are	33438	33441	O
tissue	33442	33448	O
-	33448	33449	O
specific	33449	33457	O
;	33457	33458	O
however	33459	33466	O
,	33466	33467	O
genes	33468	33473	O
associated	33474	33484	O
with	33485	33489	O
mutation	33490	33498	O
load	33499	33503	O
in	33504	33506	O
several	33507	33514	O
tissues	33515	33522	O
are	33523	33526	O
enriched	33527	33535	O
in	33536	33538	O
a	33539	33540	O
number	33541	33547	O
of	33548	33550	O
pathways	33551	33559	O
including	33560	33569	O
DNA	33570	33573	O
repair	33574	33580	O
.	33580	33581	O

These	33582	33587	O
results	33588	33595	O
paint	33596	33601	O
a	33602	33603	O
complex	33604	33611	O
landscape	33612	33621	O
where	33622	33627	O
mutational	33628	33638	O
load	33639	33643	O
across	33644	33650	O
non	33651	33654	O
-	33654	33655	O
disease	33655	33662	O
tissues	33663	33670	O
is	33671	33673	O
associated	33674	33684	O
with	33685	33689	O
a	33690	33691	O
variety	33692	33699	O
of	33700	33702	O
cellular	33703	33711	O
functions	33712	33721	O
.	33721	33722	O

Cancer	33723	33729	O
driver	33730	33736	O
genes	33737	33742	O
are	33743	33746	O
enriched	33747	33755	O
for	33756	33759	O
mutations	33760	33769	O
and	33770	33773	O
under	33774	33779	O
positive	33780	33788	O
selection	33789	33798	O
in	33799	33801	O
non	33802	33805	O
-	33805	33806	O
disease	33806	33813	O
tissues	33814	33821	O
To	33822	33824	O
investigate	33825	33836	O
the	33837	33840	O
extent	33841	33847	O
to	33848	33850	O
which	33851	33856	O
cancer	33857	33863	O
-	33863	33864	O
associated	33864	33874	O
mutations	33875	33884	O
exist	33885	33890	O
in	33891	33893	O
a	33894	33895	O
pre	33896	33899	O
-	33899	33900	O
cancerous	33900	33909	O
state	33910	33915	O
,	33915	33916	O
we	33917	33919	O
calculated	33920	33930	O
the	33931	33934	O
enrichment	33935	33945	O
of	33946	33948	O
all	33949	33952	O
COSMIC	33953	33959	O
[	33960	33961	O
35	33961	33963	O
]	33963	33964	O
cancer	33965	33971	O
point	33972	33977	O
mutations	33978	33987	O
in	33988	33990	O
our	33991	33994	O
mutation	33995	34003	O
maps	34004	34008	O
(	34009	34010	O
see	34010	34013	O
the	34014	34017	O
“	34018	34019	O
Methods	34019	34026	O
”	34026	34027	O
section	34028	34035	O
)	34035	34036	O
.	34036	34037	O

Many	34038	34042	O
samples	34043	34050	O
were	34051	34055	O
highly	34056	34062	O
enriched	34063	34071	O
(	34072	34073	O
hypergeometric	34073	34087	O
Bonferroni	34088	34098	O
-	34098	34099	O
corrected	34099	34108	O
p	34109	34110	O
<	34111	34112	O
0	34113	34114	O
.	34114	34115	O
05	34115	34117	O
)	34117	34118	O
,	34118	34119	O
with	34120	34124	O
some	34125	34129	O
having	34130	34136	O
more	34137	34141	O
than	34142	34146	O
20	34147	34149	O
%	34149	34150	O
overlap	34151	34158	O
with	34159	34163	O
COSMIC	34164	34170	O
mutations	34171	34180	O
(	34181	34182	O
Fig	34182	34185	O
.	34185	34186	O

5a	34187	34189	O
)	34189	34190	O
.	34190	34191	O

In	34192	34194	O
contrast	34195	34203	O
,	34203	34204	O
we	34205	34207	O
observed	34208	34216	O
almost	34217	34223	O
no	34224	34226	O
significant	34227	34238	O
overlaps	34239	34247	O
in	34248	34250	O
a	34251	34252	O
negative	34253	34261	O
control	34262	34269	O
(	34270	34271	O
using	34271	34276	O
a	34277	34278	O
permuted	34279	34287	O
set	34288	34291	O
of	34292	34294	O
mutations	34295	34304	O
per	34305	34308	O
-	34308	34309	O
sample	34309	34315	O
that	34316	34320	O
conserves	34321	34330	O
mutation	34331	34339	O
frequencies	34340	34351	O
and	34352	34355	O
genomic	34356	34363	O
regions	34364	34371	O
from	34372	34376	O
the	34377	34380	O
original	34381	34389	O
set	34390	34393	O
of	34394	34396	O
mutations	34397	34406	O
;	34406	34407	O
see	34408	34411	O
the	34412	34415	O
“	34416	34417	O
Methods	34417	34424	O
”	34424	34425	O
section	34426	34433	O
;	34433	34434	O
Additional	34435	34445	O
file	34446	34450	O
1	34451	34452	O
:	34452	34453	O
Figure	34454	34460	O
S11a	34461	34465	O
)	34465	34466	O
.	34466	34467	O

The	34468	34471	O
sun	34472	34475	O
-	34475	34476	O
exposed	34476	34483	O
skin	34484	34488	O
had	34489	34492	O
the	34493	34496	O
highest	34497	34504	O
level	34505	34510	O
of	34511	34513	O
overlap	34514	34521	O
(	34522	34523	O
hypergeometric	34523	34537	O
BH	34538	34540	O
-	34540	34541	O
FDR	34541	34544	O
<	34545	34546	O
0	34547	34548	O
.	34548	34549	O
05	34549	34551	O
)	34551	34552	O
,	34552	34553	O
with	34554	34558	O
100	34559	34562	O
%	34562	34563	O
of	34564	34566	O
samples	34567	34574	O
having	34575	34581	O
significant	34582	34593	O
enrichments	34594	34605	O
,	34605	34606	O
followed	34607	34615	O
by	34616	34618	O
the	34619	34622	O
sun	34623	34626	O
-	34626	34627	O
protected	34627	34636	O
skin	34637	34641	O
and	34642	34645	O
skeletal	34646	34654	O
muscle	34655	34661	O
(	34662	34663	O
Fig	34663	34666	O
.	34666	34667	O

5a	34668	34670	O
)	34670	34671	O
.	34671	34672	O

We	34673	34675	O
observed	34676	34684	O
the	34685	34688	O
lowest	34689	34695	O
overlaps	34696	34704	O
across	34705	34711	O
the	34712	34715	O
seven	34716	34721	O
brain	34722	34727	O
regions	34728	34735	O
,	34735	34736	O
aorta	34737	34742	O
,	34742	34743	O
and	34744	34747	O
spleen	34748	34754	O
.	34754	34755	O

Fig	34756	34759	O
.	34759	34760	O

5Cancer	34761	34768	O
driver	34769	34775	O
genes	34776	34781	O
evolve	34782	34788	O
under	34789	34794	O
strong	34795	34801	O
positive	34802	34810	O
selection	34811	34820	O
,	34820	34821	O
and	34822	34825	O
cancer	34826	34832	O
mutations	34833	34842	O
are	34843	34846	O
enriched	34847	34855	O
in	34856	34858	O
healthy	34859	34866	O
tissues	34867	34874	O
.	34874	34875	O

a	34876	34877	O
Percentage	34878	34888	O
of	34889	34891	O
COSMIC	34892	34898	O
cancer	34899	34905	O
mutations	34906	34915	O
observed	34916	34924	O
per	34925	34928	O
sample	34929	34935	O
and	34936	34939	O
grouped	34940	34947	O
by	34948	34950	O
tissue	34951	34957	O
;	34957	34958	O
p	34959	34960	O
values	34961	34967	O
for	34968	34971	O
enrichment	34972	34982	O
were	34983	34987	O
calculated	34988	34998	O
using	34999	35004	O
a	35005	35006	O
hypergeometric	35007	35021	O
test	35022	35026	O
accounting	35027	35037	O
for	35038	35041	O
sequencing	35042	35052	O
coverage	35053	35061	O
,	35061	35062	O
total	35063	35068	O
number	35069	35075	O
of	35076	35078	O
mutations	35079	35088	O
per	35089	35092	O
sample	35093	35099	O
,	35099	35100	O
total	35101	35106	O
number	35107	35113	O
of	35114	35116	O
COSMIC	35117	35123	O
mutations	35124	35133	O
,	35133	35134	O
and	35135	35138	O
the	35139	35142	O
three	35143	35148	O
possible	35149	35157	O
alternate	35158	35167	O
alleles	35168	35175	O
that	35176	35180	O
any	35181	35184	O
given	35185	35190	O
reference	35191	35200	O
allele	35201	35207	O
can	35208	35211	O
have	35212	35216	O
(	35217	35218	O
see	35218	35221	O
the	35222	35225	O
“	35226	35227	O
Methods	35227	35234	O
”	35234	35235	O
section	35236	35243	O
)	35243	35244	O
.	35244	35245	O

p	35246	35247	O
values	35248	35254	O
are	35255	35258	O
Bonferroni	35259	35269	O
-	35269	35270	O
corrected	35270	35279	O
across	35280	35286	O
all	35287	35290	O
samples	35291	35298	O
.	35298	35299	O

b	35300	35301	O
Relative	35302	35310	O
mutation	35311	35319	O
rates	35320	35325	O
of	35326	35328	O
a	35329	35330	O
selected	35331	35339	O
group	35340	35345	O
of	35346	35348	O
53	35349	35351	O
genes	35352	35357	O
known	35358	35363	O
to	35364	35366	O
carry	35367	35372	O
cancer	35373	35379	O
driver	35380	35386	O
mutations	35387	35396	O
[	35397	35398	O
2	35398	35399	O
]	35399	35400	O
(	35401	35402	O
only	35402	35406	O
31	35407	35409	O
of	35410	35412	O
them	35413	35417	O
had	35418	35421	O
at	35422	35424	O
least	35425	35430	O
1	35431	35432	O
mutation	35433	35441	O
in	35442	35444	O
this	35445	35449	O
study	35450	35455	O
)	35455	35456	O
;	35456	35457	O
the	35458	35461	O
tissue	35462	35468	O
-	35468	35469	O
wide	35469	35473	O
average	35474	35481	O
is	35482	35484	O
indicated	35485	35494	O
with	35495	35499	O
the	35500	35503	O
dotted	35504	35510	O
line	35511	35515	O
.	35515	35516	O

Significant	35517	35528	O
deviation	35529	35538	O
from	35539	35543	O
the	35544	35547	O
tissue	35548	35554	O
-	35554	35555	O
wide	35555	35559	O
average	35560	35567	O
was	35568	35571	O
calculated	35572	35582	O
using	35583	35588	O
the	35589	35592	O
binomial	35593	35601	O
distribution	35602	35614	O
and	35615	35618	O
the	35619	35622	O
tissue	35623	35629	O
-	35629	35630	O
wide	35630	35634	O
average	35635	35642	O
mutation	35643	35651	O
rate	35652	35656	O
.	35656	35657	O

Benjamini	35658	35667	O
-	35667	35668	O
Hochberg	35668	35676	O
FDR	35677	35680	O
:	35680	35681	O
*	35682	35683	O
*	35683	35684	O
*	35684	35685	O
FDR	35685	35688	O
<	35689	35690	O
0	35691	35692	O
.	35692	35693	O
001	35693	35696	O
,	35696	35697	O
*	35698	35699	O
*	35699	35700	O
FDR	35700	35703	O
<	35704	35705	O
0	35706	35707	O
.	35707	35708	O
01	35708	35710	O
,	35710	35711	O
*	35712	35713	O
FDR	35713	35716	O
<	35717	35718	O
0	35719	35720	O
.	35720	35721	O
05	35721	35723	O
.	35723	35724	O
c	35725	35726	O
Individual	35727	35737	O
mutation	35738	35746	O
rates	35747	35752	O
for	35753	35756	O
each	35757	35761	O
cancer	35762	35768	O
driver	35769	35775	O
gene	35776	35780	O
across	35781	35787	O
all	35788	35791	O
tissues	35792	35799	O
.	35799	35800	O

d	35801	35802	O
Percentage	35803	35813	O
of	35814	35816	O
mutations	35817	35826	O
for	35827	35830	O
each	35831	35835	O
cancer	35836	35842	O
driver	35843	35849	O
gene	35850	35854	O
stratified	35855	35865	O
by	35866	35868	O
impact	35869	35875	O
to	35876	35878	O
amino	35879	35884	O
acid	35885	35889	O
sequence	35890	35898	O
;	35898	35899	O
n	35900	35901	O
is	35902	35904	O
the	35905	35908	O
total	35909	35914	O
number	35915	35921	O
of	35922	35924	O
mutations	35925	35934	O
observed	35935	35943	O
in	35944	35946	O
a	35947	35948	O
gene	35949	35953	O
.	35953	35954	O

e	35955	35956	O
dN	35957	35959	O
/	35959	35960	O
dS	35960	35962	O
values	35963	35969	O
for	35970	35973	O
missense	35974	35982	O
(	35983	35984	O
blue	35984	35988	O
)	35988	35989	O
and	35990	35993	O
nonsense	35994	36002	O
mutations	36003	36012	O
(	36013	36014	O
orange	36014	36020	O
)	36020	36021	O
in	36022	36024	O
cancer	36025	36031	O
driver	36032	36038	O
genes	36039	36044	O
calculated	36045	36055	O
using	36056	36061	O
dndsloc	36062	36069	O
[	36070	36071	O
9	36071	36072	O
,	36072	36073	O
36	36074	36076	O
]	36076	36077	O
(	36078	36079	O
see	36079	36082	O
the	36083	36086	O
“	36087	36088	O
Methods	36088	36095	O
”	36095	36096	O
section	36097	36104	O
)	36104	36105	O
;	36105	36106	O
averages	36107	36115	O
per	36116	36119	O
group	36120	36125	O
are	36126	36129	O
shown	36130	36135	O
as	36136	36138	O
rhomboids	36139	36148	O
,	36148	36149	O
and	36150	36153	O
their	36154	36159	O
respective	36160	36170	O
genome	36171	36177	O
-	36177	36178	O
wide	36178	36182	O
averages	36183	36191	O
are	36192	36195	O
shown	36196	36201	O
as	36202	36204	O
dashed	36205	36211	O
lines	36212	36217	O
along	36218	36223	O
with	36224	36228	O
their	36229	36234	O
95	36235	36237	O
%	36237	36238	O
confidence	36239	36249	O
intervals	36250	36259	O
after	36260	36265	O
bootstrapping	36266	36279	O
10	36280	36282	O
,	36282	36283	O
000	36283	36286	O
times	36287	36292	O
.	36292	36293	O

p	36294	36295	O
values	36296	36302	O
indicate	36303	36311	O
the	36312	36315	O
probability	36316	36327	O
of	36328	36330	O
observing	36331	36340	O
a	36341	36342	O
higher	36343	36349	O
average	36350	36357	O
dN	36358	36360	O
/	36360	36361	O
dS	36361	36363	O
from	36364	36368	O
10	36369	36371	O
,	36371	36372	O
000	36372	36375	O
equally	36376	36383	O
sized	36384	36389	O
randomly	36390	36398	O
sampled	36399	36406	O
groups	36407	36413	O
of	36414	36416	O
genes	36417	36422	O
(	36423	36424	O
see	36424	36427	O
the	36428	36431	O
“	36432	36433	O
Methods	36433	36440	O
”	36440	36441	O
section	36442	36449	O
)	36449	36450	O
.	36450	36451	O

f	36452	36453	O
Median	36454	36460	O
variant	36461	36468	O
allele	36469	36475	O
frequency	36476	36485	O
(	36486	36487	O
VAF	36487	36490	O
)	36490	36491	O
for	36492	36495	O
each	36496	36500	O
mutation	36501	36509	O
type	36510	36514	O
based	36515	36520	O
on	36521	36523	O
their	36524	36529	O
impact	36530	36536	O
to	36537	36539	O
the	36540	36543	O
amino	36544	36549	O
acid	36550	36554	O
sequence	36555	36563	O
and	36564	36567	O
colored	36568	36575	O
by	36576	36578	O
their	36579	36584	O
cancer	36585	36591	O
status	36592	36598	O
.	36598	36599	O

Mutations	36600	36609	O
“	36610	36611	O
in	36611	36613	O
cancer	36614	36620	O
”	36620	36621	O
(	36622	36623	O
purple	36623	36629	O
bars	36630	36634	O
)	36634	36635	O
are	36636	36639	O
those	36640	36645	O
that	36646	36650	O
overlap	36651	36658	O
with	36659	36663	O
the	36664	36667	O
COSMIC	36668	36674	O
database	36675	36683	O
in	36684	36686	O
both	36687	36691	O
base	36692	36696	O
change	36697	36703	O
and	36704	36707	O
position	36708	36716	O
,	36716	36717	O
and	36718	36721	O
mutations	36722	36731	O
“	36732	36733	O
not	36733	36736	O
in	36737	36739	O
cancer	36740	36746	O
”	36746	36747	O
(	36748	36749	O
yellow	36749	36755	O
bars	36756	36760	O
)	36760	36761	O
are	36762	36765	O
those	36766	36771	O
that	36772	36776	O
overlap	36777	36784	O
with	36785	36789	O
COSMIC	36790	36796	O
only	36797	36801	O
in	36802	36804	O
position	36805	36813	O
but	36814	36817	O
not	36818	36821	O
in	36822	36824	O
base	36825	36829	O
change	36830	36836	O
.	36836	36837	O

Error	36838	36843	O
bars	36844	36848	O
represent	36849	36858	O
the	36859	36862	O
95	36863	36865	O
%	36865	36866	O
confidence	36867	36877	O
interval	36878	36886	O
after	36887	36892	O
bootstrapping	36893	36906	O
1000	36907	36911	O
times	36912	36917	O
;	36917	36918	O
p	36919	36920	O
values	36921	36927	O
are	36928	36931	O
from	36932	36936	O
two	36937	36940	O
-	36940	36941	O
sided	36941	36946	O
Mann	36947	36951	O
-	36951	36952	O
Whitney	36952	36959	O
tests	36960	36965	O
.	36965	36966	O

g	36967	36968	O
Mutation	36969	36977	O
maps	36978	36982	O
of	36983	36985	O
five	36986	36990	O
cancer	36991	36997	O
driver	36998	37004	O
genes	37005	37010	O
;	37010	37011	O
oncogenic	37012	37021	O
state	37022	37027	O
was	37028	37031	O
obtained	37032	37040	O
from	37041	37045	O
oncoKB	37046	37052	O
[	37053	37054	O
37	37054	37056	O
]	37056	37057	O
,	37057	37058	O
and	37059	37062	O
clustered	37063	37072	O
mutation	37073	37081	O
annotations	37082	37093	O
were	37094	37098	O
obtained	37099	37107	O
from	37108	37112	O
the	37113	37116	O
databases	37117	37126	O
Cancer	37127	37133	O
Hotspots	37134	37142	O
[	37143	37144	O
38	37144	37146	O
]	37146	37147	O
and	37148	37151	O
3D	37152	37154	O
Hotspots	37155	37163	O
of	37164	37166	O
mutations	37167	37176	O
occurring	37177	37186	O
in	37187	37189	O
close	37190	37195	O
proximity	37196	37205	O
at	37206	37208	O
the	37209	37212	O
protein	37213	37220	O
level	37221	37226	O
[	37227	37228	O
39	37228	37230	O
]	37230	37231	O
Fig	37232	37235	O
.	37235	37236	O

5	37237	37238	O
Cancer	37239	37245	O
driver	37246	37252	O
genes	37253	37258	O
evolve	37259	37265	O
under	37266	37271	O
strong	37272	37278	O
positive	37279	37287	O
selection	37288	37297	O
,	37297	37298	O
and	37299	37302	O
cancer	37303	37309	O
mutations	37310	37319	O
are	37320	37323	O
enriched	37324	37332	O
in	37333	37335	O
healthy	37336	37343	O
tissues	37344	37351	O
.	37351	37352	O

a	37353	37354	O
Percentage	37355	37365	O
of	37366	37368	O
COSMIC	37369	37375	O
cancer	37376	37382	O
mutations	37383	37392	O
observed	37393	37401	O
per	37402	37405	O
sample	37406	37412	O
and	37413	37416	O
grouped	37417	37424	O
by	37425	37427	O
tissue	37428	37434	O
;	37434	37435	O
p	37436	37437	O
values	37438	37444	O
for	37445	37448	O
enrichment	37449	37459	O
were	37460	37464	O
calculated	37465	37475	O
using	37476	37481	O
a	37482	37483	O
hypergeometric	37484	37498	O
test	37499	37503	O
accounting	37504	37514	O
for	37515	37518	O
sequencing	37519	37529	O
coverage	37530	37538	O
,	37538	37539	O
total	37540	37545	O
number	37546	37552	O
of	37553	37555	O
mutations	37556	37565	O
per	37566	37569	O
sample	37570	37576	O
,	37576	37577	O
total	37578	37583	O
number	37584	37590	O
of	37591	37593	O
COSMIC	37594	37600	O
mutations	37601	37610	O
,	37610	37611	O
and	37612	37615	O
the	37616	37619	O
three	37620	37625	O
possible	37626	37634	O
alternate	37635	37644	O
alleles	37645	37652	O
that	37653	37657	O
any	37658	37661	O
given	37662	37667	O
reference	37668	37677	O
allele	37678	37684	O
can	37685	37688	O
have	37689	37693	O
(	37694	37695	O
see	37695	37698	O
the	37699	37702	O
“	37703	37704	O
Methods	37704	37711	O
”	37711	37712	O
section	37713	37720	O
)	37720	37721	O
.	37721	37722	O

p	37723	37724	O
values	37725	37731	O
are	37732	37735	O
Bonferroni	37736	37746	O
-	37746	37747	O
corrected	37747	37756	O
across	37757	37763	O
all	37764	37767	O
samples	37768	37775	O
.	37775	37776	O

b	37777	37778	O
Relative	37779	37787	O
mutation	37788	37796	O
rates	37797	37802	O
of	37803	37805	O
a	37806	37807	O
selected	37808	37816	O
group	37817	37822	O
of	37823	37825	O
53	37826	37828	O
genes	37829	37834	O
known	37835	37840	O
to	37841	37843	O
carry	37844	37849	O
cancer	37850	37856	O
driver	37857	37863	O
mutations	37864	37873	O
[	37874	37875	O
2	37875	37876	O
]	37876	37877	O
(	37878	37879	O
only	37879	37883	O
31	37884	37886	O
of	37887	37889	O
them	37890	37894	O
had	37895	37898	O
at	37899	37901	O
least	37902	37907	O
1	37908	37909	O
mutation	37910	37918	O
in	37919	37921	O
this	37922	37926	O
study	37927	37932	O
)	37932	37933	O
;	37933	37934	O
the	37935	37938	O
tissue	37939	37945	O
-	37945	37946	O
wide	37946	37950	O
average	37951	37958	O
is	37959	37961	O
indicated	37962	37971	O
with	37972	37976	O
the	37977	37980	O
dotted	37981	37987	O
line	37988	37992	O
.	37992	37993	O

Significant	37994	38005	O
deviation	38006	38015	O
from	38016	38020	O
the	38021	38024	O
tissue	38025	38031	O
-	38031	38032	O
wide	38032	38036	O
average	38037	38044	O
was	38045	38048	O
calculated	38049	38059	O
using	38060	38065	O
the	38066	38069	O
binomial	38070	38078	O
distribution	38079	38091	O
and	38092	38095	O
the	38096	38099	O
tissue	38100	38106	O
-	38106	38107	O
wide	38107	38111	O
average	38112	38119	O
mutation	38120	38128	O
rate	38129	38133	O
.	38133	38134	O

Benjamini	38135	38144	O
-	38144	38145	O
Hochberg	38145	38153	O
FDR	38154	38157	O
:	38157	38158	O
*	38159	38160	O
*	38160	38161	O
*	38161	38162	O
FDR	38162	38165	O
<	38166	38167	O
0	38168	38169	O
.	38169	38170	O
001	38170	38173	O
,	38173	38174	O
*	38175	38176	O
*	38176	38177	O
FDR	38177	38180	O
<	38181	38182	O
0	38183	38184	O
.	38184	38185	O
01	38185	38187	O
,	38187	38188	O
*	38189	38190	O
FDR	38190	38193	O
<	38194	38195	O
0	38196	38197	O
.	38197	38198	O
05	38198	38200	O
.	38200	38201	O
c	38202	38203	O
Individual	38204	38214	O
mutation	38215	38223	O
rates	38224	38229	O
for	38230	38233	O
each	38234	38238	O
cancer	38239	38245	O
driver	38246	38252	O
gene	38253	38257	O
across	38258	38264	O
all	38265	38268	O
tissues	38269	38276	O
.	38276	38277	O

d	38278	38279	O
Percentage	38280	38290	O
of	38291	38293	O
mutations	38294	38303	O
for	38304	38307	O
each	38308	38312	O
cancer	38313	38319	O
driver	38320	38326	O
gene	38327	38331	O
stratified	38332	38342	O
by	38343	38345	O
impact	38346	38352	O
to	38353	38355	O
amino	38356	38361	O
acid	38362	38366	O
sequence	38367	38375	O
;	38375	38376	O
n	38377	38378	O
is	38379	38381	O
the	38382	38385	O
total	38386	38391	O
number	38392	38398	O
of	38399	38401	O
mutations	38402	38411	O
observed	38412	38420	O
in	38421	38423	O
a	38424	38425	O
gene	38426	38430	O
.	38430	38431	O

e	38432	38433	O
dN	38434	38436	O
/	38436	38437	O
dS	38437	38439	O
values	38440	38446	O
for	38447	38450	O
missense	38451	38459	O
(	38460	38461	O
blue	38461	38465	O
)	38465	38466	O
and	38467	38470	O
nonsense	38471	38479	O
mutations	38480	38489	O
(	38490	38491	O
orange	38491	38497	O
)	38497	38498	O
in	38499	38501	O
cancer	38502	38508	O
driver	38509	38515	O
genes	38516	38521	O
calculated	38522	38532	O
using	38533	38538	O
dndsloc	38539	38546	O
[	38547	38548	O
9	38548	38549	O
,	38549	38550	O
36	38551	38553	O
]	38553	38554	O
(	38555	38556	O
see	38556	38559	O
the	38560	38563	O
“	38564	38565	O
Methods	38565	38572	O
”	38572	38573	O
section	38574	38581	O
)	38581	38582	O
;	38582	38583	O
averages	38584	38592	O
per	38593	38596	O
group	38597	38602	O
are	38603	38606	O
shown	38607	38612	O
as	38613	38615	O
rhomboids	38616	38625	O
,	38625	38626	O
and	38627	38630	O
their	38631	38636	O
respective	38637	38647	O
genome	38648	38654	O
-	38654	38655	O
wide	38655	38659	O
averages	38660	38668	O
are	38669	38672	O
shown	38673	38678	O
as	38679	38681	O
dashed	38682	38688	O
lines	38689	38694	O
along	38695	38700	O
with	38701	38705	O
their	38706	38711	O
95	38712	38714	O
%	38714	38715	O
confidence	38716	38726	O
intervals	38727	38736	O
after	38737	38742	O
bootstrapping	38743	38756	O
10	38757	38759	O
,	38759	38760	O
000	38760	38763	O
times	38764	38769	O
.	38769	38770	O

p	38771	38772	O
values	38773	38779	O
indicate	38780	38788	O
the	38789	38792	O
probability	38793	38804	O
of	38805	38807	O
observing	38808	38817	O
a	38818	38819	O
higher	38820	38826	O
average	38827	38834	O
dN	38835	38837	O
/	38837	38838	O
dS	38838	38840	O
from	38841	38845	O
10	38846	38848	O
,	38848	38849	O
000	38849	38852	O
equally	38853	38860	O
sized	38861	38866	O
randomly	38867	38875	O
sampled	38876	38883	O
groups	38884	38890	O
of	38891	38893	O
genes	38894	38899	O
(	38900	38901	O
see	38901	38904	O
the	38905	38908	O
“	38909	38910	O
Methods	38910	38917	O
”	38917	38918	O
section	38919	38926	O
)	38926	38927	O
.	38927	38928	O

f	38929	38930	O
Median	38931	38937	O
variant	38938	38945	O
allele	38946	38952	O
frequency	38953	38962	O
(	38963	38964	O
VAF	38964	38967	O
)	38967	38968	O
for	38969	38972	O
each	38973	38977	O
mutation	38978	38986	O
type	38987	38991	O
based	38992	38997	O
on	38998	39000	O
their	39001	39006	O
impact	39007	39013	O
to	39014	39016	O
the	39017	39020	O
amino	39021	39026	O
acid	39027	39031	O
sequence	39032	39040	O
and	39041	39044	O
colored	39045	39052	O
by	39053	39055	O
their	39056	39061	O
cancer	39062	39068	O
status	39069	39075	O
.	39075	39076	O

Mutations	39077	39086	O
“	39087	39088	O
in	39088	39090	O
cancer	39091	39097	O
”	39097	39098	O
(	39099	39100	O
purple	39100	39106	O
bars	39107	39111	O
)	39111	39112	O
are	39113	39116	O
those	39117	39122	O
that	39123	39127	O
overlap	39128	39135	O
with	39136	39140	O
the	39141	39144	O
COSMIC	39145	39151	O
database	39152	39160	O
in	39161	39163	O
both	39164	39168	O
base	39169	39173	O
change	39174	39180	O
and	39181	39184	O
position	39185	39193	O
,	39193	39194	O
and	39195	39198	O
mutations	39199	39208	O
“	39209	39210	O
not	39210	39213	O
in	39214	39216	O
cancer	39217	39223	O
”	39223	39224	O
(	39225	39226	O
yellow	39226	39232	O
bars	39233	39237	O
)	39237	39238	O
are	39239	39242	O
those	39243	39248	O
that	39249	39253	O
overlap	39254	39261	O
with	39262	39266	O
COSMIC	39267	39273	O
only	39274	39278	O
in	39279	39281	O
position	39282	39290	O
but	39291	39294	O
not	39295	39298	O
in	39299	39301	O
base	39302	39306	O
change	39307	39313	O
.	39313	39314	O

Error	39315	39320	O
bars	39321	39325	O
represent	39326	39335	O
the	39336	39339	O
95	39340	39342	O
%	39342	39343	O
confidence	39344	39354	O
interval	39355	39363	O
after	39364	39369	O
bootstrapping	39370	39383	O
1000	39384	39388	O
times	39389	39394	O
;	39394	39395	O
p	39396	39397	O
values	39398	39404	O
are	39405	39408	O
from	39409	39413	O
two	39414	39417	O
-	39417	39418	O
sided	39418	39423	O
Mann	39424	39428	O
-	39428	39429	O
Whitney	39429	39436	O
tests	39437	39442	O
.	39442	39443	O

g	39444	39445	O
Mutation	39446	39454	O
maps	39455	39459	O
of	39460	39462	O
five	39463	39467	O
cancer	39468	39474	O
driver	39475	39481	O
genes	39482	39487	O
;	39487	39488	O
oncogenic	39489	39498	O
state	39499	39504	O
was	39505	39508	O
obtained	39509	39517	O
from	39518	39522	O
oncoKB	39523	39529	O
[	39530	39531	O
37	39531	39533	O
]	39533	39534	O
,	39534	39535	O
and	39536	39539	O
clustered	39540	39549	O
mutation	39550	39558	O
annotations	39559	39570	O
were	39571	39575	O
obtained	39576	39584	O
from	39585	39589	O
the	39590	39593	O
databases	39594	39603	O
Cancer	39604	39610	O
Hotspots	39611	39619	O
[	39620	39621	O
38	39621	39623	O
]	39623	39624	O
and	39625	39628	O
3D	39629	39631	O
Hotspots	39632	39640	O
of	39641	39643	O
mutations	39644	39653	O
occurring	39654	39663	O
in	39664	39666	O
close	39667	39672	O
proximity	39673	39682	O
at	39683	39685	O
the	39686	39689	O
protein	39690	39697	O
level	39698	39703	O
[	39704	39705	O
39	39705	39707	O
]	39707	39708	O
Focusing	39709	39717	O
our	39718	39721	O
analysis	39722	39730	O
on	39731	39733	O
a	39734	39735	O
panel	39736	39741	O
of	39742	39744	O
53	39745	39747	O
known	39748	39753	O
cancer	39754	39760	O
driver	39761	39767	O
genes	39768	39773	O
[	39774	39775	O
2	39775	39776	O
]	39776	39777	O
(	39778	39779	O
Additional	39779	39789	O
file	39790	39794	O
13	39795	39797	O
:	39797	39798	O
Table	39799	39804	O
S10	39805	39808	O
)	39808	39809	O
,	39809	39810	O
we	39811	39813	O
observed	39814	39822	O
mutations	39823	39832	O
in	39833	39835	O
31	39836	39838	O
of	39839	39841	O
them	39842	39846	O
(	39847	39848	O
after	39848	39853	O
excluding	39854	39863	O
potential	39864	39873	O
false	39874	39879	O
-	39879	39880	O
positive	39880	39888	O
mutations	39889	39898	O
;	39898	39899	O
see	39900	39903	O
the	39904	39907	O
“	39908	39909	O
Methods	39909	39916	O
”	39916	39917	O
section	39918	39925	O
and	39926	39929	O
Additional	39930	39940	O
file	39941	39945	O
14	39946	39948	O
:	39948	39949	O
Table	39950	39955	O
S11	39956	39959	O
)	39959	39960	O
.	39960	39961	O

Some	39962	39966	O
tissues	39967	39974	O
showed	39975	39981	O
significantly	39982	39995	O
greater	39996	40003	O
or	40004	40006	O
lower	40007	40012	O
mutation	40013	40021	O
rates	40022	40027	O
across	40028	40034	O
these	40035	40040	O
genes	40041	40046	O
(	40047	40048	O
Fig	40048	40051	O
.	40051	40052	O

5b	40053	40055	O
)	40055	40056	O
.	40056	40057	O

The	40058	40061	O
sun	40062	40065	O
-	40065	40066	O
exposed	40066	40073	O
skin	40074	40078	O
was	40079	40082	O
once	40083	40087	O
again	40088	40093	O
the	40094	40097	O
most	40098	40102	O
significant	40103	40114	O
tissue	40115	40121	O
,	40121	40122	O
with	40123	40127	O
several	40128	40135	O
others	40136	40142	O
at	40143	40145	O
FDR	40146	40149	O
<	40150	40151	O
0	40152	40153	O
.	40153	40154	O
05	40154	40156	O
,	40156	40157	O
such	40158	40162	O
as	40163	40165	O
the	40166	40169	O
muscle	40170	40176	O
and	40177	40180	O
heart	40181	40186	O
(	40187	40188	O
Fig	40188	40191	O
.	40191	40192	O

5b	40193	40195	O
)	40195	40196	O
.	40196	40197	O

Interestingly	40198	40211	O
,	40211	40212	O
MAP2K1	40213	40219	O
and	40220	40223	O
RRAS2	40224	40229	O
are	40230	40233	O
highly	40234	40240	O
mutated	40241	40248	O
in	40249	40251	O
the	40252	40255	O
muscle	40256	40262	O
,	40262	40263	O
and	40264	40267	O
IDH2	40268	40272	O
and	40273	40276	O
PPP2R1A	40277	40284	O
are	40285	40288	O
highly	40289	40295	O
mutated	40296	40303	O
in	40304	40306	O
both	40307	40311	O
the	40312	40315	O
heart	40316	40321	O
and	40322	40325	O
skeletal	40326	40334	O
muscle	40335	40341	O
(	40342	40343	O
Fig	40343	40346	O
.	40346	40347	O

5c	40348	40350	O
)	40350	40351	O
.	40351	40352	O

Conversely	40353	40363	O
,	40363	40364	O
several	40365	40372	O
tissues	40373	40380	O
—	40380	40381	O
including	40381	40390	O
most	40391	40395	O
brain	40396	40401	O
regions	40402	40409	O
—	40409	40410	O
had	40410	40413	O
significantly	40414	40427	O
lower	40428	40433	O
mutation	40434	40442	O
rates	40443	40448	O
than	40449	40453	O
average	40454	40461	O
in	40462	40464	O
these	40465	40470	O
cancer	40471	40477	O
drivers	40478	40485	O
(	40486	40487	O
Fig	40487	40490	O
.	40490	40491	O

5b	40492	40494	O
)	40494	40495	O
.	40495	40496	O

Observed	40497	40505	O
mutations	40506	40515	O
in	40516	40518	O
cancer	40519	40525	O
driver	40526	40532	O
genes	40533	40538	O
were	40539	40543	O
then	40544	40548	O
classified	40549	40559	O
by	40560	40562	O
their	40563	40568	O
impact	40569	40575	O
on	40576	40578	O
protein	40579	40586	O
sequences	40587	40596	O
.	40596	40597	O

We	40598	40600	O
found	40601	40606	O
that	40607	40611	O
some	40612	40616	O
genes	40617	40622	O
were	40623	40627	O
dominated	40628	40637	O
by	40638	40640	O
missense	40641	40649	O
mutations	40650	40659	O
,	40659	40660	O
such	40661	40665	O
as	40666	40668	O
IDH2	40669	40673	O
,	40673	40674	O
while	40675	40680	O
others	40681	40687	O
showed	40688	40694	O
an	40695	40697	O
excess	40698	40704	O
of	40705	40707	O
synonymous	40708	40718	O
mutations	40719	40728	O
,	40728	40729	O
such	40730	40734	O
as	40735	40737	O
MAP2K1	40738	40744	O
(	40745	40746	O
Fig	40746	40749	O
.	40749	40750	O

5d	40751	40753	O
)	40753	40754	O
.	40754	40755	O

To	40756	40758	O
assess	40759	40765	O
the	40766	40769	O
selective	40770	40779	O
pressures	40780	40789	O
acting	40790	40796	O
on	40797	40799	O
these	40800	40805	O
genes	40806	40811	O
,	40811	40812	O
we	40813	40815	O
used	40816	40820	O
a	40821	40822	O
dN	40823	40825	O
/	40825	40826	O
dS	40826	40828	O
approach	40829	40837	O
,	40837	40838	O
which	40839	40844	O
assesses	40845	40853	O
the	40854	40857	O
ratio	40858	40863	O
of	40864	40866	O
non	40867	40870	O
-	40870	40871	O
synonymous	40871	40881	O
to	40882	40884	O
synonymous	40885	40895	O
mutations	40896	40905	O
while	40906	40911	O
accounting	40912	40922	O
for	40923	40926	O
sequence	40927	40935	O
composition	40936	40947	O
and	40948	40951	O
variable	40952	40960	O
mutation	40961	40969	O
rates	40970	40975	O
across	40976	40982	O
the	40983	40986	O
genome	40987	40993	O
[	40994	40995	O
36	40995	40997	O
]	40997	40998	O
(	40999	41000	O
see	41000	41003	O
the	41004	41007	O
“	41008	41009	O
Methods	41009	41016	O
”	41016	41017	O
section	41018	41025	O
)	41025	41026	O
.	41026	41027	O

dN	41028	41030	O
/	41030	41031	O
dS	41031	41033	O
values	41034	41040	O
close	41041	41046	O
to	41047	41049	O
1	41050	41051	O
represent	41052	41061	O
little	41062	41068	O
or	41069	41071	O
no	41072	41074	O
detectable	41075	41085	O
selection	41086	41095	O
,	41095	41096	O
dN	41097	41099	O
/	41099	41100	O
dS	41100	41102	O
>	41103	41104	O
1	41105	41106	O
suggests	41107	41115	O
positive	41116	41124	O
selection	41125	41134	O
,	41134	41135	O
and	41136	41139	O
dN	41140	41142	O
/	41142	41143	O
dS	41143	41145	O
<	41146	41147	O
1	41148	41149	O
suggests	41150	41158	O
purifying	41159	41168	O
selection	41169	41178	O
.	41178	41179	O

Our	41180	41183	O
analysis	41184	41192	O
showed	41193	41199	O
that	41200	41204	O
most	41205	41209	O
of	41210	41212	O
these	41213	41218	O
cancer	41219	41225	O
drivers	41226	41233	O
are	41234	41237	O
evolving	41238	41246	O
under	41247	41252	O
positive	41253	41261	O
selection	41262	41271	O
(	41272	41273	O
Fig	41273	41276	O
.	41276	41277	O

5e	41278	41280	O
)	41280	41281	O
.	41281	41282	O

Missense	41283	41291	O
mutations	41292	41301	O
had	41302	41305	O
a	41306	41307	O
mean	41308	41312	O
dN	41313	41315	O
/	41315	41316	O
dS	41316	41318	O
=	41319	41320	O
1	41321	41322	O
.	41322	41323	O
06	41323	41325	O
whereas	41326	41333	O
nonsense	41334	41342	O
mutations	41343	41352	O
had	41353	41356	O
a	41357	41358	O
mean	41359	41363	O
dN	41364	41366	O
/	41366	41367	O
dS	41367	41369	O
=	41370	41371	O
9	41372	41373	O
.	41373	41374	O
14	41374	41376	O
(	41377	41378	O
indicating	41378	41388	O
over	41389	41393	O
ninefold	41394	41402	O
enrichment	41403	41413	O
for	41414	41417	O
nonsense	41418	41426	O
mutations	41427	41436	O
compared	41437	41445	O
to	41446	41448	O
the	41449	41452	O
expectation	41453	41464	O
based	41465	41470	O
on	41471	41473	O
synonymous	41474	41484	O
mutations	41485	41494	O
in	41495	41497	O
the	41498	41501	O
same	41502	41506	O
genes	41507	41512	O
)	41512	41513	O
;	41513	41514	O
the	41515	41518	O
latter	41519	41525	O
is	41526	41528	O
significantly	41529	41542	O
more	41543	41547	O
than	41548	41552	O
expected	41553	41561	O
from	41562	41566	O
genome	41567	41573	O
-	41573	41574	O
wide	41574	41578	O
values	41579	41585	O
(	41586	41587	O
permutation	41587	41598	O
-	41598	41599	O
based	41599	41604	O
p	41605	41606	O
=	41607	41608	O
0	41609	41610	O
.	41610	41611	O
1	41611	41612	O
and	41613	41616	O
p	41617	41618	O
=	41619	41620	O
0	41621	41622	O
.	41622	41623	O
009	41623	41626	O
,	41626	41627	O
respectively	41628	41640	O
;	41640	41641	O
Fig	41642	41645	O
.	41645	41646	O

5e	41647	41649	O
)	41649	41650	O
.	41650	41651	O

NOTCH1	41652	41658	O
has	41659	41662	O
been	41663	41667	O
recently	41668	41676	O
observed	41677	41685	O
to	41686	41688	O
evolve	41689	41695	O
under	41696	41701	O
positive	41702	41710	O
selection	41711	41720	O
in	41721	41723	O
the	41724	41727	O
non	41728	41731	O
-	41731	41732	O
cancerous	41732	41741	O
skin	41742	41746	O
[	41747	41748	O
15	41748	41750	O
]	41750	41751	O
and	41752	41755	O
esophagus	41756	41765	O
[	41766	41767	O
18	41767	41769	O
,	41769	41770	O
19	41771	41773	O
]	41773	41774	O
.	41774	41775	O

Consistent	41776	41786	O
with	41787	41791	O
this	41792	41796	O
,	41796	41797	O
we	41798	41800	O
found	41801	41806	O
the	41807	41810	O
highest	41811	41818	O
rates	41819	41824	O
of	41825	41827	O
NOTCH1	41828	41834	O
mutations	41835	41844	O
in	41845	41847	O
these	41848	41853	O
same	41854	41858	O
two	41859	41862	O
tissues	41863	41870	O
(	41871	41872	O
Fig	41872	41875	O
.	41875	41876	O

5c	41877	41879	O
)	41879	41880	O
,	41880	41881	O
with	41882	41886	O
strong	41887	41893	O
signals	41894	41901	O
of	41902	41904	O
positive	41905	41913	O
selection	41914	41923	O
(	41924	41925	O
NOTCH1	41925	41931	O
missense	41932	41940	O
dN	41941	41943	O
/	41943	41944	O
dS	41944	41946	O
=	41947	41948	O
1	41949	41950	O
.	41950	41951	O
46	41951	41953	O
,	41953	41954	O
nonsense	41955	41963	O
dN	41964	41966	O
/	41966	41967	O
dS	41967	41969	O
=	41970	41971	O
14	41972	41974	O
.	41974	41975	O
04	41975	41977	O
)	41977	41978	O
.	41978	41979	O

We	41980	41982	O
also	41983	41987	O
observed	41988	41996	O
NOTCH1	41997	42003	O
mutations	42004	42013	O
at	42014	42016	O
slightly	42017	42025	O
lower	42026	42031	O
rates	42032	42037	O
in	42038	42040	O
the	42041	42044	O
small	42045	42050	O
intestine	42051	42060	O
and	42061	42064	O
tibial	42065	42071	O
artery	42072	42078	O
(	42079	42080	O
Fig	42080	42083	O
.	42083	42084	O

5c	42085	42087	O
)	42087	42088	O
.	42088	42089	O

To	42090	42092	O
further	42093	42100	O
explore	42101	42108	O
the	42109	42112	O
effects	42113	42120	O
of	42121	42123	O
selection	42124	42133	O
on	42134	42136	O
cancer	42137	42143	O
-	42143	42144	O
associated	42144	42154	O
mutations	42155	42164	O
,	42164	42165	O
we	42166	42168	O
performed	42169	42178	O
a	42179	42180	O
VAF	42181	42184	O
analysis	42185	42193	O
(	42194	42195	O
similar	42195	42202	O
to	42203	42205	O
Fig	42206	42209	O
.	42209	42210	O

2d	42211	42213	O
)	42213	42214	O
.	42214	42215	O

Using	42216	42221	O
the	42222	42225	O
large	42226	42231	O
catalog	42232	42239	O
of	42240	42242	O
COSMIC	42243	42249	O
cancer	42250	42256	O
point	42257	42262	O
mutations	42263	42272	O
(	42273	42274	O
as	42274	42276	O
in	42277	42279	O
Fig	42280	42283	O
.	42283	42284	O

5a	42285	42287	O
)	42287	42288	O
,	42288	42289	O
we	42290	42292	O
created	42293	42300	O
two	42301	42304	O
subsets	42305	42312	O
of	42313	42315	O
our	42316	42319	O
somatic	42320	42327	O
mutation	42328	42336	O
list	42337	42341	O
:	42341	42342	O
those	42343	42348	O
that	42349	42353	O
have	42354	42358	O
been	42359	42363	O
observed	42364	42372	O
in	42373	42375	O
cancer	42376	42382	O
samples	42383	42390	O
and	42391	42394	O
those	42395	42400	O
at	42401	42403	O
precisely	42404	42413	O
the	42414	42417	O
same	42418	42422	O
location	42423	42431	O
as	42432	42434	O
a	42435	42436	O
known	42437	42442	O
cancer	42443	42449	O
mutation	42450	42458	O
,	42458	42459	O
but	42460	42463	O
with	42464	42468	O
a	42469	42470	O
different	42471	42480	O
base	42481	42485	O
change	42486	42492	O
(	42493	42494	O
which	42494	42499	O
act	42500	42503	O
as	42504	42506	O
well	42507	42511	O
-	42511	42512	O
matched	42512	42519	O
negative	42520	42528	O
controls	42529	42537	O
)	42537	42538	O
.	42538	42539	O

We	42540	42542	O
then	42543	42547	O
separated	42548	42557	O
each	42558	42562	O
of	42563	42565	O
these	42566	42571	O
two	42572	42575	O
subsets	42576	42583	O
into	42584	42588	O
three	42589	42594	O
mutation	42595	42603	O
types	42604	42609	O
:	42609	42610	O
synonymous	42611	42621	O
,	42621	42622	O
missense	42623	42631	O
,	42631	42632	O
and	42633	42636	O
nonsense	42637	42645	O
.	42645	42646	O

In	42647	42649	O
all	42650	42653	O
three	42654	42659	O
cases	42660	42665	O
,	42665	42666	O
the	42667	42670	O
VAFs	42671	42675	O
of	42676	42678	O
the	42679	42682	O
cancer	42683	42689	O
-	42689	42690	O
associated	42690	42700	O
mutations	42701	42710	O
were	42711	42715	O
significantly	42716	42729	O
higher	42730	42736	O
than	42737	42741	O
the	42742	42745	O
matched	42746	42753	O
non	42754	42757	O
-	42757	42758	O
cancer	42758	42764	O
-	42764	42765	O
associated	42765	42775	O
ones	42776	42780	O
(	42781	42782	O
Fig	42782	42785	O
.	42785	42786	O

5f	42787	42789	O
)	42789	42790	O
,	42790	42791	O
suggesting	42792	42802	O
that	42803	42807	O
cancer	42808	42814	O
-	42814	42815	O
associated	42815	42825	O
mutations	42826	42835	O
often	42836	42841	O
increase	42842	42850	O
cellular	42851	42859	O
proliferation	42860	42873	O
rates	42874	42879	O
(	42880	42881	O
and	42881	42884	O
thus	42885	42889	O
VAFs	42890	42894	O
)	42894	42895	O
.	42895	42896	O

Using	42897	42902	O
the	42903	42906	O
synonymous	42907	42917	O
non	42918	42921	O
-	42921	42922	O
cancer	42922	42928	O
mutations	42929	42938	O
as	42939	42941	O
representative	42942	42956	O
of	42957	42959	O
neutrality	42960	42970	O
(	42971	42972	O
similar	42972	42979	O
to	42980	42982	O
the	42983	42986	O
logic	42987	42992	O
of	42993	42995	O
dN	42996	42998	O
/	42998	42999	O
dS	42999	43001	O
)	43001	43002	O
,	43002	43003	O
we	43004	43006	O
found	43007	43012	O
that	43013	43017	O
all	43018	43021	O
three	43022	43027	O
cancer	43028	43034	O
-	43034	43035	O
associated	43035	43045	O
mutation	43046	43054	O
types	43055	43060	O
had	43061	43064	O
higher	43065	43071	O
VAF	43072	43075	O
than	43076	43080	O
these	43081	43086	O
neutral	43087	43094	O
proxies	43095	43102	O
(	43103	43104	O
Fig	43104	43107	O
.	43107	43108	O

5f	43109	43111	O
)	43111	43112	O
,	43112	43113	O
suggesting	43114	43124	O
the	43125	43128	O
action	43129	43135	O
of	43136	43138	O
positive	43139	43147	O
(	43148	43149	O
and	43149	43152	O
not	43153	43156	O
just	43157	43161	O
weaker	43162	43168	O
negative	43169	43177	O
)	43177	43178	O
selection	43179	43188	O
.	43188	43189	O

Interestingly	43190	43203	O
,	43203	43204	O
the	43205	43208	O
ratio	43209	43214	O
of	43215	43217	O
cancer	43218	43224	O
/	43224	43225	O
non	43225	43228	O
-	43228	43229	O
cancer	43229	43235	O
mutation	43236	43244	O
VAFs	43245	43249	O
was	43250	43253	O
lowest	43254	43260	O
for	43261	43264	O
synonymous	43265	43275	O
(	43276	43277	O
1	43277	43278	O
.	43278	43279	O
4	43279	43280	O
-	43280	43281	O
fold	43281	43285	O
)	43285	43286	O
,	43286	43287	O
intermediate	43288	43300	O
for	43301	43304	O
missense	43305	43313	O
(	43314	43315	O
2	43315	43316	O
.	43316	43317	O
0	43317	43318	O
-	43318	43319	O
fold	43319	43323	O
)	43323	43324	O
,	43324	43325	O
and	43326	43329	O
highest	43330	43337	O
for	43338	43341	O
nonsense	43342	43350	O
(	43351	43352	O
5	43352	43353	O
.	43353	43354	O
2	43354	43355	O
-	43355	43356	O
fold	43356	43360	O
)	43360	43361	O
,	43361	43362	O
suggesting	43363	43373	O
stronger	43374	43382	O
positive	43383	43391	O
selection	43392	43401	O
for	43402	43405	O
more	43406	43410	O
extreme	43411	43418	O
mutations	43419	43428	O
.	43428	43429	O

In	43430	43432	O
addition	43433	43441	O
,	43441	43442	O
cancer	43443	43449	O
-	43449	43450	O
associated	43450	43460	O
mutations	43461	43470	O
were	43471	43475	O
found	43476	43481	O
in	43482	43484	O
more	43485	43489	O
individuals	43490	43501	O
compared	43502	43510	O
to	43511	43513	O
other	43514	43519	O
mutations	43520	43529	O
,	43529	43530	O
particularly	43531	43543	O
in	43544	43546	O
non	43547	43550	O
-	43550	43551	O
brain	43551	43556	O
tissues	43557	43564	O
(	43565	43566	O
median	43566	43572	O
of	43573	43575	O
1	43576	43577	O
.	43577	43578	O
7	43578	43579	O
-	43579	43580	O
fold	43580	43584	O
more	43585	43589	O
individuals	43590	43601	O
for	43602	43605	O
non	43606	43609	O
-	43609	43610	O
brain	43610	43615	O
mutations	43616	43625	O
,	43625	43626	O
and	43627	43630	O
1	43631	43632	O
.	43632	43633	O
2	43633	43634	O
-	43634	43635	O
fold	43635	43639	O
for	43640	43643	O
the	43644	43647	O
brain	43648	43653	O
)	43653	43654	O
.	43654	43655	O

These	43656	43661	O
results	43662	43669	O
are	43670	43673	O
consistent	43674	43684	O
with	43685	43689	O
the	43690	43693	O
dN	43694	43696	O
/	43696	43697	O
dS	43697	43699	O
analysis	43700	43708	O
in	43709	43711	O
Fig	43712	43715	O
.	43715	43716	O

5e	43717	43719	O
,	43719	43720	O
which	43721	43726	O
also	43727	43731	O
showed	43732	43738	O
the	43739	43742	O
strongest	43743	43752	O
positive	43753	43761	O
selection	43762	43771	O
on	43772	43774	O
nonsense	43775	43783	O
mutations	43784	43793	O
in	43794	43796	O
cancer	43797	43803	O
driver	43804	43810	O
genes	43811	43816	O
,	43816	43817	O
but	43818	43821	O
the	43822	43825	O
VAF	43826	43829	O
analysis	43830	43838	O
has	43839	43842	O
substantially	43843	43856	O
more	43857	43861	O
power	43862	43867	O
due	43868	43871	O
to	43872	43874	O
the	43875	43878	O
greater	43879	43886	O
number	43887	43893	O
of	43894	43896	O
mutations	43897	43906	O
analyzed	43907	43915	O
.	43915	43916	O

To	43917	43919	O
explore	43920	43927	O
a	43928	43929	O
subset	43930	43936	O
of	43937	43939	O
cancer	43940	43946	O
driver	43947	43953	O
mutations	43954	43963	O
in	43964	43966	O
more	43967	43971	O
detail	43972	43978	O
,	43978	43979	O
we	43980	43982	O
identified	43983	43993	O
specific	43994	44002	O
mutations	44003	44012	O
in	44013	44015	O
our	44016	44019	O
catalog	44020	44027	O
that	44028	44032	O
have	44033	44037	O
been	44038	44042	O
manually	44043	44051	O
curated	44052	44059	O
as	44060	44062	O
oncogenic	44063	44072	O
or	44073	44075	O
likely	44076	44082	O
oncogenic	44083	44092	O
from	44093	44097	O
OncoKB	44098	44104	O
[	44105	44106	O
37	44106	44108	O
]	44108	44109	O
(	44110	44111	O
Additional	44111	44121	O
file	44122	44126	O
15	44127	44129	O
:	44129	44130	O
Table	44131	44136	O
S12	44137	44140	O
)	44140	44141	O
.	44141	44142	O

For	44143	44146	O
instance	44147	44155	O
,	44155	44156	O
all	44157	44160	O
nonsense	44161	44169	O
mutations	44170	44179	O
that	44180	44184	O
we	44185	44187	O
observed	44188	44196	O
in	44197	44199	O
NOTCH1	44200	44206	O
have	44207	44211	O
been	44212	44216	O
labeled	44217	44224	O
as	44225	44227	O
oncogenic	44228	44237	O
(	44238	44239	O
Fig	44239	44242	O
.	44242	44243	O

5g	44244	44246	O
)	44246	44247	O
.	44247	44248	O

We	44249	44251	O
found	44252	44257	O
many	44258	44262	O
other	44263	44268	O
oncogenic	44269	44278	O
mutations	44279	44288	O
as	44289	44291	O
well	44292	44296	O
;	44296	44297	O
for	44298	44301	O
example	44302	44309	O
,	44309	44310	O
RHOA	44311	44315	O
and	44316	44319	O
RAC1	44320	44324	O
had	44325	44328	O
oncogenic	44329	44338	O
mutations	44339	44348	O
in	44349	44351	O
their	44352	44357	O
Ras	44358	44361	O
domains	44362	44369	O
(	44370	44371	O
Fig	44371	44374	O
.	44374	44375	O

5g	44376	44378	O
)	44378	44379	O
.	44379	44380	O

Together	44381	44389	O
,	44389	44390	O
these	44391	44396	O
results	44397	44404	O
show	44405	44409	O
that	44410	44414	O
cancer	44415	44421	O
mutations	44422	44431	O
are	44432	44435	O
enriched	44436	44444	O
in	44445	44447	O
non	44448	44451	O
-	44451	44452	O
disease	44452	44459	O
tissues	44460	44467	O
and	44468	44471	O
not	44472	44475	O
only	44476	44480	O
do	44481	44483	O
they	44484	44488	O
accumulate	44489	44499	O
in	44500	44502	O
driver	44503	44509	O
genes	44510	44515	O
,	44515	44516	O
but	44517	44520	O
the	44521	44524	O
majority	44525	44533	O
of	44534	44536	O
these	44537	44542	O
genes	44543	44548	O
are	44549	44552	O
evolving	44553	44561	O
under	44562	44567	O
positive	44568	44576	O
selection	44577	44586	O
,	44586	44587	O
suggesting	44588	44598	O
that	44599	44603	O
these	44604	44609	O
mutations	44610	44619	O
increase	44620	44628	O
cellular	44629	44637	O
proliferation	44638	44651	O
well	44652	44656	O
before	44657	44663	O
any	44664	44667	O
cancer	44668	44674	O
is	44675	44677	O
observed	44678	44686	O
.	44686	44687	O

Discussion	44689	44699	O
We	44700	44702	O
developed	44703	44712	O
a	44713	44714	O
method	44715	44721	O
to	44722	44724	O
detect	44725	44731	O
rare	44732	44736	O
somatic	44737	44744	O
mutations	44745	44754	O
from	44755	44759	O
RNA	44760	44763	O
-	44763	44764	O
seq	44764	44767	O
data	44768	44772	O
and	44773	44776	O
applied	44777	44784	O
it	44785	44787	O
to	44788	44790	O
over	44791	44795	O
7500	44796	44800	O
tissue	44801	44807	O
samples	44808	44815	O
(	44816	44817	O
Fig	44817	44820	O
.	44820	44821	O

1	44822	44823	O
)	44823	44824	O
.	44824	44825	O

To	44826	44828	O
our	44829	44832	O
knowledge	44833	44842	O
,	44842	44843	O
this	44844	44848	O
is	44849	44851	O
the	44852	44855	O
largest	44856	44863	O
map	44864	44867	O
to	44868	44870	O
date	44871	44875	O
of	44876	44878	O
somatic	44879	44886	O
mutations	44887	44896	O
in	44897	44899	O
non	44900	44903	O
-	44903	44904	O
cancerous	44904	44913	O
tissues	44914	44921	O
.	44921	44922	O

It	44923	44925	O
has	44926	44929	O
been	44930	44934	O
proposed	44935	44943	O
that	44944	44948	O
somatic	44949	44956	O
mutations	44957	44966	O
contribute	44967	44977	O
to	44978	44980	O
aging	44981	44986	O
and	44987	44990	O
organ	44991	44996	O
deterioration	44997	45010	O
[	45011	45012	O
40	45012	45014	O
,	45014	45015	O
41	45016	45018	O
]	45018	45019	O
;	45019	45020	O
consistently	45021	45033	O
,	45033	45034	O
we	45035	45037	O
observed	45038	45046	O
a	45047	45048	O
positive	45049	45057	O
correlation	45058	45069	O
between	45070	45077	O
age	45078	45081	O
and	45082	45085	O
mutation	45086	45094	O
burden	45095	45101	O
in	45102	45104	O
most	45105	45109	O
tissues	45110	45117	O
.	45117	45118	O

Interestingly	45119	45132	O
,	45132	45133	O
several	45134	45141	O
brain	45142	45147	O
regions	45148	45155	O
are	45156	45159	O
among	45160	45165	O
the	45166	45169	O
tissues	45170	45177	O
exhibiting	45178	45188	O
stronger	45189	45197	O
age	45198	45201	O
correlation	45202	45213	O
,	45213	45214	O
and	45215	45218	O
somatic	45219	45226	O
mutations	45227	45236	O
have	45237	45241	O
been	45242	45246	O
shown	45247	45252	O
to	45253	45255	O
have	45256	45260	O
a	45261	45262	O
role	45263	45267	O
in	45268	45270	O
neurodegeneration	45271	45288	O
[	45289	45290	O
23	45290	45292	O
]	45292	45293	O
.	45293	45294	O

We	45295	45297	O
observed	45298	45306	O
largely	45307	45314	O
tissue	45315	45321	O
-	45321	45322	O
specific	45322	45330	O
behaviors	45331	45340	O
and	45341	45344	O
some	45345	45349	O
pervasive	45350	45359	O
observations	45360	45372	O
shared	45373	45379	O
across	45380	45386	O
tissues	45387	45394	O
,	45394	45395	O
providing	45396	45405	O
genome	45406	45412	O
-	45412	45413	O
wide	45413	45417	O
evidence	45418	45426	O
in	45427	45429	O
humans	45430	45436	O
consistent	45437	45447	O
with	45448	45452	O
earlier	45453	45460	O
gene	45461	45465	O
-	45465	45466	O
level	45466	45471	O
findings	45472	45480	O
in	45481	45483	O
mouse	45484	45489	O
models	45490	45496	O
[	45497	45498	O
42	45498	45500	O
]	45500	45501	O
.	45501	45502	O

Mutation	45503	45511	O
profiles	45512	45520	O
are	45521	45524	O
defined	45525	45532	O
by	45533	45535	O
their	45536	45541	O
tissue	45542	45548	O
-	45548	45549	O
of	45549	45551	O
-	45551	45552	O
origin	45552	45558	O
,	45558	45559	O
mutation	45560	45568	O
maps	45569	45573	O
are	45574	45577	O
delineated	45578	45588	O
by	45589	45591	O
tissue	45592	45598	O
-	45598	45599	O
specific	45599	45607	O
chromatin	45608	45617	O
organization	45618	45630	O
,	45630	45631	O
and	45632	45635	O
transcriptional	45636	45651	O
signatures	45652	45662	O
associated	45663	45673	O
with	45674	45678	O
mutation	45679	45687	O
load	45688	45692	O
are	45693	45696	O
highly	45697	45703	O
tissue	45704	45710	O
-	45710	45711	O
specific	45711	45719	O
.	45719	45720	O

These	45721	45726	O
results	45727	45734	O
suggest	45735	45742	O
that	45743	45747	O
different	45748	45757	O
cell	45758	45762	O
types	45763	45768	O
are	45769	45772	O
subjected	45773	45782	O
to	45783	45785	O
different	45786	45795	O
evolutionary	45796	45808	O
paths	45809	45814	O
that	45815	45819	O
could	45820	45825	O
be	45826	45828	O
dependent	45829	45838	O
on	45839	45841	O
environmental	45842	45855	O
or	45856	45858	O
developmental	45859	45872	O
differences	45873	45884	O
.	45884	45885	O

For	45886	45889	O
example	45890	45897	O
,	45897	45898	O
while	45899	45904	O
most	45905	45909	O
samples	45910	45917	O
exhibit	45918	45925	O
tissue	45926	45932	O
-	45932	45933	O
specific	45933	45941	O
mutation	45942	45950	O
profiles	45951	45959	O
,	45959	45960	O
some	45961	45965	O
others	45966	45972	O
like	45973	45977	O
transverse	45978	45988	O
colon	45989	45994	O
and	45995	45998	O
the	45999	46002	O
small	46003	46008	O
intestine	46009	46018	O
have	46019	46023	O
similar	46024	46031	O
profiles	46032	46040	O
.	46040	46041	O

Additionally	46042	46054	O
,	46054	46055	O
we	46056	46058	O
observed	46059	46067	O
that	46068	46072	O
genes	46073	46078	O
whose	46079	46084	O
expression	46085	46095	O
is	46096	46098	O
associated	46099	46109	O
with	46110	46114	O
mutation	46115	46123	O
load	46124	46128	O
in	46129	46131	O
several	46132	46139	O
tissues	46140	46147	O
are	46148	46151	O
enriched	46152	46160	O
in	46161	46163	O
DNA	46164	46167	O
repair	46168	46174	O
,	46174	46175	O
autophagy	46176	46185	O
,	46185	46186	O
immune	46187	46193	O
response	46194	46202	O
,	46202	46203	O
cellular	46204	46212	O
transport	46213	46222	B-CL:0000627
,	46222	46223	I-CL:0000627
cell	46224	46228	E-CL:0000627
adhesion	46229	46237	O
,	46237	46238	O
and	46239	46242	O
viral	46243	46248	O
processes	46249	46258	O
,	46258	46259	O
and	46260	46263	O
while	46264	46269	O
these	46270	46275	O
functions	46276	46285	O
have	46286	46290	O
been	46291	46295	O
implicated	46296	46306	O
in	46307	46309	O
mutagenesis	46310	46321	O
in	46322	46324	O
cancer	46325	46331	O
[	46332	46333	O
31	46333	46335	O
–	46335	46336	O
33	46336	46338	O
]	46338	46339	O
,	46339	46340	O
our	46341	46344	O
results	46345	46352	O
highlight	46353	46362	O
how	46363	46366	O
expression	46367	46377	O
variation	46378	46387	O
of	46388	46390	O
these	46391	46396	O
genes	46397	46402	O
associates	46403	46413	O
with	46414	46418	O
mutational	46419	46429	O
variation	46430	46439	O
in	46440	46442	O
healthy	46443	46450	O
tissues	46451	46458	O
.	46458	46459	O

Cancer	46460	46466	O
mutations	46467	46476	O
are	46477	46480	O
enriched	46481	46489	O
across	46490	46496	O
many	46497	46501	O
organs	46502	46508	O
.	46508	46509	O

Muscle	46510	46516	O
and	46517	46520	O
heart	46521	46526	O
tissue	46527	46533	O
are	46534	46537	O
particularly	46538	46550	O
interesting	46551	46562	O
because	46563	46570	O
they	46571	46575	O
have	46576	46580	O
lower	46581	46586	O
-	46586	46587	O
than	46587	46591	O
-	46591	46592	O
expected	46592	46600	O
mutation	46601	46609	O
rates	46610	46615	O
,	46615	46616	O
but	46617	46620	O
those	46621	46626	O
mutations	46627	46636	O
are	46637	46640	O
highly	46641	46647	O
enriched	46648	46656	O
for	46657	46660	O
cancer	46661	46667	O
mutations	46668	46677	O
and	46678	46681	O
had	46682	46685	O
high	46686	46690	O
mutation	46691	46699	O
rates	46700	46705	O
in	46706	46708	O
cancer	46709	46715	O
drivers	46716	46723	O
.	46723	46724	O

Sarcomas	46725	46733	O
are	46734	46737	O
tumors	46738	46744	O
originated	46745	46755	O
from	46756	46760	O
soft	46761	46765	O
tissues	46766	46773	O
—	46773	46774	O
including	46774	46783	O
muscle	46784	46790	O
—	46790	46791	O
that	46791	46795	O
are	46796	46799	O
relatively	46800	46810	O
uncommon	46811	46819	O
and	46820	46823	O
have	46824	46828	O
a	46829	46830	O
low	46831	46834	O
density	46835	46842	O
of	46843	46845	O
point	46846	46851	O
mutations	46852	46861	O
but	46862	46865	O
high	46866	46870	O
copy	46871	46875	O
number	46876	46882	O
variation	46883	46892	O
[	46893	46894	O
43	46894	46896	O
]	46896	46897	O
.	46897	46898	O

Our	46899	46902	O
results	46903	46910	O
show	46911	46915	O
that	46916	46920	O
low	46921	46924	O
mutation	46925	46933	O
rates	46934	46939	O
are	46940	46943	O
also	46944	46948	O
observed	46949	46957	O
in	46958	46960	O
these	46961	46966	O
soft	46967	46971	O
tissues	46972	46979	O
,	46979	46980	O
but	46981	46984	O
compared	46985	46993	O
to	46994	46996	O
tumors	46997	47003	O
,	47003	47004	O
cancer	47005	47011	O
mutations	47012	47021	O
are	47022	47025	O
frequent	47026	47034	O
.	47034	47035	O

The	47036	47039	O
functional	47040	47050	O
implications	47051	47063	O
of	47064	47066	O
this	47067	47071	O
observation	47072	47083	O
will	47084	47088	O
need	47089	47093	O
to	47094	47096	O
be	47097	47099	O
explored	47100	47108	O
in	47109	47111	O
further	47112	47119	O
detail	47120	47126	O
.	47126	47127	O

Positive	47128	47136	O
selection	47137	47146	O
of	47147	47149	O
driver	47150	47156	O
genes	47157	47162	O
has	47163	47166	O
been	47167	47171	O
recently	47172	47180	O
observed	47181	47189	O
in	47190	47192	O
healthy	47193	47200	O
tissues	47201	47208	O
[	47209	47210	O
15	47210	47212	O
,	47212	47213	O
18	47214	47216	O
]	47216	47217	O
.	47217	47218	O

Accordingly	47219	47230	O
,	47230	47231	O
we	47232	47234	O
confirmed	47235	47244	O
that	47245	47249	O
NOTCH1	47250	47256	O
is	47257	47259	O
under	47260	47265	O
positive	47266	47274	O
selection	47275	47284	O
in	47285	47287	O
the	47288	47291	O
skin	47292	47296	O
and	47297	47300	O
esophagus	47301	47310	O
.	47310	47311	O

We	47312	47314	O
found	47315	47320	O
other	47321	47326	O
genes	47327	47332	O
positively	47333	47343	O
selected	47344	47352	O
both	47353	47357	O
broadly	47358	47365	O
(	47366	47367	O
e	47367	47368	O
.	47368	47369	O
g	47369	47370	O
.	47370	47371	O
,	47371	47372	O
IDH2	47373	47377	O
,	47377	47378	O
CTNNB1	47379	47385	O
,	47385	47386	O
NFE2L2	47387	47393	O
)	47393	47394	O
and	47395	47398	O
with	47399	47403	O
more	47404	47408	O
tissue	47409	47415	O
-	47415	47416	O
specific	47416	47424	O
patterns	47425	47433	O
(	47434	47435	O
e	47435	47436	O
.	47436	47437	O
g	47437	47438	O
.	47438	47439	O
,	47439	47440	O
KEAP1	47441	47446	O
in	47447	47449	O
the	47450	47453	O
prostate	47454	47462	O
,	47462	47463	O
thyroid	47464	47471	O
,	47471	47472	O
and	47473	47476	O
muscle	47477	47483	O
;	47483	47484	O
RAC1	47485	47489	O
in	47490	47492	O
the	47493	47496	O
skin	47497	47501	O
,	47501	47502	O
esophagus	47503	47512	O
,	47512	47513	O
and	47514	47517	O
breast	47518	47524	O
)	47524	47525	O
,	47525	47526	O
which	47527	47532	O
will	47533	47537	O
be	47538	47540	O
important	47541	47550	O
subjects	47551	47559	O
for	47560	47563	O
future	47564	47570	O
studies	47571	47578	O
.	47578	47579	O

In	47580	47582	O
general	47583	47590	O
,	47590	47591	O
mutations	47592	47601	O
previously	47602	47612	O
observed	47613	47621	O
in	47622	47624	O
cancer	47625	47631	O
studies	47632	47639	O
were	47640	47644	O
found	47645	47650	O
in	47651	47653	O
high	47654	47658	O
abundance	47659	47668	O
across	47669	47675	O
many	47676	47680	O
healthy	47681	47688	O
tissues	47689	47696	O
,	47696	47697	O
and	47698	47701	O
our	47702	47705	O
VAF	47706	47709	O
analysis	47710	47718	O
showed	47719	47725	O
signatures	47726	47736	O
of	47737	47739	O
positive	47740	47748	O
selection	47749	47758	O
acting	47759	47765	O
on	47766	47768	O
them	47769	47773	O
.	47773	47774	O

In	47775	47777	O
contrast	47778	47786	O
,	47786	47787	O
when	47788	47792	O
looking	47793	47800	O
at	47801	47803	O
all	47804	47807	O
mutations	47808	47817	O
and	47818	47821	O
in	47822	47824	O
particular	47825	47835	O
those	47836	47841	O
not	47842	47845	O
previously	47846	47856	O
seen	47857	47861	O
in	47862	47864	O
cancer	47865	47871	O
,	47871	47872	O
we	47873	47875	O
found	47876	47881	O
that	47882	47886	O
missense	47887	47895	O
and	47896	47899	O
nonsense	47900	47908	O
mutations	47909	47918	O
are	47919	47922	O
generally	47923	47932	O
under	47933	47938	O
negative	47939	47947	O
selection	47948	47957	O
.	47957	47958	O

Our	47959	47962	O
results	47963	47970	O
reconcile	47971	47980	O
recent	47981	47987	O
studies	47988	47995	O
reporting	47996	48005	O
prevalent	48006	48015	O
positive	48016	48024	O
[	48025	48026	O
9	48026	48027	O
]	48027	48028	O
or	48029	48031	O
negative	48032	48040	O
[	48041	48042	O
11	48042	48044	O
,	48044	48045	O
44	48046	48048	O
]	48048	48049	O
selection	48050	48059	O
in	48060	48062	O
somatic	48063	48070	O
evolution	48071	48080	O
,	48080	48081	O
as	48082	48084	O
we	48085	48087	O
find	48088	48092	O
evidence	48093	48101	O
of	48102	48104	O
both	48105	48109	O
co	48110	48112	O
-	48112	48113	O
existing	48113	48121	O
in	48122	48124	O
different	48125	48134	O
sets	48135	48139	O
of	48140	48142	O
mutations	48143	48152	O
.	48152	48153	O

After	48154	48159	O
this	48160	48164	O
manuscript	48165	48175	O
was	48176	48179	O
submitted	48180	48189	O
for	48190	48193	O
publication	48194	48205	O
,	48205	48206	O
another	48207	48214	O
study	48215	48220	O
was	48221	48224	O
published	48225	48234	O
that	48235	48239	O
also	48240	48244	O
called	48245	48251	O
mutations	48252	48261	O
using	48262	48267	O
GTEx	48268	48272	O
samples	48273	48280	O
[	48281	48282	O
45	48282	48284	O
]	48284	48285	O
.	48285	48286	O

Reassuringly	48287	48299	O
,	48299	48300	O
their	48301	48306	O
results	48307	48314	O
are	48315	48318	O
largely	48319	48326	O
consistent	48327	48337	O
with	48338	48342	O
ours	48343	48347	O
,	48347	48348	O
including	48349	48358	O
the	48359	48362	O
higher	48363	48369	O
mutation	48370	48378	O
rate	48379	48383	O
in	48384	48386	O
female	48387	48393	O
breast	48394	48400	O
tissue	48401	48407	O
(	48408	48409	O
vs	48409	48411	O
male	48412	48416	O
)	48416	48417	O
and	48418	48421	O
in	48422	48424	O
the	48425	48428	O
sun	48429	48432	O
-	48432	48433	O
exposed	48433	48440	O
skin	48441	48445	O
(	48446	48447	O
vs	48447	48449	O
the	48450	48453	O
non	48454	48457	O
-	48457	48458	O
sun	48458	48461	O
-	48461	48462	O
exposed	48462	48469	O
skin	48470	48474	O
)	48474	48475	O
of	48476	48478	O
Caucasians	48479	48489	O
but	48490	48493	O
not	48494	48497	O
African	48498	48505	O
-	48505	48506	O
Americans	48506	48515	O
,	48515	48516	O
as	48517	48519	O
well	48520	48524	O
as	48525	48527	O
the	48528	48531	O
excess	48532	48538	O
of	48539	48541	O
nonsense	48542	48550	O
mutations	48551	48560	O
in	48561	48563	O
NOTCH1	48564	48570	O
.	48570	48571	O

However	48572	48579	O
,	48579	48580	O
a	48581	48582	O
major	48583	48588	O
difference	48589	48599	O
between	48600	48607	O
the	48608	48611	O
two	48612	48615	O
studies	48616	48623	O
is	48624	48626	O
in	48627	48629	O
the	48630	48633	O
number	48634	48640	O
and	48641	48644	O
confidence	48645	48655	O
of	48656	48658	O
mutations	48659	48668	O
called	48669	48675	O
.	48675	48676	O

Specifically	48677	48689	O
,	48689	48690	O
Yizhak	48691	48697	O
et	48698	48700	O
al	48701	48703	O
.	48703	48704	O

called	48705	48711	O
8870	48712	48716	O
somatic	48717	48724	O
mutations	48725	48734	O
in	48735	48737	O
6707	48738	48742	O
RNA	48743	48746	O
-	48746	48747	O
seq	48747	48750	O
samples	48751	48758	O
;	48758	48759	O
this	48760	48764	O
is	48765	48767	O
1	48768	48769	O
.	48769	48770	O
3	48770	48771	O
mutations	48772	48781	O
per	48782	48785	O
sample	48786	48792	O
,	48792	48793	O
which	48794	48799	O
is	48800	48802	O
actually	48803	48811	O
smaller	48812	48819	O
than	48820	48824	O
their	48825	48830	O
expected	48831	48839	O
2	48840	48841	O
–	48841	48842	O
4	48842	48843	O
false	48844	48849	O
positives	48850	48859	O
per	48860	48863	O
sample	48864	48870	O
,	48870	48871	O
suggesting	48872	48882	O
that	48883	48887	O
most	48888	48892	O
of	48893	48895	O
their	48896	48901	O
calls	48902	48907	O
are	48908	48911	O
false	48912	48917	O
positives	48918	48927	O
.	48927	48928	O

This	48929	48933	O
is	48934	48936	O
supported	48937	48946	O
by	48947	48949	O
their	48950	48955	O
validation	48956	48966	O
of	48967	48969	O
5	48970	48971	O
/	48971	48972	O
28	48972	48974	O
tested	48975	48981	O
variants	48982	48990	O
(	48991	48992	O
82	48992	48994	O
%	48994	48995	O
FDR	48996	48999	O
)	48999	49000	O
in	49001	49003	O
GTEx	49004	49008	O
samples	49009	49016	O
and	49017	49020	O
13	49021	49023	O
/	49023	49024	O
86	49024	49026	O
variants	49027	49035	O
(	49036	49037	O
85	49037	49039	O
%	49039	49040	O
FDR	49041	49044	O
)	49044	49045	O
in	49046	49048	O
TCGA	49049	49053	O
cancer	49054	49060	O
samples	49061	49068	O
.	49068	49069	O

In	49070	49072	O
contrast	49073	49081	O
,	49081	49082	O
we	49083	49085	O
called	49086	49092	O
over	49093	49097	O
280	49098	49101	O
,	49101	49102	O
000	49102	49105	O
mutations	49106	49115	O
with	49116	49120	O
a	49121	49122	O
34	49123	49125	O
%	49125	49126	O
FDR	49127	49130	O
,	49130	49131	O
based	49132	49137	O
on	49138	49140	O
thousands	49141	49150	O
of	49151	49153	O
validated	49154	49163	O
variants	49164	49172	O
in	49173	49175	O
exome	49176	49181	O
data	49182	49186	O
.	49186	49187	O

Thus	49188	49192	O
,	49192	49193	O
our	49194	49197	O
method	49198	49204	O
called	49205	49211	O
~	49212	49213	O
115	49214	49217	O
times	49218	49223	O
as	49224	49226	O
many	49227	49231	O
true	49232	49236	O
positive	49237	49245	O
mutations	49246	49255	O
,	49255	49256	O
at	49257	49259	O
substantially	49260	49273	O
higher	49274	49280	O
confidence	49281	49291	O
(	49292	49293	O
Additional	49293	49303	O
file	49304	49308	O
1	49309	49310	O
:	49310	49311	O
Figure	49312	49318	O
S12a	49319	49323	O
)	49323	49324	O
.	49324	49325	O

Additionally	49326	49338	O
,	49338	49339	O
632	49340	49343	O
(	49344	49345	O
7	49345	49346	O
%	49346	49347	O
)	49347	49348	O
of	49349	49351	O
their	49352	49357	O
mutation	49358	49366	O
calls	49367	49372	O
were	49373	49377	O
flagged	49378	49385	O
by	49386	49388	O
one	49389	49392	O
or	49393	49395	O
more	49396	49400	O
of	49401	49403	O
our	49404	49407	O
filters	49408	49415	O
in	49416	49418	O
the	49419	49422	O
corresponding	49423	49436	O
tissues	49437	49444	O
(	49445	49446	O
Additional	49446	49456	O
file	49457	49461	O
1	49462	49463	O
:	49463	49464	O
Figure	49465	49471	O
S12b	49472	49476	O
)	49476	49477	O
.	49477	49478	O

As	49479	49481	O
a	49482	49483	O
result	49484	49490	O
of	49491	49493	O
our	49494	49497	O
increased	49498	49507	O
power	49508	49513	O
,	49513	49514	O
we	49515	49517	O
were	49518	49522	O
able	49523	49527	O
to	49528	49530	O
connect	49531	49538	O
somatic	49539	49546	O
mutations	49547	49556	O
with	49557	49561	O
tissue	49562	49568	O
-	49568	49569	O
specific	49569	49577	O
chromatin	49578	49587	O
and	49588	49591	O
gene	49592	49596	O
expression	49597	49607	O
levels	49608	49614	O
(	49615	49616	O
Fig	49616	49619	O
.	49619	49620	O

2g	49621	49623	O
,	49623	49624	O
Fig	49625	49628	O
.	49628	49629	O

4	49630	49631	O
)	49631	49632	O
,	49632	49633	O
detect	49634	49640	O
both	49641	49645	O
negative	49646	49654	O
and	49655	49658	O
positive	49659	49667	O
selection	49668	49677	O
acting	49678	49684	O
on	49685	49687	O
different	49688	49697	O
subsets	49698	49705	O
of	49706	49708	O
mutations	49709	49718	O
(	49719	49720	O
Fig	49720	49723	O
.	49723	49724	O

2d	49725	49727	O
,	49727	49728	O
Fig	49729	49732	O
.	49732	49733	O

5e	49734	49736	O
,	49736	49737	O
f	49738	49739	O
)	49739	49740	O
,	49740	49741	O
and	49742	49745	O
discover	49746	49754	O
widespread	49755	49765	O
strand	49766	49772	O
asymmetry	49773	49782	O
(	49783	49784	O
Fig	49784	49787	O
.	49787	49788	O

3	49789	49790	O
)	49790	49791	O
.	49791	49792	O

One	49793	49796	O
notable	49797	49804	O
difference	49805	49815	O
is	49816	49818	O
that	49819	49823	O
Yizhak	49824	49830	O
et	49831	49833	O
al	49834	49836	O
.	49836	49837	O

detected	49838	49846	O
TP53	49847	49851	O
and	49852	49855	O
PIK3CA	49856	49862	O
as	49863	49865	O
the	49866	49869	O
genes	49870	49875	O
with	49876	49880	O
the	49881	49884	O
most	49885	49889	O
hotspot	49890	49897	O
mutations	49898	49907	O
genome	49908	49914	O
-	49914	49915	O
wide	49915	49919	O
,	49919	49920	O
whereas	49921	49928	O
these	49929	49934	O
were	49935	49939	O
not	49940	49943	O
outliers	49944	49952	O
in	49953	49955	O
our	49956	49959	O
analysis	49960	49968	O
(	49969	49970	O
Fig	49970	49973	O
.	49973	49974	O

5d	49975	49977	O
)	49977	49978	O
.	49978	49979	O

However	49980	49987	O
,	49987	49988	O
it	49989	49991	O
should	49992	49998	O
be	49999	50001	O
noted	50002	50007	O
that	50008	50012	O
these	50013	50018	O
two	50019	50022	O
genes	50023	50028	O
were	50029	50033	O
also	50034	50038	O
the	50039	50042	O
only	50043	50047	O
two	50048	50051	O
genes	50052	50057	O
that	50058	50062	O
Yizhak	50063	50069	O
et	50070	50072	O
al	50073	50075	O
.	50075	50076	O

excluded	50077	50085	O
from	50086	50090	O
their	50091	50096	O
“	50097	50098	O
panel	50098	50103	O
of	50104	50106	O
normals	50107	50114	O
”	50114	50115	O
filter	50116	50122	O
when	50123	50127	O
calling	50128	50135	O
mutations	50136	50145	O
,	50145	50146	O
which	50147	50152	O
of	50153	50155	O
course	50156	50162	O
inflates	50163	50171	O
their	50172	50177	O
number	50178	50184	O
of	50185	50187	O
mutations	50188	50197	O
,	50197	50198	O
making	50199	50205	O
this	50206	50210	O
result	50211	50217	O
difficult	50218	50227	O
to	50228	50230	O
interpret	50231	50240	O
.	50240	50241	O

Conclusions	50243	50254	O
Our	50255	50258	O
findings	50259	50267	O
paint	50268	50273	O
a	50274	50275	O
complex	50276	50283	O
landscape	50284	50293	O
of	50294	50296	O
somatic	50297	50304	O
mutation	50305	50313	O
across	50314	50320	O
the	50321	50324	O
human	50325	50330	O
body	50331	50335	O
,	50335	50336	O
highlighting	50337	50349	O
their	50350	50355	O
tissue	50356	50362	O
-	50362	50363	O
specific	50363	50371	O
distributions	50372	50385	O
and	50386	50389	O
functional	50390	50400	O
associations	50401	50413	O
.	50413	50414	O

The	50415	50418	O
prevalence	50419	50429	O
of	50430	50432	O
cancer	50433	50439	O
mutations	50440	50449	O
and	50450	50453	O
positive	50454	50462	O
selection	50463	50472	O
of	50473	50475	O
cancer	50476	50482	O
driver	50483	50489	O
genes	50490	50495	O
in	50496	50498	O
non	50499	50502	O
-	50502	50503	O
diseased	50503	50511	O
tissues	50512	50519	O
suggests	50520	50528	O
the	50529	50532	O
possibility	50533	50544	O
of	50545	50547	O
a	50548	50549	O
poised	50550	50556	O
pre	50557	50560	O
-	50560	50561	O
cancerous	50561	50570	O
state	50571	50576	O
,	50576	50577	O
which	50578	50583	O
could	50584	50589	O
also	50590	50594	O
contribute	50595	50605	O
to	50606	50608	O
aging	50609	50614	O
.	50614	50615	O

Finally	50616	50623	O
,	50623	50624	O
our	50625	50628	O
method	50629	50635	O
for	50636	50639	O
inferring	50640	50649	O
somatic	50650	50657	O
mutations	50658	50667	O
from	50668	50672	O
RNA	50673	50676	O
-	50676	50677	O
seq	50677	50680	O
data	50681	50685	O
may	50686	50689	O
help	50690	50694	O
accelerate	50695	50705	O
the	50706	50709	O
study	50710	50715	O
of	50716	50718	O
somatic	50719	50726	O
evolution	50727	50736	O
and	50737	50740	O
its	50741	50744	O
role	50745	50749	O
in	50750	50752	O
aging	50753	50758	O
and	50759	50762	O
disease	50763	50770	O
.	50770	50771	O

Methods	50773	50780	O
Raw	50781	50784	O
RNA	50785	50788	O
-	50788	50789	O
seq	50789	50792	O
retrieval	50793	50802	O
and	50803	50806	O
processing	50807	50817	O
We	50818	50820	O
downloaded	50821	50831	O
raw	50832	50835	O
RNA	50836	50839	O
-	50839	50840	O
sequencing	50840	50850	O
reads	50851	50856	O
from	50857	50861	O
the	50862	50865	O
dbGAP	50866	50871	O
GTEx	50872	50876	O
[	50877	50878	O
46	50878	50880	O
]	50880	50881	O
project	50882	50889	O
version	50890	50897	O
7	50898	50899	O
(	50900	50901	O
phs000424	50901	50910	O
.	50910	50911	O
v7	50911	50913	O
.	50913	50914	O
p2	50914	50916	O
)	50916	50917	O
.	50917	50918	O

We	50919	50921	O
included	50922	50930	O
36	50931	50933	O
tissues	50934	50941	O
with	50942	50946	O
a	50947	50948	O
total	50949	50954	O
of	50955	50957	O
7584	50958	50962	O
samples	50963	50970	O
(	50971	50972	O
Additional	50972	50982	O
file	50983	50987	O
4	50988	50989	O
:	50989	50990	O
Table	50991	50996	O
S2	50997	50999	O
)	50999	51000	O
after	51001	51006	O
applying	51007	51015	O
all	51016	51019	O
filters	51020	51027	O
in	51028	51030	O
the	51031	51034	O
mutation	51035	51043	O
calling	51044	51051	O
pipeline	51052	51060	O
(	51061	51062	O
see	51062	51065	O
below	51066	51071	O
)	51071	51072	O
.	51072	51073	O

We	51074	51076	O
also	51077	51081	O
processed	51082	51091	O
DNA	51092	51095	O
exome	51096	51101	O
sequencing	51102	51112	O
reads	51113	51118	O
from	51119	51123	O
105	51124	51127	O
whole	51128	51133	O
-	51133	51134	O
blood	51134	51139	O
samples	51140	51147	O
that	51148	51152	O
had	51153	51156	O
a	51157	51158	O
matched	51159	51166	O
RNA	51167	51170	O
-	51170	51171	O
seq	51171	51174	O
sample	51175	51181	O
.	51181	51182	O

Reads	51183	51188	O
were	51189	51193	O
mapped	51194	51200	O
to	51201	51203	O
the	51204	51207	O
human	51208	51213	O
genome	51214	51220	O
Hg19	51221	51225	O
(	51226	51227	O
NCBI	51227	51231	O
build	51232	51237	O
GRCh37	51238	51244	O
.	51244	51245	O
p13	51245	51248	O
)	51248	51249	O
using	51250	51255	O
STAR	51256	51260	O
[	51261	51262	O
47	51262	51264	O
]	51264	51265	O
with	51266	51270	O
the	51271	51274	O
following	51275	51284	O
parameters	51285	51295	O
:	51295	51296	O
requiring	51297	51306	O
uniquely	51307	51315	O
mapping	51316	51323	O
reads	51324	51329	O
(	51330	51331	O
-	51331	51332	O
-	51332	51333	O
outFilterMultimapNmax	51333	51354	O
1	51355	51356	O
)	51356	51357	O
,	51357	51358	O
clipping	51359	51367	O
6	51368	51369	O
bases	51370	51375	O
in	51376	51378	O
the	51379	51382	O
5	51383	51384	O
′	51384	51385	O
end	51386	51389	O
of	51390	51392	O
reads	51393	51398	O
(	51399	51400	O
-	51400	51401	O
-	51401	51402	O
clip5pNbases	51402	51414	O
6	51415	51416	O
)	51416	51417	O
,	51417	51418	O
and	51419	51422	O
keeping	51423	51430	O
reads	51431	51436	O
with	51437	51441	O
10	51442	51444	O
or	51445	51447	O
fewer	51448	51453	O
mismatches	51454	51464	O
and	51465	51468	O
less	51469	51473	O
than	51474	51478	O
10	51479	51481	O
%	51481	51482	O
mismatches	51483	51493	O
of	51494	51496	O
the	51497	51500	O
read	51501	51505	O
length	51506	51512	O
that	51513	51517	O
effectively	51518	51529	O
mapped	51530	51536	O
to	51537	51539	O
genome	51540	51546	O
(	51547	51548	O
-	51548	51549	O
-	51549	51550	O
outFilterMismatchNmax	51550	51571	O
10	51572	51574	O
,	51574	51575	O
-	51576	51577	O
-	51577	51578	O
outFilterMismatchNoverLmax	51578	51604	O
0	51605	51606	O
.	51606	51607	O
1	51607	51608	O
)	51608	51609	O
.	51609	51610	O

To	51611	51613	O
avoid	51614	51619	O
germline	51620	51628	O
variant	51629	51636	O
contamination	51637	51650	O
during	51651	51657	O
the	51658	51661	O
somatic	51662	51669	O
mutation	51670	51678	O
calling	51679	51686	O
phase	51687	51692	O
,	51692	51693	O
all	51694	51697	O
SNPs	51698	51702	O
from	51703	51707	O
dbSNP	51708	51713	O
[	51714	51715	O
48	51715	51717	O
]	51717	51718	O
v142	51719	51723	O
were	51724	51728	O
masked	51729	51735	O
to	51736	51738	O
Ns	51739	51741	O
and	51742	51745	O
ignored	51746	51753	O
in	51754	51756	O
downstream	51757	51767	O
processing	51768	51778	O
(	51779	51780	O
https	51780	51785	O
:	51785	51786	O
/	51786	51787	O
/	51787	51788	O
ftp	51788	51791	O
.	51791	51792	O
ncbi	51792	51796	O
.	51796	51797	O
nlm	51797	51800	O
.	51800	51801	O
nih	51801	51804	O
.	51804	51805	O
gov	51805	51808	O
/	51808	51809	O
snp	51809	51812	O
/	51812	51813	O
organisms	51813	51822	O
/	51822	51823	O
human	51823	51828	O
_	51828	51829	O
9606	51829	51833	O
_	51833	51834	O
b142	51834	51838	O
_	51838	51839	O
GRCh37p13	51839	51848	O
/	51848	51849	O
BED	51849	51852	O
)	51852	51853	O
.	51853	51854	O

After	51855	51860	O
mapping	51861	51868	O
,	51868	51869	O
we	51870	51872	O
removed	51873	51880	O
duplicate	51881	51890	O
reads	51891	51896	O
to	51897	51899	O
avoid	51900	51905	O
biases	51906	51912	O
arising	51913	51920	O
from	51921	51925	O
PCR	51926	51929	O
duplicates	51930	51940	O
during	51941	51947	O
library	51948	51955	O
preparation	51956	51967	O
using	51968	51973	O
a	51974	51975	O
custom	51976	51982	O
python	51983	51989	O
script	51990	51996	O
.	51996	51997	O

DNA	51998	52001	O
somatic	52002	52009	O
mutation	52010	52018	O
calling	52019	52026	O
from	52027	52031	O
RNA	52032	52035	O
sequencing	52036	52046	O
Identifying	52047	52058	O
DNA	52059	52062	O
variants	52063	52071	O
from	52072	52076	O
RNA	52077	52080	O
-	52080	52081	O
seq	52081	52084	O
requires	52085	52093	O
filtering	52094	52103	O
out	52104	52107	O
many	52108	52112	O
sources	52113	52120	O
of	52121	52123	O
false	52124	52129	O
positives	52130	52139	O
.	52139	52140	O

These	52141	52146	O
include	52147	52154	O
sequencing	52155	52165	O
errors	52166	52172	O
,	52172	52173	O
RNA	52174	52177	O
editing	52178	52185	O
events	52186	52192	O
,	52192	52193	O
mapping	52194	52201	O
errors	52202	52208	O
around	52209	52215	O
splice	52216	52222	O
junctions	52223	52232	O
,	52232	52233	O
germline	52234	52242	O
variants	52243	52251	O
,	52251	52252	O
and	52253	52256	O
other	52257	52262	O
sequencing	52263	52273	O
/	52273	52274	O
mapping	52274	52281	O
biases	52282	52288	O
.	52288	52289	O

To	52290	52292	O
address	52293	52300	O
these	52301	52306	O
issues	52307	52313	O
,	52313	52314	O
we	52315	52317	O
developed	52318	52327	O
a	52328	52329	O
custom	52330	52336	O
mutation	52337	52345	O
calling	52346	52353	O
pipeline	52354	52362	O
that	52363	52367	O
borrows	52368	52375	O
ideas	52376	52381	O
from	52382	52386	O
classical	52387	52396	O
DNA	52397	52400	O
-	52400	52401	O
based	52401	52406	O
variant	52407	52414	O
calling	52415	52422	O
coupled	52423	52430	O
with	52431	52435	O
extra	52436	52441	O
filters	52442	52449	O
to	52450	52452	O
increase	52453	52461	O
the	52462	52465	O
fidelity	52466	52474	O
of	52475	52477	O
the	52478	52481	O
mutation	52482	52490	O
calls	52491	52496	O
from	52497	52501	O
RNA	52502	52505	O
-	52505	52506	O
seq	52506	52509	O
.	52509	52510	O

After	52511	52516	O
mapping	52517	52524	O
the	52525	52528	O
raw	52529	52532	O
RNA	52533	52536	O
-	52536	52537	O
seq	52537	52540	O
reads	52541	52546	O
,	52546	52547	O
the	52548	52551	O
pipeline	52552	52560	O
consists	52561	52569	O
of	52570	52572	O
three	52573	52578	O
main	52579	52583	O
parts	52584	52589	O
:	52589	52590	O
(	52591	52592	O
1	52592	52593	O
)	52593	52594	O
identifying	52595	52606	O
positions	52607	52616	O
with	52617	52621	O
two	52622	52625	O
base	52626	52630	O
calls	52631	52636	O
,	52636	52637	O
(	52638	52639	O
2	52639	52640	O
)	52640	52641	O
removing	52642	52650	O
germline	52651	52659	O
variants	52660	52668	O
,	52668	52669	O
and	52670	52673	O
(	52674	52675	O
3	52675	52676	O
)	52676	52677	O
filtering	52678	52687	O
out	52688	52691	O
other	52692	52697	O
potentially	52698	52709	O
spurious	52710	52718	O
variants	52719	52727	O
.	52727	52728	O

Identifying	52729	52740	O
positions	52741	52750	O
with	52751	52755	O
two	52756	52759	O
base	52760	52764	O
calls	52765	52770	O
After	52771	52776	O
mapping	52777	52784	O
,	52784	52785	O
bam	52786	52789	O
files	52790	52795	O
were	52796	52800	O
scanned	52801	52808	O
to	52809	52811	O
identify	52812	52820	O
genomic	52821	52828	O
positions	52829	52838	O
that	52839	52843	O
were	52844	52848	O
covered	52849	52856	O
by	52857	52859	O
reads	52860	52865	O
having	52866	52872	O
exactly	52873	52880	O
two	52881	52884	O
different	52885	52894	O
base	52895	52899	O
calls	52900	52905	O
.	52905	52906	O

Given	52907	52912	O
the	52913	52916	O
intrinsic	52917	52926	O
sequencing	52927	52937	O
error	52938	52943	O
rate	52944	52948	O
,	52948	52949	O
we	52950	52952	O
only	52953	52957	O
considered	52958	52968	O
positions	52969	52978	O
with	52979	52983	O
high	52984	52988	O
coverage	52989	52997	O
and	52998	53001	O
high	53002	53006	O
sequencing	53007	53017	O
quality	53018	53025	O
for	53026	53029	O
this	53030	53034	O
step	53035	53039	O
.	53039	53040	O

Stringent	53041	53050	O
cutoffs	53051	53058	O
were	53059	53063	O
set	53064	53067	O
for	53068	53071	O
coverage	53072	53080	O
(	53081	53082	O
c	53082	53083	O
≥	53084	53085	O
40	53086	53088	O
reads	53089	53094	O
)	53094	53095	O
and	53096	53099	O
sequencing	53100	53110	O
quality	53111	53118	O
(	53119	53120	O
qs	53120	53122	O
≥	53123	53124	O
30	53125	53127	O
in	53128	53130	O
Phred	53131	53136	O
scale	53137	53142	O
)	53142	53143	O
;	53143	53144	O
this	53145	53149	O
is	53150	53152	O
in	53153	53155	O
comparison	53156	53166	O
twice	53167	53172	O
what	53173	53177	O
some	53178	53182	O
DNA	53183	53186	O
-	53186	53187	O
based	53187	53192	O
calling	53193	53200	O
algorithms	53201	53211	O
have	53212	53216	O
used	53217	53221	O
[	53222	53223	O
21	53223	53225	O
]	53225	53226	O
.	53226	53227	O

Finally	53228	53235	O
,	53235	53236	O
only	53237	53241	O
positions	53242	53251	O
in	53252	53254	O
which	53255	53260	O
the	53261	53264	O
minor	53265	53270	O
allele	53271	53277	O
was	53278	53281	O
supported	53282	53291	O
by	53292	53294	O
at	53295	53297	O
least	53298	53303	O
6	53304	53305	O
reads	53306	53311	O
were	53312	53316	O
considered	53317	53327	O
(	53328	53329	O
n	53329	53330	O
≥	53331	53332	O
6	53333	53334	O
)	53334	53335	O
.	53335	53336	O

In	53337	53339	O
combination	53340	53351	O
,	53351	53352	O
these	53353	53358	O
parameters	53359	53369	O
define	53370	53376	O
a	53377	53378	O
theoretical	53379	53390	O
distribution	53391	53403	O
of	53404	53406	O
the	53407	53410	O
probability	53411	53422	O
of	53423	53425	O
observing	53426	53435	O
a	53436	53437	O
mutation	53438	53446	O
due	53447	53450	O
to	53451	53453	O
sequencing	53454	53464	O
errors	53465	53471	O
,	53471	53472	O
which	53473	53478	O
is	53479	53481	O
small	53482	53487	O
for	53488	53491	O
a	53492	53493	O
wide	53494	53498	O
range	53499	53504	O
of	53505	53507	O
sequence	53508	53516	O
coverage	53517	53525	O
levels	53526	53532	O
(	53533	53534	O
Additional	53534	53544	O
file	53545	53549	O
1	53550	53551	O
:	53551	53552	O
Figure	53553	53559	O
S1a	53560	53563	O
)	53563	53564	O
.	53564	53565	O

In	53566	53568	O
addition	53569	53577	O
,	53577	53578	O
we	53579	53581	O
included	53582	53590	O
a	53591	53592	O
filter	53593	53599	O
to	53600	53602	O
only	53603	53607	O
consider	53608	53616	O
variants	53617	53625	O
with	53626	53630	O
a	53631	53632	O
probability	53633	53644	O
of	53645	53647	O
sequencing	53648	53658	O
error	53659	53664	O
p	53665	53666	O
<	53667	53668	O
0	53669	53670	O
.	53670	53671	O
0001	53671	53675	O
(	53676	53677	O
see	53677	53680	O
filters	53681	53688	O
below	53689	53694	O
)	53694	53695	O
.	53695	53696	O

These	53697	53702	O
strict	53703	53709	O
cutoffs	53710	53717	O
ensure	53718	53724	O
a	53725	53726	O
low	53727	53730	O
probability	53731	53742	O
of	53743	53745	O
observing	53746	53755	O
sequencing	53756	53766	O
errors	53767	53773	O
even	53774	53778	O
in	53779	53781	O
highly	53782	53788	O
covered	53789	53796	O
genes	53797	53802	O
;	53802	53803	O
nonetheless	53804	53815	O
,	53815	53816	O
we	53817	53819	O
still	53820	53825	O
apply	53826	53831	O
further	53832	53839	O
filters	53840	53847	O
to	53848	53850	O
account	53851	53858	O
for	53859	53862	O
sequencing	53863	53873	O
errors	53874	53880	O
(	53881	53882	O
see	53882	53885	O
below	53886	53891	O
)	53891	53892	O
.	53892	53893	O

Identifying	53894	53905	O
and	53906	53909	O
eliminating	53910	53921	O
germline	53922	53930	O
variants	53931	53939	O
Common	53940	53946	O
and	53947	53950	O
rare	53951	53955	O
germline	53956	53964	O
variants	53965	53973	O
have	53974	53978	O
to	53979	53981	O
be	53982	53984	O
excluded	53985	53993	O
for	53994	53997	O
the	53998	54001	O
proper	54002	54008	O
identification	54009	54023	O
of	54024	54026	O
somatic	54027	54034	O
mutations	54035	54044	O
.	54044	54045	O

To	54046	54048	O
eliminate	54049	54058	O
common	54059	54065	O
variants	54066	54074	O
,	54074	54075	O
a	54076	54077	O
strict	54078	54084	O
filter	54085	54091	O
was	54092	54095	O
applied	54096	54103	O
by	54104	54106	O
using	54107	54112	O
a	54113	54114	O
human	54115	54120	O
genome	54121	54127	O
masked	54128	54134	O
with	54135	54139	O
Ns	54140	54142	O
for	54143	54146	O
positions	54147	54156	O
known	54157	54162	O
to	54163	54165	O
have	54166	54170	O
common	54171	54177	O
variants	54178	54186	O
from	54187	54191	O
dbSNP	54192	54197	O
v142	54198	54202	O
(	54203	54204	O
see	54204	54207	O
above	54208	54213	O
)	54213	54214	O
.	54214	54215	O

To	54216	54218	O
eliminate	54219	54228	O
all	54229	54232	O
other	54233	54238	O
germline	54239	54247	O
variants	54248	54256	O
,	54256	54257	O
including	54258	54267	O
rare	54268	54272	O
ones	54273	54277	O
,	54277	54278	O
we	54279	54281	O
utilized	54282	54290	O
the	54291	54294	O
low	54295	54298	O
confidence	54299	54309	O
germline	54310	54318	O
variants	54319	54327	O
called	54328	54334	O
by	54335	54337	O
GTEx	54338	54342	O
.	54342	54343	O

These	54344	54349	O
calls	54350	54355	O
were	54356	54360	O
made	54361	54365	O
by	54366	54368	O
GTEx	54369	54373	O
using	54374	54379	O
GATK	54380	54384	O
’	54384	54385	O
s	54385	54386	O
HaplotypeCaller	54387	54402	O
v3	54403	54405	O
.	54405	54406	O
4	54406	54407	O
on	54408	54410	O
whole	54411	54416	O
-	54416	54417	O
genome	54417	54423	O
sequencing	54424	54434	O
data	54435	54439	O
at	54440	54442	O
30x	54443	54446	O
coverage	54447	54455	O
from	54456	54460	O
whole	54461	54466	O
-	54466	54467	O
blood	54467	54472	O
samples	54473	54480	O
.	54480	54481	O

We	54482	54484	O
specifically	54485	54497	O
used	54498	54502	O
the	54503	54506	O
vcf	54507	54510	O
file	54511	54515	O
GTEx	54516	54520	O
_	54520	54521	O
Analysis	54521	54529	O
_	54529	54530	O
2016	54530	54534	O
-	54534	54535	O
01	54535	54537	O
-	54537	54538	O
15	54538	54540	O
_	54540	54541	O
v7	54541	54543	O
_	54543	54544	O
WholeGenomeSeq	54544	54558	O
_	54558	54559	O
652Ind	54559	54565	O
_	54565	54566	O
GATK	54566	54570	O
_	54570	54571	O
HaplotypeCaller	54571	54586	O
.	54586	54587	O
vcf	54587	54590	O
which	54591	54596	O
contains	54597	54605	O
all	54606	54609	O
germline	54610	54618	O
variants	54619	54627	O
before	54628	54634	O
filtering	54635	54644	O
for	54645	54648	O
MAF	54649	54652	O
and	54653	54656	O
low	54657	54660	O
-	54660	54661	O
quality	54661	54668	O
variants	54669	54677	O
.	54677	54678	O

Our	54679	54682	O
goal	54683	54687	O
was	54688	54691	O
to	54692	54694	O
exclude	54695	54702	O
as	54703	54705	O
many	54706	54710	O
germline	54711	54719	O
variants	54720	54728	O
as	54729	54731	O
possible	54732	54740	O
,	54740	54741	O
so	54742	54744	O
we	54745	54747	O
reasoned	54748	54756	O
that	54757	54761	O
using	54762	54767	O
all	54768	54771	O
germline	54772	54780	O
variants	54781	54789	O
called	54790	54796	O
by	54797	54799	O
GTEx	54800	54804	O
—	54804	54805	O
including	54805	54814	O
the	54815	54818	O
low	54819	54822	O
-	54822	54823	O
quality	54823	54830	O
ones	54831	54835	O
—	54835	54836	O
was	54836	54839	O
the	54840	54843	O
safest	54844	54850	O
option	54851	54857	O
to	54858	54860	O
minimize	54861	54869	O
germline	54870	54878	O
mutation	54879	54887	O
contamination	54888	54901	O
in	54902	54904	O
our	54905	54908	O
somatic	54909	54916	O
mutation	54917	54925	O
calls	54926	54931	O
.	54931	54932	O

While	54933	54938	O
these	54939	54944	O
variants	54945	54953	O
were	54954	54958	O
called	54959	54965	O
in	54966	54968	O
whole	54969	54974	O
-	54974	54975	O
blood	54975	54980	O
samples	54981	54988	O
,	54988	54989	O
germline	54990	54998	O
variants	54999	55007	O
should	55008	55014	O
be	55015	55017	O
present	55018	55025	O
in	55026	55028	O
all	55029	55032	O
tissues	55033	55040	O
of	55041	55043	O
an	55044	55046	O
individual	55047	55057	O
and	55058	55061	O
as	55062	55064	O
such	55065	55069	O
these	55070	55075	O
variants	55076	55084	O
were	55085	55089	O
excluded	55090	55098	O
in	55099	55101	O
a	55102	55103	O
per	55104	55107	O
-	55107	55108	O
individual	55108	55118	O
basis	55119	55124	O
across	55125	55131	O
all	55132	55135	O
tissues	55136	55143	O
of	55144	55146	O
that	55147	55151	O
individual	55152	55162	O
.	55162	55163	O

Only	55164	55168	O
sites	55169	55174	O
that	55175	55179	O
had	55180	55183	O
heterozygous	55184	55196	O
or	55197	55199	O
homozygous	55200	55210	O
variants	55211	55219	O
for	55220	55223	O
the	55224	55227	O
alternate	55228	55237	O
allele	55238	55244	O
were	55245	55249	O
excluded	55250	55258	O
from	55259	55263	O
the	55264	55267	O
mutation	55268	55276	O
calls	55277	55282	O
of	55283	55285	O
the	55286	55289	O
given	55290	55295	O
individual	55296	55306	O
.	55306	55307	O

Filtering	55308	55317	O
out	55318	55321	O
artifacts	55322	55331	O
A	55332	55333	O
total	55334	55339	O
of	55340	55342	O
13	55343	55345	O
filters	55346	55353	O
were	55354	55358	O
applied	55359	55366	O
to	55367	55369	O
exclude	55370	55377	O
a	55378	55379	O
variety	55380	55387	O
of	55388	55390	O
artifacts	55391	55400	O
:	55400	55401	O
Blacklisted	55402	55413	O
regions	55414	55421	O
.	55421	55422	O

We	55423	55425	O
excluded	55426	55434	O
sex	55435	55438	O
chromosomes	55439	55450	O
,	55450	55451	O
unfinished	55452	55462	O
chromosomal	55463	55474	O
scaffolds	55475	55484	O
,	55484	55485	O
the	55486	55489	O
mitochondrial	55490	55503	O
genome	55504	55510	O
,	55510	55511	O
and	55512	55515	O
the	55516	55519	O
HLA	55520	55523	O
locus	55524	55529	O
in	55530	55532	O
chromosome	55533	55543	O
6	55544	55545	O
which	55546	55551	O
is	55552	55554	O
known	55555	55560	O
to	55561	55563	O
contain	55564	55571	O
a	55572	55573	O
high	55574	55578	O
density	55579	55586	O
of	55587	55589	O
germline	55590	55598	O
variants	55599	55607	O
[	55608	55609	O
49	55609	55611	O
]	55611	55612	O
making	55613	55619	O
accurate	55620	55628	O
mapping	55629	55636	O
challenging	55637	55648	O
and	55649	55652	O
is	55653	55655	O
hence	55656	55661	O
a	55662	55663	O
potential	55664	55673	O
source	55674	55680	O
of	55681	55683	O
false	55684	55689	O
-	55689	55690	O
positive	55690	55698	O
calls	55699	55704	O
.	55704	55705	O
RNA	55705	55708	O
edits	55709	55714	O
.	55714	55715	O

The	55716	55719	O
most	55720	55724	O
prevalent	55725	55734	O
type	55735	55739	O
of	55740	55742	O
RNA	55743	55746	O
editing	55747	55754	O
in	55755	55757	O
humans	55758	55764	O
is	55765	55767	O
Adenine	55768	55775	O
-	55775	55776	O
to	55776	55778	O
-	55778	55779	O
Inosine	55779	55786	O
(	55787	55788	O
A	55788	55789	O
>	55789	55790	O
I	55790	55791	O
)	55791	55792	O
which	55793	55798	O
is	55799	55801	O
observed	55802	55810	O
as	55811	55813	O
an	55814	55816	O
A	55817	55818	O
>	55818	55819	O
G	55819	55820	O
/	55820	55821	O
T	55821	55822	O
>	55822	55823	O
C	55823	55824	O
substitution	55825	55837	O
in	55838	55840	O
sequencing	55841	55851	O
data	55852	55856	O
.	55856	55857	O

The	55858	55861	O
Rigorously	55862	55872	O
Annotated	55873	55882	O
Database	55883	55891	O
of	55892	55894	O
A	55895	55896	O
-	55896	55897	O
to	55897	55899	O
-	55899	55900	O
I	55900	55901	O
RNA	55902	55905	O
editing	55906	55913	O
(	55914	55915	O
RADAR	55915	55920	O
)	55920	55921	O
[	55922	55923	O
50	55923	55925	O
]	55925	55926	O
has	55927	55930	O
extensively	55931	55942	O
curated	55943	55950	O
RNA	55951	55954	O
-	55954	55955	O
edit	55955	55959	O
events	55960	55966	O
including	55967	55976	O
calls	55977	55982	O
identified	55983	55993	O
using	55994	55999	O
the	56000	56003	O
GTEx	56004	56008	O
data	56009	56013	O
[	56014	56015	O
51	56015	56017	O
]	56017	56018	O
.	56018	56019	O

We	56020	56022	O
also	56023	56027	O
obtained	56028	56036	O
RNA	56037	56040	O
-	56040	56041	O
edit	56041	56045	O
information	56046	56057	O
from	56058	56062	O
the	56063	56066	O
Database	56067	56075	O
of	56076	56078	O
RNA	56079	56082	O
editing	56083	56090	O
(	56091	56092	O
DARNED	56092	56098	O
)	56098	56099	O
that	56100	56104	O
includes	56105	56113	O
further	56114	56121	O
edit	56122	56126	O
types	56127	56132	O
curated	56133	56140	O
from	56141	56145	O
published	56146	56155	O
studies	56156	56163	O
[	56164	56165	O
52	56165	56167	O
]	56167	56168	O
.	56168	56169	O

We	56170	56172	O
excluded	56173	56181	O
all	56182	56185	O
positions	56186	56195	O
described	56196	56205	O
in	56206	56208	O
RADAR	56209	56214	O
v2	56215	56217	O
(	56218	56219	O
http	56219	56223	O
:	56223	56224	O
/	56224	56225	O
/	56225	56226	O
lilab	56226	56231	O
.	56231	56232	O
stanford	56232	56240	O
.	56240	56241	O
edu	56241	56244	O
/	56244	56245	O
GokulR	56245	56251	O
/	56251	56252	O
database	56252	56260	O
/	56260	56261	O
Human	56261	56266	O
_	56266	56267	O
AG	56267	56269	O
_	56269	56270	O
all	56270	56273	O
_	56273	56274	O
hg19	56274	56278	O
_	56278	56279	O
v2	56279	56281	O
.	56281	56282	O
txt	56282	56285	O
)	56285	56286	O
and	56287	56290	O
in	56291	56293	O
DARNED	56294	56300	O
(	56301	56302	O
https	56302	56307	O
:	56307	56308	O
/	56308	56309	O
/	56309	56310	O
darned	56310	56316	O
.	56316	56317	O
ucc	56317	56320	O
.	56320	56321	O
ie	56321	56323	O
/	56323	56324	O
static	56324	56330	O
/	56330	56331	O
downloads	56331	56340	O
/	56340	56341	O
hg19	56341	56345	O
.	56345	56346	O
txt	56346	56349	O
)	56349	56350	O
and	56351	56354	O
observed	56355	56363	O
an	56364	56366	O
average	56367	56374	O
decrease	56375	56383	O
of	56384	56386	O
10	56387	56389	O
%	56389	56390	O
mutations	56391	56400	O
per	56401	56404	O
sample	56405	56411	O
in	56412	56414	O
our	56415	56418	O
RNA	56419	56422	O
-	56422	56423	O
sequencing	56423	56433	O
calls	56434	56439	O
but	56440	56443	O
not	56444	56447	O
in	56448	56450	O
our	56451	56454	O
DNA	56455	56458	O
-	56458	56459	O
sequencing	56459	56469	O
calls	56470	56475	O
from	56476	56480	O
GTEx	56481	56485	O
(	56486	56487	O
Additional	56487	56497	O
file	56498	56502	O
1	56503	56504	O
:	56504	56505	O
Figure	56506	56512	O
S2a	56513	56516	O
)	56516	56517	O
,	56517	56518	O
indicating	56519	56529	O
that	56530	56534	O
we	56535	56537	O
are	56538	56541	O
indeed	56542	56548	O
eliminating	56549	56560	O
real	56561	56565	O
RNA	56566	56569	O
-	56569	56570	O
edit	56570	56574	O
events	56575	56581	O
that	56582	56586	O
would	56587	56592	O
otherwise	56593	56602	O
be	56603	56605	O
false	56606	56611	O
-	56611	56612	O
positive	56612	56620	O
mutation	56621	56629	O
calls	56630	56635	O
.	56635	56636	O
Splice	56636	56642	O
junction	56643	56651	O
artifacts	56652	56661	O
.	56661	56662	O

Splice	56663	56669	O
junctions	56670	56679	O
are	56680	56683	O
difficult	56684	56693	O
to	56694	56696	O
resolve	56697	56704	O
during	56705	56711	O
mapping	56712	56719	O
because	56720	56727	O
a	56728	56729	O
gap	56730	56733	O
has	56734	56737	O
to	56738	56740	O
be	56741	56743	O
introduced	56744	56754	O
in	56755	56757	O
reads	56758	56763	O
spanning	56764	56772	O
a	56773	56774	O
splice	56775	56781	O
junction	56782	56790	O
to	56791	56793	O
map	56794	56797	O
it	56798	56800	O
to	56801	56803	O
the	56804	56807	O
corresponding	56808	56821	O
exons	56822	56827	O
in	56828	56830	O
the	56831	56834	O
genome	56835	56841	O
.	56841	56842	O

We	56843	56845	O
observed	56846	56854	O
that	56855	56859	O
the	56860	56863	O
mutation	56864	56872	O
rate	56873	56877	O
was	56878	56881	O
higher	56882	56888	O
close	56889	56894	O
to	56895	56897	O
annotated	56898	56907	O
exon	56908	56912	O
ends	56913	56917	O
and	56918	56921	O
it	56922	56924	O
stabilized	56925	56935	O
at	56936	56938	O
~	56939	56940	O
7	56941	56942	O
bp	56943	56945	O
away	56946	56950	O
from	56951	56955	O
the	56956	56959	O
exon	56960	56964	O
end	56965	56968	O
across	56969	56975	O
all	56976	56979	O
tissues	56980	56987	O
(	56988	56989	O
Genecode	56989	56997	O
v19	56998	57001	O
genes	57002	57007	O
v7	57008	57010	O
annotation	57011	57021	O
file	57022	57026	O
)	57026	57027	O
(	57028	57029	O
Additional	57029	57039	O
file	57040	57044	O
1	57045	57046	O
:	57046	57047	O
Figure	57048	57054	O
S1b	57055	57058	O
)	57058	57059	O
.	57059	57060	O

Most	57061	57065	O
of	57066	57068	O
these	57069	57074	O
are	57075	57078	O
likely	57079	57085	O
mapping	57086	57093	O
artifacts	57094	57103	O
,	57103	57104	O
and	57105	57108	O
we	57109	57111	O
therefore	57112	57121	O
excluded	57122	57130	O
all	57131	57134	O
mutations	57135	57144	O
located	57145	57152	O
less	57153	57157	O
than	57158	57162	O
7	57163	57164	O
bp	57165	57167	O
away	57168	57172	O
from	57173	57177	O
an	57178	57180	O
annotated	57181	57190	O
exon	57191	57195	O
end	57196	57199	O
.	57199	57200	O
Sequencing	57200	57210	O
errors	57211	57217	O
.	57217	57218	O

While	57219	57224	O
sequencing	57225	57235	O
errors	57236	57242	O
are	57243	57246	O
unlikely	57247	57255	O
to	57256	57258	O
be	57259	57261	O
found	57262	57267	O
given	57268	57273	O
the	57274	57277	O
parameters	57278	57288	O
established	57289	57300	O
in	57301	57303	O
the	57304	57307	O
first	57308	57313	O
part	57314	57318	O
of	57319	57321	O
the	57322	57325	O
mutation	57326	57334	O
calling	57335	57342	O
pipeline	57343	57351	O
(	57352	57353	O
see	57353	57356	O
above	57357	57362	O
)	57362	57363	O
,	57363	57364	O
we	57365	57367	O
additionally	57368	57380	O
filtered	57381	57389	O
out	57390	57393	O
mutations	57394	57403	O
that	57404	57408	O
had	57409	57412	O
a	57413	57414	O
probability	57415	57426	O
of	57427	57429	O
being	57430	57435	O
sequencing	57436	57446	O
errors	57447	57453	O
greater	57454	57461	O
than	57462	57466	O
0	57467	57468	O
.	57468	57469	O
01	57469	57471	O
%	57471	57472	O
.	57472	57473	O

This	57474	57478	O
probability	57479	57490	O
was	57491	57494	O
calculated	57495	57505	O
using	57506	57511	O
the	57512	57515	O
upper	57516	57521	O
tail	57522	57526	O
integral	57527	57535	O
of	57536	57538	O
the	57539	57542	O
binomial	57543	57551	O
distribution	57552	57564	O
where	57565	57570	O
the	57571	57574	O
number	57575	57581	O
of	57582	57584	O
successes	57585	57594	O
is	57595	57597	O
the	57598	57601	O
number	57602	57608	O
of	57609	57611	O
reads	57612	57617	O
supporting	57618	57628	O
the	57629	57632	O
alternate	57633	57642	O
allele	57643	57649	O
,	57649	57650	O
the	57651	57654	O
number	57655	57661	O
of	57662	57664	O
events	57665	57671	O
is	57672	57674	O
the	57675	57678	O
coverage	57679	57687	O
in	57688	57690	O
that	57691	57695	O
position	57696	57704	O
,	57704	57705	O
and	57706	57709	O
the	57710	57713	O
probability	57714	57725	O
of	57726	57728	O
success	57729	57736	O
is	57737	57739	O
the	57740	57743	O
conservative	57744	57756	O
assumption	57757	57767	O
of	57768	57770	O
p	57771	57772	O
=	57773	57774	O
0	57775	57776	O
.	57776	57777	O
001	57777	57780	O
which	57781	57786	O
equals	57787	57793	O
our	57794	57797	O
cutoff	57798	57804	O
of	57805	57807	O
phred	57808	57813	O
score	57814	57819	O
30	57820	57822	O
during	57823	57829	O
the	57830	57833	O
first	57834	57839	O
part	57840	57844	O
of	57845	57847	O
the	57848	57851	O
pipeline	57852	57860	O
(	57861	57862	O
see	57862	57865	O
above	57866	57871	O
)	57871	57872	O
.	57872	57873	O

This	57874	57878	O
is	57879	57881	O
extremely	57882	57891	O
conservative	57892	57904	O
because	57905	57912	O
it	57913	57915	O
does	57916	57920	O
not	57921	57924	O
incorporate	57925	57936	O
the	57937	57940	O
probability	57941	57952	O
of	57953	57955	O
observing	57956	57965	O
the	57966	57969	O
exact	57970	57975	O
same	57976	57980	O
base	57981	57985	O
call	57986	57990	O
across	57991	57997	O
all	57998	58001	O
reads	58002	58007	O
supporting	58008	58018	O
the	58019	58022	O
alternate	58023	58032	O
allele	58033	58039	O
.	58039	58040	O
Read	58040	58044	O
position	58045	58053	O
bias	58054	58058	O
.	58058	58059	O

To	58060	58062	O
eliminate	58063	58072	O
any	58073	58076	O
systematic	58077	58087	O
bias	58088	58092	O
of	58093	58095	O
a	58096	58097	O
mutation	58098	58106	O
being	58107	58112	O
consistently	58113	58125	O
called	58126	58132	O
around	58133	58139	O
the	58140	58143	O
same	58144	58148	O
position	58149	58157	O
along	58158	58163	O
reads	58164	58169	O
supporting	58170	58180	O
it	58181	58183	O
versus	58184	58190	O
the	58191	58194	O
rest	58195	58199	O
of	58200	58202	O
the	58203	58206	O
reads	58207	58212	O
,	58212	58213	O
we	58214	58216	O
excluded	58217	58225	O
mutations	58226	58235	O
that	58236	58240	O
had	58241	58244	O
a	58245	58246	O
p	58247	58248	O
value	58249	58254	O
less	58255	58259	O
than	58260	58264	O
0	58265	58266	O
.	58266	58267	O
05	58267	58269	O
when	58270	58274	O
applying	58275	58283	O
a	58284	58285	O
Mann	58286	58290	O
-	58290	58291	O
Whitney	58291	58298	O
U	58299	58300	O
test	58301	58305	O
of	58306	58308	O
the	58309	58312	O
positions	58313	58322	O
in	58323	58325	O
the	58326	58329	O
read	58330	58334	O
supporting	58335	58345	O
the	58346	58349	O
alternate	58350	58359	O
allele	58360	58366	O
vs	58367	58369	O
the	58370	58373	O
positions	58374	58383	O
supporting	58384	58394	O
the	58395	58398	O
reference	58399	58408	O
allele	58409	58415	O
.	58415	58416	O

For	58417	58420	O
these	58421	58426	O
tests	58427	58432	O
,	58432	58433	O
we	58434	58436	O
used	58437	58441	O
BCFtools	58442	58450	O
[	58451	58452	O
53	58452	58454	O
]	58454	58455	O
mpileup	58456	58463	O
.	58463	58464	O
Mapping	58464	58471	O
quality	58472	58479	O
bias	58480	58484	O
.	58484	58485	O

We	58486	58488	O
excluded	58489	58497	O
mutations	58498	58507	O
that	58508	58512	O
had	58513	58516	O
a	58517	58518	O
p	58519	58520	O
value	58521	58526	O
less	58527	58531	O
than	58532	58536	O
0	58537	58538	O
.	58538	58539	O
05	58539	58541	O
when	58542	58546	O
applying	58547	58555	O
a	58556	58557	O
Mann	58558	58562	O
-	58562	58563	O
Whitney	58563	58570	O
U	58571	58572	O
test	58573	58577	O
comparing	58578	58587	O
mapping	58588	58595	O
quality	58596	58603	O
scores	58604	58610	O
of	58611	58613	O
the	58614	58617	O
base	58618	58622	O
calls	58623	58628	O
supporting	58629	58639	O
the	58640	58643	O
alternate	58644	58653	O
allele	58654	58660	O
vs	58661	58663	O
the	58664	58667	O
mapping	58668	58675	O
quality	58676	58683	O
scores	58684	58690	O
of	58691	58693	O
reads	58694	58699	O
supporting	58700	58710	O
the	58711	58714	O
reference	58715	58724	O
allele	58725	58731	O
.	58731	58732	O

For	58733	58736	O
these	58737	58742	O
tests	58743	58748	O
,	58748	58749	O
we	58750	58752	O
used	58753	58757	O
BCFtools	58758	58766	O
[	58767	58768	O
53	58768	58770	O
]	58770	58771	O
mpileup	58772	58779	O
.	58779	58780	O
Sequence	58780	58788	O
quality	58789	58796	O
bias	58797	58801	O
.	58801	58802	O

We	58803	58805	O
excluded	58806	58814	O
mutations	58815	58824	O
with	58825	58829	O
a	58830	58831	O
p	58832	58833	O
value	58834	58839	O
less	58840	58844	O
than	58845	58849	O
0	58850	58851	O
.	58851	58852	O
05	58852	58854	O
when	58855	58859	O
applying	58860	58868	O
a	58869	58870	O
Mann	58871	58875	O
-	58875	58876	O
Whitney	58876	58883	O
U	58884	58885	O
test	58886	58890	O
comparing	58891	58900	O
sequencing	58901	58911	O
quality	58912	58919	O
scores	58920	58926	O
of	58927	58929	O
base	58930	58934	O
calls	58935	58940	O
supporting	58941	58951	O
the	58952	58955	O
alternate	58956	58965	O
allele	58966	58972	O
vs	58973	58975	O
the	58976	58979	O
scores	58980	58986	O
of	58987	58989	O
base	58990	58994	O
calls	58995	59000	O
supporting	59001	59011	O
the	59012	59015	O
reference	59016	59025	O
allele	59026	59032	O
.	59032	59033	O

For	59034	59037	O
these	59038	59043	O
tests	59044	59049	O
,	59049	59050	O
we	59051	59053	O
used	59054	59058	O
BCFtools	59059	59067	O
[	59068	59069	O
53	59069	59071	O
]	59071	59072	O
mpileup	59073	59080	O
.	59080	59081	O
Strand	59081	59087	O
bias	59088	59092	O
.	59092	59093	O

We	59094	59096	O
excluded	59097	59105	O
mutations	59106	59115	O
with	59116	59120	O
a	59121	59122	O
p	59123	59124	O
value	59125	59130	O
less	59131	59135	O
than	59136	59140	O
0	59141	59142	O
.	59142	59143	O
05	59143	59145	O
when	59146	59150	O
applying	59151	59159	O
a	59160	59161	O
Mann	59162	59166	O
-	59166	59167	O
Whitney	59167	59174	O
U	59175	59176	O
test	59177	59181	O
comparing	59182	59191	O
strand	59192	59198	O
bias	59199	59203	O
of	59204	59206	O
bases	59207	59212	O
supporting	59213	59223	O
the	59224	59227	O
reference	59228	59237	O
and	59238	59241	O
alternate	59242	59251	O
allele	59252	59258	O
(	59259	59260	O
i	59260	59261	O
.	59261	59262	O
e	59262	59263	O
.	59263	59264	O
,	59264	59265	O
cases	59266	59271	O
where	59272	59277	O
mutations	59278	59287	O
were	59288	59292	O
only	59293	59297	O
observed	59298	59306	O
on	59307	59309	O
one	59310	59313	O
strand	59314	59320	O
were	59321	59325	O
excluded	59326	59334	O
;	59334	59335	O
this	59336	59340	O
is	59341	59343	O
not	59344	59347	O
related	59348	59355	O
to	59356	59358	O
the	59359	59362	O
strand	59363	59369	O
asymmetry	59370	59379	O
we	59380	59382	O
observed	59383	59391	O
for	59392	59395	O
some	59396	59400	O
mutation	59401	59409	O
types	59410	59415	O
)	59415	59416	O
.	59416	59417	O

For	59418	59421	O
these	59422	59427	O
tests	59428	59433	O
,	59433	59434	O
we	59435	59437	O
used	59438	59442	O
the	59443	59446	O
“	59447	59448	O
Mann	59448	59452	O
-	59452	59453	O
Whitney	59453	59460	O
U	59461	59462	O
test	59463	59467	O
of	59468	59470	O
Mapping	59471	59478	O
Quality	59479	59486	O
vs	59487	59489	O
Strand	59490	59496	O
Bias	59497	59501	O
”	59501	59502	O
of	59503	59505	O
BCFtools	59506	59514	O
[	59515	59516	O
53	59516	59518	O
]	59518	59519	O
mpileup	59520	59527	O
.	59527	59528	O
Variant	59528	59535	O
distance	59536	59544	O
bias	59545	59549	O
.	59549	59550	O

We	59551	59553	O
excluded	59554	59562	O
variants	59563	59571	O
that	59572	59576	O
showed	59577	59583	O
a	59584	59585	O
high	59586	59590	O
or	59591	59593	O
low	59594	59597	O
mean	59598	59602	O
pairwise	59603	59611	O
distance	59612	59620	O
between	59621	59628	O
the	59629	59632	O
alternate	59633	59642	O
allele	59643	59649	O
positions	59650	59659	O
in	59660	59662	O
the	59663	59666	O
reads	59667	59672	O
supporting	59673	59683	O
it	59684	59686	O
.	59686	59687	O

Similar	59688	59695	O
to	59696	59698	O
the	59699	59702	O
read	59703	59707	O
position	59708	59716	O
bias	59717	59721	O
filter	59722	59728	O
,	59728	59729	O
this	59730	59734	O
ensures	59735	59742	O
that	59743	59747	O
we	59748	59750	O
filter	59751	59757	O
mutations	59758	59767	O
that	59768	59772	O
are	59773	59776	O
consistently	59777	59789	O
observed	59790	59798	O
around	59799	59805	O
the	59806	59809	O
same	59810	59814	O
region	59815	59821	O
of	59822	59824	O
all	59825	59828	O
the	59829	59832	O
reads	59833	59838	O
that	59839	59843	O
support	59844	59851	O
it	59852	59854	O
.	59854	59855	O

We	59856	59858	O
used	59859	59863	O
a	59864	59865	O
cutoff	59866	59872	O
of	59873	59875	O
p	59876	59877	O
<	59878	59879	O
0	59880	59881	O
.	59881	59882	O
05	59882	59884	O
for	59885	59888	O
a	59889	59890	O
two	59891	59894	O
-	59894	59895	O
tail	59895	59899	O
distribution	59900	59912	O
of	59913	59915	O
simulated	59916	59925	O
mean	59926	59930	O
pairwise	59931	59939	O
distances	59940	59949	O
from	59950	59954	O
the	59955	59958	O
BCFtools	59959	59967	O
[	59968	59969	O
53	59969	59971	O
]	59971	59972	O
implementation	59973	59987	O
.	59987	59988	O
RNA	59988	59991	O
-	59991	59992	O
specific	59992	60000	O
allele	60001	60007	O
frequency	60008	60017	O
bias	60018	60022	O
.	60022	60023	O

We	60024	60026	O
observed	60027	60035	O
an	60036	60038	O
enrichment	60039	60049	O
of	60050	60052	O
variants	60053	60061	O
having	60062	60068	O
a	60069	60070	O
variant	60071	60078	O
allele	60079	60085	O
frequency	60086	60095	O
(	60096	60097	O
VAF	60097	60100	O
)	60100	60101	O
greater	60102	60109	O
than	60110	60114	O
0	60115	60116	O
.	60116	60117	O
9	60117	60118	O
only	60119	60123	O
in	60124	60126	O
mutation	60127	60135	O
calls	60136	60141	O
from	60142	60146	O
RNA	60147	60150	O
-	60150	60151	O
sequencing	60151	60161	O
but	60162	60165	O
not	60166	60169	O
from	60170	60174	O
the	60175	60178	O
matched	60179	60186	O
DNA	60187	60190	O
-	60190	60191	O
sequencing	60191	60201	O
samples	60202	60209	O
.	60209	60210	O

This	60211	60215	O
RNA	60216	60219	O
-	60219	60220	O
specific	60220	60228	O
bias	60229	60233	O
could	60234	60239	O
be	60240	60242	O
due	60243	60246	O
to	60247	60249	O
several	60250	60257	O
factors	60258	60265	O
,	60265	60266	O
including	60267	60276	O
allele	60277	60283	O
-	60283	60284	O
specific	60284	60292	O
expression	60293	60303	O
leading	60304	60311	O
to	60312	60314	O
enrichment	60315	60325	O
of	60326	60328	O
the	60329	60332	O
alternate	60333	60342	O
allele	60343	60349	O
,	60349	60350	O
RNA	60351	60354	O
editing	60355	60362	O
,	60362	60363	O
or	60364	60366	O
systematic	60367	60377	O
artifacts	60378	60387	O
during	60388	60394	O
RNA	60395	60398	O
extraction	60399	60409	O
,	60409	60410	O
library	60411	60418	O
construction	60419	60431	O
,	60431	60432	O
and	60433	60436	O
sequencing	60437	60447	O
.	60447	60448	O

We	60449	60451	O
took	60452	60456	O
a	60457	60458	O
conservative	60459	60471	O
approach	60472	60480	O
and	60481	60484	O
excluded	60485	60493	O
all	60494	60497	O
mutations	60498	60507	O
that	60508	60512	O
had	60513	60516	O
a	60517	60518	O
VAF	60519	60522	O
greater	60523	60530	O
than	60531	60535	O
0	60536	60537	O
.	60537	60538	O
7	60538	60539	O
.	60539	60540	O
Tissue	60540	60546	O
-	60546	60547	O
specific	60547	60555	O
mutation	60556	60564	O
effects	60565	60572	O
.	60572	60573	O

To	60574	60576	O
eliminate	60577	60586	O
false	60587	60592	O
positives	60593	60602	O
arising	60603	60610	O
by	60611	60613	O
systematic	60614	60624	O
artifacts	60625	60634	O
of	60635	60637	O
unknown	60638	60645	O
origin	60646	60652	O
,	60652	60653	O
we	60654	60656	O
first	60657	60662	O
looked	60663	60669	O
for	60670	60673	O
recurrent	60674	60683	O
mutations	60684	60693	O
observed	60694	60702	O
in	60703	60705	O
many	60706	60710	O
samples	60711	60718	O
of	60719	60721	O
a	60722	60723	O
given	60724	60729	O
tissue	60730	60736	O
.	60736	60737	O

While	60738	60743	O
these	60744	60749	O
mutations	60750	60759	O
could	60760	60765	O
be	60766	60768	O
real	60769	60773	O
and	60774	60777	O
have	60778	60782	O
a	60783	60784	O
biological	60785	60795	O
impact	60796	60802	O
,	60802	60803	O
they	60804	60808	O
may	60809	60812	O
also	60813	60817	O
reflect	60818	60825	O
a	60826	60827	O
shared	60828	60834	O
systematic	60835	60845	O
artifact	60846	60854	O
that	60855	60859	O
is	60860	60862	O
producing	60863	60872	O
the	60873	60876	O
same	60877	60881	O
exact	60882	60887	O
mutation	60888	60896	O
across	60897	60903	O
several	60904	60911	O
samples	60912	60919	O
of	60920	60922	O
the	60923	60926	O
same	60927	60931	O
tissue	60932	60938	O
.	60938	60939	O

We	60940	60942	O
decided	60943	60950	O
to	60951	60953	O
take	60954	60958	O
a	60959	60960	O
conservative	60961	60973	O
approach	60974	60982	O
and	60983	60986	O
eliminated	60987	60997	O
all	60998	61001	O
mutations	61002	61011	O
that	61012	61016	O
were	61017	61021	O
called	61022	61028	O
in	61029	61031	O
at	61032	61034	O
least	61035	61040	O
40	61041	61043	O
%	61043	61044	O
of	61045	61047	O
the	61048	61051	O
samples	61052	61059	O
in	61060	61062	O
one	61063	61066	O
tissue	61067	61073	O
.	61073	61074	O

Even	61075	61079	O
though	61080	61086	O
we	61087	61089	O
labeled	61090	61097	O
these	61098	61103	O
mutations	61104	61113	O
on	61114	61116	O
a	61117	61118	O
per	61119	61122	O
-	61122	61123	O
tissue	61123	61129	O
basis	61130	61135	O
,	61135	61136	O
once	61137	61141	O
identified	61142	61152	O
,	61152	61153	O
we	61154	61156	O
removed	61157	61164	O
them	61165	61169	O
from	61170	61174	O
any	61175	61178	O
sample	61179	61185	O
in	61186	61188	O
any	61189	61192	O
tissue	61193	61199	O
that	61200	61204	O
had	61205	61208	O
them	61209	61213	O
.	61213	61214	O
Overall	61214	61221	O
systematic	61222	61232	O
mutation	61233	61241	O
bias	61242	61246	O
.	61246	61247	O

We	61248	61250	O
further	61251	61258	O
eliminated	61259	61269	O
mutations	61270	61279	O
that	61280	61284	O
were	61285	61289	O
present	61290	61297	O
in	61298	61300	O
at	61301	61303	O
least	61304	61309	O
4	61310	61311	O
%	61311	61312	O
of	61313	61315	O
all	61316	61319	O
samples	61320	61327	O
.	61327	61328	O

Similarly	61329	61338	O
,	61338	61339	O
as	61340	61342	O
in	61343	61345	O
the	61346	61349	O
previous	61350	61358	O
step	61359	61363	O
,	61363	61364	O
these	61365	61370	O
mutations	61371	61380	O
are	61381	61384	O
more	61385	61389	O
likely	61390	61396	O
to	61397	61399	O
have	61400	61404	O
originated	61405	61415	O
from	61416	61420	O
a	61421	61422	O
systematic	61423	61433	O
artifact	61434	61442	O
.	61442	61443	O
Hyper	61443	61448	O
-	61448	61449	O
mutated	61449	61456	O
samples	61457	61464	O
.	61464	61465	O

We	61466	61468	O
excluded	61469	61477	O
samples	61478	61485	O
that	61486	61490	O
had	61491	61494	O
an	61495	61497	O
excess	61498	61504	O
of	61505	61507	O
mutations	61508	61517	O
compared	61518	61526	O
to	61527	61529	O
what	61530	61534	O
it	61535	61537	O
was	61538	61541	O
expected	61542	61550	O
from	61551	61555	O
sequencing	61556	61566	O
depth	61567	61572	O
and	61573	61576	O
biological	61577	61587	O
factors	61588	61595	O
.	61595	61596	O

To	61597	61599	O
do	61600	61602	O
so	61603	61605	O
,	61605	61606	O
we	61607	61609	O
looked	61610	61616	O
at	61617	61619	O
the	61620	61623	O
residuals	61624	61633	O
after	61634	61639	O
applying	61640	61648	O
a	61649	61650	O
linear	61651	61657	O
regression	61658	61668	O
on	61669	61671	O
mutation	61672	61680	O
numbers	61681	61688	O
using	61689	61694	O
as	61695	61697	O
features	61698	61706	O
sequencing	61707	61717	O
depth	61718	61723	O
,	61723	61724	O
age	61725	61728	O
,	61728	61729	O
sex	61730	61733	O
,	61733	61734	O
and	61735	61738	O
BMI	61739	61742	O
.	61742	61743	O

We	61744	61746	O
observed	61747	61755	O
48	61756	61758	O
samples	61759	61766	O
that	61767	61771	O
had	61772	61775	O
residual	61776	61784	O
values	61785	61791	O
greater	61792	61799	O
than	61800	61804	O
1500	61805	61809	O
(	61810	61811	O
i	61811	61812	O
.	61812	61813	O
e	61813	61814	O
.	61814	61815	O
,	61815	61816	O
they	61817	61821	O
had	61822	61825	O
>	61826	61827	O
1500	61828	61832	O
more	61833	61837	O
mutations	61838	61847	O
than	61848	61852	O
expected	61853	61861	O
by	61862	61864	O
other	61865	61870	O
factors	61871	61878	O
)	61878	61879	O
(	61880	61881	O
Additional	61881	61891	O
file	61892	61896	O
1	61897	61898	O
:	61898	61899	O
Figure	61900	61906	O
S1	61907	61909	O
g	61910	61911	O
)	61911	61912	O
and	61913	61916	O
excluded	61917	61925	O
them	61926	61930	O
from	61931	61935	O
further	61936	61943	O
analysis	61944	61952	O
,	61952	61953	O
leaving	61954	61961	O
7584	61962	61966	O
remaining	61967	61976	O
.	61976	61977	O

We	61978	61980	O
did	61981	61984	O
not	61985	61988	O
observe	61989	61996	O
any	61997	62000	O
hypo	62001	62005	O
-	62005	62006	O
mutated	62006	62013	O
samples	62014	62021	O
having	62022	62028	O
similar	62029	62036	O
residual	62037	62045	O
values	62046	62052	O
in	62053	62055	O
the	62056	62059	O
opposite	62060	62068	O
direction	62069	62078	O
.	62078	62079	O

Blacklisted	62080	62091	O
regions	62092	62099	O
.	62099	62100	O

We	62101	62103	O
excluded	62104	62112	O
sex	62113	62116	O
chromosomes	62117	62128	O
,	62128	62129	O
unfinished	62130	62140	O
chromosomal	62141	62152	O
scaffolds	62153	62162	O
,	62162	62163	O
the	62164	62167	O
mitochondrial	62168	62181	O
genome	62182	62188	O
,	62188	62189	O
and	62190	62193	O
the	62194	62197	O
HLA	62198	62201	O
locus	62202	62207	O
in	62208	62210	O
chromosome	62211	62221	O
6	62222	62223	O
which	62224	62229	O
is	62230	62232	O
known	62233	62238	O
to	62239	62241	O
contain	62242	62249	O
a	62250	62251	O
high	62252	62256	O
density	62257	62264	O
of	62265	62267	O
germline	62268	62276	O
variants	62277	62285	O
[	62286	62287	O
49	62287	62289	O
]	62289	62290	O
making	62291	62297	O
accurate	62298	62306	O
mapping	62307	62314	O
challenging	62315	62326	O
and	62327	62330	O
is	62331	62333	O
hence	62334	62339	O
a	62340	62341	O
potential	62342	62351	O
source	62352	62358	O
of	62359	62361	O
false	62362	62367	O
-	62367	62368	O
positive	62368	62376	O
calls	62377	62382	O
.	62382	62383	O

RNA	62384	62387	O
edits	62388	62393	O
.	62393	62394	O

The	62395	62398	O
most	62399	62403	O
prevalent	62404	62413	O
type	62414	62418	O
of	62419	62421	O
RNA	62422	62425	O
editing	62426	62433	O
in	62434	62436	O
humans	62437	62443	O
is	62444	62446	O
Adenine	62447	62454	O
-	62454	62455	O
to	62455	62457	O
-	62457	62458	O
Inosine	62458	62465	O
(	62466	62467	O
A	62467	62468	O
>	62468	62469	O
I	62469	62470	O
)	62470	62471	O
which	62472	62477	O
is	62478	62480	O
observed	62481	62489	O
as	62490	62492	O
an	62493	62495	O
A	62496	62497	O
>	62497	62498	O
G	62498	62499	O
/	62499	62500	O
T	62500	62501	O
>	62501	62502	O
C	62502	62503	O
substitution	62504	62516	O
in	62517	62519	O
sequencing	62520	62530	O
data	62531	62535	O
.	62535	62536	O

The	62537	62540	O
Rigorously	62541	62551	O
Annotated	62552	62561	O
Database	62562	62570	O
of	62571	62573	O
A	62574	62575	O
-	62575	62576	O
to	62576	62578	O
-	62578	62579	O
I	62579	62580	O
RNA	62581	62584	O
editing	62585	62592	O
(	62593	62594	O
RADAR	62594	62599	O
)	62599	62600	O
[	62601	62602	O
50	62602	62604	O
]	62604	62605	O
has	62606	62609	O
extensively	62610	62621	O
curated	62622	62629	O
RNA	62630	62633	O
-	62633	62634	O
edit	62634	62638	O
events	62639	62645	O
including	62646	62655	O
calls	62656	62661	O
identified	62662	62672	O
using	62673	62678	O
the	62679	62682	O
GTEx	62683	62687	O
data	62688	62692	O
[	62693	62694	O
51	62694	62696	O
]	62696	62697	O
.	62697	62698	O

We	62699	62701	O
also	62702	62706	O
obtained	62707	62715	O
RNA	62716	62719	O
-	62719	62720	O
edit	62720	62724	O
information	62725	62736	O
from	62737	62741	O
the	62742	62745	O
Database	62746	62754	O
of	62755	62757	O
RNA	62758	62761	O
editing	62762	62769	O
(	62770	62771	O
DARNED	62771	62777	O
)	62777	62778	O
that	62779	62783	O
includes	62784	62792	O
further	62793	62800	O
edit	62801	62805	O
types	62806	62811	O
curated	62812	62819	O
from	62820	62824	O
published	62825	62834	O
studies	62835	62842	O
[	62843	62844	O
52	62844	62846	O
]	62846	62847	O
.	62847	62848	O

We	62849	62851	O
excluded	62852	62860	O
all	62861	62864	O
positions	62865	62874	O
described	62875	62884	O
in	62885	62887	O
RADAR	62888	62893	O
v2	62894	62896	O
(	62897	62898	O
http	62898	62902	O
:	62902	62903	O
/	62903	62904	O
/	62904	62905	O
lilab	62905	62910	O
.	62910	62911	O
stanford	62911	62919	O
.	62919	62920	O
edu	62920	62923	O
/	62923	62924	O
GokulR	62924	62930	O
/	62930	62931	O
database	62931	62939	O
/	62939	62940	O
Human	62940	62945	O
_	62945	62946	O
AG	62946	62948	O
_	62948	62949	O
all	62949	62952	O
_	62952	62953	O
hg19	62953	62957	O
_	62957	62958	O
v2	62958	62960	O
.	62960	62961	O
txt	62961	62964	O
)	62964	62965	O
and	62966	62969	O
in	62970	62972	O
DARNED	62973	62979	O
(	62980	62981	O
https	62981	62986	O
:	62986	62987	O
/	62987	62988	O
/	62988	62989	O
darned	62989	62995	O
.	62995	62996	O
ucc	62996	62999	O
.	62999	63000	O
ie	63000	63002	O
/	63002	63003	O
static	63003	63009	O
/	63009	63010	O
downloads	63010	63019	O
/	63019	63020	O
hg19	63020	63024	O
.	63024	63025	O
txt	63025	63028	O
)	63028	63029	O
and	63030	63033	O
observed	63034	63042	O
an	63043	63045	O
average	63046	63053	O
decrease	63054	63062	O
of	63063	63065	O
10	63066	63068	O
%	63068	63069	O
mutations	63070	63079	O
per	63080	63083	O
sample	63084	63090	O
in	63091	63093	O
our	63094	63097	O
RNA	63098	63101	O
-	63101	63102	O
sequencing	63102	63112	O
calls	63113	63118	O
but	63119	63122	O
not	63123	63126	O
in	63127	63129	O
our	63130	63133	O
DNA	63134	63137	O
-	63137	63138	O
sequencing	63138	63148	O
calls	63149	63154	O
from	63155	63159	O
GTEx	63160	63164	O
(	63165	63166	O
Additional	63166	63176	O
file	63177	63181	O
1	63182	63183	O
:	63183	63184	O
Figure	63185	63191	O
S2a	63192	63195	O
)	63195	63196	O
,	63196	63197	O
indicating	63198	63208	O
that	63209	63213	O
we	63214	63216	O
are	63217	63220	O
indeed	63221	63227	O
eliminating	63228	63239	O
real	63240	63244	O
RNA	63245	63248	O
-	63248	63249	O
edit	63249	63253	O
events	63254	63260	O
that	63261	63265	O
would	63266	63271	O
otherwise	63272	63281	O
be	63282	63284	O
false	63285	63290	O
-	63290	63291	O
positive	63291	63299	O
mutation	63300	63308	O
calls	63309	63314	O
.	63314	63315	O

Splice	63316	63322	O
junction	63323	63331	O
artifacts	63332	63341	O
.	63341	63342	O

Splice	63343	63349	O
junctions	63350	63359	O
are	63360	63363	O
difficult	63364	63373	O
to	63374	63376	O
resolve	63377	63384	O
during	63385	63391	O
mapping	63392	63399	O
because	63400	63407	O
a	63408	63409	O
gap	63410	63413	O
has	63414	63417	O
to	63418	63420	O
be	63421	63423	O
introduced	63424	63434	O
in	63435	63437	O
reads	63438	63443	O
spanning	63444	63452	O
a	63453	63454	O
splice	63455	63461	O
junction	63462	63470	O
to	63471	63473	O
map	63474	63477	O
it	63478	63480	O
to	63481	63483	O
the	63484	63487	O
corresponding	63488	63501	O
exons	63502	63507	O
in	63508	63510	O
the	63511	63514	O
genome	63515	63521	O
.	63521	63522	O

We	63523	63525	O
observed	63526	63534	O
that	63535	63539	O
the	63540	63543	O
mutation	63544	63552	O
rate	63553	63557	O
was	63558	63561	O
higher	63562	63568	O
close	63569	63574	O
to	63575	63577	O
annotated	63578	63587	O
exon	63588	63592	O
ends	63593	63597	O
and	63598	63601	O
it	63602	63604	O
stabilized	63605	63615	O
at	63616	63618	O
~	63619	63620	O
7	63621	63622	O
bp	63623	63625	O
away	63626	63630	O
from	63631	63635	O
the	63636	63639	O
exon	63640	63644	O
end	63645	63648	O
across	63649	63655	O
all	63656	63659	O
tissues	63660	63667	O
(	63668	63669	O
Genecode	63669	63677	O
v19	63678	63681	O
genes	63682	63687	O
v7	63688	63690	O
annotation	63691	63701	O
file	63702	63706	O
)	63706	63707	O
(	63708	63709	O
Additional	63709	63719	O
file	63720	63724	O
1	63725	63726	O
:	63726	63727	O
Figure	63728	63734	O
S1b	63735	63738	O
)	63738	63739	O
.	63739	63740	O

Most	63741	63745	O
of	63746	63748	O
these	63749	63754	O
are	63755	63758	O
likely	63759	63765	O
mapping	63766	63773	O
artifacts	63774	63783	O
,	63783	63784	O
and	63785	63788	O
we	63789	63791	O
therefore	63792	63801	O
excluded	63802	63810	O
all	63811	63814	O
mutations	63815	63824	O
located	63825	63832	O
less	63833	63837	O
than	63838	63842	O
7	63843	63844	O
bp	63845	63847	O
away	63848	63852	O
from	63853	63857	O
an	63858	63860	O
annotated	63861	63870	O
exon	63871	63875	O
end	63876	63879	O
.	63879	63880	O

Sequencing	63881	63891	O
errors	63892	63898	O
.	63898	63899	O

While	63900	63905	O
sequencing	63906	63916	O
errors	63917	63923	O
are	63924	63927	O
unlikely	63928	63936	O
to	63937	63939	O
be	63940	63942	O
found	63943	63948	O
given	63949	63954	O
the	63955	63958	O
parameters	63959	63969	O
established	63970	63981	O
in	63982	63984	O
the	63985	63988	O
first	63989	63994	O
part	63995	63999	O
of	64000	64002	O
the	64003	64006	O
mutation	64007	64015	O
calling	64016	64023	O
pipeline	64024	64032	O
(	64033	64034	O
see	64034	64037	O
above	64038	64043	O
)	64043	64044	O
,	64044	64045	O
we	64046	64048	O
additionally	64049	64061	O
filtered	64062	64070	O
out	64071	64074	O
mutations	64075	64084	O
that	64085	64089	O
had	64090	64093	O
a	64094	64095	O
probability	64096	64107	O
of	64108	64110	O
being	64111	64116	O
sequencing	64117	64127	O
errors	64128	64134	O
greater	64135	64142	O
than	64143	64147	O
0	64148	64149	O
.	64149	64150	O
01	64150	64152	O
%	64152	64153	O
.	64153	64154	O

This	64155	64159	O
probability	64160	64171	O
was	64172	64175	O
calculated	64176	64186	O
using	64187	64192	O
the	64193	64196	O
upper	64197	64202	O
tail	64203	64207	O
integral	64208	64216	O
of	64217	64219	O
the	64220	64223	O
binomial	64224	64232	O
distribution	64233	64245	O
where	64246	64251	O
the	64252	64255	O
number	64256	64262	O
of	64263	64265	O
successes	64266	64275	O
is	64276	64278	O
the	64279	64282	O
number	64283	64289	O
of	64290	64292	O
reads	64293	64298	O
supporting	64299	64309	O
the	64310	64313	O
alternate	64314	64323	O
allele	64324	64330	O
,	64330	64331	O
the	64332	64335	O
number	64336	64342	O
of	64343	64345	O
events	64346	64352	O
is	64353	64355	O
the	64356	64359	O
coverage	64360	64368	O
in	64369	64371	O
that	64372	64376	O
position	64377	64385	O
,	64385	64386	O
and	64387	64390	O
the	64391	64394	O
probability	64395	64406	O
of	64407	64409	O
success	64410	64417	O
is	64418	64420	O
the	64421	64424	O
conservative	64425	64437	O
assumption	64438	64448	O
of	64449	64451	O
p	64452	64453	O
=	64454	64455	O
0	64456	64457	O
.	64457	64458	O
001	64458	64461	O
which	64462	64467	O
equals	64468	64474	O
our	64475	64478	O
cutoff	64479	64485	O
of	64486	64488	O
phred	64489	64494	O
score	64495	64500	O
30	64501	64503	O
during	64504	64510	O
the	64511	64514	O
first	64515	64520	O
part	64521	64525	O
of	64526	64528	O
the	64529	64532	O
pipeline	64533	64541	O
(	64542	64543	O
see	64543	64546	O
above	64547	64552	O
)	64552	64553	O
.	64553	64554	O

This	64555	64559	O
is	64560	64562	O
extremely	64563	64572	O
conservative	64573	64585	O
because	64586	64593	O
it	64594	64596	O
does	64597	64601	O
not	64602	64605	O
incorporate	64606	64617	O
the	64618	64621	O
probability	64622	64633	O
of	64634	64636	O
observing	64637	64646	O
the	64647	64650	O
exact	64651	64656	O
same	64657	64661	O
base	64662	64666	O
call	64667	64671	O
across	64672	64678	O
all	64679	64682	O
reads	64683	64688	O
supporting	64689	64699	O
the	64700	64703	O
alternate	64704	64713	O
allele	64714	64720	O
.	64720	64721	O

Read	64722	64726	O
position	64727	64735	O
bias	64736	64740	O
.	64740	64741	O

To	64742	64744	O
eliminate	64745	64754	O
any	64755	64758	O
systematic	64759	64769	O
bias	64770	64774	O
of	64775	64777	O
a	64778	64779	O
mutation	64780	64788	O
being	64789	64794	O
consistently	64795	64807	O
called	64808	64814	O
around	64815	64821	O
the	64822	64825	O
same	64826	64830	O
position	64831	64839	O
along	64840	64845	O
reads	64846	64851	O
supporting	64852	64862	O
it	64863	64865	O
versus	64866	64872	O
the	64873	64876	O
rest	64877	64881	O
of	64882	64884	O
the	64885	64888	O
reads	64889	64894	O
,	64894	64895	O
we	64896	64898	O
excluded	64899	64907	O
mutations	64908	64917	O
that	64918	64922	O
had	64923	64926	O
a	64927	64928	O
p	64929	64930	O
value	64931	64936	O
less	64937	64941	O
than	64942	64946	O
0	64947	64948	O
.	64948	64949	O
05	64949	64951	O
when	64952	64956	O
applying	64957	64965	O
a	64966	64967	O
Mann	64968	64972	O
-	64972	64973	O
Whitney	64973	64980	O
U	64981	64982	O
test	64983	64987	O
of	64988	64990	O
the	64991	64994	O
positions	64995	65004	O
in	65005	65007	O
the	65008	65011	O
read	65012	65016	O
supporting	65017	65027	O
the	65028	65031	O
alternate	65032	65041	O
allele	65042	65048	O
vs	65049	65051	O
the	65052	65055	O
positions	65056	65065	O
supporting	65066	65076	O
the	65077	65080	O
reference	65081	65090	O
allele	65091	65097	O
.	65097	65098	O

For	65099	65102	O
these	65103	65108	O
tests	65109	65114	O
,	65114	65115	O
we	65116	65118	O
used	65119	65123	O
BCFtools	65124	65132	O
[	65133	65134	O
53	65134	65136	O
]	65136	65137	O
mpileup	65138	65145	O
.	65145	65146	O

Mapping	65147	65154	O
quality	65155	65162	O
bias	65163	65167	O
.	65167	65168	O

We	65169	65171	O
excluded	65172	65180	O
mutations	65181	65190	O
that	65191	65195	O
had	65196	65199	O
a	65200	65201	O
p	65202	65203	O
value	65204	65209	O
less	65210	65214	O
than	65215	65219	O
0	65220	65221	O
.	65221	65222	O
05	65222	65224	O
when	65225	65229	O
applying	65230	65238	O
a	65239	65240	O
Mann	65241	65245	O
-	65245	65246	O
Whitney	65246	65253	O
U	65254	65255	O
test	65256	65260	O
comparing	65261	65270	O
mapping	65271	65278	O
quality	65279	65286	O
scores	65287	65293	O
of	65294	65296	O
the	65297	65300	O
base	65301	65305	O
calls	65306	65311	O
supporting	65312	65322	O
the	65323	65326	O
alternate	65327	65336	O
allele	65337	65343	O
vs	65344	65346	O
the	65347	65350	O
mapping	65351	65358	O
quality	65359	65366	O
scores	65367	65373	O
of	65374	65376	O
reads	65377	65382	O
supporting	65383	65393	O
the	65394	65397	O
reference	65398	65407	O
allele	65408	65414	O
.	65414	65415	O

For	65416	65419	O
these	65420	65425	O
tests	65426	65431	O
,	65431	65432	O
we	65433	65435	O
used	65436	65440	O
BCFtools	65441	65449	O
[	65450	65451	O
53	65451	65453	O
]	65453	65454	O
mpileup	65455	65462	O
.	65462	65463	O

Sequence	65464	65472	O
quality	65473	65480	O
bias	65481	65485	O
.	65485	65486	O

We	65487	65489	O
excluded	65490	65498	O
mutations	65499	65508	O
with	65509	65513	O
a	65514	65515	O
p	65516	65517	O
value	65518	65523	O
less	65524	65528	O
than	65529	65533	O
0	65534	65535	O
.	65535	65536	O
05	65536	65538	O
when	65539	65543	O
applying	65544	65552	O
a	65553	65554	O
Mann	65555	65559	O
-	65559	65560	O
Whitney	65560	65567	O
U	65568	65569	O
test	65570	65574	O
comparing	65575	65584	O
sequencing	65585	65595	O
quality	65596	65603	O
scores	65604	65610	O
of	65611	65613	O
base	65614	65618	O
calls	65619	65624	O
supporting	65625	65635	O
the	65636	65639	O
alternate	65640	65649	O
allele	65650	65656	O
vs	65657	65659	O
the	65660	65663	O
scores	65664	65670	O
of	65671	65673	O
base	65674	65678	O
calls	65679	65684	O
supporting	65685	65695	O
the	65696	65699	O
reference	65700	65709	O
allele	65710	65716	O
.	65716	65717	O

For	65718	65721	O
these	65722	65727	O
tests	65728	65733	O
,	65733	65734	O
we	65735	65737	O
used	65738	65742	O
BCFtools	65743	65751	O
[	65752	65753	O
53	65753	65755	O
]	65755	65756	O
mpileup	65757	65764	O
.	65764	65765	O

Strand	65766	65772	O
bias	65773	65777	O
.	65777	65778	O

We	65779	65781	O
excluded	65782	65790	O
mutations	65791	65800	O
with	65801	65805	O
a	65806	65807	O
p	65808	65809	O
value	65810	65815	O
less	65816	65820	O
than	65821	65825	O
0	65826	65827	O
.	65827	65828	O
05	65828	65830	O
when	65831	65835	O
applying	65836	65844	O
a	65845	65846	O
Mann	65847	65851	O
-	65851	65852	O
Whitney	65852	65859	O
U	65860	65861	O
test	65862	65866	O
comparing	65867	65876	O
strand	65877	65883	O
bias	65884	65888	O
of	65889	65891	O
bases	65892	65897	O
supporting	65898	65908	O
the	65909	65912	O
reference	65913	65922	O
and	65923	65926	O
alternate	65927	65936	O
allele	65937	65943	O
(	65944	65945	O
i	65945	65946	O
.	65946	65947	O
e	65947	65948	O
.	65948	65949	O
,	65949	65950	O
cases	65951	65956	O
where	65957	65962	O
mutations	65963	65972	O
were	65973	65977	O
only	65978	65982	O
observed	65983	65991	O
on	65992	65994	O
one	65995	65998	O
strand	65999	66005	O
were	66006	66010	O
excluded	66011	66019	O
;	66019	66020	O
this	66021	66025	O
is	66026	66028	O
not	66029	66032	O
related	66033	66040	O
to	66041	66043	O
the	66044	66047	O
strand	66048	66054	O
asymmetry	66055	66064	O
we	66065	66067	O
observed	66068	66076	O
for	66077	66080	O
some	66081	66085	O
mutation	66086	66094	O
types	66095	66100	O
)	66100	66101	O
.	66101	66102	O

For	66103	66106	O
these	66107	66112	O
tests	66113	66118	O
,	66118	66119	O
we	66120	66122	O
used	66123	66127	O
the	66128	66131	O
“	66132	66133	O
Mann	66133	66137	O
-	66137	66138	O
Whitney	66138	66145	O
U	66146	66147	O
test	66148	66152	O
of	66153	66155	O
Mapping	66156	66163	O
Quality	66164	66171	O
vs	66172	66174	O
Strand	66175	66181	O
Bias	66182	66186	O
”	66186	66187	O
of	66188	66190	O
BCFtools	66191	66199	O
[	66200	66201	O
53	66201	66203	O
]	66203	66204	O
mpileup	66205	66212	O
.	66212	66213	O

Variant	66214	66221	O
distance	66222	66230	O
bias	66231	66235	O
.	66235	66236	O

We	66237	66239	O
excluded	66240	66248	O
variants	66249	66257	O
that	66258	66262	O
showed	66263	66269	O
a	66270	66271	O
high	66272	66276	O
or	66277	66279	O
low	66280	66283	O
mean	66284	66288	O
pairwise	66289	66297	O
distance	66298	66306	O
between	66307	66314	O
the	66315	66318	O
alternate	66319	66328	O
allele	66329	66335	O
positions	66336	66345	O
in	66346	66348	O
the	66349	66352	O
reads	66353	66358	O
supporting	66359	66369	O
it	66370	66372	O
.	66372	66373	O

Similar	66374	66381	O
to	66382	66384	O
the	66385	66388	O
read	66389	66393	O
position	66394	66402	O
bias	66403	66407	O
filter	66408	66414	O
,	66414	66415	O
this	66416	66420	O
ensures	66421	66428	O
that	66429	66433	O
we	66434	66436	O
filter	66437	66443	O
mutations	66444	66453	O
that	66454	66458	O
are	66459	66462	O
consistently	66463	66475	O
observed	66476	66484	O
around	66485	66491	O
the	66492	66495	O
same	66496	66500	O
region	66501	66507	O
of	66508	66510	O
all	66511	66514	O
the	66515	66518	O
reads	66519	66524	O
that	66525	66529	O
support	66530	66537	O
it	66538	66540	O
.	66540	66541	O

We	66542	66544	O
used	66545	66549	O
a	66550	66551	O
cutoff	66552	66558	O
of	66559	66561	O
p	66562	66563	O
<	66564	66565	O
0	66566	66567	O
.	66567	66568	O
05	66568	66570	O
for	66571	66574	O
a	66575	66576	O
two	66577	66580	O
-	66580	66581	O
tail	66581	66585	O
distribution	66586	66598	O
of	66599	66601	O
simulated	66602	66611	O
mean	66612	66616	O
pairwise	66617	66625	O
distances	66626	66635	O
from	66636	66640	O
the	66641	66644	O
BCFtools	66645	66653	O
[	66654	66655	O
53	66655	66657	O
]	66657	66658	O
implementation	66659	66673	O
.	66673	66674	O

RNA	66675	66678	O
-	66678	66679	O
specific	66679	66687	O
allele	66688	66694	O
frequency	66695	66704	O
bias	66705	66709	O
.	66709	66710	O

We	66711	66713	O
observed	66714	66722	O
an	66723	66725	O
enrichment	66726	66736	O
of	66737	66739	O
variants	66740	66748	O
having	66749	66755	O
a	66756	66757	O
variant	66758	66765	O
allele	66766	66772	O
frequency	66773	66782	O
(	66783	66784	O
VAF	66784	66787	O
)	66787	66788	O
greater	66789	66796	O
than	66797	66801	O
0	66802	66803	O
.	66803	66804	O
9	66804	66805	O
only	66806	66810	O
in	66811	66813	O
mutation	66814	66822	O
calls	66823	66828	O
from	66829	66833	O
RNA	66834	66837	O
-	66837	66838	O
sequencing	66838	66848	O
but	66849	66852	O
not	66853	66856	O
from	66857	66861	O
the	66862	66865	O
matched	66866	66873	O
DNA	66874	66877	O
-	66877	66878	O
sequencing	66878	66888	O
samples	66889	66896	O
.	66896	66897	O

This	66898	66902	O
RNA	66903	66906	O
-	66906	66907	O
specific	66907	66915	O
bias	66916	66920	O
could	66921	66926	O
be	66927	66929	O
due	66930	66933	O
to	66934	66936	O
several	66937	66944	O
factors	66945	66952	O
,	66952	66953	O
including	66954	66963	O
allele	66964	66970	O
-	66970	66971	O
specific	66971	66979	O
expression	66980	66990	O
leading	66991	66998	O
to	66999	67001	O
enrichment	67002	67012	O
of	67013	67015	O
the	67016	67019	O
alternate	67020	67029	O
allele	67030	67036	O
,	67036	67037	O
RNA	67038	67041	O
editing	67042	67049	O
,	67049	67050	O
or	67051	67053	O
systematic	67054	67064	O
artifacts	67065	67074	O
during	67075	67081	O
RNA	67082	67085	O
extraction	67086	67096	O
,	67096	67097	O
library	67098	67105	O
construction	67106	67118	O
,	67118	67119	O
and	67120	67123	O
sequencing	67124	67134	O
.	67134	67135	O

We	67136	67138	O
took	67139	67143	O
a	67144	67145	O
conservative	67146	67158	O
approach	67159	67167	O
and	67168	67171	O
excluded	67172	67180	O
all	67181	67184	O
mutations	67185	67194	O
that	67195	67199	O
had	67200	67203	O
a	67204	67205	O
VAF	67206	67209	O
greater	67210	67217	O
than	67218	67222	O
0	67223	67224	O
.	67224	67225	O
7	67225	67226	O
.	67226	67227	O

Tissue	67228	67234	O
-	67234	67235	O
specific	67235	67243	O
mutation	67244	67252	O
effects	67253	67260	O
.	67260	67261	O

To	67262	67264	O
eliminate	67265	67274	O
false	67275	67280	O
positives	67281	67290	O
arising	67291	67298	O
by	67299	67301	O
systematic	67302	67312	O
artifacts	67313	67322	O
of	67323	67325	O
unknown	67326	67333	O
origin	67334	67340	O
,	67340	67341	O
we	67342	67344	O
first	67345	67350	O
looked	67351	67357	O
for	67358	67361	O
recurrent	67362	67371	O
mutations	67372	67381	O
observed	67382	67390	O
in	67391	67393	O
many	67394	67398	O
samples	67399	67406	O
of	67407	67409	O
a	67410	67411	O
given	67412	67417	O
tissue	67418	67424	O
.	67424	67425	O

While	67426	67431	O
these	67432	67437	O
mutations	67438	67447	O
could	67448	67453	O
be	67454	67456	O
real	67457	67461	O
and	67462	67465	O
have	67466	67470	O
a	67471	67472	O
biological	67473	67483	O
impact	67484	67490	O
,	67490	67491	O
they	67492	67496	O
may	67497	67500	O
also	67501	67505	O
reflect	67506	67513	O
a	67514	67515	O
shared	67516	67522	O
systematic	67523	67533	O
artifact	67534	67542	O
that	67543	67547	O
is	67548	67550	O
producing	67551	67560	O
the	67561	67564	O
same	67565	67569	O
exact	67570	67575	O
mutation	67576	67584	O
across	67585	67591	O
several	67592	67599	O
samples	67600	67607	O
of	67608	67610	O
the	67611	67614	O
same	67615	67619	O
tissue	67620	67626	O
.	67626	67627	O

We	67628	67630	O
decided	67631	67638	O
to	67639	67641	O
take	67642	67646	O
a	67647	67648	O
conservative	67649	67661	O
approach	67662	67670	O
and	67671	67674	O
eliminated	67675	67685	O
all	67686	67689	O
mutations	67690	67699	O
that	67700	67704	O
were	67705	67709	O
called	67710	67716	O
in	67717	67719	O
at	67720	67722	O
least	67723	67728	O
40	67729	67731	O
%	67731	67732	O
of	67733	67735	O
the	67736	67739	O
samples	67740	67747	O
in	67748	67750	O
one	67751	67754	O
tissue	67755	67761	O
.	67761	67762	O

Even	67763	67767	O
though	67768	67774	O
we	67775	67777	O
labeled	67778	67785	O
these	67786	67791	O
mutations	67792	67801	O
on	67802	67804	O
a	67805	67806	O
per	67807	67810	O
-	67810	67811	O
tissue	67811	67817	O
basis	67818	67823	O
,	67823	67824	O
once	67825	67829	O
identified	67830	67840	O
,	67840	67841	O
we	67842	67844	O
removed	67845	67852	O
them	67853	67857	O
from	67858	67862	O
any	67863	67866	O
sample	67867	67873	O
in	67874	67876	O
any	67877	67880	O
tissue	67881	67887	O
that	67888	67892	O
had	67893	67896	O
them	67897	67901	O
.	67901	67902	O

Overall	67903	67910	O
systematic	67911	67921	O
mutation	67922	67930	O
bias	67931	67935	O
.	67935	67936	O

We	67937	67939	O
further	67940	67947	O
eliminated	67948	67958	O
mutations	67959	67968	O
that	67969	67973	O
were	67974	67978	O
present	67979	67986	O
in	67987	67989	O
at	67990	67992	O
least	67993	67998	O
4	67999	68000	O
%	68000	68001	O
of	68002	68004	O
all	68005	68008	O
samples	68009	68016	O
.	68016	68017	O

Similarly	68018	68027	O
,	68027	68028	O
as	68029	68031	O
in	68032	68034	O
the	68035	68038	O
previous	68039	68047	O
step	68048	68052	O
,	68052	68053	O
these	68054	68059	O
mutations	68060	68069	O
are	68070	68073	O
more	68074	68078	O
likely	68079	68085	O
to	68086	68088	O
have	68089	68093	O
originated	68094	68104	O
from	68105	68109	O
a	68110	68111	O
systematic	68112	68122	O
artifact	68123	68131	O
.	68131	68132	O

Hyper	68133	68138	O
-	68138	68139	O
mutated	68139	68146	O
samples	68147	68154	O
.	68154	68155	O

We	68156	68158	O
excluded	68159	68167	O
samples	68168	68175	O
that	68176	68180	O
had	68181	68184	O
an	68185	68187	O
excess	68188	68194	O
of	68195	68197	O
mutations	68198	68207	O
compared	68208	68216	O
to	68217	68219	O
what	68220	68224	O
it	68225	68227	O
was	68228	68231	O
expected	68232	68240	O
from	68241	68245	O
sequencing	68246	68256	O
depth	68257	68262	O
and	68263	68266	O
biological	68267	68277	O
factors	68278	68285	O
.	68285	68286	O

To	68287	68289	O
do	68290	68292	O
so	68293	68295	O
,	68295	68296	O
we	68297	68299	O
looked	68300	68306	O
at	68307	68309	O
the	68310	68313	O
residuals	68314	68323	O
after	68324	68329	O
applying	68330	68338	O
a	68339	68340	O
linear	68341	68347	O
regression	68348	68358	O
on	68359	68361	O
mutation	68362	68370	O
numbers	68371	68378	O
using	68379	68384	O
as	68385	68387	O
features	68388	68396	O
sequencing	68397	68407	O
depth	68408	68413	O
,	68413	68414	O
age	68415	68418	O
,	68418	68419	O
sex	68420	68423	O
,	68423	68424	O
and	68425	68428	O
BMI	68429	68432	O
.	68432	68433	O

We	68434	68436	O
observed	68437	68445	O
48	68446	68448	O
samples	68449	68456	O
that	68457	68461	O
had	68462	68465	O
residual	68466	68474	O
values	68475	68481	O
greater	68482	68489	O
than	68490	68494	O
1500	68495	68499	O
(	68500	68501	O
i	68501	68502	O
.	68502	68503	O
e	68503	68504	O
.	68504	68505	O
,	68505	68506	O
they	68507	68511	O
had	68512	68515	O
>	68516	68517	O
1500	68518	68522	O
more	68523	68527	O
mutations	68528	68537	O
than	68538	68542	O
expected	68543	68551	O
by	68552	68554	O
other	68555	68560	O
factors	68561	68568	O
)	68568	68569	O
(	68570	68571	O
Additional	68571	68581	O
file	68582	68586	O
1	68587	68588	O
:	68588	68589	O
Figure	68590	68596	O
S1	68597	68599	O
g	68600	68601	O
)	68601	68602	O
and	68603	68606	O
excluded	68607	68615	O
them	68616	68620	O
from	68621	68625	O
further	68626	68633	O
analysis	68634	68642	O
,	68642	68643	O
leaving	68644	68651	O
7584	68652	68656	O
remaining	68657	68666	O
.	68666	68667	O

We	68668	68670	O
did	68671	68674	O
not	68675	68678	O
observe	68679	68686	O
any	68687	68690	O
hypo	68691	68695	O
-	68695	68696	O
mutated	68696	68703	O
samples	68704	68711	O
having	68712	68718	O
similar	68719	68726	O
residual	68727	68735	O
values	68736	68742	O
in	68743	68745	O
the	68746	68749	O
opposite	68750	68758	O
direction	68759	68768	O
.	68768	68769	O

Method	68771	68777	O
validation	68778	68788	O
To	68789	68791	O
validate	68792	68800	O
the	68801	68804	O
precision	68805	68814	O
of	68815	68817	O
our	68818	68821	O
DNA	68822	68825	O
somatic	68826	68833	O
mutation	68834	68842	O
calls	68843	68848	O
from	68849	68853	O
RNA	68854	68857	O
-	68857	68858	O
seq	68858	68861	O
,	68861	68862	O
we	68863	68865	O
sought	68866	68872	O
to	68873	68875	O
compare	68876	68883	O
those	68884	68889	O
calls	68890	68895	O
to	68896	68898	O
DNA	68899	68902	O
sequencing	68903	68913	O
from	68914	68918	O
the	68919	68922	O
exome	68923	68928	O
.	68928	68929	O

The	68930	68933	O
GTEx	68934	68938	O
Consortium	68939	68949	O
performed	68950	68959	O
DNA	68960	68963	O
exome	68964	68969	O
capture	68970	68977	O
followed	68978	68986	O
by	68987	68989	O
sequencing	68990	69000	O
in	69001	69003	O
blood	69004	69009	O
samples	69010	69017	O
with	69018	69022	O
a	69023	69024	O
median	69025	69031	O
coverage	69032	69040	O
of	69041	69043	O
80x	69044	69047	O
.	69047	69048	O

From	69049	69053	O
the	69054	69057	O
GTEx	69058	69062	O
dbGaP	69063	69068	O
repository	69069	69079	O
(	69080	69081	O
phs000424	69081	69090	O
.	69090	69091	O
v7	69091	69093	O
.	69093	69094	O
p2	69094	69096	O
)	69096	69097	O
,	69097	69098	O
we	69099	69101	O
downloaded	69102	69112	O
raw	69113	69116	O
DNA	69117	69120	O
exome	69121	69126	O
sequencing	69127	69137	O
runs	69138	69142	O
from	69143	69147	O
105	69148	69151	O
randomly	69152	69160	O
chosen	69161	69167	O
donors	69168	69174	O
.	69174	69175	O

We	69176	69178	O
mapped	69179	69185	O
the	69186	69189	O
reads	69190	69195	O
and	69196	69199	O
called	69200	69206	O
mutations	69207	69216	O
identically	69217	69228	O
to	69229	69231	O
our	69232	69235	O
RNA	69236	69239	O
-	69239	69240	O
seq	69240	69243	O
samples	69244	69251	O
.	69251	69252	O

Throughout	69253	69263	O
the	69264	69267	O
study	69268	69273	O
,	69273	69274	O
we	69275	69277	O
used	69278	69282	O
the	69283	69286	O
mutation	69287	69295	O
calls	69296	69301	O
from	69302	69306	O
exome	69307	69312	O
to	69313	69315	O
validate	69316	69324	O
certain	69325	69332	O
results	69333	69340	O
when	69341	69345	O
appropriate	69346	69357	O
.	69357	69358	O

To	69359	69361	O
validate	69362	69370	O
the	69371	69374	O
overall	69375	69382	O
mutation	69383	69391	O
calling	69392	69399	O
pipeline	69400	69408	O
,	69408	69409	O
we	69410	69412	O
matched	69413	69420	O
RNA	69421	69424	O
-	69424	69425	O
seq	69425	69428	O
to	69429	69431	O
exome	69432	69437	O
DNA	69438	69441	O
-	69441	69442	O
seq	69442	69445	O
samples	69446	69453	O
of	69454	69456	O
the	69457	69460	O
same	69461	69465	O
individuals	69466	69477	O
.	69477	69478	O

Then	69479	69483	O
,	69483	69484	O
we	69485	69487	O
asked	69488	69493	O
what	69494	69498	O
percentage	69499	69509	O
of	69510	69512	O
the	69513	69516	O
mutation	69517	69525	O
calls	69526	69531	O
from	69532	69536	O
RNA	69537	69540	O
-	69540	69541	O
seq	69541	69544	O
had	69545	69548	O
reads	69549	69554	O
supporting	69555	69565	O
the	69566	69569	O
alternate	69570	69579	O
allele	69580	69586	O
in	69587	69589	O
the	69590	69593	O
matched	69594	69601	O
exome	69602	69607	O
DNA	69608	69611	O
-	69611	69612	O
seq	69612	69615	O
.	69615	69616	O

To	69617	69619	O
account	69620	69627	O
for	69628	69631	O
coverage	69632	69640	O
differences	69641	69652	O
between	69653	69660	O
RNA	69661	69664	O
-	69664	69665	O
seq	69665	69668	O
and	69669	69672	O
DNA	69673	69676	O
-	69676	69677	O
seq	69677	69680	O
,	69680	69681	O
we	69682	69684	O
focused	69685	69692	O
this	69693	69697	O
analysis	69698	69706	O
only	69707	69711	O
on	69712	69714	O
mutation	69715	69723	O
calls	69724	69729	O
for	69730	69733	O
which	69734	69739	O
we	69740	69742	O
had	69743	69746	O
reasonable	69747	69757	O
power	69758	69763	O
of	69764	69766	O
detection	69767	69776	O
to	69777	69779	O
validate	69780	69788	O
mutations	69789	69798	O
in	69799	69801	O
DNA	69802	69805	O
-	69805	69806	O
seq	69806	69809	O
data	69810	69814	O
.	69814	69815	O

This	69816	69820	O
is	69821	69823	O
especially	69824	69834	O
relevant	69835	69843	O
because	69844	69851	O
in	69852	69854	O
highly	69855	69861	O
expressed	69862	69871	O
genes	69872	69877	O
,	69877	69878	O
sequencing	69879	69889	O
coverage	69890	69898	O
can	69899	69902	O
be	69903	69905	O
>	69906	69907	O
1000x	69908	69913	O
in	69914	69916	O
RNA	69917	69920	O
-	69920	69921	O
seq	69921	69924	O
;	69924	69925	O
therefore	69926	69935	O
,	69935	69936	O
we	69937	69939	O
could	69940	69945	O
detect	69946	69952	O
mutations	69953	69962	O
with	69963	69967	O
VAF	69968	69971	O
as	69972	69974	O
low	69975	69978	O
as	69979	69981	O
0	69982	69983	O
.	69983	69984	O
006	69984	69987	O
for	69988	69991	O
a	69992	69993	O
1000x	69994	69999	O
-	69999	70000	O
covered	70000	70007	O
position	70008	70016	O
(	70017	70018	O
given	70018	70023	O
our	70024	70027	O
minimum	70028	70035	O
alternate	70036	70045	O
allele	70046	70052	O
6	70053	70054	O
-	70054	70055	O
read	70055	70059	O
cutoff	70060	70066	O
described	70067	70076	O
above	70077	70082	O
)	70082	70083	O
.	70083	70084	O

In	70085	70087	O
comparison	70088	70098	O
,	70098	70099	O
in	70100	70102	O
exome	70103	70108	O
DNA	70109	70112	O
-	70112	70113	O
seq	70113	70116	O
given	70117	70122	O
the	70123	70126	O
80x	70127	70130	O
median	70131	70137	O
coverage	70138	70146	O
,	70146	70147	O
we	70148	70150	O
expect	70151	70157	O
to	70158	70160	O
see	70161	70164	O
only	70165	70169	O
0	70170	70171	O
.	70171	70172	O
48	70172	70174	O
reads	70175	70180	O
supporting	70181	70191	O
the	70192	70195	O
alternate	70196	70205	O
allele	70206	70212	O
of	70213	70215	O
a	70216	70217	O
variant	70218	70225	O
with	70226	70230	O
VAF	70231	70234	O
=	70235	70236	O
0	70237	70238	O
.	70238	70239	O
006	70239	70242	O
.	70242	70243	O

We	70244	70246	O
therefore	70247	70256	O
devised	70257	70264	O
a	70265	70266	O
way	70267	70270	O
to	70271	70273	O
account	70274	70281	O
for	70282	70285	O
this	70286	70290	O
coverage	70291	70299	O
difference	70300	70310	O
between	70311	70318	O
RNA	70319	70322	O
-	70322	70323	O
seq	70323	70326	O
and	70327	70330	O
DNA	70331	70334	O
-	70334	70335	O
seq	70335	70338	O
,	70338	70339	O
and	70340	70343	O
only	70344	70348	O
compared	70349	70357	O
positions	70358	70367	O
where	70368	70373	O
we	70374	70376	O
had	70377	70380	O
power	70381	70386	O
of	70387	70389	O
detection	70390	70399	O
in	70400	70402	O
both	70403	70407	O
experiments	70408	70419	O
.	70419	70420	O

We	70421	70423	O
first	70424	70429	O
made	70430	70434	O
the	70435	70438	O
following	70439	70448	O
calculation	70449	70460	O
:	70460	70461	O
\	70462	70463	O
documentclass	70463	70476	O
[	70476	70477	O
12pt	70477	70481	O
]	70481	70482	O
{	70482	70483	O
minimal	70483	70490	O
}	70490	70491	O
\	70496	70497	O
usepackage	70497	70507	O
{	70507	70508	O
amsmath	70508	70515	O
}	70515	70516	O
\	70521	70522	O
usepackage	70522	70532	O
{	70532	70533	O
wasysym	70533	70540	O
}	70540	70541	O
\	70547	70548	O
usepackage	70548	70558	O
{	70558	70559	O
amsfonts	70559	70567	O
}	70567	70568	O
\	70574	70575	O
usepackage	70575	70585	O
{	70585	70586	O
amssymb	70586	70593	O
}	70593	70594	O
\	70600	70601	O
usepackage	70601	70611	O
{	70611	70612	O
amsbsy	70612	70618	O
}	70618	70619	O
\	70624	70625	O
usepackage	70625	70635	O
{	70635	70636	O
mathrsfs	70636	70644	O
}	70644	70645	O
\	70650	70651	O
usepackage	70651	70661	O
{	70661	70662	O
upgreek	70662	70669	O
}	70669	70670	O
\	70675	70676	O
setlength	70676	70685	O
{	70685	70686	O
\	70686	70687	O
oddsidemargin	70687	70700	O
}	70700	70701	O
{	70701	70702	O
-	70702	70703	O
69pt	70703	70707	O
}	70707	70708	O
\	70713	70714	O
begin	70714	70719	O
{	70719	70720	O
document	70720	70728	O
}	70728	70729	O
$	70729	70730	O
$	70730	70731	O
{	70732	70733	O
r	70733	70734	O
}	70734	70735	O
_	70735	70736	O
i	70736	70737	O
=	70737	70738	O
{	70738	70739	O
C	70739	70740	O
}	70740	70741	O
_	70741	70742	O
{	70742	70743	O
i	70743	70744	O
,	70744	70745	O
\	70745	70746	O
mathrm	70746	70752	O
{	70752	70753	O
DNA	70753	70756	O
}	70756	70757	O
-	70757	70758	O
\	70758	70759	O
mathrm	70759	70765	O
{	70765	70766	O
seq	70766	70769	O
}	70769	70770	O
}	70770	70771	O
\	70771	70772	O
left	70772	70776	O
(	70776	70777	O
\	70777	70778	O
frac	70778	70782	O
{	70782	70783	O
A	70783	70784	O
_	70784	70785	O
{	70785	70786	O
i	70786	70787	O
,	70787	70788	O
\	70788	70789	O
mathrm	70789	70795	O
{	70795	70796	O
RNA	70796	70799	O
}	70799	70800	O
-	70800	70801	O
\	70801	70802	O
mathrm	70802	70808	O
{	70808	70809	O
seq	70809	70812	O
}	70812	70813	O
}	70813	70814	O
}	70814	70815	O
{	70815	70816	O
C	70816	70817	O
_	70817	70818	O
{	70818	70819	O
i	70819	70820	O
,	70820	70821	O
\	70821	70822	O
mathrm	70822	70828	O
{	70828	70829	O
RNA	70829	70832	O
}	70832	70833	O
-	70833	70834	O
\	70834	70835	O
mathrm	70835	70841	O
{	70841	70842	O
seq	70842	70845	O
}	70845	70846	O
}	70846	70847	O
}	70847	70848	O
\	70848	70849	O
right	70849	70854	O
)	70854	70855	O
$	70856	70857	O
$	70857	70858	O
\	70858	70859	O
end	70859	70862	O
{	70862	70863	O
document	70863	70871	O
}	70871	70872	O
ri	70872	70874	O
=	70874	70875	O
Ci	70875	70877	O
,	70877	70878	O
DNA	70878	70881	O
−	70881	70882	O
seqAi	70882	70887	O
,	70887	70888	O
RNA	70888	70891	O
−	70891	70892	O
seqCi	70892	70897	O
,	70897	70898	O
RNA	70898	70901	O
−	70901	70902	O
seq	70902	70905	O
where	70906	70911	O
Ci	70912	70914	O
and	70915	70918	O
Ai	70919	70921	O
are	70922	70925	O
total	70926	70931	O
and	70932	70935	O
alternate	70936	70945	O
read	70946	70950	O
counts	70951	70957	O
for	70958	70961	O
a	70962	70963	O
mutation	70964	70972	O
in	70973	70975	O
position	70976	70984	O
i	70985	70986	O
and	70987	70990	O
ri	70991	70993	O
effectively	70994	71005	O
represents	71006	71016	O
the	71017	71020	O
number	71021	71027	O
of	71028	71030	O
expected	71031	71039	O
reads	71040	71045	O
to	71046	71048	O
support	71049	71056	O
the	71057	71060	O
alternate	71061	71070	O
allele	71071	71077	O
in	71078	71080	O
DNA	71081	71084	O
-	71084	71085	O
seq	71085	71088	O
at	71089	71091	O
position	71092	71100	O
i	71101	71102	O
given	71103	71108	O
the	71109	71112	O
VAF	71113	71116	O
observed	71117	71125	O
in	71126	71128	O
RNA	71129	71132	O
-	71132	71133	O
seq	71133	71136	O
.	71136	71137	O

As	71138	71140	O
shown	71141	71146	O
in	71147	71149	O
Additional	71150	71160	O
file	71161	71165	O
1	71166	71167	O
:	71167	71168	O
Figure	71169	71175	O
S1f	71176	71179	O
,	71179	71180	O
we	71181	71183	O
took	71184	71188	O
a	71189	71190	O
conservative	71191	71203	O
approach	71204	71212	O
and	71213	71216	O
only	71217	71221	O
compared	71222	71230	O
genomic	71231	71238	O
positions	71239	71248	O
where	71249	71254	O
r	71255	71256	O
≥	71257	71258	O
8	71259	71260	O
,	71260	71261	O
to	71262	71264	O
ensure	71265	71271	O
sufficient	71272	71282	O
power	71283	71288	O
of	71289	71291	O
validation	71292	71302	O
.	71302	71303	O

Since	71304	71309	O
this	71310	71314	O
method	71315	71321	O
will	71322	71326	O
inherently	71327	71337	O
select	71338	71344	O
mutations	71345	71354	O
in	71355	71357	O
a	71358	71359	O
way	71360	71363	O
that	71364	71368	O
shifts	71369	71375	O
the	71376	71379	O
VAF	71380	71383	O
distribution	71384	71396	O
towards	71397	71404	O
higher	71405	71411	O
values	71412	71418	O
,	71418	71419	O
we	71420	71422	O
have	71423	71427	O
estimated	71428	71437	O
a	71438	71439	O
VAF	71440	71443	O
-	71443	71444	O
corrected	71444	71453	O
FDR	71454	71457	O
by	71458	71460	O
binning	71461	71468	O
all	71469	71472	O
validation	71473	71483	O
variants	71484	71492	O
by	71493	71495	O
VAF	71496	71499	O
(	71500	71501	O
as	71501	71503	O
in	71504	71506	O
Additional	71507	71517	O
file	71518	71522	O
1	71523	71524	O
:	71524	71525	O
Figure	71526	71532	O
S1d	71533	71536	O
)	71536	71537	O
and	71538	71541	O
then	71542	71546	O
calculating	71547	71558	O
an	71559	71561	O
average	71562	71569	O
FDR	71570	71573	O
weighted	71574	71582	O
by	71583	71585	O
the	71586	71589	O
fraction	71590	71598	O
of	71599	71601	O
all	71602	71605	O
mutation	71606	71614	O
calls	71615	71620	O
present	71621	71628	O
in	71629	71631	O
each	71632	71636	O
bin	71637	71640	O
.	71640	71641	O

For	71642	71645	O
example	71646	71653	O
,	71653	71654	O
if	71655	71657	O
20	71658	71660	O
%	71660	71661	O
of	71662	71664	O
mutations	71665	71674	O
had	71675	71678	O
a	71679	71680	O
VAF	71681	71684	O
-	71684	71685	O
matched	71685	71692	O
FDR	71693	71696	O
of	71697	71699	O
25	71700	71702	O
%	71702	71703	O
and	71704	71707	O
80	71708	71710	O
%	71710	71711	O
of	71712	71714	O
mutations	71715	71724	O
had	71725	71728	O
a	71729	71730	O
VAF	71731	71734	O
-	71734	71735	O
matched	71735	71742	O
FDR	71743	71746	O
of	71747	71749	O
30	71750	71752	O
%	71752	71753	O
,	71753	71754	O
then	71755	71759	O
the	71760	71763	O
overall	71764	71771	O
FDR	71772	71775	O
would	71776	71781	O
be	71782	71784	O
29	71785	71787	O
%	71787	71788	O
.	71788	71789	O

Applying	71790	71798	O
this	71799	71803	O
approach	71804	71812	O
,	71812	71813	O
our	71814	71817	O
VAF	71818	71821	O
-	71821	71822	O
corrected	71822	71831	O
FDR	71832	71835	O
was	71836	71839	O
34	71840	71842	O
%	71842	71843	O
.	71843	71844	O

For	71845	71848	O
all	71849	71852	O
positions	71853	71862	O
selected	71863	71871	O
,	71871	71872	O
we	71873	71875	O
then	71876	71880	O
calculated	71881	71891	O
the	71892	71895	O
percentage	71896	71906	O
of	71907	71909	O
mutations	71910	71919	O
observed	71920	71928	O
in	71929	71931	O
an	71932	71934	O
RNA	71935	71938	O
-	71938	71939	O
seq	71939	71942	O
sample	71943	71949	O
that	71950	71954	O
had	71955	71958	O
at	71959	71961	O
least	71962	71967	O
one	71968	71971	O
read	71972	71976	O
supporting	71977	71987	O
the	71988	71991	O
variant	71992	71999	O
allele	72000	72006	O
in	72007	72009	O
the	72010	72013	O
exome	72014	72019	O
DNA	72020	72023	O
-	72023	72024	O
seq	72024	72027	O
,	72027	72028	O
effectively	72029	72040	O
resulting	72041	72050	O
in	72051	72053	O
a	72054	72055	O
false	72056	72061	O
-	72061	72062	O
discovery	72062	72071	O
rate	72072	72076	O
.	72076	72077	O

When	72078	72082	O
assigning	72083	72092	O
a	72093	72094	O
random	72095	72101	O
alternate	72102	72111	O
allele	72112	72118	O
(	72119	72120	O
not	72120	72123	O
including	72124	72133	O
the	72134	72137	O
reference	72138	72147	O
allele	72148	72154	O
among	72155	72160	O
the	72161	72164	O
choices	72165	72172	O
)	72172	72173	O
to	72174	72176	O
the	72177	72180	O
mutated	72181	72188	O
positions	72189	72198	O
in	72199	72201	O
RNA	72202	72205	O
-	72205	72206	O
seq	72206	72209	O
,	72209	72210	O
we	72211	72213	O
did	72214	72217	O
not	72218	72221	O
observe	72222	72229	O
support	72230	72237	O
for	72238	72241	O
>	72242	72243	O
98	72244	72246	O
%	72246	72247	O
of	72248	72250	O
the	72251	72254	O
position	72255	72263	O
-	72263	72264	O
permuted	72264	72272	O
mutations	72273	72282	O
,	72282	72283	O
validating	72284	72294	O
this	72295	72299	O
FDR	72300	72303	O
calculation	72304	72315	O
(	72316	72317	O
Additional	72317	72327	O
file	72328	72332	O
1	72333	72334	O
:	72334	72335	O
Figure	72336	72342	O
S1c	72343	72346	O
)	72346	72347	O
.	72347	72348	O

Discovery	72349	72358	O
of	72359	72361	O
mutation	72362	72370	O
associations	72371	72383	O
with	72384	72388	O
biological	72389	72399	O
and	72400	72403	O
non	72404	72407	O
-	72407	72408	O
biological	72408	72418	O
factors	72419	72426	O
We	72427	72429	O
first	72430	72435	O
sought	72436	72442	O
to	72443	72445	O
identify	72446	72454	O
and	72455	72458	O
subtract	72459	72467	O
the	72468	72471	O
effects	72472	72479	O
of	72480	72482	O
non	72483	72486	O
-	72486	72487	O
biological	72487	72497	O
factors	72498	72505	O
influencing	72506	72517	O
the	72518	72521	O
number	72522	72528	O
of	72529	72531	O
mutations	72532	72541	O
observed	72542	72550	O
per	72551	72554	O
sample	72555	72561	O
.	72561	72562	O

To	72563	72565	O
this	72566	72570	O
end	72571	72574	O
,	72574	72575	O
we	72576	72578	O
grouped	72579	72586	O
samples	72587	72594	O
by	72595	72597	O
tissue	72598	72604	O
and	72605	72608	O
performed	72609	72618	O
a	72619	72620	O
linear	72621	72627	O
regression	72628	72638	O
on	72639	72641	O
the	72642	72645	O
mutation	72646	72654	O
numbers	72655	72662	O
using	72663	72668	O
non	72669	72672	O
-	72672	72673	O
biological	72673	72683	O
factors	72684	72691	O
as	72692	72694	O
explanatory	72695	72706	O
variables	72707	72716	O
,	72716	72717	O
which	72718	72723	O
included	72724	72732	O
sequencing	72733	72743	O
depth	72744	72749	O
,	72749	72750	O
transcriptome	72751	72764	O
Shannon	72765	72772	O
diversity	72773	72782	O
,	72782	72783	O
time	72784	72788	O
spent	72789	72794	O
in	72795	72797	O
the	72798	72801	O
PAXgene	72802	72809	O
fixative	72810	72818	O
(	72819	72820	O
SMTSPAX	72820	72827	O
from	72828	72832	O
GTEx	72833	72837	O
sample	72838	72844	O
attributes	72845	72855	O
)	72855	72856	O
,	72856	72857	O
total	72858	72863	O
ischemic	72864	72872	O
time	72873	72877	O
(	72878	72879	O
SMTSISCH	72879	72887	O
from	72888	72892	O
GTEx	72893	72897	O
sample	72898	72904	O
attributes	72905	72915	O
)	72915	72916	O
,	72916	72917	O
and	72918	72921	O
RNA	72922	72925	O
integrity	72926	72935	O
number	72936	72942	O
(	72943	72944	O
SMRIN	72944	72949	O
from	72950	72954	O
GTEx	72955	72959	O
sample	72960	72966	O
attributes	72967	72977	O
)	72977	72978	O
.	72978	72979	O

We	72980	72982	O
assessed	72983	72991	O
the	72992	72995	O
significance	72996	73008	O
of	73009	73011	O
association	73012	73023	O
between	73024	73031	O
mutation	73032	73040	O
number	73041	73047	O
and	73048	73051	O
any	73052	73055	O
factor	73056	73062	O
by	73063	73065	O
the	73066	73069	O
p	73070	73071	O
value	73072	73077	O
of	73078	73080	O
each	73081	73085	O
coefficient	73086	73097	O
in	73098	73100	O
a	73101	73102	O
multiple	73103	73111	O
regression	73112	73122	O
(	73123	73124	O
Additional	73124	73134	O
file	73135	73139	O
6	73140	73141	O
:	73141	73142	O
Table	73143	73148	O
S4	73149	73151	O
)	73151	73152	O
.	73152	73153	O

To	73154	73156	O
discover	73157	73165	O
biological	73166	73176	O
factors	73177	73184	O
associated	73185	73195	O
with	73196	73200	O
mutation	73201	73209	O
numbers	73210	73217	O
,	73217	73218	O
we	73219	73221	O
took	73222	73226	O
the	73227	73230	O
residuals	73231	73240	O
of	73241	73243	O
the	73244	73247	O
previous	73248	73256	O
linear	73257	73263	O
regression	73264	73274	O
(	73275	73276	O
constructed	73276	73287	O
with	73288	73292	O
non	73293	73296	O
-	73296	73297	O
biological	73297	73307	O
explanatory	73308	73319	O
variables	73320	73329	O
)	73329	73330	O
and	73331	73334	O
performed	73335	73344	O
another	73345	73352	O
regression	73353	73363	O
using	73364	73369	O
biological	73370	73380	O
factors	73381	73388	O
as	73389	73391	O
explanatory	73392	73403	O
variables	73404	73413	O
.	73413	73414	O

Biological	73415	73425	O
factors	73426	73433	O
included	73434	73442	O
biological	73443	73453	O
sex	73454	73457	O
,	73457	73458	O
age	73459	73462	O
,	73462	73463	O
BMI	73464	73467	O
,	73467	73468	O
and	73469	73472	O
the	73473	73476	O
first	73477	73482	O
three	73483	73488	O
genotype	73489	73497	O
principal	73498	73507	O
components	73508	73518	O
constructed	73519	73530	O
from	73531	73535	O
the	73536	73539	O
~	73540	73541	O
107	73542	73545	O
SNPs	73546	73550	O
with	73551	73555	O
MAF	73556	73559	O
≥	73560	73561	O
0	73562	73563	O
.	73563	73564	O
1	73564	73565	O
available	73566	73575	O
from	73576	73580	O
GTEx	73581	73585	O
.	73585	73586	O

Significance	73587	73599	O
was	73600	73603	O
assessed	73604	73612	O
by	73613	73615	O
the	73616	73619	O
p	73620	73621	O
value	73622	73627	O
of	73628	73630	O
each	73631	73635	O
coefficient	73636	73647	O
in	73648	73650	O
a	73651	73652	O
multiple	73653	73661	O
regression	73662	73672	O
(	73673	73674	O
Additional	73674	73684	O
file	73685	73689	O
6	73690	73691	O
:	73691	73692	O
Table	73693	73698	O
S4	73699	73701	O
)	73701	73702	O
.	73702	73703	O

Additionally	73704	73716	O
,	73716	73717	O
Spearman	73718	73726	O
correlations	73727	73739	O
were	73740	73744	O
independently	73745	73758	O
performed	73759	73768	O
between	73769	73776	O
each	73777	73781	O
biological	73782	73792	O
factor	73793	73799	O
and	73800	73803	O
the	73804	73807	O
residuals	73808	73817	O
from	73818	73822	O
the	73823	73826	O
linear	73827	73833	O
regression	73834	73844	O
between	73845	73852	O
mutation	73853	73861	O
number	73862	73868	O
and	73869	73872	O
non	73873	73876	O
-	73876	73877	O
biological	73877	73887	O
factors	73888	73895	O
.	73895	73896	O

Analysis	73897	73905	O
of	73906	73908	O
sample	73909	73915	O
mutation	73916	73924	O
profile	73925	73932	O
similarity	73933	73943	O
(	73944	73945	O
tSNE	73945	73949	O
)	73949	73950	O
To	73951	73953	O
assess	73954	73960	O
the	73961	73964	O
mutation	73965	73973	O
profile	73974	73981	O
similarity	73982	73992	O
across	73993	73999	O
samples	74000	74007	O
and	74008	74011	O
to	74012	74014	O
evaluate	74015	74023	O
their	74024	74029	O
tissue	74030	74036	O
specificity	74037	74048	O
,	74048	74049	O
we	74050	74052	O
performed	74053	74062	O
clustering	74063	74073	O
analysis	74074	74082	O
on	74083	74085	O
mutation	74086	74094	O
profiles	74095	74103	O
using	74104	74109	O
tSNE	74110	74114	O
followed	74115	74123	O
by	74124	74126	O
silhouette	74127	74137	O
scoring	74138	74145	O
.	74145	74146	O

tSNE	74147	74151	O
was	74152	74155	O
performed	74156	74165	O
on	74166	74168	O
a	74169	74170	O
matrix	74171	74177	O
of	74178	74180	O
m	74181	74182	O
rows	74183	74187	O
and	74188	74191	O
n	74192	74193	O
columns	74194	74201	O
,	74201	74202	O
where	74203	74208	O
m	74209	74210	O
are	74211	74214	O
samples	74215	74222	O
and	74223	74226	O
n	74227	74228	O
are	74229	74232	O
mutation	74233	74241	O
type	74242	74246	O
counts	74247	74253	O
.	74253	74254	O

We	74255	74257	O
used	74258	74262	O
a	74263	74264	O
1536	74265	74269	O
-	74269	74270	O
type	74270	74274	O
mutation	74275	74283	O
profile	74284	74291	O
including	74292	74301	O
two	74302	74305	O
base	74306	74310	O
-	74310	74311	O
pairs	74311	74316	O
upstream	74317	74325	O
and	74326	74329	O
downstream	74330	74340	O
of	74341	74343	O
the	74344	74347	O
mutation	74348	74356	O
site	74357	74361	O
(	74362	74363	O
pentanucleotide	74363	74378	O
profile	74379	74386	O
)	74386	74387	O
.	74387	74388	O

The	74389	74392	O
content	74393	74400	O
of	74401	74403	O
the	74404	74407	O
background	74408	74418	O
pentanucleotide	74419	74434	O
sequences	74435	74444	O
can	74445	74448	O
be	74449	74451	O
influenced	74452	74462	O
by	74463	74465	O
sample	74466	74472	O
-	74472	74473	O
specific	74473	74481	O
gene	74482	74486	O
expression	74487	74497	O
,	74497	74498	O
which	74499	74504	O
in	74505	74507	O
turns	74508	74513	O
shapes	74514	74520	O
the	74521	74524	O
probability	74525	74536	O
of	74537	74539	O
observing	74540	74549	O
mutations	74550	74559	O
across	74560	74566	O
different	74567	74576	O
pentanucleotide	74577	74592	O
sequences	74593	74602	O
,	74602	74603	O
thus	74604	74608	O
obscuring	74609	74618	O
the	74619	74622	O
underlying	74623	74633	O
de	74634	74636	O
facto	74637	74642	O
mutation	74643	74651	O
profile	74652	74659	O
.	74659	74660	O

To	74661	74663	O
account	74664	74671	O
for	74672	74675	O
these	74676	74681	O
background	74682	74692	O
sequence	74693	74701	O
differences	74702	74713	O
driven	74714	74720	O
by	74721	74723	O
expression	74724	74734	O
differences	74735	74746	O
,	74746	74747	O
we	74748	74750	O
used	74751	74755	O
a	74756	74757	O
normalized	74758	74768	O
mutation	74769	74777	O
count	74778	74783	O
.	74783	74784	O

The	74785	74788	O
normalized	74789	74799	O
mutation	74800	74808	O
count	74809	74814	O
(	74815	74816	O
muti	74816	74820	O
)	74820	74821	O
was	74822	74825	O
obtained	74826	74834	O
as	74835	74837	O
follows	74838	74845	O
:	74845	74846	O
\	74847	74848	O
documentclass	74848	74861	O
[	74861	74862	O
12pt	74862	74866	O
]	74866	74867	O
{	74867	74868	O
minimal	74868	74875	O
}	74875	74876	O
\	74881	74882	O
usepackage	74882	74892	O
{	74892	74893	O
amsmath	74893	74900	O
}	74900	74901	O
\	74906	74907	O
usepackage	74907	74917	O
{	74917	74918	O
wasysym	74918	74925	O
}	74925	74926	O
\	74932	74933	O
usepackage	74933	74943	O
{	74943	74944	O
amsfonts	74944	74952	O
}	74952	74953	O
\	74959	74960	O
usepackage	74960	74970	O
{	74970	74971	O
amssymb	74971	74978	O
}	74978	74979	O
\	74985	74986	O
usepackage	74986	74996	O
{	74996	74997	O
amsbsy	74997	75003	O
}	75003	75004	O
\	75009	75010	O
usepackage	75010	75020	O
{	75020	75021	O
mathrsfs	75021	75029	O
}	75029	75030	O
\	75035	75036	O
usepackage	75036	75046	O
{	75046	75047	O
upgreek	75047	75054	O
}	75054	75055	O
\	75060	75061	O
setlength	75061	75070	O
{	75070	75071	O
\	75071	75072	O
oddsidemargin	75072	75085	O
}	75085	75086	O
{	75086	75087	O
-	75087	75088	O
69pt	75088	75092	O
}	75092	75093	O
\	75098	75099	O
begin	75099	75104	O
{	75104	75105	O
document	75105	75113	O
}	75113	75114	O
$	75114	75115	O
$	75115	75116	O
{	75117	75118	O
mut	75118	75121	O
}	75121	75122	O
_	75122	75123	O
i	75123	75124	O
=	75124	75125	O
\	75125	75126	O
frac	75126	75130	O
{	75130	75131	O
c	75131	75132	O
_	75132	75133	O
i	75133	75134	O
}	75134	75135	O
{	75135	75136	O
\	75136	75137	O
sum	75137	75140	O
\	75141	75142	O
limits	75142	75148	O
_	75148	75149	O
g	75149	75150	O
^	75150	75151	O
{	75151	75152	O
genes	75152	75157	O
}	75157	75158	O
{	75158	75159	O
s	75159	75160	O
}	75160	75161	O
_	75161	75162	O
{	75162	75163	O
g	75163	75164	O
,	75164	75165	O
i	75165	75166	O
}	75166	75167	O
{	75167	75168	O
e	75168	75169	O
}	75169	75170	O
_	75170	75171	O
g	75171	75172	O
}	75172	75173	O
$	75174	75175	O
$	75175	75176	O
\	75176	75177	O
end	75177	75180	O
{	75180	75181	O
document	75181	75189	O
}	75189	75190	O
muti	75190	75194	O
=	75194	75195	O
ci	75195	75197	O
∑	75197	75198	O
ggenessg	75198	75206	O
,	75206	75207	O
ieg	75207	75210	O
where	75211	75216	O
ci	75217	75219	O
is	75220	75222	O
the	75223	75226	O
count	75227	75232	O
of	75233	75235	O
the	75236	75239	O
mutation	75240	75248	O
type	75249	75253	O
i	75254	75255	O
,	75255	75256	O
sg	75257	75259	O
,	75259	75260	O
i	75260	75261	O
is	75262	75264	O
the	75265	75268	O
number	75269	75275	O
of	75276	75278	O
occurrences	75279	75290	O
of	75291	75293	O
the	75294	75297	O
i	75298	75299	O
sequence	75300	75308	O
context	75309	75316	O
in	75317	75319	O
gene	75320	75324	O
g	75325	75326	O
,	75326	75327	O
eg	75328	75330	O
is	75331	75333	O
the	75334	75337	O
expression	75338	75348	O
in	75349	75351	O
TMP	75352	75355	O
of	75356	75358	O
gene	75359	75363	O
g	75364	75365	O
,	75365	75366	O
and	75367	75370	O
genes	75371	75376	O
are	75377	75380	O
all	75381	75384	O
genes	75385	75390	O
with	75391	75395	O
TPM	75396	75399	O
≥	75400	75401	O
1	75402	75403	O
in	75404	75406	O
the	75407	75410	O
given	75411	75416	O
sample	75417	75423	O
.	75423	75424	O

This	75425	75429	O
calculation	75430	75441	O
was	75442	75445	O
performed	75446	75455	O
separately	75456	75466	O
for	75467	75470	O
every	75471	75476	O
sample	75477	75483	O
.	75483	75484	O

We	75485	75487	O
used	75488	75492	O
the	75493	75496	O
tSNE	75497	75501	O
implementation	75502	75516	O
in	75517	75519	O
R	75520	75521	O
(	75522	75523	O
Rtsne	75523	75528	O
)	75528	75529	O
with	75530	75534	O
parameters	75535	75545	O
dims	75546	75550	O
=	75551	75552	O
2	75553	75554	O
,	75554	75555	O
max	75556	75559	O
_	75559	75560	O
iter	75560	75564	O
=	75565	75566	O
500	75567	75570	O
,	75570	75571	O
perplexity	75572	75582	O
=	75583	75584	O
30	75585	75587	O
,	75587	75588	O
pca	75589	75592	O
=	75593	75594	O
TRUE	75595	75599	O
,	75599	75600	O
theta	75601	75606	O
=	75607	75608	O
0	75609	75610	O
.	75610	75611	O
5	75611	75612	O
.	75612	75613	O

To	75614	75616	O
quantify	75617	75625	O
the	75626	75629	O
clustering	75630	75640	O
among	75641	75646	O
different	75647	75656	O
groupings	75657	75666	O
in	75667	75669	O
the	75670	75673	O
tSNE	75674	75678	O
two	75679	75682	O
-	75682	75683	O
dimensional	75683	75694	O
space	75695	75700	O
,	75700	75701	O
we	75702	75704	O
calculated	75705	75715	O
a	75716	75717	O
silhouette	75718	75728	O
score	75729	75734	O
(	75735	75736	O
SS	75736	75738	O
)	75738	75739	O
for	75740	75743	O
each	75744	75748	O
group	75749	75754	O
defined	75755	75762	O
in	75763	75765	O
Fig	75766	75769	O
.	75769	75770	O

2f	75771	75773	O
by	75774	75776	O
first	75777	75782	O
obtaining	75783	75792	O
a	75793	75794	O
silhouette	75795	75805	O
score	75806	75811	O
(	75812	75813	O
si	75813	75815	O
)	75815	75816	O
for	75817	75820	O
each	75821	75825	O
sample	75826	75832	O
in	75833	75835	O
each	75836	75840	O
group	75841	75846	O
:	75846	75847	O
\	75848	75849	O
documentclass	75849	75862	O
[	75862	75863	O
12pt	75863	75867	O
]	75867	75868	O
{	75868	75869	O
minimal	75869	75876	O
}	75876	75877	O
\	75882	75883	O
usepackage	75883	75893	O
{	75893	75894	O
amsmath	75894	75901	O
}	75901	75902	O
\	75907	75908	O
usepackage	75908	75918	O
{	75918	75919	O
wasysym	75919	75926	O
}	75926	75927	O
\	75933	75934	O
usepackage	75934	75944	O
{	75944	75945	O
amsfonts	75945	75953	O
}	75953	75954	O
\	75960	75961	O
usepackage	75961	75971	O
{	75971	75972	O
amssymb	75972	75979	O
}	75979	75980	O
\	75986	75987	O
usepackage	75987	75997	O
{	75997	75998	O
amsbsy	75998	76004	O
}	76004	76005	O
\	76010	76011	O
usepackage	76011	76021	O
{	76021	76022	O
mathrsfs	76022	76030	O
}	76030	76031	O
\	76036	76037	O
usepackage	76037	76047	O
{	76047	76048	O
upgreek	76048	76055	O
}	76055	76056	O
\	76061	76062	O
setlength	76062	76071	O
{	76071	76072	O
\	76072	76073	O
oddsidemargin	76073	76086	O
}	76086	76087	O
{	76087	76088	O
-	76088	76089	O
69pt	76089	76093	O
}	76093	76094	O
\	76099	76100	O
begin	76100	76105	O
{	76105	76106	O
document	76106	76114	O
}	76114	76115	O
$	76115	76116	O
$	76116	76117	O
{	76118	76119	O
s	76119	76120	O
}	76120	76121	O
_	76121	76122	O
i	76122	76123	O
=	76123	76124	O
\	76124	76125	O
frac	76125	76129	O
{	76129	76130	O
b	76130	76131	O
_	76131	76132	O
i	76132	76133	O
-	76133	76134	O
{	76134	76135	O
a	76135	76136	O
}	76136	76137	O
_	76137	76138	O
i	76138	76139	O
}	76139	76140	O
{	76140	76141	O
\	76141	76142	O
max	76142	76145	O
\	76146	76147	O
left	76147	76151	O
(	76151	76152	O
{	76152	76153	O
a	76153	76154	O
}	76154	76155	O
_	76155	76156	O
i	76156	76157	O
,	76157	76158	O
{	76158	76159	O
b	76159	76160	O
}	76160	76161	O
_	76161	76162	O
i	76162	76163	O
\	76163	76164	O
right	76164	76169	O
)	76169	76170	O
}	76170	76171	O
$	76172	76173	O
$	76173	76174	O
\	76174	76175	O
end	76175	76178	O
{	76178	76179	O
document	76179	76187	O
}	76187	76188	O
si	76188	76190	O
=	76190	76191	O
bi	76191	76193	O
−	76193	76194	O
aimaxaibi	76194	76203	O
where	76204	76209	O
ai	76210	76212	O
is	76213	76215	O
the	76216	76219	O
average	76220	76227	O
distance	76228	76236	O
of	76237	76239	O
sample	76240	76246	O
i	76247	76248	O
to	76249	76251	O
all	76252	76255	O
other	76256	76261	O
samples	76262	76269	O
inside	76270	76276	O
the	76277	76280	O
group	76281	76286	O
and	76287	76290	O
bi	76291	76293	O
is	76294	76296	O
the	76297	76300	O
average	76301	76308	O
distance	76309	76317	O
of	76318	76320	O
sample	76321	76327	O
i	76328	76329	O
to	76330	76332	O
samples	76333	76340	O
outside	76341	76348	O
the	76349	76352	O
group	76353	76358	O
.	76358	76359	O

We	76360	76362	O
then	76363	76367	O
calculated	76368	76378	O
the	76379	76382	O
average	76383	76390	O
score	76391	76396	O
s	76397	76398	O
of	76399	76401	O
all	76402	76405	O
samples	76406	76413	O
in	76414	76416	O
a	76417	76418	O
given	76419	76424	O
group	76425	76430	O
and	76431	76434	O
the	76435	76438	O
95	76439	76441	O
%	76441	76442	O
confidence	76443	76453	O
intervals	76454	76463	O
based	76464	76469	O
on	76470	76472	O
bootstrapping	76473	76486	O
10	76487	76489	O
,	76489	76490	O
000	76490	76493	O
times	76494	76499	O
.	76499	76500	O

We	76501	76503	O
performed	76504	76513	O
the	76514	76517	O
individual	76518	76528	O
-	76528	76529	O
based	76529	76534	O
grouping	76535	76543	O
by	76544	76546	O
calculating	76547	76558	O
silhouette	76559	76569	O
scores	76570	76576	O
for	76577	76580	O
all	76581	76584	O
tissues	76585	76592	O
from	76593	76597	O
20	76598	76600	O
randomly	76601	76609	O
selected	76610	76618	O
individuals	76619	76630	O
and	76631	76634	O
then	76635	76639	O
averaging	76640	76649	O
them	76650	76654	O
.	76654	76655	O

The	76656	76659	O
random	76660	76666	O
expectation	76667	76678	O
was	76679	76682	O
calculated	76683	76693	O
by	76694	76696	O
permuting	76697	76706	O
the	76707	76710	O
tissue	76711	76717	O
labels	76718	76724	O
across	76725	76731	O
samples	76732	76739	O
10	76740	76742	O
times	76743	76748	O
,	76748	76749	O
repeating	76750	76759	O
the	76760	76763	O
SS	76764	76766	O
calculation	76767	76778	O
across	76779	76785	O
tissues	76786	76793	O
and	76794	76797	O
then	76798	76802	O
averaging	76803	76812	O
all	76813	76816	O
SSs	76817	76820	O
.	76820	76821	O

Cell	76822	76826	O
type	76827	76831	O
decomposition	76832	76845	O
for	76846	76849	O
blood	76850	76855	O
and	76856	76859	O
lung	76860	76864	O
samples	76865	76872	O
We	76873	76875	O
used	76876	76880	O
CIBERSORT	76881	76890	O
[	76891	76892	O
54	76892	76894	O
]	76894	76895	O
to	76896	76898	O
identify	76899	76907	O
the	76908	76911	O
cell	76912	76916	O
type	76917	76921	O
composition	76922	76933	O
of	76934	76936	O
each	76937	76941	O
whole	76942	76947	O
-	76947	76948	O
blood	76948	76953	O
sample	76954	76960	O
in	76961	76963	O
the	76964	76967	O
GTEx	76968	76972	O
data	76973	76977	O
.	76977	76978	O

Briefly	76979	76986	O
,	76986	76987	O
CIBERSORT	76988	76997	O
applies	76998	77005	O
a	77006	77007	O
support	77008	77015	O
vector	77016	77022	O
regression	77023	77033	O
on	77034	77036	O
a	77037	77038	O
gene	77039	77043	O
expression	77044	77054	O
profile	77055	77062	O
(	77062	77063	O
s	77063	77064	O
)	77064	77065	O
using	77066	77071	O
reference	77072	77081	O
gene	77082	77086	O
expression	77087	77097	O
signatures	77098	77108	O
from	77109	77113	O
different	77114	77123	O
cell	77124	77128	O
types	77129	77134	O
,	77134	77135	O
and	77136	77139	O
then	77140	77144	O
retrieves	77145	77154	O
the	77155	77158	O
cell	77159	77163	O
type	77164	77168	O
composition	77169	77180	O
from	77181	77185	O
the	77186	77189	O
signatures	77190	77200	O
in	77201	77203	O
the	77204	77207	O
original	77208	77216	O
expression	77217	77227	O
profile	77228	77235	O
(	77235	77236	O
s	77236	77237	O
)	77237	77238	O
.	77238	77239	O

We	77240	77242	O
used	77243	77247	O
the	77248	77251	O
online	77252	77258	O
portal	77259	77265	O
(	77266	77267	O
https	77267	77272	O
:	77272	77273	O
/	77273	77274	O
/	77274	77275	O
cibersort	77275	77284	O
.	77284	77285	O
stanford	77285	77293	O
.	77293	77294	O
edu	77294	77297	O
/	77297	77298	O
)	77298	77299	O
and	77300	77303	O
the	77304	77307	O
default	77308	77315	O
LM22	77316	77320	O
expression	77321	77331	O
signatures	77332	77342	O
composed	77343	77351	O
of	77352	77354	O
the	77355	77358	O
most	77359	77363	O
prevalent	77364	77373	O
immune	77374	77380	B-CL:0000738
cell	77381	77385	E-CL:0000738
types	77386	77391	O
.	77391	77392	O

CIBERSORT	77393	77402	O
was	77403	77406	O
run	77407	77410	O
on	77411	77413	O
the	77414	77417	O
blood	77418	77423	O
gene	77424	77428	O
expression	77429	77439	O
profiles	77440	77448	O
with	77449	77453	O
default	77454	77461	O
parameters	77462	77472	O
:	77472	77473	O
100	77474	77477	O
permutations	77478	77490	O
and	77491	77494	O
“	77495	77496	O
absolute	77496	77504	O
”	77504	77505	O
mode	77506	77510	O
.	77510	77511	O

Gene	77512	77516	O
expression	77517	77527	O
associations	77528	77540	O
To	77541	77543	O
avoid	77544	77549	O
population	77550	77560	O
-	77560	77561	O
based	77561	77566	O
effects	77567	77574	O
for	77575	77578	O
all	77579	77582	O
expression	77583	77593	O
association	77594	77605	O
analyses	77606	77614	O
in	77615	77617	O
this	77618	77622	O
study	77623	77628	O
,	77628	77629	O
we	77630	77632	O
only	77633	77637	O
used	77638	77642	O
self	77643	77647	O
-	77647	77648	O
reported	77648	77656	O
Caucasian	77657	77666	O
people	77667	77673	O
.	77673	77674	O

For	77675	77678	O
each	77679	77683	O
tissue	77684	77690	O
,	77690	77691	O
we	77692	77694	O
used	77695	77699	O
individual	77700	77710	O
gene	77711	77715	O
expression	77716	77726	O
to	77727	77729	O
model	77730	77735	O
mutation	77736	77744	O
counts	77745	77751	O
in	77752	77754	O
a	77755	77756	O
linear	77757	77763	O
regression	77764	77774	O
as	77775	77777	O
follows	77778	77785	O
:	77785	77786	O
\	77787	77788	O
documentclass	77788	77801	O
[	77801	77802	O
12pt	77802	77806	O
]	77806	77807	O
{	77807	77808	O
minimal	77808	77815	O
}	77815	77816	O
\	77821	77822	O
usepackage	77822	77832	O
{	77832	77833	O
amsmath	77833	77840	O
}	77840	77841	O
\	77846	77847	O
usepackage	77847	77857	O
{	77857	77858	O
wasysym	77858	77865	O
}	77865	77866	O
\	77872	77873	O
usepackage	77873	77883	O
{	77883	77884	O
amsfonts	77884	77892	O
}	77892	77893	O
\	77899	77900	O
usepackage	77900	77910	O
{	77910	77911	O
amssymb	77911	77918	O
}	77918	77919	O
\	77925	77926	O
usepackage	77926	77936	O
{	77936	77937	O
amsbsy	77937	77943	O
}	77943	77944	O
\	77949	77950	O
usepackage	77950	77960	O
{	77960	77961	O
mathrsfs	77961	77969	O
}	77969	77970	O
\	77975	77976	O
usepackage	77976	77986	O
{	77986	77987	O
upgreek	77987	77994	O
}	77994	77995	O
\	78000	78001	O
setlength	78001	78010	O
{	78010	78011	O
\	78011	78012	O
oddsidemargin	78012	78025	O
}	78025	78026	O
{	78026	78027	O
-	78027	78028	O
69pt	78028	78032	O
}	78032	78033	O
\	78038	78039	O
begin	78039	78044	O
{	78044	78045	O
document	78045	78053	O
}	78053	78054	O
$	78054	78055	O
$	78055	78056	O
{	78057	78058	O
p	78058	78059	O
}	78059	78060	O
_	78060	78061	O
i	78061	78062	O
=	78062	78063	O
{	78063	78064	O
\	78064	78065	O
beta	78065	78069	O
}	78069	78070	O
_	78070	78071	O
0	78071	78072	O
+	78072	78073	O
\	78073	78074	O
sum	78074	78077	O
\	78078	78079	O
limits	78079	78085	O
_	78085	78086	O
n	78086	78087	O
{	78087	78088	O
\	78088	78089	O
beta	78089	78093	O
}	78093	78094	O
_	78094	78095	O
n	78095	78096	O
{	78096	78097	O
\	78097	78098	O
mathit	78098	78104	O
{	78104	78105	O
\	78105	78106	O
operatorname	78106	78118	O
{	78118	78119	O
cov	78119	78122	O
}	78122	78123	O
}	78123	78124	O
}	78124	78125	O
_	78125	78126	O
{	78126	78127	O
n	78127	78128	O
,	78128	78129	O
i	78129	78130	O
}	78130	78131	O
+	78131	78132	O
\	78132	78133	O
gamma	78133	78138	O
{	78139	78140	O
x	78140	78141	O
}	78141	78142	O
_	78142	78143	O
i	78143	78144	O
$	78145	78146	O
$	78146	78147	O
\	78147	78148	O
end	78148	78151	O
{	78151	78152	O
document	78152	78160	O
}	78160	78161	O
pi	78161	78163	O
=	78163	78164	O
β0	78164	78166	O
+	78166	78167	O
∑	78167	78168	O
nβncovn	78168	78175	O
,	78175	78176	O
i	78176	78177	O
+	78177	78178	O
γxi	78178	78181	O
where	78182	78187	O
x	78188	78189	O
is	78190	78192	O
the	78193	78196	O
expression	78197	78207	O
of	78208	78210	O
a	78211	78212	O
given	78213	78218	O
gene	78219	78223	O
in	78224	78226	O
TPM	78227	78230	O
,	78230	78231	O
cov	78232	78235	O
is	78236	78238	O
a	78239	78240	O
covariate	78241	78250	O
variable	78251	78259	O
,	78259	78260	O
and	78261	78264	O
there	78265	78270	O
are	78271	78274	O
n	78275	78276	O
covariates	78277	78287	O
.	78287	78288	O

To	78289	78291	O
estimate	78292	78300	O
the	78301	78304	O
effects	78305	78312	O
of	78313	78315	O
a	78316	78317	O
SNP	78318	78321	O
on	78322	78324	O
the	78325	78328	O
phenotype	78329	78338	O
,	78338	78339	O
γ	78340	78341	O
is	78342	78344	O
calculated	78345	78355	O
for	78356	78359	O
each	78360	78364	O
gene	78365	78369	O
in	78370	78372	O
the	78373	78376	O
genome	78377	78383	O
that	78384	78388	O
has	78389	78392	O
a	78393	78394	O
TPM	78395	78398	O
>	78399	78400	O
1	78401	78402	O
in	78403	78405	O
at	78406	78408	O
least	78409	78414	O
20	78415	78417	O
%	78417	78418	O
of	78419	78421	O
the	78422	78425	O
samples	78426	78433	O
.	78433	78434	O

Significance	78435	78447	O
is	78448	78450	O
measured	78451	78459	O
based	78460	78465	O
on	78466	78468	O
the	78469	78472	O
p	78473	78474	O
value	78475	78480	O
of	78481	78483	O
a	78484	78485	O
non	78486	78489	O
-	78489	78490	O
zero	78490	78494	O
t	78495	78496	O
test	78497	78501	O
performed	78502	78511	O
on	78512	78514	O
γ	78515	78516	O
.	78516	78517	O
p	78518	78519	O
values	78520	78526	O
are	78527	78530	O
adjusted	78531	78539	O
using	78540	78545	O
Bonferroni	78546	78556	O
correction	78557	78567	O
.	78567	78568	O

When	78569	78573	O
pi	78574	78576	O
is	78577	78579	O
the	78580	78583	O
vector	78584	78590	O
of	78591	78593	O
mutation	78594	78602	O
loads	78603	78608	O
,	78608	78609	O
we	78610	78612	O
defined	78613	78620	O
it	78621	78623	O
as	78624	78626	O
the	78627	78630	O
residuals	78631	78640	O
after	78641	78646	O
regressing	78647	78657	O
non	78658	78661	O
-	78661	78662	O
biological	78662	78672	O
factors	78673	78680	O
as	78681	78683	O
described	78684	78693	O
previously	78694	78704	O
(	78705	78706	O
see	78706	78709	O
above	78710	78715	O
in	78716	78718	O
the	78719	78722	O
“	78723	78724	O
Discovery	78724	78733	O
of	78734	78736	O
mutation	78737	78745	O
associations	78746	78758	O
with	78759	78763	O
biological	78764	78774	O
and	78775	78778	O
non	78779	78782	O
-	78782	78783	O
biological	78783	78793	O
factors	78794	78801	O
”	78801	78802	O
section	78803	78810	O
)	78810	78811	O
.	78811	78812	O

The	78813	78816	O
covariates	78817	78827	O
included	78828	78836	O
in	78837	78839	O
this	78840	78844	O
model	78845	78850	O
are	78851	78854	O
the	78855	78858	O
first	78859	78864	O
3	78865	78866	O
PCs	78867	78870	O
of	78871	78873	O
the	78874	78877	O
whole	78878	78883	O
-	78883	78884	O
genome	78884	78890	O
genotypes	78891	78900	O
,	78900	78901	O
age	78902	78905	O
,	78905	78906	O
sex	78907	78910	O
,	78910	78911	O
and	78912	78915	O
BMI	78916	78919	O
.	78919	78920	O

In	78921	78923	O
all	78924	78927	O
cases	78928	78933	O
,	78933	78934	O
both	78935	78939	O
pi	78940	78942	O
and	78943	78946	O
γ	78947	78948	O
were	78949	78953	O
normalized	78954	78964	O
by	78965	78967	O
converting	78968	78978	O
the	78979	78982	O
values	78983	78989	O
into	78990	78994	O
quantiles	78995	79004	O
and	79005	79008	O
mapping	79009	79016	O
them	79017	79021	O
to	79022	79024	O
the	79025	79028	O
corresponding	79029	79042	O
values	79043	79049	O
of	79050	79052	O
the	79053	79056	O
standard	79057	79065	O
normal	79066	79072	O
distribution	79073	79085	O
quantiles	79086	79095	O
,	79095	79096	O
following	79097	79106	O
standard	79107	79115	O
GTEx	79116	79120	O
practices	79121	79130	O
[	79131	79132	O
46	79132	79134	O
]	79134	79135	O
.	79135	79136	O

Gene	79137	79141	O
Ontology	79142	79150	O
analysis	79151	79159	O
For	79160	79163	O
gene	79164	79168	O
expression	79169	79179	O
associations	79180	79192	O
with	79193	79197	O
mutation	79198	79206	O
load	79207	79211	O
,	79211	79212	O
we	79213	79215	O
assessed	79216	79224	O
enrichment	79225	79235	O
in	79236	79238	O
GO	79239	79241	O
biological	79242	79252	O
processes	79253	79262	O
using	79263	79268	O
GOrilla	79269	79276	O
[	79277	79278	O
55	79278	79280	O
]	79280	79281	O
.	79281	79282	O

We	79283	79285	O
used	79286	79290	O
as	79291	79293	O
input	79294	79299	O
a	79300	79301	O
ranked	79302	79308	O
list	79309	79313	O
of	79314	79316	O
genes	79317	79322	O
based	79323	79328	O
on	79329	79331	O
the	79332	79335	O
number	79336	79342	O
of	79343	79345	O
tissues	79346	79353	O
they	79354	79358	O
were	79359	79363	O
significant	79364	79375	O
in	79376	79378	O
(	79379	79380	O
and	79380	79383	O
only	79384	79388	O
including	79389	79398	O
genes	79399	79404	O
that	79405	79409	O
were	79410	79414	O
tested	79415	79421	O
in	79422	79424	O
more	79425	79429	O
than	79430	79434	O
the	79435	79438	O
median	79439	79445	O
number	79446	79452	O
of	79453	79455	O
tissues	79456	79463	O
all	79464	79467	O
genes	79468	79473	O
were	79474	79478	O
tested	79479	79485	O
in	79486	79488	O
,	79488	79489	O
p	79490	79491	O
<	79492	79493	O
0	79494	79495	O
.	79495	79496	O
05	79496	79498	O
after	79499	79504	O
Bonferroni	79505	79515	O
correction	79516	79526	O
,	79526	79527	O
see	79528	79531	O
above	79532	79537	O
in	79538	79540	O
the	79541	79544	O
“	79545	79546	O
Gene	79546	79550	O
expression	79551	79561	O
associations	79562	79574	O
”	79574	79575	O
section	79576	79583	O
)	79583	79584	O
and	79585	79588	O
breaking	79589	79597	O
ties	79598	79602	O
by	79603	79605	O
significance	79606	79618	O
.	79618	79619	O

We	79620	79622	O
then	79623	79627	O
used	79628	79632	O
REVIGO	79633	79639	O
[	79640	79641	O
56	79641	79643	O
]	79643	79644	O
to	79645	79647	O
obtain	79648	79654	O
non	79655	79658	O
-	79658	79659	O
redundant	79659	79668	O
categories	79669	79679	O
.	79679	79680	O

Expression	79681	79691	O
associations	79692	79704	O
with	79705	79709	O
genomic	79710	79717	O
instability	79718	79729	O
genes	79730	79735	O
We	79736	79738	O
selected	79739	79747	O
a	79748	79749	O
panel	79750	79755	O
of	79756	79758	O
genes	79759	79764	O
known	79765	79770	O
to	79771	79773	O
be	79774	79776	O
involved	79777	79785	O
in	79786	79788	O
different	79789	79798	O
pathways	79799	79807	O
of	79808	79810	O
DNA	79811	79814	O
repair	79815	79821	O
or	79822	79824	O
translesion	79825	79836	O
replication	79837	79848	O
(	79849	79850	O
Fig	79850	79853	O
.	79853	79854	O

4	79855	79856	O
)	79856	79857	O
and	79858	79861	O
performed	79862	79871	O
association	79872	79883	O
analyses	79884	79892	O
between	79893	79900	O
their	79901	79906	O
expression	79907	79917	O
and	79918	79921	O
the	79922	79925	O
mutational	79926	79936	O
load	79937	79941	O
for	79942	79945	O
all	79946	79949	O
different	79950	79959	O
mutation	79960	79968	O
types	79969	79974	O
on	79975	79977	O
a	79978	79979	O
per	79980	79983	O
-	79983	79984	O
tissue	79984	79990	O
basis	79991	79996	O
.	79996	79997	O

We	79998	80000	O
followed	80001	80009	O
the	80010	80013	O
same	80014	80018	O
linear	80019	80025	O
regression	80026	80036	O
strategy	80037	80045	O
as	80046	80048	O
described	80049	80058	O
above	80059	80064	O
in	80065	80067	O
the	80068	80071	O
“	80072	80073	O
Gene	80073	80077	O
expression	80078	80088	O
associations	80089	80101	O
.	80101	80102	O
”	80102	80103	O
We	80104	80106	O
devised	80107	80114	O
customized	80115	80125	O
strategies	80126	80136	O
to	80137	80139	O
calculate	80140	80149	O
FDRs	80150	80154	O
for	80155	80158	O
individual	80159	80169	O
gene	80170	80174	O
-	80174	80175	O
tissue	80175	80181	O
associations	80182	80194	O
,	80194	80195	O
gene	80196	80200	O
enrichment	80201	80211	O
across	80212	80218	O
all	80219	80222	O
tissues	80223	80230	O
,	80230	80231	O
and	80232	80235	O
pathway	80236	80243	O
(	80244	80245	O
gene	80245	80249	O
group	80250	80255	O
)	80255	80256	O
associations	80257	80269	O
in	80270	80272	O
each	80273	80277	O
tissue	80278	80284	O
.	80284	80285	O

For	80286	80289	O
individual	80290	80300	O
gene	80301	80305	O
-	80305	80306	O
tissue	80306	80312	O
associations	80313	80325	O
,	80325	80326	O
we	80327	80329	O
calculated	80330	80340	O
an	80341	80343	O
FDR	80344	80347	O
based	80348	80353	O
on	80354	80356	O
the	80357	80360	O
distribution	80361	80373	O
of	80374	80376	O
p	80377	80378	O
values	80379	80385	O
of	80386	80388	O
the	80389	80392	O
linear	80393	80399	O
regressions	80400	80411	O
from	80412	80416	O
the	80417	80420	O
tests	80421	80426	O
of	80427	80429	O
all	80430	80433	O
genes	80434	80439	O
in	80440	80442	O
the	80443	80446	O
genome	80447	80453	O
(	80454	80455	O
see	80455	80458	O
above	80459	80464	O
for	80465	80468	O
additional	80469	80479	O
filters	80480	80487	O
)	80487	80488	O
.	80488	80489	O

Then	80490	80494	O
,	80494	80495	O
for	80496	80499	O
each	80500	80504	O
gene	80505	80509	O
of	80510	80512	O
interest	80513	80521	O
,	80521	80522	O
we	80523	80525	O
calculated	80526	80536	O
the	80537	80540	O
FDR	80541	80544	O
as	80545	80547	O
the	80548	80551	O
percentage	80552	80562	O
of	80563	80565	O
genes	80566	80571	O
from	80572	80576	O
all	80577	80580	O
tests	80581	80586	O
that	80587	80591	O
had	80592	80595	O
an	80596	80598	O
equal	80599	80604	O
or	80605	80607	O
lower	80608	80613	O
p	80614	80615	O
value	80616	80621	O
.	80621	80622	O

To	80623	80625	O
obtain	80626	80632	O
an	80633	80635	O
FDR	80636	80639	O
of	80640	80642	O
the	80643	80646	O
enrichment	80647	80657	O
for	80658	80661	O
different	80662	80671	O
pathways	80672	80680	O
across	80681	80687	O
tissues	80688	80695	O
,	80695	80696	O
for	80697	80700	O
each	80701	80705	O
pathway	80706	80713	O
of	80714	80716	O
interest	80717	80725	O
,	80725	80726	O
we	80727	80729	O
obtained	80730	80738	O
the	80739	80742	O
p	80743	80744	O
values	80745	80751	O
from	80752	80756	O
the	80757	80760	O
individual	80761	80771	O
linear	80772	80778	O
regressions	80779	80790	O
of	80791	80793	O
each	80794	80798	O
gene	80799	80803	O
.	80803	80804	O

We	80805	80807	O
then	80808	80812	O
created	80813	80820	O
10	80821	80823	O
,	80823	80824	O
000	80824	80827	O
groups	80828	80834	O
with	80835	80839	O
randomly	80840	80848	O
selected	80849	80857	O
genes	80858	80863	O
with	80864	80868	O
the	80869	80872	O
same	80873	80877	O
size	80878	80882	O
as	80883	80885	O
the	80886	80889	O
pathway	80890	80897	O
of	80898	80900	O
interest	80901	80909	O
and	80910	80913	O
within	80914	80920	O
the	80921	80924	O
tissue	80925	80931	O
of	80932	80934	O
interest	80935	80943	O
and	80944	80947	O
performed	80948	80957	O
linear	80958	80964	O
regressions	80965	80976	O
with	80977	80981	O
mutation	80982	80990	O
load	80991	80995	O
(	80996	80997	O
as	80997	80999	O
described	81000	81009	O
above	81010	81015	O
in	81016	81018	O
the	81019	81022	O
“	81023	81024	O
Gene	81024	81028	O
expression	81029	81039	O
associations	81040	81052	O
”	81052	81053	O
section	81054	81061	O
)	81061	81062	O
.	81062	81063	O

Finally	81064	81071	O
,	81071	81072	O
for	81073	81076	O
each	81077	81081	O
p	81082	81083	O
value	81084	81089	O
in	81090	81092	O
the	81093	81096	O
original	81097	81105	O
group	81106	81111	O
,	81111	81112	O
we	81113	81115	O
calculated	81116	81126	O
the	81127	81130	O
FDR	81131	81134	O
by	81135	81137	O
dividing	81138	81146	O
the	81147	81150	O
percentage	81151	81161	O
of	81162	81164	O
p	81165	81166	O
values	81167	81173	O
of	81174	81176	O
equal	81177	81182	O
or	81183	81185	O
lower	81186	81191	O
value	81192	81197	O
in	81198	81200	O
all	81201	81204	O
permuted	81205	81213	O
regressions	81214	81225	O
by	81226	81228	O
the	81229	81232	O
percentage	81233	81243	O
of	81244	81246	O
p	81247	81248	O
values	81249	81255	O
of	81256	81258	O
equal	81259	81264	O
or	81265	81267	O
lower	81268	81273	O
value	81274	81279	O
in	81280	81282	O
the	81283	81286	O
original	81287	81295	O
regressions	81296	81307	O
.	81307	81308	O

For	81309	81312	O
example	81313	81320	O
,	81320	81321	O
if	81322	81324	O
0	81325	81326	O
.	81326	81327	O
1	81327	81328	O
%	81328	81329	O
of	81330	81332	O
permuted	81333	81341	O
regressions	81342	81353	O
reached	81354	81361	O
p	81362	81363	O
<	81364	81365	O
0	81366	81367	O
.	81367	81368	O
001	81368	81371	O
,	81371	81372	O
compared	81373	81381	O
to	81382	81384	O
1	81385	81386	O
%	81386	81387	O
of	81388	81390	O
unpermuted	81391	81401	O
regressions	81402	81413	O
,	81413	81414	O
the	81415	81418	O
FDR	81419	81422	O
at	81423	81425	O
p	81426	81427	O
<	81428	81429	O
0	81430	81431	O
.	81431	81432	O
001	81432	81435	O
would	81436	81441	O
be	81442	81444	O
0	81445	81446	O
.	81446	81447	O
1	81447	81448	O
/	81448	81449	O
1	81449	81450	O
=	81451	81452	O
10	81453	81455	O
%	81455	81456	O
.	81456	81457	O

Lastly	81458	81464	O
,	81464	81465	O
to	81466	81468	O
calculate	81469	81478	O
FDR	81479	81482	O
for	81483	81486	O
the	81487	81490	O
enrichment	81491	81501	O
of	81502	81504	O
individual	81505	81515	O
genes	81516	81521	O
across	81522	81528	O
all	81529	81532	O
tissues	81533	81540	O
,	81540	81541	O
we	81542	81544	O
used	81545	81549	O
a	81550	81551	O
similar	81552	81559	O
strategy	81560	81568	O
as	81569	81571	O
the	81572	81575	O
FDR	81576	81579	O
calculation	81580	81591	O
for	81592	81595	O
gene	81596	81600	O
pathways	81601	81609	O
described	81610	81619	O
in	81620	81622	O
the	81623	81626	O
previous	81627	81635	O
paragraph	81636	81645	O
.	81645	81646	O

We	81647	81649	O
first	81650	81655	O
obtained	81656	81664	O
the	81665	81668	O
p	81669	81670	O
values	81671	81677	O
of	81678	81680	O
individual	81681	81691	O
linear	81692	81698	O
regression	81699	81709	O
of	81710	81712	O
a	81713	81714	O
given	81715	81720	O
gene	81721	81725	O
across	81726	81732	O
all	81733	81736	O
tissues	81737	81744	O
.	81744	81745	O

We	81746	81748	O
then	81749	81753	O
created	81754	81761	O
a	81762	81763	O
permuted	81764	81772	O
set	81773	81776	O
of	81777	81779	O
p	81780	81781	O
values	81782	81788	O
from	81789	81793	O
the	81794	81797	O
regressions	81798	81809	O
of	81810	81812	O
one	81813	81816	O
gene	81817	81821	O
from	81822	81826	O
each	81827	81831	O
of	81832	81834	O
the	81835	81838	O
10	81839	81841	O
,	81841	81842	O
000	81842	81845	O
permuted	81846	81854	O
groups	81855	81861	O
in	81862	81864	O
all	81865	81868	O
tissues	81869	81876	O
.	81876	81877	O

Finally	81878	81885	O
,	81885	81886	O
we	81887	81889	O
calculated	81890	81900	O
the	81901	81904	O
FDR	81905	81908	O
of	81909	81911	O
the	81912	81915	O
p	81916	81917	O
values	81918	81924	O
in	81925	81927	O
the	81928	81931	O
original	81932	81940	O
group	81941	81946	O
(	81947	81948	O
one	81948	81951	O
across	81952	81958	O
all	81959	81962	O
tissues	81963	81970	O
)	81970	81971	O
by	81972	81974	O
dividing	81975	81983	O
the	81984	81987	O
percentage	81988	81998	O
of	81999	82001	O
p	82002	82003	O
values	82004	82010	O
of	82011	82013	O
equal	82014	82019	O
or	82020	82022	O
lower	82023	82028	O
p	82029	82030	O
value	82031	82036	O
in	82037	82039	O
all	82040	82043	O
permuted	82044	82052	O
regressions	82053	82064	O
by	82065	82067	O
the	82068	82071	O
percentage	82072	82082	O
of	82083	82085	O
p	82086	82087	O
values	82088	82094	O
of	82095	82097	O
equal	82098	82103	O
or	82104	82106	O
lower	82107	82112	O
value	82113	82118	O
in	82119	82121	O
the	82122	82125	O
original	82126	82134	O
regressions	82135	82146	O
.	82146	82147	O

Chromatin	82148	82157	O
analysis	82158	82166	O
To	82167	82169	O
address	82170	82177	O
the	82178	82181	O
influence	82182	82191	O
of	82192	82194	O
chromatin	82195	82204	O
on	82205	82207	O
somatic	82208	82215	O
mutations	82216	82225	O
,	82225	82226	O
we	82227	82229	O
first	82230	82235	O
manually	82236	82244	O
mapped	82245	82251	O
tissues	82252	82259	O
from	82260	82264	O
GTEx	82265	82269	O
to	82270	82272	O
tissues	82273	82280	O
of	82281	82283	O
the	82284	82287	O
Roadmap	82288	82295	O
Epigenomics	82296	82307	O
Project	82308	82315	O
[	82316	82317	O
27	82317	82319	O
]	82319	82320	O
.	82320	82321	O

We	82322	82324	O
were	82325	82329	O
able	82330	82334	O
to	82335	82337	O
do	82338	82340	O
such	82341	82345	O
mapping	82346	82353	O
for	82354	82357	O
18	82358	82360	O
tissues	82361	82368	O
(	82369	82370	O
Additional	82370	82380	O
file	82381	82385	O
10	82386	82388	O
:	82388	82389	O
Table	82390	82395	O
S7	82396	82398	O
)	82398	82399	O
.	82399	82400	O

For	82401	82404	O
each	82405	82409	O
tissue	82410	82416	O
,	82416	82417	O
on	82418	82420	O
a	82421	82422	O
per	82423	82426	O
-	82426	82427	O
exon	82427	82431	O
basis	82432	82437	O
,	82437	82438	O
we	82439	82441	O
calculated	82442	82452	O
both	82453	82457	O
mutation	82458	82466	O
rates	82467	82472	O
and	82473	82476	O
signal	82477	82483	O
for	82484	82487	O
H3K36me3	82488	82496	O
,	82496	82497	O
H3K4me1	82498	82505	O
,	82505	82506	O
H3K4me3	82507	82514	O
,	82514	82515	O
H3K27me3	82516	82524	O
,	82524	82525	O
and	82526	82529	O
H3K9me3	82530	82537	O
.	82537	82538	O

To	82539	82541	O
account	82542	82549	O
for	82550	82553	O
sequencing	82554	82564	O
depth	82565	82570	O
(	82571	82572	O
expression	82572	82582	O
)	82582	82583	O
of	82584	82586	O
an	82587	82589	O
exon	82590	82594	O
when	82595	82599	O
calculating	82600	82611	O
mutation	82612	82620	O
rates	82621	82626	O
,	82626	82627	O
we	82628	82630	O
assigned	82631	82639	O
exons	82640	82645	O
to	82646	82648	O
100	82649	82652	O
bins	82653	82657	O
based	82658	82663	O
on	82664	82666	O
their	82667	82672	O
sequencing	82673	82683	O
depth	82684	82689	O
,	82689	82690	O
where	82691	82696	O
each	82697	82701	O
bin	82702	82705	O
contains	82706	82714	O
1	82715	82716	O
%	82716	82717	O
of	82718	82720	O
exons	82721	82726	O
.	82726	82727	O

We	82728	82730	O
then	82731	82735	O
calculated	82736	82746	O
the	82747	82750	O
median	82751	82757	O
number	82758	82764	O
of	82765	82767	O
mutations	82768	82777	O
observed	82778	82786	O
in	82787	82789	O
each	82790	82794	O
bin	82795	82798	O
,	82798	82799	O
and	82800	82803	O
finally	82804	82811	O
,	82811	82812	O
the	82813	82816	O
mutation	82817	82825	O
rate	82826	82830	O
per	82831	82834	O
exon	82835	82839	O
was	82840	82843	O
obtained	82844	82852	O
by	82853	82855	O
subtracting	82856	82867	O
expected	82868	82876	O
number	82877	82883	O
of	82884	82886	O
mutations	82887	82896	O
(	82897	82898	O
the	82898	82901	O
median	82902	82908	O
for	82909	82912	O
all	82913	82916	O
exons	82917	82922	O
in	82923	82925	O
that	82926	82930	O
bin	82931	82934	O
)	82934	82935	O
from	82936	82940	O
the	82941	82944	O
observed	82945	82953	O
number	82954	82960	O
for	82961	82964	O
that	82965	82969	O
exon	82970	82974	O
.	82974	82975	O

Chromatin	82976	82985	O
signal	82986	82992	O
for	82993	82996	O
each	82997	83001	O
exon	83002	83006	O
was	83007	83010	O
obtained	83011	83019	O
from	83020	83024	O
Roadmap	83025	83032	O
ChIP	83033	83037	O
-	83037	83038	O
seq	83038	83041	O
data	83042	83046	O
.	83046	83047	O

We	83048	83050	O
calculated	83051	83061	O
the	83062	83065	O
average	83066	83073	O
base	83074	83078	O
-	83078	83079	O
pair	83079	83083	O
ratios	83084	83090	O
of	83091	83093	O
IP	83094	83096	O
/	83096	83097	O
input	83097	83102	O
obtained	83103	83111	O
from	83112	83116	O
the	83117	83120	O
Roadmap	83121	83128	O
bigwig	83129	83135	O
files	83136	83141	O
.	83141	83142	O

Significance	83143	83155	O
of	83156	83158	O
the	83159	83162	O
association	83163	83174	O
between	83175	83182	O
each	83183	83187	O
histone	83188	83195	O
modification	83196	83208	O
and	83209	83212	O
mutation	83213	83221	O
rate	83222	83226	O
was	83227	83230	O
assessed	83231	83239	O
by	83240	83242	O
applying	83243	83251	O
a	83252	83253	O
linear	83254	83260	O
regression	83261	83271	O
on	83272	83274	O
the	83275	83278	O
mutation	83279	83287	O
rate	83288	83292	O
using	83293	83298	O
all	83299	83302	O
histone	83303	83310	O
modifications	83311	83324	O
as	83325	83327	O
features	83328	83336	O
and	83337	83340	O
assessing	83341	83350	O
the	83351	83354	O
significance	83355	83367	O
(	83368	83369	O
p	83369	83370	O
value	83371	83376	O
)	83376	83377	O
of	83378	83380	O
each	83381	83385	O
coefficient	83386	83397	O
(	83398	83399	O
histone	83399	83406	O
modification	83407	83419	O
)	83419	83420	O
.	83420	83421	O

Individual	83422	83432	O
effect	83433	83439	O
sizes	83440	83445	O
(	83446	83447	O
r	83447	83448	O
)	83448	83449	O
for	83450	83453	O
each	83454	83458	O
histone	83459	83466	O
modification	83467	83479	O
were	83480	83484	O
obtained	83485	83493	O
as	83494	83496	O
follows	83497	83504	O
:	83504	83505	O
for	83506	83509	O
each	83510	83514	O
histone	83515	83522	O
modification	83523	83535	O
,	83535	83536	O
a	83537	83538	O
linear	83539	83545	O
regression	83546	83556	O
was	83557	83560	O
performed	83561	83570	O
using	83571	83576	O
the	83577	83580	O
rest	83581	83585	O
of	83586	83588	O
the	83589	83592	O
histone	83593	83600	O
modifications	83601	83614	O
as	83615	83617	O
features	83618	83626	O
.	83626	83627	O

The	83628	83631	O
residuals	83632	83641	O
of	83642	83644	O
those	83645	83650	O
regressions	83651	83662	O
were	83663	83667	O
then	83668	83672	O
used	83673	83677	O
in	83678	83680	O
a	83681	83682	O
separate	83683	83691	O
linear	83692	83698	O
regression	83699	83709	O
with	83710	83714	O
mutation	83715	83723	O
rate	83724	83728	O
as	83729	83731	O
the	83732	83735	O
response	83736	83744	O
variable	83745	83753	O
,	83753	83754	O
from	83755	83759	O
which	83760	83765	O
the	83766	83769	O
variance	83770	83778	O
explained	83779	83788	O
(	83789	83790	O
r2	83790	83792	O
)	83792	83793	O
was	83794	83797	O
then	83798	83802	O
obtained	83803	83811	O
.	83811	83812	O

Mutation	83813	83821	O
enrichment	83822	83832	O
in	83833	83835	O
COSMIC	83836	83842	O
cancer	83843	83849	O
mutations	83850	83859	O
We	83860	83862	O
downloaded	83863	83873	O
the	83874	83877	O
entire	83878	83884	O
set	83885	83888	O
of	83889	83891	O
cancer	83892	83898	O
mutations	83899	83908	O
from	83909	83913	O
COSMIC	83914	83920	O
[	83921	83922	O
35	83922	83924	O
]	83924	83925	O
v86	83926	83929	O
,	83929	83930	O
and	83931	83934	O
we	83935	83937	O
further	83938	83945	O
filtered	83946	83954	O
them	83955	83959	O
to	83960	83962	O
only	83963	83967	O
keep	83968	83972	O
single	83973	83979	O
nucleotide	83980	83990	O
variants	83991	83999	O
without	84000	84007	O
indels	84008	84014	O
.	84014	84015	O

For	84016	84019	O
each	84020	84024	O
sample	84025	84031	O
,	84031	84032	O
we	84033	84035	O
calculated	84036	84046	O
the	84047	84050	O
percentage	84051	84061	O
(	84062	84063	O
overlap	84063	84070	O
)	84070	84071	O
of	84072	84074	O
their	84075	84080	O
mutations	84081	84090	O
that	84091	84095	O
are	84096	84099	O
present	84100	84107	O
in	84108	84110	O
COSMIC	84111	84117	O
mutations	84118	84127	O
,	84127	84128	O
and	84129	84132	O
we	84133	84135	O
calculated	84136	84146	O
the	84147	84150	O
significance	84151	84163	O
of	84164	84166	O
the	84167	84170	O
overlap	84171	84178	O
using	84179	84184	O
the	84185	84188	O
integral	84189	84197	O
of	84198	84200	O
the	84201	84204	O
upper	84205	84210	O
tail	84211	84215	O
from	84216	84220	O
a	84221	84222	O
hypergeometric	84223	84237	O
distribution	84238	84250	O
,	84250	84251	O
that	84252	84256	O
is	84257	84259	O
p	84260	84261	O
(	84261	84262	O
X	84262	84263	O
>	84264	84265	O
k	84266	84267	O
)	84267	84268	O
,	84268	84269	O
where	84270	84275	O
X	84276	84277	O
follows	84278	84285	O
a	84286	84287	O
hypergeometric	84288	84302	O
distribution	84303	84315	O
with	84316	84320	O
parameters	84321	84331	O
K	84332	84333	O
(	84334	84335	O
number	84335	84341	O
of	84342	84344	O
mutations	84345	84354	O
in	84355	84357	O
sample	84358	84364	O
)	84364	84365	O
,	84365	84366	O
n	84367	84368	O
(	84369	84370	O
number	84370	84376	O
of	84377	84379	O
COSMIC	84380	84386	O
mutations	84387	84396	O
whose	84397	84402	O
positions	84403	84412	O
were	84413	84417	O
covered	84418	84425	O
by	84426	84428	O
≥	84429	84430	O
40	84431	84433	O
reads	84434	84439	O
in	84440	84442	O
the	84443	84446	O
RNA	84447	84450	O
-	84450	84451	O
seq	84451	84454	O
sample	84455	84461	O
)	84461	84462	O
,	84462	84463	O
N	84464	84465	O
×	84466	84467	O
3	84468	84469	O
(	84470	84471	O
the	84471	84474	O
total	84475	84480	O
number	84481	84487	O
of	84488	84490	O
base	84491	84495	O
pairs	84496	84501	O
covered	84502	84509	O
by	84510	84512	O
≥	84513	84514	O
40	84515	84517	O
reads	84518	84523	O
in	84524	84526	O
the	84527	84530	O
RNA	84531	84534	O
-	84534	84535	O
seq	84535	84538	O
sample	84539	84545	O
multiplied	84546	84556	O
by	84557	84559	O
the	84560	84563	O
three	84564	84569	O
possible	84570	84578	O
alternate	84579	84588	O
alleles	84589	84596	O
that	84597	84601	O
any	84602	84605	O
reference	84606	84615	O
can	84616	84619	O
have	84620	84624	O
)	84624	84625	O
,	84625	84626	O
and	84627	84630	O
k	84631	84632	O
(	84633	84634	O
the	84634	84637	O
overlap	84638	84645	O
of	84646	84648	O
mutations	84649	84658	O
,	84658	84659	O
K	84660	84661	O
and	84662	84665	O
n	84666	84667	O
)	84667	84668	O
.	84668	84669	O

As	84670	84672	O
a	84673	84674	O
control	84675	84682	O
,	84682	84683	O
for	84684	84687	O
each	84688	84692	O
sample	84693	84699	O
,	84699	84700	O
this	84701	84705	O
calculation	84706	84717	O
was	84718	84721	O
repeated	84722	84730	O
using	84731	84736	O
a	84737	84738	O
permuted	84739	84747	O
set	84748	84751	O
of	84752	84754	O
mutations	84755	84764	O
.	84764	84765	O

This	84766	84770	O
set	84771	84774	O
was	84775	84778	O
constructed	84779	84790	O
by	84791	84793	O
randomly	84794	84802	O
selecting	84803	84812	O
genomic	84813	84820	O
positions	84821	84830	O
that	84831	84835	O
were	84836	84840	O
covered	84841	84848	O
by	84849	84851	O
≥	84852	84853	O
40	84854	84856	O
reads	84857	84862	O
in	84863	84865	O
the	84866	84869	O
sample	84870	84876	O
and	84877	84880	O
then	84881	84885	O
mutations	84886	84895	O
were	84896	84900	O
simulated	84901	84910	O
in	84911	84913	O
those	84914	84919	O
positions	84920	84929	O
.	84929	84930	O

We	84931	84933	O
preserved	84934	84943	O
the	84944	84947	O
number	84948	84954	O
of	84955	84957	O
reference	84958	84967	O
alleles	84968	84975	O
and	84976	84979	O
their	84980	84985	O
corresponding	84986	84999	O
alternate	85000	85009	O
alleles	85010	85017	O
from	85018	85022	O
the	85023	85026	O
original	85027	85035	O
mutations	85036	85045	O
in	85046	85048	O
this	85049	85053	O
permuted	85054	85062	O
set	85063	85066	O
.	85066	85067	O

dN	85068	85070	O
/	85070	85071	O
dS	85071	85073	O
analysis	85074	85082	O
To	85083	85085	O
calculate	85086	85095	O
dN	85096	85098	O
/	85098	85099	O
dS	85099	85101	O
ratios	85102	85108	O
,	85108	85109	O
we	85110	85112	O
applied	85113	85120	O
a	85121	85122	O
previously	85123	85133	O
described	85134	85143	O
method	85144	85150	O
[	85151	85152	O
36	85152	85154	O
]	85154	85155	O
that	85156	85160	O
uses	85161	85165	O
a	85166	85167	O
Poisson	85168	85175	O
distribution	85176	85188	O
to	85189	85191	O
model	85192	85197	O
the	85198	85201	O
number	85202	85208	O
of	85209	85211	O
mutations	85212	85221	O
with	85222	85226	O
different	85227	85236	O
impacts	85237	85244	O
(	85245	85246	O
i	85246	85247	O
.	85247	85248	O
e	85248	85249	O
.	85249	85250	O
,	85250	85251	O
synonymous	85252	85262	O
vs	85263	85265	O
non	85266	85269	O
-	85269	85270	O
synonymous	85270	85280	O
)	85280	85281	O
.	85281	85282	O

Briefly	85283	85290	O
,	85290	85291	O
the	85292	85295	O
Poisson	85296	85303	O
distribution	85304	85316	O
is	85317	85319	O
based	85320	85325	O
on	85326	85328	O
the	85329	85332	O
relative	85333	85341	O
content	85342	85349	O
of	85350	85352	O
a	85353	85354	O
mutation	85355	85363	O
type	85364	85368	O
(	85369	85370	O
e	85370	85371	O
.	85371	85372	O
g	85372	85373	O
.	85373	85374	O
,	85374	85375	O
C	85376	85377	O
>	85377	85378	O
T	85378	85379	O
)	85379	85380	O
across	85381	85387	O
all	85388	85391	O
types	85392	85397	O
,	85397	85398	O
the	85399	85402	O
total	85403	85408	O
content	85409	85416	O
of	85417	85419	O
that	85420	85424	O
mutation	85425	85433	O
type	85434	85438	O
,	85438	85439	O
and	85440	85443	O
the	85444	85447	O
density	85448	85455	O
of	85456	85458	O
mutations	85459	85468	O
per	85469	85472	O
site	85473	85477	O
.	85477	85478	O

For	85479	85482	O
non	85483	85486	O
-	85486	85487	O
synonymous	85487	85497	O
mutations	85498	85507	O
,	85507	85508	O
an	85509	85511	O
extra	85512	85517	O
parameter	85518	85527	O
represents	85528	85538	O
the	85539	85542	O
effect	85543	85549	O
of	85550	85552	O
selection	85553	85562	O
(	85563	85564	O
dN	85564	85566	O
/	85566	85567	O
dS	85567	85569	O
)	85569	85570	O
,	85570	85571	O
and	85572	85575	O
maximum	85576	85583	O
-	85583	85584	O
likelihood	85584	85594	O
estimates	85595	85604	O
are	85605	85608	O
calculated	85609	85619	O
by	85620	85622	O
Poisson	85623	85630	O
regression	85631	85641	O
for	85642	85645	O
all	85646	85649	O
parameters	85650	85660	O
.	85660	85661	O

This	85662	85666	O
framework	85667	85676	O
accounts	85677	85685	O
for	85686	85689	O
different	85690	85699	O
substitution	85700	85712	O
rates	85713	85718	O
across	85719	85725	O
different	85726	85735	O
genes	85736	85741	O
as	85742	85744	O
well	85745	85749	O
as	85750	85752	O
sequence	85753	85761	O
composition	85762	85773	O
.	85773	85774	O

We	85775	85777	O
used	85778	85782	O
dndsloc	85783	85790	O
,	85790	85791	O
which	85792	85797	O
is	85798	85800	O
the	85801	85804	O
implementation	85805	85819	O
of	85820	85822	O
this	85823	85827	O
method	85828	85834	O
in	85835	85837	O
R	85838	85839	O
[	85840	85841	O
9	85841	85842	O
]	85842	85843	O
(	85844	85845	O
https	85845	85850	O
:	85850	85851	O
/	85851	85852	O
/	85852	85853	O
github	85853	85859	O
.	85859	85860	O
com	85860	85863	O
/	85863	85864	O
im3sanger	85864	85873	O
/	85873	85874	O
dndscv	85874	85880	O
)	85880	85881	O
.	85881	85882	O

Mutation	85883	85891	O
analyses	85892	85900	O
on	85901	85903	O
cancer	85904	85910	O
driver	85911	85917	O
genes	85918	85923	O
We	85924	85926	O
downloaded	85927	85937	O
the	85938	85941	O
list	85942	85946	O
of	85947	85949	O
genes	85950	85955	O
known	85956	85961	O
to	85962	85964	O
contain	85965	85972	O
at	85973	85975	O
least	85976	85981	O
one	85982	85985	O
cancer	85986	85992	O
driver	85993	85999	O
mutation	86000	86008	O
,	86008	86009	O
based	86010	86015	O
on	86016	86018	O
the	86019	86022	O
latest	86023	86029	O
TCGA	86030	86034	O
publication	86035	86046	O
on	86047	86049	O
cancer	86050	86056	O
driver	86057	86063	O
genes	86064	86069	O
[	86070	86071	O
2	86071	86072	O
]	86072	86073	O
(	86074	86075	O
Additional	86075	86085	O
file	86086	86090	O
13	86091	86093	O
:	86093	86094	O
Table	86095	86100	O
S10	86101	86104	O
)	86104	86105	O
.	86105	86106	O

Since	86107	86112	O
we	86113	86115	O
did	86116	86119	O
more	86120	86124	O
in	86125	86127	O
depth	86128	86133	O
analysis	86134	86142	O
in	86143	86145	O
this	86146	86150	O
set	86151	86154	O
of	86155	86157	O
genes	86158	86163	O
,	86163	86164	O
we	86165	86167	O
further	86168	86175	O
removed	86176	86183	O
potential	86184	86193	O
false	86194	86199	O
-	86199	86200	O
positive	86200	86208	O
mutation	86209	86217	O
calls	86218	86223	O
that	86224	86228	O
could	86229	86234	O
bias	86235	86239	O
gene	86240	86244	O
-	86244	86245	O
level	86245	86250	O
analysis	86251	86259	O
but	86260	86263	O
are	86264	86267	O
not	86268	86271	O
necessarily	86272	86283	O
an	86284	86286	O
issue	86287	86292	O
for	86293	86296	O
genome	86297	86303	O
-	86303	86304	O
wide	86304	86308	O
analysis	86309	86317	O
.	86317	86318	O

For	86319	86322	O
some	86323	86327	O
of	86328	86330	O
these	86331	86336	O
genes	86337	86342	O
,	86342	86343	O
we	86344	86346	O
observed	86347	86355	O
a	86356	86357	O
high	86358	86362	O
number	86363	86369	O
of	86370	86372	O
total	86373	86378	O
mutations	86379	86388	O
but	86389	86392	O
low	86393	86396	O
number	86397	86403	O
of	86404	86406	O
unique	86407	86413	O
mutations	86414	86423	O
;	86423	86424	O
in	86425	86427	O
other	86428	86433	O
words	86434	86439	O
,	86439	86440	O
some	86441	86445	O
mutations	86446	86455	O
accounted	86456	86465	O
for	86466	86469	O
most	86470	86474	O
of	86475	86477	O
the	86478	86481	O
unique	86482	86488	O
mutated	86489	86496	O
sites	86497	86502	O
,	86502	86503	O
which	86504	86509	O
may	86510	86513	O
be	86514	86516	O
artifactual	86517	86528	O
[	86529	86530	O
9	86530	86531	O
]	86531	86532	O
.	86532	86533	O

To	86534	86536	O
flag	86537	86541	O
these	86542	86547	O
events	86548	86554	O
,	86554	86555	O
for	86556	86559	O
each	86560	86564	O
mutation	86565	86573	O
,	86573	86574	O
we	86575	86577	O
calculated	86578	86588	O
a	86589	86590	O
metric	86591	86597	O
t	86598	86599	O
as	86600	86602	O
the	86603	86606	O
ratio	86607	86612	O
of	86613	86615	O
the	86616	86619	O
counts	86620	86626	O
of	86627	86629	O
that	86630	86634	O
mutation	86635	86643	O
divided	86644	86651	O
by	86652	86654	O
the	86655	86658	O
unique	86659	86665	O
number	86666	86672	O
of	86673	86675	O
mutations	86676	86685	O
found	86686	86691	O
in	86692	86694	O
the	86695	86698	O
gene	86699	86703	O
-	86703	86704	O
of	86704	86706	O
-	86706	86707	O
origin	86707	86713	O
.	86713	86714	O

Mutations	86715	86724	O
with	86725	86729	O
high	86730	86734	O
t	86735	86736	O
values	86737	86743	O
account	86744	86751	O
for	86752	86755	O
most	86756	86760	O
of	86761	86763	O
the	86764	86767	O
unique	86768	86774	O
mutated	86775	86782	O
sites	86783	86788	O
in	86789	86791	O
their	86792	86797	O
gene	86798	86802	O
-	86802	86803	O
of	86803	86805	O
-	86805	86806	O
origin	86806	86812	O
,	86812	86813	O
leading	86814	86821	O
to	86822	86824	O
a	86825	86826	O
low	86827	86830	O
diversity	86831	86840	O
in	86841	86843	O
mutations	86844	86853	O
of	86854	86856	O
a	86857	86858	O
given	86859	86864	O
gene	86865	86869	O
.	86869	86870	O

These	86871	86876	O
mutations	86877	86886	O
may	86887	86890	O
be	86891	86893	O
artifacts	86894	86903	O
and	86904	86907	O
can	86908	86911	O
bias	86912	86916	O
dN	86917	86919	O
/	86919	86920	O
dS	86920	86922	O
ratios	86923	86929	O
[	86930	86931	O
9	86931	86932	O
]	86932	86933	O
.	86933	86934	O

The	86935	86938	O
distribution	86939	86951	O
of	86952	86954	O
t	86955	86956	O
values	86957	86963	O
for	86964	86967	O
mutations	86968	86977	O
in	86978	86980	O
this	86981	86985	O
set	86986	86989	O
of	86990	86992	O
genes	86993	86998	O
was	86999	87002	O
bimodal	87003	87010	O
(	87011	87012	O
Additional	87012	87022	O
file	87023	87027	O
9	87028	87029	O
:	87029	87030	O
Note	87031	87035	O
S11b	87036	87040	O
)	87040	87041	O
,	87041	87042	O
and	87043	87046	O
we	87047	87049	O
therefore	87050	87059	O
excluded	87060	87068	O
mutations	87069	87078	O
with	87079	87083	O
r	87084	87085	O
>	87086	87087	O
3	87088	87089	O
.	87089	87090	O
5	87090	87091	O
.	87091	87092	O

To	87093	87095	O
assess	87096	87102	O
the	87103	87106	O
mutation	87107	87115	O
load	87116	87120	O
on	87121	87123	O
these	87124	87129	O
genes	87130	87135	O
and	87136	87139	O
their	87140	87145	O
significance	87146	87158	O
,	87158	87159	O
for	87160	87163	O
each	87164	87168	O
tissue	87169	87175	O
,	87175	87176	O
we	87177	87179	O
calculated	87180	87190	O
the	87191	87194	O
mutation	87195	87203	O
rate	87204	87208	O
of	87209	87211	O
these	87212	87217	O
genes	87218	87223	O
and	87224	87227	O
then	87228	87232	O
calculated	87233	87243	O
whether	87244	87251	O
this	87252	87256	O
mutation	87257	87265	O
rate	87266	87270	O
was	87271	87274	O
higher	87275	87281	O
or	87282	87284	O
lower	87285	87290	O
than	87291	87295	O
expected	87296	87304	O
from	87305	87309	O
the	87310	87313	O
overall	87314	87321	O
mutation	87322	87330	O
rate	87331	87335	O
of	87336	87338	O
these	87339	87344	O
genes	87345	87350	O
across	87351	87357	O
all	87358	87361	O
tissues	87362	87369	O
(	87370	87371	O
Fig	87371	87374	O
.	87374	87375	O

5b	87376	87378	O
)	87378	87379	O
.	87379	87380	O

To	87381	87383	O
do	87384	87386	O
so	87387	87389	O
,	87389	87390	O
we	87391	87393	O
calculated	87394	87404	O
the	87405	87408	O
overall	87409	87416	O
mutation	87417	87425	O
rate	87426	87430	O
in	87431	87433	O
cancer	87434	87440	O
driver	87441	87447	O
genes	87448	87453	O
across	87454	87460	O
all	87461	87464	O
tissues	87465	87472	O
(	87473	87474	O
k	87474	87475	O
)	87475	87476	O
and	87477	87480	O
then	87481	87485	O
for	87486	87489	O
each	87490	87494	O
tissue	87495	87501	O
we	87502	87504	O
calculated	87505	87515	O
the	87516	87519	O
probability	87520	87531	O
of	87532	87534	O
the	87535	87538	O
number	87539	87545	O
of	87546	87548	O
observed	87549	87557	O
mutations	87558	87567	O
(	87568	87569	O
n	87569	87570	O
)	87570	87571	O
in	87572	87574	O
these	87575	87580	O
genes	87581	87586	O
using	87587	87592	O
the	87593	87596	O
binomial	87597	87605	O
distribution	87606	87618	O
[	87619	87620	O
X	87620	87621	O
~	87622	87623	O
binom	87624	87629	O
(	87629	87630	O
n	87630	87631	O
,	87631	87632	O
k	87632	87633	O
)	87633	87634	O
]	87634	87635	O
.	87635	87636	O

For	87637	87640	O
tissues	87641	87648	O
showing	87649	87656	O
more	87657	87661	O
mutations	87662	87671	O
than	87672	87676	O
expected	87677	87685	O
,	87685	87686	O
we	87687	87689	O
used	87690	87694	O
the	87695	87698	O
integral	87699	87707	O
of	87708	87710	O
the	87711	87714	O
right	87715	87720	O
tail	87721	87725	O
of	87726	87728	O
the	87729	87732	O
binomial	87733	87741	O
distribution	87742	87754	O
to	87755	87757	O
calculate	87758	87767	O
the	87768	87771	O
probability	87772	87783	O
of	87784	87786	O
observing	87787	87796	O
n	87797	87798	O
mutations	87799	87808	O
,	87808	87809	O
and	87810	87813	O
conversely	87814	87824	O
,	87824	87825	O
for	87826	87829	O
tissues	87830	87837	O
showing	87838	87845	O
fewer	87846	87851	O
mutations	87852	87861	O
,	87861	87862	O
we	87863	87865	O
used	87866	87870	O
the	87871	87874	O
integral	87875	87883	O
of	87884	87886	O
the	87887	87890	O
left	87891	87895	O
tail	87896	87900	O
of	87901	87903	O
the	87904	87907	O
distribution	87908	87920	O
.	87920	87921	O

FDR	87922	87925	O
was	87926	87929	O
calculated	87930	87940	O
using	87941	87946	O
Benjamini	87947	87956	O
-	87956	87957	O
Hochberg	87957	87965	O
method	87966	87972	O
on	87973	87975	O
the	87976	87979	O
p	87980	87981	O
values	87982	87988	O
.	87988	87989	O

We	87990	87992	O
annotated	87993	88002	O
the	88003	88006	O
oncogenic	88007	88016	O
status	88017	88023	O
for	88024	88027	O
the	88028	88031	O
mutations	88032	88041	O
in	88042	88044	O
these	88045	88050	O
driver	88051	88057	O
genes	88058	88063	O
using	88064	88069	O
the	88070	88073	O
oncokb	88074	88080	O
[	88081	88082	O
37	88082	88084	O
]	88084	88085	O
tool	88086	88090	O
MafAnnotator	88091	88103	O
.	88103	88104	O
py	88104	88106	O
.	88106	88107	O

Supplementary	88109	88122	O
information	88123	88134	O
Additional	88135	88145	O
file	88146	88150	O
1	88151	88152	O
:	88152	88153	O
Figure	88154	88160	O
S1	88161	88163	O
.	88163	88164	O

Statistics	88165	88175	O
associated	88176	88186	O
to	88187	88189	O
a	88190	88191	O
method	88192	88198	O
for	88199	88202	O
calling	88203	88210	O
DNA	88211	88214	O
mutations	88215	88224	O
from	88225	88229	O
RNA	88230	88233	O
-	88233	88234	O
seq	88234	88237	O
data	88238	88242	O
.	88242	88243	O

Figure	88244	88250	O
S2	88251	88253	O
.	88253	88254	O

Calling	88255	88262	O
of	88263	88265	O
somatic	88266	88273	O
DNA	88274	88277	O
-	88277	88278	O
mutations	88278	88287	O
in	88288	88290	O
the	88291	88294	O
GTEx	88295	88299	O
cohort	88300	88306	O
.	88306	88307	O

Figure	88308	88314	O
S3	88315	88317	O
.	88317	88318	O

Mutation	88319	88327	O
load	88328	88332	O
across	88333	88339	O
different	88340	88349	O
mutation	88350	88358	O
types	88359	88364	O
in	88365	88367	O
non	88368	88371	O
-	88371	88372	O
disease	88372	88379	O
human	88380	88385	O
tissues	88386	88393	O
.	88393	88394	O

Figure	88395	88401	O
S4	88402	88404	O
.	88404	88405	O

Phenotypic	88406	88416	O
associations	88417	88429	O
and	88430	88433	O
properties	88434	88444	O
of	88445	88447	O
mutation	88448	88456	O
load	88457	88461	O
in	88462	88464	O
the	88465	88468	O
human	88469	88474	O
body	88475	88479	O
.	88479	88480	O

Figure	88481	88487	O
S5	88488	88490	O
.	88490	88491	O

Number	88492	88498	O
of	88499	88501	O
stem	88502	88506	B-CL:0000034
cell	88507	88511	E-CL:0000034
divisions	88512	88521	O
correlates	88522	88532	O
weakly	88533	88539	O
with	88540	88544	O
mutation	88545	88553	O
load	88554	88558	O
in	88559	88561	O
human	88562	88567	O
tissues	88568	88575	O
.	88575	88576	O

Figure	88577	88583	O
S6	88584	88586	O
.	88586	88587	O

Mutation	88588	88596	O
profiles	88597	88605	O
cluster	88606	88613	O
by	88614	88616	O
tissue	88617	88623	O
.	88623	88624	O

Figure	88625	88631	O
S7	88632	88634	O
.	88634	88635	O

Inter	88636	88641	O
-	88641	88642	O
tissue	88642	88648	O
mutational	88649	88659	O
strand	88660	88666	O
asymmetry	88667	88676	O
correlations	88677	88689	O
and	88690	88693	O
cell	88694	88698	O
type	88699	88703	O
associations	88704	88716	O
.	88716	88717	O

Figure	88718	88724	O
S8	88725	88727	O
.	88727	88728	O

Gene	88729	88733	O
expression	88734	88744	O
associations	88745	88757	O
with	88758	88762	O
C	88763	88764	O
>	88764	88765	O
T	88765	88766	O
mutation	88767	88775	O
load	88776	88780	O
.	88780	88781	O

Figure	88782	88788	O
S9	88789	88791	O
.	88791	88792	O

Gene	88793	88797	O
expression	88798	88808	O
associations	88809	88821	O
with	88822	88826	O
overall	88827	88834	O
mutation	88835	88843	O
load	88844	88848	O
.	88848	88849	O

Figure	88850	88856	O
S10	88857	88860	O
.	88860	88861	O

Mutation	88862	88870	O
load	88871	88875	O
associations	88876	88888	O
with	88889	88893	O
expression	88894	88904	O
of	88905	88907	O
genes	88908	88913	O
involved	88914	88922	O
in	88923	88925	O
DNA	88926	88929	O
repair	88930	88936	O
or	88937	88939	O
DNA	88940	88943	O
mutagenesis	88944	88955	O
.	88955	88956	O

Figure	88957	88963	O
S11	88964	88967	O
.	88967	88968	O

Negative	88969	88977	O
controls	88978	88986	O
and	88987	88990	O
filters	88991	88998	O
for	88999	89002	O
cancer	89003	89009	O
mutation	89010	89018	O
enrichment	89019	89029	O
in	89030	89032	O
non	89033	89036	O
-	89036	89037	O
disease	89037	89044	O
human	89045	89050	O
tissues	89051	89058	O
.	89058	89059	O

Figure	89060	89066	O
S12	89067	89070	O
.	89070	89071	O

Comparison	89072	89082	O
of	89083	89085	O
mutation	89086	89094	O
calls	89095	89100	O
to	89101	89103	O
those	89104	89109	O
from	89110	89114	O
Yizhak	89115	89121	O
et	89122	89124	O
al	89125	89127	O
.	89127	89128	O

Additional	89129	89139	O
file	89140	89144	O
2	89145	89146	O
:	89146	89147	O
Legends	89148	89155	O
for	89156	89159	O
Tables	89160	89166	O
S1	89167	89169	O
–	89169	89170	O
S13	89170	89173	O
.	89173	89174	O

(	89175	89176	O
PDF	89176	89179	O
40	89180	89182	O
kb	89183	89185	O
)	89185	89186	O
Additional	89187	89197	O
file	89198	89202	O
3	89203	89204	O
:	89204	89205	O
Table	89206	89211	O
S1	89212	89214	O
.	89214	89215	O

Average	89216	89223	O
percentage	89224	89234	O
elimination	89235	89246	O
of	89247	89249	O
putative	89250	89258	O
mutation	89259	89267	O
calls	89268	89273	O
by	89274	89276	O
per	89277	89280	O
-	89280	89281	O
sample	89281	89287	O
false	89288	89293	O
-	89293	89294	O
positive	89294	89302	O
filters	89303	89310	O
across	89311	89317	O
all	89318	89321	O
tissues	89322	89329	O
.	89329	89330	O

(	89331	89332	O
TSV	89332	89335	O
5	89336	89337	O
kb	89338	89340	O
)	89340	89341	O
Additional	89342	89352	O
file	89353	89357	O
4	89358	89359	O
:	89359	89360	O
Table	89361	89366	O
S2	89367	89369	O
.	89369	89370	O

Total	89371	89376	O
number	89377	89383	O
of	89384	89386	O
samples	89387	89394	O
per	89395	89398	O
tissue	89399	89405	O
included	89406	89414	O
for	89415	89418	O
the	89419	89422	O
final	89423	89428	O
set	89429	89432	O
of	89433	89435	O
mutation	89436	89444	O
calls	89445	89450	O
.	89450	89451	O

(	89452	89453	O
TSV	89453	89456	O
784	89457	89460	O
bytes	89461	89466	O
)	89466	89467	O
Additional	89468	89478	O
file	89479	89483	O
5	89484	89485	O
:	89486	89487	O
Table	89488	89493	O
S3	89494	89496	O
.	89496	89497	O

List	89498	89502	O
of	89503	89505	O
all	89506	89509	O
somatic	89510	89517	O
mutations	89518	89527	O
identified	89528	89538	O
in	89539	89541	O
this	89542	89546	O
study	89547	89552	O
.	89552	89553	O

(	89554	89555	O
TSV	89555	89558	O
,	89558	89559	O
187	89560	89563	O
MB	89564	89566	O
)	89566	89567	O
.	89567	89568	O

(	89569	89570	O
TSV	89570	89573	O
182623	89574	89580	O
kb	89581	89583	O
)	89583	89584	O
Additional	89585	89595	O
file	89596	89600	O
6	89601	89602	O
:	89602	89603	O
Table	89604	89609	O
S4	89610	89612	O
.	89612	89613	O

P	89614	89615	O
-	89615	89616	O
values	89616	89622	O
(	89623	89624	O
−	89624	89625	O
log10	89625	89630	O
[	89630	89631	O
p	89631	89632	O
-	89632	89633	O
value	89633	89638	O
]	89638	89639	O
)	89639	89640	O
for	89641	89644	O
the	89645	89648	O
coefficients	89649	89661	O
of	89662	89664	O
each	89665	89669	O
feature	89670	89677	O
used	89678	89682	O
in	89683	89685	O
a	89686	89687	O
linear	89688	89694	O
regression	89695	89705	O
on	89706	89708	O
the	89709	89712	O
total	89713	89718	O
number	89719	89725	O
of	89726	89728	O
mutations	89729	89738	O
per	89739	89742	O
tissue	89743	89749	O
.	89749	89750	O

(	89751	89752	O
TSV	89752	89755	O
6	89756	89757	O
kb	89758	89760	O
)	89760	89761	O
Additional	89762	89772	O
file	89773	89777	O
7	89778	89779	O
:	89779	89780	O
Table	89781	89786	O
S5	89787	89789	O
.	89789	89790	O

Average	89791	89798	O
percentage	89799	89809	O
of	89810	89812	O
each	89813	89817	O
mutation	89818	89826	O
type	89827	89831	O
across	89832	89838	O
samples	89839	89846	O
of	89847	89849	O
the	89850	89853	O
given	89854	89859	O
tissue	89860	89866	O
.	89866	89867	O

(	89868	89869	O
TSV	89869	89872	O
3	89873	89874	O
kb	89875	89877	O
)	89877	89878	O
Additional	89879	89889	O
file	89890	89894	O
8	89895	89896	O
:	89896	89897	O
Table	89898	89903	O
S6	89904	89906	O
.	89906	89907	O

Significant	89908	89919	O
associations	89920	89932	O
between	89933	89940	O
biological	89941	89951	O
sex	89952	89955	O
and	89956	89959	O
mutation	89960	89968	O
load	89969	89973	O
across	89974	89980	O
tissues	89981	89988	O
and	89989	89992	O
mutation	89993	90001	O
types	90002	90007	O
.	90007	90008	O

(	90009	90010	O
TSV	90010	90013	O
854	90014	90017	O
bytes	90018	90023	O
)	90023	90024	O
Additional	90025	90035	O
file	90036	90040	O
9	90041	90042	O
:	90042	90043	O
Notes	90044	90049	O
S1	90050	90052	O
–	90052	90053	O
S3	90053	90055	O
.	90055	90056	O

Additional	90057	90067	O
file	90068	90072	O
10	90073	90075	O
:	90075	90076	O
Table	90077	90082	O
S7	90083	90085	O
.	90085	90086	O

Tissue	90087	90093	O
correspondence	90094	90108	O
between	90109	90116	O
the	90117	90120	O
GTEx	90121	90125	O
[	90126	90127	O
46	90127	90129	O
]	90129	90130	O
and	90131	90134	O
Roadmap	90135	90142	O
Epigenomics	90143	90154	O
projects	90155	90163	O
[	90164	90165	O
27	90165	90167	O
]	90167	90168	O
.	90168	90169	O

(	90170	90171	O
TSV	90171	90174	O
1	90175	90176	O
kb	90177	90179	O
)	90179	90180	O
Additional	90181	90191	O
file	90192	90196	O
11	90197	90199	O
:	90199	90200	O
Table	90201	90206	O
S8	90207	90209	O
Significant	90210	90221	O
GO	90222	90224	O
enrichments	90225	90236	O
for	90237	90240	O
genes	90241	90246	O
whose	90247	90252	O
expression	90253	90263	O
is	90264	90266	O
significantly	90267	90280	O
and	90281	90284	O
negatively	90285	90295	O
associated	90296	90306	O
with	90307	90311	O
C	90312	90313	O
>	90314	90315	O
T	90316	90317	O
mutation	90318	90326	O
load	90327	90331	O
across	90332	90338	O
several	90339	90346	O
tissues	90347	90354	O
.	90354	90355	O

(	90356	90357	O
TSV	90357	90360	O
2	90361	90362	O
kb	90363	90365	O
)	90365	90366	O
Additional	90367	90377	O
file	90378	90382	O
12	90383	90385	O
:	90385	90386	O
Table	90387	90392	O
S9	90393	90395	O
.	90395	90396	O

Significant	90397	90408	O
GO	90409	90411	O
enrichments	90412	90423	O
for	90424	90427	O
genes	90428	90433	O
whose	90434	90439	O
expression	90440	90450	O
is	90451	90453	O
significantly	90454	90467	O
and	90468	90471	O
positively	90472	90482	O
associated	90483	90493	O
with	90494	90498	O
C	90499	90500	O
>	90501	90502	O
T	90503	90504	O
mutation	90505	90513	O
load	90514	90518	O
across	90519	90525	O
several	90526	90533	O
tissues	90534	90541	O
.	90541	90542	O

(	90543	90544	O
TSV	90544	90547	O
1	90548	90549	O
kb	90550	90552	O
)	90552	90553	O
Additional	90554	90564	O
file	90565	90569	O
13	90570	90572	O
:	90572	90573	O
Table	90574	90579	O
S10	90580	90583	O
.	90583	90584	O

List	90585	90589	O
of	90590	90592	O
cancer	90593	90599	O
driver	90600	90606	O
genes	90607	90612	O
used	90613	90617	O
in	90618	90620	O
this	90621	90625	O
study	90626	90631	O
[	90632	90633	O
2	90633	90634	O
]	90634	90635	O
.	90635	90636	O

(	90637	90638	O
TSV	90638	90641	O
312	90642	90645	O
bytes	90646	90651	O
)	90651	90652	O
Additional	90653	90663	O
file	90664	90668	O
14	90669	90671	O
:	90671	90672	O
Table	90673	90678	O
S11	90679	90682	O
.	90682	90683	O

List	90684	90688	O
of	90689	90691	O
mutations	90692	90701	O
in	90702	90704	O
cancer	90705	90711	O
driver	90712	90718	O
genes	90719	90724	O
after	90725	90730	O
further	90731	90738	O
elimination	90739	90750	O
of	90751	90753	O
potential	90754	90763	O
false	90764	90769	O
positives	90770	90779	O
.	90779	90780	O

(	90781	90782	O
TSV	90782	90785	O
97	90786	90788	O
kb	90789	90791	O
)	90791	90792	O
Additional	90793	90803	O
file	90804	90808	O
15	90809	90811	O
:	90811	90812	O
Table	90813	90818	O
S12	90819	90822	O
.	90822	90823	O

List	90824	90828	O
of	90829	90831	O
mutations	90832	90841	O
in	90842	90844	O
cancer	90845	90851	O
driver	90852	90858	O
genes	90859	90864	O
annotated	90865	90874	O
in	90875	90877	O
Oncokb	90878	90884	O
[	90885	90886	O
37	90886	90888	O
]	90888	90889	O
.	90889	90890	O

(	90891	90892	O
TSV	90892	90895	O
4	90896	90897	O
kb	90898	90900	O
)	90900	90901	O
Additional	90902	90912	O
file	90913	90917	O
16	90918	90920	O
.	90920	90921	O

Review	90922	90928	O
history	90929	90936	O
Additional	90937	90947	O
file	90948	90952	O
1	90953	90954	O
:	90954	90955	O
Figure	90956	90962	O
S1	90963	90965	O
.	90965	90966	O

Statistics	90967	90977	O
associated	90978	90988	O
to	90989	90991	O
a	90992	90993	O
method	90994	91000	O
for	91001	91004	O
calling	91005	91012	O
DNA	91013	91016	O
mutations	91017	91026	O
from	91027	91031	O
RNA	91032	91035	O
-	91035	91036	O
seq	91036	91039	O
data	91040	91044	O
.	91044	91045	O

Figure	91046	91052	O
S2	91053	91055	O
.	91055	91056	O

Calling	91057	91064	O
of	91065	91067	O
somatic	91068	91075	O
DNA	91076	91079	O
-	91079	91080	O
mutations	91080	91089	O
in	91090	91092	O
the	91093	91096	O
GTEx	91097	91101	O
cohort	91102	91108	O
.	91108	91109	O

Figure	91110	91116	O
S3	91117	91119	O
.	91119	91120	O

Mutation	91121	91129	O
load	91130	91134	O
across	91135	91141	O
different	91142	91151	O
mutation	91152	91160	O
types	91161	91166	O
in	91167	91169	O
non	91170	91173	O
-	91173	91174	O
disease	91174	91181	O
human	91182	91187	O
tissues	91188	91195	O
.	91195	91196	O

Figure	91197	91203	O
S4	91204	91206	O
.	91206	91207	O

Phenotypic	91208	91218	O
associations	91219	91231	O
and	91232	91235	O
properties	91236	91246	O
of	91247	91249	O
mutation	91250	91258	O
load	91259	91263	O
in	91264	91266	O
the	91267	91270	O
human	91271	91276	O
body	91277	91281	O
.	91281	91282	O

Figure	91283	91289	O
S5	91290	91292	O
.	91292	91293	O

Number	91294	91300	O
of	91301	91303	O
stem	91304	91308	B-CL:0000034
cell	91309	91313	E-CL:0000034
divisions	91314	91323	O
correlates	91324	91334	O
weakly	91335	91341	O
with	91342	91346	O
mutation	91347	91355	O
load	91356	91360	O
in	91361	91363	O
human	91364	91369	O
tissues	91370	91377	O
.	91377	91378	O

Figure	91379	91385	O
S6	91386	91388	O
.	91388	91389	O

Mutation	91390	91398	O
profiles	91399	91407	O
cluster	91408	91415	O
by	91416	91418	O
tissue	91419	91425	O
.	91425	91426	O

Figure	91427	91433	O
S7	91434	91436	O
.	91436	91437	O

Inter	91438	91443	O
-	91443	91444	O
tissue	91444	91450	O
mutational	91451	91461	O
strand	91462	91468	O
asymmetry	91469	91478	O
correlations	91479	91491	O
and	91492	91495	O
cell	91496	91500	O
type	91501	91505	O
associations	91506	91518	O
.	91518	91519	O

Figure	91520	91526	O
S8	91527	91529	O
.	91529	91530	O

Gene	91531	91535	O
expression	91536	91546	O
associations	91547	91559	O
with	91560	91564	O
C	91565	91566	O
>	91566	91567	O
T	91567	91568	O
mutation	91569	91577	O
load	91578	91582	O
.	91582	91583	O

Figure	91584	91590	O
S9	91591	91593	O
.	91593	91594	O

Gene	91595	91599	O
expression	91600	91610	O
associations	91611	91623	O
with	91624	91628	O
overall	91629	91636	O
mutation	91637	91645	O
load	91646	91650	O
.	91650	91651	O

Figure	91652	91658	O
S10	91659	91662	O
.	91662	91663	O

Mutation	91664	91672	O
load	91673	91677	O
associations	91678	91690	O
with	91691	91695	O
expression	91696	91706	O
of	91707	91709	O
genes	91710	91715	O
involved	91716	91724	O
in	91725	91727	O
DNA	91728	91731	O
repair	91732	91738	O
or	91739	91741	O
DNA	91742	91745	O
mutagenesis	91746	91757	O
.	91757	91758	O

Figure	91759	91765	O
S11	91766	91769	O
.	91769	91770	O

Negative	91771	91779	O
controls	91780	91788	O
and	91789	91792	O
filters	91793	91800	O
for	91801	91804	O
cancer	91805	91811	O
mutation	91812	91820	O
enrichment	91821	91831	O
in	91832	91834	O
non	91835	91838	O
-	91838	91839	O
disease	91839	91846	O
human	91847	91852	O
tissues	91853	91860	O
.	91860	91861	O

Figure	91862	91868	O
S12	91869	91872	O
.	91872	91873	O

Comparison	91874	91884	O
of	91885	91887	O
mutation	91888	91896	O
calls	91897	91902	O
to	91903	91905	O
those	91906	91911	O
from	91912	91916	O
Yizhak	91917	91923	O
et	91924	91926	O
al	91927	91929	O
.	91929	91930	O

Additional	91931	91941	O
file	91942	91946	O
2	91947	91948	O
:	91948	91949	O
Legends	91950	91957	O
for	91958	91961	O
Tables	91962	91968	O
S1	91969	91971	O
–	91971	91972	O
S13	91972	91975	O
.	91975	91976	O

(	91977	91978	O
PDF	91978	91981	O
40	91982	91984	O
kb	91985	91987	O
)	91987	91988	O
Additional	91989	91999	O
file	92000	92004	O
3	92005	92006	O
:	92006	92007	O
Table	92008	92013	O
S1	92014	92016	O
.	92016	92017	O

Average	92018	92025	O
percentage	92026	92036	O
elimination	92037	92048	O
of	92049	92051	O
putative	92052	92060	O
mutation	92061	92069	O
calls	92070	92075	O
by	92076	92078	O
per	92079	92082	O
-	92082	92083	O
sample	92083	92089	O
false	92090	92095	O
-	92095	92096	O
positive	92096	92104	O
filters	92105	92112	O
across	92113	92119	O
all	92120	92123	O
tissues	92124	92131	O
.	92131	92132	O

(	92133	92134	O
TSV	92134	92137	O
5	92138	92139	O
kb	92140	92142	O
)	92142	92143	O
Additional	92144	92154	O
file	92155	92159	O
4	92160	92161	O
:	92161	92162	O
Table	92163	92168	O
S2	92169	92171	O
.	92171	92172	O

Total	92173	92178	O
number	92179	92185	O
of	92186	92188	O
samples	92189	92196	O
per	92197	92200	O
tissue	92201	92207	O
included	92208	92216	O
for	92217	92220	O
the	92221	92224	O
final	92225	92230	O
set	92231	92234	O
of	92235	92237	O
mutation	92238	92246	O
calls	92247	92252	O
.	92252	92253	O

(	92254	92255	O
TSV	92255	92258	O
784	92259	92262	O
bytes	92263	92268	O
)	92268	92269	O
Additional	92270	92280	O
file	92281	92285	O
5	92286	92287	O
:	92288	92289	O
Table	92290	92295	O
S3	92296	92298	O
.	92298	92299	O

List	92300	92304	O
of	92305	92307	O
all	92308	92311	O
somatic	92312	92319	O
mutations	92320	92329	O
identified	92330	92340	O
in	92341	92343	O
this	92344	92348	O
study	92349	92354	O
.	92354	92355	O

(	92356	92357	O
TSV	92357	92360	O
,	92360	92361	O
187	92362	92365	O
MB	92366	92368	O
)	92368	92369	O
.	92369	92370	O

(	92371	92372	O
TSV	92372	92375	O
182623	92376	92382	O
kb	92383	92385	O
)	92385	92386	O
Additional	92387	92397	O
file	92398	92402	O
6	92403	92404	O
:	92404	92405	O
Table	92406	92411	O
S4	92412	92414	O
.	92414	92415	O

P	92416	92417	O
-	92417	92418	O
values	92418	92424	O
(	92425	92426	O
−	92426	92427	O
log10	92427	92432	O
[	92432	92433	O
p	92433	92434	O
-	92434	92435	O
value	92435	92440	O
]	92440	92441	O
)	92441	92442	O
for	92443	92446	O
the	92447	92450	O
coefficients	92451	92463	O
of	92464	92466	O
each	92467	92471	O
feature	92472	92479	O
used	92480	92484	O
in	92485	92487	O
a	92488	92489	O
linear	92490	92496	O
regression	92497	92507	O
on	92508	92510	O
the	92511	92514	O
total	92515	92520	O
number	92521	92527	O
of	92528	92530	O
mutations	92531	92540	O
per	92541	92544	O
tissue	92545	92551	O
.	92551	92552	O

(	92553	92554	O
TSV	92554	92557	O
6	92558	92559	O
kb	92560	92562	O
)	92562	92563	O
Additional	92564	92574	O
file	92575	92579	O
7	92580	92581	O
:	92581	92582	O
Table	92583	92588	O
S5	92589	92591	O
.	92591	92592	O

Average	92593	92600	O
percentage	92601	92611	O
of	92612	92614	O
each	92615	92619	O
mutation	92620	92628	O
type	92629	92633	O
across	92634	92640	O
samples	92641	92648	O
of	92649	92651	O
the	92652	92655	O
given	92656	92661	O
tissue	92662	92668	O
.	92668	92669	O

(	92670	92671	O
TSV	92671	92674	O
3	92675	92676	O
kb	92677	92679	O
)	92679	92680	O
Additional	92681	92691	O
file	92692	92696	O
8	92697	92698	O
:	92698	92699	O
Table	92700	92705	O
S6	92706	92708	O
.	92708	92709	O

Significant	92710	92721	O
associations	92722	92734	O
between	92735	92742	O
biological	92743	92753	O
sex	92754	92757	O
and	92758	92761	O
mutation	92762	92770	O
load	92771	92775	O
across	92776	92782	O
tissues	92783	92790	O
and	92791	92794	O
mutation	92795	92803	O
types	92804	92809	O
.	92809	92810	O

(	92811	92812	O
TSV	92812	92815	O
854	92816	92819	O
bytes	92820	92825	O
)	92825	92826	O
Additional	92827	92837	O
file	92838	92842	O
9	92843	92844	O
:	92844	92845	O
Notes	92846	92851	O
S1	92852	92854	O
–	92854	92855	O
S3	92855	92857	O
.	92857	92858	O

Additional	92859	92869	O
file	92870	92874	O
10	92875	92877	O
:	92877	92878	O
Table	92879	92884	O
S7	92885	92887	O
.	92887	92888	O

Tissue	92889	92895	O
correspondence	92896	92910	O
between	92911	92918	O
the	92919	92922	O
GTEx	92923	92927	O
[	92928	92929	O
46	92929	92931	O
]	92931	92932	O
and	92933	92936	O
Roadmap	92937	92944	O
Epigenomics	92945	92956	O
projects	92957	92965	O
[	92966	92967	O
27	92967	92969	O
]	92969	92970	O
.	92970	92971	O

(	92972	92973	O
TSV	92973	92976	O
1	92977	92978	O
kb	92979	92981	O
)	92981	92982	O
Additional	92983	92993	O
file	92994	92998	O
11	92999	93001	O
:	93001	93002	O
Table	93003	93008	O
S8	93009	93011	O
Significant	93012	93023	O
GO	93024	93026	O
enrichments	93027	93038	O
for	93039	93042	O
genes	93043	93048	O
whose	93049	93054	O
expression	93055	93065	O
is	93066	93068	O
significantly	93069	93082	O
and	93083	93086	O
negatively	93087	93097	O
associated	93098	93108	O
with	93109	93113	O
C	93114	93115	O
>	93116	93117	O
T	93118	93119	O
mutation	93120	93128	O
load	93129	93133	O
across	93134	93140	O
several	93141	93148	O
tissues	93149	93156	O
.	93156	93157	O

(	93158	93159	O
TSV	93159	93162	O
2	93163	93164	O
kb	93165	93167	O
)	93167	93168	O
Additional	93169	93179	O
file	93180	93184	O
12	93185	93187	O
:	93187	93188	O
Table	93189	93194	O
S9	93195	93197	O
.	93197	93198	O

Significant	93199	93210	O
GO	93211	93213	O
enrichments	93214	93225	O
for	93226	93229	O
genes	93230	93235	O
whose	93236	93241	O
expression	93242	93252	O
is	93253	93255	O
significantly	93256	93269	O
and	93270	93273	O
positively	93274	93284	O
associated	93285	93295	O
with	93296	93300	O
C	93301	93302	O
>	93303	93304	O
T	93305	93306	O
mutation	93307	93315	O
load	93316	93320	O
across	93321	93327	O
several	93328	93335	O
tissues	93336	93343	O
.	93343	93344	O

(	93345	93346	O
TSV	93346	93349	O
1	93350	93351	O
kb	93352	93354	O
)	93354	93355	O
Additional	93356	93366	O
file	93367	93371	O
13	93372	93374	O
:	93374	93375	O
Table	93376	93381	O
S10	93382	93385	O
.	93385	93386	O

List	93387	93391	O
of	93392	93394	O
cancer	93395	93401	O
driver	93402	93408	O
genes	93409	93414	O
used	93415	93419	O
in	93420	93422	O
this	93423	93427	O
study	93428	93433	O
[	93434	93435	O
2	93435	93436	O
]	93436	93437	O
.	93437	93438	O

(	93439	93440	O
TSV	93440	93443	O
312	93444	93447	O
bytes	93448	93453	O
)	93453	93454	O
Additional	93455	93465	O
file	93466	93470	O
14	93471	93473	O
:	93473	93474	O
Table	93475	93480	O
S11	93481	93484	O
.	93484	93485	O

List	93486	93490	O
of	93491	93493	O
mutations	93494	93503	O
in	93504	93506	O
cancer	93507	93513	O
driver	93514	93520	O
genes	93521	93526	O
after	93527	93532	O
further	93533	93540	O
elimination	93541	93552	O
of	93553	93555	O
potential	93556	93565	O
false	93566	93571	O
positives	93572	93581	O
.	93581	93582	O

(	93583	93584	O
TSV	93584	93587	O
97	93588	93590	O
kb	93591	93593	O
)	93593	93594	O
Additional	93595	93605	O
file	93606	93610	O
15	93611	93613	O
:	93613	93614	O
Table	93615	93620	O
S12	93621	93624	O
.	93624	93625	O

List	93626	93630	O
of	93631	93633	O
mutations	93634	93643	O
in	93644	93646	O
cancer	93647	93653	O
driver	93654	93660	O
genes	93661	93666	O
annotated	93667	93676	O
in	93677	93679	O
Oncokb	93680	93686	O
[	93687	93688	O
37	93688	93690	O
]	93690	93691	O
.	93691	93692	O

(	93693	93694	O
TSV	93694	93697	O
4	93698	93699	O
kb	93700	93702	O
)	93702	93703	O
Additional	93704	93714	O
file	93715	93719	O
16	93720	93722	O
.	93722	93723	O

Review	93724	93730	O
history	93731	93738	O
